<SEC-DOCUMENT>0001628280-21-003277.txt : 20210225
<SEC-HEADER>0001628280-21-003277.hdr.sgml : 20210225
<ACCEPTANCE-DATETIME>20210225160111
ACCESSION NUMBER:		0001628280-21-003277
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210225
DATE AS OF CHANGE:		20210225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		21680143

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>trov-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db,d:c18fbad9195b40d5a98c7f466e8a6118--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:trov="http://www.trovagene.com/20201231" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>trov-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl80LTEtMS0xLTA_0176921b-48b7-40c0-97cc-bce08ba7c664">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl85LTEtMS0xLTA_515f2481-56a9-4715-95ad-736999a11eb1">2020</ix:nonNumeric><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl8xMC0xLTEtMS0w_5e719e23-56b9-47ca-9e41-dd465d0ac350">FY</ix:nonNumeric><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl8xMS0xLTEtMS0w_ab5cfa64-b54c-4d91-9013-fe8efc7b70ab">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i64c8a7607231401e81a5f9c31f0790fd_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="trov-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1213689b20964f7fbaa4756853223720_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8031ad7778c04e03886ac0ae3c6c9cbf_I20210218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i076def4a10c84321bb8feceb11551055_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1033093be1a94f1586671f93e4cc0292_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i974c8d2976844fc9bd37ad841b476746_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f64d58d38fe4c52a90346b804d8222a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dfeebbffde848a39dd21015892f17ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31167c9f6df4b2e98fed3a3ab5827c9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90cbda9b433948c4bfec12adb85eece5_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283c7589044745a697aba89af3b8c955_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1fd37d65d4a45768c5f933a4c55cf0f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f11be824704ccaaa3be62c269b68d3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i489cb20610fb450193a4a09194d885a8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8da706562440a48c86522c944d0df6_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1533dc281f3416c87c9cc063e238300_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e843a6b44054990807074b9f697e695_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d5e02556184c789e5d3265173db41e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb0dc0c25b98439290e7f74e7dbe5c33_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ab9019c9754577b27a546943f63815_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c0726d301e947e5a55d7dfb699e13f1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id024008e76784d04a81dc04cad256492_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b60188329974ccba428036634f386c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775f6829cd0442b4abd291c9e9c043f2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7848a306518c4d3c8d2ceace32f45c19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede24d64c8eb47a38bf93edc43a4580d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b536880233430693517dce3f18592b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08acffb99e614dc58b610354b475758f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0556eb8a6c2a44c2be25fabc0712fbd4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>trov:segment</xbrli:measure></xbrli:unit><xbrli:context id="i0656cf347232476bae791a60c6bd570f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1105733d073744cd9a3e52b232486c1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1514b777a3114342923aade0d19fa7c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c8a7607231401e81a5f9c31f0790fd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8aaa0c125e84dba929af4a1e45d11b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4f241b55b904f8e929edc9f63cfb4ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb66c3828dd94b5e81231528bde5fed7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia954f550392d4591a6b546fb05b6c57d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba7031dc6fd14ef19e26c971fe76416a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7aa2f04b48e40b6bb9e10276579135f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04cf8ba00be248f88818392f53a19b98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ad1a7639b14aabab7b8f0710ecdb7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4c13518b4c74daca4beaea86298f527_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6436bbbd26f24becadccf4b1d782084d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975673dd341547dabdaf95c95b6524fb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib040744e101141f9aea1e9d4756978f4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic35f2ef7d35840b9bfab3082034c4696_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddb22003c74244c696720a265e0f7c37_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if08e7553905d4d068f485877b9048505_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b16d8ca860f495a9615c84058672eac_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73a4197db9564a4db2a4ad3445548a58_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i92fe3d8ede834ee9b4dfe1e82c7e0271_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f65a990a66462c9a37eb46069c65f5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i421f1d41857b4805963135b3663ab8d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd98c4fc531042d897b1d757e7b223e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f48dc38e8b943eb97849002ada03817_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3451a9182b0d4178a8fc3c09f942e860_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d1170ef6f54edc88cd4268fb361f16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256c4368010c4206a56da927baa4bb4e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i776cee27efa541a2acc891f09e09f352_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id456584ebb174aeabb2b1a0753b4e83e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i471d5f109548413d9e884f49a86cd7e3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0b2dbac0ba4dff9255fe336b8f7f15_D20050701-20050930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-07-01</xbrli:startDate><xbrli:endDate>2005-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-03-17</xbrli:startDate><xbrli:endDate>2006-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie42a61e34be3441d8bb072f33438bcea_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a1c4888a02426788234b406ae96f2e_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee37ec60282489987c4762ccebbab95_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5153c4279f4ab9989ac4ac9a3a516d_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02b699fc73a48aa943cf6fb99f91912_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i231a9537948e4825940975cf85f361b7_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id008b8758bbe4bd891a3f82bf9a4b6a6_I20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba125ce9af574f5f8548ad377e3f93e9_D20190125-20190125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-25</xbrli:startDate><xbrli:endDate>2019-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf104fb4e174434837dcfd628d05782_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i076c4c3a873c4a759be050208a345aa5_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d3f12d14ad342198f5284373cca8a23_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ce3c54cec224ad18a266a3636ffa8b2_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdfaba1492ec4f509a70416341174b1f_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a917753e1624c298122e4b830a4e135_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b02bac98214f3d9f8953ec814372be_I20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52c1c34006664ee7ac7c7c4e9e79e509_D20200508-20200508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-08</xbrli:startDate><xbrli:endDate>2020-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0668fc29bb0148d58510684753bd2cfc_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">trov:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b284544740a435bad1c3cec495cbf9f_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27074d7d656d4fbf85a8b9980795b54a_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfc040695af4d6a9817380661ebcf2e_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6b57d40d4354884b0510a8fef627c3d_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95bc585cf217481b97c06b8337a64fe3_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb24decc5bd454e83658b10c3fc8307_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesIWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i896119a0fd374e00971913227a456947_I20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesJWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesJWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-30</xbrli:startDate><xbrli:endDate>2020-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be9212423e34a67a70f23c6f9b5ddf4_I20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesKWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d26bfbbbd5422086f3c9920448c373_I20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesLWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesLWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-09</xbrli:startDate><xbrli:endDate>2020-04-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b38eb10663b489e9809321fc0276e7c_D20200511-20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6a9b93851e4335a8b8cb89237848bc_I20200511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56c03a47441c4536b67faa8e4cf731b7_D20200514-20200514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-14</xbrli:startDate><xbrli:endDate>2020-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf127176380c423fa60e0abdd61fd762_I20200514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e071b9425b74972bb38758dd9e5d35d_D20200511-20200514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-11</xbrli:startDate><xbrli:endDate>2020-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesMWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesMWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-02</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i544a15f619624305a7fd2f23ac7f07e8_I20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i201a9eb09e9e4e4d976772527902f4c8_D20201002-20201002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-02</xbrli:startDate><xbrli:endDate>2020-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ddee99771547b8a737dfc7a950fa46_I20140917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i091e321edee343b38a892516ab3dfeee_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86676dbd4e74419a825725ca27223263_I20190606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideda534790df48cc8af65a740c9c751e_I20200406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac8de1ad73340dabca4d672d5539b0c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5389a4fe9a914abba2617db418a0173f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd6a7a4e022447ca67831dd187fe59e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9460ddaf54074df7bfec5889e2b4845d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4aec0ea85e845048d3ce2ddb7213732_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i282b0d837b364a6894a32526001160d0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99ea3b979294094999f121f98b5bde6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d3e6472816445c1a3ca937b4efafb70_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72aca79d4804a8284025a9bab28eb5e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i978ad2c8eb824931bb5e88b64023d145_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica41068d79e14cf38ab901aaf00addb4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i229ba083ae0546d499ab31088af51e73_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ab39cf4fc841beb603ef348cdce603_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d8190644bee425ea8f517bd7095ed17_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1742e003e63146e896137b7e99fc50bf_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018bdbce7fca40e082dacb672d84b913_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44266fc1522f4f4eb8386f8c708948d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3fca2ac35d14a2384fef909655332d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0b1c58ab8b54dfc863c667221a34301_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85416ca7f414db49fe52bc843a8e2d4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3794493459f24ebfbe863d8937e8cad5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fb8cbc4edb14870b358d288e5800248_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d3620e40923403582678ccccc8f11fa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4f8972453604ec193d1df9f7e4ddac0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cc7198d6c034a22b424dd61cae5fd7c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1106ab4e606c4769a8f986403de38037_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76a88eeb56a477fa5ae7aa8b08acf1d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd3060e53a504b04a348d4ba80c3b484_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfe962c2ee074fbe9e3a0a8ee9b2fc05_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i090a771b6a4c49029aca107400020091_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73ffea244a27445a8d5f0970bdc9898e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031d703e2ea24364b5f7af43c8fb47c0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ac205ca24f94fe293ef86874c82e1e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice81c716c97c41b5bc001dfa532b8fdb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3345cb0517cc4b0284c813555e82d7d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b746e4199184cacad6f602a3b40b8e9_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i747d6a62e34a472c83d5644420b34a22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984ff34a2fe742088f9f828b91b563ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe390a53d1244859cc856f61f4542ae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice44ef262276432684d43f12b496e84d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdcc0804110481f8528b0ba7253bd83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e1bf59004804ff0a735f759a0b05ec6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6111128fd05424493681c4a0b3eb66d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e9a24fb323452cbc514841b9fbe098_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cad480a48a41da8b00597bbd01b912_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbc8e0a3804c47c4ae77c14738fc2399_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedf02bb4675b4a2d940c16f6f69cb7c4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b865da6863477b8c4c5144516016d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id661a46404df44e0b0e9dbdd6e3e8364_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a27f9e1adc4f6dacd046a2f6a03585_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac1d9ffb9c364277ad0f0ae113dd82f7_D20170301-20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">trov:NorvianoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f2ba9a7769e4c3981f5515bac81bee0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">trov:NorvianoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i014c4430e11a4a7ba478369860aa6b07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d1eafc280542e8a75a72c3e54779ac_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9ba25d98442435ab13367e9dd32ebd2_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7103d5be24a4480abffa7afe4b21824f_I20200415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">trov:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-15</xbrli:instant></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2 id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:4pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjA3_dc307505-b7ab-4a32-8866-0a55015628cc">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NTYyZGYyNDI2NjNhNGNiNTk5MTZkMzdiNDAwZDkxYjIvdGFibGVyYW5nZTo1NjJkZjI0MjY2M2E0Y2I1OTkxNmQzN2I0MDBkOTFiMl8wLTAtMS0xLTQwMzM_ed5ecc43-7b22-4707-a9df-1a0acddb3853">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjY0_73869461-e93d-4085-b9c6-b34fc24b2fa6"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjY0_764fa1f3-3e13-4764-a342-459e218908a0">December 31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6OWIyZmEzOGFiZjBmNDQyMmI3OTNhNDZlMzliNzMyZWQvdGFibGVyYW5nZTo5YjJmYTM4YWJmMGY0NDIyYjc5M2E0NmUzOWI3MzJlZF8wLTAtMS0xLTQwMzY_c2d0b682-e073-4456-81a5-a9c73e041d6f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjA4_a5d76c63-9488-4f73-ad8c-5c2616230377">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjEx_2687050c-f0ed-4c2f-a94b-476822e30790">CARDIFF ONCOLOGY, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8wLTAtMS0xLTQwNTQ_47fb88ca-9efe-4c31-82f7-d46070902012">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8wLTItMS0xLTQwNTY_550e6344-e4f6-40fb-a516-848ea8a7c635">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODQ3_cc0f8ca1-ff2c-4c59-b559-7d04a05dd678">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODU5_e14e1d25-b902-4e5d-a318-a618c18c9254">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODcy_b5b9fee8-549c-4243-abaa-9abb1f0acc12">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTItMS0xLTQwNTg_8a617306-1100-4f37-a9f0-5ca24da51f4b">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF80LTAtMS0xLTQxMTIvdGV4dHJlZ2lvbjoyN2U0YzlkYzYzNjM0NTczOWUwODk5NTVhNjMzMGZlYV8xMDk5NTExNjI3Nzk3_2a49c72d-034f-4df9-a047-5d393f34ece8">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF80LTAtMS0xLTQxMTIvdGV4dHJlZ2lvbjoyN2U0YzlkYzYzNjM0NTczOWUwODk5NTVhNjMzMGZlYV8xMDk5NTExNjI3ODA4_611ab1bb-0160-4cd7-9f03-ecac822baaf2">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF84LTAtMS0xLTQwNjA_60262024-f7a6-4aac-9bf7-408b79f4be7f">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The NASDAQ Capital Market</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">None</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM2_f9e1e491-bee5-469f-a6ef-4905c1224aab">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d)&#160;of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM3_4048ed76-f1e9-4b69-86c5-c6a357670d8e">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM4_9606915d-9d1f-4708-9142-196438c26abc">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM5_059efa0a-87c2-43b0-b0fe-a0cbb06b7695">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160; See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTQtMS0xLTQxMTUvdGV4dHJlZ2lvbjplYjgwNDM1NTdlMmE0MzY1OGVmYTY3ZDcwNjQ3OWU3Yl8xMDk5NTExNjI3ODI5_daf54356-3e0a-4181-8df6-af8bbc0f4119">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTYtMS0xLTQxMTgvdGV4dHJlZ2lvbjphMGNiYWMwYjM5ODc0ZDZiYThkYTQwNzFiZjg2MTkzZl8xMDk5NTExNjI3ODEy_d050b77a-05e0-48ba-b1f0-b196827d8b04">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTgtMS0xLTQxMjEvdGV4dHJlZ2lvbjo3NTk4MjRkZWU0Yjc0ZGViYmExYzI4ODJhMTQ4MzQ0ZV8xMDk5NTExNjI3ODE0_18866fef-64a4-4e93-8a95-f7e83e02bdc5">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMzNzg0_dfa8146c-7461-41ff-9449-7d1a5d5e7060">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160; Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjQw_7215f9cb-b8b0-4088-b768-d77ff1b3b1dc">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates based on a closing sale price of $5.01 per share, which was the last sale price of the common stock as of June&#160;30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="i1213689b20964f7fbaa4756853223720_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8yNjc4_df3a1079-6680-41fd-8174-3f993b1bb7bb">103,720,151</ix:nonFraction>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;February&#160;18, 2021, <ix:nonFraction unitRef="shares" contextRef="i8031ad7778c04e03886ac0ae3c6c9cbf_I20210218" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8yNjkz_caac5338-b565-4298-824b-7eccd74a8552">37,052,129</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.0001 par value per share, were issued and outstanding.</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:4pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_13">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_16">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_52">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_52">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_52">18</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_64">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_64">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_64">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_67">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_67">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_67">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_70">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_70">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_70">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_73">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_73">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_73">41</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_76">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_79">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_79">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_79">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_91">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_91">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_91">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_94">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_94">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_121">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_121">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_121">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_124">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_124">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_124">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_127">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_127">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_127">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_130">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_130">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_130">50</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_133">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_133">51</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2581">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2587">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2587">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2587">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2610">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2610">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2610">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2605">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2605">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2605">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2600">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2600">Certain Relationship and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2600">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2595">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2595">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_2595">51</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_211">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_211">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_214">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_214">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_214">52</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_217">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_217">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_217">54</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_220">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_220">55</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the reasons described in our &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management Discussion and Analysis of Financial Condition and Result of Operations,&#8221; sections. In some cases, you can identify these forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;depends,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and business prospects are always subject to risks and uncertainties including, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory submissions;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our existing product candidate and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approvals for clinical trials may be delayed or withheld by regulatory agencies;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-clinical and clinical studies will not be successful or confirm earlier results or meet expectations or meet regulatory requirements or meet performance thresholds for commercial success;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to the timing and costs of clinical trials, the timing and costs of other expenses;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with obtaining funding from third parties;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management and employee operations and execution risks;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of key personnel;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to market acceptance of products;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property risks;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the uncertainty of future financial results;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract collaborators and partners; and</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with our reliance on third party organizations. </span></div><div style="padding-left:54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of filing of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221;, together with the other information in this Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are a clinical stage company and may never earn a profit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will need to raise substantial additional capital to develop and commercialize onvansertib and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidate, onvansertib, is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we materially breach or default under the Nerviano Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.  BUSINESS</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer (&#8220;mCRC&#8221;), pancreatic cancer, metastatic castrate-resistant prostate cancer (&#8220;mCRPC&#8221;) and leukemias. By integrating biomarkers into our clinical development programs, we will be able to identify patients who are most likely to respond to treatment across a number of cancer types and associated indications. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidate, onvansertib, is a first-in-class, third-generation, oral and highly selective Polo-like Kinase 1 (&#8220;PLK1&#8221;) adenosine triphosphate (&#8220;ATP&#8221;) competitive inhibitor. PLK1 is essential for precisely regulating the cell division and maintaining genome stability in mitosis (cell division), spindle assembly, and DNA damage response. Studies have shown that PLK1 is over-expressed in most cancers, which is associated with poor prognosis in patients. Data has shown that blocking the expression of PLK1 by kinase inhibitors can effectively inhibit proliferation and induce apoptosis (death) of tumor cells.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2017, we announced the licensing of onvansertib from Nerviano Medical Sciences S.r.l. (&#8220;Nerviano&#8221;), the largest company in Italy committed to innovation and research and development in oncology and a leader in protein kinase drug development (Polo-like Kinase Inhibitors). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe onvansertib is the only PLK1 selective ATP competitive inhibitor administered orally with apparent antitumor activity in different preclinical models currently in clinical development.  PLK1 is the most well-characterized member of the family of serine/threonine protein kinases and strongly promotes the progression of cells through mitosis. PLK1 performs several important functions throughout the mitotic (M) phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of anaphase-promoting complex/cyclosome inhibitors, and the regulation of mitotic exit and cytokinesis. PLK1 is ubiquitously expressed in normal proliferating tissues and is over-expressed in a wide variety of human tumors (including lung, colon, prostate, ovary, breast, and head and neck squamous cell carcinoma). Onvansertib was developed to have high selectivity for PLK1, to be administered orally, and to have a relatively short drug half-life of approximately 24 hours compared to previous pan Polo-like inhibitors.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib has been tested in-vivo in different xenograft and transgenic models at times suggesting tumor growth inhibition or tumor regression. Onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a measure concentration for 50% target inhibition) below 100 nM in 75 cell lines and IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> values below 1 uM in 133 out of 148 cell lines.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 safety study was successfully completed in patients with advanced metastatic solid tumors and published in 2017 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have four active Investigational New Drug (&#8220;IND&#8221;) applications in place with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), and three ongoing clinical studies. The first study is TROV-052 (ClinicalTrials.gov Identifier NCT03303339), a Phase 1b/2 open-label clinical trial of onvansertib in combination with standard-of-care low-dose cytarabine (&#8220;LDAC&#8221;) or decitabine for patients with relapsed or refractory AML. The second study is TROV-053 (ClinicalTrials.gov Identifier NCT03414034), a Phase 2 open-label clinical trial of onvansertib in combination with Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(abiraterone acetate)/prednisone, all administered orally, for patients with metastatic Castration-Resistant Prostate Cancer (&#8220;mCRPC&#8221;). The third study is TROV-054 (ClincalTrials.gov Identifier NCT03829410), a Phase 1b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil and irinotecan) and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bevacizumab) for patients with mCRC, who have a KRAS mutation. A new Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) is planned for initiation in the first half of 2021 (ClinicalTrials.gov Identifier NCT04752696)</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of onvansertib, as part of a combination regimen with already approved drugs, has the potential to bring new treatment options to patients across a wide array of cancers. Onvansertib has been evaluated preclinically in combination with several different chemotherapies, including irinotecan, cisplatin, cytarabine, doxorubicin, gemcitabine and paclitaxel, and with targeted therapeutics such as abiraterone, histone deacetylase (HDAC) inhibitors, fms-like tyrosine kinase 3 (FLT3) inhibitors, and bortezomib. These therapies are used clinically for the treatment of many hematologic and solid cancers, including acute myeloid leukemia (AML), non-Hodgkin&#8217;s lymphoma (NHL), metastatic CRC, metastatic castration resistant prostate cancer (mCRPC), adrenocortical carcinoma (ACC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), and ovarian cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy includes integrating a predictive clinical biomarker approach into our onvansertib clinical development programs, which we believe may enable us to tailor treatment to specific sub-populations of patients who are most likely to respond and have a positive clinical impact. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onvansertib Phase 1 Safety Study in Solid Tumors</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 safety study of onvansertib was completed in patients with advanced metastatic solid tumor cancers and published in July 2017, in the peer-reviewed journal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Dr. Glen Weiss, Medical Oncologist at Goodyear, AZ and affiliated with Cancer Treatment Centers of America at Western Regional Medical Center, was the principal investigator and first author of the publication, entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Phase 1 Dose-Escalation Study of NMS-1286937, an Orally Available Polo-like Kinase 1 Inhibitor, in Patients with Advanced or Metastatic Solid Tumors&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This study evaluated first-cycle dose limiting toxicities and related maximum tolerated dose with data indicating a manageable safety profile for onvansertib (also known as PCM-075 and NMS-1286937) for the treatment of advanced or metastatic solid tumors, with transient adverse events that were likely related to the drug&#8217;s mechanism of action. The authors believe that data from preclinical work, coupled with the results of the Phase 1 trial, suggest that onvansertib could become a new therapeutic option for the treatment of solid tumor and hematologic cancers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this trial, onvansertib was administered orally, once daily for five consecutive days, every three weeks, to evaluate first cycle dose-limiting toxicities and related maximum tolerated dose in adult subjects with advanced/metastatic solid tumors. The study was also intended to evaluate onvansertib&#8217;s pharmacokinetic profile in plasma, its anti-tumor activity, and its ability to modulate intracellular targets in biopsied tissue. The study identified thrombocytopenia and neutropenia as the primary toxicities, which is consistent with the expected mechanism of action of onvansertib and results from preclinical studies. These hematologic toxicities were reversible, with recovery usually occurring within 3 weeks.  No GI disorders, mucositis, or alopecia was observed, confirming that bone marrow cells are the most sensitive to onvansertib inhibition with the applied dosing schedule.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are utilizing the existing IND applications to develop onvansertib in solid tumors as part of our clinical development expansion plans, with our initial focus in mCRC and mCRPC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onvansertib Phase 2 Study in metastatic Castration-Resistant Prostate Cancer</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2017, we announced the submission of our Phase 2 protocol of onvansertib in combination with abiraterone acetate (Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Johnson &amp; Johnson) for the treatment of mCRPC, to the FDA and our active solid tumor IND. In this multi-center, open-label, Phase 2 trial, onvansertib in combination with the standard dose of Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and prednisone, all administered orally, will be evaluated for safety and efficacy. The primary efficacy endpoint is the proportion of patients achieving disease control after 12 weeks of study treatment, as defined by lack of Prostate Specific Antigen (&#8220;PSA&#8221;) progression in patients who are showing signs of early progressive disease (rise in PSA but minimally symptomatic or asymptomatic) while currently receiving androgen deprivation therapy (&#8220;ADT&#8221;), abiraterone and prednisone.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ongoing Phase 2 clinical study is being conducted at three Harvard Medical sites: Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital, in Boston Massachusetts. Dr. David Einstein at the Genitourinary Oncology Program at Beth Israel Deaconess Medical Center and Harvard Medical School is the principal investigator for the Phase 2 mCRPC trial.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onvansertib Phase 1b/2 Study in metastatic Colorectal Cancer </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, we submitted a new IND application and protocol for our Phase 1b/2 trial of onvansertib in combination </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (bevacizumab) for the second-line treatment of mCRC with a KRAS mutation. On January 16, 2019, we received notification from the FDA that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">study may proceed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and on January 29, 2019, we announced an agreement with PoC Capital, LLC to fund the clinical development program. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this open-label, Phase 1b/2 trial, onvansertib in combination with standard-of-care FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is being evaluated for safety and efficacy. The trial will enroll up to 44 patients to assess the safety and preliminary efficacy of the combination regimen. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase1b segment of this clinical study has been conducted at two prestigious cancer centers: USC Norris Comprehensive Cancer Center and The Mayo Clinic Arizona. Dr. Heinz-Josef Lenz, Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center, is the principal investigator for the Phase 1b/2 mCRC trial. The Phase 2 segment is being conducted at USC Norris Comprehensive Cancer Center, the Mayo Clinic (Arizona, Minnesota and Florida), Kansas University Medical Center and CARTI Cancer Research.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Onvansertib Phase 1b/2 Study in Acute Myeloid Leukemia</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we announced the submission of our IND application and our Phase 1b/2 protocol of onvansertib in combination with standard-of-care chemotherapy for the treatment of AML to the FDA.  In July 2017, we received notification from the FDA that our Phase 1b/2 clinical trial of onvansertib in patients with AML &#8220;may proceed&#8221;. On October 9, 2017, we announced that the FDA granted Orphan Drug Designation to onvansertib for the treatment of AML. We initiated our Phase 1b/2 AML trial in November 2017 and enrolled our first patient in February 2018. On August 29, 2018, we announced that the European Medicinal Agency granted Orphan Drug Designation to onvansertib for the treatment of AML in the European Union (&#8220;EU&#8221;).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 1b/2 clinical study is an open-label trial to evaluate the safety and anti-leukemic activity of onvansertib in combination with standard-of-care chemotherapy in patients with AML. Phase 1b is a dose escalation trial to evaluate the safety, tolerability, dose and scheduling of onvansertib, and to determine a recommended clinical treatment dose for the Phase 2 continuation trial. Enrollment of Phase 2 was completed in 2020. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacokinetics of onvansertib and correlative biomarker activity have been assessed throughout the Phase 1b and Phase 2 segments of the trial. The Phase 2 continuation trial is open-label with administration of the recommended onvansertib clinical dose in combination with standard-of-care chemotherapy to further evaluate safety and assess efficacy. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we completed the Phase 1b segment of this trial and enrollment in Phase 2 was completed in October 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of eight sites are conducting this trial, which is being led by Hematologist Amer Zeidan, MBBS, MHS, Assistant Professor of Medicine at Yale School of Medicine, Hematology expert at Yale Cancer Center.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Optimizing Drug Development with Correlative Biomarker Analysis using Circulating Tumor DNA</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant experience and expertise with biomarkers and technology in cancer. In our ongoing clinical trial in KRAS-mutated mCRC, we are quantitatively assessing changes in the KRAS mutational burden with a simple blood test. Decreases in KRAS mutant allelic frequency (MAF) after the first cycle of treatment are highly predictive of subsequent radiographic response observed as tumor shrinkage.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological advancements in the molecular characterization of cancers have enabled researchers to identify an increasing number of key molecular drivers of cancer progression. These discoveries have led to multiple novel anticancer therapeutics and clinical benefit in selected patient populations. As a clinical-stage biotechnology company developing new treatment options for cancer patients in indications with the greatest medical need, our objective is to optimize drug development by using our biomarker strategy as part of our approach.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory in San Diego, California, enables us to optimize drug development and patient care. In the clinical development of our drug candidate, onvansertib, correlative biomarker analyses are being used to help inform decisions in the evaluation of dose-response and optimal regimen for desired pharmacologic effect and safety.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some biomarkers can be used as a surrogate endpoint for efficacy and/or toxicity, as well as predicting patients&#8217; response by identifying certain patient populations that are more likely to respond to the drug therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Segment and Geographic Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, using one measurement of profitability to manage our business. We do not assess the performance of geographic regions on measures of revenue or comprehensive income or expense. In addition, all of our principal operations, assets and decision-making functions are located in the U.S.  We do not produce reports for, or measure the performance of, geographic regions on any asset-based metrics. Therefore, geographic information is not presented for revenues or long-lived assets.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Market</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Onvansertib</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with our primary focus on the development of our drug candidate, onvansertib, a first-in-class, third generation, oral and highly selective PLK1 inhibitor to treat solid tumor cancers and hematologic malignancies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several drug candidates in this class of targeted oncology therapeutics to enter clinical trials; however, we believe onvansertib is the only oral candidate currently in clinical trials and is differentiated from other ATP competitive inhibitors in that:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">its inhibition of PLK1 is highly-selective and the half maximal inhibitory concentration (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for PLK2 and PLK3 is over 5,000-fold of that for PLK1;</span></div><div style="padding-left:63pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it has a relatively short half-life of approximately 24 hours;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is available in an oral gelcap formulation;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it allows for flexible dosing and scheduling;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it has demonstrated safety, tolerability and preliminary efficacy; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is synergistic in combination with numerous chemotherapies and targeted therapeutics, which may enhance efficacy and duration of response.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unacceptable toxicity of prior PLK inhibitors, such as volasertib from Boehringer Ingelheim, may be due to non-selective inhibition of PLK2 and PLK3 and a much longer half-life (approximately 135 hours) that could result in drug accumulation, which ultimately may have led to unsatisfactory clinical and safety outcomes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we initiated a Phase 1b/2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy in AML patients to evaluate the safety/tolerability, determine the maximum tolerated dose (&#8220;MTD&#8221;), and assess preliminary efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This study is on file at ClinicalTrials.gov with the Identifier NCT03303339.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also initiated a Phase 2 open-label clinical trial in patients with mCRPC in combination with Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The mCRPC Phase 2 trial is on file at ClinicalTrials.gov with the Identifier NCT03414034. In 2019 we initiated a Phase 1b/2 open-label clinical trial in mCRC in patients with a KRAS mutation in combination with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the second-line treatment setting. This study is on file at ClinicalTrials.gov with the Identifier NCT03829410.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 2020 we have four active IND applications in place with the FDA, one with the hematologic division and three with the solid tumor division. This enables us to quickly initiate additional clinical trials of our drug candidate, onvansertib, in solid tumor cancers and hematologic malignancies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug Development and Monitoring of Therapeutic Outcomes</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cell-free DNA diagnostic technology has significant potential as a simple, quick, noninvasive way of monitoring clinical responses to drugs in clinical development and evaluating patient-specific responses to already approved and marketed therapies.&#160;Specific target applications include, but are not limited to, optimizing drug development to identify patients most likely to respond to targeted therapeutics.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the largest costs associated with development of a new therapy is the phases and size of human clinical studies required to identify the cohort of responders, and the resulting statistical power required. By measuring specific genetic markers, it may be possible to pre-identify, and subsequently screen for, the most likely responders to the therapy, and to limit patient recruitment to this subset. This strategy could significantly reduce the cost to develop a drug and improve development timelines. We believe that there is significant research potential technology and expertise to be incorporated into ongoing and future clinical trial protocols, and ultimately into post-approval patient identification protocols.</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Strategy</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage, biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated mCRC, pancreatic cancer, mCRPC and leukemia. By integrating </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biomarkers into our clinical development programs, we believe we will be able to identify patients who are most likely to respond to treatment. Specifically, we are developing onvansertib, a first-in-class, third generation PLK1 inhibitor that targets mitosis (cell division) to treat a variety of cancers and associated indications. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically made substantial investments in research and development. Our research and development efforts are prioritized on the clinical development of our drug candidate, onvansertib, and our related biomarker assay development and pre-clinical research. Our research and development team is composed of researchers and scientists (PhD&#8217;s), laboratory associate scientists, and experts in drug development and tumor genomics. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the years ended December&#160;31, 2020 and 2019 were approximately $11.2 million and $11.2 million, respectively.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical element in the success of our business. &#160;As of December&#160;31, 2020, our owned and licensed intellectual property included 57 issued patents and 11&#160;pending patent applications in the U.S. and abroad.&#160;The pending patent applications include multiple international patent applications filed under the Patent Cooperation Treaty that may be used as the basis for multiple additional patent applications worldwide.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to protect our intellectual property position by, among other things, licensing or filing our own U.S. and foreign patent applications related to our proprietary technologies and products, and any inventions or improvements that are important to the development and implementation of our business. We also may seek patent protection, if available, with respect to biomarkers and diagnostic methods that may be used to determine optimal patient populations for use of our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreement with Nerviano dated March 15, 2017 grants us exclusive, worldwide licenses under a portfolio of three patent families of U.S. and foreign patents covering three broad areas: (1) onvansertib (composition of matter), related compounds and processes for making compounds; pharmaceutical compositions and methods of treating diseases characterized by dysregulated protein kinase activity; (2) salts and pharmaceutical compositions of onvansertib; methods of treating mammals in need of PLK inhibition; and (3) synergistic combinations of onvansertib and one or more of a broad range of antineoplastic agents, and pharmaceutical compositions of those combinations.  Patents of this licensed portfolio will expire between 2027 and 2030. U.S. patents of this licensed patent portfolio will expire in 2030, with patent term extension up to 2035.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2018, we entered into an Exclusive Patent License Agreement with MIT to a patent family directed to combination therapies including an antiandrogen or androgen antagonist and a polo-like kinase inhibitor (such as onvansertib) for the treatment of cancer. The license agreement covers the rights to develop combination therapies and identified predictive clinical biomarkers across cancer types, expanding potential indications for onvansertib. Under the agreement, Cardiff Oncology has exclusive rights to develop, make, use, and sell combination therapies that include an anti-androgen or androgen antagonist and a PLK inhibitor for the treatment of cancer. The exclusive license agreement is part of our strategy to explore the efficacy of onvansertib in combination with anti-androgen drugs in cancers including prostate, breast, pancreatic, lung and gastrointestinal. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensed MIT patent family includes U.S. Patent Nos. 9,566,280, 10,155,006, and 10,772,898, which will expire in 2035, with patent term extension up to 2040. U.S. Patent No. 9,566,280 encompasses using abiraterone in combination with onvansertib to treat cancer. U.S. Patent Nos. 10,155,006 and 10,772,898 broaden previously issued U.S. Patent No. 9,566,280, by expanding the use of onvansertib to encompass combination therapies with any anti-androgen and androgen antagonist drug, such as Zytiga&#174;, Xtandi&#174; and Erleada&#174; for the treatment of metastatic and non-metastatic castrate-resistant prostate cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned intellectual property included eight patent families related to onvansertib. These families include patent applications directed to treating cancer using PLK1 inhibitors and determining efficacy of the treatment, treating benign prostatic hyperplasia using onvansertib, treating prostate cancer using PLK1 inhibitors, determining efficacy of PLK1 treatment based on biomarkers, and treating leukemia and lymphoma using combination therapies including a B-cell lymphoma 2 and a PLK1 inhibitor. Any patents issued in these families will expire between 2039 and 2041.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wherever possible, we seek to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select countries. Because patent applications in the U.S. are maintained in secrecy for at least eighteen months after the applications are filed, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first to file for protection of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party patents or other intellectual property rights, in which case continued development and marketing of our products would require a license.  Required licenses may not be available to us on commercially acceptable terms, if at all.  If we do not obtain these licenses, we could encounter delays in product introductions while we attempt to design around the patents, or we could find that the development, manufacture or sale of products requiring such licenses are not possible.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of which can be difficult to protect.  We seek to protect some of our proprietary technologies and processes by entering into confidentiality agreements with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for any breach and our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our employees or our consultants or contractors use intellectual property owned by others in their work for us, disputes may also arise as to the rights in related or resulting know-how and inventions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Distribution</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a supply agreement with NerPharMa, S.r.l., a GMP and FDA validated pharmaceutical manufacturing company and a subsidiary of Nerviano, to manufacture drug product for onvansertib. The agreement covers the clinical and commercial supply of onvansertib, and includes both Active Pharmaceutical Ingredients (&#8220;API&#8221;) and Good Manufacturing Process (&#8220;GMP&#8221;) production of capsules. </span></div><div style="text-indent:27pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our present and future business has been, and will continue to be, subject to a variety of laws including, the Federal Food, Drug, and Cosmetic Act (&#8220;FDC Act&#8221;), and the Public Health Service Act, among others.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDC Act and other federal and state statutes and regulations govern the testing, manufacturing, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these laws and regulations, product development and product approval processes are very expensive and time-consuming.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceutical products, including biologics, are subject to extensive regulation by the FDA. The FDC Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacturing, storage, record keeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications (&#8220;NDAs&#8221;) or biologic license applications (&#8220;BLAs&#8221;) warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug or biologic for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical tests include laboratory evaluation as well as animal trials to assess the characteristics and potential pharmacology and toxicity of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements including good laboratory practices. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not objected to the IND within this 30-day period, the clinical trial proposed in the IND may begin. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with federal regulations and good clinical practices (&#8220;GCP&#8221;) as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (&#8220;IRB&#8221;) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs or BLAs, which are applications for marketing approval, are typically conducted in three sequential Phases, but the Phases may overlap. In Phase 1, the initial introduction of the investigational drug candidate into healthy human subjects or patients, the investigational drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population, to determine the effectiveness of the investigational drug for a particular indication or indications, dosage tolerance and optimum dosage, and identify common adverse effects and safety risks. In the case of product candidates for severe or life-threatening diseases such as pneumonia, the initial human testing is often conducted in patients rather than in healthy volunteers. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an investigational drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the investigational drug and to provide adequate information for its labeling. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA or, in the case of a biologic, a BLA, is prepared and submitted to the FDA. FDA approval of the marketing application is required before marketing of the product may begin in the United States. The marketing application must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of marketing applications. Most such applications for non-priority drug products are reviewed within ten months. The review process may be extended by the FDA for three additional months to consider new information submitted during the review or clarification regarding information already provided in the submission. The FDA may also refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a marketing application, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA will inspect the facility or the facilities at which the drug product is manufactured. The FDA will not approve the NDA or, in the case of a biologic, the BLA unless compliance with Current Good Manufacturing Process ("CGMPs") is satisfactory and the marketing application contains data that provide substantial evidence that the product is safe and effective in the indication studied. Manufacturers of biologics also must comply with FDA&#8217;s general biological product standards. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed in a resubmission of the marketing application, the FDA will re-initiate their review. If the FDA is satisfied that the deficiencies have been addressed, the agency will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. It is not unusual for the FDA to issue a complete response letter </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">because it believes that the drug product is not safe enough or effective enough or because it does not believe that the data submitted are reliable or conclusive. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug product with specific prescribing information for specific indications. As a condition of approval of the marketing application, the FDA may require substantial post-approval testing and surveillance to monitor the drug product&#8217;s safety or efficacy and may impose other conditions, including labeling restrictions, which can materially affect the product&#8217;s potential market and profitability. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of therapeutic products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. We cannot be certain that the FDA or any other regulatory agency will grant approval for our product candidate for any other indications or any other product candidate for any indication on a timely basis, if at all. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging, and labeling procedures must continue to conform to CGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with CGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with CGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Foreign Corrupt Practices Act </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Fraud and Abuse Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug and biologic product candidates which obtain marketing approval. In addition to FDA restrictions on marketing of pharmaceutical products, pharmaceutical manufacturers are exposed, directly, or indirectly, through customers, to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which a pharmaceutical manufacturer can market, sell and distribute drug and biologic products. These laws include, but are not limited to: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute which prohibits, any person or entity from, among other things, knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in-kind, to induce or reward either the referring of an individual for, or the purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid, or any other federally financed healthcare program. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescribers, purchasers, and formulary managers on the other hand. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims and civil monetary penalty laws, including the Federal False Claims Act, which imposes significant penalties and can be enforced by private citizens through civil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to the federal government, or knowingly making, using or causing to be made, a false statement or record material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the company&#8217;s marketing of the product for unapproved, and thus non-reimbursable, uses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, benefits, items or services.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and its implementing regulations, which impose certain requirements relating to the privacy, security, transmission and breach reporting of individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act,&#8221; and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services (&#8220;HHS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers, and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some business activities can be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations.  Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that business arrangements with third parties comply with applicable healthcare laws and regulations is costly and time consuming. If business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s ability to operate its business and the results of its operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform in the United States</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect the future results of pharmaceutical manufactures&#8217; operations. In particular, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. The Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) was enacted in March 2010, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act&#8221;;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (&#8220;AMP&#8221;);</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some of the provisions of the PPACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the PPACA. During President Trump's administration, he signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Congress may consider other legislation to repeal or replace elements of the PPACA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would have on a pharmaceutical manufacturer remains unclear. In particular, there is uncertainty surrounding the applicability of the biosimilars provisions under the PPACA. The FDA has issued several guidance documents, but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. The regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way pharmaceutical manufacturers conduct their business and may require changes to current strategies. A biosimilar is a biological product that is highly similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer&#8217;s business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure on product pricing, which could negatively affect a pharmaceutical manufacturer&#8217;s business, results of operations, financial condition and prospects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare and Medicaid programs. While no one can predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm a pharmaceutical manufacturer&#8217;s ability to generate revenue. Increases in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure on a pharmaceutical manufacturer&#8217;s ability to profitably price products, which, in turn, could adversely affect business, results of operations, financial condition and prospects. A pharmaceutical manufacturer might elect not to seek approval for or market products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue generated from product sales. It is also possible that other legislative proposals having similar effects will be adopted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. No one can be sure whether future changes to the regulatory environment will be favorable or unfavorable to business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation in the European Union </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics are also subject to extensive regulation outside of the United States. In the European Union, for example, there is a centralized approval procedure that authorizes marketing of a product in all countries of the European Union, which includes most major countries in Europe. If this procedure is not used, approval in one country of the European Union can be used to obtain approval in another country of the European Union under two simplified application processes, the mutual recognition procedure or the decentralized procedure, both of which rely on the principle of mutual recognition. After receiving regulatory approval through any of the European registration procedures, pricing and reimbursement approvals are also required in most countries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulations </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances and biological materials. We may incur significant costs to comply with such laws and regulations now or in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some drugs benefit from additional government incentives.&#160;Orphan drugs&#160;receive special consideration from the FDA in order to encourage pharmaceutical companies to develop treatments for rare diseases. Incentives for the development of orphan drugs include quicker approval time and potential financial assistance, including waiver of the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;). Companies are often permitted to charge substantial prices for orphan drugs, making them more profitable than they would be without government intervention. As a result, the development of orphan drugs continues to grow at a faster rate than the development of traditional pharmaceuticals. The FDA granted Orphan Drug Designation (&#8220;ODD&#8221;) to onvansertib in the treatment of AML in October 2017. The European Commission granted ODD to onvansertib in the treatment of AML in Europe in August 2018.</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is not the first PLK inhibitor that has entered clinical development; however, we believe it currently is the only oral PLK1 inhibitor in active clinical development and delivers highly selective PLK1 inhibition. Onvansertib is also synergistic in combination with numerous chemotherapies and targeted therapeutics and may enhance and/or extend response to treatment across a number of solid tumor cancers and hematologic malignancies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 trial in advanced metastatic solid tumor cancers has been completed and published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A Phase 1b/2 trial in AML was initiated in November 2017, with the first patient treated in February, 2018 and a total of eight sites participating. A Phase 2 trial in mCRPC was initiated in June, 2018 with the Harvard Medical Cancer Centers - Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute and Massachusetts General Hospital - with the first patient treated in August, 2018. A Phase 1b/2 trial in mCRC was initiated in July, 2019 with USC Norris Comprehensive Cancer Center and The Mayo Clinic (Arizona) - with the first patient treated in August, 2019. At the end of 2020 and early 2021, five additional sites were added including The Mayo Clinics (Minnesota and Florida), CARTI Cancer Center, Kansas University Medical Center and Inova Schar Cancer Institute. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most prominent PLK inhibitor tested in late-stage clinical development, thus far, is volasertib, developed by Boehringer Ingelheim. In a randomized Phase 2 trial of volasertib plus LDAC in 87 AML patients not eligible for induction therapy, patients received LDAC 20mg twice-daily subcutaneously on days 1-10 or LDAC plus volasertib 350 mg IV on days 1 + 15 every four weeks.&#160; The response rate (complete remission and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib vs LDAC (31.0% vs 13.3%; p=0.052). Median event-free survival was significantly prolonged by LDAC + volasertib compared with LDAC (5.6 vs 2.3 months). The encouraging results led to the Phase 3 POLO-AML-2 study in early 2013, which enrolled 666 elderly patients (65 years or older) with newly diagnosed AML, who were not eligible for intensive induction therapy. However, in June, 2016, Boehringer Ingelheim reported that LDAC + volasertib did not meet the primary endpoint of objective response; although better than LDAC alone, the difference was not statistically significant. The data also showed an unfavorable overall survival trend for the experimental arm, with the safety profile of the LDAC + volasertib dosing regimen considered as the main reason for the trend. The fact that volasertib demonstrated survival benefits in the Phase 2 trial provided proof-of-concept for PLK inhibition as a mechanism of action for an AML therapy; however, its unacceptable safety profile may have resulted from the fact that volasertib&#8217;s inhibition of PLK1 is not highly selective and it also inhibits PLK2 and PLK3. By contrast, onvansertib is able to deliver much more selective inhibition of PLK1 than volasertib.&#160;Onvansertib also has a half-life of 24 hours vs volasertib&#8217;s 135 hours and it is orally administered.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK461364, developed by GSK, appears to have less sensitivity to PLK2 and PLK3 than volasertib, although it is not as specific to PLK1 as onvansertib. GSK461364 was investigated in a Phase 1 study in patients with advanced solid tumor cancers. The best response was prolonged stable disease of more than 16 weeks that occurred in 15% of patients. However, GSK461364 had off target adverse events including grade 4 pulmonary emboli. Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4 drug-related events; and VTE occurred in 20% of patients, which demanded co-administration of anticoagulants. The trial was completed in 2009 and there are no further clinical updates for GSK461364 after the Phase 1 study.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other PLK inhibitors that have been evaluated include rigosertib (Oncova) and CY140 (Cyclacel).  Rigosertib, a non-targeted broad-spectrum multi-kinase inhibitor (RAF, PI3K, PLK), was evaluated for myelodysplastic syndrome (&#8220;MDS&#8221;), and failed to achieve the primary endpoint of overall survival in a Phase 3 trial (2020). CY140, an inhibitor of PLK1,  PLK2 and PLK3, is currently in a phase 1 first-in-human study for advanced leukemias and MDS (2020). </span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The human capital objectives we focus on in managing our business include attracting, developing, and retaining key personnel. Our employees are critical to the success of our organization and we are committed to supporting our employees&#8217; professional development. We believe our management team has the experience necessary to effectively implement our growth strategy and continue to drive shareholder value. We provide competitive compensation and benefits to attract and retain key personnel, while also providing a safe, inclusive and respectful workplace.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2021, we had a total of 12 employees, 11 of whom were full-time. None of our employees are covered by a collective bargaining agreement, and we consider our relations with our employees to be good.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporation Information</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated under the laws of the State of Florida in April 2002. In January&#160;2010, we re-incorporated under the laws of the State of Delaware and changed our name to Trovagene,&#160;Inc. In May&#160;2012, our common stock was listed on The Nasdaq Capital Market under the ticker symbol TROV. In May 2020 we changed our name to Cardiff Oncology, Inc. and our Nasdaq ticker symbol changed to CRDF. Our corporate website address is www.cardiffoncology.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge at www.cardiffoncology.com as soon as reasonably practicable after electronically filing such reports with the Securities and Exchange Commission. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way a part of, this Annual Report on Form 10-K. These reports are also available at www.sec.gov. </span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. An investor should carefully consider the risks described below as well as other information contained in this Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our securities could decline, and investors in our company may lose all or part of their investment.</span></div><div style="text-indent:20.25pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical stage company and may never earn a profit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage company and have incurred losses since our formation. As of December&#160;31, 2020, we have an accumulated total deficit of approximately $231.5 million. For the fiscal years ended December&#160;31, 2020 and 2019, we had a net loss attributable to common stockholders of approximately $22.6 million and $16.7 million, respectively. To date, we have experienced negative cash flow from development of our product candidate,&#160;onvansertib. We have generated limited revenue from operations, and we expect to incur substantial net losses for the foreseeable future as we seek to further develop and commercialize&#160;onvansertib. We cannot predict the extent of these future net losses, or when we may attain profitability, if at all. If we are unable to generate significant revenue from&#160;onvansertib or attain profitability, we will not be able to sustain operations.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing and commercializing&#160;onvansertib, we are unable to predict the extent of any future losses or when we will attain profitability, if ever. We may never become profitable and you may never receive a return on an investment in our common stock. An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of&#160;onvansertib. We may never successfully commercialize&#160;onvansertib, and our business may not be successful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional capital to develop and commercialize&#160;onvansertib&#160;and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, our cash and cash equivalents balance was approximately $131.0 million and our working capital was approximately $127.2 million. Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our current product candidate. We have historically relied upon private and public sales of our equity, as well as debt financings to fund our operations. In order to raise additional capital, we may seek to sell additional equity and/or debt securities or obtain a credit facility or other loan, which we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our product candidate, restrict our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital at acceptable terms would result in a material and adverse impact on our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate,&#160;onvansertib,&#160;is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near-term, failure to successfully advance the development of our product candidate may have a material adverse effect on us. To date, we have not successfully developed or commercially marketed, distributed or sold any product candidate. The success of our business depends primarily upon our ability to successfully advance the development of our product candidate through preclinical studies and clinical trials, have the product candidate approved for sale by the FDA or regulatory authorities in other countries, and ultimately have the product candidate successfully commercialized by us or a strategic partner. We cannot assure you that the results of our ongoing preclinical studies or clinical trials will support or justify the continued development of our product candidate, or that we will receive approval from the FDA, or similar regulatory authorities in other countries, to advance the development of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate must satisfy rigorous regulatory standards of safety and efficacy before we can advance or complete its clinical development or it can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical studies and clinical trials, develop acceptable manufacturing processes, and obtain regulatory approval of our product candidate. Despite these efforts, our product candidate may not:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer therapeutic or other medical benefits over existing drugs or other product candidates in development to treat the same patient population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be proven to be safe and effective in current and future preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the desired effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be free from undesirable or unexpected effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meet applicable regulatory standards;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be capable of being formulated and manufactured in commercially suitable quantities and at an acceptable cost; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be successfully commercialized by us or by collaborators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we demonstrate favorable results in preclinical studies and early-stage clinical trials, we cannot assure you that the results of late-stage clinical trials will be favorable enough to support the continued development of our product candidate. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays, setbacks and failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical testing or early-stage clinical trials. Accordingly, results from completed preclinical studies and early-stage clinical trials of our product candidate may not be predictive of the results we may obtain in later-stage trials. Furthermore, even if the data collected from preclinical studies and clinical trials involving our product candidate demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a NDA or a BLA to obtain regulatory approval from the FDA in the U.S., or other similar regulatory agencies in other jurisdictions, which is required to market and sell the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate will require significant additional research and development efforts, the commitment of substantial financial resources, and regulatory approvals prior to advancing into further clinical development or being commercialized by us or collaborators. We cannot assure you that our product candidate will successfully progress through the drug development process or will result in commercially viable products. We do not expect our product candidate to be commercialized by us or collaborators for at least several years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products or investigational new drugs, which may delay or preclude further development or regulatory approval, or limit their use if approved.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the drug development process, we must continually demonstrate the safety and tolerability of our product candidate to obtain regulatory approval to further advance clinical development or to market it. Even if our product candidate demonstrates biologic activity and clinical efficacy, any unacceptable adverse side effects or toxicities, when administered alone or in the presence of other pharmaceutical products, which can arise at any stage of development, may outweigh potential benefits. In preclinical studies and clinical trials we have conducted to date, our product candidate&#8217;s safety profile is based on studies and trials that have involved a small number of subjects or patients over a limited period of time. We may observe adverse or significant adverse events or drug-drug interactions in future preclinical studies or clinical trial candidates, which could result in the delay or termination of development, prevent regulatory approval, or limit market acceptance if ultimately approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to further advance the development of, and ultimately receive regulatory approval to sell, our product candidate, we must conduct extensive preclinical studies and clinical trials to demonstrate its safety and efficacy to the satisfaction of the FDA or similar regulatory authorities in other countries, as the case may be. Preclinical studies and clinical trials are expensive, complex, can take many years to complete, and have highly uncertain outcomes. Delays, setbacks, or failures can occur at any time, or in any phase of preclinical or clinical testing, and can result from concerns about safety or toxicity, a lack of demonstrated efficacy or superior efficacy over other similar products that have been approved for sale or are in more advanced stages of development, poor study or trial design, and issues related to the formulation or manufacturing process of the materials used to conduct the trials. The results of prior preclinical studies or clinical trials are not necessarily predictive of the results we may observe in later stage clinical trials. In many cases, product candidates in clinical development may fail to show desired safety and efficacy characteristics despite having favorably demonstrated such characteristics in preclinical studies or earlier stage clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience numerous unforeseen events during, or as a result of, preclinical studies and the clinical trial process, which could delay or impede our ability to advance the development of, receive regulatory approval for, or commercialize our product candidate, including, but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">communications with the FDA, or similar regulatory authorities in different countries, regarding the scope or design of a trial or trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities, including an IRB or Ethical Committee (&#8220;EC&#8221;),&#160;not authorizing us to commence or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in our clinical trials being delayed, or proceeding at a slower pace than we expected, because we have difficulty recruiting patients or participants dropping out of our clinical trials at a higher rate than we anticipated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third party contractors, upon whom we rely for conducting preclinical studies, clinical trials and manufacturing of our trial materials, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having to suspend or ultimately terminate our clinical trials if participants are being exposed to unacceptable health or safety risks;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRBs, ECs or regulators requiring that we hold, suspend or terminate our preclinical studies and clinical trials for various reasons, including&#160;non-compliance&#160;with regulatory requirements; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of drug material necessary to conduct our preclinical studies or clinical trials being insufficient, inadequate or unavailable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the data collected from preclinical studies or clinical trials involving our product candidates demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a NDA or BLA to obtain regulatory approval from the FDA in the U.S., or other similar foreign regulatory authorities in foreign jurisdictions, which is required to market and sell the product.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources dedicated to designing, conducting and managing preclinical studies and clinical trials. We intend to rely on third parties, including clinical research organizations, consultants and principal investigators, to assist us in designing, managing, monitoring and conducting our preclinical studies and clinical trials. We intend to rely on these vendors and individuals to perform many facets of the drug development process, including certain preclinical studies, the recruitment of sites and patients for participation in our clinical trials, maintenance of good relations with the clinical sites, and ensuring that these sites are conducting our trials in compliance with the trial protocol, including safety monitoring and applicable regulations. If these third parties fail to perform satisfactorily, or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the preclinical studies and clinical trials of our product candidate may be delayed or prove unsuccessful. Further, the FDA, or other similar foreign regulatory authorities, may inspect some of the clinical sites participating in our clinical trials in the U.S., or our third-party vendors&#8217; sites, to determine if our clinical trials are being conducted according to Good Clinical Practices. If we or the FDA determine that our third-party vendors are not in compliance with, or have not conducted our clinical trials according to, applicable regulations we may be forced to delay, repeat or terminate such clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials of our product candidate and materially harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capacity to recruit and manage the clinical trials necessary to obtain FDA approval or approval by other regulatory authorities. By contrast, larger pharmaceutical and&#160;bio-pharmaceutical&#160;companies often have substantial staff with extensive experience in conducting clinical trials with multiple product candidates across multiple indications. In addition, they may have greater financial resources to compete for the same clinical investigators and patients that we are attempting to recruit for our clinical trials. If potential competitors are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand for&#160;onvansertib.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be at a competitive disadvantage that could delay the initiation, recruitment, timing, completion of our clinical trials and obtaining regulatory approvals, if at all, for our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product candidate that we, or our collaborators, are developing requires regulatory approval to advance through clinical development and to ultimately be marketed and sold, and are subject to extensive and rigorous domestic and foreign government regulation. In the U.S., the FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical and biopharmaceutical products. Our product candidate is also subject to similar regulation by foreign governments to the extent we seek to develop or market it in those countries. We, or our collaborators, must provide the FDA and foreign regulatory authorities, if applicable, with preclinical and clinical data, as well as data supporting an acceptable manufacturing process, that appropriately demonstrate our product candidate&#8217;s safety and efficacy before it can be approved for the targeted indications. Our product candidate has not been approved for sale in the U.S. or any foreign market, and we cannot predict whether we or our collaborators will obtain regulatory approval for any product candidates we are developing or plan to develop. The regulatory review and approval process can take many years, is dependent upon the type, complexity, novelty of, and medical need for the product candidate, requires the expenditure of substantial resources, and involves post-marketing surveillance and vigilance and ongoing requirements for post-marketing studies or Phase&#160;4 clinical trials. In addition, we or our collaborators may encounter delays in, or fail to gain, regulatory approval for our product candidate based upon additional governmental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation resulting from future legislative, administrative action or changes in FDA&#8217;s or other similar foreign regulatory authorities&#8217; policy or interpretation during the period of product development. Delays or failures in obtaining regulatory approval to advance our product candidate through clinical development, and ultimately commercialize them, may: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely impact our ability to raise sufficient capital to fund the development of our product candidate; </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect our ability to further develop or commercialize our product candidate; </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminish any competitive advantages that we or our collaborators may have or attain; and</span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect the receipt of potential milestone payments and royalties from the sale of our products or product revenues.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any regulatory approvals, if granted, may later be withdrawn. If we or our collaborators fail to comply with applicable regulatory requirements at any time, or if post-approval safety concerns arise, we or our collaborators may be subject to restrictions or a number of actions, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays, suspension or termination of clinical trials related to our products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by regulatory authorities to review pending applications or supplements to approved applications;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of manufacturing;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawals of previously approved marketing applications; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, civil penalties and criminal prosecutions.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, at any time we or our collaborators may voluntarily suspend or terminate the preclinical or clinical development of a product candidate, or withdraw any approved product from the market if we believe that it may pose an unacceptable safety risk to patients, or if the product candidate or approved product no longer meets our business objectives. The ability to develop or market a pharmaceutical product outside of the U.S. is contingent upon receiving appropriate authorization from the respective foreign regulatory authorities. Foreign regulatory approval processes typically include many, if not all, of the risks and requirements associated with the FDA regulatory process for drug development and may include additional risks.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the discovery, development and manufacturing of therapeutic compounds. In order to successfully develop our product candidate, we must continuously supplement our research, clinical development, regulatory, medicinal chemistry, virology and manufacturing capabilities through the addition of key employees, consultants or third-party contractors to provide certain capabilities and skill sets that we do not possess.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we have adopted an operating model that largely relies on the outsourcing of a number of responsibilities and key activities to third-party consultants, and contract research and manufacturing organizations in order to advance the development of our product candidate. Therefore, our success depends in part on our ability to retain highly qualified key management, personnel, and directors to develop, implement and execute our business strategy, operate the company and oversee the activities of our consultants and contractors, as well as academic and corporate advisors or consultants to assist us in this regard. We are currently highly dependent upon the efforts of our management team. In order to develop our product candidate, we need to retain or attract certain personnel, consultants or advisors with experience in drug development activities that include a number of disciplines, including research and development, clinical trials, medical matters, government regulation of pharmaceuticals, manufacturing, formulation and chemistry, business development, accounting, finance, regulatory affairs, human resources and information systems. We are highly dependent upon our senior management and scientific staff, particularly Mark Erlander, our Chief Executive Officer (&#8220;CEO&#8221;). The loss of services of Dr. Erlander or one or more of our other members of senior management could delay or prevent the successful completion of our planned clinical trials or the commercialization of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. The competition for qualified personnel in the biotechnology and pharmaceuticals field is intense. We will need to hire additional personnel as we expand our clinical development and commercial activities. While we have not had difficulties recruiting qualified individuals, to date, we may not be able to attract and retain quality personnel on acceptable terms given the competition for such personnel among biotechnology, pharmaceutical and other companies. Although we have not experienced material difficulties in retaining key personnel in the past, we may not be able to continue to do so in the future on acceptable terms, if at all. If we lose any key managers or employees, or are unable to attract and retain qualified key personnel, directors, advisors or consultants, the development of our product candidate could be delayed or terminated and our business may be harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate may not prove to be safe and efficacious in clinical trials and may not meet all the applicable regulatory requirements needed to receive regulatory approval. In order to receive regulatory approval for the commercialization of our product candidate, we must conduct, at our own expense, extensive preclinical testing and clinical trials to demonstrate safety and efficacy of our product candidate for the intended indication of use. Clinical testing is expensive, can take many years to complete, if at all, and its outcome is uncertain. Failure can occur at any time during the clinical trial process.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and early clinical trials of new drugs do not necessarily predict the results of later-stage clinical trials</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of our clinical trials is based on many assumptions about the expected effects of our product candidate, and if those assumptions are incorrect it may not produce statistically significant results. Preliminary results may not be confirmed on full analysis of the detailed results of an early clinical trial. Product candidates in later stages of clinical trials may fail to show safety and efficacy sufficient to support intended use claims despite having progressed through initial clinical testing. The data collected from clinical trials of our product candidate may not be sufficient to support the filing of an NDA or to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated with drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization or achieve sales or profits.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing clinical trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether to offer their patients enrollment in clinical trials of our product candidate versus treating these patients with commercially available drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that our existing product candidate or any product candidate we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with partners; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidate, which would significantly harm our business, results of operations and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidate for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a BLA, or a NDA, to the FDA, or similar drug approval filings to comparable foreign authorities, for our product candidate, and we cannot be certain that our product candidate will be successful in clinical trials or receive regulatory approval. Further, our product candidate may not receive regulatory approval even if it is successful in clinical trials. If we do not receive regulatory approvals for our product candidate, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon our collaborators&#8217; ability to obtain regulatory approval of the companion diagnostics to be used with our product candidates, as well as the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting for our product candidate are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval and to commercialize our product candidate, directly or with a collaborator, worldwide including the United States, the European Union and other additional foreign countries which we have not yet identified. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidate.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administering our product candidate to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval of our product candidate for any or all targeted indications. Ultimately, our product candidate may prove to be unsafe for human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result of participating in our clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a developer of pharmaceuticals, even though we do not intend to make referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse, false claims and patients&#8217; privacy rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse laws and patient privacy laws of both the federal government and the states in which we conduct our business. The laws include:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing information to customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug manufacturing and product marketing, prohibits manufacturers from marketing drug products for&#160;off-label&#160;use and regulates the distribution of drug samples; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our product candidate in the United States. If we fail to obtain FDA approval to market our product candidate, we will be unable to sell our product candidate in the United States and we will not generate any revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s review and approval process, including among other things, evaluation of preclinical studies and clinical trials of a product candidate as well as the manufacturing process and facility, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-designed and well-controlled&#160;pre-&#160;clinical testing and clinical trials that the product candidate is both safe and effective for each indication for which approval is sought. Satisfaction of these requirements typically takes several years and the time needed to satisfy them may vary </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantially, based on the type, complexity and novelty of the pharmaceutical product. We cannot predict if or when we will submit an NDA for approval for our product candidate currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval or may contain significant limitations on the conditions of use.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the NDA review process and may either refuse to file our NDA for substantive review or may decide that our data is insufficient to support approval of our product candidate for the claimed intended uses. Following any regulatory approval of our product candidate, we will be subject to continuing regulatory obligations such as safety reporting, required and additional post marketing obligations, and regulatory oversight of promotion and marketing. Even if we receive regulatory approvals, the FDA may subsequently seek to withdraw approval of our NDA if we determine that new data or a reevaluation of existing data show the product is unsafe for use under the conditions of use upon the basis of which the NDA was approved, or based on new evidence of adverse effects or adverse clinical experience, or upon other new information. If the FDA does not file or approve our NDA or withdraws approval of our NDA, the FDA may require that we conduct additional clinical trials, preclinical or manufacturing studies and submit that data before it will reconsider our application. Depending on the extent of these or any other requested studies, approval of any applications that we submit may be delayed by several years, may require us to expend more resources than we have available, or may never be obtained at all.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be subject to a wide variety of foreign regulations governing the development, manufacture and marketing of our products to the extent we seek regulatory approval to develop and market our product candidate in a foreign jurisdiction. As of the date hereof we have not identified any foreign jurisdictions which we intend to seek approval from. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must still be obtained prior to marketing the product in those countries. The approval process varies and the time needed to secure approval in any region such as the European Union or in a country with an independent review procedure may be longer or shorter than that required for FDA approval. We cannot assure you that clinical trials conducted in one country will be accepted by other countries or that an approval in one country or region will result in approval elsewhere.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition generally from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize any drugs that are safer, more effective, have fewer side effects or are less expensive than our product candidate. These potential competitors compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If approved and commercialized,&#160;onvansertib&#160;would compete with several currently approved prescription therapies for the treatment of AML. To our knowledge, other potential competitors are in earlier stages of development. If potential competitors are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand for&#160;onvansertib.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our ability to compete effectively will depend upon our ability to:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully identify and develop key points of product differentiations from currently available therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully and rapidly complete clinical trials and submit for and obtain all requisite regulatory approvals in a cost-effective manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain a proprietary position for our products and manufacturing processes and other related product technology;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop relationships with physicians prescribing these products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build an adequate sales and marketing infrastructure for our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we will be competing against significantly larger companies with established track records, we will have to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our products, if approved, are competitive with other products. If we are unable to compete effectively and differentiate our products from other marketed drugs, we may never generate meaningful revenue. If a competitor markets the same drug for the treatment of AML, before us, we may not receive orphan drug marketing exclusivity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently possess internal manufacturing capacity. We plan to utilize the services of GMP, FDA validated contract manufacturers to manufacture our clinical supplies. Any curtailment in the availability of&#160;onvansertib,&#160;however, could result in production or other delays with consequent adverse effects on us. In addition, because regulatory authorities must generally approve raw material sources for pharmaceutical products, changes in raw material suppliers may result in production delays or higher raw material costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue API and drug product supply agreements with other manufacturers. We may be required to agree to minimum volume requirements, exclusivity arrangements or other restrictions with the contract manufacturers. We may not be able to enter into long-term agreements on commercially reasonable terms, or at all. If we change or add manufacturers, the FDA and comparable foreign regulators may require approval of the changes. Approval of these changes could require new testing by the manufacturer and compliance inspections to ensure the manufacturer is conforming to all applicable laws and regulations and GMP. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for the production of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products may encounter difficulties in production, particularly in scaling up production. These problems include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state and foreign regulations. In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with conducting our clinical trials and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense or to terminate a clinical trial.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be responsible for ensuring that each of our future contract manufacturers comply with the GMP requirements of the FDA and other regulatory authorities from which we seek to obtain product approval. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The approval process for NDAs includes a review of the manufacturer&#8217;s compliance with GMP requirements. We will be responsible for regularly assessing a contract manufacturer&#8217;s compliance with GMP requirements through record reviews and periodic audits and for ensuring that the contract manufacturer takes responsibility and corrective action for any identified deviations. Manufacturers of our product candidates may be unable to comply with these GMP requirements and with other FDA and foreign regulatory requirements, if any.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will oversee compliance by our contract manufacturers, ultimately we will not have control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of our product candidate is compromised due to a manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of&#160;onvansertib&#160;or other product candidates, entail higher costs or result in us being unable to effectively commercialize our product candidates. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis and at commercially reasonable prices, we may be unable to meet demand for any approved products and would lose potential revenues.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manufacture our product candidate in commercial quantities, which would prevent us from commercializing our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our product candidate has been manufactured in small quantities for preclinical studies and clinical trials. If our product candidate is approved by the FDA or comparable regulatory authorities in other countries for commercial sale, we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will need to manufacture such product candidate in larger quantities. We may not be able to increase successfully the manufacturing capacity for our product candidate in a timely or economic manner, or at all. Significant&#160;scale-up&#160;of manufacturing may require additional validation studies, which the FDA must review and approve. If we are unable to increase successfully the manufacturing capacity for a product candidate, the clinical trials as well as the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in supply. Our product candidate requires precise, high quality manufacturing. Our failure to achieve and maintain these high quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence of manufacturing errors, could result in patient injury or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could harm our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Materials necessary to manufacture our product candidate may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product candidate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on NerPharMa, S.r.l., to purchase from third-party suppliers the materials necessary to produce bulk APIs, and product candidates for our clinical trials, and we will rely on such manufacturers to purchase such materials to produce the APIs and finished products for any commercial distribution of our products if we obtain marketing approval. Suppliers may not sell these materials to our manufacturers at the time they need them in order to meet our required delivery schedule or on commercially reasonable terms, if at all. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. Moreover, we currently do not have any agreements for the production of these materials. If our manufacturers are unable to obtain these materials for our clinical trials, testing of the affected product candidate would be delayed, which may significantly impact our ability to develop the product candidate. If we or our manufacturers are unable to purchase these materials after regulatory approval has been obtained for one of our products, the commercial launch of such product would be delayed or there would be a shortage in supply of such product, which would harm our ability to generate revenues from such product and achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidate is approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product by physicians, healthcare professionals and third-party payors and our profitability and growth will depend on a number of factors, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of safety and efficacy;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the practice guidelines and the standard of care for the targeted indication;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">budget impact of adoption of our product on relevant drug formularies and the availability, cost and potential advantages of alternative treatments, including less expensive generic drugs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing, reimbursement and cost effectiveness, which may be subject to regulatory control;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of our or any of our partners&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product labeling or product insert required by the FDA or regulatory authority in other countries; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party insurance coverage or reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be substantially reduced. In addition, our efforts to educate the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">medical community and third-party payors on the benefits of our product candidates may require significant resources, may be constrained by FDA rules&#160;and policies on product promotion, and may never be successful.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guidelines and recommendations published by various organizations can impact the use of our product.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our product. In addition, professional societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the healthcare and patient communities. Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients and healthcare providers could result in decreased use of our proposed product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party contract manufacturers upon whom we rely to formulate and manufacture our product candidate do not perform, fail to manufacture according to our specifications or fail to comply with strict regulations, our preclinical studies or clinical trials could be adversely affected and the development of our product candidate could be delayed or terminated or we could incur significant additional expenses.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate any manufacturing facilities. We intend to rely on GMP, FDA validated third-party contractors, at least for the foreseeable future, to formulate and manufacture these preclinical and clinical materials. Our reliance on third-party contract manufacturers exposes us to a number of risks, any of which could delay or prevent the completion of our preclinical studies or clinical trials, or the regulatory approval or commercialization of our product candidate, result in higher costs, or deprive us of potential product revenues. Some of these risks include:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors failing to develop an acceptable formulation to support later-stage clinical trials for, or the commercialization of, our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers failing to manufacture our product candidate according to their own standards, our specifications, CGMPs, or otherwise manufacturing material that we or the FDA may deem to be unsuitable in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers being unable to increase the scale of, increase the capacity for, or reformulate the form of our product candidate. We may experience a shortage in supply, or the cost to manufacture our products may increase to the point where it adversely affects the cost of our product candidate. We cannot assure you that our contract manufacturers will be able to manufacture our products at a suitable scale, or we will be able to find alternative manufacturers acceptable to us that can do so;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers placing a priority on the manufacture of their own products, or other customers&#8217; products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers failing to perform as agreed or not remain in the contract manufacturing business; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers&#8217; plants being closed as a result of regulatory sanctions or a natural disaster.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of pharmaceutical products are subject to ongoing periodic inspections by the FDA, the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) and corresponding state and foreign agencies to ensure strict compliance with&#160;FDA-mandated&#160;current good marketing practices or CGMPs, other government regulations and corresponding foreign standards. While we are obligated to audit their performance, we do not have control over our third-party contract manufacturers&#8217; compliance with these regulations and standards. Failure by our third-party manufacturers, or us, to comply with applicable regulations could result in sanctions being imposed on us or the drug manufacturer from the production of other third-party products. These sanctions may include fines, injunctions, civil penalties, failure of the government to grant&#160;pre-market&#160;approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization of our product candidate could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to regulatory restrictions inherent in an IND, NDA or BLA, various steps in the manufacture of our product candidate may need to be sole-sourced. In accordance with CGMPs, changing manufacturers may require the&#160;re-validation&#160;of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing processes and procedures, and may require further preclinical studies or clinical trials to show comparability between the materials produced by different manufacturers. Changing our current or future contract manufacturers may be difficult for us and could be costly, which could result in our inability to manufacture our product candidate for an extended period of time and therefore a delay in the development of our product candidate. Further, in order to maintain our development time lines in the event of a change in our third-party contract manufacturer, we may incur significantly higher costs to manufacture our product candidate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently have any internal drug discovery capabilities, and therefore we are dependent on&#160;in-licensing&#160;or acquiring development programs from third parties in order to obtain additional product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future we decide to further expand our pipeline, we will be dependent on&#160;in-licensing&#160;or acquiring product candidates as we do not have significant internal discovery capabilities at this time. Accordingly, in order to generate and expand our development pipeline, we have relied, and will continue to rely, on obtaining discoveries, new technologies, intellectual property and product candidates from third-parties through sponsored research,&#160;in-licensing&#160;arrangements or acquisitions. We may face substantial competition from other biotechnology and pharmaceutical companies, many of which may have greater resources then we have, in obtaining these&#160;in-licensing,&#160;sponsored research or acquisition opportunities. Additional&#160;in-licensing&#160;or acquisition opportunities may not be available to us on terms we find acceptable, if at all.&#160;In-licensed&#160;compounds that appear promising in research or in preclinical studies may fail to progress into further preclinical studies or clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose us to significant product liability claims. We have product liability insurance coverage for our proposed clinical trials; however, such insurance coverage may not protect us against any or all of the product liability claims that may be brought against us now or in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim brought successfully against us. In the event our product candidate is approved for sale by the FDA and commercialized, we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we materially breach or default under the Nerviano Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is substantially dependent upon certain intellectual property rights that we license from Nerviano. Therefore, our commercial success will depend to a large extent on our ability to maintain and comply with our obligations under the Nerviano Agreement. The Nerviano Agreement provides the right to terminate for an uncured breach by us, or if we are insolvent or the subject of a bankruptcy proceeding, or potentially other reasons. We expect that other technology&#160;in-licenses&#160;that we may enter into in the future will contain similar provisions and impose similar obligations on us. If we fail to comply with any such obligations such licensor will likely terminate their&#160;out-licenses&#160;to us, in which case we would not be able to market products covered by these licenses, including our&#160;onvansertib&#160;asset. The loss of our license with Nerviano with respect to onvansertib,&#160;and potentially other licenses that we enter into in the future, would have a material adverse effect on our business. In addition, our failure to comply with obligations under our material&#160;in-licenses&#160;may cause us to become subject to litigation or other potential disputes under any such license agreements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Nerviano Agreement requires us to make certain payments, including license fees, milestone payments, royalties, and other such terms typically required under licensing agreements and these types of technology&#160;in-licenses&#160;generally could make it difficult for us to find corporate partners and less profitable for us to develop product candidates utilizing these existing product candidates and technologies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may delay or terminate the development of our product candidate at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the results of preclinical studies and clinical trials that have been conducted or may conduct in the future may support further development of our product candidate, we may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons, including the determination or belief that the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">emerging profile of the product candidate is such that it may not receive FDA approval, gain meaningful market acceptance, generate a significant return to shareholders, or otherwise provide any competitive advantages in its intended indication or market.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a small company with 13 employees as of December 31, 2020. Future growth of our company will impose significant additional responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel. We may increase the number of employees in the future depending on the progress of our development of our product candidate. Our future financial performance and our ability to commercialize our product candidate and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical studies effectively;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative, manufacturing and regulatory personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire and train additional qualified personnel.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that we will be able to accomplish these tasks, and our failure to accomplish any of them could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our operations, and those of our third-party manufacturers, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or&#160;man-made&#160;disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our corporate headquarters are located in San Diego, California, an area prone to wildfires and earthquakes. These and other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Any disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, could have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, we rely on a third-party manufacturer, which is located in Italy,&#160;to manufacture API for our product candidate. Any disruption in production or inability of our manufacturer in Italy to produce&#160;or ship&#160;adequate quantities to meet our needs, whether as a result of a natural disaster or other causes (such as the recent outbreak of the coronavirus in Italy), could impair our ability to operate our business on a day-to-day basis and to continue our research and development of our product candidate. In addition, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Italian governments, political unrest or unstable economic conditions in Italy. Any recall of the manufacturing lots or similar action regarding our API used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidate and impair our competitive position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is essential to our business strategy that our technology and network infrastructure and our physical buildings remain secure and are perceived by our customers and corporate partners to be secure. Despite security measures, however, any </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">network infrastructure may be vulnerable to cyber-attacks by hackers and other security threats. We may face cyber-attacks that attempt to penetrate our network security, sabotage or otherwise disable our research, products and services, misappropriate our or our customers&#8217; and partners&#8217; proprietary information, which may include personally identifiable information, or cause interruptions of our internal systems and services. Despite security measures, we also cannot guarantee security of our physical buildings. Physical building penetration or any cyber-attacks could negatively affect our reputation, damage our network infrastructure and our ability to deploy our products and services, harm our relationship with customers and partners that are affected, and expose us to financial liability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are a number of state, federal and international laws protecting the privacy and security of health information and personal data. For example, HIPAA imposes limitations on the use and disclosure of an individual&#8217;s healthcare information by healthcare providers, healthcare clearinghouses, and health insurance plans, or, collectively, covered entities, and also grants individuals rights with respect to their health information. HIPAA also imposes compliance obligations and corresponding penalties for&#160;non-compliance on individuals and entities that provide services to healthcare providers and other covered entities. As part of the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;), the privacy and security provisions of HIPAA were amended. ARRA also made significant increases in the penalties for improper use or disclosure of an individual&#8217;s health information under HIPAA and extended enforcement authority to state attorneys general. As amended by ARRA and subsequently by the final omnibus rule adopted in 2013, HIPAA also imposes notification requirements on covered entities in the event that certain health information has been inappropriately accessed or disclosed: notification requirements to individuals, federal regulators, and in some cases, notification to local and national media. Notification is not required under HIPAA if the health information that is improperly used or disclosed is deemed secured in accordance with encryption or other standards developed by the U.S. Department of Health and Human Services. Most states have laws requiring notification of affected individuals and/or state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms, to ensure ongoing protection of personal information. Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for&#160;non-compliance.&#160;We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate problems caused by such breaches.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General economic or business conditions may have a negative impact on our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continuing concerns over U.S. healthcare reform legislation and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the U.S. and other countries have contributed to increased volatility and diminished expectations for the global economy. If the economic climate does not improve, or if it deteriorates, our business, including our access to patient samples and the addressable market for tests that we may successfully develop, as well as the financial condition of our suppliers and our third-party payors, could be negatively impacted, which could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities currently require the controlled use of potentially harmful biological materials and chemicals. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations may become significant and could materially adversely affect our business, prospects and financial condition. Moreover, in the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits or approvals or be held liable for damages or penalized with fines.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. In 2010, the PPACA was enacted, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act&#8221;;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the AMP;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the PPACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the PPACA. During President Trump's administration, he signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed repeal legislation, the TCJA includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Congress may consider other legislation to repeal or replace elements of the PPACA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would have on our business remains unclear. In particular, there is uncertainty surrounding the applicability of the biosimilars provisions under the PPACA to our product candidates. The FDA has issued several guidance documents, but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. It is not certain that we will receive 12 years of biologics marketing exclusivity for any of our products. The regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way we conduct our business and may require us to change current strategies. A biosimilar is a biological product that is highly similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and to encourage importation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare and Medicaid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ability to generate revenues. Increases in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure on our ability to profitably price our products, which, in turn, could adversely affect our business, results of operations, financial condition and prospects. We might elect not to seek approval for or market our products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue we generate from our product sales. It is also possible that other legislative proposals having similar effects will be adopted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The outbreak of the novel coronavirus disease, COVID-19, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the World Health Organization declared the outbreak of COVID-19 as a &#8220;Public Health Emergency of International Concern,&#8221; which continues to spread throughout the world and has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The COVID-19 outbreak and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. We continue to monitor the impact of the COVID-19 outbreak closely. The extent to which the COVID-19 outbreak will impact our operations or financial results is uncertain.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outbreak and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material adverse effect on our business, financial condition and results of operations. As a result of the COVID-19 pandemic, we may experience disruptions that could severely impact our business and clinical trials, including:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in enrolling and retaining patients in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures (such as endoscopies that are deemed non-essential), which may impact the integrity of subject data and clinical study endpoints;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;<br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of, or delays in receiving, supplies of our product candidate from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption or delays to our sourced clinical activities; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in clinical site procedures and requirements as well as regulatory requirements for conducting clinical trials during the pandemic.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the COVID-19 virus. For example, in March 2020, the FDA issued guidance, which FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19 pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to evolve rapidly, with the status of operations and government restrictions evolving weekly. The extent to which the outbreak impacts our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic, the ultimate geographic spread of the disease, additional or modified government actions, new information that will emerge concerning the severity and impact of COVID-19 and the actions taken to contain COVID-19 or address its impact in the short and long term, among others. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business could be materially adversely affected by other business disruptions to us or our third-party providers that could materially adversely affect our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those of our contract research organizations ("CROs"), contract manufacturing organizations ("CMOs"), and other contractors, consultants and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidate. Our ability to obtain clinical supplies of our product candidate could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as a combination of trademark, copyright and trade secret protection, and other contractual restrictions, to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We may not be successful in defending challenges made in connection with our patents and patent applications. If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patents, we rely on contractual restrictions to protect our proprietary technology. We require our employees and third parties to sign confidentiality agreements and our employees are also required to sign agreements assigning to us all intellectual property arising from their work for us. Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual property rights. Any failure to protect our intellectual property rights could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently pending or future patent applications may not result in issued patents and any patents issued to us may be challenged, invalidated or held unenforceable. Furthermore, we cannot be certain that we were the first to make the invention claimed in our issued patents or pending patent applications in the U.S., or that we were the first to file for protection of the inventions claimed in our foreign issued patents or pending patent applications. In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO, which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, in September 2011, the U.S. enacted sweeping changes to the U.S. patent system under the Leahy-Smith America Invents Act, including changes that transitioned the U.S. from a&#160;&#8220;first-to-invent&#8221;&#160;system to a&#160;&#8220;first-to-file&#8221;&#160;system and alter the processes for challenging issued patents. These changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, we may become subject to interference proceedings conducted in the patent and trademark offices of various countries to determine our entitlement to patents, and these proceedings may conclude that other patents or patent applications have priority over our patents or patent applications. It is also possible that a competitor may successfully challenge our patents through various proceedings and those challenges may result in the elimination or narrowing of our patents, and therefore reduce our patent protection. Accordingly, rights under any of our issued patents, patent applications or future patents may not provide us with commercially meaningful protection for our products or afford us a commercial advantage against our competitors or their competitive products or processes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patents issued to us may not be broad enough to provide any meaningful protection, one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to protect our proprietary technology, trade secrets and&#160;know-how,&#160;our competitors may use our inventions to develop competing products. Our patents may not protect us against our competitors, and patent litigation is very expensive. We may not have sufficient cash available to pursue any patent litigation to its conclusion because we currently do not generate revenues other than licensing, milestone and royalty income.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot rely solely on our current patents to be successful. The standards that the USPTO and foreign patent offices use to grant patents, and the standards that U.S. and foreign courts use to interpret patents, are not the same, are not always applied predictably or uniformly and can change, particularly as new technologies develop. As such, the degree of patent protection obtained in the U.S. may differ substantially from that obtained in various foreign countries. In some instances, patents have been issued in the U.S. while substantially less or no protection has been obtained in Europe or other countries.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain of the level of protection, if any, that will be provided by our patents if they are challenged in court, where our competitors may raise defenses such as invalidity, unenforceability or possession of a valid license. In addition, the type and extent of any patent claims that may be issued to us in the future are uncertain. Any patents that are issued may not contain claims that will permit us to stop competitors from using similar technology.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may challenge the validity of our patents and other intellectual property rights, resulting in costly litigation or other time-consuming and expensive proceedings, which could deprive us of valuable rights. If we become involved in any intellectual property litigation, interference or other judicial or administrative proceedings, we will incur substantial expenses and the attention of our technical and management personnel will be diverted. An adverse determination may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, if such claims are proven valid, through litigation or otherwise, we may be required to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the affected products and intellectual property rights.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications and could further require us to obtain rights to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued patents covering such technologies. There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our potential products or processes. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our U.S. patent position with respect to such inventions. In addition, we cannot assure you that we would prevail in any of these suits or that the damages or other remedies that we are ordered to pay, if any, would not be substantial. Claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties that may not be available on acceptable terms, if at all. We may also be subject to injunctions against the further development and use of our technology, which could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could materially adversely affect our ability to raise the funds necessary to continue our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain rights that we in-license from third-parties are not within our control, and we may be negatively impacted if we lose those rights.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license some of the technology that is necessary for our products and services from third parties. In connection with such&#160;in-licenses,&#160;we may agree to pay the licensor royalties based on sales of our products, which become a cost of product revenues and impact the margins on our products and services. We may need to&#160;in-license&#160;other technologies in the future to commercialize on our products and services. We may also need to negotiate licenses after launching our products and services. Our business may suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid, or if we are unable to enter into necessary licenses on acceptable terms.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards allow companies to use past year net operating losses to offset against future years&#8217; profits, if any, to reduce future tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986 limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. federal income tax reform could adversely affect us.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, President Trump signed into law the &#8220;Tax Cuts and Jobs Act&#8221; (&#8220;TCJA&#8221;) that significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. We do not expect tax reform to have a material impact to our projection of minimal cash taxes or to our net operating losses. Further, any eligibility we may have or may someday have for tax credits associated with the qualified clinical testing expenses arising out of the development of orphan drugs will be reduced to 25% as a result of the TCJA; thus, our net future taxable income may be affected. We continue to examine the impact this tax reform legislation may have on our business. The impact of this tax reform on holders of our common stock is uncertain and could be adverse. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rights of the holders of our common stock may be impaired by the potential issuance of preferred stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation gives our board of directors the right to create one or more new series of preferred stock. As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights that could adversely affect the voting power and equity interests of the holders of our common stock. Preferred stock, which could be issued with the right to more than one vote per share, could be used to discourage, delay or prevent a change of control of our company, which could materially adversely affect the price of our common stock. Without the consent of the holders of the outstanding shares of our Series A Convertible Preferred Stock, we may not adversely alter or change the rights of the holders of the Series A Convertible Preferred Stock or increase the number of authorized shares of Series A Convertible Preferred Stock, create a class of stock that is senior to or on parity with the Series A Convertible Preferred Stock, amend our certificate of incorporation in breach of these provisions or agree to any of the foregoing.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time. For example, during the year ended December&#160;31, 2020, the closing price of our common stock ranged from a low of $0.74 to a high of $24.71. These fluctuations may be due to various factors, many of which are beyond our control, including:</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations or new products and services introduced by us or our competitors;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results relating to our tests or those of our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements or press releases relating to the industry or to our own business or prospects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement decisions by third party payors, such as Medicare and other managed care organizations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulation and oversight of our product candidates and services, including by the FDA, Centers for Medicare &amp; Medicaid Services and comparable foreign agencies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of partnerships with clinical reference laboratories;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property disputes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate operations, technology, products and services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute our business plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating results below expectations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of any strategic relationship;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry developments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease outbreaks, such as the recent COVID-19 pandemic; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, market fluctuations, as well as general political and economic conditions, could materially adversely affect the market price of our securities. Because we are a development stage company with no revenue from operations to date, other than licensing, milestone and royalty income, you should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the foregoing.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid any cash dividends on our common stock. We expect that any income received from operations will be devoted to our future operations and growth. We do not expect to pay cash dividends on our common stock in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors that our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor&#8217;s investment will only occur if our stock price appreciates. In addition, the terms of the Series A Convertible Preferred Stock prohibit us from paying dividends to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid. Investors in our common stock should not rely on an investment in our company if they require dividend income.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control of our company or changes in our management. For example, our board of directors has the authority to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the powers, preferences and rights of each series without stockholder approval. The ability to issue preferred stock could discourage unsolicited acquisition proposals or make it more difficult for a third party to gain control of our company, or otherwise could materially adversely affect the market price of our common stock.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware. This provision may prohibit or restrict large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us, which could discourage potential takeover attempts, reduce the price that investors may be willing to pay for shares of our common stock in the future and result in our market price being lower than it would without these provisions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance transactions resulting in a large amount of newly issued shares that become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of our common stock. In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our stockholders sell, or the market perceives that our stockholders may sell for various reasons, including the ending of restriction on resale, substantial amounts of our common stock in the public market, including shares issued upon the exercise of outstanding options or warrants, the market price of our common stock could fall. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to stockholder litigation, thereby diverting our resources, which could materially adversely affect our profitability and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock is characterized by significant price volatility, and we expect that our share price will continue to be at least as volatile for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price for its securities. In addition, stockholders may bring actions against companies relating to past transactions or other matters. Any such actions could give rise to substantial damages and thereby materially adversely affect our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with stockholder actions could materially adversely affect our business, prospects and financial condition. Litigation can be costly, time-consuming and disruptive to business operations. The defense of lawsuits could also result in diversion of our management&#8217;s time and attention away from business operations, which could harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the continued minimum closing bid requirements of the Nasdaq or other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not maintain compliance with Nasdaq requirements for continued listing or fail to comply with other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. A delisting of our common stock from The Nasdaq Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2689"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the rules under the Sarbanes-Oxley Act, related to disclosure controls and procedures, or if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important in helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly. We previously identified a material weakness in our internal control over financial reporting, which was subsequently remedied. We cannot be certain that additional material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company and our management expects to continue to devote substantial time to public company compliance programs.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC, and the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;). The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. For example, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (&#8220;Dodd-Frank Act&#8221;) was enacted. There is significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that have required the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. Our management and other personnel devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and, as a result of the new corporate governance and executive compensation related rules, regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules and regulations will continue to cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease laboratory and office space for our headquarters in San Diego, California under a lease agreement, as amended from time to time, that expires in December 2021. We (as a sublessor) also sublease portions of our facility to third parties under three separate subleases. We believe that our facilities are adequate for our current and near-term needs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm our business. As of the date of this report, management believes that there are no claims against us, which it believes will result in a material adverse effect on our business or financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.  MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has traded on The Nasdaq Capital Market under the symbol &#8220;CRDF&#8221; since May 8, 2020, and was previously traded as &#8220;TROV&#8221; from May 30, 2012 to May 7, 2020.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;18, 2021, we had approximately 58 stockholders of record of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have not paid any dividends to the holders of shares of our common stock and we do not expect to pay any such dividends in the foreseeable future as we expect to retain our future earnings for use in the operation and expansion of our business. Pursuant to the terms of our outstanding shares of Series A Convertible Preferred Stock, dividends cannot be paid to the holders of shares of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12 of Part III of this Annual Report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.  SELECTED FINANCIAL DATA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="text-align:center"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage biotechnology company, developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, extend duration of response and increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed onvansertib from Nerviano Medical Sciences ("NMS") pursuant to a license agreement with NMS dated March 13, 2017. This exclusive, world-wide license agreement includes 3 issued patents for onvansertib which cover composition of matter, salt forms of onvansertib and combination of onvansertib with other drugs. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is highly potent against the PLK1 enzyme (concentration for 50% inhibition [IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">] = 2nM), whereas low or no activity was observed on a panel of 63 kinases (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&gt;10 &#956;M).  Onvansertib was developed to have ideal pharmacokinetics, including oral bioavailability and administration and a drug half-life of approximately 24 hours, allowing for flexible dosing and scheduling, and is well tolerated and safe with only mild to moderate side effects reported to-date. A Phase 1 safety study of onvansertib was successfully completed in patients with advanced metastatic solid tumors and published in 2017 in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigational New Drugs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PLK1, a serine/threonine kinase, is a master regulator of mitotic progression with various roles and localizations during the different mitotic phases. Upon PLK1 depletion in cancer cells by RNA interference ("RNAi"), inhibition of proliferation and decreased viability, resulting from cell cycle arrest with 4N DNA content followed by apoptosis, are observed. PLK1 depletion also results in an increase in the number of cells containing abnormal spindle formation and misaligned chromosomes. Expression of PLK1 is seen in all proliferating normal tissues, and PLK1 is overexpressed in a number of tumors (including breast, prostate, ovary, lung, gastric and colon cancers), as well as in hematologic cancers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a measure concentration for 50% target inhibition) below 100 nM in 75 cell lines and IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> values below 1 uM in 133 out of 148 cell lines. Onvansertib also appears active in cells expressing multi-drug resistant (&#8220;MDR&#8221;) transporter proteins and we believe its apparent ability to overcome the MDR transporter resistance mechanism in cancer cells could prove useful in broader drug combination applications.  Additionally, onvansertib has been tested in in-vivo xenograft and transgenic models of different cancer types with the demonstration of tumor growth inhibition or tumor regression.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib has been evaluated preclinically in combination with several different chemotherapies, including irinotecan, cisplatin, cytarabine, doxorubicin, gemcitabine and paclitaxel, and with targeted therapeutics such as abiraterone, histone deacetylase ("HDAC") inhibitors, fms-like tyrosine kinase 3 ("FLT3") inhibitors, and bortezomib. These therapies are used clinically for the treatment of many hematologic and solid cancers, including acute myeloid leukemia ("AML"), non-Hodgkin&#8217;s lymphoma ("NHL"), metastatic CRC, metastatic castration resistant prostate cancer ("mCRPC"), adrenocortical carcinoma ("ACC"), triple negative breast cancer ("TNBC"), small cell lung cancer ("SCLC"), and ovarian cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the high-selectivity of onvansertib to PLK1, its 24-hour half-life and oral bioavailability, as well as its demonstrated safety and tolerability, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Clinical Program Updates</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have three active clinical trials: </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-054 is a Phase 1b/2 open-label clinical trial of onvansertib in combination with FOLFIRI and bevacizumab ("Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at 6 clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota and Florida), Kansas University Medical Center ("KUMC") and CARTI Cancer Center; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-053 is a Phase 2 open-label clinical trial of onvansertib in combination with abiraterone acetate (Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and prednisone in patients with mCRPC, which is being conducted at Beth Israel Deaconess Medical Center ("BIDMC"), Dana-Farber Cancer Institute ("DFCI"), and Massachusetts General Hospital ("MGH"); </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TROV-052 is a Phase 2 open-label clinical trial of onvansertib in combination with standard-of-care chemotherapy, decitabine, in patients with relapsed or refractory AML, which is being conducted at nine sites across the U.S. The Phase 1b portion of the AML trial was completed in the fourth quarter of 2019 and enrollment in Phase 2 was completed in October 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 study of onvansertib for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer ("mCRC") in combination with standard-of-care FOLFIRI and bevacizumab (Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this study is to evaluate the dose-limiting toxicities ("DLTs") and maximum tolerated dose ("MTD") or recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab (Phase 2).</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this clinical trial is based on three key principles including synthetic lethality, synergy and proof-of-concept clinical benefit. Synthetic lethality arises when a combination of deficiencies in the expression of two genes leads to cell death, whereas a deficiency in only one of these genes does not. The deficiencies can arise through mutations, epigenetic alterations or inhibitors of the protein encoded by one of the genes. In reference to onvansertib, CRC tumor cells harboring KRAS mutations are more vulnerable to cell death with PLK1 inhibition versus KRAS wild-type isogenic cells. Synergy occurs when the combination of two drugs results in an unexpected greater activity than an expected additive effect of the two drugs. Onvansertib in combination with irinotecan and 5-FU (components of FOLFIRI) demonstrate synergy in colorectal cancer cell lines and the combination has demonstrated significantly greater tumor growth inhibition than either drug alone.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proof-of-concept clinical response has been demonstrated in a previously completed Phase 1 trial in solid tumors in which 3 of 5 patients showing stable disease had a KRAS mutation; 2 in colorectal cancer and 1 in pancreatic cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on January 15, 2021, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (&#8220;ASCO-GI&#8221;), demonstrated the safety and efficacy of onvansertib. Of the 12 patients evaluable for efficacy, 5 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42%) achieved a partial response (PR); 4 patients had a confirmed PR; 1 patient went on to curative surgery; 1 patient with a non-confirmed PR went off study due to an unrelated event prior to their 16-week confirmatory scan. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8 (67%) patients showed a durable response to treatment of &gt;6 months with a range from 6.1 to 13.7 months. Time to achieving a PR ranges from 2 to 6 months in patients on treatment. 10 of 12 patients had a KRAS variant detected by ddPCR at baseline (all had a KRAS mutation detected by NGS). Clinical responses were observed across different KRAS variants, including the 3 most common in CRC. The greatest decreases in KRAS mutant allelic frequency (MAF) after 1 cycle of treatment were observed in patients achieving a PR (ranging from -78% to -100%), while the 2 patients who progressed showed a more modest reduction in KRAS MAF (-55% and -26%). Patients with PR and stable disease (SD) tended to have lower on-treatment KRAS MAF than patients with early progressive disease (PD). Onvansertib in combination with FOLFIRI/bevacizumab is safe and well tolerated with only 9% of all adverse events (AEs) being grade 3 or 4. Grade 4 adverse events were attributed to the 5-FU bolus component of the combination regimen, which was eliminated in subsequent cycles of treatment per protocol and institutional guidelines. The only G3/G4 AEs reported in &#8805;2 patients were neutropenia (n=8), which were managed by dose delay, growth factor therapy and/or discontinuation of the 5-FU bolus; no patients went off trial due to neutropenia. No major or unexpected toxicities were attributed to onvansertib.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Key News Releases</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 15, 2021, we announced an electronic poster presentation of clinical data further demonstrating the clinical benefit of onvansertib in KRAS-mutate mCRC and initial findings from our Expanded Access Program (EAP) in mCRC.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2020, we announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response of onvansertib in KRAS-mutated mCRC patients at the European Society of Medical Oncology ("ESMO") Virtual Congress 2020.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 9, 2020, we announced the initiation of our Expanded Access Program ("EAP") for onvansertib, in combination with standard-of-care FOLFIRI and bevacizumab, for second-line treatment of patients with KRAS-mutated mCRC. This announcement followed the FDA granting Fast Track Designation for onvansertib in KRAS-mutated mCRC.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">mCRPC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-053 is a Phase 2 study of onvansertib in combination with Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (abiraterone) and prednisone for the treatment of patients with metastatic castration resistant prostate cancer ("mCRPC").</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of this study is to observe the effects of onvansertib in combination with abiraterone and prednisone on disease control as assessed by prostate specific antigen ("PSA") decline or stabilization after 12 weeks of study treatment in patients with mCRPC showing early signs of resistance to abiraterone.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rationale for this trial is based on the mechanism of action ("MOA") of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the synergy of these two drugs when used in combination. Onvansertib inhibits tumor cell division (mitosis) by inducing G2/M arrest of tumor cells and the combination of onvansertib and Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> significantly increases mitotic arrest and is synergistic when used in combination.  Additionally, PLK1 inhibition appears to enhance the efficacy of androgen signaling blockade in castration-resistant prostate cancer.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on February 11, 2021, at the American Society of Clinical Oncology Genitourinary Cancers Symposium (&#8220;ASCO-GU&#8221;) demonstrated safety and efficacy of onvansertib in combination with abiraterone. Arms A (n=17) and B (n=12) showed similar efficacy with 29% and 25% of patients achieving the primary endpoint and 53% and 42% of patients with SD at 12 weeks, respectively. The more continuous dosing schedule of Arm C (n=8) has shown a higher response rate with 63% of patients, to-date, achieving the primary endpoint and 75% with SD at 12 weeks. Efficacy was observed in patients harboring AR alterations across all 3 arms. ctDNA analysis revealed differences in baseline genomic profiles of patients achieving SD at 12 weeks vs patients progressing before or at 12 weeks. Mutations exclusively present in patients with SD were associated with cell cycle and DNA repair pathways that may result in increased sensitivity to onvansertib and efficacy of the combination. Onvansertib + abiraterone has demonstrated safety across all 3 dosing schedules.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key News Releases</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On February 11, 2021, we announced an electronic poster presentation of clinical data further demonstrating the safety, efficacy and durability of response in patient with mCRPC at the American Society of Clinical Oncology Genitourinary Cancers Symposium (&#8220;ASCO-GU&#8221;).</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">AML</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-052 is a Phase 2 Study of onvansertib in combination with standard-of-care chemotherapy, decitabine, for the treatment of patients with relapsed or refractory acute myeloid leukemia ("AML").  The Phase 1b portion of this trial was completed in the fourth quarter of 2019.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to evaluate the DLTs and MTD or RP2D of onvansertib (Phase 1b &#8211; completed in October 2019). In Phase 2, the objective is to assess the safety, tolerability and preliminary efficacy of the combination of onvansertib at the RP2D and decitabine in patients with relapsed or refractory AML (Phase 2 enrollment completed in October 2020). Additionally, as a correlative objective, this trial is evaluating potential pharmacodynamic ("PD") and diagnostic biomarkers of onvansertib in patients with AML. We were granted Orphan Drug Designation ("ODD") for onvansertib for the treatment of AML from the FDA and the European Commission.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on December 6, 2020 at the 62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> American Society of Hematology ("ASH") conference, demonstrated the safety, tolerability and anti-leukemic activity of onvansertib in combination with decitabine in patients with difficult-to-treat relapsed/refractory AML. Nine of 45 (20%) patients achieved a complete remission with or without hematologic count recovery (CR/CRi &#8211; 5 in Phase 1b and 4 in Phase 2); 55% of responders had a mutation in a splicing factor. Two patients proceeded to transplant following CR and four patients remain on treatment with duration of response of 9, 10, 17 and 20 months, respectively. Together with data demonstrating the safety and tolerability of the combination therapy, these findings highlight onvansertib&#8217;s potential to address critical unmet needs in hematologic malignancies.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Key News Releases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 6, 2020, we announced an electronic poster presentation of data from the Phase 1b/2 trial in AML demonstrating the safety and efficacy of onvansertib in relapsed or refractory patients at the annual American Society of Hematology (&#8220;ASH&#8221;) conference.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Financial and Company Updates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Financial</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On September 29, 2020 we announced pricing of an underwritten public offering of 6,500,000 shares of our common stock at a price of $13.50 per share. The underwriters had an option to purchase an additional 975,000 shares, which was exercised in full. The offering was completed on October 2, 2020 and the gross proceeds were $100.9 million. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:103%">Company</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2020 we announced that Dr. Thomas Adams has stepped down from his positions as Executive Chairman and Chairman of the Board of Directors and will continue to serve as a Director. Dr. Rodney Markin was appointed by the Board of Directors as our new Chairman of the Board.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020 we changed our company name from Trovagene, Inc. to Cardiff Oncology, Inc., and our Nasdaq ticker symbol to &#8216;CRDF.&#8217; The web address for the Cardiff Oncology website is www.cardiffoncology.com. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020 Mark Erlander, PhD, assumed the role of Chief Executive Officer and Thomas Adams, PhD, transitioned from Chief Executive Officer and Chairman to Executive Chairman.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 22, 2020, we announced the election of three new independent Directors to our Board of Directors; Dr. James Armitage, Dr. Gary Pace and Ms. L&#226;le White. Each new Director brings extensive and relevant experience to our company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated deficit through December&#160;31, 2020 is $231,495,279.&#160;To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drugs.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:29.25pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in Part II, Item 8. Financial Statements&#8212;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. We believe that the following discussion represents our critical accounting policies.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development expenditures as incurred, which include costs related to clinical trial activities. We accrue costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December 31, 2020 our clinical trial accrual balance of $1,683,195 is included in accrued liabilities and other liabilities. Our related 2020 clinical trial expenses are included in research and development expense of $11,235,396. Certain accrued clinical trial expenses are released from service receivables classified within equity as clinical trial services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#8217; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of our Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;gain (loss) from changes in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. Accordingly, the fair value of the warrants is sensitive to changes in these estimates.&#160;At December&#160;31, 2020 and 2019, the fair value of such warrants was $284,971 and $4,127, respectively, and was recorded as a liability under the caption &#8220;derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants&#8221; on the balance sheet.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period. We estimate the grant date fair value using a Black-Scholes model. Stock-based compensation recorded in our statement of operations is based on awards expected to ultimately vest and has been reduced for estimated forfeitures. We recognize the value of the awards on a straight-line basis over the awards&#8217; requisite service periods. The requisite service period is generally the time over which our stock-based awards vest. Compensation expense for RSU's is measured at the grant date and recognized ratably over the vesting period in the statement of operations. The fair value of RSU's is determined based on the closing market price of our common stock on the grant date.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we did not have any off-balance sheet arrangements as described by Item 303(a)(4) of Regulation S-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8. Financial Statements&#8212;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Annual Report on Form 10-K for a discussion of recent accounting pronouncements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_109"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31, 2020 and 2019 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenues were $365,993 and $244,632 for the years ended December&#160;31, 2020 and 2019, respectively. Total revenues consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,495)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,632&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,361&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenues for the year ended December&#160;31, 2020 as compared to the prior period is primarily from fluctuations of our sales-based or usage-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723,601&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,585,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,692&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,995)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,388,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,250,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768,621&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(158,234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,235,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,162,236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,160&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $73,160 to $11,235,396 for the year ended December&#160;31, 2020 from $11,162,236 for the year ended December&#160;31, 2019. The increase in salaries and staff costs is primarily due to promotions, merit increases and increased headcount. The increase in costs associated with clinical programs and outside service costs is primarily related to assay development and recruiting fees. Facilities and other decreased primarily due to decreased travel and conference expenses to present data related to our drug candidate, onvansertib. Due to COVID-19 presentation of data has transitioned to virtual conferences. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,430,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,955,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">924,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,334,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,216,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,760,890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,455,581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses increased by $2,455,581 to $8,216,471 for the year ended December&#160;31, 2020, from $5,760,890 for the year ended December&#160;31, 2019. The increase of stock-based compensation expense and salaries and staff costs is primarily related to the Separation Agreement with Thomas Adams which includes accelerated vesting of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock options of approximately $583,000 and a one-time severance payment of $300,000. The increase in outside services and professional fees is primarily related to legal and patent fees to analyze our competitive landscape and evergreen patent strategy. The increase in facilities and other cost was due to a decrease in sublease income, an increase in Delaware franchise tax and an increase in insurance costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $89,809 and $234,169 for the years ended December&#160;31, 2020 and 2019, respectively. The decrease of interest income is due to significantly lower average interest rates during 2020 as compared to 2019. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued warrants to purchase shares of our common stock that are accounted for as derivative liabilities.&#160;As of December&#160;31, 2020, the derivative financial instruments&#8212;warrants liabilities related to securities issued were revalued to $284,971, resulting in a increase in fair value of $280,844 from December&#160;31, 2019 based primarily upon the change in our stock price from $1.24 at December&#160;31, 2019 to $17.99 at December&#160;31, 2020, and the changes in the expected term, volatility and risk-free interest rates for the expected term. The increase in value was recorded as non-operating loss for the year ended December&#160;31, 2020. </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,306,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,414,159)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,892,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,240)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend on preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,266,484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(268,269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,597,396)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,706,668)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,890,728&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.08)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,874,665&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,900,759&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $5,890,728 net loss attributable to common stockholders is primarily related to an increase of deemed dividends on preferred stock of $2,998,215, related to the beneficial conversion upon issuance of preferred stock and an increase of net loss of $2,892,513. The increase of 14,900,759 basic and diluted weighted-average shares outstanding primarily resulting from the sales of common stock through public and direct offerings and the issuance of common stock upon exercise of warrants. The $1.72 decrease in basic and diluted net loss per share was impacted by the increase in net loss attributable to shareholders and the increase in basic and weighted average shares outstanding.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused business disruptions. The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on our clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. The economic effects of the outbreak could also have an adverse effect on our ability to raise additional capital. At this point, the extent to which COVID-19 may impact our future financial condition or results of operations is uncertain. There has not been a material impact on the Company's financial statements for the twelve months ended December&#160;31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had $130,980,681 in cash and cash equivalents. Net cash used in operating activities for the year ended December&#160;31, 2020 was $16,314,962, compared to $13,267,500 for the year ended December&#160;31, 2019. Our use of cash was primarily a result of the net loss of $19,306,672 for the year ended December&#160;31, 2020, adjusted for items mainly related to stock-based compensation of $1,764,804, release of clinical trial funding commitment of $1,100,415, and depreciation of $466,009. The net change in our operating assets and liabilities was $654,531 increasing cash used in operations.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used by investing activities was $211,880 and $67,622 for the years ended December&#160;31, 2020 and 2019, respectively. Investing activities during the year ended December&#160;31, 2020 and 2019 consisted of the purchase of capital equipment. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $137,312,231 during the year ended December&#160;31, 2020, compared to $12,077,281 provided in financing activities during the year ended December&#160;31, 2019. Financing activities during the year ended December&#160;31, 2020 and 2019 related primarily to sales of Common Stock, Preferred Stock, Warrants and proceeds from exercise of warrants. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020 and 2019, we had working capital of $127,237,483 and $6,571,985, respectively. The increase in working capital is primarily due to the increase in cash and cash equivalents from financing activities during the year ended  December&#160;31, 2020.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of December&#160;31, 2020, we had $130,980,681 in cash and cash equivalents and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on our ability to raise additional capital. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital requirements will depend upon numerous factors including but not limited to the nature, cost and timing of our research and development programs.&#160;To date, our sources of cash have been primarily limited to the sale of equity securities.&#160;We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates, all of which may have a material adverse impact on our operations. We may also be required to (i)&#160;seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (ii)&#160;relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves on unfavorable terms. We are evaluating all options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen our liquidity position, which may include the following: (1) Raising capital through public and private equity offerings; (2) Introducing operation and business development initiatives to bring in new revenue streams; (3) Reducing operating costs by identifying internal synergies; and (4) Engaging in strategic partnerships. We continually assess our spending plans to effectively and efficiently address our liquidity needs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Controlled Equity Offerings and Public Offerings</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See Note 5 to the financial statements. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nasdaq Compliance</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 5, 2017, we received a written notice from Nasdaq notifying us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, as the minimum bid price of our common stock had been below $1.00 per share for 30 consecutive business days. The Notice had no immediate effect on the listing of our common stock, and our common stock continued to trade on the Nasdaq Capital Market under the symbol &#8220;TROV&#8221;. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we had until March 5, 2018, to regain compliance with the minimum bid price requirement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were eligible for extensions and hearings and ultimately announced on February 12, 2019 that our stockholders approved a reverse stock split of our issued and outstanding shares of common stock and on February 19, 2019, we effected a six for one reverse stock split of our issued and outstanding shares of common stock. On March 11, 2019 we received a letter from Nasdaq, informing us that we had regained compliance with the minimum bid price requirement. We were subject to a Nasdaq Panel Monitor until March 10, 2020. We received a letter from Nasdaq on May 29, 2020 informing us that we are in compliance with applicable Nasdaq Listing Rules.</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents primarily consists of deposits and money market deposits managed by commercial banks as of December&#160;31, 2020.&#160;The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates, particularly because our investments were in short-term money marketable funds during the years ended December&#160;31, 2020 and 2019. Due to the short-term duration of our investment portfolio and the relatively low risk profile of our investments, a sudden change in interest rates would not have a material effect on the fair market value of our portfolio, nor our operating results or cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe our cash and cash equivalents have significant risk of default issues; however, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits. Given the current stability of financial institutions, we believe that we will not experience losses on these deposits.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face foreign currency risk as a result of entering into transactions denominated in currencies other than U.S. dollars. Changes in foreign currency exchange rates can create foreign exchange gains or losses to us. We did not incur significant foreign currency gains or losses for the years ended December&#160;31, 2020 and 2019.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effects of Inflation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that inflation and changing prices during the years ended December&#160;31, 2020 and 2019 had a significant impact on our results of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial information required by this Item is attached hereto at the end of this report beginning on page F-1 and is hereby incorporated by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.  CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2020.&#160; The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms.&#160; Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.&#160; Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decisions regarding required disclosure.&#160; Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule&#160;13a-15(f).&#160; Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December&#160;31, 2020, our internal control over financial reporting was effective based on those criteria.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended&#160;December&#160;31, 2020&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.  OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2581"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div style="text-align:center"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2587"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the Annual Meeting of Stockholders to be held in 2021 (the &#8220;2021 Proxy Statement&#8221;), under the headings &#8220;Election of Directors.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2610"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.  EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement under the heading &#8220;Executive Compensation.&#8221;</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2605"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2600"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement under the headings &#8220;Certain Relationships and Related Transactions.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2595"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2021 Proxy Statement under the heading &#8220;Proposal 2: Ratification of the Appointment of Our Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2021&#8221;.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_214"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Statements</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The financial statements required by this item are submitted in a separate section beginning on page&#160;F-1 of this Annual Report on Form 10-K.</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b) Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912019409/a12-6668_1def14a.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Trovagene,&#160;Inc. (incorporated by reference to Appendix B to the Company&#8217;s Proxy Statement on Schedule 14A filed on March&#160;20, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d2.htm">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-Laws of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518181824/d598311dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Amended and Restated Certificate of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on June 1, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex31.htm">3.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 12, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519021144/d692543dex31.htm">3.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 29, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519024055/d647432dex31.htm">3.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 31, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519044909/d711195dex31.htm">3.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on February 20, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020006555/trov050620ex31.htm">3.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on May 6, 2020).    </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex31crdf051320.htm">3.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a31crdf061620.htm">3.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex4d1.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Common Stock Certificate of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000103883804000631/ex43form8k070204.txt">4.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2004 Stock Option Plan (incorporated by reference to Exhibit&#160;4.3 to the Company&#8217;s Current Report on Form&#160;8-K filed on July&#160;19, 2004)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914049723/a14-16399_1ex4d2.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914049723/a14-16399_1ex4d2.htm">3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit&#160;4.2 to the Company&#8217;s Current Report on Form 8-K filed on July 1, 2014).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914052781/a14-17541_1def14a.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914052781/a14-17541_1def14a.htm">4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trovagene, Inc. 2014 Equity Incentive Plan (incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed on July 23, 2014).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465916134373/a16-15453_1ex4d1.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465916134373/a16-15453_1ex4d1.htm">5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to Form 8-K filed on July 26, 2016).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex41.htm">4.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex41.htm">6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 12, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/exhibit416q42019.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Incorporated by reference to Exhibit 4.16 to Form 10-K filed on February 27, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d3.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary of Terms of Lease Agreement dated as of October&#160;28, 2009 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d4.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of First Amendment to Standard Industrial Net Lease dated September&#160;28, 2011 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d5.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Second Amendment to Standard Industrial Net Lease dated October&#160;2011 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d6.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Third Amendment to Standard Industrial Net Lease dated October&#160;22, 2012 between Trovagene,&#160;Inc. and BMR-Sorrento West, LP. (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d7.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Fourth Amendment to Standard Industrial Net Lease dated December&#160;2, 2013 between Trovagene,&#160;Inc. and BMR-Coast 9 LP. (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d8.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Fifth Amendment to Standard Industrial Net Lease dated May&#160;14, 2014 between Trovagene,&#160;Inc. and BMR-Coast 9 LP. (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915058213/a15-12061_1ex10d1.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sixth Amendment to Standard Industrial Net Lease dated June 11, 2015 between Trovagene,&#160;Inc. and BMR-Coast 9 LP (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed on August 10, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915084905/a15-25019_1ex10d1.htm">10.8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnification Agreement to be entered into between the Company and its directors and executive officers (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 15, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a109ex022521.htm">10.9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amended and Restated Employment Agreement, dated February 22, 2021, by and between the Company and Mark Erlander .</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828016018502/trov-0630x16exhibit102.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Seventh Amendment to Standard Industrial Net Lease dated April 4, 2016 between Trovagene,&#160;Inc. and BMR-Coast 9 LP (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2016). </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828017002601/exhibit1034q42016.htm">10.11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License Agreement dated as of March 13, 2017 between Nerviano Medical Sciences S.r.l. and Trovagene, Inc. (incorporated by reference to Exhibit 10.34 to the Company&#8217;s Annual Report on Form 10-K filed on March 15, 2017).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex101crdf053220.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock and Warrant Subscription Agreement entered into as of May 8, 2020 by and between Cardiff Oncology, Inc. and POC Capital, LLC. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex102crdf051320.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008004/a101crdf51920.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 19, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a101crdf061620.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 16, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020017686/a101ex122120.htm">10.15</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Separation Agreement between Thomas Adams and Cardiff Oncology, Inc. dated December 21, 2020 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on December 21, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1016ex022521.htm">10.16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, dated February 22, 2021 by and between the Company and Vicki Keleman.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1017ex022321.htm">10.17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, dated February 22, 2021 by and between the Company and Brigitte Lindsay.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a231exq42020.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of BDO USA, LLP.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_220">24</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included on signature page hereto).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a311exq42020.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer required under Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a312exq42020.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer required under Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a321exq42020.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a322exq42020.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:237.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</span></div><div style="text-align:center"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_217"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160; FORM 10-K SUMMARY</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_220"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Erlander as his or her attorney-in-fact, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:26.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brigitte Lindsay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VP, Finance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rodney S. Markin</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rodney S. Markin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Adams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Adams</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James O. Armitage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James O. Armitage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Brancaccio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;John Brancaccio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gary S. Jacob</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Gary S. Jacob</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gary W. Pace</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ L&#226;le White</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/2021</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_226"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Report of Independent Registered Public Accounting Firm</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_229">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_232">Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_232">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_238">Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_238">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_244">Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_244">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_247">Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_247">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_253">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_253">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Cardiff Oncology, Inc. (the &#8220;Company&#8221;) as of December 31, 2020 and 2019, the related statements of operations, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for the years then ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee of the Company&#8217;s board of directors and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued clinical trial expenses </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As disclosed in Note 2 to the consolidated financial statements, the Company expenses research and development expenditures as incurred, which include costs relating to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services performed and costs incurred that have not been invoiced by the service providers. The Company&#8217;s clinical trial accrual balance at December 31, 2020 is $1.69 million, and the Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $11.2 million for the year ended December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified accrued clinical trial expenses as a critical audit matter. When estimating clinical trial expenses, the Company considers several factors including clinical trial budgets, contract amendments and the progress toward completion.  Auditing these elements involves especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters and a high degree of auditor subjectivity.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary procedures we performed to address the critical audit matter included:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing management&#8217;s process for estimating accrued clinical trial expenses by (i) obtaining and inspecting significant agreements, clinical trial budgets, and contract amendments, (ii) evaluating the Company&#8217;s documentation of trial progress and status (including consideration of patient enrollment and milestones achieved), (iii) confirming clinical trial progress with third party service providers, and (iv) testing a sample of transactions by comparing the costs against the related invoices and agreements. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Testing the completeness of the Company&#8217;s clinical trial accruals by (i) evaluating publicly available information (such as press releases, investor presentations and public databases that track clinical trials) and board of directors&#8217; minutes which discuss the status of clinical trials, (ii) inquiring of clinical staff outside of finance to gain an understanding of the status of significant on-going clinical trials, and (iii) testing a sample of  payments subsequent to the year end to evaluate the completeness of clinical trial accruals. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ BDO USA, LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2007.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;25, 2021 </span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMtMS0xLTEtMA_993af1d2-36d8-4a14-a7c5-befb2a256e42">130,980,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMtMy0xLTEtMA_afdf2418-4564-4771-9e78-bcf24a921bcc">10,195,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzUtMS0xLTEtMA_d641c79e-93ab-4933-989c-ed612166bdbe">320,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzUtMy0xLTEtMA_a4eca15e-8b75-489d-a062-d88473eee436">203,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzYtMS0xLTEtMA_2cb9d23d-bb41-445a-90bb-3cae2685826a">2,055,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzYtMy0xLTEtMA_19b50b4f-920b-478b-9478-36e46ceab5ad">954,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzctMS0xLTEtMA_c25d577b-7d6b-4981-9b10-27330a404968">133,356,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzctMy0xLTEtMA_b414242b-19dc-4ede-ab7d-7ffb85417ee4">11,353,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzgtMS0xLTEtMA_de31ac7c-68d8-4f05-9508-a62d77b95992">623,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzgtMy0xLTEtMA_f5093453-f387-4b9c-9ab0-68848a42f143">877,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzktMS0xLTEtMA_ad367ff0-8407-498f-b7e3-e1e2ca7a745c">343,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzktMy0xLTEtMA_4fb49bc8-81ea-4432-880b-be9956483b0b">697,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzEwLTEtMS0xLTA_42c697c6-09de-4723-a778-48d76ce182ca">404,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzEwLTMtMS0xLTA_4605fc76-852e-4965-ae46-1f811acd6805">157,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzExLTEtMS0xLTA_c0375079-0d29-432d-bdaa-b813bb6af7a3">134,727,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzExLTMtMS0xLTA_f143ad67-bb58-45b0-b732-06f04d0579ad">13,086,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE1LTEtMS0xLTA_c4fc6541-54cc-4efc-9f52-a43eb44f11c3">1,366,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE1LTMtMS0xLTA_ce9c5fa6-e0a5-4d1c-8d61-4a83a52965d8">656,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE2LTEtMS0xLTA_a1024d19-4f33-4b1b-9dbc-c51a330d7510">3,850,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE2LTMtMS0xLTA_d5b6d4d9-d01a-4573-9fa7-7735e7459e80">3,260,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE4LTEtMS0xLTA_eb816f5d-6b26-4ce7-b62f-7b4d3d0db90f">860,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE4LTMtMS0xLTA_d24a3b36-c37e-40b3-876b-2662820021c9">865,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE5LTEtMS0xLTE2NzY_2db1855e-288e-45f6-8405-cf47fe9ceef5">42,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE5LTMtMS0xLTE2NzY_63a75994-8bd8-4dfa-8122-a794930c9f67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIwLTEtMS0xLTA_90001259-8e3b-48a7-a631-c9ad345f29ac">6,118,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIwLTMtMS0xLTA_7d355ada-226d-45ad-b039-8d6b8c0493a9">4,781,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIyLTEtMS0xLTA_f79239b6-a31d-4222-b6f8-84ad2c20f868">284,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIyLTMtMS0xLTA_e707702f-0947-4fc2-aae4-53288382a076">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIzLTEtMS0xLTA_8cc7bb16-8f81-4044-aad8-055e79c73be8">9,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIzLTMtMS0xLTA_d834c593-7f30-4b8c-b3b9-f915211a0adb">860,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI1LTEtMS0xLTA_2072b3ab-1ca8-4e7a-bb13-fa7de599d14c">156,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI1LTMtMS0xLTA_4afb79dd-7652-4381-88cd-0585ded99578">128,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI2LTEtMS0xLTA_bca39d76-6554-4a76-acd9-52742f662c31">6,569,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI2LTMtMS0xLTA_238373db-d00a-4653-99e2-ce48d302b45c">5,775,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI4LTEtMS0xLTA_cfcfc7ba-38b2-45ad-b9d7-bdfa90e7c2b8"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI4LTMtMS0xLTA_103b53c3-823d-4beb-8fae-cb0767fea3c3"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzEy_492c4252-1163-4a83-80c6-c0ca068d9b2b"><ix:nonFraction unitRef="usdPerShare" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzEy_88311fd3-8d89-4ae1-ab59-4030ab1c4f89">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzI1_cc541971-ae3a-4a8f-915f-9f390d3bceb5"><ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzI1_dd7aea53-0562-4f08-b7d4-a2da6efeecb1">20,000,000</ix:nonFraction></ix:nonFraction> shares authorized; (Note 5)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTEtMS0xLTA_cfd28210-bbcb-42f2-b5ab-2579d0df9910">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTMtMS0xLTA_daacb5e8-8a60-4c5a-abba-42f8d67cb444">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTYy_cb934514-e0f7-414f-9900-c25ff6d02a35"><ix:nonFraction unitRef="usdPerShare" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTYy_d5b5c191-721e-4d7b-b53a-0aa0b8bceb4c">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTc2_2708dc86-cef9-4cdb-9f90-519b6ddd93eb"><ix:nonFraction unitRef="shares" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTc2_ece2dc6d-7445-406f-9198-79a69d149e14">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTg4_3517a79b-7db2-42ae-8ea8-d9ccf49afb66"><ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTg4_f845276c-a825-44ac-b8c2-5de9dc44c0af">36,780,805</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI4MDAw_8c07a703-db6f-49fc-aff2-117e07dd07e1"><ix:nonFraction unitRef="shares" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI4MDAw_aa6df686-861d-4a34-aadb-1f642cc04425">8,593,633</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTEtMS0xLTA_ea0c358e-7826-4c4f-af03-e27744437f72">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTMtMS0xLTA_e24fcb8a-1a2f-478f-a4b0-b500e4822de9">8,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMzLTEtMS0xLTA_518f5ef9-5a18-490f-a421-0ad2a0ae1567">361,820,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMzLTMtMS0xLTA_642aef90-0acb-4230-8ba6-a83f8221e608">217,172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Servicereceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM1LTEtMS0xLTA_24c0ab15-87f8-41b6-aa28-5cff1d8b62a9">2,171,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Servicereceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM1LTMtMS0xLTA_db5bb344-c415-41e0-bf4b-bf37bb59efb4">971,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM2LTEtMS0xLTA_f40549c0-625d-401a-b0a1-663e8432125c">231,495,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM2LTMtMS0xLTA_afcac260-fc35-435d-a8ea-06ffa543596a">208,897,883</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM3LTEtMS0xLTA_164af2a0-7a5e-4016-9572-8fb7b9cd6cf9">128,157,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM3LTMtMS0xLTA_87026a3d-87b7-42e2-9eb8-1984cb044c13">7,311,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM4LTEtMS0xLTA_fcb7a433-c0af-4bcf-87d5-051cb7f2d1fb">134,727,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM4LTMtMS0xLTA_83411724-4756-4b66-aa27-3cb4c1f2dca7">13,086,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology,&#160;Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i974c8d2976844fc9bd37ad841b476746_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMtMS0xLTEtMA_fc06cb78-1902-4eee-9d7a-2341071bf4be">365,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f64d58d38fe4c52a90346b804d8222a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMtMy0xLTEtMA_0b8d5857-09a9-4d62-aa2f-14829f08e2c6">243,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dfeebbffde848a39dd21015892f17ee_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzYtMS0xLTEtMA_374404a4-a7a1-467f-bbc4-a1e43944691e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31167c9f6df4b2e98fed3a3ab5827c9_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzYtMy0xLTEtMA_e8636e4a-9a1b-4249-baa6-eee19747fc69">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzgtMS0xLTEtMA_a272aeb4-8e7a-4253-beea-39fcf0928763">365,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzgtMy0xLTEtMA_ac29ceaa-b9fa-47a5-ad6c-20be38ee62e9">244,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzExLTEtMS0xLTA_54cdcd1f-68b5-4ac5-9a00-7a3b816ffddd">11,235,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzExLTMtMS0xLTA_a7bdc178-b7d2-4ac1-814b-791d22a33b2a">11,162,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzEyLTEtMS0xLTA_cdb0f64d-8e3d-4838-9f36-f7df6d58d976">8,216,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzEyLTMtMS0xLTA_7ef23814-f6ad-439c-aa50-f0b3787eba38">5,760,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE1LTEtMS0xLTA_028c8bb8-7351-402b-aa7a-2b5e758fd6ab">19,451,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE1LTMtMS0xLTA_5461ebd6-01e5-4d65-92b0-a0ef50ef5c6a">16,923,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE3LTEtMS0xLTA_f31427f9-ce76-48ce-8c93-b33f01bd7058">19,085,874</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE3LTMtMS0xLTA_0a877e31-2abb-47f5-adfe-825dc7e55355">16,678,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE5LTEtMS0xLTA_f30b2603-377a-43ed-8ab3-9469abe7c0f0">89,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE5LTMtMS0xLTA_8251b1c9-484e-4b7e-b861-b17436b2d13d">234,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIwLTEtMS0xLTA_a1f7cf68-14b0-4e6b-8bdc-18ad3a561fcb">1,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:InterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIwLTMtMS0xLTA_b19fa447-87e7-4f6c-bea4-7e233fb9f794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other gain (loss), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIxLTEtMS0xLTA_920d23b6-6d6d-4ec1-8eb2-ea4ad0785e07">28,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIxLTMtMS0xLTA_d0c516d4-33e4-4282-a6a5-5f891ba6a542">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from changes in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIzLTEtMS0xLTA_f6fa637e-9b7a-4814-9cc1-9780237879fd">280,844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIzLTMtMS0xLTA_bbc5bb68-f65a-4b52-b871-0355bb745deb">28,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI0LTEtMS0xLTA_e383d515-bbbd-4398-93ef-c0d65852bbb0">19,306,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI0LTMtMS0xLTA_0e1722d7-f670-46c4-a4e9-8ae204ff897a">16,414,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI2LTEtMS0xLTA_f2c0a508-967d-4d35-87fb-cd849696ab6d">24,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI2LTMtMS0xLTA_3ef5ad5d-d90e-4798-b13e-818eb4729dfb">24,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI4LTEtMS0xLTA_97438e71-13ed-4fe8-a7d8-d84ff8e3a500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI4LTMtMS0xLTA_3f6be8f8-cc2d-4e6d-aa89-c9b5d8ec45e2">268,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTEtMS0xLTE2OTU_9a5ea0db-4e8e-4e47-b1de-44e407bfaee3">601,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTMtMS0xLTE2OTU_0c8fa2ee-d671-4ed6-90bd-909d73192ad7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMwLTEtMS0xLTE2OTU_948f1572-ca6f-4601-bc0e-a7cf05991b90">2,664,717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMwLTMtMS0xLTE2OTU_0835d810-a17b-42f7-b576-80e6d1244868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable&#160;to&#160;common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTEtMS0xLTA_c70e33eb-15f7-4e72-8862-8bbae94939c6">22,597,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTMtMS0xLTA_cef0e47a-ba7f-41e1-aaba-589f6d07e006">16,706,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMxLTEtMS0xLTA_30ad0949-39ba-444a-8301-1cec5cdaf32a">1.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMxLTMtMS0xLTA_1135f1ca-76e2-49ac-9e26-f8fa656464dc">2.80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzM0LTEtMS0xLTA_897f2333-55c0-4049-a253-e9bd43cf58fa">20,874,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzM0LTMtMS0xLTA_d2bbb105-6abe-47f7-b818-6f39820c0ce4">5,973,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_244"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Stockholders&#8217; Equity</span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.783%"><tr><td style="width:1.0%"></td><td style="width:38.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.299%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.166%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90cbda9b433948c4bfec12adb85eece5_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTEtMS0xLTA_a0ddcea3-6e26-4b52-ab0c-7832661c63a5">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90cbda9b433948c4bfec12adb85eece5_I20181231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTMtMS0xLTA_02a17061-9ef4-4e95-8f37-aa9320f33005">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i283c7589044745a697aba89af3b8c955_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTUtMS0xLTA_84ddd1fd-fc49-46b5-97e0-28cd038b8826">3,831,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283c7589044745a697aba89af3b8c955_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTctMS0xLTA_e42c6fe2-2058-4dd1-8843-57796ca13490">7,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1fd37d65d4a45768c5f933a4c55cf0f_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTktMS0xLTA_848e4c7c-1194-4c48-a9cd-d8d91e744324">202,267,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f11be824704ccaaa3be62c269b68d3_I20181231" decimals="0" format="ixt:zerodash" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTExLTEtMS0w_115ed770-49e6-4859-bd3e-e1d32881ff7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i489cb20610fb450193a4a09194d885a8_I20181231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTE1LTEtMS0w_c5131479-d901-4d8f-a00a-f85009b07deb">192,191,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8da706562440a48c86522c944d0df6_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTE3LTEtMS0w_9fa91d78-5e4e-4afa-8790-f6437706c29d">10,084,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock and warrants, net of expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="trov:SaleOfStockCommonAndWarrantsNetShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTUtMS0xLTA_9c3e43cc-b5c6-44f3-980a-309224262f9f">1,994,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="0" sign="-" name="trov:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTctMS0xLTA_d704820b-23d9-419d-aab0-38a90e7d77bc">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTktMS0xLTA_9c7cc98c-ad21-44c0-94a1-bec8c1beefb5">8,817,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:SaleOfStockValueCommonAndWarrantsNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTE3LTEtMS0w_0e75b024-005b-4e21-a756-3b8228f6ad3c">8,817,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTEtMS0xLTA_e088d52e-dab6-4a64-9b8f-f3e8b0e8eab3">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTMtMS0xLTA_c1e16236-347d-42a6-87aa-a904e6b30960">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTUtMS0xLTA_2ee5a22c-7376-47eb-97f9-837257186e6f">183,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTctMS0xLTA_3f8bf0dc-a1c2-478b-b2e9-56364a2737f9">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTktMS0xLTA_70310fb5-acb8-4a73-b8a0-1d86517086a8">1,634,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTExLTEtMS0w_beaf641f-ee16-4027-adfc-29819ea4cf03">1,675,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTE3LTEtMS0w_eae4410e-c1f0-4bdd-b65f-bae7e000115d">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUwLTktMS0xLTA_f295da2e-19e2-4d50-b885-60ba7aefa0d7">884,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUwLTE3LTEtMS0w_2e83bab0-ac26-418b-83b9-3658852a9085">884,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTUtMS0xLTA_00fefd3f-697a-4c6c-b916-563821c66603">2,221,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="0" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTctMS0xLTA_c5fa4b57-fd09-49fa-9b00-537ed9a0387a">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTktMS0xLTA_6283418b-0f70-4167-863c-8fddf31a2fe8">3,299,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTE3LTEtMS0w_d28f8faf-fa1e-4fd0-aa20-12fd1d6b6b70">3,299,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTUtMS0xLTA_6463489d-dce4-4b2e-a701-787ceb92a0d6">22,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTctMS0xLTA_b29aec29-e453-435e-8671-a6c30c7df653">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTktMS0xLTA_6bfbda19-c099-4b9e-97a4-2f0e6c44d56d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTE3LTEtMS0w_798a8254-545c-435a-b0da-3fa08cbc4e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTktMS0xLTA_f95d42c0-5e9d-4ded-b74f-8fb002a6a8e7">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTE1LTEtMS0w_7b6eacf2-2cea-4182-94d4-d2d4eb722172">268,269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTE3LTEtMS0w_79608760-16d9-4597-9a8f-24929c13309c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series C Convertible Preferred Stock</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTEtMS0xLTA_23b7f6be-43d1-468f-9544-f8dbbf1fb92f">200,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTMtMS0xLTA_89a7dfb0-1456-4e66-963f-f0e69ded8eb9">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTUtMS0xLTA_096b87c5-5adc-4180-8f95-67862acf9548">333,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTctMS0xLTA_f21ae747-ec46-49f7-9e5e-7848b0397a9f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTktMS0xLTA_328cff8b-a25e-425b-ab2a-c33c51c4dba6">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTE3LTEtMS0w_21c3efb9-ecd5-4a2d-bafc-c95d5d91bee9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU1LTE1LTEtMS0w_bbd71bfd-28c1-4f83-be7e-5d3221e4f9ff">24,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU1LTE3LTEtMS0w_9e3c83e0-2c06-4b47-b982-c15ed974bccd">24,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for share rounding as a result of reverse stock split</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU2LTUtMS0xLTA_803603ba-127a-467c-8882-f44db317bdde">6,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU3LTExLTEtMS0w_348cb94e-3331-4876-bcba-9c5042222239">703,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU3LTE3LTEtMS0w_213fe0f1-87e9-4b03-b384-085b66f6eaef">703,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU4LTE1LTEtMS0w_96f72273-5383-4444-a04f-4a011836b2a5">16,414,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU4LTE3LTEtMS0w_1f31d147-f891-4bea-b658-b1b505bc03ae">16,414,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTEtMS0xLTA_70b87fff-fe30-400b-886b-8b02eb9ecd31">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTMtMS0xLTA_9062d36f-9240-47a7-b187-3ef0eed621b3">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1533dc281f3416c87c9cc063e238300_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTUtMS0xLTA_76a06980-1a82-461a-aeaf-064c45266634">8,593,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1533dc281f3416c87c9cc063e238300_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTctMS0xLTA_639fde36-7a08-4c0c-b65f-f2bad89b8f8e">8,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e843a6b44054990807074b9f697e695_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTktMS0xLTA_a0cf97de-3ffd-4689-a3e8-491c17f8fdc0">217,172,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45d5e02556184c789e5d3265173db41e_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTExLTEtMS0w_0bc207eb-6dc6-48c3-b1fc-a23636a602db">971,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifb0dc0c25b98439290e7f74e7dbe5c33_I20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTE1LTEtMS0w_f636befa-e4db-452c-b711-b381b40c136b">208,897,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTE3LTEtMS0w_0a750663-3dbb-4ba4-bc1e-44ed5d544b63">7,311,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock, preferred stock and warrants, net of expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231" decimals="0" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2">12,964,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373">112,297,786</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b">112,299,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTEtMS0xLTE3NzQ_c87a733e-28bf-463d-8d83-914c3687f2d8">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTMtMS0xLTE3NzQ_ecc7e417-a59a-4380-a832-95bfa6184ff5">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTUtMS0xLTE3NzQ_ec864365-514f-4140-bf96-f2c75263ea4a">602,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTctMS0xLTE3NzQ_a38600e4-f22d-4193-bb36-eb0c03942a86">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTktMS0xLTE3NzQ_a3182bd8-3ebe-4cd5-9af1-8671e4fce0a1">2,292,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTExLTEtMS0xNzc0_2f02bc56-504c-4627-86c9-806944ff7483">2,300,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTE3LTEtMS0xNzc0_c96e4303-587f-4197-be78-e33f468b93e5">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYyLTktMS0xLTE3NzQ_ab0e7e74-4c68-4e59-ab69-9ff55daabd5e">1,764,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYyLTE3LTEtMS0xNzc0_852af7d0-b8e1-45a8-be16-f88412e2a09a">1,764,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTUtMS0xLTE3NzQ_e1c0e253-240c-44f4-a73c-29fd473d9181">12,138,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTctMS0xLTE3NzQ_3b6650da-94bc-49a0-9989-c049e497bedb">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTktMS0xLTE3NzQ_ad0c37b8-82f0-423a-b842-0b50de06bfdc">24,870,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTE3LTEtMS0xNzc0_edb70611-8257-4bd4-9ee9-074536a01ebb">24,871,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTUtMS0xLTE3NzQ_1d84826e-4bb0-423d-8de0-9555263e66dd">10,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTctMS0xLTE3NzQ_9bddcb5a-35c9-487c-8477-b37ca0ae7a93">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTktMS0xLTE3NzQ_5a61dc17-99d4-4c5c-960e-d0e8a7ba99fa">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTE3LTEtMS0xNzc0_89524660-a5b4-43df-8d2c-92533f1142bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTktMS0xLTE3NzQ_ce7fb358-d39b-468d-8c49-312066e0e528">601,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45ab9019c9754577b27a546943f63815_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTE1LTEtMS0xNzc0_c2b277a4-410e-4361-b4ad-553ff685ced2">601,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTE3LTEtMS0xNzc0_bd27533d-9e45-496a-bd8e-dd4492aef676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deemed dividend recognized on beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTktMS0xLTE3NzQ_96357246-8dfa-4a2e-ba9c-42507c4d069f">2,664,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c0726d301e947e5a55d7dfb699e13f1_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTE1LTEtMS0xNzc0_bb6ffdc6-8888-40ef-9866-4eeea226bc91">2,664,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTE3LTEtMS0xNzc0_7ae6c232-c506-48af-b49a-15c82758c128">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series D Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTEtMS0xLTE3NzQ_bce34515-f2e2-4b8a-8942-1541c8a75d87">154,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTMtMS0xLTE3NzQ_6edd9365-d826-430b-b2d7-bf3b2f357100">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTUtMS0xLTE3NzQ_42a187b0-a58f-4424-b404-759b4f1baa13">1,546,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTctMS0xLTE3NzQ_6530e7eb-f060-44d2-b340-9bd9ba36951f">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTktMS0xLTE3NzQ_7ccbab59-c652-40ea-b339-620f3f65da32">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTE3LTEtMS0xNzc0_c04d397d-c874-4edb-b4c5-6131949ef215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231" decimals="INF" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTEtMS0xLTE3NzQ_f7ade7fc-726b-4ea7-9152-98c5acc3c783">210,780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTMtMS0xLTE3NzQ_89eeb495-75d9-4df7-b911-ec2448d53036">210</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTUtMS0xLTE3NzQ_c58c11ac-3716-43ca-84c6-1f26d6bf314e">863,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTctMS0xLTE3NzQ_4e20047d-88dc-4c35-a8bb-bd93125135b6">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTktMS0xLTE3NzQ_827ba553-81ea-49ae-85fe-6a10ce09fb88">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTE3LTEtMS0xNzc0_58a8c42e-60b8-4170-b83a-b93bd1a12edc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY5LTE1LTEtMS0xNzc0_5bd4db76-8eed-4590-8428-5185b05221c4">24,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY5LTE3LTEtMS0xNzc0_9fc8e9e7-422c-4082-9d29-4a02a2d98cb8">24,240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcwLTExLTEtMS0xNzc0_728cbfbc-501b-4a7f-832e-0598bde26377">1,100,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:ReleaseOfClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcwLTE3LTEtMS0xNzc0_acea5c7e-57d2-441c-a15d-cc9446868a71">1,100,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock par value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTctMS0xLTE3NzQ_2cb42d9e-7af5-4a51-bedd-416ce6ac5044">7,453</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTktMS0xLTE3NzQ_a84fa506-e7dd-4543-a187-9acd6a5a44b9">7,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTE3LTEtMS0xNzc0_fbd6f170-413b-444d-b32d-0060aece64cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTUtMS0xLTE3NzQ_56f145fd-e6fe-4c5b-9a93-cc181bc29436">60,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTctMS0xLTE3NzQ_7878798d-5c3e-4ea5-a72e-a9ef7d1c3fe9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTktMS0xLTE3NzQ_f57fd520-711c-44b8-9e7b-ee7ee2160ef9">148,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTE3LTEtMS0xNzc0_f7a8652e-a34a-4e08-b22a-765faede1aec">148,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzczLTE1LTEtMS0xNzc0_160c09b9-bae6-4a38-b681-79218438b3d2">19,306,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzczLTE3LTEtMS0xNzc0_33041b25-2966-46ac-8d8d-823e654fbcd3">19,306,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b60188329974ccba428036634f386c6_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTEtMS0xLTE3NzA_886d0aac-7b90-4ba3-9d56-8d2ba6cc05d1">715,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b60188329974ccba428036634f386c6_I20201231" decimals="0" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTMtMS0xLTE3NzA_1c4622ba-0a79-49bb-b874-df3fb84e1042">716</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i775f6829cd0442b4abd291c9e9c043f2_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTUtMS0xLTE3NzA_84fd19f7-3dfb-4e40-80a2-a5a40345de2b">36,780,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775f6829cd0442b4abd291c9e9c043f2_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTctMS0xLTE3NzA_c9ddeb28-15a6-4155-9443-2f2e0d915e60">3,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7848a306518c4d3c8d2ceace32f45c19_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTktMS0xLTE3NzA_2307eab7-131a-4f05-969e-673dced04f6e">361,820,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iede24d64c8eb47a38bf93edc43a4580d_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTExLTEtMS0xNzcw_40f56741-6972-4abf-84fd-63a0ebe0a65a">2,171,258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01b536880233430693517dce3f18592b_I20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTE1LTEtMS0xNzcw_b555b698-59a2-4085-bf06-8b8710b51ffe">231,495,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTE3LTEtMS0xNzcw_d703defe-75d0-4ac7-bcd4-0f5854885569">128,157,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzE2NDkyNjc0NDE5MDE_129aec48-0ea3-4144-a109-09aa5f91649c">7,507,123</ix:nonFraction>, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:WarrantsFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMjc_319d52f4-e735-4cab-bcdf-216a19dee449">370,666</ix:nonFraction></ix:footnote></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_247"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMtMS0xLTEtMA_64a81a31-f0ce-4f2e-9956-012562b1d7cc">19,306,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMtMy0xLTEtMA_350c6f95-5009-40d3-91ae-6c0a3a962a5e">16,414,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYtMS0xLTEtMA_2db562ba-241c-4e4a-bc54-fd7d7e2884cf">34,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYtMy0xLTEtMA_6654a324-0030-4902-981c-b8831a165627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzctMS0xLTEtMA_c3d31295-11c8-40e8-a662-93dae2a070c3">466,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzctMy0xLTEtMA_1f00696f-06d2-41e3-bd2f-999bce07492f">494,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzgtMS0xLTEtMA_ed3dd197-b182-4ac0-acf2-994c0a295a68">1,764,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzgtMy0xLTEtMA_54ff9451-b779-4d0d-a728-fcca8260384a">884,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE2LTEtMS0xLTA_4252fb99-1807-4f85-ace9-b4709120058e">280,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE2LTMtMS0xLTA_c2f706c8-5745-439b-ad15-5abb125ff9d6">28,188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE3LTEtMS0xLTA_66183beb-80bf-4b2d-8123-8a44ab36d504">1,100,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE3LTMtMS0xLTA_11690ec9-aeaf-43ab-867c-adf97d46f898">703,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIwLTEtMS0xLTA_3c62cbbd-1c00-481c-86a3-74a1641838f3">246,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIwLTMtMS0xLTA_1a7a752b-7746-4787-8ac6-139040fba720">54,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIxLTEtMS0xLTA_89d91b25-3ee1-4384-9a05-36076e5d8c7e">116,978</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIxLTMtMS0xLTA_65b535e3-f143-4cfe-b277-03423962bb68">35,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIyLTEtMS0xLTA_d7649d16-9d1a-4d56-83ae-77f999a9f93c">1,100,364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIyLTMtMS0xLTA_64083b92-132e-476c-8e11-c49d607b0099">115,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIzLTEtMS0xLTA_dc523360-0568-4b1c-a1de-025966f2a211">320,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIzLTMtMS0xLTA_669729fb-8ace-41de-991f-700a79719cb4">302,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI0LTEtMS0xLTA_2c27aab3-3890-408c-be80-e0c190d91dd9">1,276,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI0LTMtMS0xLTA_107a8127-1016-453b-ad4d-af608de515e7">1,455,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:IncreaseDecreaseInOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI1LTEtMS0xLTA_94e62423-f071-4bd1-807c-b1afccfc1819">856,845</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="trov:IncreaseDecreaseInOperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI1LTMtMS0xLTA_3ee3c13c-6159-44a9-9d6c-e9f4b1387151">776,806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI2LTEtMS0xLTA_4b9e6a78-e423-4507-8468-f617b017a9ba">69,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI2LTMtMS0xLTA_63b50482-bc80-4fce-beba-ddc35a70968a">86,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI3LTEtMS0xLTA_b0d276c7-7764-4aed-9816-2c4899584c94">16,314,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI3LTMtMS0xLTA_880b682a-ded2-4bce-8307-c89a4ea874c5">13,267,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMwLTEtMS0xLTA_6a4d3b81-860e-47a4-820e-ac7006ed33c9">211,880</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMwLTMtMS0xLTA_db431591-4971-4df2-943e-a499ad20cb55">67,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM1LTEtMS0xLTA_606ca0bb-f00f-45f4-a9b6-98148a4f8387">211,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM1LTMtMS0xLTA_71d57646-43c9-4436-8c0f-71c3eeffb7cd">67,622</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i08acffb99e614dc58b610354b475758f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNjU3MzAwYzQ5Njc0MTNkYjZkYWMwNjlhMzYyMzlmOV8xMDk5NTExNjI3ODkx_8a124ec8-0a27-407d-b209-e23bb9b96db6">7,507,123</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0556eb8a6c2a44c2be25fabc0712fbd4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNjU3MzAwYzQ5Njc0MTNkYjZkYWMwNjlhMzYyMzlmOV8xMDk5NTExNjI3OTAz_a89ebba6-4f0e-4bd6-9944-0e4155b34938">158,678</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTEtMS0xLTA_4f87d1e1-5d1f-4064-9391-25fc038da000">112,299,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTMtMS0xLTA_e12dc9e7-725d-422a-84f1-71cdc380cc1e">8,817,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs related to the clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQxLTEtMS0xLTA_7de85364-ca4d-494f-b0b9-1efb5d81d89d">7,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQxLTMtMS0xLTA_25dcec08-ff7c-43f1-9762-e2c6236c6591">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQyLTEtMS0xLTA_9be89f58-205c-4814-9e49-215acf398f3c">24,871,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQyLTMtMS0xLTA_361e94f9-99e9-4b59-8fa9-50d3e89a5123">3,299,509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQzLTEtMS0xLTA_20209d97-47da-46fe-8c47-653cd213264a">148,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQzLTMtMS0xLTA_445a2fc6-5b1a-40d8-a44f-90f16c335faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings under note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ2LTEtMS0xLTA_3113b23e-cad7-4b33-8eed-035ab7a83b44">305,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ2LTMtMS0xLTA_50b81851-78c0-4b59-82b0-d1ca1f7ba892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of note payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ3LTEtMS0xLTA_6e37e804-74f3-4f95-91a6-d35c0b35dab7">305,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ3LTMtMS0xLTA_558fc841-576f-42a3-970c-cde503c89394">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ5LTEtMS0xLTA_81cdda9e-881b-4e00-8c4f-e080a804c543">137,312,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ5LTMtMS0xLTA_df2a467b-2712-4476-9d29-5806d838bc7f">12,077,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUxLTEtMS0xLTA_08dbdddd-a3be-4a85-8906-39da5f8343d9">120,785,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUxLTMtMS0xLTA_4ae755f0-38e5-475e-ba51-5e6c7d994c05">1,257,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUyLTEtMS0xLTA_5a5c1989-2f31-4cb5-9146-2f5310f46d80">10,195,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e8da706562440a48c86522c944d0df6_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUyLTMtMS0xLTA_2da04ffe-426d-46b0-84ca-d9aaac8953c1">11,453,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUzLTEtMS0xLTA_30ce9ab5-51d2-45d6-82d2-c452f92ee7c2">130,980,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUzLTMtMS0xLTA_ebb4a4c9-0904-4da7-bd4c-52e61727e9e8">10,195,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" name="us-gaap:IncomeTaxesPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzU1LTEtMS0xLTA_843893a1-fa63-418b-9dc3-13e487e6e171">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" name="us-gaap:IncomeTaxesPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzU1LTMtMS0xLTA_1eee3f23-c825-40b0-b281-8ba78c2189b9">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:PreferredStockDividendAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYxLTEtMS0xLTA_3ea90098-6510-4d93-bac0-fd069755ef61">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:PreferredStockDividendAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYxLTMtMS0xLTA_ff319cba-5456-42e5-b9cb-5d55db2be776">24,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYzLTEtMS0xLTA_314eb440-b308-449c-9e1f-4565b850cba9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYzLTMtMS0xLTA_18df931c-ddcb-4ffd-90d7-42716302c691">268,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series D Convertible Preferred Stock issuance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTEtMS0xLTE3MzM_f2ac619b-1f70-46dd-9a49-630a374051b4">601,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTMtMS0xLTE3MzM_ea383009-317b-42cf-8249-497e7d7e2072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deemed dividend recognized for beneficial conversion features of Series E Convertible Preferred Stock issuance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTEtMS0xLTE3MzM_b0655bbc-fbf0-4af4-be50-ea60128d1ef1">2,664,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTMtMS0xLTE3MzM_ad1a88f4-65d2-4361-a34b-a0cbdab19807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $<ix:nonFraction unitRef="usd" contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZGM3ZjViNWMwYmQ0OGZjYjhhOWM2M2ZiMGZlNDU5Zl8xMDk5NTExNjI3OTQw_9f788b15-4b52-49e8-8030-90447f267e52">235,640</ix:nonFraction></span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231" decimals="0" format="ixt:zerodash" name="trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTEtMS0xLTA_a6c4ee79-97b0-4d88-8c2d-e7fbb8bfaf8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTMtMS0xLTA_9edb1c78-eff1-4896-b128-7d6190dee5a3">1,675,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, Series D Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $<ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTAtMS0xLTgzNy90ZXh0cmVnaW9uOmVjNGUxYTIyYWFjZjRlZDk5MWQ2Zjg4MzVmMmJkMThiXzIxOTkwMjMyNTU3MDE_e46ac66e-26c8-4f59-9924-fcd7fdd1f83e">488,270</ix:nonFraction></span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY3LTEtMS0xLTE3MjE_eaae4dbe-6e16-4994-9aac-d1bd214a9032">2,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY3LTMtMS0xLTE3MjE_a8ebe505-5925-40b4-bbbd-ef0ff0f7918b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon conversion of Series C Convertible Preferred Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231" decimals="0" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY2LTEtMS0xLTA_c164d374-e6a3-4860-9444-ce9777ebf49c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231" decimals="0" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY2LTMtMS0xLTA_c52b2ca6-1003-483a-91fb-e796dcef335f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon conversion of Series D Convertible Preferred Stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231" decimals="0" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcwLTEtMS0xLTE3Mzc_23502484-e842-4524-b1d8-9c4ac6ba861a">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcwLTMtMS0xLTE3Mzc_4f654c0a-d816-4d61-b2bb-bcc03ccbce41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issued upon conversion of Series E Convertible Preferred Stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231" decimals="0" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcxLTEtMS0xLTE3Mzc_0018e49d-2180-4adb-bc57-cf0236bcd72b">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcxLTMtMS0xLTE3Mzc_9feb71a1-d419-428a-adc4-86e8acf5df14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_256"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTYvZnJhZzo4YmUwOTg0YzgwYzQ0ODYwODg3YTg5YzNiOTVlYmIzNS90ZXh0cmVnaW9uOjhiZTA5ODRjODBjNDQ4NjA4ODdhODljM2I5NWViYjM1XzQxMTk_dc9a1d4c-8b5a-48d8-af59-a0b72110e863" continuedAt="ib74ff2b109b14adfa05d8922793b71c9" escape="true">Business Overview and Liquidity</ix:nonNumeric></span></div><ix:continuation id="ib74ff2b109b14adfa05d8922793b71c9"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology,&#160;Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, Zytiga&#174;-resistant metastatic castration-resistant prostate cancer and leukemias. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTYvZnJhZzo4YmUwOTg0YzgwYzQ0ODYwODg3YTg5YzNiOTVlYmIzNS90ZXh0cmVnaW9uOjhiZTA5ODRjODBjNDQ4NjA4ODdhODljM2I5NWViYjM1XzE2NDkyNjc0NTE2MTY_3d7d9c66-7dbf-4d6f-ad9f-5336a5130745">131.0</ix:nonFraction> million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 13 to the financial statements for further information.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_259"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjE5_6e4ebf1f-92f3-4374-a486-69d36371f4f5" continuedAt="i7a6305b6fcb549ce8e454c83cf4d1c92" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i7a6305b6fcb549ce8e454c83cf4d1c92" continuedAt="ic9db298b7c4a42cda4b13ec445b735f7"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6, effective February&#160;19, 2019. All share and per share information in the financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjM3_69c0c8c6-5224-4c55-b842-8670a4508f16" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzEwMzY_d26fd6a4-bd5e-4dd6-90ad-1c70e6cf0c19">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTU4_d4cc92ca-381d-4ca3-b74c-459b161ecb5f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="trov:AccruedClinicalTrialExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzEwOTk1MTE2Njg4NTY_9614dc84-cd49-4051-bd34-1fc8eef76ef6" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December 31, 2020 the Company&#8217;s Clinical trial accrual balance of $<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:AccruedClinicalTrialExpenses" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE2NDkyNjc0ODE2NTI_3a7f6617-8cd7-425c-905e-20ae1efb9c80">1,683,195</ix:nonFraction> is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE2NDkyNjc0ODAwMDM_d6534c58-57f5-4d5d-a779-58ab35fee04c">11,235,396</ix:nonFraction>. Certain accrued clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc1_7e59d529-7a23-49f1-944f-97dd6e099ea7" continuedAt="i3ae988ca24cd4337a14f846a334c9fe3" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3ae988ca24cd4337a14f846a334c9fe3">Cash and cash equivalents consist of operating and money market accounts as of December&#160;31, 2020 and 2019 on deposit. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTkw_9ae847d4-aaf4-42cd-854f-a2d6fbbf58ab" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="ic9db298b7c4a42cda4b13ec445b735f7" continuedAt="i881dca331a3d4dec8580b37fb0c52820"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTYy_110e5211-6edd-4659-90e6-44eacda22c6e" continuedAt="id40553b9fcca491f9a2b2bfc34c516a7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.&#160;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id40553b9fcca491f9a2b2bfc34c516a7"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjIw_1cb969f9-5762-41df-b4d4-493ea1150a5d">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.</ix:nonNumeric> Minimum royalties are generally due quarterly or annually.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjMx_53ef1846-be6d-4f05-9d41-aa0c5e90bf06" continuedAt="i1e0c11a6cced4fdf84cf2091eaa2e803" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings.&#160;Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#8217; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of the Company&#8217;s Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><ix:continuation id="i1e0c11a6cced4fdf84cf2091eaa2e803" continuedAt="i01ecae87c5dd46659d4b9f72fea380b3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i01ecae87c5dd46659d4b9f72fea380b3">below).</ix:continuation>&#160;At December&#160;31, 2020 and 2019, the fair value of these warrants was $<ix:nonFraction unitRef="usd" contextRef="i0656cf347232476bae791a60c6bd570f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzY4MzA_939986b1-1dc3-46bb-a96e-9b1cf1e58106">284,971</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzY4Mzc_b3c518a0-6f1b-4f00-917b-605da47aeb61">4,127</ix:nonFraction>, respectively, and was recorded as a liability under the caption &#8220;derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants&#8221; on the balance sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc2_b71ec729-6cde-4933-9201-835d6369ec1f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTUz_1187aff3-4038-4df9-9dda-c1f388247dba" continuedAt="i0b5cf55e41224b28ada3e502cf1fe014" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i881dca331a3d4dec8580b37fb0c52820" continuedAt="i69a523aee481499a93d0fe3baa77e441"><ix:continuation id="i0b5cf55e41224b28ada3e502cf1fe014"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTU0_848f875a-5959-4853-9fbd-83ab9ce70544" continuedAt="ibc7fab70e4a34b41bd957fb58871700a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc7fab70e4a34b41bd957fb58871700a">Long-lived assets consist of property and equipment. The Company records property and equipment at cost, and records other intangible assets based on their fair values at the date of acquisition. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of <ix:nonNumeric contextRef="i1514b777a3114342923aade0d19fa7c0_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzM4NDgyOTA3MTY4NzA_4a34ba36-0776-404d-9363-0dc11054e7d9">five years</ix:nonNumeric> for laboratory equipment and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb">three</span> to <ix:nonNumeric contextRef="ic8aaa0c125e84dba929af4a1e45d11b7_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzM4NDgyOTA3MTY4OTA_bc8483ba-9d9e-4656-8f30-5500200aad79">five years</ix:nonNumeric> for furniture and office equipment. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTYz_16ac1fff-ee04-44e5-807c-4559ae576b08" escape="true">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</ix:nonNumeric> </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjQw_59db30d1-75a3-4138-997d-675f9208a158" continuedAt="i3979f8fa6b47458ca4c7961d53d45869" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company&#8217;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3979f8fa6b47458ca4c7961d53d45869">Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.</ix:continuation> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i69a523aee481499a93d0fe3baa77e441" continuedAt="ie00dc458bb754794b0b4e7eaaa03a0ce"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjA0_28bd6cc7-e80e-44bf-9578-e4dccfb0c5b5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTg3_176f35a2-1d8c-4839-9372-23851fdfa26a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTcy_51c15b1e-1928-48a7-b88d-bd1e1f4ef214" continuedAt="ib0df378b13794a7b851285c9dd53c04c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib0df378b13794a7b851285c9dd53c04c">Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc4_432be31d-86a6-43aa-a718-e4355f0804d8" continuedAt="i28cbc9cb007e4670a41d71dd05e56f50" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i28cbc9cb007e4670a41d71dd05e56f50">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTcz_947c8099-dbc6-4445-a816-528398cecf95" continuedAt="i85aed9bc4d89454d857796814d88905d" escape="true">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</ix:nonNumeric></span></div><ix:continuation id="i85aed9bc4d89454d857796814d88905d"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id4f241b55b904f8e929edc9f63cfb4ce_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzItMS0xLTEtMA_a07fa594-d031-42cb-be9d-0050d72e6eeb">1,860,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icb66c3828dd94b5e81231528bde5fed7_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzItMy0xLTEtMA_f3d2bc02-ffe9-4da3-a338-94e9fc9883c3">1,015,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia954f550392d4591a6b546fb05b6c57d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzMtMS0xLTEtMA_8bcce4c9-6bd0-4db2-b455-123c92a144c0">5,260,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba7031dc6fd14ef19e26c971fe76416a_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzMtMy0xLTEtMA_7fcdb4c2-d122-447d-92dc-7641454d927b">10,589,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7aa2f04b48e40b6bb9e10276579135f_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzUtMS0xLTEtMA_2039def7-049c-4371-b1c6-d0c0127282f8">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04cf8ba00be248f88818392f53a19b98_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzUtMy0xLTEtMA_516af3b1-cf87-48c3-8bd0-5f10aa9691d3">11,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9ad1a7639b14aabab7b8f0710ecdb7d_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzYtMS0xLTEtMA_f4470135-d4aa-462d-aa6a-da6f32ac502c">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4c13518b4c74daca4beaea86298f527_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzYtMy0xLTEtMA_48bf7cae-e1dd-4c54-910d-db24aad5b766">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6436bbbd26f24becadccf4b1d782084d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMS0xLTEtOTIx_4d738b2e-344f-4998-87b8-7c322d91dd22">2,684,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i975673dd341547dabdaf95c95b6524fb_D20190101-20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMy0xLTEtOTIx_98c69827-56bd-4645-94cb-ab8a87f9e586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMS0xLTEtMA_dc85dbe9-1aad-4600-84a2-a5a83e04c945">9,807,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMy0xLTEtMA_d88886d6-a00c-461e-83de-aeb5c14230b7">11,617,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTQ4_e282f0d5-4957-46df-a68d-5564d6ce4533" continuedAt="i604d57e88f054651b76b3555f1844e1c" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ie00dc458bb754794b0b4e7eaaa03a0ce" continuedAt="ic658dbb037904ac09bb77c3970ae4bc9"><ix:continuation id="i604d57e88f054651b76b3555f1844e1c" continuedAt="ice72cee4c86746738cf34783e822c523">Recent Accounting Pronouncement Not Yet Adopted</ix:continuation></ix:continuation></span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><ix:continuation id="ic658dbb037904ac09bb77c3970ae4bc9" continuedAt="i3d8a5790a1d044ac808c3bcc0bdfc673"><ix:continuation id="ice72cee4c86746738cf34783e822c523" continuedAt="i5db53dbb1fd44fecb98ea38bf2fada60"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3d8a5790a1d044ac808c3bcc0bdfc673"><ix:continuation id="i5db53dbb1fd44fecb98ea38bf2fada60">. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</ix:continuation></ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzMw_44eeb07f-149f-4b46-8f15-24f1c6b97dc9" continuedAt="i580b3937e5f04301a2227845aceee716" escape="true">Supplementary Balance Sheet Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i580b3937e5f04301a2227845aceee716"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzI3OQ_de896e7e-3d0f-40d3-9d59-15bc08f1bd59">466,009</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzI4Ng_84ec72d0-fcd5-44ff-aa5a-fa729fbecaad">494,232</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzMQ_7feb45e9-3492-498d-9f2c-ac5da2679d51" continuedAt="i23eee5ccafed4409b1e2844bf35a8b2d" escape="true">Property and equipment consisted of the following:</ix:nonNumeric></span></div><ix:continuation id="i23eee5ccafed4409b1e2844bf35a8b2d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib040744e101141f9aea1e9d4756978f4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzItMS0xLTEtMA_901ced57-9a64-47e9-a4a1-1e6dd5411ae4">797,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35f2ef7d35840b9bfab3082034c4696_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzItMy0xLTEtMA_fb1a62f3-4968-406c-a8ab-50ca50ec4052">775,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb22003c74244c696720a265e0f7c37_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzMtMS0xLTEtMA_1a78be38-8e5c-4c53-8976-585f3c4a2dd1">1,962,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08e7553905d4d068f485877b9048505_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzMtMy0xLTEtMA_0f12491f-4139-480c-bab9-4cbc3d8c158f">1,962,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b16d8ca860f495a9615c84058672eac_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzQtMS0xLTEtMA_d0f7755e-bc7c-447d-9789-16cf0a936b34">867,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a4197db9564a4db2a4ad3445548a58_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzQtMy0xLTEtMA_043b0758-539c-4ce6-be73-5f6ff64bf470">744,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzUtMS0xLTEtMA_252570a6-5251-4630-9f14-be757493d365">3,627,719</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzUtMy0xLTEtMA_31d8822e-bb82-4adf-84b3-39f93d4fae47">3,482,116</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzYtMS0xLTEtMA_5fee9e37-1bbb-4d02-96a0-60f2d3fdf813">3,004,025</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzYtMy0xLTEtMA_409c9556-ae8b-462c-aaeb-36500fc0d9d4">2,604,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzctMS0xLTEtMA_ac11df92-6bff-4c88-af15-8edaa2159ad0">623,694</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzctMy0xLTEtMA_85c520bc-2c91-4fe5-9e7d-be8531d298d6">877,823</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzOA_369cd43a-9205-4bcd-b00e-c6143acbeddd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzItMS0xLTEtMA_144067ab-9b42-4aaf-9bfc-1764a40812c2">1,523,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzItMy0xLTEtMA_b0f81062-1501-4b38-bfce-30486fc4b250">1,003,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:AccruedPreferredStockDividend" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzMtMS0xLTEtMA_2943c652-6b5e-4720-8b6b-260f15e57252">389,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:AccruedPreferredStockDividend" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzMtMy0xLTEtMA_5fa61370-2bac-48aa-b5b9-84698ac573b6">365,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:AccruedClinicalTrial" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzQtMS0xLTEtMA_d07e1a91-b945-4170-9c85-c9a217500a5f">1,557,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:AccruedClinicalTrial" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzQtMy0xLTEtMA_1d264428-236c-4c8f-b73a-fd1e66b4b0b7">1,504,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Accruedresearchagreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMS0xLTEtMjc4OA_debfc8a9-3afd-4aab-8d50-5e123800d69e">66,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Accruedresearchagreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMy0xLTEtMjc4OA_04e8397b-7cd1-4ef9-ab0d-683e1fadf8e9">181,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Accrueddirectorfees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMS0xLTEtMA_eb54c793-eb77-4651-b888-f6e420aa71d2">92,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Accrueddirectorfees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMy0xLTEtMA_44177389-c056-48e7-a231-92070c6212d2">67,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzYtMS0xLTEtMA_18eddb06-57de-4396-8c60-3280ec08d6cb">38,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzYtMy0xLTEtMA_fa04d20b-79eb-4931-8294-7cc381c334be">21,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:Patentlicenseandotherfeespayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzctMS0xLTEtMA_80f3dbac-12b2-475b-9694-9460f3b7fbe0">117,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="trov:Patentlicenseandotherfeespayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzctMy0xLTEtMA_a4ecfa2a-afea-4256-9ba1-7ec8737acbdb">69,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzktMS0xLTEtMA_f12bf1f8-a366-4280-a6c0-234dfa333d47">66,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzktMy0xLTEtMA_d8e31c29-6c2f-4145-9274-d4cbe2c9748f">46,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzEwLTEtMS0xLTA_61e06510-154a-4ca7-83ec-7511a8faae3c">3,850,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzEwLTMtMS0xLTA_1fdee98c-8abe-4e59-8b47-ebca4cec08c4">3,260,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_268"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODA_f197b77a-6251-4589-a9dc-8062f9fc3d1d" continuedAt="i008a6fba8d744cdb919df9e5e98b9e1b" escape="true"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODE_05019a2f-96f2-4023-95d7-537f0ba4ab6e" continuedAt="i8e09a450b1ee4db285c198831aeefbdf" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i008a6fba8d744cdb919df9e5e98b9e1b" continuedAt="i0ec9730fb7434b0f840192ba402ba23f"><ix:continuation id="i8e09a450b1ee4db285c198831aeefbdf" continuedAt="i6d9cfa350d054843b730191009215f4c"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="trov:LesseeOperatingLeaseMonthlyRentPayment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzYxNA_94a92ef9-bce5-4af8-8199-7b42b4c02448">78,000</ix:nonFraction>, with <ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" name="trov:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzYyMw_be07949b-3d10-4398-8460-c7071fff7a74">3</ix:nonFraction>% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased space to third parties under <ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt-sec:numwordsen" name="trov:LessorNumberOfSubleases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzExNTA_ff54c55b-80db-4dc1-b119-67e0f8484168">three</ix:nonFraction> separate sublease agreements, which all expire December 31, 2021. Income is recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i0ec9730fb7434b0f840192ba402ba23f"><ix:continuation id="i6d9cfa350d054843b730191009215f4c"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzIxOTkwMjMyNTg2OTU_5b1142ae-c519-4d8e-8430-f7afc7295299">34,169</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" name="us-gaap:OperatingLeaseImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzIxOTkwMjMyNTg2OTE_990d2268-5212-43ea-a2ba-12b46bf93fa1">0</ix:nonFraction> for the twelve months ending December 31, 2020 and 2019, respectively. The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss. The loss was recorded within operating expenses in the statement of operations. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODI_327e5437-0e3d-48cc-a96d-f390876dcf78" continuedAt="i2a0414cdcd964b1c9333b2a950f7bb0a" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.174%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.108%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzEtNC0xLTEtOTM4_e40e1ada-09c4-4c48-a856-e4c20d1702f2">441,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzEtNC0xLTEtMA_b67d6e3f-d04d-4af2-a8f3-933993cd3cb0">444,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzItNC0xLTEtOTM4_2338f900-1d37-46d0-84f2-188f719ff5a4">291,173</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SubleaseIncome" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzItNC0xLTEtMA_a662104b-4e3a-4a10-8f3f-38444ef2085b">381,653</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzMtNC0xLTEtOTM4_a73afbfd-d603-4721-9132-932ba153c805">150,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzMtNC0xLTEtMA_aca7c3b7-6d74-4298-b766-2a9281c77b60">63,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="trov:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODM_9b0d1232-ead9-407c-b9a0-8c7b4af204f8" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzEtMS0xLTEtOTc4_6ce0e4ec-cf39-465d-aaf2-7c06c83fa2ad">343,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzEtMi0xLTEtMA_06b0c827-64a5-4fab-a468-30c1979d97d2">697,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzMtMS0xLTEtOTc4_8af6fbc5-bd8e-4c1d-b84b-15c6b64009bc">860,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzMtMi0xLTEtMA_83f84350-2d0f-44c3-b269-6100f1ebde8c">865,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzQtMS0xLTEtOTc4_c4d32b43-ec9b-4904-acf7-045d68e1703b">9,291</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzQtMi0xLTEtMA_855c543d-5d85-4646-a841-8c86e684894f">860,963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzUtMS0xLTEtOTc4_a505d09f-5fb1-4507-a5b0-4588d22c7e09">869,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzUtMi0xLTEtMA_e5854e73-6426-482d-b0e6-16e459c1424f">1,726,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i076def4a10c84321bb8feceb11551055_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzctMS0xLTEtOTc4_0484822e-75df-4f28-b86f-95eb2a2e628b">1.0</ix:nonNumeric> year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzctMi0xLTEtMA_36e853e0-fca6-4ee1-a983-f72c88fefbbd">2.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzgtMS0xLTEtOTc4_fb9c6066-70c5-4377-813e-9cebcea1b2ba">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzgtMi0xLTEtMA_6440830e-7833-4866-a7eb-9968f17d17bb">6.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="i2a0414cdcd964b1c9333b2a950f7bb0a"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo1N2QwODRkYmNjOGU0MWY2OTI3MmZiYjRkZjdkMzlmYi90YWJsZXJhbmdlOjU3ZDA4NGRiY2M4ZTQxZjY5MjcyZmJiNGRmN2QzOWZiXzItMS0xLTEtMTU1Mw_36b92760-0b29-43ed-ba24-0ae55071d68a">943,959</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo1N2QwODRkYmNjOGU0MWY2OTI3MmZiYjRkZjdkMzlmYi90YWJsZXJhbmdlOjU3ZDA4NGRiY2M4ZTQxZjY5MjcyZmJiNGRmN2QzOWZiXzItNC0xLTEtMA_2e4bdb29-694b-447d-b433-dd73978a5e67">916,762</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzEwOTk1MTE2MzI1NjM_b27dc2a2-a575-4614-a40a-30d464f9e0e8" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.996%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItMi0xLTEtMA_2e23c29b-5230-4484-a739-c44f8d72d3d3">889,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItNC0xLTEtMA_0cd85bb3-c76d-4976-8e22-8fefc2207821">403,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItNi0xLTEtMA_c631b938-ef3c-41a0-95f1-7843ca3000d1">486,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtMi0xLTEtMA_4433777e-a99a-454f-a07f-bddcac674c89">5,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtNC0xLTEtMA_d66f9fd8-e973-4525-a071-ca54b8f64301">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtNi0xLTEtMA_a8bc62c0-b548-4b6c-a51c-3840317f8800">5,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtMi0xLTEtMA_232adb3c-f61c-443c-a510-aaaceeabfe33">3,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtNC0xLTEtMA_de3f9c15-342b-472b-a65f-9fa9864ef896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtNi0xLTEtMA_44135859-d38d-42fc-8674-5181ed4f272f">3,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtMi0xLTEtMA_9475242e-fa4a-49d4-86f4-26f0b4f72998">898,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtNC0xLTEtMA_495eb47b-f8de-486b-bbe7-67e6eace3224">403,345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtNi0xLTEtMA_a2ccc514-2a03-4d35-8ba1-b82e766cbf73">495,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzctMi0xLTEtMA_b2469b30-2920-4cd7-9ce4-bd106edea22e">29,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzgtMi0xLTEtMA_207bb247-203f-44cb-837a-585cc0253c9e">869,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzExNTEw_5991b7f2-c7e6-4982-9bf5-d502cf761a13" continuedAt="i9fa4954e9d68472ea915835725c6a3c4" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i9fa4954e9d68472ea915835725c6a3c4" continuedAt="i7409b66895fa4d279911a551ad9e81e3"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzExNTE0_18b84b16-5519-48ab-b98c-c5fffcf44ce7" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.150%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e8da706562440a48c86522c944d0df6_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtMS0xLTEtMA_391f3204-6450-42b0-b7d4-938a2c2ae003">3,649,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8da706562440a48c86522c944d0df6_I20181231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtMy0xLTEtMA_824f8e23-ae57-49b4-bbf0-fd118eab3fc7">8.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i92fe3d8ede834ee9b4dfe1e82c7e0271_D20180101-20181231" format="ixt-sec:duryear" name="trov:WarrantsWeightedAverageContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtNS0xLTEtMA_599ff1d0-077d-4551-8228-c681abba8a79">4.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzYtMS0xLTEtMA_77e4ef71-3f18-493b-bd4b-b4ab1f92eac2">7,437,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzYtMy0xLTEtMA_4d687274-d556-45a0-9c59-5eeb0a836e1d">1.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzctMS0xLTEtMA_92d08811-3ae0-4c1d-8ff9-d9a97adbba7c">497,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzctMy0xLTEtMA_68993ddb-95df-4bb7-9c92-cbcf79ea9535">6.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktMS0xLTEtMA_d2259b0e-0669-4099-b940-741c69c4304d">10,589,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktMy0xLTEtMA_9419cc86-eaa4-4e67-bff0-858f39853f58">4.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" format="ixt-sec:duryear" name="trov:WarrantsWeightedAverageContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktNS0xLTEtMA_86184924-462e-4aa7-921a-2e6d1bf5b9ca">3.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEwLTEtMS0xLTA_39b4c491-1d45-43af-b9b5-3fdd13c3b906">5,831,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEwLTMtMS0xLTA_e75e07fa-5dd8-4021-a242-6835509d352a">1.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzExLTEtMS0xLTA_4823cda8-aa40-43a4-b9d8-a47eb8f51b7c">11,159,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzExLTMtMS0xLTA_5c87120d-486a-4c97-842a-af8d005c5ea4">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTEtMS0xLTA_2dad6cf8-bb06-4c97-9a28-8c67b434190a">5,260,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="2" name="trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTMtMS0xLTA_01f64952-164b-49e3-aebf-0bd5032d2280">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" format="ixt-sec:duryear" name="trov:WarrantsWeightedAverageContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTUtMS0xLTA_cb78bd34-e80a-443e-bc1a-b96d85e32592">4.1</ix:nonNumeric> years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above table excludes pre-funded warrants with a nominal exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxODQ_53e70483-907e-41e9-87e4-7ee0ab0798e0">.01</ix:nonFraction> per share: </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"><ix:nonFraction unitRef="shares" contextRef="id7f65a990a66462c9a37eb46069c65f5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzM0NDI_e90bb5a8-1b28-4e17-b8af-76e0462b4009">605,072</ix:nonFraction> pre-funded warrants outstanding as of December 31, 2019; </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"><ix:nonFraction unitRef="shares" contextRef="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzQyNTY_96d728d4-a71c-40d0-bf9f-a61e07c305c4">386,967</ix:nonFraction> pre-funded warrants which were issued during the twelve months ending December 31, 2020;</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">All <ix:nonFraction unitRef="shares" contextRef="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzQyNjU_2000fba6-b9e9-4149-ad72-bc2900673b81">992,039</ix:nonFraction> pre-funded warrants were exercised in full during the twelve months ending December 31, 2020.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxODI_3b88dc1f-368d-4b28-aa68-d16dbf1529ba" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItMi0xLTEtMzcyNQ_f4098c72-e12c-43fb-aa71-9d86abe8558e">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItNC0xLTEtMzcyNQ_e45df128-d76a-4920-90ed-7b0caa74f8a9">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockLiquidationPreferenceValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItNi0xLTEtMzcyNQ_83f145d5-de6f-4b47-9dc1-97b8ad6ce1e1">606,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItOC0xLTEtMzcyNQ_f8d4ac35-e378-4d85-98c2-b71307caa9ec">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i421f1d41857b4805963135b3663ab8d6_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItMTAtMS0xLTM3MjU_80259cc8-7f8d-4619-ab50-e154ba0b76c9">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtMi0xLTEtMzcyNQ_e3866d23-1c22-4fe2-8bf1-7c6f6ed24372">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtNC0xLTEtMzcyNQ_3cbc5b2e-8770-4c72-80f0-32bb9661a08b">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtOC0xLTEtMzcyNQ_7cd661d5-0172-4131-872c-77e8f2e20231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f48dc38e8b943eb97849002ada03817_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtMTAtMS0xLTM3MjU_9a7c3220-1c2b-4a48-bbf9-2cdd3702f709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtMi0xLTEtMzcyNQ_4bf72005-cd8f-4c2a-be93-f97931d38984">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtNC0xLTEtMzcyNQ_ca3ba3a0-275e-4963-be19-998b7e2e69eb">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtOC0xLTEtMzcyNQ_6cec43a8-a4c9-4df9-af4f-f91b1c5b62bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3451a9182b0d4178a8fc3c09f942e860_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtMTAtMS0xLTM3MjU_d4f44a7a-8bee-4679-bf45-eef9c3efe760">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtMi0xLTEtMzcyNQ_6bb1c0e0-c9c7-483e-b5ee-48c9187ca089">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtNC0xLTEtMzcyNQ_5a521562-026f-4841-9a62-d161bf130312">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtOC0xLTEtMzcyNQ_d5e8dd8e-d0e8-4272-992d-1b9f7ac5ed26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i256c4368010c4206a56da927baa4bb4e_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtMTAtMS0xLTM3MjU_b92fc469-8256-43db-a9da-cf1a258e96fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i776cee27efa541a2acc891f09e09f352_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtMi0xLTEtMzcyNQ_bfd8e4d6-0bea-4f19-b0dd-6bd332641dad">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776cee27efa541a2acc891f09e09f352_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtNC0xLTEtMzcyNQ_0dca01eb-80a1-41be-8934-527be419fdc1">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i776cee27efa541a2acc891f09e09f352_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtOC0xLTEtMzcyNQ_4bcb85cb-40ec-40ac-8b10-dec6cdebb4da">655,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id456584ebb174aeabb2b1a0753b4e83e_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtMTAtMS0xLTM3MjU_b72bc285-8cef-4c4e-a3f8-92f1915a3891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material terms of the Series A Convertible Preferred Stock consist of:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Dividends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Company&#8217;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of <ix:nonFraction unitRef="number" contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM2Mzk_3d598e13-4b51-489f-a706-66251f2e0bcb">4</ix:nonFraction>% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#8217;s sole election, in cash or shares of common stock. As of December&#160;31, 2020 and 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAmountOfPreferredDividendsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM4ODE_40b2e87c-8eed-45b5-9b03-bd040172cd95">389,495</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i471d5f109548413d9e884f49a86cd7e3_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAmountOfPreferredDividendsInArrears" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM4ODg_520595c6-34b1-4413-9838-cadac6904b97">365,255</ix:nonFraction>, respectively in accrued cumulative unpaid preferred stock dividends, included in accrued liabilities in the Company&#8217;s balance sheets, and $<ix:nonFraction unitRef="usd" contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzQwMzA_73147fb2-82d4-46d6-b871-35612bfa4770">24,240</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzQwMzc_160964eb-481b-4c05-83de-c705460357e3">24,240</ix:nonFraction> of accrued dividends were recorded during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Voting Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i7409b66895fa4d279911a551ad9e81e3" continuedAt="i871c736fedc04d2aaa6ae9fd016f1e02"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Liquidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $<ix:nonFraction unitRef="usdPerShare" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" name="trov:ConvertiblePreferredStockStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzUxMjk_2a146e7e-4e32-4e49-a3b9-38d5a447e314">10</ix:nonFraction> per share plus any accrued and unpaid dividends.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Conversion Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $<ix:nonFraction unitRef="usdPerShare" contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231" decimals="INF" name="trov:ConvertiblePreferredStockStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzUzOTI_d8dda24b-7654-425f-8e22-97abd3748fb0">10</ix:nonFraction> per share, by the conversion price, which at the time of issuance was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0d0b2dbac0ba4dff9255fe336b8f7f15_D20050701-20050930" decimals="2" name="trov:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU0NjU_05efd61c-8f36-4af4-b98e-1387eed22c09">928.80</ix:nonFraction> per share, and subsequently adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" decimals="2" name="trov:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU1MDg_10a273a5-2819-43f1-9661-0b171a2e91ea">691.20</ix:nonFraction> per share.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Subsequent Equity Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion price is subject to adjustment for dilutive issuances for a period of <ix:nonNumeric contextRef="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317" format="ixt-sec:durmonth" name="trov:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU2MzY_19a818ec-630c-4828-8360-7824503d04e0">12</ix:nonNumeric> months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock. The relevant registration statement became effective on March 17, 2006 and the conversion price was adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317" decimals="2" name="trov:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU4NTI_2dce21e6-86ec-4a11-8551-5e234030165d">691.20</ix:nonFraction> per share.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"> Automatic Conversion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the price of the Company&#8217;s common stock equals $<ix:nonFraction unitRef="usdPerShare" contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" decimals="2" format="ixt:numdotdecimal" name="trov:SharePriceForAutomaticConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU5NDM_755ac59e-8d80-4590-9680-3981c82bf093">1,857.60</ix:nonFraction> per share for <ix:nonNumeric contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" format="ixt-sec:durday" name="trov:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU5NjA_e9f14d7a-a0c9-4d55-b88c-8eea4e9980b9">20</ix:nonNumeric> consecutive trading days, and an average of <ix:nonFraction unitRef="shares" contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" decimals="INF" name="trov:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzYwMDc_a30ac0d2-2288-419c-9b15-403b8040283a">116</ix:nonFraction> shares of common stock per day are traded during the <ix:nonNumeric contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231" format="ixt-sec:durday" name="trov:PreferredStockConversionObligationNumberOfTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzYwNjM_2b503b76-8cee-4bb5-acef-969ad8bd842d">20</ix:nonNumeric> trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Convertible Preferred Stock and Service Receivable</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#8220;PoC&#8221;), whereby PoC agreed to finance $<ix:nonFraction unitRef="usd" contextRef="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125" decimals="-3" format="ixt:numdotdecimal" name="trov:AmountFinancedUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MDQ_fa25543f-28da-4b4c-9623-921b50999da7">1.675</ix:nonFraction>&#160;million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic Colorectal Cancer (&#8220;mCRC&#8221;) harboring KRAS mutation in exchange for (i)<ix:nonFraction unitRef="shares" contextRef="ie42a61e34be3441d8bb072f33438bcea_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU1OTU_9ce0eeb7-73db-423f-a855-6dfaef4b90c1">183,334</ix:nonFraction> shares of common stock, (ii) warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightNumberGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxOTA_79d91950-8468-4281-8599-26a9cafd4227">150,000</ix:nonFraction> shares of common stock, with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="if8a1c4888a02426788234b406ae96f2e_I20190125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxOTk_9f695c5a-cbb2-4f35-9faf-25c9e2529de9">3.762</ix:nonFraction> per share, expiring on January 25, 2024, and (iii) <ix:nonFraction unitRef="shares" contextRef="iaee37ec60282489987c4762ccebbab95_D20190125-20190125" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MjA_23aadb88-d620-43c0-adcb-6c59aba5c132">200,000</ix:nonFraction> shares of Series C Convertible Preferred Stock, each share of which was convertible into <ix:nonFraction unitRef="shares" contextRef="i2f5153c4279f4ab9989ac4ac9a3a516d_I20190125" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2Mjk_fda5bfd1-ded4-426d-a4c7-8c48c7dbd17e">1.67</ix:nonFraction> shares of common stock. In April of 2019, all <ix:nonFraction unitRef="shares" contextRef="ia02b699fc73a48aa943cf6fb99f91912_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MzU_496216b4-2ebd-4da7-a83f-bd8dfc9b5acb">200,000</ix:nonFraction> shares of Series C Convertible Preferred Stock were converted into <ix:nonFraction unitRef="shares" contextRef="i231a9537948e4825940975cf85f361b7_D20190401-20190430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2NDQ_54c8613f-0b3f-48f3-99a0-1660d20b80bc">333,333</ix:nonFraction> shares of the Company's common stock.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="id008b8758bbe4bd891a3f82bf9a4b6a6_I20190125" decimals="-3" format="ixt:numdotdecimal" name="trov:Servicereceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2NTM_521119dc-8479-4037-b224-bcb86e483008">1.675</ix:nonFraction>&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="iba125ce9af574f5f8548ad377e3f93e9_D20190125-20190125" decimals="-5" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMDc_3bd393e5-9f50-476b-9d67-14adfe54a424">0.3</ix:nonFraction>&#160;million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series D Convertible Preferred Stock and Service Receivable</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $<ix:nonFraction unitRef="usd" contextRef="iccf104fb4e174434837dcfd628d05782_D20200508-20200508" decimals="-5" format="ixt:numdotdecimal" name="trov:AmountFinancedUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2Njk_eee47db7-c940-41ca-9471-0220e99718be">2.3</ix:nonFraction>&#160;million for a clinical trial in exchange for (i) <ix:nonFraction unitRef="shares" contextRef="i076c4c3a873c4a759be050208a345aa5_D20200508-20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2ODM_699510a2-369b-4efc-a4a4-3c9157a32d0d">602,833</ix:nonFraction> shares of its common stock (the &#8220;Common Stock&#8221;), (ii) <ix:nonFraction unitRef="shares" contextRef="i2d3f12d14ad342198f5284373cca8a23_D20200508-20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MDE_f2a0c6bf-b83c-4da9-adc9-70aeba1f2aac">154,670</ix:nonFraction> shares of its Series D Preferred Stock and (iii) a warrant exercisable for <ix:nonFraction unitRef="shares" contextRef="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2OTI_48697acd-c079-4dc1-a954-76ac1f6ffdf5">859,813</ix:nonFraction> shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019, as amended. The warrant will be exercisable <ix:nonNumeric contextRef="i1ce3c54cec224ad18a266a3636ffa8b2_D20200508-20200508" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMzU_ea9b8962-e5d8-41f9-a9e1-03b8564e9775">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MTk_be9cb2a5-9225-4409-9a6a-28842491083f">1.50</ix:nonFraction> per share and will expire on November 7, 2025. In June of 2020, all <ix:nonFraction unitRef="shares" contextRef="icdfaba1492ec4f509a70416341174b1f_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MTA_8a48f608-8e8c-4eef-ade7-47648c40e44c">154,670</ix:nonFraction> Series D Preferred Stock were converted to <ix:nonFraction unitRef="shares" contextRef="i5a917753e1624c298122e4b830a4e135_D20200601-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MjY_cefe434b-172b-4618-9697-36ca690cb7ed">1,546,700</ix:nonFraction> shares of Common Stock. </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i871c736fedc04d2aaa6ae9fd016f1e02" continuedAt="iba56745a69a843e98881bac3e5f9e9d8"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i18b02bac98214f3d9f8953ec814372be_I20200508" decimals="-5" format="ixt:numdotdecimal" name="trov:Servicereceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3Mzc_e374c1cf-1a9a-413a-97c4-704b568a84b5">2.3</ix:nonFraction>&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="i52c1c34006664ee7ac7c7c4e9e79e509_D20200508-20200508" decimals="-5" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NTE_6ef2cce2-7967-4535-915a-5c2ec8a09249">0.6</ix:nonFraction>&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#8220;CDK&#8221;) and Third Street Holdings LLC (&#8220;Third Street&#8221;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i0668fc29bb0148d58510684753bd2cfc_D20200615-20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NjU_0f8e5462-07a4-4a88-8194-6e549002877c">1,984,328</ix:nonFraction> shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9b284544740a435bad1c3cec495cbf9f_D20200615-20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NzY_f4506df8-1568-4742-8928-0c16718c8bb6">865,824</ix:nonFraction> shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3ODU_2004b6bb-b558-43d4-a216-8df2e7ebb4be">2,213,115</ix:nonFraction> shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3OTY_06603e16-b5dc-40ea-b9f4-1cb89c346f4e">10</ix:nonFraction> stated value per share of the Series E Preferred Stock by a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615" decimals="INF" name="trov:PreferredStockConvertibleConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MDE_6ad2db62-9dfc-4b75-a00e-14e15c3c3313">2.44</ix:nonFraction> per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable <ix:nonNumeric contextRef="ifdfc040695af4d6a9817380661ebcf2e_D20200615-20200615" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMjA_d2e07fbc-6161-41c3-a4d2-c2cd9fa9e843">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib6b57d40d4354884b0510a8fef627c3d_I20200615" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MDg_0095fcf1-9780-4f3d-bfae-35ff4d80fdd3">2.39</ix:nonFraction> per share and will expire on December 16, 2025. Certain investors converted <ix:nonFraction unitRef="shares" contextRef="i95bc585cf217481b97c06b8337a64fe3_D20201201-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MTU_7c16423b-5a51-448d-acbe-6ac5548257ce">210,780</ix:nonFraction> shares of Series E Convertible Preferred stock to <ix:nonFraction unitRef="shares" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MjQ_4e32c971-0576-40cb-aa43-9da5966d0808">863,852</ix:nonFraction> shares of Common Stock during December 2020.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $<ix:nonFraction unitRef="usd" contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615" decimals="-5" format="ixt:numdotdecimal" name="trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MzM_c97440b3-c51a-4df6-8666-a180ca4e18c0">2.7</ix:nonFraction>&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued <ix:nonFraction unitRef="shares" contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615" decimals="INF" format="ixt:numdotdecimal" name="trov:ClassOfWarrantOrRightIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NDc_3491bdf0-9b90-468b-9e08-9912a6d574f6">184,426</ix:nonFraction> warrants as an advisory fee. These warrants are exercisable <ix:nonNumeric contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNTA_a9436aeb-18f4-49fc-bb0c-37191c86cca4">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NTY_08d4b1a5-a507-43da-b66c-693b22096ee9">3.05</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615" format="ixt-sec:duryear" name="trov:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NjU_04eaacc5-7111-48e5-86c1-5f9045f1fc57">5.5</ix:nonNumeric> years following the date of issuance. These warrants are classified as equity and its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615" decimals="0" format="ixt:numdotdecimal" name="trov:WarrantsFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NzA_cf843f65-2305-49d8-a1e7-3d39aa0893bc">370,666</ix:nonFraction> was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreements with Lincoln Park Capital Fund, LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) <ix:nonFraction unitRef="shares" contextRef="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4ODA_2f9acb81-fcde-4896-9e71-1bb3c5dc1e54">800,000</ix:nonFraction> shares of common stock and (b) Series I warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="ibfb24decc5bd454e83658b10c3fc8307_I20200330" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4ODk_c793b0c3-c15c-4e27-ba8d-2354de053baf">131,967</ix:nonFraction> shares (the &#8220;Series I Warrant Shares&#8221;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#8220;Series J Warrants&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="i896119a0fd374e00971913227a456947_I20200330" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNjU_cbd955c6-8879-4c50-8ca7-a3f894b15e0e">one</ix:nonFraction> share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable <ix:nonNumeric contextRef="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNzM_fc9cbf53-0fb4-4a46-8997-126cab90c054">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i896119a0fd374e00971913227a456947_I20200330" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4OTg_8b82bf82-f1b1-4917-9aac-2d152602ccbd">0.948</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330" format="ixt-sec:duryear" name="trov:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MjA_d178e9ee-a061-4552-82ff-a86de77e5679">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330" decimals="-5" format="ixt:numdotdecimal" name="trov:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MDY_4bb488d1-6be2-47b4-a58e-4fdc2d509ef5">1.0</ix:nonFraction>&#160;million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) <ix:nonFraction unitRef="shares" contextRef="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMDA_5ef63716-c5f7-4cc9-a575-ea1f55942f33">904,970</ix:nonFraction> shares of common stock and (b) Series K warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i8be9212423e34a67a70f23c6f9b5ddf4_I20200409" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMDk_51b90ce4-6896-4cf8-9c25-b5f92d6ffe84">255,000</ix:nonFraction> shares (the &#8220;Series K Warrant Shares&#8221;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#8220;Series L Warrants&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="i81d26bfbbbd5422086f3c9920448c373_I20200409" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMjQ_23e1e28d-a004-43f5-8540-144122e68f3e">one</ix:nonFraction> share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable <ix:nonNumeric contextRef="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMzI_77d4af00-b671-4eba-8b04-466f8181f24e">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i81d26bfbbbd5422086f3c9920448c373_I20200409" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMTg_5e6fe183-a2dd-43c1-bb66-537c615845c0">0.81</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409" format="ixt-sec:duryear" name="trov:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNDg_b865dd06-ab40-4006-8078-072c2b8229f6">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409" decimals="-5" format="ixt:numdotdecimal" name="trov:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNjM_298dac78-1087-4777-b05a-76d8f3911198">1.1</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement with Certain Directors and Executives</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold <ix:nonFraction unitRef="shares" contextRef="i3b38eb10663b489e9809321fc0276e7c_D20200511-20200511" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MjU_f3493afd-6f01-40b3-83c2-d6c4023853f0">447,761</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i0f6a9b93851e4335a8b8cb89237848bc_I20200511" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MzQ_5bdef5e5-579e-4512-bdae-e995b08d9fe1">1.34</ix:nonFraction> per share and <ix:nonFraction unitRef="shares" contextRef="i56c03a47441c4536b67faa8e4cf731b7_D20200514-20200514" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NDE_1d04a21e-600a-4453-a265-923483d8aa63">146,854</ix:nonFraction> shares of common stock at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf127176380c423fa60e0abdd61fd762_I20200514" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NTA_5d33d750-0a30-46c2-b61b-c93a83e364ba">1.43</ix:nonFraction> per share. The gross proceeds from these purchases were $<ix:nonFraction unitRef="usd" contextRef="i2e071b9425b74972bb38758dd9e5d35d_D20200511-20200514" decimals="0" format="ixt:numdotdecimal" name="trov:SaleOfStockConsiderationReceivedOnTransactionGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NTc_efce3244-ebee-423a-a727-92335166b67b">810,000</ix:nonFraction>. </span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="iba56745a69a843e98881bac3e5f9e9d8" continuedAt="i87591259872b45faa2738ca32f27748d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Purchase Agreement with Acorn Bioventures LP</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5Njc_4e2deab4-6197-4f03-ad6c-1c0f5682ba29">1,205,400</ix:nonFraction> shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5Nzg_69146c08-af2a-4f33-96a3-c85c9f40630d">482,160</ix:nonFraction> shares of common stock. The Series M Warrants are exercisable <ix:nonNumeric contextRef="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526" format="ixt-sec:durwordsen" name="trov:ClassOfWarrantOrRightMonthsUntilExercisable" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNzY_4494370d-925d-4c9b-babb-f2fa2f91da4a">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5ODc_9b4579df-aa80-4203-a8b5-6a0657189e43">2.024</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526" format="ixt-sec:duryear" name="trov:ClassOfWarrantOrRightExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzOTI_9fe0e3d0-92d7-43bd-8093-3c27d5c4d809">5.5</ix:nonNumeric> years following the date of issuance. The gross proceeds from this purchase were $<ix:nonFraction unitRef="usd" contextRef="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526" decimals="-5" format="ixt:numdotdecimal" name="trov:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5OTU_865a4002-01a9-4f94-9e39-4e572bddd294">2.5</ix:nonFraction>&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Public Offering</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87591259872b45faa2738ca32f27748d">On October 2, 2020 the Company completed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMDk_fbae78ad-84f1-4d01-92b6-36e77fd201e9">6,500,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i544a15f619624305a7fd2f23ac7f07e8_I20201002" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMjA_644faef8-f31d-4f58-a912-9664f2547c5a">13.50</ix:nonFraction> per share. In addition, the underwriters exercised in full an option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i201a9eb09e9e4e4d976772527902f4c8_D20201002-20201002" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMjg_f9df3a39-c8e9-4063-b6eb-43dd9e932429">975,000</ix:nonFraction> shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002" decimals="-5" format="ixt:numdotdecimal" name="trov:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMzc_8b645bde-6a22-4113-969e-43587b3636ca">100.9</ix:nonFraction>&#160;million, and net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwNTM_6bd12a6f-bdb5-4c0d-aa20-2c289d3a879c">94.0</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTI_0999bd45-c49b-4719-a249-ab940a3fb8ca" continuedAt="i879ff6fed6f94728984518703be61b5e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i879ff6fed6f94728984518703be61b5e" continuedAt="i4e7034bfa1014792abd10db0eb5801a5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cardiff Oncology, Inc. 2014 Equity Incentive Plan (the &#8220;2014 EIP&#8221;), authorizing up to <ix:nonFraction unitRef="shares" contextRef="i26ddee99771547b8a737dfc7a950fa46_I20140917" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzExOA_0b37b288-2686-454e-8190-3e8279e327aa">34,722</ix:nonFraction> shares of common stock for issuance under the 2014 EIP, was approved by the Board in June 2014 and approved by the stockholders of the Company at the September 17, 2014 Annual Meeting of Stockholders. The total number of authorized shares was increased to <ix:nonFraction unitRef="shares" contextRef="i091e321edee343b38a892516ab3dfeee_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM3Nw_e53cee46-1a32-466a-b4ef-02a965ef32fb">243,056</ix:nonFraction> between the inception of the 2014 EIP through December 31, 2018. At the June 6, 2019 Annual Meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to <ix:nonFraction unitRef="shares" contextRef="i86676dbd4e74419a825725ca27223263_I20190606" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzczMQ_9a62972d-72b3-4d11-af93-6116c2aa482b">1,243,056</ix:nonFraction>. At the April 6, 2020 Annual meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to <ix:nonFraction unitRef="shares" contextRef="ideda534790df48cc8af65a740c9c751e_I20200406" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzIxOTkwMjMyNTkyNTU_c898b1d2-f9a1-492e-950b-21ffa4d0e034">2,243,056</ix:nonFraction> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ieac8de1ad73340dabca4d672d5539b0c_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzc1OQ_4d826219-c8bc-47c0-b928-1ea07bf259dc">260,446</ix:nonFraction> shares available for issuance under the 2014 EIP.</span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NjI_b5583301-1f10-495b-afe4-b46df0654b10" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5389a4fe9a914abba2617db418a0173f_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzMtMS0xLTEtMA_95be235d-e021-42b4-9d47-1b5d3ab91dd9">354,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd6a7a4e022447ca67831dd187fe59e_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzMtMy0xLTEtMA_384b4b0c-b2c7-44bc-85d5-3b33bc19f587">399,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9460ddaf54074df7bfec5889e2b4845d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzUtMS0xLTEtMA_bd9b7515-926e-4eb8-8b39-42a1ce571046">1,410,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4aec0ea85e845048d3ce2ddb7213732_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzUtMy0xLTEtMA_e425cc60-bf1c-457b-bfbf-71e0e1fe6224">485,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzctMS0xLTEtMA_74a61bf0-c031-4bba-87e6-fbc891795e9a">1,764,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzctMy0xLTEtMA_9a07e692-3ab0-4fec-8565-5059e92f46f4">884,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NDk_9b0e8c5c-7f5b-4952-ada6-2db125e6b9c8" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY3YzRkODNiNjIzYTQ4NGFhMmU0ZDE1YWZhMmI3NTliXzM4NDgyOTA2OTcyMzg_58c9a51a-d7ed-412f-832b-d66c34d323da">0.39</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i282b0d837b364a6894a32526001160d0_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY3YzRkODNiNjIzYTQ4NGFhMmU0ZDE1YWZhMmI3NTliXzM4NDgyOTA2OTcyNDY_2e6e97c3-ddd4-4d52-a254-4e51b29f4efd">0.93</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if99ea3b979294094999f121f98b5bde6_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMy0xLTEtMC90ZXh0cmVnaW9uOjYyZDFiMDZmNTYyZDQzMTFhOGI1ZmIxYTNlYTAxMjczXzM4NDgyOTA2OTcyMzg_903abedb-ede9-448d-8faf-d0535a751dd6">1.66</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMy0xLTEtMC90ZXh0cmVnaW9uOjYyZDFiMDZmNTYyZDQzMTFhOGI1ZmIxYTNlYTAxMjczXzM4NDgyOTA2OTcyNDY_903d3cba-03e7-448b-8208-ce07044f281a">2.33</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzMtMS0xLTEtMA_f121a7be-ea1e-459e-b1d1-fcb649845dea">0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzMtMy0xLTEtMA_d41897b9-d4f8-4cc3-a52c-4e08f29123d2">0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOmI1Y2I2MGFhYWQ3MjQ5YzNiZjNhMmM4ZDQxYjczODNmXzM4NDgyOTA2OTcyMzI_3070397e-5b0a-419e-9f5c-c9d6484a2e9f">102</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i282b0d837b364a6894a32526001160d0_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOmI1Y2I2MGFhYWQ3MjQ5YzNiZjNhMmM4ZDQxYjczODNmXzM4NDgyOTA2OTcyMzg_714a245e-a02d-49f5-b88d-03ca39fecd47">106</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if99ea3b979294094999f121f98b5bde6_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjVkMDQzMGI2ZDQzMjQ2NGE4NDNiNjg0YjJmNzg2NTQzXzM4NDgyOTA2OTcyMzI_33d649ca-ede3-4931-b613-1786c78f041f">95</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjVkMDQzMGI2ZDQzMjQ2NGE4NDNiNjg0YjJmNzg2NTQzXzM4NDgyOTA2OTcyMzg_603b3dd1-399c-4047-a639-5a93b3b3a05a">99</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzUtMS0xLTEtMA_dd5bceb5-f639-4709-b3c0-45392c273ebd">105</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzUtMy0xLTEtMA_55187f9e-330e-4c3e-9bce-51b1014f13ce">96</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzYtMS0xLTEtMA_e7130680-198d-4bea-8ed4-ec843073e209">5.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzYtMy0xLTEtMA_15f5f3a2-9d5f-4517-af3b-86e1c3ff7282">5.9</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#8217;s stock options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the historical volatility of Cardiff Oncology&#8217;s common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain vanilla&#8221; share options. Options are considered to be &#8220;plain vanilla&#8221; if they have the following basic characteristics: (1) are granted &#8220;at-the-money&#8221;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates forfeitures based on its historical experience.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2020 and 2019, estimated as of the grant date using the Black-Scholes option valuation model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI0NzE_05eb6c5c-8df6-4782-a001-a8ab8fc2f991">2.09</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI0Nzg_d1ecc55d-30a6-454b-8d04-663518fd264e">1.91</ix:nonFraction> per share, respectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i4e7034bfa1014792abd10db0eb5801a5" continuedAt="ic7adf140d0a64e1b8ef910994dfe7837"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI2MDg_81facc58-a7ac-44d0-8cd3-c5b17ff18bca">1,519,004</ix:nonFraction>. The weighted-average remaining amortization period at December&#160;31, 2020 for non-vested stock options was <ix:nonNumeric contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI3MzA_76c2f2e5-cbc8-47ab-aada-17b35b4d49f2">1.9</ix:nonNumeric> years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested during the years ended December&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI4MzI_b2d64e57-caad-4cab-b91f-4d561262894f">1,522,984</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI4Mzk_70af91f1-85dd-4521-a5ce-300a2e7aeea7">386,654</ix:nonFraction>, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of stock options exercised during the year ended December 31, 2019 was $<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzE2NDkyNjc0NDU3ODU_a9cdc733-57ac-47db-8ee0-688a0a445c2f">0</ix:nonFraction>. </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTA_d871dde1-ac94-4934-b0bb-8538ea3f845d" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTEtMS0xLTA_3f0106e8-17d8-4e90-9323-cacabc8fcc98">1,015,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTMtMS0xLTA_c5cdcd3b-3c45-416d-a4b5-2bb08e0da363">12.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTUtMS0xLTA_e66f4959-f56d-444c-a898-df39ccd6a2f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTctMS0xLTA_0a4aeb2d-8994-4bf1-a31e-e4d035d92808">9.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzExLTEtMS0xLTA_aab7c560-6dd2-49fe-becc-b8ecf444de87">969,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzExLTMtMS0xLTA_e0e755dc-3a09-43a4-acc4-f9f71d6fee44">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTEtMS0xLTA_a32ca087-14a3-46c8-9ea9-bd5eab5b5847">60,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTMtMS0xLTA_db95b6ac-771d-4571-9617-8feacf081f41">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTUtMS0xLTI2ODk_b530837d-26d2-4906-b917-90906f079a44">970,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEzLTEtMS0xLTA_7c551138-c53d-4b8e-b76e-b3355c380655">48,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEzLTMtMS0xLTA_5299020d-a8c6-49eb-ae3e-cf7008111289">22.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="trov:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE0LTEtMS0xLTA_bd162d96-a484-482c-b170-43d319865875">16,144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" decimals="2" name="trov:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE0LTMtMS0xLTA_43e4c181-3215-429c-b2f0-95e87690f582">21.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTEtMS0xLTA_a394f890-76a4-4daf-9478-e44bb81cd520">1,860,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTMtMS0xLTA_26a8ece8-24ec-4a8f-8329-6afce6e00358">7.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTUtMS0xLTA_5e19d661-60db-48c2-9a89-36e10d6a830e">27,963,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTctMS0xLTA_32acacaf-f466-4d9d-bedd-caf788b93071">8.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTEtMS0xLTA_0781810d-e13f-46e0-86b3-bb24d003d754">753,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTMtMS0xLTA_b428f586-3fcb-470f-8834-8de153caf290">14.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTUtMS0xLTA_1b0ecda2-f0e4-4b42-9c79-77a04af5dbd8">10,837,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTctMS0xLTA_ed651b38-ab13-47f6-b6b1-06b51420aae6">8.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTEtMS0xLTI2OTY_8bd9b39a-6923-4d30-9578-ced4b80af53c">1,777,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTMtMS0xLTI2OTY_8bee0d24-d298-4e1b-9f8c-696973320142">7.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTUtMS0xLTI2OTY_2df6003d-be3d-4e26-9f13-549d46ac0599">26,682,849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTctMS0xLTI2OTY_471589eb-212b-471e-9807-3760cf308bde">8.9</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU's are measured at the grant date based on the closing market price of the Company&#8217;s common stock at the grant date and recognized ratably over the service period through the vesting date. All RSU's were granted with no purchase price. Vesting of the RSU's is generally subject to service conditions. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTg_6640951c-5fa6-4e1a-a4d0-c3debb351687" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU's activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:51.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.175%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtMS0xLTEtMA_be82b37a-070f-432e-835e-17a205fc636c">30,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtMy0xLTEtMA_93988c3c-f1bc-40c9-9dd9-7e6fb5d5cfb3">14.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtNS0xLTEtMA_f655c52b-08ad-4c87-ad18-237ea9dbea64">95,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzItMS0xLTEtMA_30dcd7d5-497c-410b-b7c5-95aa47a80e78">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzItMy0xLTEtMA_2b4355b2-0a1d-44c1-a836-f165660ce3a1">1.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzMtMS0xLTEtMA_d5700651-5581-424b-9924-fa91153c1d66">22,057</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzMtMy0xLTEtMA_a81f3d10-3034-4ace-86e2-703f44bbebad">8.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzQtMS0xLTEtMA_65c0c331-744b-4a82-bc61-d611eee27312">5,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzQtMy0xLTEtMA_8881af51-0c67-4883-a516-4a5b2f6ca608">13.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtMS0xLTEtMA_55b91b37-7761-4202-a4c1-583fc2c45bea">11,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtMy0xLTEtMA_c8edd50e-3d76-4bff-a817-e11841f97579">15.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtNS0xLTEtMA_a0a6ee34-a54a-49a6-825e-f8276f342ee3">14,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzctMS0xLTEtMA_f7a1c158-fd3e-424a-9f64-68ef1ac24f0e">10,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzctMy0xLTEtMA_c7f1261e-9d0c-4706-95b9-dea82e8e6de4">9.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktMS0xLTEtMA_364a6844-b28a-48e8-ad55-b178464144ed">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktMy0xLTEtMA_5d9ac826-5070-424e-ac84-5a3e5d69d2eb">147.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktNS0xLTEtMA_5393dc5e-91bb-49e2-9f17-63313bba4a83">7,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic7adf140d0a64e1b8ef910994dfe7837">The total fair values of RSU's vested during the year ended December&#160;31, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0MjM_27a4b70b-543b-4854-b5c8-033ed3e32ab7">101,290</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0MzA_390088c4-97d9-4f6b-ae00-21562a9138a8">191,436</ix:nonFraction>, respectively.</ix:continuation> </span></div><div><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2Njg_9f743abf-d7d5-442b-bd23-42dee29769b8" continuedAt="i0813e2aa0f6a4701b9c175755fdc776e" escape="true">Derivative Financial Instruments &#8212; Warrants</ix:nonNumeric></span></div><ix:continuation id="i0813e2aa0f6a4701b9c175755fdc776e" continuedAt="i6d8ca51351eb4ffeb48d6120f7ec6614"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#8217;s equity financings are accounted for as derivative liabilities.  Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model.  Changes in fair value are recorded within Company&#8217;s statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i229ba083ae0546d499ab31088af51e73_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2NzE_aadea163-ca9e-45a0-ba6d-3271df0cbcb2" continuedAt="i0ea8d12d44ab48868f98b53eac488635" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="i6d8ca51351eb4ffeb48d6120f7ec6614"><ix:continuation id="i0ea8d12d44ab48868f98b53eac488635" continuedAt="ia52ec9da07f3422aa3dd54e98a8b9150"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i32ab39cf4fc841beb603ef348cdce603_D20200101-20201231" decimals="2" name="trov:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMS0xLTEtMC90ZXh0cmVnaW9uOjhhNjVhNTcwYTc5NzQzMGY4ZmQyY2IyODNiZDQ0OGYwXzM4NDgyOTA2OTcyMzg_47456436-b589-4fa3-b13d-a9874da77790">1.01</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i4d8190644bee425ea8f517bd7095ed17_D20200101-20201231" decimals="2" name="trov:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMS0xLTEtMC90ZXh0cmVnaW9uOjhhNjVhNTcwYTc5NzQzMGY4ZmQyY2IyODNiZDQ0OGYwXzM4NDgyOTA2OTcyNDY_bc57f9f7-6b20-488a-9ece-fd12aadb2421">17.99</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1742e003e63146e896137b7e99fc50bf_D20190101-20191231" decimals="2" name="trov:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMy0xLTEtMC90ZXh0cmVnaW9uOmU3MDYxYzM4ZjJlZDRlOGNiNjJjZTBjMjJjYTdkZWVhXzM4NDgyOTA2OTcyMzg_5549b2b0-9695-4dde-b937-7abdcedcfb1a">1.24</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="i018bdbce7fca40e082dacb672d84b913_D20190101-20191231" decimals="2" name="trov:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMy0xLTEtMC90ZXh0cmVnaW9uOmU3MDYxYzM4ZjJlZDRlOGNiNjJjZTBjMjJjYTdkZWVhXzM4NDgyOTA2OTcyNDY_3d1de484-bf62-4f06-b0c9-437145aa44ae">3.75</ix:nonFraction></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i44266fc1522f4f4eb8386f8c708948d6_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFmZGY1YzcwOThjYTRmNGJiZDE0NDRiNjA4Zjc2ZWRlXzM4NDgyOTA2OTcyMzg_5160814e-b5b9-4695-810d-aa4674dec368">2.1</ix:nonNumeric> - <ix:nonNumeric contextRef="id3fca2ac35d14a2384fef909655332d4_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFmZGY1YzcwOThjYTRmNGJiZDE0NDRiNjA4Zjc2ZWRlXzM4NDgyOTA2OTcyNDQ_ff374c02-e68c-47cf-8802-0613d1865bb8">3.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0b1c58ab8b54dfc863c667221a34301_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjA2MTA1ZjZmOGE0MzQ0MmZhNzhjZTY2NzJiOWFlYzcwXzM4NDgyOTA2OTcyMzg_9be260b4-0ae0-4acc-bf69-21f475b69ca8">3.1</ix:nonNumeric> - <ix:nonNumeric contextRef="ie85416ca7f414db49fe52bc843a8e2d4_I20191231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjA2MTA1ZjZmOGE0MzQ0MmZhNzhjZTY2NzJiOWFlYzcwXzM4NDgyOTA2OTcyNDQ_bd7ba974-9910-4959-b9e0-eaa552b20032">4.1</ix:nonNumeric> years</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3794493459f24ebfbe863d8937e8cad5_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc2NDUyMDZiN2ZjNjQ5MzRiMzI2ZjhjNmJmNjIxZDZlXzM4NDgyOTA2OTcyMzg_45c3885c-e5cb-4b30-baa3-b7de33cbf52f">0.13</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i0fb8cbc4edb14870b358d288e5800248_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc2NDUyMDZiN2ZjNjQ5MzRiMzI2ZjhjNmJmNjIxZDZlXzM4NDgyOTA2OTcyNDY_4ed10f9a-2c7a-4aa4-bb00-e92a86d77042">1.62</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d3620e40923403582678ccccc8f11fa_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY5NzE5YzQ5N2Y5NjRjMGE5MTYzM2VmOGJlNmUwZmQwXzM4NDgyOTA2OTcyMzg_656151a0-9e10-4de3-93df-7163b2c208fd">1.56</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ib4f8972453604ec193d1df9f7e4ddac0_I20191231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY5NzE5YzQ5N2Y5NjRjMGE5MTYzM2VmOGJlNmUwZmQwXzM4NDgyOTA2OTcyNDY_30a19f20-7cb3-4adc-890c-94b727eb3d76">2.49</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cc7198d6c034a22b424dd61cae5fd7c_I20201231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjA4MWNmMGQ0MjRlYjQ5MmRhZDhlMTRiODA1NWQxNWM1XzM4NDgyOTA2OTcyMzU_f437c671-6372-48a7-802b-3dfa63ad8ae2">110</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i1106ab4e606c4769a8f986403de38037_I20201231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjA4MWNmMGQ0MjRlYjQ5MmRhZDhlMTRiODA1NWQxNWM1XzM4NDgyOTA2OTcyNDI_5ea0a4c4-0077-4762-a8c0-822963bae974">118</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id76a88eeb56a477fa5ae7aa8b08acf1d_I20191231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMy0xLTEtMC90ZXh0cmVnaW9uOmU4YWVmZTgxYmYyYTRiMzZhMGM2MWZkMTQ0OTg0MjI4XzM4NDgyOTA2OTcyMzU_e667386a-5ad8-4903-9bb5-ce3ab7679584">102</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ifd3060e53a504b04a348d4ba80c3b484_I20191231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMy0xLTEtMC90ZXh0cmVnaW9uOmU4YWVmZTgxYmYyYTRiMzZhMGM2MWZkMTQ0OTg0MjI4XzM4NDgyOTA2OTcyNDI_6b5e82dd-e06d-413e-8f97-25fd2bc7791a">111</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibfe962c2ee074fbe9e3a0a8ee9b2fc05_I20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzYtMS0xLTEtMA_7a5c3d25-07bd-4488-b8b8-b64cc1a55037">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i090a771b6a4c49029aca107400020091_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzYtMy0xLTEtMA_ee8bd7de-ecb1-4987-987b-502e9145406d">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i73ffea244a27445a8d5f0970bdc9898e_D20200101-20201231" decimals="2" name="trov:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEwLTEtMS0xLTEyMDE_79fc9bee-846a-4ee7-891f-c27e35a9404c">17.99</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i031d703e2ea24364b5f7af43c8fb47c0_I20201231" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzExLTEtMS0xLTEyMDE_fbb5df18-1088-4fbe-938b-5d404c6ca687">2.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ac205ca24f94fe293ef86874c82e1e2_I20201231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEyLTEtMS0xLTEyMDE_9fd31fef-4cbb-4eba-93d5-c6694a79391c">0.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice81c716c97c41b5bc001dfa532b8fdb_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEzLTEtMS0xLTEyMDE_b938d224-7efa-46fd-abc7-826778a9be82">116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3345cb0517cc4b0284c813555e82d7d2_I20201231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzE0LTEtMS0xLTEyMDE_da327878-3278-4d4a-a214-9f3dc3a090e2">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div></ix:continuation><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia52ec9da07f3422aa3dd54e98a8b9150">(2) The weighted average was calculated using the relative fair value method.</ix:continuation> </span></div><div style="padding-left:36pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of Cardiff Oncology&#8217;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i229ba083ae0546d499ab31088af51e73_D20200101-20201231" name="trov:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2NzQ_3887e0fe-e489-4e8c-9578-675e66b35ebd" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:15.468%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.618%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b746e4199184cacad6f602a3b40b8e9_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzEtNC0xLTEtMA_27a13b76-c8f1-4143-8ead-714577912d92">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b746e4199184cacad6f602a3b40b8e9_I20181231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzEtNi0xLTEtMA_b2d08098-faab-480e-b8ee-6ccd0391492e">32,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i747d6a62e34a472c83d5644420b34a22_D20190101-20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzMtNi0xLTEtMA_ba99f6f1-4413-4baf-9e22-024a32331609">28,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzQtNC0xLTEtMA_bf25e59e-06ce-46b6-b3ae-d281b36b7ebc">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzQtNi0xLTEtMA_baed9f8a-b5ef-494b-a072-5a74c7fbfa3e">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984ff34a2fe742088f9f828b91b563ea_D20200101-20201231" decimals="0" sign="-" format="ixt:numdotdecimal" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzYtNi0xLTEtMA_b4a29f4f-dac8-4794-a151-89b8c68f096f">280,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0656cf347232476bae791a60c6bd570f_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzctNC0xLTEtMA_1dc30525-60ff-4c44-92bd-332ff4ede9cd">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0656cf347232476bae791a60c6bd570f_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzctNi0xLTEtMA_4ab8abe7-b013-4bb4-abf3-b5863d0daa5e">284,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining contractual term of the warrants outstanding at December&#160;31, 2020 and 2019 was approximately <ix:nonNumeric contextRef="iffe390a53d1244859cc856f61f4542ae_D20200101-20201231" format="ixt-sec:duryear" name="trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzEzMzQ_71b4edf5-c69f-4700-91b9-822b561d81d3">2.1</ix:nonNumeric> and <ix:nonNumeric contextRef="ice44ef262276432684d43f12b496e84d_D20190101-20191231" format="ixt-sec:duryear" name="trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzEzNDE_4be6dc8c-d7f6-41f6-a730-b566b2eb864d">3.1</ix:nonNumeric> years, respectively.</span></div></ix:continuation><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90ZXh0cmVnaW9uOmMyYTA2NDY0NTEyMDRlYzA5NjE3MTM4M2JmMWFlNTJhXzEwNTM_4136c392-97ca-47dd-ad8c-735595e0c469" continuedAt="i2cbb7bdbb6a74e3eb92a5f74d8945851" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i2cbb7bdbb6a74e3eb92a5f74d8945851"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90ZXh0cmVnaW9uOmMyYTA2NDY0NTEyMDRlYzA5NjE3MTM4M2JmMWFlNTJhXzEwNTE_7df802bc-598b-4bdc-a67c-b24ebbcc2890" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2020 and 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtMS0xLTEtMA_b7c134da-9f12-42e8-a13f-b8c289cea0de">129,987,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtMy0xLTEtMA_a0a08325-994d-4ddd-940f-7f010093b7d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtNS0xLTEtMA_a3a12bb1-949a-40ad-ba5d-c32338a4f15e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtNy0xLTEtMA_6a3bd062-5da4-4166-84d9-bc84ac743191">129,987,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctMS0xLTEtMA_f37e7cf8-f8e3-4da1-a4e9-3a97a1a8d913">129,987,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctMy0xLTEtMA_24b75b71-3d09-4047-8d92-8ec562d96f3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctNS0xLTEtMA_ecd7b9a3-30df-4959-b80c-0635f9739875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctNy0xLTEtMA_83f5f9f0-594f-4a8c-a9b9-adb488ed57bd">129,987,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktMS0xLTEtMA_aee71586-8bf2-4abf-9f1e-2dbb9bd4d2fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktMy0xLTEtMA_6bfbbdf5-b4ef-472b-a6d4-d9e49b21fb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktNS0xLTEtMA_fb6aae4f-92eb-4e47-8d7f-17697133feef">284,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktNy0xLTEtMA_b6eb2ff6-41b4-4b22-9a9c-e4ab0345c576">284,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTEtMS0xLTA_d3b8f9be-3c1c-4404-bf61-1c21718533d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTMtMS0xLTA_eab22ce5-4eaa-45ff-8958-15c7f2b109aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTUtMS0xLTA_bd1a6ece-fa32-4a78-98d1-b54c5670a343">284,971</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTctMS0xLTA_e35eb192-8b16-4108-b179-7145f70dc72b">284,971</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:41.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtMS0xLTEtMA_8a93a0f7-0220-4e96-af00-0eb289771a22">10,131,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtMy0xLTEtMA_adda4828-8817-49e2-bf0c-05731b1fdae5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtNS0xLTEtMA_5870210c-94a5-4bc4-b072-e3cb3eff28e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtNy0xLTEtMA_cd26097d-e153-46ca-bc9b-4494df9bcc0d">10,131,240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctMS0xLTEtMA_6d18f45e-c787-49a7-a9d5-7d4bdb66b651">10,131,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctMy0xLTEtMA_bed769fe-9c9c-4fd6-ab41-3a0a09bd4875">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctNS0xLTEtMA_1b60cef3-4afb-40c5-83c0-2c6d9e612736">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctNy0xLTEtMA_b2dab4ea-ee78-49d2-b178-3b67530b28d6">10,131,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktMS0xLTEtMA_6bc1c56c-898b-4a18-aa1a-e88e6a1fb73e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktMy0xLTEtMA_ad792ead-ab79-46f4-b754-3a732f6acd0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktNS0xLTEtMA_aa1f4cbc-2621-4964-80ad-52c6c56744c4">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktNy0xLTEtMA_0db936ea-5fc1-4e1c-b046-d0aeb9ef3039">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTEtMS0xLTA_4773bc95-2ed5-4fd0-a3b2-5123bfed7f4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231" decimals="0" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTMtMS0xLTA_5247d8f2-0381-41c7-9f8b-c9fa87313343">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTUtMS0xLTA_76f34688-ed20-4679-b4b1-c922711f917a">4,127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTctMS0xLTA_83077580-9aff-414e-a7c5-9dcb033806f4">4,127</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included as a component of cash and cash equivalents on the accompanying balance sheet.</span></div></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the &#8220;derivative financial instruments&#8212;warrants&#8221; is recorded as a gain or loss in the Company&#8217;s statement of operations. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_295"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIwOTY_e630ad9f-8caa-480f-878b-cd79d8bde55f" continuedAt="iae32c3b4d781499a81372a2d091237f0" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iae32c3b4d781499a81372a2d091237f0" continuedAt="ie9e3e736b0f1496ca547cc2aeef61003"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, Cardiff Oncology had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $<ix:nonFraction unitRef="usd" contextRef="idbc8e0a3804c47c4ae77c14738fc2399_I20201231" decimals="-5" format="ixt:numdotdecimal" name="trov:OperatingLossCarryforwardsSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzExMg_0c0e4080-0f7e-42be-92cb-588435273e82">128.9</ix:nonFraction> million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="idbc8e0a3804c47c4ae77c14738fc2399_I20201231" decimals="-5" format="ixt:numdotdecimal" name="trov:OperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIyMQ_9e854e6f-adab-43d0-8fb1-f5f4aa698061">48.4</ix:nonFraction> million, which do not expire. Cardiff Oncology also has California NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="iedf02bb4675b4a2d940c16f6f69cb7c4_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzI5OA_4197710b-ea4e-4049-94f9-2937b1bbd715">70.7</ix:nonFraction> million which, if not used, will begin to expire in 2029. Cardiff Oncology has Federal and California capital loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ic9b865da6863477b8c4c5144516016d8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzE2NDkyNjc0NDYwOTg_6bf58e50-e330-4932-8c04-836da6cafc12">0.7</ix:nonFraction> million which, if not used, will begin to expire in 2022. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="id661a46404df44e0b0e9dbdd6e3e8364_I20201231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzQ2NA_1cef7df4-e325-442b-a326-1ae82d8e25c2">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i29a27f9e1adc4f6dacd046a2f6a03585_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzQ3MQ_29958a80-9433-4d3f-8d98-2758cb69933e">1.8</ix:nonFraction> million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of a company&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has not completed such an analysis pursuant to Sections 382 and 383 and therefore has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTM_1b25e5f1-cdb7-4084-aba1-c40a1d8e623e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzQtMS0xLTEtMA_3e69dfd6-f4a3-4cde-ab96-c719d29fac7f">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzQtMy0xLTEtMA_f6baae06-b414-4b9e-bf38-9f97e722fd81">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzUtMS0xLTEtMA_b2ea64c0-cdaa-4283-a756-30c66f5760df">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzUtMy0xLTEtMA_ed28a624-f258-4e5a-9ec3-a98a4aeee5b4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzctMS0xLTEtMA_19b99ed7-6aaa-478d-9397-08f48a2be917">4,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzctMy0xLTEtMA_220ba88d-95eb-4c2e-b682-8d11bcadd5dc">2,634</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzgtMS0xLTEtMA_3163e6a9-7561-46ed-b586-3dda2c8f28d2">92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzgtMy0xLTEtMA_07221610-621c-4990-9c14-9b3909c5b625">148</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEwLTEtMS0xLTA_daf0a7f3-e180-4973-b499-6612fd8b0344">4,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEwLTMtMS0xLTA_af20fcb0-539b-4804-bcba-31c947b3dfd7">2,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="trov:ValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzExLTEtMS0xLTA_409981d7-4ab4-4453-8ec8-6b7c12c01fbd">4,134</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="trov:ValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzExLTMtMS0xLTA_94eb7d6a-a303-473f-8eb7-d663805b6832">2,781</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEyLTEtMS0xLTA_8f5dd19f-08fc-4a2d-ac6c-df6d28166965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEyLTMtMS0xLTA_79558e95-f9e5-4fc8-bf9e-ff46cb249371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTA_49b90d96-bb22-4156-bf8a-9db62658f698" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below (in thousands, except percentages): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItMS0xLTEtMA_f37b12b9-ad95-4f87-a0c2-106c3ced9d58">4,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItMy0xLTEtMA_c45e6581-9e1b-4d67-87fa-09e1a952d934">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItNS0xLTEtMA_57e6b8bb-6f12-4edd-a637-8728f2e4fb38">3,447</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItNy0xLTEtMA_5c78c745-2409-42c7-a476-d8ef5a9ca742">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtMS0xLTEtMA_79930f4a-69cc-40c1-ac3c-db05264936d4">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtMy0xLTEtMA_949b0c91-9537-4b88-9207-c2dee37c11f5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtNS0xLTEtMA_31b9f2ba-d6ca-4201-bac9-b27de9d12051">177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtNy0xLTEtMA_89c7d362-fbab-453d-882e-ac1b9a98699f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent Items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" name="trov:IncomeTaxReconciliationPermanentItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtMS0xLTEtMA_6c724d0f-cb13-45cf-9084-bbeee0dcac22">261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" sign="-" name="trov:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtMy0xLTEtMA_a765eab2-8265-47ed-88af-b1825d4b2255">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" name="trov:IncomeTaxReconciliationPermanentItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtNS0xLTEtMA_7ac1dade-0179-4829-b39f-15055370d65f">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" sign="-" name="trov:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtNy0xLTEtMA_73b00ca7-5822-4d75-9b06-ce9133c250bd">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtMS0xLTEtMA_d21f580f-c829-4207-940a-e2ddc6ae5da8">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtMy0xLTEtMA_5eefcb14-e85c-49b4-9a33-e184e4a84941">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtNS0xLTEtMA_f846f424-3836-4557-8ea9-3e986fb1b2cd">875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtNy0xLTEtMA_71c159a2-6be4-46e6-b68f-ddd08a1d6e89">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctMS0xLTEtMA_040f0d0f-8677-4d0a-b602-ddf6ad72fbdf">300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctMy0xLTEtMA_2cce8c57-cc53-49b6-a8ce-d97295136447">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctNS0xLTEtMA_97b80712-c15d-4f54-9240-fea71614a700">384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctNy0xLTEtMA_493df92b-f95e-4e31-946f-74cb7be7eef6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtMS0xLTEtMA_db3b9938-909d-4d58-aad8-753a1049e6b6">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtMy0xLTEtMA_24e0f5e2-e71e-4388-bc16-d9276f792570">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtNS0xLTEtMA_8dd2771a-76bc-4f5d-8111-d15c6820f74a">2,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtNy0xLTEtMA_3f4bb7cd-5cf2-4d28-8ae7-af6058b5dda5">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTEtMS0xLTA_e5a4f95f-03a0-4742-8967-8f8552483dfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTMtMS0xLTA_cb5fc666-1227-4d02-891d-ea45bb80d955">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTUtMS0xLTA_cb831085-3f92-4c43-b2e3-af2756009f63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTctMS0xLTA_41f3135a-1c79-4773-9b8b-bf8a4cceb468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><ix:continuation id="ie9e3e736b0f1496ca547cc2aeef61003"><ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTE_9e2da743-88fd-46ff-834a-8ada8324828a" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzMtMS0xLTEtMA_c7b8858c-736e-4a00-85a2-7f997f7502ae">42,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzMtMy0xLTEtMA_7fee9673-caa2-4eff-a267-4a540da68600">38,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzQtMS0xLTEtMA_6a21da92-360d-46d1-a232-df3100986706">3,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzQtMy0xLTEtMA_349feeb5-e49e-4639-9e1b-998cbc4739e1">3,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzUtMS0xLTEtMA_220dda54-80a8-4671-a587-534851017a1d">684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzUtMy0xLTEtMA_77b3b726-674d-4645-a1e1-2117c4c66ca5">531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzYtMS0xLTEtMA_c6b3c32d-fdbb-4531-867f-dfda840b3382">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzYtMy0xLTEtMA_ef1bdb08-3fec-4076-8c53-303979c68d53">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzctMS0xLTEtMA_e1a68c55-2777-474e-92de-c757c4c00b32">48,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzctMy0xLTEtMA_9b3ccdcb-cb06-466a-8777-94bca6994b38">43,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzktMS0xLTEtMA_42f599ea-3a5b-4994-90ae-195da5c2fa83">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzktMy0xLTEtMA_2899547a-de39-4af9-a889-ca3ad62309d9">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEwLTEtMS0xLTA_dbe0a937-3554-421c-b9bd-3b87452b5c5f">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEwLTMtMS0xLTA_88d500fb-b637-457d-bd4a-dbb5780974f2">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzExLTEtMS0xLTA_3827565d-0098-4212-9adc-ba2ee148594b">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzExLTMtMS0xLTA_8b88dfc8-b4ee-4196-ad82-dfaabadbed78">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="trov:DeferredTaxAssetsNetBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEyLTEtMS0xLTA_44ae6d31-d89f-4d1c-8d38-ee336f822b18">47,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="trov:DeferredTaxAssetsNetBeforeValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEyLTMtMS0xLTA_3c11d468-b761-44a2-be7d-d3806df32a4f">43,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEzLTEtMS0xLTA_da24c8e1-8af1-4705-bce6-7f3fa835d7dd">47,955</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEzLTMtMS0xLTA_cfd69c28-34e5-4af3-b908-1dfc4eea9ae3">43,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i076def4a10c84321bb8feceb11551055_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzE0LTEtMS0xLTA_3f6176d5-f9d2-4b61-956d-85ea1360272c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzE0LTMtMS0xLTA_ee353d91-2703-4cdf-8e56-3f5e1610a821">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and <ix:nonFraction unitRef="usd" contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIwNjU_2094d459-c350-42d0-bc19-cb2ec450f485">none</ix:nonFraction> have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_298"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3XzIxMTg_ada04545-6419-4d7d-b8d1-a141e37179bc" continuedAt="i019a747277d240d09cd27057de4bfaf0" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i019a747277d240d09cd27057de4bfaf0" continuedAt="i511f43f12d6d49b1af2e84fe9fa2dd98"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $<ix:nonFraction unitRef="usd" contextRef="iac1d9ffb9c364277ad0f0ae113dd82f7_D20170301-20170331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3Xzc1NA_cb23b467-1be5-4367-9cc7-ef822b09cf76">2.0</ix:nonFraction> million in license fees which were expensed to research and development costs. The Company was committed to order $<ix:nonFraction unitRef="usd" contextRef="i9f2ba9a7769e4c3981f5515bac81bee0_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherCommitment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3Xzg2MQ_04311c01-95e3-49d9-b451-d6b7b070d714">1.0</ix:nonFraction> million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic18fbad9195b40d5a98c7f466e8a6118_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i511f43f12d6d49b1af2e84fe9fa2dd98">from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</ix:continuation></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_301"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDEvZnJhZzo2NTc4YmEwNDA5ZTg0MTk5ODE0YTNkN2IzZDYyZTY2Ny90ZXh0cmVnaW9uOjY1NzhiYTA0MDllODQxOTk4MTRhM2Q3YjNkNjJlNjY3XzM4Nw_df31955c-17c5-46d6-9e66-60cf1350b043" continuedAt="iddb3e7375a9f4102a0ee3caece8081ed" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="iddb3e7375a9f4102a0ee3caece8081ed"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_307"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzgzMg_81da19df-1a97-405a-83e1-22e0e48fca57" continuedAt="i67db2f33991a4ee88ec1b64333150ac8" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i67db2f33991a4ee88ec1b64333150ac8" continuedAt="i5bbfb3d3c92f4e3d893f6b920535d105"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leucadia Life Sciences</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;).  One of the Company&#8217;s Directors, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the years ended December&#160;31, 2020 and 2019, the Company incurred and recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i014c4430e11a4a7ba478369860aa6b07_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzcxNw_66bcf723-b591-49c6-83c0-981d15a11ef5">1,083,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i94d1eafc280542e8a75a72c3e54779ac_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzcyNA_2b58abe3-f35e-4242-9a58-80ab99bd24d1">1,005,000</ix:nonFraction>, respectively, of research and development expenses for services performed by Leucadia and Tommy Adams. The assay was completed in December 2020. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gary Pace Securities Purchase Agreement</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5bbfb3d3c92f4e3d893f6b920535d105">In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased <ix:nonFraction unitRef="shares" contextRef="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNDQ_004f791d-3582-4c0a-ad80-685ecc8e48b9">447,761</ix:nonFraction> shares of the Company's common stock at $<ix:nonFraction unitRef="usdPerShare" contextRef="id9ba25d98442435ab13367e9dd32ebd2_I20200531" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNTM_898889ee-cd19-43e5-bc16-79b3264d22af">1.34</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNjA_ab5665b8-1d84-483b-9e73-dd8bf1397ab6">600,000</ix:nonFraction> (see Note 5).</ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div id="ic18fbad9195b40d5a98c7f466e8a6118_2566"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231" name="us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xMDk5NTExNjMwMTUx_05edb536-3064-4c32-83c2-21baf1594b61" continuedAt="ic7fb419aba9d4d658fb7cd713c26eb15" escape="true">COVID-19</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ic7fb419aba9d4d658fb7cd713c26eb15"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's financial statements for the twelve months ended December&#160;31, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the twelve months ended December&#160;31, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment of Small Business Administration Payroll Protection Program Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 15, 2020, the Company was granted a loan (the &#8220;Loan&#8221;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="i7103d5be24a4480abffa7afe4b21824f_I20200415" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:NotesPayable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xNjQ5MjY3NDQzNjIz_eb5012e2-46b5-4338-8171-a1986a146984">305,000</ix:nonFraction>, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act with an interest rate of <ix:nonFraction unitRef="number" contextRef="i7103d5be24a4480abffa7afe4b21824f_I20200415" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xNjQ5MjY3NDQzNzUy_fe18ac3c-e7ae-411f-ae7c-5b9862c9244d">0.98</ix:nonFraction>% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.</span></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>a109ex022521.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia3bfe9a7d37645fb800dab24ece62726_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.9</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Amended and Restated Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into effective as of February 22, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Mark Erlander (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Cardiff Oncology, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R E C I T A L S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive serves as the Chief Executive Officer of the Company&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in order to provide Executive with financial security, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believes that it is in the best interests of the Company to provide Executive with certain engagement terms and severance benefits as set forth herein&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company and the Executive entered into that certain Employment Agreement dated February 18, 2016.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the mutual covenants herein contained and the employment of Executive by the Company, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following terms referred to in this Agreement shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following&#58;  (i) the commission of a material act of fraud, embezzlement or misappropriation, which is intended to result in substantial personal enrichment of Executive in connection with Executive&#8217;s employment with the Company&#59; (ii)&#160;Executive&#8217;s conviction of, or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to a crime constituting a felony (other than traffic-related offenses)&#59; (iii)&#160;a material breach of Executive&#8217;s proprietary information agreement that is materially injurious to the Company&#59; or (iv)&#160;Executive&#8217;s (1)&#160;material failure to perform his duties as set forth in this Agreement, and (2)&#160;failure to &#8220;cure&#8221; any such failure within thirty (30)&#160;days after receipt of written notice from the Company delineating the specific acts that constituted such material failure and the specific actions necessary, if any, to &#8220;cure&#8221; such failure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)the date on which any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), obtains &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act) or a pecuniary interest in fifty percent (50%)&#160;or more of the combined voting power of the Company&#8217;s then outstanding securities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)the consummation of a merger, consolidation, reorganization, or similar transaction involving the Company, other than a transaction&#58;  (1) in which substantially all of the holders of the Voting Stock immediately prior to such transaction hold or receive directly or indirectly more than fifty percent (50%)&#160;or more of the voting stock of the resulting entity or a parent company thereof, in substantially the same proportions as their ownership of the Company immediately prior to the transaction&#59; or (2)&#160;in which the holders of the Company&#8217;s capital stock immediately before such transaction will, immediately after such transaction, hold as a group on a fully diluted basis the ability to elect at least a majority of the authorized directors of the surviving entity (or a parent company)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)there is consummated a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale, lease, license or disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means totally and permanently disabled as defined in the Company&#8217;s disability benefit plan applicable to senior executive officers as in effect on the date thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without Executive&#8217;s express written consent any of the following&#58;  (i) a material reduction of Executive&#8217;s duties, position or responsibilities relative to Executive&#8217;s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of Executive from such position, duties or responsibilities&#59; (ii)&#160;a reduction of Executive&#8217;s compensation as in effect immediately prior to such reduction&#59; (iii)&#160;the relocation of Executive to a facility or a location more than twenty-five (25)&#160;miles from the Company&#8217;s then current principal location&#59; (iv)&#160;a material breach by the Company of this Agreement or any other agreement with Executive that is not corrected within fifteen (15)&#160;days after written notice from Executive (or such earlier date that the Company has notice of such material breach)&#59; or (v)&#160;the failure of the Company to obtain the written assumption of this Agreement by any successor contemplated in Section&#160;12 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Duties and Scope of Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term (as defined below), Executive will serve as Chief Executive Officer of the Company, reporting to the Board of Directors, and assuming and discharging such responsibilities as are commensurate with Executive&#8217;s position.  During the Term, Executive will provide services in a manner that will faithfully and diligently further the business of the Company and will devote a substantial portion of Executive&#8217;s business time, attention and energy thereto.  Notwithstanding the foregoing, nothing in this Agreement shall restrict Executive from managing his investments, other business affairs and other matters or serving on civic or charitable boards or committees, provided that no such activities unduly interfere with the performance of his obligations under this Agreement, provided that Executive shall honor the non-competition and non-solicitation terms as per Section&#160;15 below.  During the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Term, Executive agrees to disclose to the Company those other companies of which he is a member of the Board of Directors, an executive officer, or a consultant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of Executive&#8217;s employment under this Agreement shall commence as of February 22, 2021 (the &#8220;Effective Date&#8221;) and shall continue until February 21, 2024, unless earlier terminated in accordance with Section&#160;9 hereof.  The term of Executive&#8217;s employment shall be automatically renewed for successive one (1)&#160;year periods until the Executive or the Company delivers to the other party a written notice of their intent not to renew such employment, such written notice to be delivered at least sixty (60)&#160;days prior to the expiration of the then-effective Term as that term is defined below.  The period commencing as of the Effective Date and ending on Executive&#8217;s last date of employment with the Company under this Agreement is the &#8220;Term&#8221; and the end of the Term is referred to herein as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall pay to Executive a base compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of $533,000 per year (prorated for any partial year), payable at such times as the Company customarily pays its other senior executives (but in any event no less often than monthly).  In addition, each year during the Term, Executive shall be reviewed for purposes of determining the appropriateness of his Base Compensation hereunder.  The Base Compensation shall be subject to all federal, state and local payroll tax withholding and any other withholdings required by law.  For purposes of the Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as of any point in time shall refer to the Base Compensation as adjusted pursuant to this Section&#160;4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits&#59; Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Executive shall be entitled to participate in all company employee benefit plans.  In the event Executive elects to pay to a self-funded health insurance program, Executive shall be reimbursed by the Company for such costs up to the maximum amount the Company would be obligated to pay for similar benefits pursuant to its health insurance plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, the Company shall promptly reimburse Executive for all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to his Base Compensation, during the Term Executive shall be given the opportunity to earn an annual bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of up to 50% of Base Compensation.  The Bonus shall be earned by Executive upon the Company&#8217;s achievement of performance milestones for a fiscal year (in each case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be mutually agreed upon by the Executive and the Board or its compensation committee.  In the event Executive is employed by the Company for less than the full Target Year for which a Bonus is earned pursuant to this Section &#160;6, Executive shall be entitled to receive a pro-rated Bonus for such Target Year based on the number of days Executive was employed by the Company during such Target Year divided by 365.  The determinations of the Board or its compensation committee with respect to Bonuses will be final and binding.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, the Company may terminate Executive&#8217;s employment at any time and for any reason (or no reason), and with or without Cause, and without prejudice to any other right or remedy to which the Company or Executive may be entitled at law or in equity or under this Agreement.  Notwithstanding the foregoing, in the event the Company desires to terminate the Executive&#8217;s employment without Cause, the Company shall give the Executive not less than sixty (60)&#160;days advance written notice.  Executive&#8217;s employment shall terminate automatically in the event of his death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive may voluntarily terminate the Term upon sixty (60)&#160;days&#8217; prior written notice for any reason or no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, Executive&#8217;s employment shall terminate automatically upon his death.  Subject to the obligations of the Company set forth in Section&#160;10 below, in the event Executive is unable to perform his duties as a result of Disability during the Term, the Company shall have the right to terminate the employment of Executive by providing written notice of the effective date of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Payments Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Cause, Death or Disability or Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment hereunder is terminated during the Term by the Company for Cause, as a result of Executive&#8217;s death or Disability, or voluntarily by Executive without Good Reason, the Company shall compensate Executive (or in the case of death, Executive&#8217;s estate) as follows&#58;  on the date of termination, the Company shall pay Executive a lump sum amount equal to (i)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (ii)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (iii)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive or Executive&#8217;s estate, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, the Company shall compensate Executive as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination, the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">effective date of termination&#59; (B)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59; and, provided that Executive executes a written release, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, of any and all claims against the Company and all related parties with respect to all matters arising out of Executive&#8217;s employment by the Company, the Company shall pay Executive the Base Compensation for twelve (12)&#160;months from the date of termination, the potential Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period following the termination and any benefits (or benefits reimbursement payments) pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period.  Without limiting the foregoing, Executive also shall be entitled to the severance benefits set forth under Section&#160;10(c) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination in the Context of a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything in Section&#160;10(a) or 10(b) herein to the contrary, in the event of Executive&#8217;s termination of employment with the Company either (i)&#160;by the Company without Cause at any time within twelve (12)&#160;months prior to the consummation of a Change of Control if, prior to, or as of such termination, a Change of Control transaction was Pending (as defined in Section&#160;10(d) below) at any time during such twelve (12)-month period, (ii)&#160;by Executive for Good Reason at any time within twelve (12)&#160;months after the consummation of a Change of Control, or (iii)&#160;by the Company without Cause at any time upon or within twelve (12)&#160;months after the consummation of a Change of Control, then, Executive shall be entitled to the following payments and other benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination (except as specified in clause&#160;(C)), the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus earned and not yet paid through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)on the date of termination, the Company shall pay to Executive a lump sum amount equal to twelve (12)&#160;months of Executive&#8217;s Base Compensation then in effect as of the day of termination, the maximum Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period and any benefits pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)notwithstanding any provision of any stock incentive plan, stock option agreement, restricted stock agreement or other agreement relating to capital stock of the Company, all of the shares and equity awards held by Executive that are then unvested shall immediately vest and, with respect to all options, warrants and other convertible securities of the Company beneficially held by Executive, become fully exercisable for (A)&#160;a period of six months following the date of termination only if at the time of such termination there is a Change </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">of Control transaction Pending (as defined in Section&#160;10(d) below) or (B)&#160;if clause&#160;(A) does not apply, then such period of time set forth in the agreement evidencing the security&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)Severance benefits under this Section&#160;10(c) and Section&#160;10(b) above shall be mutually exclusive and severance under one such section shall prohibit severance under the other.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to effectuate the provisions of Section&#160;10(c)(iii) hereof, in the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, no equity award held by Executive shall expire or terminate prior to the earlier to occur of (a)&#160;ten (10)&#160;years after the date of the award and (b)&#160;fifteen (15)&#160;months after Executive&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Definition of &#8220;Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  For purposes of Section&#160;10(c) herein, a Change of Control transaction shall be deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; each time any of the following circumstances exist&#58;  (A) the Company and a third party have entered into a confidentiality agreement that has been signed by a duly-authorized officer of the Company and that is related to a potential Change of Control transaction&#59; (B)&#160;the Company has received a written expression of interest from a third party, including a binding or non-binding term sheet or letter of intent, related to a potential Change of Control transaction&#59; or (C)&#160;a third party has publicly announced, through a filing with the Securities and Exchange Commission, its intent to commence a tender offer or similar transaction to acquire 50% or more of the outstanding voting interests of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder to the extent applicable (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive under Code Section&#160;409A or any damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; If Executive is deemed on the date of termination to be a &#8220;specified employee&#8221; within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Code Section 409A payable on account of a &#8220;separation from service,&#8221; such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six&#160;(6)-month period measured from the date of such &#8220;separation from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">service&#8221; of Executive, and (ii) the date of Executive&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of the Delay Period to Executive in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)For purposes of Code Section 409A, Executive&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;payment shall be made within thirty (30) days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and&#47;or assets or otherwise pursuant to a Change of Control shall assume the Company's obligations under this Agreement and agree expressly in writing delivered to Executive, at or prior to such Change of Control, to perform the Company&#8217;s obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a Change of Control.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company's business and&#47;or assets (including any parent company to the Company), whether or not in connection with a Change of Control, which becomes bound by the terms of this Agreement by contract, operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given (a)&#160;when personally delivered (if to the Company, addressed to its Secretary at the Company&#8217;s principal place of business on a non-holiday weekday between the hours of 9 a.m. and 5 p.m.&#59; if to Executive, via personal service to his last known residence) or (b)&#160;three business days following the date it is mailed by U.S.&#160;registered or certified mail, return receipt requested and postage prepaid.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive recognizes and acknowledges that by reason of Executive&#8217;s employment by and service to the Company before, during and, if applicable, after the Term, Executive will have access to certain confidential and proprietary information relating to the Company&#8217;s business, which may include, but is not limited to, trade secrets, trade &#8220;know-how,&#8221; product development techniques and plans, formulas, customer lists and addresses, financing services, funding programs, cost and pricing information, marketing and sales techniques, strategy and programs, computer programs and software and financial information (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Executive acknowledges that such Confidential Information is a valuable and unique asset of the Company and Executive covenants that he will not, unless expressly authorized in writing by the Company, at any time during the course of Executive&#8217;s employment use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Executive also covenants that at any time after the termination of such employment, directly or indirectly, he will not use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation, unless such information is in the public domain through no fault of Executive or except when required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order Executive to divulge, disclose or make accessible such information.  All written Confidential Information (including, without limitation, in any computer or other electronic format) which comes into Executive&#8217;s possession during the course of Executive&#8217;s employment shall remain the property of the Company.  Unless expressly authorized in writing by the Company, Executive shall not remove any written Confidential Information from the Company&#8217;s premises, except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Upon termination of Executive&#8217;s employment, the Executive agrees to immediately return to the Company all written Confidential Information (including, without limitation, in any computer or other electronic format) in Executive&#8217;s possession.  As a condition of Executive&#8217;s employment with the Company and in order to protect the Company&#8217;s interest in such proprietary information, the Company shall require Executive&#8217;s execution of a Confidentiality Agreement and Inventions Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and incorporated herein by this reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Non-Competition&#59; Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Executive hereby covenants and agrees that during the Term and for a period of one year following the Expiration Date, the Executive will not, without the prior written consent of the Company, directly or indirectly, on his own behalf or in the service or on behalf of others, whether or not for compensation, engage in any business activity, or have any interest in any person, firm, corporation or business, through a subsidiary or parent entity or other entity (whether as a shareholder, agent, joint venturer, security holder, trustee, partner, Executive, creditor lending credit or money for the purpose of establishing or operating any such business, partner or otherwise) with any Competing Business in the Covered </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Area.  For the purpose of this Section&#160;15 (a), (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competing Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the current business of the Company and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all geographical areas of the United States and other foreign jurisdictions where Company then has offices and&#47;or sells its products directly or indirectly through distributors and&#47;or other sales agents.  Notwithstanding the foregoing, the Executive may own shares of companies whose securities are publicly traded, so long as ownership of such securities do not constitute more than one percent (1%)&#160;of the outstanding securities of any such company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive further agrees that during the Term and for a period of one (1)&#160;year from the Expiration Date, the Executive will not divert any business of the Company and&#47;or its affiliates or any customers or suppliers of the Company and&#47;or the Company&#8217;s and&#47;or its affiliates&#8217; business to any other person, entity or competitor, or induce or attempt to induce, directly or indirectly, any person to leave his or her employment with the Company and&#47;or its affiliates&#59; provided, however, that the foregoing provisions shall not apply to a general advertisement or solicitation program that is not specifically targeted at such employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive acknowledges and agrees that his obligations provided herein are necessary and reasonable in order to protect the Company and its affiliates and their respective business and Executive expressly agrees that monetary damages would be inadequate to compensate the Company and&#47;or its affiliates for any breach by Executive of his covenants and agreements set forth herein.  Accordingly, Executive agrees and acknowledges that any such violation of this Section&#160;15 will cause irreparable injury to the Company and that, in addition to any other remedies that may be available, in law, in equity or otherwise, the Company and its affiliates shall be entitled to seek injunctive relief against the breach of this Section&#160;15 or the continuation of any such breach by the Executive without the necessity of proving actual damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Employment Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that either Executive or the Company may terminate Executive&#8217;s employment at any time and for any reason, with or without Cause or Good Reason.  Any contrary representations that may have been made to Executive are superseded by this Agreement.  This is the full and complete agreement between Executive and the Company on this term.  Although Executive&#8217;s duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Executive&#8217;s employment may only be changed in an express written agreement signed by Executive and a duly authorized officer of the Company (other than Executive).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sections&#160;1, 5, 6, 10, 11, 13, 14, 15 and 17 herein, including this Section&#160;17(a), shall survive the termination of Executive&#8217;s employment with the Company, the expiration of this Agreement and the termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Modifications&#59; No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement supersedes, amends and restates all prior agreements and understandings between the parties, oral or written, including, without limitation, the Executive Agreement.  No modification, termination or attempted waiver shall be valid unless in writing, signed by the party against whom such modification, termination or waiver is sought to be enforced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, and may be delivered by facsimile or other electronic means, but all of which shall be deemed originals and taken together will constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10-</font></div></div></div><div id="ia3bfe9a7d37645fb800dab24ece62726_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">COMPANY&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc.</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Rodney Markin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">______</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Rodney Markin</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Chairman of the Board</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EXECUTIVE&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Mark Erlander</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">___________</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Mark Erlander                                                                         &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;A</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Release Agreement</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;B</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality and Inventions Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>a1016ex022521.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie4c79124b4e247c99490f86058446e17_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into effective as of February 22, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Vicki Kelemen (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Cardiff Oncology, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R E C I T A L S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive serves as the Executive Vice President and Chief Operating  Officer of the Company&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in order to provide Executive with financial security, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believes that it is in the best interests of the Company to provide Executive with certain engagement terms and severance benefits as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the mutual covenants herein contained and the employment of Executive by the Company, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following terms referred to in this Agreement shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following&#58;  (i) the commission of a material act of fraud, embezzlement or misappropriation, which is intended to result in substantial personal enrichment of Executive in connection with Executive&#8217;s employment with the Company&#59; (ii)&#160;Executive&#8217;s conviction of, or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to a crime constituting a felony (other than traffic-related offenses)&#59; (iii)&#160;a material breach of Executive&#8217;s proprietary information agreement that is materially injurious to the Company&#59; or (iv)&#160;Executive&#8217;s (1)&#160;material failure to perform his duties as set forth in this Agreement, and (2)&#160;failure to &#8220;cure&#8221; any such failure within thirty (30)&#160;days after receipt of written notice from the Company delineating the specific acts that constituted such material failure and the specific actions necessary, if any, to &#8220;cure&#8221; such failure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)the date on which any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), obtains &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act) or a pecuniary interest in fifty percent (50%)&#160;or more of the combined voting power of the Company&#8217;s then outstanding securities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)the consummation of a merger, consolidation, reorganization, or similar transaction involving the Company, other than a transaction&#58;  (1) in which substantially all of the holders of the Voting Stock immediately prior to such transaction hold or receive directly or indirectly more than fifty percent (50%)&#160;or more of the voting stock of the resulting entity or a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">parent company thereof, in substantially the same proportions as their ownership of the Company immediately prior to the transaction&#59; or (2)&#160;in which the holders of the Company&#8217;s capital stock immediately before such transaction will, immediately after such transaction, hold as a group on a fully diluted basis the ability to elect at least a majority of the authorized directors of the surviving entity (or a parent company)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)there is consummated a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale, lease, license or disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means totally and permanently disabled as defined in the Company&#8217;s disability benefit plan applicable to senior executive officers as in effect on the date thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without Executive&#8217;s express written consent any of the following&#58;  (i) a material reduction of Executive&#8217;s duties, position or responsibilities relative to Executive&#8217;s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of Executive from such position, duties or responsibilities&#59; (ii)&#160;a reduction of Executive&#8217;s compensation as in effect immediately prior to such reduction&#59; (iii)&#160;the relocation of Executive to a facility or a location more than twenty-five (25)&#160;miles from the Company&#8217;s then current principal location&#59; (iv)&#160;a material breach by the Company of this Agreement or any other agreement with Executive that is not corrected within fifteen (15)&#160;days after written notice from Executive (or such earlier date that the Company has notice of such material breach)&#59; or (v)&#160;the failure of the Company to obtain the written assumption of this Agreement by any successor contemplated in Section&#160;12 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Duties and Scope of Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term (as defined below), Executive will serve as Executive Vice President, Chief Operating Officer of the Company, reporting to the Chief Executive Officer, and assuming and discharging such responsibilities as are commensurate with Executive&#8217;s position.  During the Term, Executive will provide services in a manner that will faithfully and diligently further the business of the Company and will devote a substantial portion of Executive&#8217;s business time, attention and energy thereto.  Notwithstanding the foregoing, nothing in this Agreement shall restrict Executive from managing her investments, other business affairs and other matters or serving on civic or charitable boards or committees, provided that no such activities unduly interfere with the performance of her obligations under this Agreement, provided that Executive shall honor the non-competition and non-solicitation terms as per Section&#160;15 below.  During the Term, Executive agrees to disclose to the Company those other companies of which she is a member of the Board of Directors, an executive officer, or a consultant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of Executive&#8217;s employment under this Agreement shall commence as of February 22, 2021 (the &#8220;Effective Date&#8221;) and shall continue until February 21, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2024, unless earlier terminated in accordance with Section&#160;9 hereof.  The term of Executive&#8217;s employment shall be automatically renewed for successive one (1)&#160;year periods until the Executive or the Company delivers to the other party a written notice of their intent not to renew such employment, such written notice to be delivered at least sixty (60)&#160;days prior to the expiration of the then-effective Term as that term is defined below.  The period commencing as of the Effective Date and ending on Executive&#8217;s last date of employment with the Company under this Agreement is the &#8220;Term&#8221; and the end of the Term is referred to herein as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall pay to Executive a base compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of $360,000 per year (prorated for any partial year), payable at such times as the Company customarily pays its other senior executives (but in any event no less often than monthly).  In addition, each year during the Term, Executive shall be reviewed for purposes of determining the appropriateness of his Base Compensation hereunder.  The Base Compensation shall be subject to all federal, state and local payroll tax withholding and any other withholdings required by law.  For purposes of the Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as of any point in time shall refer to the Base Compensation as adjusted pursuant to this Section&#160;4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits&#59; Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Executive shall be entitled to participate in all company employee benefit plans.  In the event Executive elects to pay to a self-funded health insurance program, Executive shall be reimbursed by the Company for such costs up to the maximum amount the Company would be obligated to pay for similar benefits pursuant to its health insurance plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, the Company shall promptly reimburse Executive for all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to her Base Compensation, during the Term Executive shall be given the opportunity to earn an annual bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of up to 45% of Base Compensation.  The Bonus shall be earned by Executive upon the Company&#8217;s achievement of performance milestones for a fiscal year (in each case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be mutually agreed upon by the Executive and the Board or its compensation committee.  In the event Executive is employed by the Company for less than the full Target Year for which a Bonus is earned pursuant to this Section &#160;6, Executive shall be entitled to receive a pro-rated Bonus for such Target Year based on the number of days Executive was employed by the Company during such Target Year divided by 365.  The determinations of the Board or its compensation committee with respect to Bonuses will be final and binding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, the Company may terminate Executive&#8217;s employment at any time and for any reason (or no reason), and with or without Cause, and without prejudice to any other right or remedy to which the Company or Executive may be entitled at law or in equity or under this Agreement.  Notwithstanding the foregoing, in the event the Company desires to terminate the Executive&#8217;s employment without Cause, the Company shall give the Executive not less than sixty (60)&#160;days advance written notice.  Executive&#8217;s employment shall terminate automatically in the event of his death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive may voluntarily terminate the Term upon sixty (60)&#160;days&#8217; prior written notice for any reason or no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, Executive&#8217;s employment shall terminate automatically upon his death.  Subject to the obligations of the Company set forth in Section&#160;10 below, in the event Executive is unable to perform his duties as a result of Disability during the Term, the Company shall have the right to terminate the employment of Executive by providing written notice of the effective date of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Payments Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Cause, Death or Disability or Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment hereunder is terminated during the Term by the Company for Cause, as a result of Executive&#8217;s death or Disability, or voluntarily by Executive without Good Reason, the Company shall compensate Executive (or in the case of death, Executive&#8217;s estate) as follows&#58;  on the date of termination, the Company shall pay Executive a lump sum amount equal to (i)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (ii)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (iii)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive or Executive&#8217;s estate, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, the Company shall compensate Executive as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination, the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59; and, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that Executive executes a written release, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, of any and all claims against the Company and all related parties with respect to all matters arising out of Executive&#8217;s employment by the Company, the Company shall pay Executive the Base Compensation for twelve (12)&#160;months from the date of termination, the potential Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period following the termination and any benefits (or benefits reimbursement payments) pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period.  Without limiting the foregoing, Executive also shall be entitled to the severance benefits set forth under Section&#160;10(c) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination in the Context of a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything in Section&#160;10(a) or 10(b) herein to the contrary, in the event of Executive&#8217;s termination of employment with the Company either (i)&#160;by the Company without Cause at any time within twelve (12)&#160;months prior to the consummation of a Change of Control if, prior to, or as of such termination, a Change of Control transaction was Pending (as defined in Section&#160;10(d) below) at any time during such twelve (12)-month period, (ii)&#160;by Executive for Good Reason at any time within twelve (12)&#160;months after the consummation of a Change of Control, or (iii)&#160;by the Company without Cause at any time upon or within twelve (12)&#160;months after the consummation of a Change of Control, then, Executive shall be entitled to the following payments and other benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination (except as specified in clause&#160;(C)), the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus earned and not yet paid through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)on the date of termination, the Company shall pay to Executive a lump sum amount equal to twelve (12)&#160;months of Executive&#8217;s Base Compensation then in effect as of the day of termination, the maximum Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period and any benefits pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)notwithstanding any provision of any stock incentive plan, stock option agreement, restricted stock agreement or other agreement relating to capital stock of the Company, all of the shares and equity awards held by Executive that are then unvested shall immediately vest and, with respect to all options, warrants and other convertible securities of the Company beneficially held by Executive, become fully exercisable for (A)&#160;a period of six months following the date of termination only if at the time of such termination there is a Change of Control transaction Pending (as defined in Section&#160;10(d) below) or (B)&#160;if clause&#160;(A) does not apply, then such period of time set forth in the agreement evidencing the security&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)Severance benefits under this Section&#160;10(c) and Section&#160;10(b) above shall be mutually exclusive and severance under one such section shall prohibit severance under the other.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to effectuate the provisions of Section&#160;10(c)(iii) hereof, in the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, no equity award held by Executive shall expire or terminate prior to the earlier to occur of (a)&#160;ten (10)&#160;years after the date of the award and (b)&#160;fifteen (15)&#160;months after Executive&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Definition of &#8220;Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  For purposes of Section&#160;10(c) herein, a Change of Control transaction shall be deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; each time any of the following circumstances exist&#58;  (A) the Company and a third party have entered into a confidentiality agreement that has been signed by a duly-authorized officer of the Company and that is related to a potential Change of Control transaction&#59; (B)&#160;the Company has received a written expression of interest from a third party, including a binding or non-binding term sheet or letter of intent, related to a potential Change of Control transaction&#59; or (C)&#160;a third party has publicly announced, through a filing with the Securities and Exchange Commission, its intent to commence a tender offer or similar transaction to acquire 50% or more of the outstanding voting interests of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder to the extent applicable (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive under Code Section&#160;409A or any damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; If Executive is deemed on the date of termination to be a &#8220;specified employee&#8221; within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Code Section 409A payable on account of a &#8220;separation from service,&#8221; such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six&#160;(6)-month period measured from the date of such &#8220;separation from service&#8221; of Executive, and (ii) the date of Executive&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of the Delay Period to Executive in a lump sum, and any remaining payments and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)For purposes of Code Section 409A, Executive&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;payment shall be made within thirty (30) days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and&#47;or assets or otherwise pursuant to a Change of Control shall assume the Company's obligations under this Agreement and agree expressly in writing delivered to Executive, at or prior to such Change of Control, to perform the Company&#8217;s obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a Change of Control.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company's business and&#47;or assets (including any parent company to the Company), whether or not in connection with a Change of Control, which becomes bound by the terms of this Agreement by contract, operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given (a)&#160;when personally delivered (if to the Company, addressed to its Secretary at the Company&#8217;s principal place of business on a non-holiday weekday between the hours of 9 a.m. and 5 p.m.&#59; if to Executive, via personal service to his last known residence) or (b)&#160;three business days following the date it is mailed by U.S.&#160;registered or certified mail, return receipt requested and postage prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive recognizes and acknowledges that by reason of Executive&#8217;s employment by and service to the Company before, during and, if applicable, after the Term, Executive will have access to certain confidential and proprietary information relating to the Company&#8217;s business, which may include, but is not limited to, trade secrets, trade &#8220;know-how,&#8221; product development techniques and plans, formulas, customer lists and addresses, financing services, funding programs, cost and pricing information, marketing and sales </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">techniques, strategy and programs, computer programs and software and financial information (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Executive acknowledges that such Confidential Information is a valuable and unique asset of the Company and Executive covenants that he will not, unless expressly authorized in writing by the Company, at any time during the course of Executive&#8217;s employment use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Executive also covenants that at any time after the termination of such employment, directly or indirectly, he will not use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation, unless such information is in the public domain through no fault of Executive or except when required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order Executive to divulge, disclose or make accessible such information.  All written Confidential Information (including, without limitation, in any computer or other electronic format) which comes into Executive&#8217;s possession during the course of Executive&#8217;s employment shall remain the property of the Company.  Unless expressly authorized in writing by the Company, Executive shall not remove any written Confidential Information from the Company&#8217;s premises, except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Upon termination of Executive&#8217;s employment, the Executive agrees to immediately return to the Company all written Confidential Information (including, without limitation, in any computer or other electronic format) in Executive&#8217;s possession.  As a condition of Executive&#8217;s employment with the Company and in order to protect the Company&#8217;s interest in such proprietary information, the Company shall require Executive&#8217;s execution of a Confidentiality Agreement and Inventions Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and incorporated herein by this reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Non-Competition&#59; Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Executive hereby covenants and agrees that during the Term and for a period of one year following the Expiration Date, the Executive will not, without the prior written consent of the Company, directly or indirectly, on his own behalf or in the service or on behalf of others, whether or not for compensation, engage in any business activity, or have any interest in any person, firm, corporation or business, through a subsidiary or parent entity or other entity (whether as a shareholder, agent, joint venturer, security holder, trustee, partner, Executive, creditor lending credit or money for the purpose of establishing or operating any such business, partner or otherwise) with any Competing Business in the Covered Area.  For the purpose of this Section&#160;15 (a), (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competing Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the current business of the Company and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all geographical areas of the United States and other foreign jurisdictions where Company then has offices and&#47;or sells its products directly or indirectly through distributors and&#47;or other sales agents.  Notwithstanding the foregoing, the Executive may own shares of companies whose securities are publicly traded, so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">long as ownership of such securities do not constitute more than one percent (1%)&#160;of the outstanding securities of any such company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive further agrees that during the Term and for a period of one (1)&#160;year from the Expiration Date, the Executive will not divert any business of the Company and&#47;or its affiliates or any customers or suppliers of the Company and&#47;or the Company&#8217;s and&#47;or its affiliates&#8217; business to any other person, entity or competitor, or induce or attempt to induce, directly or indirectly, any person to leave his or her employment with the Company and&#47;or its affiliates&#59; provided, however, that the foregoing provisions shall not apply to a general advertisement or solicitation program that is not specifically targeted at such employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive acknowledges and agrees that his obligations provided herein are necessary and reasonable in order to protect the Company and its affiliates and their respective business and Executive expressly agrees that monetary damages would be inadequate to compensate the Company and&#47;or its affiliates for any breach by Executive of his covenants and agreements set forth herein.  Accordingly, Executive agrees and acknowledges that any such violation of this Section&#160;15 will cause irreparable injury to the Company and that, in addition to any other remedies that may be available, in law, in equity or otherwise, the Company and its affiliates shall be entitled to seek injunctive relief against the breach of this Section&#160;15 or the continuation of any such breach by the Executive without the necessity of proving actual damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Employment Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that either Executive or the Company may terminate Executive&#8217;s employment at any time and for any reason, with or without Cause or Good Reason.  Any contrary representations that may have been made to Executive are superseded by this Agreement.  This is the full and complete agreement between Executive and the Company on this term.  Although Executive&#8217;s duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Executive&#8217;s employment may only be changed in an express written agreement signed by Executive and a duly authorized officer of the Company (other than Executive).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sections&#160;1, 5, 6, 10, 11, 13, 14, 15 and 17 herein, including this Section&#160;17(a), shall survive the termination of Executive&#8217;s employment with the Company, the expiration of this Agreement and the termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Modifications&#59; No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement supersedes, amends and restates all prior agreements and understandings between the parties, oral or written, including, without limitation, the Executive Agreement.  No modification, termination or attempted waiver shall be valid unless in writing, signed by the party against whom such modification, termination or waiver is sought to be enforced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, and may be delivered by facsimile or other electronic means, but all of which shall be deemed originals and taken together will constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10-</font></div></div></div><div id="ie4c79124b4e247c99490f86058446e17_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">COMPANY&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc.</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Mark Erlander</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_______</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Mark Erlander</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EXECUTIVE&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Vicki Kelemen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">____________</font></div><div style="margin-bottom:0.12pt;padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Vicki Kelemen               </font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;A</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Release Agreement</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;B</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality and Inventions Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>4
<FILENAME>a1017ex022321.htm
<DESCRIPTION>EX-10.17
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie21c8c1ded774aee8c9a14dcfa1c571f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.17</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Employment Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into effective as of February 22, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between Brigitte Lindsay (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Cardiff Oncology, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">R E C I T A L S</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Executive serves as the Vice President, Finance of the Company&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in order to provide Executive with financial security, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) believes that it is in the best interests of the Company to provide Executive with certain engagement terms and severance benefits as set forth herein.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In consideration of the mutual covenants herein contained and the employment of Executive by the Company, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following terms referred to in this Agreement shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any of the following&#58;  (i) the commission of a material act of fraud, embezzlement or misappropriation, which is intended to result in substantial personal enrichment of Executive in connection with Executive&#8217;s employment with the Company&#59; (ii)&#160;Executive&#8217;s conviction of, or plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, to a crime constituting a felony (other than traffic-related offenses)&#59; (iii)&#160;a material breach of Executive&#8217;s proprietary information agreement that is materially injurious to the Company&#59; or (iv)&#160;Executive&#8217;s (1)&#160;material failure to perform his duties as set forth in this Agreement, and (2)&#160;failure to &#8220;cure&#8221; any such failure within thirty (30)&#160;days after receipt of written notice from the Company delineating the specific acts that constituted such material failure and the specific actions necessary, if any, to &#8220;cure&#8221; such failure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following events&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)the date on which any &#8220;person&#8221; (as such term is used in Sections&#160;13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)), obtains &#8220;beneficial ownership&#8221; (as defined in Rule&#160;13d-3 of the Exchange Act) or a pecuniary interest in fifty percent (50%)&#160;or more of the combined voting power of the Company&#8217;s then outstanding securities (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)the consummation of a merger, consolidation, reorganization, or similar transaction involving the Company, other than a transaction&#58;  (1) in which substantially all of the holders of the Voting Stock immediately prior to such transaction hold or receive directly or indirectly more than fifty percent (50%)&#160;or more of the voting stock of the resulting entity or a </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">parent company thereof, in substantially the same proportions as their ownership of the Company immediately prior to the transaction&#59; or (2)&#160;in which the holders of the Company&#8217;s capital stock immediately before such transaction will, immediately after such transaction, hold as a group on a fully diluted basis the ability to elect at least a majority of the authorized directors of the surviving entity (or a parent company)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)there is consummated a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries, other than a sale, lease, license or disposition of all or substantially all of the consolidated assets of the Company and its subsidiaries to an entity, more than fifty percent (50%)&#160;of the combined voting power of the voting securities of which are owned by stockholders of the Company in substantially the same proportions as their ownership of the Company immediately prior to such sale, lease, license or disposition.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means totally and permanently disabled as defined in the Company&#8217;s disability benefit plan applicable to senior executive officers as in effect on the date thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean without Executive&#8217;s express written consent any of the following&#58;  (i) a material reduction of Executive&#8217;s duties, position or responsibilities relative to Executive&#8217;s duties, position or responsibilities in effect immediately prior to such reduction, or the removal of Executive from such position, duties or responsibilities&#59; (ii)&#160;a reduction of Executive&#8217;s compensation as in effect immediately prior to such reduction&#59; (iii)&#160;the relocation of Executive to a facility or a location more than twenty-five (25)&#160;miles from the Company&#8217;s then current principal location&#59; (iv)&#160;a material breach by the Company of this Agreement or any other agreement with Executive that is not corrected within fifteen (15)&#160;days after written notice from Executive (or such earlier date that the Company has notice of such material breach)&#59; or (v)&#160;the failure of the Company to obtain the written assumption of this Agreement by any successor contemplated in Section&#160;12 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Duties and Scope of Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term (as defined below), Executive will serve as Vice President, Finance of the Company, reporting to the Chief Executive Officer and Chief Operating Officer, and assuming and discharging such responsibilities as are commensurate with Executive&#8217;s position.  During the Term, Executive will provide services in a manner that will faithfully and diligently further the business of the Company and will devote a substantial portion of Executive&#8217;s business time, attention and energy thereto.  Notwithstanding the foregoing, nothing in this Agreement shall restrict Executive from managing her investments, other business affairs and other matters or serving on civic or charitable boards or committees, provided that no such activities unduly interfere with the performance of her obligations under this Agreement, provided that Executive shall honor the non-competition and non-solicitation terms as per Section&#160;15 below.  During the Term, Executive agrees to disclose to the Company those other companies of which she is a member of the Board of Directors, an executive officer, or a consultant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The term of Executive&#8217;s employment under this Agreement shall commence as of _February 22, 2021 (the &#8220;Effective Date&#8221;) and shall continue until February 21, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2024, unless earlier terminated in accordance with Section&#160;9 hereof.  The term of Executive&#8217;s employment shall be automatically renewed for successive one (1)&#160;year periods until the Executive or the Company delivers to the other party a written notice of their intent not to renew such employment, such written notice to be delivered at least sixty (60)&#160;days prior to the expiration of the then-effective Term as that term is defined below.  The period commencing as of the Effective Date and ending on Executive&#8217;s last date of employment with the Company under this Agreement is the &#8220;Term&#8221; and the end of the Term is referred to herein as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall pay to Executive a base compensation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of $246,600 per year (prorated for any partial year), payable at such times as the Company customarily pays its other senior executives (but in any event no less often than monthly).  In addition, each year during the Term, Executive shall be reviewed for purposes of determining the appropriateness of his Base Compensation hereunder.  The Base Compensation shall be subject to all federal, state and local payroll tax withholding and any other withholdings required by law.  For purposes of the Agreement, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; as of any point in time shall refer to the Base Compensation as adjusted pursuant to this Section&#160;4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Benefits&#59; Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, Executive shall be entitled to participate in all company employee benefit plans.  In the event Executive elects to pay to a self-funded health insurance program, Executive shall be reimbursed by the Company for such costs up to the maximum amount the Company would be obligated to pay for similar benefits pursuant to its health insurance plans.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Term, the Company shall promptly reimburse Executive for all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to her Base Compensation, during the Term Executive shall be given the opportunity to earn an annual bonus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of up to 40% of Base Compensation.  The Bonus shall be earned by Executive upon the Company&#8217;s achievement of performance milestones for a fiscal year (in each case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to be mutually agreed upon by the Executive and the Board or its compensation committee.  In the event Executive is employed by the Company for less than the full Target Year for which a Bonus is earned pursuant to this Section &#160;6, Executive shall be entitled to receive a pro-rated Bonus for such Target Year based on the number of days Executive was employed by the Company during such Target Year divided by 365.  The determinations of the Board or its compensation committee with respect to Bonuses will be final and binding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Intentionally omitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination by the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, the Company may terminate Executive&#8217;s employment at any time and for any reason (or no reason), and with or without Cause, and without prejudice to any other right or remedy to which the Company or Executive may be entitled at law or in equity or under this Agreement.  Notwithstanding the foregoing, in the event the Company desires to terminate the Executive&#8217;s employment without Cause, the Company shall give the Executive not less than sixty (60)&#160;days advance written notice.  Executive&#8217;s employment shall terminate automatically in the event of his death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive may voluntarily terminate the Term upon sixty (60)&#160;days&#8217; prior written notice for any reason or no reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to the obligations of the Company set forth in Section&#160;10 below, Executive&#8217;s employment shall terminate automatically upon his death.  Subject to the obligations of the Company set forth in Section&#160;10 below, in the event Executive is unable to perform his duties as a result of Disability during the Term, the Company shall have the right to terminate the employment of Executive by providing written notice of the effective date of such termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Payments Upon Termination of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination for Cause, Death or Disability or Termination by Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment hereunder is terminated during the Term by the Company for Cause, as a result of Executive&#8217;s death or Disability, or voluntarily by Executive without Good Reason, the Company shall compensate Executive (or in the case of death, Executive&#8217;s estate) as follows&#58;  on the date of termination, the Company shall pay Executive a lump sum amount equal to (i)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (ii)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (iii)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive or Executive&#8217;s estate, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Termination by Company Without Cause or by Executive for Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, the Company shall compensate Executive as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination, the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus and Options earned and not yet paid or granted, as applicable, through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59; and, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that Executive executes a written release, substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, of any and all claims against the Company and all related parties with respect to all matters arising out of Executive&#8217;s employment by the Company, the Company shall pay Executive the Base Compensation for nine (9)&#160;months from the date of termination, the potential Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such nine (9)&#160;month period following the termination and any benefits (or benefits reimbursement payments) pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such nine (9)&#160;month period.  Without limiting the foregoing, Executive also shall be entitled to the severance benefits set forth under Section&#160;10(c) below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Termination in the Context of a Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything in Section&#160;10(a) or 10(b) herein to the contrary, in the event of Executive&#8217;s termination of employment with the Company either (i)&#160;by the Company without Cause at any time within twelve (12)&#160;months prior to the consummation of a Change of Control if, prior to, or as of such termination, a Change of Control transaction was Pending (as defined in Section&#160;10(d) below) at any time during such twelve (12)-month period, (ii)&#160;by Executive for Good Reason at any time within twelve (12)&#160;months after the consummation of a Change of Control, or (iii)&#160;by the Company without Cause at any time upon or within twelve (12)&#160;months after the consummation of a Change of Control, then, Executive shall be entitled to the following payments and other benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)on the date of termination (except as specified in clause&#160;(C)), the Company shall pay Executive a lump sum amount equal to (A)&#160;any portion of unpaid Base Compensation then due for periods prior to the effective date of termination&#59; (B)&#160;any Bonus earned and not yet paid through the date of termination&#59; and (C)&#160;within 2-1&#47;2&#160;months following submission of proper expense reports by Executive, all expenses reasonably and necessarily incurred by Executive in connection with the business of the Company prior to the date of termination&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)on the date of termination, the Company shall pay to Executive a lump sum amount equal to nine (9)&#160;months of Executive&#8217;s Base Compensation then in effect as of the day of termination, the maximum Bonus the Executive is or would be eligible for pursuant to Section&#160;6 herein during such twelve (12)&#160;month period and any benefits pursuant to Section&#160;5 herein that the Executive is or would be eligible for during such twelve (12)&#160;month period&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)notwithstanding any provision of any stock incentive plan, stock option agreement, restricted stock agreement or other agreement relating to capital stock of the Company, all of the shares and equity awards held by Executive that are then unvested shall immediately vest and, with respect to all options, warrants and other convertible securities of the Company beneficially held by Executive, become fully exercisable for (A)&#160;a period of six months following the date of termination only if at the time of such termination there is a Change of Control transaction Pending (as defined in Section&#160;10(d) below) or (B)&#160;if clause&#160;(A) does not apply, then such period of time set forth in the agreement evidencing the security&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)Severance benefits under this Section&#160;10(c) and Section&#160;10(b) above shall be mutually exclusive and severance under one such section shall prohibit severance under the other.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In order to effectuate the provisions of Section&#160;10(c)(iii) hereof, in the event that Executive&#8217;s employment is terminated during the Term by the Company without Cause or by Executive for Good Reason, no equity award held by Executive shall expire or terminate prior to the earlier to occur of (a)&#160;ten (10)&#160;years after the date of the award and (b)&#160;fifteen (15)&#160;months after Executive&#8217;s termination of employment with the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Definition of &#8220;Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;  For purposes of Section&#160;10(c) herein, a Change of Control transaction shall be deemed to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Pending</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; each time any of the following circumstances exist&#58;  (A) the Company and a third party have entered into a confidentiality agreement that has been signed by a duly-authorized officer of the Company and that is related to a potential Change of Control transaction&#59; (B)&#160;the Company has received a written expression of interest from a third party, including a binding or non-binding term sheet or letter of intent, related to a potential Change of Control transaction&#59; or (C)&#160;a third party has publicly announced, through a filing with the Securities and Exchange Commission, its intent to commence a tender offer or similar transaction to acquire 50% or more of the outstanding voting interests of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:96.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)The parties agree that this Agreement shall be interpreted to comply with or be exempt from Section 409A of the Code and the regulations and guidance promulgated thereunder to the extent applicable (collectively &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Code Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and all provisions of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Code Section 409A. In no event whatsoever will the Company be liable for any additional tax, interest or penalties that may be imposed on Executive under Code Section&#160;409A or any damages for failing to comply with Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:93.36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A upon or following a termination of employment unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; If Executive is deemed on the date of termination to be a &#8220;specified employee&#8221; within the meaning of that term under Code Section 409A(a)(2)(B), then with regard to any payment or the provision of any benefit that is considered nonqualified deferred compensation under Code Section 409A payable on account of a &#8220;separation from service,&#8221; such payment or benefit shall be made or provided at the date which is the earlier of (i) the expiration of the six&#160;(6)-month period measured from the date of such &#8220;separation from service&#8221; of Executive, and (ii) the date of Executive&#8217;s death (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delay Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Upon the expiration of the Delay Period, all payments and benefits delayed pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13.7(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such delay) shall be paid or reimbursed on the first business day following the expiration of the Delay Period to Executive in a lump sum, and any remaining payments and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.03pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits, except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits, to be provided in any other taxable year, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that, this clause (ii) shall not be violated with regard to expenses reimbursed under any arrangement covered by Internal Revenue Code Section 105(b) solely because such expenses are subject to a limit related to the period the arrangement is in effect and (iii) such payments shall be made on or before the last day of Executive&#8217;s taxable year following the taxable year in which the expense occurred.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:90.69pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)For purposes of Code Section 409A, Executive&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, &#8220;payment shall be made within thirty (30) days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company's business and&#47;or assets or otherwise pursuant to a Change of Control shall assume the Company's obligations under this Agreement and agree expressly in writing delivered to Executive, at or prior to such Change of Control, to perform the Company&#8217;s obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a Change of Control.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company's business and&#47;or assets (including any parent company to the Company), whether or not in connection with a Change of Control, which becomes bound by the terms of this Agreement by contract, operation of law or otherwise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given (a)&#160;when personally delivered (if to the Company, addressed to its Secretary at the Company&#8217;s principal place of business on a non-holiday weekday between the hours of 9 a.m. and 5 p.m.&#59; if to Executive, via personal service to his last known residence) or (b)&#160;three business days following the date it is mailed by U.S.&#160;registered or certified mail, return receipt requested and postage prepaid.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive recognizes and acknowledges that by reason of Executive&#8217;s employment by and service to the Company before, during and, if applicable, after the Term, Executive will have access to certain confidential and proprietary information relating to the Company&#8217;s business, which may include, but is not limited to, trade secrets, trade &#8220;know-how,&#8221; product development techniques and plans, formulas, customer lists and addresses, financing services, funding programs, cost and pricing information, marketing and sales </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">techniques, strategy and programs, computer programs and software and financial information (collectively referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Executive acknowledges that such Confidential Information is a valuable and unique asset of the Company and Executive covenants that he will not, unless expressly authorized in writing by the Company, at any time during the course of Executive&#8217;s employment use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Executive also covenants that at any time after the termination of such employment, directly or indirectly, he will not use any Confidential Information or divulge or disclose any Confidential Information to any person, firm or corporation, unless such information is in the public domain through no fault of Executive or except when required to do so by a court of law, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order Executive to divulge, disclose or make accessible such information.  All written Confidential Information (including, without limitation, in any computer or other electronic format) which comes into Executive&#8217;s possession during the course of Executive&#8217;s employment shall remain the property of the Company.  Unless expressly authorized in writing by the Company, Executive shall not remove any written Confidential Information from the Company&#8217;s premises, except in connection with the performance of Executive&#8217;s duties for and on behalf of the Company and in a manner consistent with the Company&#8217;s policies regarding Confidential Information.  Upon termination of Executive&#8217;s employment, the Executive agrees to immediately return to the Company all written Confidential Information (including, without limitation, in any computer or other electronic format) in Executive&#8217;s possession.  As a condition of Executive&#8217;s employment with the Company and in order to protect the Company&#8217;s interest in such proprietary information, the Company shall require Executive&#8217;s execution of a Confidentiality Agreement and Inventions Agreement in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, and incorporated herein by this reference.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Non-Competition&#59; Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Non-Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Executive hereby covenants and agrees that during the Term and for a period of one year following the Expiration Date, the Executive will not, without the prior written consent of the Company, directly or indirectly, on his own behalf or in the service or on behalf of others, whether or not for compensation, engage in any business activity, or have any interest in any person, firm, corporation or business, through a subsidiary or parent entity or other entity (whether as a shareholder, agent, joint venturer, security holder, trustee, partner, Executive, creditor lending credit or money for the purpose of establishing or operating any such business, partner or otherwise) with any Competing Business in the Covered Area.  For the purpose of this Section&#160;15 (a), (i) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competing Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the current business of the Company and (ii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Covered Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all geographical areas of the United States and other foreign jurisdictions where Company then has offices and&#47;or sells its products directly or indirectly through distributors and&#47;or other sales agents.  Notwithstanding the foregoing, the Executive may own shares of companies whose securities are publicly traded, so </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">long as ownership of such securities do not constitute more than one percent (1%)&#160;of the outstanding securities of any such company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive further agrees that during the Term and for a period of one (1)&#160;year from the Expiration Date, the Executive will not divert any business of the Company and&#47;or its affiliates or any customers or suppliers of the Company and&#47;or the Company&#8217;s and&#47;or its affiliates&#8217; business to any other person, entity or competitor, or induce or attempt to induce, directly or indirectly, any person to leave his or her employment with the Company and&#47;or its affiliates&#59; provided, however, that the foregoing provisions shall not apply to a general advertisement or solicitation program that is not specifically targeted at such employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive acknowledges and agrees that his obligations provided herein are necessary and reasonable in order to protect the Company and its affiliates and their respective business and Executive expressly agrees that monetary damages would be inadequate to compensate the Company and&#47;or its affiliates for any breach by Executive of his covenants and agreements set forth herein.  Accordingly, Executive agrees and acknowledges that any such violation of this Section&#160;15 will cause irreparable injury to the Company and that, in addition to any other remedies that may be available, in law, in equity or otherwise, the Company and its affiliates shall be entitled to seek injunctive relief against the breach of this Section&#160;15 or the continuation of any such breach by the Executive without the necessity of proving actual damages.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Employment Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive&#8217;s employment with the Company will be &#8220;at will,&#8221; meaning that either Executive or the Company may terminate Executive&#8217;s employment at any time and for any reason, with or without Cause or Good Reason.  Any contrary representations that may have been made to Executive are superseded by this Agreement.  This is the full and complete agreement between Executive and the Company on this term.  Although Executive&#8217;s duties, title, compensation and benefits, as well as the Company&#8217;s personnel policies and procedures, may change from time-to-time, the &#8220;at will&#8221; nature of Executive&#8217;s employment may only be changed in an express written agreement signed by Executive and a duly authorized officer of the Company (other than Executive).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sections&#160;1, 5, 6, 10, 11, 13, 14, 15 and 17 herein, including this Section&#160;17(a), shall survive the termination of Executive&#8217;s employment with the Company, the expiration of this Agreement and the termination of this Agreement for any reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Modifications&#59; No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of this Agreement may be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement supersedes, amends and restates all prior agreements and understandings between the parties, oral or written, including, without limitation, the Executive Agreement.  No modification, termination or attempted waiver shall be valid unless in writing, signed by the party against whom such modification, termination or waiver is sought to be enforced.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the internal substantive laws, but not the conflicts of law rules, of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, and may be delivered by facsimile or other electronic means, but all of which shall be deemed originals and taken together will constitute one and the same Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of the Articles and Sections hereof are inserted for convenience only and shall not be deemed to constitute a part hereof nor to affect the meaning thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Construction of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event of a conflict between the text of the Agreement and any summary, description or other information regarding the Agreement, the text of the Agreement shall control.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10-</font></div></div></div><div id="ie21c8c1ded774aee8c9a14dcfa1c571f_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year first above written.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font><br></font></div><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">COMPANY&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc.</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Mark Erlander</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">_______</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Mark Erlander</font></div><div style="text-indent:216pt"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Title&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">   </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">EXECUTIVE&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:0.12pt;padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47; Brigitte Lindsay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">__________             </font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Brigitte Lindsay      </font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;A</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form of Release Agreement</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit&#160;B</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidentiality and Inventions Agreement</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>a231exq42020.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ib3e5498e40e340f993108674f391774d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">Cardiff Oncology, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">San Diego, California </font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-239464, 333-238623, 333-234442, and 333-233568), Form  S-3 (Nos. 333-232321, 333-229693) and Form S-8 (Nos. 333-239725 and 333-232363) of Cardiff Oncology, Inc. (the &#8220;Company&#8221;) of our report dated February&#160;25, 2021, relating to the financial statements which appears in this Annual Report form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">February&#160;25, 2021 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>a311exq42020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iadefc2a3b4e34a7892de68da05d4d2a2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form&#160;10-K of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;25&#47;2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)<br></font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>a312exq42020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i4049de29c5004291bb8add0a5fc9c26e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brigitte Lindsay, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form&#160;10-K of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;25&#47;2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VP, Finance (Principal Financial and Accounting Officer)<br></font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>a321exq42020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i00923bb874394e73b9c77c6916aa7169_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;25&#47;2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>a322exq42020.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ief0a5d7cf25f49e4981dfb24fa27f55a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Brigitte Lindsay, Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#47;25&#47;2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brigitte Lindsay</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">VP, Finance (Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>trov-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:trov="http://www.trovagene.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.trovagene.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trov-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trov-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trov-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="trov-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.trovagene.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.trovagene.com/role/BalanceSheets">
        <link:definition>1001002 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.trovagene.com/role/BalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.trovagene.com/role/StatementsofOperations">
        <link:definition>1003004 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquity" roleURI="http://www.trovagene.com/role/StatementsofStockholdersEquity">
        <link:definition>1004005 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofShareholdersEquityParenthetical" roleURI="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Statement of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.trovagene.com/role/StatementsofCashFlows">
        <link:definition>1006007 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlowsParenthetical" roleURI="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical">
        <link:definition>1007008 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandLiquidity" roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidity">
        <link:definition>2101101 - Disclosure - Business Overview and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandLiquidityDetails" roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails">
        <link:definition>2402401 - Disclosure - Business Overview and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformation" roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation">
        <link:definition>2110103 - Disclosure - Supplementary Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationTables" roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables">
        <link:definition>2311302 - Disclosure - Supplementary Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
        <link:definition>2412406 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationAccruedExpensesDetails" roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails">
        <link:definition>2413407 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.trovagene.com/role/Leases">
        <link:definition>2114104 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.trovagene.com/role/LeasesTables">
        <link:definition>2315303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.trovagene.com/role/LeasesNarrativeDetails">
        <link:definition>2416408 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseDetails" roleURI="http://www.trovagene.com/role/LeasesLeaseExpenseDetails">
        <link:definition>2417409 - Disclosure - Leases - Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2418410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>2419411 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>2420412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2420412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.trovagene.com/role/StockholdersEquity">
        <link:definition>2121105 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.trovagene.com/role/StockholdersEquityTables">
        <link:definition>2322304 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofWarrantsDetails" roleURI="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails">
        <link:definition>2423413 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofPreferredStockDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails">
        <link:definition>2424414 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesAConvertiblePreferredStockDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails">
        <link:definition>2425415 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesCConvertiblePreferredStockDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails">
        <link:definition>2426416 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesDConvertiblePreferredStockDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails">
        <link:definition>2427417 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesEConvertiblePreferredStockDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails">
        <link:definition>2428418 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySecuritiesPurchaseAgreementsDetails" roleURI="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails">
        <link:definition>2429419 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.trovagene.com/role/StockBasedCompensation">
        <link:definition>2130106 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.trovagene.com/role/StockBasedCompensationTables">
        <link:definition>2331305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2432420 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails">
        <link:definition>2433421 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" roleURI="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails">
        <link:definition>2434422 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionsActivityDetails" roleURI="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails">
        <link:definition>2435423 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>2436424 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrants" roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants">
        <link:definition>2137107 - Disclosure - Derivative Financial Instruments - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsTables" roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables">
        <link:definition>2338306 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsDetails" roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails">
        <link:definition>2439425 - Disclosure - Derivative Financial Instruments - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.trovagene.com/role/FairValueMeasurements">
        <link:definition>2140108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.trovagene.com/role/FairValueMeasurementsTables">
        <link:definition>2341307 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.trovagene.com/role/FairValueMeasurementsDetails">
        <link:definition>2442426 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.trovagene.com/role/IncomeTaxes">
        <link:definition>2143109 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.trovagene.com/role/IncomeTaxesTables">
        <link:definition>2344308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2445427 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2446428 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofCompanysTaxesDetails" roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails">
        <link:definition>2447429 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2448430 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.trovagene.com/role/CommitmentsandContingencies">
        <link:definition>2149110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" roleURI="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails">
        <link:definition>2450431 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.trovagene.com/role/EmployeeBenefitPlan">
        <link:definition>2151111 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.trovagene.com/role/RelatedPartyTransactions">
        <link:definition>2152112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.trovagene.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2453432 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19" roleURI="http://www.trovagene.com/role/COVID19">
        <link:definition>2154113 - Disclosure - COVID-19</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COVID19Details" roleURI="http://www.trovagene.com/role/COVID19Details">
        <link:definition>2455433 - Disclosure - COVID-19 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="trov_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_SeriesNWarrantMember" abstract="true" name="SeriesNWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_SeriesJWarrantMember" abstract="true" name="SeriesJWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_SaleOfStockCommonAndWarrantsNetShares" abstract="false" name="SaleOfStockCommonAndWarrantsNetShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_SeriesMWarrantMember" abstract="true" name="SeriesMWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightNumberExercised" abstract="false" name="ClassOfWarrantOrRightNumberExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_IncomeTaxReconciliationPermanentItems" abstract="false" name="IncomeTaxReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightMonthsUntilExercisable" abstract="false" name="ClassOfWarrantOrRightMonthsUntilExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" abstract="false" name="PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_DerivativeFinancialInstrumentsLiabilityRollForward" abstract="true" name="DerivativeFinancialInstrumentsLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_IncreaseDecreaseInOperatingLeaseLiability" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_CommonStockAndWarrantsMember" abstract="true" name="CommonStockAndWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_NorvianoMember" abstract="true" name="NorvianoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_EffectiveIncomeTaxRateReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="trov_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" abstract="false" name="DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" abstract="false" name="CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_AccruedClinicalTrial" abstract="false" name="AccruedClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightExpirationTerm" abstract="false" name="ClassOfWarrantOrRightExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" abstract="false" name="BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_DeferredTaxAssetsNetBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_SaleOfStockValueCommonAndWarrantsNet" abstract="false" name="SaleOfStockValueCommonAndWarrantsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="trov_SeriesLWarrantsMember" abstract="true" name="SeriesLWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_Accruedresearchagreements" abstract="false" name="Accruedresearchagreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_WarrantsFairValue" abstract="false" name="WarrantsFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_PreferredStockConversionObligationNumberOfTradingDays" abstract="false" name="PreferredStockConversionObligationNumberOfTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_ValuationAllowance" abstract="false" name="ValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" abstract="false" name="FairValueAssumptionsWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_AccruedPreferredStockDividend" abstract="false" name="AccruedPreferredStockDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_Accrueddirectorfees" abstract="false" name="Accrueddirectorfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_Patentlicenseandotherfeespayable" abstract="false" name="Patentlicenseandotherfeespayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_BlackScholesOptionPricingMethodMember" abstract="true" name="BlackScholesOptionPricingMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_PreferredStockConversionPricePerShare" abstract="false" name="PreferredStockConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" abstract="false" name="PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" abstract="true" name="LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" abstract="false" name="DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_PreferredStockDividendAccrued" abstract="false" name="PreferredStockDividendAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_SeriesIWarrantMember" abstract="true" name="SeriesIWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_PreferredStockConvertibleConversionPrice" abstract="false" name="PreferredStockConvertibleConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" abstract="false" name="PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_SeriesKWarrantMember" abstract="true" name="SeriesKWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" abstract="false" name="Releaseofclinicaltrialfundingcommitmentforservicesreceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_Servicereceivable" abstract="false" name="Servicereceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_LessorNumberOfSubleases" abstract="false" name="LessorNumberOfSubleases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="trov_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ConvertiblePreferredStockStatedValuePerShare" abstract="false" name="ConvertiblePreferredStockStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_SharePriceForAutomaticConversion" abstract="false" name="SharePriceForAutomaticConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightNumberGranted" abstract="false" name="ClassOfWarrantOrRightNumberGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" abstract="false" name="ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_AmountFinancedUnderAgreement" abstract="false" name="AmountFinancedUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="trov_WarrantsWeightedAverageContractualTerm" abstract="false" name="WarrantsWeightedAverageContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" abstract="false" name="Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="trov_AccruedClinicalTrialExpensesPolicyTextBlock" abstract="false" name="AccruedClinicalTrialExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="trov_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="trov_EstimatedFairValueOfWarrant" abstract="false" name="EstimatedFairValueOfWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>trov-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheets" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6bcd41f-8c63-43ea-9e06-e5f5c551a023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42b62e37-6074-493b-9fe0-054e3be7580f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6bcd41f-8c63-43ea-9e06-e5f5c551a023" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42b62e37-6074-493b-9fe0-054e3be7580f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9fce5323-39e4-40ce-bb2d-f19535b7e398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6bcd41f-8c63-43ea-9e06-e5f5c551a023" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9fce5323-39e4-40ce-bb2d-f19535b7e398" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c2223ea6-cca6-4a8b-8b6c-41198832ce5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e6bcd41f-8c63-43ea-9e06-e5f5c551a023" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c2223ea6-cca6-4a8b-8b6c-41198832ce5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e0d380c5-4d4d-4034-a113-5f6d6611bc04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_40b8ff19-5e98-4b86-8d8e-620201227f09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0d380c5-4d4d-4034-a113-5f6d6611bc04" xlink:to="loc_us-gaap_AccountsPayableCurrent_40b8ff19-5e98-4b86-8d8e-620201227f09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4ca6dca4-ff66-4652-bb9d-93a02dfd3ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0d380c5-4d4d-4034-a113-5f6d6611bc04" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4ca6dca4-ff66-4652-bb9d-93a02dfd3ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_261aee4c-3ff3-458c-9db2-a801c47e2db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0d380c5-4d4d-4034-a113-5f6d6611bc04" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_261aee4c-3ff3-458c-9db2-a801c47e2db1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_e16210a3-c670-48cb-8b55-d32f47f08186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e0d380c5-4d4d-4034-a113-5f6d6611bc04" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_e16210a3-c670-48cb-8b55-d32f47f08186" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f012bfe8-c776-4054-94d1-dbde1c492ec1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7ed8b4ef-99ea-4944-ab9e-324bab1558f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f012bfe8-c776-4054-94d1-dbde1c492ec1" xlink:to="loc_us-gaap_LiabilitiesCurrent_7ed8b4ef-99ea-4944-ab9e-324bab1558f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_d7b2f41a-fdde-49bc-8ef4-5727c4c39965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f012bfe8-c776-4054-94d1-dbde1c492ec1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_d7b2f41a-fdde-49bc-8ef4-5727c4c39965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6eeec08f-f428-4d41-9658-a2e0228a9b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f012bfe8-c776-4054-94d1-dbde1c492ec1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6eeec08f-f428-4d41-9658-a2e0228a9b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8b7fe9b8-fbfa-47ef-9937-c4c14aec3e4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_f012bfe8-c776-4054-94d1-dbde1c492ec1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8b7fe9b8-fbfa-47ef-9937-c4c14aec3e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_85f39a21-2e6a-4b70-8a50-25d420159bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10414fa1-6f4e-4707-acdb-a433b6272e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_85f39a21-2e6a-4b70-8a50-25d420159bc9" xlink:to="loc_us-gaap_Liabilities_10414fa1-6f4e-4707-acdb-a433b6272e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c3f4cb62-cd0d-4455-8d4d-75f7b997497c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_85f39a21-2e6a-4b70-8a50-25d420159bc9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c3f4cb62-cd0d-4455-8d4d-75f7b997497c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7f1f088e-007a-4515-bdc0-739aec3508bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_85f39a21-2e6a-4b70-8a50-25d420159bc9" xlink:to="loc_us-gaap_StockholdersEquity_7f1f088e-007a-4515-bdc0-739aec3508bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8ef784e2-dd18-45c6-b4ca-9346cd022147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:to="loc_us-gaap_PreferredStockValue_8ef784e2-dd18-45c6-b4ca-9346cd022147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d65f2d3a-18f7-492f-ba59-e35209a72332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:to="loc_us-gaap_CommonStockValue_d65f2d3a-18f7-492f-ba59-e35209a72332" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e1340cad-a730-4e7e-a5c9-556a666e661c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e1340cad-a730-4e7e-a5c9-556a666e661c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef7e5852-0924-4ac2-9239-c86c58d8c15e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef7e5852-0924-4ac2-9239-c86c58d8c15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_c9c86c27-d326-453a-a508-d301bfcd5406" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_441d2166-131d-4b2b-a926-5c52fcd921c1" xlink:to="loc_trov_Servicereceivable_c9c86c27-d326-453a-a508-d301bfcd5406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6ed1e7c8-2214-49bc-a282-7e75ed25c710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1987a0f5-10af-4b7a-ba6e-95e929c37b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ed1e7c8-2214-49bc-a282-7e75ed25c710" xlink:to="loc_us-gaap_AssetsCurrent_1987a0f5-10af-4b7a-ba6e-95e929c37b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6dd81e4c-f409-4843-b443-a13733bfb5a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ed1e7c8-2214-49bc-a282-7e75ed25c710" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6dd81e4c-f409-4843-b443-a13733bfb5a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7fea6eda-292d-48b7-82ed-7efcbd9bef9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ed1e7c8-2214-49bc-a282-7e75ed25c710" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7fea6eda-292d-48b7-82ed-7efcbd9bef9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b36663d-f876-4a93-b5bf-0791d5fc154a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ed1e7c8-2214-49bc-a282-7e75ed25c710" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8b36663d-f876-4a93-b5bf-0791d5fc154a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofOperations" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ed8d1339-16ad-4af8-b83c-96a8f330c452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3ee8406a-5d03-487c-8d9f-4ff8244c93ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed8d1339-16ad-4af8-b83c-96a8f330c452" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3ee8406a-5d03-487c-8d9f-4ff8244c93ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2f14c0ed-b8df-4398-bb03-81c2bda6cc90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ed8d1339-16ad-4af8-b83c-96a8f330c452" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2f14c0ed-b8df-4398-bb03-81c2bda6cc90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_834e5bf8-965a-4be7-9160-dd9bb1cfab1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ca91c97d-0e42-4899-a162-68b75f957d0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_834e5bf8-965a-4be7-9160-dd9bb1cfab1e" xlink:to="loc_us-gaap_NetIncomeLoss_ca91c97d-0e42-4899-a162-68b75f957d0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_6f5c4416-e0bf-4cf0-bc2d-1169f1c15383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_834e5bf8-965a-4be7-9160-dd9bb1cfab1e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_6f5c4416-e0bf-4cf0-bc2d-1169f1c15383" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_4eec1213-8625-438b-ac8d-2e5e8b6bbb80" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_834e5bf8-965a-4be7-9160-dd9bb1cfab1e" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_4eec1213-8625-438b-ac8d-2e5e8b6bbb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8e46a0e8-17a4-4e08-af90-ccbd62f21bbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:to="loc_us-gaap_OperatingIncomeLoss_8e46a0e8-17a4-4e08-af90-ccbd62f21bbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fb502d32-cc36-49d1-8b68-5a60aca61204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fb502d32-cc36-49d1-8b68-5a60aca61204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f2d14d1e-0d07-40e6-9ee8-1071e4d00261" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:to="loc_us-gaap_InterestExpense_f2d14d1e-0d07-40e6-9ee8-1071e4d00261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1087c27a-2b87-437d-ad50-b5d69296db3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1087c27a-2b87-437d-ad50-b5d69296db3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_58dc6869-17b3-40a3-bbc4-7cde62883773" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_98a69723-e92f-423d-af0f-87d61be25c6e" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_58dc6869-17b3-40a3-bbc4-7cde62883773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_8bdf39b1-c37a-4cf3-a8ee-5e915ca0a8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_3ccc0de4-2d3a-436a-a17d-3d911884ce06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8bdf39b1-c37a-4cf3-a8ee-5e915ca0a8ce" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_3ccc0de4-2d3a-436a-a17d-3d911884ce06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f749246-e760-4d49-b82f-d5d7559cf034" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_8bdf39b1-c37a-4cf3-a8ee-5e915ca0a8ce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f749246-e760-4d49-b82f-d5d7559cf034" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b7caf766-7b55-4f99-8241-43e4f53e3939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b8f14728-4e3f-4573-8a77-bbe94c044821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b7caf766-7b55-4f99-8241-43e4f53e3939" xlink:to="loc_us-gaap_Revenues_b8f14728-4e3f-4573-8a77-bbe94c044821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cda0e1f2-c64f-49e4-99ae-9455cb6deaf7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_b7caf766-7b55-4f99-8241-43e4f53e3939" xlink:to="loc_us-gaap_OperatingExpenses_cda0e1f2-c64f-49e4-99ae-9455cb6deaf7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementofShareholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f6e8b170-6e78-4853-8751-461541039706" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f6e8b170-6e78-4853-8751-461541039706" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ba59ea43-93fc-4908-aeb4-26b94e814639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_ba59ea43-93fc-4908-aeb4-26b94e814639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d635c8d2-4876-4bed-88e9-23b620500086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d635c8d2-4876-4bed-88e9-23b620500086" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6f48bf65-1db3-4ec8-ad4a-26beb04396a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6f48bf65-1db3-4ec8-ad4a-26beb04396a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_3aa567fc-7172-46d9-9eba-8d7825aaa741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_3aa567fc-7172-46d9-9eba-8d7825aaa741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5133e3e3-e7ed-42db-90ac-8371681375b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_be811f24-4ce0-496e-aa81-4f359b5ccad3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_5133e3e3-e7ed-42db-90ac-8371681375b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_440c91c3-47f8-4446-b6bd-d39c75f797a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_NetIncomeLoss_440c91c3-47f8-4446-b6bd-d39c75f797a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_c2fae87f-d79f-4dd0-b8f2-edd6c6f0c00c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_c2fae87f-d79f-4dd0-b8f2-edd6c6f0c00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_05331f61-e239-4426-b24d-b555eb611a01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_05331f61-e239-4426-b24d-b555eb611a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_978a1456-dc56-41d6-bd53-bc6cd5803e1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_ShareBasedCompensation_978a1456-dc56-41d6-bd53-bc6cd5803e1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_752f78ae-ee16-4ba2-8193-107325a8cbde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_752f78ae-ee16-4ba2-8193-107325a8cbde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_e40bce05-f16e-4568-8972-927fdcbe8147" xlink:href="trov-20201231.xsd#trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_e40bce05-f16e-4568-8972-927fdcbe8147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e872db1d-c281-46af-804f-a393f6215bf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e872db1d-c281-46af-804f-a393f6215bf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_86f0a18b-cf25-4fd8-8e53-c3f5046cf18d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_86f0a18b-cf25-4fd8-8e53-c3f5046cf18d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8565d253-a6fe-401f-9793-e6753cbf5a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8565d253-a6fe-401f-9793-e6753cbf5a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_f06972db-20d1-408a-ae37-ae4b46dad128" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_f06972db-20d1-408a-ae37-ae4b46dad128" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7b09acae-94cf-499d-ae88-4564c1222cf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7b09acae-94cf-499d-ae88-4564c1222cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_15d4f36e-8759-4f9a-a3ff-9b5b4568de03" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_15d4f36e-8759-4f9a-a3ff-9b5b4568de03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9ae0d8bd-821b-48cd-89dc-88813875d0aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e024150e-6992-4936-8185-7bf919129a76" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9ae0d8bd-821b-48cd-89dc-88813875d0aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e01f6c-7e02-4eaf-8c21-eebb5f1b88c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6f08d22-0fb7-4564-88e4-61d39a037779" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e01f6c-7e02-4eaf-8c21-eebb5f1b88c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6f08d22-0fb7-4564-88e4-61d39a037779" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb023a70-32ec-4cea-a696-1159cb15b6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e01f6c-7e02-4eaf-8c21-eebb5f1b88c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_eb023a70-32ec-4cea-a696-1159cb15b6c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80885fe7-172b-49f4-a9cc-244f11a04cc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e01f6c-7e02-4eaf-8c21-eebb5f1b88c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_80885fe7-172b-49f4-a9cc-244f11a04cc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_244f5448-3294-4c44-807f-16e390a71adb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c13571ef-a079-4a7a-8c29-f37beffa9d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_244f5448-3294-4c44-807f-16e390a71adb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c13571ef-a079-4a7a-8c29-f37beffa9d8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlowsParenthetical"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidity"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidityDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformation"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2614e804-c255-410c-8797-59ed23ba42d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a11448bc-a41d-4f96-82bc-e86e721ac0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2614e804-c255-410c-8797-59ed23ba42d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a11448bc-a41d-4f96-82bc-e86e721ac0f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31bcd249-5a34-4692-a319-e41d96cc223f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_2614e804-c255-410c-8797-59ed23ba42d7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_31bcd249-5a34-4692-a319-e41d96cc223f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5351578-1df4-4c80-8260-b4f77e37dc9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a5351578-1df4-4c80-8260-b4f77e37dc9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedPreferredStockDividend_ebd15069-31ce-40d0-abd4-c5a188027e28" xlink:href="trov-20201231.xsd#trov_AccruedPreferredStockDividend"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_trov_AccruedPreferredStockDividend_ebd15069-31ce-40d0-abd4-c5a188027e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accruedresearchagreements_aa939f1b-0fb2-4cd3-b15b-b102bca75be5" xlink:href="trov-20201231.xsd#trov_Accruedresearchagreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_trov_Accruedresearchagreements_aa939f1b-0fb2-4cd3-b15b-b102bca75be5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accrueddirectorfees_8e174f6d-dbf1-4181-a381-044a73d83ace" xlink:href="trov-20201231.xsd#trov_Accrueddirectorfees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_trov_Accrueddirectorfees_8e174f6d-dbf1-4181-a381-044a73d83ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7fe3974f-0c2f-47c6-a993-8482b78ff2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7fe3974f-0c2f-47c6-a993-8482b78ff2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Patentlicenseandotherfeespayable_cfe6f8ae-60c4-435a-84cd-9ebbb8cb1bd2" xlink:href="trov-20201231.xsd#trov_Patentlicenseandotherfeespayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_trov_Patentlicenseandotherfeespayable_cfe6f8ae-60c4-435a-84cd-9ebbb8cb1bd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_401dfdea-4e84-48a3-aa12-122173565141" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_401dfdea-4e84-48a3-aa12-122173565141" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrial_747d06d3-4356-4224-ad3b-12edf16044d9" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrial"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_b909a45b-afce-45a0-8bc8-d8921616cf27" xlink:to="loc_trov_AccruedClinicalTrial_747d06d3-4356-4224-ad3b-12edf16044d9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/Leases" xlink:type="simple" xlink:href="trov-20201231.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bfa28f5e-b186-4336-9350-fbc263721e9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f52183d9-b906-4961-869e-37c35f4d563e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bfa28f5e-b186-4336-9350-fbc263721e9d" xlink:to="loc_us-gaap_OperatingLeaseCost_f52183d9-b906-4961-869e-37c35f4d563e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_89a5bc8d-cf8f-45c7-adca-61460af01401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_bfa28f5e-b186-4336-9350-fbc263721e9d" xlink:to="loc_us-gaap_SubleaseIncome_89a5bc8d-cf8f-45c7-adca-61460af01401" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_35b35a44-2f7f-41fb-8a74-e6a268fbbc00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f668b59-debd-4a31-aabf-54bd7cce9836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_35b35a44-2f7f-41fb-8a74-e6a268fbbc00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f668b59-debd-4a31-aabf-54bd7cce9836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6dec422c-3778-4030-8397-aec5ad7eaeaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_35b35a44-2f7f-41fb-8a74-e6a268fbbc00" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6dec422c-3778-4030-8397-aec5ad7eaeaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_56fec267-d267-4588-b8c5-de98109d0b5b" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_bb94cdfd-bb94-4314-a148-b9f72aa8f5a0" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_56fec267-d267-4588-b8c5-de98109d0b5b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_bb94cdfd-bb94-4314-a148-b9f72aa8f5a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_7a05df2e-7381-4fbb-bbc1-904ca43b113d" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_56fec267-d267-4588-b8c5-de98109d0b5b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_7a05df2e-7381-4fbb-bbc1-904ca43b113d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_9958a9f3-7c20-4007-aae6-6c7d0e192bbc" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_56fec267-d267-4588-b8c5-de98109d0b5b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_9958a9f3-7c20-4007-aae6-6c7d0e192bbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_32e7a8b5-7250-4507-ac91-427329a3baa6" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6a4920e0-de95-4377-a394-0fd7ffe7c837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_32e7a8b5-7250-4507-ac91-427329a3baa6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6a4920e0-de95-4377-a394-0fd7ffe7c837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_ab7c9fda-975c-4728-bf42-73c3d4ba94e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_32e7a8b5-7250-4507-ac91-427329a3baa6" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_ab7c9fda-975c-4728-bf42-73c3d4ba94e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_27086e01-61f0-4096-870e-283504f70a05" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b3d97b9-ad89-4b54-8a9b-bc20c0e48be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_27086e01-61f0-4096-870e-283504f70a05" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b3d97b9-ad89-4b54-8a9b-bc20c0e48be0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_5f77d3c0-0ea0-4029-9d00-30977da7509b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_27086e01-61f0-4096-870e-283504f70a05" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_5f77d3c0-0ea0-4029-9d00-30977da7509b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_3d14deff-8a2d-4210-a068-409bef43f0bf" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dcbba8e0-7b08-48c6-9cf1-95d5b662423e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_3d14deff-8a2d-4210-a068-409bef43f0bf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dcbba8e0-7b08-48c6-9cf1-95d5b662423e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_396b2ac6-0fc3-4d93-9111-d4ec6b4b7656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_3d14deff-8a2d-4210-a068-409bef43f0bf" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_396b2ac6-0fc3-4d93-9111-d4ec6b4b7656" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_720b87ac-a806-486d-817d-4b84f546c1c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4bd3e25-dc05-492f-b66c-158c9a5fefd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_720b87ac-a806-486d-817d-4b84f546c1c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4bd3e25-dc05-492f-b66c-158c9a5fefd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58cf3864-addb-4aa2-ae0f-b8abb0f64570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_720b87ac-a806-486d-817d-4b84f546c1c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_58cf3864-addb-4aa2-ae0f-b8abb0f64570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cc725f0-7f13-4073-b330-f63593973733" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_720b87ac-a806-486d-817d-4b84f546c1c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cc725f0-7f13-4073-b330-f63593973733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1e23e80b-453a-4b2a-aa68-75d6a97785ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_2963c4a5-8570-4fc9-820d-9fbe9a5b066d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1e23e80b-453a-4b2a-aa68-75d6a97785ac" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_2963c4a5-8570-4fc9-820d-9fbe9a5b066d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_70f18c01-37d4-44c2-a199-3d336e8659a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1e23e80b-453a-4b2a-aa68-75d6a97785ac" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_70f18c01-37d4-44c2-a199-3d336e8659a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_fd55f18a-baf9-4ff4-9594-b7509cc5973f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1e23e80b-453a-4b2a-aa68-75d6a97785ac" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_fd55f18a-baf9-4ff4-9594-b7509cc5973f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_65d6a3b1-97dd-4ded-bc0a-7cd847fe1dcd" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37c1aebc-5a77-4620-a518-f83ed972f76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_65d6a3b1-97dd-4ded-bc0a-7cd847fe1dcd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_37c1aebc-5a77-4620-a518-f83ed972f76d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f194801b-7919-44a2-9136-fa3dc5c29fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_65d6a3b1-97dd-4ded-bc0a-7cd847fe1dcd" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_f194801b-7919-44a2-9136-fa3dc5c29fe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efea7a8b-325c-466b-824b-fd990076a31f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a2c1c18-c7b8-4b7f-816c-2c656805b7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efea7a8b-325c-466b-824b-fd990076a31f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9a2c1c18-c7b8-4b7f-816c-2c656805b7ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_153bb39d-3bc0-4920-9993-08af07a25d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_efea7a8b-325c-466b-824b-fd990076a31f" xlink:to="loc_us-gaap_OperatingLeaseLiability_153bb39d-3bc0-4920-9993-08af07a25d01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityScheduleofWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesAConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySecuritiesPurchaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationStockBasedCompensationDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationSummaryofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_6f09b1df-cf7e-4b83-a8ae-804e029f8089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_a4cacc19-1d5f-420c-8700-a8b60c89036f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_6f09b1df-cf7e-4b83-a8ae-804e029f8089" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_a4cacc19-1d5f-420c-8700-a8b60c89036f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_84a8d117-2f0e-4b93-a51f-fa0f8fa65fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_d23fec64-bb4a-4809-b67a-5bd84a2c98c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_84a8d117-2f0e-4b93-a51f-fa0f8fa65fea" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_d23fec64-bb4a-4809-b67a-5bd84a2c98c6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ababc05d-644c-4c92-aa05-95e7196d32cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ab318e2-cc99-4aeb-8ddd-71feb255920c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ababc05d-644c-4c92-aa05-95e7196d32cd" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1ab318e2-cc99-4aeb-8ddd-71feb255920c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8ec7dd10-e1e7-473b-983a-f1c4c6f6bc2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c4fa4a20-b17a-455a-8a3a-a165ac1d7601" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8ec7dd10-e1e7-473b-983a-f1c4c6f6bc2a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c4fa4a20-b17a-455a-8a3a-a165ac1d7601" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52aab0c3-fa2a-49ed-858d-9f91c69438a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8ec7dd10-e1e7-473b-983a-f1c4c6f6bc2a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52aab0c3-fa2a-49ed-858d-9f91c69438a2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33116bf7-4737-4e63-a577-dd2334fd1d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_33116bf7-4737-4e63-a577-dd2334fd1d56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_eafed738-3ec0-43f4-8216-54b232a345a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_eafed738-3ec0-43f4-8216-54b232a345a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncomeTaxReconciliationPermanentItems_7da1f08d-cf6e-4774-86c3-07633bdb5c2a" xlink:href="trov-20201231.xsd#trov_IncomeTaxReconciliationPermanentItems"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_trov_IncomeTaxReconciliationPermanentItems_7da1f08d-cf6e-4774-86c3-07633bdb5c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_63805fce-3928-406a-9827-a1cb90adf1f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_63805fce-3928-406a-9827-a1cb90adf1f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7de0ecb-97e7-4b15-8917-590f3e18e49c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7de0ecb-97e7-4b15-8917-590f3e18e49c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_4015680d-6419-4930-acb2-34ebed5969de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_f31a6851-bd97-45dc-a628-ff4adc7589d7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_4015680d-6419-4930-acb2-34ebed5969de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a247b72-06ca-494e-8583-f6516e9e1aa7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6a247b72-06ca-494e-8583-f6516e9e1aa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62754ad9-ed71-47d0-a743-10c19c721fe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_62754ad9-ed71-47d0-a743-10c19c721fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_d8f128b0-8d4a-4089-895f-8a7feaaf3f9a" xlink:href="trov-20201231.xsd#trov_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_d8f128b0-8d4a-4089-895f-8a7feaaf3f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3c513888-9d2d-43cc-89e5-649c4c06f24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_3c513888-9d2d-43cc-89e5-649c4c06f24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8bba1a12-3b05-4ff2-9746-e9218ba156d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8bba1a12-3b05-4ff2-9746-e9218ba156d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_336cf318-3826-4950-8d3e-cb6ca4403c5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3a07c462-ef3f-4f8b-adc0-de4feaa91844" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_336cf318-3826-4950-8d3e-cb6ca4403c5c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8355591b-cf5b-4403-b71c-d94823b4c03e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b5b305a2-a24d-47e9-9af8-2b71b92ad662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8355591b-cf5b-4403-b71c-d94823b4c03e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b5b305a2-a24d-47e9-9af8-2b71b92ad662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0588476d-1365-4950-84fd-145699f82c4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8355591b-cf5b-4403-b71c-d94823b4c03e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0588476d-1365-4950-84fd-145699f82c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_9e2a0bb4-a194-4aac-ad8e-bd95b20f94c9" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8355591b-cf5b-4403-b71c-d94823b4c03e" xlink:to="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_9e2a0bb4-a194-4aac-ad8e-bd95b20f94c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08ebad56-6e2c-4deb-8d1c-36f191ccfdf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_8355591b-cf5b-4403-b71c-d94823b4c03e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_08ebad56-6e2c-4deb-8d1c-36f191ccfdf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f43fa8f0-ef06-4636-af4e-07a401304439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_71121bae-2a83-4000-a585-f9d315be2d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f43fa8f0-ef06-4636-af4e-07a401304439" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_71121bae-2a83-4000-a585-f9d315be2d60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_acd53bd4-ce07-4259-972e-5bbe2c5d92ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_f43fa8f0-ef06-4636-af4e-07a401304439" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_acd53bd4-ce07-4259-972e-5bbe2c5d92ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_fcfc3efd-e43c-4479-99ed-4ce112316c26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_e1ee355c-5553-41d3-8213-1bf2a2beff28" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_fcfc3efd-e43c-4479-99ed-4ce112316c26" xlink:to="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_e1ee355c-5553-41d3-8213-1bf2a2beff28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_29da58d3-8375-4ba1-a442-7bacc9e4b87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_fcfc3efd-e43c-4479-99ed-4ce112316c26" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_29da58d3-8375-4ba1-a442-7bacc9e4b87d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_ac9dfca7-fbb7-4aea-b155-df6862e3c05c" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_7b275630-66c5-46ce-8189-60353ca92255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_ac9dfca7-fbb7-4aea-b155-df6862e3c05c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_7b275630-66c5-46ce-8189-60353ca92255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fe2964d1-a1ba-4558-8fda-b2de43f14bb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_ac9dfca7-fbb7-4aea-b155-df6862e3c05c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_fe2964d1-a1ba-4558-8fda-b2de43f14bb2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="trov-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/COVID19" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19Details" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19Details"/>
  <link:calculationLink xlink:role="http://www.trovagene.com/role/COVID19Details" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>trov-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="extended" id="ie9aa9903d264496894c316dda84f8e27_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheets" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheets"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BalanceSheets" xlink:type="extended" id="idc22b48846c3467a9ab374d0cec52a4c_BalanceSheets"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="extended" id="i666d2bd97eed4804863a2d5f809f807e_BalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofOperations" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StatementsofOperations" xlink:type="extended" id="i79060c87dc864b85927de73b2dc8d74d_StatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b590cdd6-017f-4fd1-8035-ac34d59729b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b590cdd6-017f-4fd1-8035-ac34d59729b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_4da85fc7-63f8-477f-84ed-c2f8b9681c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_4da85fc7-63f8-477f-84ed-c2f8b9681c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1820ce0c-0370-4771-960f-b202887237a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_Revenues_1820ce0c-0370-4771-960f-b202887237a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_06bcceae-7b00-4ff1-9970-8d2b647047d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_06bcceae-7b00-4ff1-9970-8d2b647047d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6eac2193-41f7-43eb-9056-7351d5c2ef7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6eac2193-41f7-43eb-9056-7351d5c2ef7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_51df5c25-5c5d-4a66-967a-050c8a90d092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_OperatingExpenses_51df5c25-5c5d-4a66-967a-050c8a90d092" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1542083b-a77c-48cc-a50a-3561bb2daa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OperatingIncomeLoss_1542083b-a77c-48cc-a50a-3561bb2daa25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9e9a492b-9847-4f59-8b39-d426210a4917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9e9a492b-9847-4f59-8b39-d426210a4917" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cb7bd9c7-3cc9-4fd8-b82b-8a3cd43f1ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_InterestExpense_cb7bd9c7-3cc9-4fd8-b82b-8a3cd43f1ff4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_037c2ff4-ad5d-416c-a368-f10ac7e50673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_037c2ff4-ad5d-416c-a368-f10ac7e50673" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ceacc0b5-9fac-4ff3-b09c-872ef8e9733b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ceacc0b5-9fac-4ff3-b09c-872ef8e9733b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3bcd15a-ad50-418c-bf86-b111dfa33a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_NetIncomeLoss_b3bcd15a-ad50-418c-bf86-b111dfa33a78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_c27b5464-b052-47e6-a0b1-071037cb3568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_c27b5464-b052-47e6-a0b1-071037cb3568" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_7b6fd7b6-7056-40bb-92a5-28fadce6b78b" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_7b6fd7b6-7056-40bb-92a5-28fadce6b78b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4c4b792-3f2c-4ead-8829-c76a15ba0309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4c4b792-3f2c-4ead-8829-c76a15ba0309" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_0ec27523-d725-4ba9-9bdc-1e8a1112f1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_0ec27523-d725-4ba9-9bdc-1e8a1112f1ac" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_187a5c24-77f5-4742-ac8a-2327b91da67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_187a5c24-77f5-4742-ac8a-2327b91da67c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_11771056-87d1-4fe7-acf5-89cf45514c4b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:to="loc_us-gaap_ClassOfStockDomain_11771056-87d1-4fe7-acf5-89cf45514c4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:to="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_53254115-99d1-4a80-bb38-f2a480462eb5" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_53254115-99d1-4a80-bb38-f2a480462eb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_6d9adb5a-d410-4636-8c33-9670933ed0aa" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_6d9adb5a-d410-4636-8c33-9670933ed0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_ed5de3ef-6149-4348-9689-b28fe9e12a09" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_ed5de3ef-6149-4348-9689-b28fe9e12a09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:to="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0c333ca6-6184-42f2-9086-e8750a98e396_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:to="loc_srt_ProductsAndServicesDomain_0c333ca6-6184-42f2-9086-e8750a98e396_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:to="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0f53804f-2bba-4534-ab87-56d0152fccb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:to="loc_us-gaap_RoyaltyMember_0f53804f-2bba-4534-ab87-56d0152fccb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_53eb73e2-3848-4231-b312-83729997d056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:to="loc_us-gaap_ServiceMember_53eb73e2-3848-4231-b312-83729997d056" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="extended" id="iee01e8e5c52a40f295d363549a7cf574_StatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8d3e8d7-a9d5-43b1-bbf9-1abf889ea80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SharesIssued_e8d3e8d7-a9d5-43b1-bbf9-1abf889ea80f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a79974e-b926-4924-9d46-93bdf7050539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockholdersEquity_3a79974e-b926-4924-9d46-93bdf7050539" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockCommonAndWarrantsNetShares_aa025bb8-1df2-469a-b45e-ef0986b4b8f6" xlink:href="trov-20201231.xsd#trov_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_SaleOfStockCommonAndWarrantsNetShares_aa025bb8-1df2-469a-b45e-ef0986b4b8f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockValueCommonAndWarrantsNet_ba8c0d5c-ac87-4a75-94ed-800a02c30d6b" xlink:href="trov-20201231.xsd#trov_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_SaleOfStockValueCommonAndWarrantsNet_ba8c0d5c-ac87-4a75-94ed-800a02c30d6b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_30ca52b3-42d2-402b-8669-ab988e2430a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_30ca52b3-42d2-402b-8669-ab988e2430a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_08aa82e0-6760-44a1-8993-b98b826943b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_08aa82e0-6760-44a1-8993-b98b826943b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92f82532-59b8-482a-be32-510e02a1dff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92f82532-59b8-482a-be32-510e02a1dff9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised_918aa113-20fd-488d-af6a-d15e921441d4" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised_918aa113-20fd-488d-af6a-d15e921441d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised_0e6e621c-8694-4f2a-be0f-5604020fb595" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised_0e6e621c-8694-4f2a-be0f-5604020fb595" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_eeac2576-094e-4d1e-9e46-6063792f99fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_eeac2576-094e-4d1e-9e46-6063792f99fe" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4079ee7e-547f-401d-9a32-fc56b0d02f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4079ee7e-547f-401d-9a32-fc56b0d02f35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_a6bcecd4-1308-448e-acb0-d624a12ae8e8" xlink:href="trov-20201231.xsd#trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_a6bcecd4-1308-448e-acb0-d624a12ae8e8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31f8e561-a636-48ff-9d1b-30f530180f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31f8e561-a636-48ff-9d1b-30f530180f5f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_312ad5f3-aa45-4fea-ae51-bb08f3d9a410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_312ad5f3-aa45-4fea-ae51-bb08f3d9a410" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_cbfcdf3e-d7ab-4dc2-9dfa-fe3116e0f86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_DividendsPreferredStock_cbfcdf3e-d7ab-4dc2-9dfa-fe3116e0f86a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_83a8a95c-9817-4dca-bb03-f914d39c3602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_83a8a95c-9817-4dca-bb03-f914d39c3602" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ReleaseOfClinicalTrialFundingCommitment_18353064-6a0e-458a-96d8-5d5b38c48f5e" xlink:href="trov-20201231.xsd#trov_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_ReleaseOfClinicalTrialFundingCommitment_18353064-6a0e-458a-96d8-5d5b38c48f5e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d87a912-b8ef-4ca2-b9c5-d37022ca403a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_NetIncomeLoss_0d87a912-b8ef-4ca2-b9c5-d37022ca403a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a7d9a2a-f557-4c71-8396-482b5186ad90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a7d9a2a-f557-4c71-8396-482b5186ad90" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac1cc251-10b5-47a2-8238-7f07fbe104f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac1cc251-10b5-47a2-8238-7f07fbe104f0" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_4584b288-09ea-461f-bd58-a42e21372641" xlink:href="trov-20201231.xsd#trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_4584b288-09ea-461f-bd58-a42e21372641" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e80a20e-32dd-4cba-8b4a-5a01e5589a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e80a20e-32dd-4cba-8b4a-5a01e5589a23" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87f4ce8a-5970-4282-86e6-6915b453a3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87f4ce8a-5970-4282-86e6-6915b453a3ae" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6b2691ff-e03b-4b4a-a23e-2aebc40f9468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34891307-e015-49d5-a3be-dde12026cac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:to="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:to="loc_us-gaap_EquityComponentDomain_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:to="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ae011492-caad-4307-bd7e-4fff2ee9bfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_PreferredStockMember_ae011492-caad-4307-bd7e-4fff2ee9bfa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9923a0be-d60c-409a-8c5f-49ac978fc1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_CommonStockMember_9923a0be-d60c-409a-8c5f-49ac978fc1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1671d486-670c-463b-aeea-1c61cc983da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1671d486-670c-463b-aeea-1c61cc983da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ServiceReceivableMember_18a1f4f5-d7db-4bca-afa2-07901fa538b8" xlink:href="trov-20201231.xsd#trov_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_trov_ServiceReceivableMember_18a1f4f5-d7db-4bca-afa2-07901fa538b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b735daac-14e4-45ec-a5ec-5807448e7002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_RetainedEarningsMember_b735daac-14e4-45ec-a5ec-5807448e7002" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_be939d0a-fe11-4d7e-9576-84039c3e1151_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:to="loc_us-gaap_ClassOfStockDomain_be939d0a-fe11-4d7e-9576-84039c3e1151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:to="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_cb903c03-1db3-42c3-afe0-e15295b64136" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_cb903c03-1db3-42c3-afe0-e15295b64136" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_19f90738-fa9b-458a-8c9d-1c6d7423625c" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_19f90738-fa9b-458a-8c9d-1c6d7423625c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementofShareholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="extended" id="i8a6aec462aa34394967eb77b1edbf0e5_StatementofShareholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="extended" id="i002fadef56354a4db66bb75f00d897eb_StatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a5c8f17-22ae-4267-ae4f-23e2f009e783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_NetIncomeLoss_8a5c8f17-22ae-4267-ae4f-23e2f009e783" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_cd937201-5034-4fee-b62f-4c4ceb85d7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_cd937201-5034-4fee-b62f-4c4ceb85d7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_062aa050-8c6d-4fbc-9a45-da71fafc893d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_062aa050-8c6d-4fbc-9a45-da71fafc893d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c59bad9a-9699-4ca5-ad85-c841a6e994da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_ShareBasedCompensation_c59bad9a-9699-4ca5-ad85-c841a6e994da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ffdde75d-86ce-42c0-b4c2-fa3682248e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ffdde75d-86ce-42c0-b4c2-fa3682248e32" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_10e0f20d-8ed1-48c3-bdc0-f8ba269dbb30" xlink:href="trov-20201231.xsd#trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_10e0f20d-8ed1-48c3-bdc0-f8ba269dbb30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_969fc2c8-3e14-49ef-bc23-101d91366d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_969fc2c8-3e14-49ef-bc23-101d91366d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9cac653-2531-4336-b947-c4c19b5e3928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9cac653-2531-4336-b947-c4c19b5e3928" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5f987f54-0fa2-4749-97ff-dbe187981052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5f987f54-0fa2-4749-97ff-dbe187981052" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_940c3c5e-6778-4bbd-a490-58ee81b095ec" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_940c3c5e-6778-4bbd-a490-58ee81b095ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d88694e-3c62-4e3f-bdd2-f7d5dbfce250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d88694e-3c62-4e3f-bdd2-f7d5dbfce250" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_84a4cf24-b64b-4a4e-b359-4408b739d3f9" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_84a4cf24-b64b-4a4e-b359-4408b739d3f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2de632e3-3c7b-4789-8b18-842359c80146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2de632e3-3c7b-4789-8b18-842359c80146" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59b27d42-3662-4ae6-bc94-9917ff73728a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59b27d42-3662-4ae6-bc94-9917ff73728a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc68d03e-2350-40a0-857e-82d0d232d01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc68d03e-2350-40a0-857e-82d0d232d01f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0703661-a40f-4cfe-bb70-ff4e9a009a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0703661-a40f-4cfe-bb70-ff4e9a009a2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d73c04e-6540-436a-ba1b-159476b33636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d73c04e-6540-436a-ba1b-159476b33636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5b5697b7-a56d-458a-b15c-eb927b89aaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5b5697b7-a56d-458a-b15c-eb927b89aaab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29b723d3-df73-45d3-9191-cd774cefc6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29b723d3-df73-45d3-9191-cd774cefc6cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_38a0e8c0-14a7-4e49-8ce5-662711846d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_38a0e8c0-14a7-4e49-8ce5-662711846d06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1eccf688-b716-4289-a9c7-55b182904c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1eccf688-b716-4289-a9c7-55b182904c19" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6073893b-48e4-4744-a530-d4dacda511e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6073893b-48e4-4744-a530-d4dacda511e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84e58fef-7645-441e-869c-2710936f66a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84e58fef-7645-441e-869c-2710936f66a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b382ad44-7ec8-4366-b749-c66d424eaf4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b382ad44-7ec8-4366-b749-c66d424eaf4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dd5a923-43c5-4314-ad84-e257756fc741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dd5a923-43c5-4314-ad84-e257756fc741" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b01e0af2-79a5-4846-a544-b586c4ea37ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e16a53e9-d8fc-4b0b-96ff-6c3e62ad2284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:to="loc_us-gaap_IncomeTaxesPaid_e16a53e9-d8fc-4b0b-96ff-6c3e62ad2284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockDividendAccrued_450f5da7-f854-4be3-8a18-18dbc1ea9121" xlink:href="trov-20201231.xsd#trov_PreferredStockDividendAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_PreferredStockDividendAccrued_450f5da7-f854-4be3-8a18-18dbc1ea9121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a307ef61-f5bb-46fb-b3ad-f565420a1150" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a307ef61-f5bb-46fb-b3ad-f565420a1150" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_14478a26-acca-4204-940a-a28847d36d69" xlink:href="trov-20201231.xsd#trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_14478a26-acca-4204-940a-a28847d36d69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_0bae15e3-3681-44fd-9758-9666ad57606e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_0bae15e3-3681-44fd-9758-9666ad57606e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6041e890-68f8-4185-90aa-9c995c15a53c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:to="loc_us-gaap_ClassOfStockDomain_6041e890-68f8-4185-90aa-9c995c15a53c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:to="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CommonStockAndWarrantsMember_e1ce06f6-d3f5-4f04-9b80-7a83b09e1717" xlink:href="trov-20201231.xsd#trov_CommonStockAndWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_CommonStockAndWarrantsMember_e1ce06f6-d3f5-4f04-9b80-7a83b09e1717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_405e0d17-d3da-485e-8415-f0ab484cb2ee" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_405e0d17-d3da-485e-8415-f0ab484cb2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_4be1ad97-2387-49fa-bed7-c17139dea01e" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_4be1ad97-2387-49fa-bed7-c17139dea01e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_fc3f82e0-2527-4c10-b684-ec25211e39cb" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_fc3f82e0-2527-4c10-b684-ec25211e39cb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="extended" id="i0aa8f1c1eac04a7cb73b54a797531f12_StatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_12f37002-b886-4238-9d97-947dddc4aabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_12f37002-b886-4238-9d97-947dddc4aabe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_35f8a55e-7840-4d54-b524-65f683f3dfe7" xlink:href="trov-20201231.xsd#trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:to="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_35f8a55e-7840-4d54-b524-65f683f3dfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:to="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4563707e-4d9e-4acc-9fe7-d136efdcb417_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:to="loc_us-gaap_ClassOfStockDomain_4563707e-4d9e-4acc-9fe7-d136efdcb417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:to="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CommonStockAndWarrantsMember_b65dc4f6-aea7-4032-b863-9eb1d00e1272" xlink:href="trov-20201231.xsd#trov_CommonStockAndWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_CommonStockAndWarrantsMember_b65dc4f6-aea7-4032-b863-9eb1d00e1272" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_42f0f311-6ac5-475f-b6b0-1fcb0b9d228f" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_42f0f311-6ac5-475f-b6b0-1fcb0b9d228f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_d3dbbdc8-0cbd-42b3-b399-ed5251f8cb2a" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_d3dbbdc8-0cbd-42b3-b399-ed5251f8cb2a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidity"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="extended" id="ie04b5ce763a94f9f87252646cbc09b41_BusinessOverviewandLiquidity"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidityDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="extended" id="i0bdec0944b9b402a989003f43dfcc152_BusinessOverviewandLiquidityDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="id139a24610294692b4ad3d776ac17908_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ia6c0c4b92d8b45bfba3c85b9560817b8_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i0ef59408a2df4da3b8268eb3fb84f747_BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i04d5a130f29a454a97d2bc0bafa748f0_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="extended" id="ie89de660349847e7a9ae4c2d273ee4af_BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0e94e23d-9a51-4fac-8ade-06a09ef4f9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0e94e23d-9a51-4fac-8ade-06a09ef4f9c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:to="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_146ed21a-f062-4118-b77e-e478c17c6915_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_146ed21a-f062-4118-b77e-e478c17c6915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_728cd0d6-03e5-4e78-b771-e86567eeda26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:to="loc_us-gaap_WarrantMember_728cd0d6-03e5-4e78-b771-e86567eeda26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ec543c39-0278-4b19-ba0a-f9485c1696fd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ec543c39-0278-4b19-ba0a-f9485c1696fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_7068056c-0d1a-474b-be5d-a439cac58422" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_7068056c-0d1a-474b-be5d-a439cac58422" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended" id="i1ff309545651436fa6ff1260a6039605_BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d8bbad3-604c-4e28-9658-14709cbaa394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d8bbad3-604c-4e28-9658-14709cbaa394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8f9051e-746a-4570-82a1-ea3943686ca8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e8f9051e-746a-4570-82a1-ea3943686ca8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_71b12bc4-2d23-4c8d-8129-a45c1bd47e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:to="loc_us-gaap_EquipmentMember_71b12bc4-2d23-4c8d-8129-a45c1bd47e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FurnitureAndOfficeEquipmentMember_8080fc5f-1359-4f13-ad25-36f6a59e496b" xlink:href="trov-20201231.xsd#trov_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:to="loc_trov_FurnitureAndOfficeEquipmentMember_8080fc5f-1359-4f13-ad25-36f6a59e496b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:to="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:to="loc_srt_RangeMember_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:to="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea508a4d-44ab-48f3-9f67-8cc9a06e81cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:to="loc_srt_MinimumMember_ea508a4d-44ab-48f3-9f67-8cc9a06e81cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e47d454-8b0a-400c-b1b5-3c4a99b3b553" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:to="loc_srt_MaximumMember_5e47d454-8b0a-400c-b1b5-3c4a99b3b553" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="extended" id="i24c9b6e4c8934ca4a6b1babb9b9c4dbe_BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5638c4f-cc29-44f5-a76f-2d5c715a3c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5638c4f-cc29-44f5-a76f-2d5c715a3c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c7e54fd0-6fb7-426b-81c6-80674d4d7236_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c7e54fd0-6fb7-426b-81c6-80674d4d7236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40aec47b-d814-455f-bf77-53356f8f5072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40aec47b-d814-455f-bf77-53356f8f5072" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_322e6d27-b9cf-43f4-a420-33e7646063f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_WarrantMember_322e6d27-b9cf-43f4-a420-33e7646063f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb25da96-c6a0-4dd9-8818-f3554260cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb25da96-c6a0-4dd9-8818-f3554260cbac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88d2fba3-6f80-4eb0-963e-9d2dc4b95bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88d2fba3-6f80-4eb0-963e-9d2dc4b95bb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_bf973dd3-08b6-45f0-acaf-273774c46423" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_bf973dd3-08b6-45f0-acaf-273774c46423" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformation"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended" id="ie36eea24eadf4ef2a664d69ef2324e7a_SupplementaryBalanceSheetInformation"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended" id="i41936e8b21ba45019265fb373a91d8a7_SupplementaryBalanceSheetInformationTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended" id="i25ee947612274e4ea1c6d2b48fcb8783_SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ce060c2c-2a4b-4734-9142-da8c8d221381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_Depreciation_ce060c2c-2a4b-4734-9142-da8c8d221381" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d0c4b6e8-a83e-4ffa-a185-fbb710b68007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d0c4b6e8-a83e-4ffa-a185-fbb710b68007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a87d419-37f8-449d-b252-f54b86b3fea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a87d419-37f8-449d-b252-f54b86b3fea3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e38be577-c489-4155-a284-2ce869f05445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e38be577-c489-4155-a284-2ce869f05445" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_016fb8d4-c4d8-4965-96fb-24302d24f0ed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_016fb8d4-c4d8-4965-96fb-24302d24f0ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FurnitureAndOfficeEquipmentMember_d87a8e3d-533b-406f-ad23-51f66a254e57" xlink:href="trov-20201231.xsd#trov_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_trov_FurnitureAndOfficeEquipmentMember_d87a8e3d-533b-406f-ad23-51f66a254e57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_69586d4d-5715-4f1f-bc5b-902c0956aeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_69586d4d-5715-4f1f-bc5b-902c0956aeb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ab062f97-7e16-42b1-9e5d-4b3afdebf033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_us-gaap_EquipmentMember_ab062f97-7e16-42b1-9e5d-4b3afdebf033" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="extended" id="i342ea17c867145f4a85461f3af6f7d69_SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/Leases" xlink:type="simple" xlink:href="trov-20201231.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/Leases" xlink:type="extended" id="i52007f980723413fa666043098e5654d_Leases"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesTables" xlink:type="extended" id="i6c610019304f4f36a9f10a0321f62f39_LeasesTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i2ad2215615b5408493ed710120966bb5_LeasesNarrativeDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="extended" id="i315f2f3ac92f46d1801b8f06256e6ead_LeasesLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended" id="ia359a5649136454d9816b1726cc9f81b_LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended" id="i60e0ab4a1ea74f93a172ee6e55f98fea_LeasesSupplementalCashFlowInformationDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" id="idcc4d070b0394ef2a2ee435ce0b2cc0d_LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquity" xlink:type="extended" id="i59c542130485488d8ab782ab1bd9038e_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="extended" id="ib096b830ae8845abb7a70ff72cc5cd3c_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityScheduleofWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="extended" id="i9a3492bd86e34074b03a813580dbe593_StockholdersEquityScheduleofWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:href="trov-20201231.xsd#trov_WarrantsAndRightsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5283bc3b-e014-4bde-81a3-635ec114f340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5283bc3b-e014-4bde-81a3-635ec114f340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberGranted_21723ab4-3e8e-41dc-a11f-215ba38fe1fb" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_trov_ClassOfWarrantOrRightNumberGranted_21723ab4-3e8e-41dc-a11f-215ba38fe1fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberExercised_e585c916-4a04-4d43-8e2c-f1265eadf05f" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_trov_ClassOfWarrantOrRightNumberExercised_e585c916-4a04-4d43-8e2c-f1265eadf05f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5b03f32a-2c15-4306-92b8-e5a5950ded3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c0ad2943-c4b0-458f-8df6-79124fbbf1f2" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c0ad2943-c4b0-458f-8df6-79124fbbf1f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_665e6df4-8145-4a15-84b3-4c67097d4a0e" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_665e6df4-8145-4a15-84b3-4c67097d4a0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_c09d628f-0165-4da0-b9d5-eb68e4d2e088" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_c09d628f-0165-4da0-b9d5-eb68e4d2e088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e518ea97-3bae-43bf-9866-59c065904e23" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsWeightedAverageContractualTerm_7430712c-b57f-4246-9798-586a9cbc5c8a" xlink:href="trov-20201231.xsd#trov_WarrantsWeightedAverageContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:to="loc_trov_WarrantsWeightedAverageContractualTerm_7430712c-b57f-4246-9798-586a9cbc5c8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e58ea7a3-6904-41fc-b435-5cf43357c36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e58ea7a3-6904-41fc-b435-5cf43357c36c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f41746b5-d71c-4872-8214-9359db536bad_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:to="loc_us-gaap_EquityComponentDomain_f41746b5-d71c-4872-8214-9359db536bad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:to="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreFundedWarrantsMember_cb8a838b-1c0c-4aa2-a777-4eb3339fbce9" xlink:href="trov-20201231.xsd#trov_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:to="loc_trov_PreFundedWarrantsMember_cb8a838b-1c0c-4aa2-a777-4eb3339fbce9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended" id="id90912f918b94733876605b7fe3e87d6_StockholdersEquitySummaryofPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bd68724-8e1f-47b4-ab49-dd5e975decf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bd68724-8e1f-47b4-ab49-dd5e975decf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af4bc6d0-93f1-4e06-ba21-53ca33e6a0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af4bc6d0-93f1-4e06-ba21-53ca33e6a0e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_bacceab5-3629-40f3-a986-43ae1b7ba7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_bacceab5-3629-40f3-a986-43ae1b7ba7b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78a6cce6-b7e3-483c-89e2-86cc29e7df8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78a6cce6-b7e3-483c-89e2-86cc29e7df8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6c213278-4058-4710-9a10-57ff77e62024_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:to="loc_us-gaap_ClassOfStockDomain_6c213278-4058-4710-9a10-57ff77e62024_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:to="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesAConvertiblePreferredStockMember_53e6c107-f75d-4434-b739-4ec4f41aab6b" xlink:href="trov-20201231.xsd#trov_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesAConvertiblePreferredStockMember_53e6c107-f75d-4434-b739-4ec4f41aab6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesBConvertiblePreferredStockMember_e069845f-f7a0-4077-a114-142c1ba2d1a3" xlink:href="trov-20201231.xsd#trov_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesBConvertiblePreferredStockMember_e069845f-f7a0-4077-a114-142c1ba2d1a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_27b249a4-52c2-42a1-ac14-744b166acf15" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_27b249a4-52c2-42a1-ac14-744b166acf15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_cb1a2210-b720-4994-997a-393bb27ba764" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_cb1a2210-b720-4994-997a-393bb27ba764" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_893043af-a194-4968-a068-a31e4e3e8197" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_893043af-a194-4968-a068-a31e4e3e8197" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesAConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="extended" id="i2eb407ab89b64647b4fa6eb036f51ce5_StockholdersEquitySeriesAConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_13bf0ae7-244f-4c51-b401-b7229ec91f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_13bf0ae7-244f-4c51-b401-b7229ec91f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_681ce971-061b-435a-b9f3-48c254ed0d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_681ce971-061b-435a-b9f3-48c254ed0d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_79f61bc2-d3cd-4f61-ac55-4c79cfd9b0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_DividendsPreferredStock_79f61bc2-d3cd-4f61-ac55-4c79cfd9b0f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ConvertiblePreferredStockStatedValuePerShare_255adddf-4a45-4e26-938d-f8971119aac2" xlink:href="trov-20201231.xsd#trov_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_ConvertiblePreferredStockStatedValuePerShare_255adddf-4a45-4e26-938d-f8971119aac2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionPricePerShare_74e536b0-082f-4a14-8f00-0ce50035258b" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionPricePerShare_74e536b0-082f-4a14-8f00-0ce50035258b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_35d86698-c9cc-429f-b926-ec5d33c091fd" xlink:href="trov-20201231.xsd#trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_35d86698-c9cc-429f-b926-ec5d33c091fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SharePriceForAutomaticConversion_7712db3f-4af8-4483-b4a0-bc0c4783cb8f" xlink:href="trov-20201231.xsd#trov_SharePriceForAutomaticConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_SharePriceForAutomaticConversion_7712db3f-4af8-4483-b4a0-bc0c4783cb8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_5c33e407-1ce0-41ab-b809-7db17bca5381" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_5c33e407-1ce0-41ab-b809-7db17bca5381" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_306fd519-22e5-44ec-a1f8-d09a743e7070" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_306fd519-22e5-44ec-a1f8-d09a743e7070" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationNumberOfTradingDays_03d7dda7-6c3b-4956-8c83-fbee4f784ce5" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationNumberOfTradingDays_03d7dda7-6c3b-4956-8c83-fbee4f784ce5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d742a147-e2c4-4d7e-a096-6fa3950359c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:to="loc_us-gaap_ClassOfStockDomain_d742a147-e2c4-4d7e-a096-6fa3950359c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:to="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesAConvertiblePreferredStockMember_94bebfbc-12e8-4c1a-a891-4b9b3b081dbe" xlink:href="trov-20201231.xsd#trov_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:to="loc_trov_SeriesAConvertiblePreferredStockMember_94bebfbc-12e8-4c1a-a891-4b9b3b081dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e78f353-6c95-4f42-baff-a2a43e1cc2b6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:to="loc_us-gaap_EquityComponentDomain_0e78f353-6c95-4f42-baff-a2a43e1cc2b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:to="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b96703b6-3269-4232-afed-1ba5f6f5460f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:to="loc_us-gaap_RetainedEarningsMember_b96703b6-3269-4232-afed-1ba5f6f5460f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended" id="icf81e44f1b6146c887893a3bbb6bc5f0_StockholdersEquitySeriesCConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AmountFinancedUnderAgreement_1588ac65-5ca9-4a17-94cc-ea24a3069f20" xlink:href="trov-20201231.xsd#trov_AmountFinancedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_AmountFinancedUnderAgreement_1588ac65-5ca9-4a17-94cc-ea24a3069f20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d7a745fe-fa58-49dd-aa7e-c9d4160e842e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d7a745fe-fa58-49dd-aa7e-c9d4160e842e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberGranted_c6a52bb1-3439-47fc-a57e-48ac664a4847" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_ClassOfWarrantOrRightNumberGranted_c6a52bb1-3439-47fc-a57e-48ac664a4847" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b032a22-4a95-4ae4-b344-81ef247560b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b032a22-4a95-4ae4-b344-81ef247560b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5b8d1a35-c588-4eeb-9794-4d256918342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5b8d1a35-c588-4eeb-9794-4d256918342f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_abb8b5c1-1490-454a-bfa9-21f0af44f047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_abb8b5c1-1490-454a-bfa9-21f0af44f047" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_af378ffd-9018-4f46-9df7-5142efa0d3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_af378ffd-9018-4f46-9df7-5142efa0d3bc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_fa1b88c3-de9e-463d-a01c-f84ce8cb1517" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_Servicereceivable_fa1b88c3-de9e-463d-a01c-f84ce8cb1517" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_efa83635-f865-491a-a676-b2a31dcb21ed" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_efa83635-f865-491a-a676-b2a31dcb21ed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_16a729f3-04ee-4bf0-b48c-0c8cdcaecf45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:to="loc_us-gaap_PrivatePlacementMember_16a729f3-04ee-4bf0-b48c-0c8cdcaecf45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:to="loc_us-gaap_ClassOfStockDomain_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:to="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_877223e1-eac6-4ba8-820f-ce49257c67c4" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_877223e1-eac6-4ba8-820f-ce49257c67c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6f48bf94-8361-45da-a117-2dd7eb1920ac_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:to="loc_us-gaap_EquityComponentDomain_6f48bf94-8361-45da-a117-2dd7eb1920ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:to="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29da9105-349b-4213-a32e-872e12abde23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:to="loc_us-gaap_CommonStockMember_29da9105-349b-4213-a32e-872e12abde23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_30c138b8-fb28-4794-a3ae-1a9e411270ca" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_30c138b8-fb28-4794-a3ae-1a9e411270ca" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended" id="i69cb8524775d4976a68f08a67a18e43d_StockholdersEquitySeriesDConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AmountFinancedUnderAgreement_a8bc57af-3690-4518-842f-773916867c6d" xlink:href="trov-20201231.xsd#trov_AmountFinancedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_AmountFinancedUnderAgreement_a8bc57af-3690-4518-842f-773916867c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25bafb38-fd90-417a-984d-2ad46bd839d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25bafb38-fd90-417a-984d-2ad46bd839d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6ea63cc9-2ffb-4ceb-bc4e-a01fc3b0c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6ea63cc9-2ffb-4ceb-bc4e-a01fc3b0c9e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e77eab5c-3614-455b-906e-f9b1ced4d1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e77eab5c-3614-455b-906e-f9b1ced4d1f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_cbcabbad-8c30-483e-a058-039f5a319417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_cbcabbad-8c30-483e-a058-039f5a319417" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_5375f946-a593-4d98-a7f6-e5cc5a9135dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_5375f946-a593-4d98-a7f6-e5cc5a9135dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_fb5e3c54-0158-4b77-b499-fb4f7917f2ca" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_Servicereceivable_fb5e3c54-0158-4b77-b499-fb4f7917f2ca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_d9710a26-0dab-401f-9a7d-440de5d47dc5" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_d9710a26-0dab-401f-9a7d-440de5d47dc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_17f4ed01-34dc-46e5-9870-51d59426f3ce" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_17f4ed01-34dc-46e5-9870-51d59426f3ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1d664a1-9235-4ee6-a2c3-744228762880_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1d664a1-9235-4ee6-a2c3-744228762880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4fa659e3-dd7e-49a3-922c-77e93d64df74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:to="loc_us-gaap_PrivatePlacementMember_4fa659e3-dd7e-49a3-922c-77e93d64df74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:to="loc_us-gaap_EquityComponentDomain_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:to="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4db4853a-25f9-4f3a-babf-960933371d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:to="loc_us-gaap_CommonStockMember_4db4853a-25f9-4f3a-babf-960933371d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_10f0f1b0-359c-4bbb-b592-a553581adaa7" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_10f0f1b0-359c-4bbb-b592-a553581adaa7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended" id="ib9f77a18276d442999f808202d039e75_StockholdersEquitySeriesEConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_809a9e6a-2d1d-43b2-87c7-9044b8b69961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_809a9e6a-2d1d-43b2-87c7-9044b8b69961" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2311223c-db6b-4701-98f0-740278302673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2311223c-db6b-4701-98f0-740278302673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConvertibleConversionPrice_e97c6363-1a96-4b16-ae5f-6bc6420d1536" xlink:href="trov-20201231.xsd#trov_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_PreferredStockConvertibleConversionPrice_e97c6363-1a96-4b16-ae5f-6bc6420d1536" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_6f8d56b7-60b7-4ee3-9dbc-cf4cf4276c77" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_6f8d56b7-60b7-4ee3-9dbc-cf4cf4276c77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1df154cf-a923-44b0-ab8a-6621d3c32476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1df154cf-a923-44b0-ab8a-6621d3c32476" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a5ee5d76-4881-4f7a-9e31-c48d91b68360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a5ee5d76-4881-4f7a-9e31-c48d91b68360" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d64c813e-0afd-4cc6-862e-0bda458f405c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d64c813e-0afd-4cc6-862e-0bda458f405c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightIssued_952ba52b-2a9a-4491-b94f-e3a3fe87e16e" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightIssued_952ba52b-2a9a-4491-b94f-e3a3fe87e16e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_881bfdc9-b29d-437c-9717-ab303d0d191e" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_881bfdc9-b29d-437c-9717-ab303d0d191e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightExpirationTerm_557f0451-9010-4bc5-9542-2d6eb24860e2" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightExpirationTerm_557f0451-9010-4bc5-9542-2d6eb24860e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsFairValue_3e3a785a-f748-4c98-a064-85c16fa32e37" xlink:href="trov-20201231.xsd#trov_WarrantsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_WarrantsFairValue_3e3a785a-f748-4c98-a064-85c16fa32e37" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c426d810-9364-4ba1-a737-83221c638a84_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c426d810-9364-4ba1-a737-83221c638a84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_RegisteredDirectOfferingMember_bfa65e3d-82d9-4fa4-b824-c4a22eecbcb1" xlink:href="trov-20201231.xsd#trov_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:to="loc_trov_RegisteredDirectOfferingMember_bfa65e3d-82d9-4fa4-b824-c4a22eecbcb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_42db420b-4b87-44a2-b947-7453f97866b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:to="loc_us-gaap_PrivatePlacementMember_42db420b-4b87-44a2-b947-7453f97866b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:to="loc_us-gaap_ClassOfStockDomain_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:to="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_dc5bb2ce-d043-4b89-9d9d-63d2cdf82304" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_dc5bb2ce-d043-4b89-9d9d-63d2cdf82304" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_da276d53-1bbe-4da3-a497-34e8c4a22fc4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_da276d53-1bbe-4da3-a497-34e8c4a22fc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesNWarrantMember_67a77470-e05a-47e2-ae17-5b7b52cc9e76" xlink:href="trov-20201231.xsd#trov_SeriesNWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:to="loc_trov_SeriesNWarrantMember_67a77470-e05a-47e2-ae17-5b7b52cc9e76" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySecuritiesPurchaseAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="extended" id="ief8e9dd929af4c91a6f9c0f781245358_StockholdersEquitySecuritiesPurchaseAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cb95d240-aade-4a16-9632-9cbaa097d256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cb95d240-aade-4a16-9632-9cbaa097d256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0bc36609-1cd6-42ea-bb73-da329fd2f2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0bc36609-1cd6-42ea-bb73-da329fd2f2f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ec1cd43a-14a9-4748-a4a2-fa73b2fd1573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ec1cd43a-14a9-4748-a4a2-fa73b2fd1573" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_ff5b95f9-0110-462f-b329-014cf193eea8" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_ff5b95f9-0110-462f-b329-014cf193eea8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14824c7c-d9e7-4787-acf8-ce8ff6e2258e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14824c7c-d9e7-4787-acf8-ce8ff6e2258e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightExpirationTerm_50bcbf9b-913d-4afd-ba39-842dc87decec" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_ClassOfWarrantOrRightExpirationTerm_50bcbf9b-913d-4afd-ba39-842dc87decec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross_506ca675-5323-4913-a29a-c2c095b01e5e" xlink:href="trov-20201231.xsd#trov_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross_506ca675-5323-4913-a29a-c2c095b01e5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_74db3cf3-fa59-4811-b3f9-3bf22d182091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_74db3cf3-fa59-4811-b3f9-3bf22d182091" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c78be281-49da-4a9e-adce-cd8078f99ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c78be281-49da-4a9e-adce-cd8078f99ed1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1f933687-ee2a-4a9a-b9c3-626dec63d835_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1f933687-ee2a-4a9a-b9c3-626dec63d835_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesIWarrantMember_fc83943f-914b-4d53-960f-911135941a5f" xlink:href="trov-20201231.xsd#trov_SeriesIWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesIWarrantMember_fc83943f-914b-4d53-960f-911135941a5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesJWarrantMember_f50068d6-f6a5-4a42-8567-f2857f9bafb6" xlink:href="trov-20201231.xsd#trov_SeriesJWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesJWarrantMember_f50068d6-f6a5-4a42-8567-f2857f9bafb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesKWarrantMember_83455aed-1332-4cd9-a0a5-d7a4980e58f5" xlink:href="trov-20201231.xsd#trov_SeriesKWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesKWarrantMember_83455aed-1332-4cd9-a0a5-d7a4980e58f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesLWarrantsMember_eb0c5fa7-f378-41e9-87bd-433943fc7c83" xlink:href="trov-20201231.xsd#trov_SeriesLWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesLWarrantsMember_eb0c5fa7-f378-41e9-87bd-433943fc7c83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesMWarrantMember_335992fa-c8c1-476d-b99d-e4c6e59dff61" xlink:href="trov-20201231.xsd#trov_SeriesMWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesMWarrantMember_335992fa-c8c1-476d-b99d-e4c6e59dff61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c72e91d-dc4b-4786-a734-43cb94144b27_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4c72e91d-dc4b-4786-a734-43cb94144b27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9c942b85-b8b9-410e-a5e7-6f5434d051fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9c942b85-b8b9-410e-a5e7-6f5434d051fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="extended" id="i0e41e073734242fc9af5425d6e8e6c8f_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="extended" id="i15554af65e254c32b9359396a9cdad23_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i5980d62e12bc4e4885b544dfed6ebac0_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e6d387b-18ff-4d75-bd97-405020bd9222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e6d387b-18ff-4d75-bd97-405020bd9222" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c688bad5-987b-4607-99ae-b9a15a02a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c688bad5-987b-4607-99ae-b9a15a02a297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc9df738-206e-4744-ac3a-22d2dcd7770d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc9df738-206e-4744-ac3a-22d2dcd7770d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f60676ca-ca3f-4675-a8c6-21b44536dde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f60676ca-ca3f-4675-a8c6-21b44536dde6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39fe492f-8c0b-43b4-8138-220c2d27ffd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39fe492f-8c0b-43b4-8138-220c2d27ffd3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_83cf8106-cd2d-4060-99fb-93fd6e68923f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_83cf8106-cd2d-4060-99fb-93fd6e68923f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3acfd42d-d194-4add-b8d1-05e0cd680c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3acfd42d-d194-4add-b8d1-05e0cd680c97" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_37e25110-5afd-4995-9406-90c47045ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_37e25110-5afd-4995-9406-90c47045ee75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:to="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c19effd8-c484-460a-83d3-50971008c042_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:to="loc_us-gaap_PlanNameDomain_c19effd8-c484-460a-83d3-50971008c042_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:to="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EquityIncentivePlan2014Member_96bf9a9a-d2e4-48ab-81c4-c311b351af2d" xlink:href="trov-20201231.xsd#trov_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:to="loc_trov_EquityIncentivePlan2014Member_96bf9a9a-d2e4-48ab-81c4-c311b351af2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:to="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b6a6a887-52c7-4f94-857d-8f9767ff4e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b6a6a887-52c7-4f94-857d-8f9767ff4e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2864967e-ab81-4346-9a9a-01e1e65043af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2864967e-ab81-4346-9a9a-01e1e65043af" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" id="i9b9d059e386f4fafa80cfbae7491b9c6_StockBasedCompensationStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b183622-6a35-4761-a75b-6e26f417f34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b183622-6a35-4761-a75b-6e26f417f34a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e33bda24-344b-41e4-9b51-6a4c2e976eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e33bda24-344b-41e4-9b51-6a4c2e976eef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_479a26b5-1844-4d57-84e5-bdddc77d5103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_479a26b5-1844-4d57-84e5-bdddc77d5103" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="extended" id="i42216ffaad3b49db826ff402908b6b93_StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_015c0973-7c50-4bbd-bf7b-c2b683937a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_015c0973-7c50-4bbd-bf7b-c2b683937a32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b52727d4-bdd3-40b3-94b2-1f64701b893f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b52727d4-bdd3-40b3-94b2-1f64701b893f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d90d912-0e29-432d-a6c1-e50e2f616cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d90d912-0e29-432d-a6c1-e50e2f616cdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dbb0bc13-d599-4520-9bf7-db3efbb848a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dbb0bc13-d599-4520-9bf7-db3efbb848a3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47df3cc4-7785-4a1b-aba0-5077448c8b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47df3cc4-7785-4a1b-aba0-5077448c8b20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:to="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:to="loc_srt_RangeMember_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:to="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7243134-3438-4b91-99d8-d1362c730bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:to="loc_srt_MinimumMember_e7243134-3438-4b91-99d8-d1362c730bec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_17d34363-4177-44a7-b1fe-9ffa0a922222" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:to="loc_srt_MaximumMember_17d34363-4177-44a7-b1fe-9ffa0a922222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:to="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9560c0c0-9cad-43f5-ae9e-afcb7a3d9eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9560c0c0-9cad-43f5-ae9e-afcb7a3d9eef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationSummaryofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="extended" id="i82c1d3b2da224d7c899b7abe7b98f5a0_StockBasedCompensationSummaryofStockOptionsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ccec90e-b7ac-4143-ba2a-3fb407ae8b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ccec90e-b7ac-4143-ba2a-3fb407ae8b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b302e4c3-bf7d-4829-81eb-8250d054bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b302e4c3-bf7d-4829-81eb-8250d054bc6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f44052f-7fa4-4087-9612-5eee64a90990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f44052f-7fa4-4087-9612-5eee64a90990" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d46d5234-323a-4633-b11f-bb2555fd6b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d46d5234-323a-4633-b11f-bb2555fd6b91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_24df315a-da71-40d3-9400-c79256157c48" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_24df315a-da71-40d3-9400-c79256157c48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1715cd6-1acc-4b5b-9ecd-f079bd902f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7877b46d-5e27-4d23-a2e7-6ed57cd77c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7877b46d-5e27-4d23-a2e7-6ed57cd77c47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a9df1243-efd5-4590-aa8a-0cbf4e802ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a9df1243-efd5-4590-aa8a-0cbf4e802ef8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37f31017-4de3-4fff-9eec-3e9a70b9c6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37f31017-4de3-4fff-9eec-3e9a70b9c6f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8f11e4a6-61e7-4822-9087-9b99daa55ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8f11e4a6-61e7-4822-9087-9b99daa55ea7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_454bf878-ce53-448d-89fc-82013a5716ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_454bf878-ce53-448d-89fc-82013a5716ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ffe91d7-c9ba-497b-b741-c3ca31be408e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ffe91d7-c9ba-497b-b741-c3ca31be408e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_4d18f725-1128-447f-9c85-dfa69ebfec5d" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_4d18f725-1128-447f-9c85-dfa69ebfec5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_61209c04-a516-412e-87ad-2670b1998be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a05e1a7f-c654-4370-b35a-2e7f64b0ef08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a05e1a7f-c654-4370-b35a-2e7f64b0ef08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_25623b32-b018-4220-a563-71cf69627c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_25623b32-b018-4220-a563-71cf69627c90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26470187-1be6-4199-b8d7-4b8f67dfb9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26470187-1be6-4199-b8d7-4b8f67dfb9fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4bccb71a-b369-42be-8d65-82ff3b4178ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4bccb71a-b369-42be-8d65-82ff3b4178ca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6d3588b3-31f6-4dbc-83ca-02ca3acc3d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6d3588b3-31f6-4dbc-83ca-02ca3acc3d49" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8cc847d3-91b9-4957-b351-d392856d85f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8cc847d3-91b9-4957-b351-d392856d85f3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e380261a-ccfe-4843-bd8c-ec5a0d2ea226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e380261a-ccfe-4843-bd8c-ec5a0d2ea226" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a316dcbf-4438-4427-bd12-76c5c5f351fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a316dcbf-4438-4427-bd12-76c5c5f351fd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6569be86-cbf8-4019-88c7-f7f10c042940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6569be86-cbf8-4019-88c7-f7f10c042940" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:to="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28a4675f-d9e2-4520-8c36-f1e5ac8368a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28a4675f-d9e2-4520-8c36-f1e5ac8368a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" id="i656f4149fafb4f0ca4b9a1e2efaa5a4b_StockBasedCompensationRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e5eb6744-bfe5-4921-819d-9e72d44dd1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e5eb6744-bfe5-4921-819d-9e72d44dd1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_847e744a-5887-4dbe-9b2c-a22744e6de40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_847e744a-5887-4dbe-9b2c-a22744e6de40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a80f156e-db34-4827-af65-5351f6aad814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a80f156e-db34-4827-af65-5351f6aad814" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c5aa9193-573e-4d47-99d0-b94cb158f698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c5aa9193-573e-4d47-99d0-b94cb158f698" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3eff8982-c75b-4b9b-b8d3-c219b599cf50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f7308f5-6ace-4d68-8c4e-aeae34009c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f7308f5-6ace-4d68-8c4e-aeae34009c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8301a065-7309-49b9-92e4-4de3d7968b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8301a065-7309-49b9-92e4-4de3d7968b20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_46ce0ab5-64cd-4b39-9813-ce6130729544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_46ce0ab5-64cd-4b39-9813-ce6130729544" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dfba400d-fd62-4eb7-b059-acbaf6793d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dfba400d-fd62-4eb7-b059-acbaf6793d9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7eef2c1-6ae8-4f76-9844-6a4c6fc50413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_3f566762-49ae-49ed-9a49-2194cebc540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_3f566762-49ae-49ed-9a49-2194cebc540d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:to="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd357b0-0cda-4a77-a66c-62bbef0a6560_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7cd357b0-0cda-4a77-a66c-62bbef0a6560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4e3ada5b-04b9-4da2-aff8-d4d49f47c18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4e3ada5b-04b9-4da2-aff8-d4d49f47c18e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended" id="ia114a95557544dbaaf72f2bf481d5352_DerivativeFinancialInstrumentsWarrants"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended" id="i132b7b2e2c444a9a89df52cc2c968873_DerivativeFinancialInstrumentsWarrantsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a9ca3683-cd89-4635-8b35-9b298ffa0569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a9ca3683-cd89-4635-8b35-9b298ffa0569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_72200cbb-5494-4172-9e99-8f0cf646b991" xlink:href="trov-20201231.xsd#trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:to="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_72200cbb-5494-4172-9e99-8f0cf646b991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:to="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_7dc73ea5-a26a-4a66-9ac1-225c826a14a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_7dc73ea5-a26a-4a66-9ac1-225c826a14a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_eaa80835-0b53-4fef-9f62-502acc8fe4ed" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_eaa80835-0b53-4fef-9f62-502acc8fe4ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended" id="ia03a6772aaf14716be1b713ea33b44ba_DerivativeFinancialInstrumentsWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EstimatedFairValueOfWarrant_c99c7215-aaf7-4685-96eb-0204791a99e4" xlink:href="trov-20201231.xsd#trov_EstimatedFairValueOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_trov_EstimatedFairValueOfWarrant_c99c7215-aaf7-4685-96eb-0204791a99e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_33a8737f-f964-4446-bdde-be13852ef321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_33a8737f-f964-4446-bdde-be13852ef321" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18791ebd-b904-4698-9e50-3fa1a926412c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18791ebd-b904-4698-9e50-3fa1a926412c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:href="trov-20201231.xsd#trov_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3d9815e1-4620-4312-9f41-750a098c224c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3d9815e1-4620-4312-9f41-750a098c224c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71801ba6-1c3d-4967-b504-6c0287b488c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_efdd9159-7437-4d76-afbd-7bf23e5e24ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_efdd9159-7437-4d76-afbd-7bf23e5e24ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_d03cec9d-ec11-4948-8a5e-0f61522fdc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_d03cec9d-ec11-4948-8a5e-0f61522fdc67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e4731ca5-7080-44e1-b55b-df96bb3d2817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_a6ab4d53-d0df-4b71-b38b-70a5a9b47df6" xlink:href="trov-20201231.xsd#trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_a6ab4d53-d0df-4b71-b38b-70a5a9b47df6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6b9dfc19-45ee-4637-aabf-40f7fc93d376_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6b9dfc19-45ee-4637-aabf-40f7fc93d376_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1543d0b1-f129-431f-85c8-ba882a5cac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1543d0b1-f129-431f-85c8-ba882a5cac43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_28f09244-b65c-430d-ac4d-5a9df0a726ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_28f09244-b65c-430d-ac4d-5a9df0a726ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_6922ef60-23c3-400b-b7aa-7fb5dfaa1496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_6922ef60-23c3-400b-b7aa-7fb5dfaa1496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9fbec5f-6030-4be6-9e9f-b5e09b49a5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9fbec5f-6030-4be6-9e9f-b5e09b49a5dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cfe790a6-12e0-4dcd-9119-b3d7918ed96e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cfe790a6-12e0-4dcd-9119-b3d7918ed96e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04c343f1-4b7e-4922-b00b-e94f2a32c584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:to="loc_us-gaap_WarrantMember_04c343f1-4b7e-4922-b00b-e94f2a32c584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_f36f99a3-9178-481e-9391-03c864551789" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_f36f99a3-9178-481e-9391-03c864551789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:to="loc_srt_RangeMember_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:to="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2741ce83-a08d-43d7-9c28-3aa8884b1154" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_MinimumMember_2741ce83-a08d-43d7-9c28-3aa8884b1154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3b3c1c99-c51b-4dc5-a598-39df4e4916d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_MaximumMember_3b3c1c99-c51b-4dc5-a598-39df4e4916d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2b394764-381c-4ade-809f-0787f030e8fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_WeightedAverageMember_2b394764-381c-4ade-809f-0787f030e8fe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="extended" id="i29a2536bdba84a90b1e13cfadf58bab5_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i02eb9199d148468187e4da5865f26277_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i0226a6d24f9641d08d7083d9f76e495e_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_003d80ba-28a0-4c61-bf55-0700779fd017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_003d80ba-28a0-4c61-bf55-0700779fd017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c3aa762f-02c0-4711-aa7c-7ce4e0f30276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c3aa762f-02c0-4711-aa7c-7ce4e0f30276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_195aded2-ee05-494c-af2d-caf4cda19ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_195aded2-ee05-494c-af2d-caf4cda19ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b147c0aa-bacf-48cc-8667-b4da3f7d485c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b147c0aa-bacf-48cc-8667-b4da3f7d485c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_294f992f-7cc0-48ae-bdfe-f3df5516d246_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_294f992f-7cc0-48ae-bdfe-f3df5516d246_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f188cfa3-1fd4-4607-81e8-97a4d9b65a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f188cfa3-1fd4-4607-81e8-97a4d9b65a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaaac25e-af04-41f9-bbe6-1b2b805820d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_eaaac25e-af04-41f9-bbe6-1b2b805820d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_28078708-d63b-4feb-9878-2bb60b033306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_28078708-d63b-4feb-9878-2bb60b033306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_124e23f0-7c3e-4b0f-96ea-86b8fc94ba01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_124e23f0-7c3e-4b0f-96ea-86b8fc94ba01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5fdd52b3-1b5d-4071-b2da-4efe51409553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5fdd52b3-1b5d-4071-b2da-4efe51409553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6a519621-a957-4d86-a2ab-a5fe27fd3d60_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_6a519621-a957-4d86-a2ab-a5fe27fd3d60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d325820f-8aa0-4d91-bfb9-516b37ac9fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d325820f-8aa0-4d91-bfb9-516b37ac9fdf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxes" xlink:type="extended" id="i1dd50802d0304291b64a99bd2e5c4139_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="extended" id="i1bb75fc36a72429dadfc422386785b7f_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i8a8b32fcc37f4c149b0b170ba6379266_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsSubjectToExpiration_84f514c7-c1a5-41fd-943f-2387bd1ece18" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_trov_OperatingLossCarryforwardsSubjectToExpiration_84f514c7-c1a5-41fd-943f-2387bd1ece18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration_1d704349-55ab-42eb-85c9-7340f7213960" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration_1d704349-55ab-42eb-85c9-7340f7213960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89494938-5d3b-4f20-a416-89bd72bb49e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89494938-5d3b-4f20-a416-89bd72bb49e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c03cff9e-6600-4429-993e-69ecc7b11ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c03cff9e-6600-4429-993e-69ecc7b11ccc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_d9213963-88e9-4524-b879-a476da3f5f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_d9213963-88e9-4524-b879-a476da3f5f30" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_57d1ca07-8c00-4cbf-9529-f736184291f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_57d1ca07-8c00-4cbf-9529-f736184291f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_be84f7c7-26c3-4dde-ad82-93fa7be68e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_be84f7c7-26c3-4dde-ad82-93fa7be68e31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_24d6ef49-4b84-42fd-bb5b-931d8dfb100e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:to="loc_us-gaap_ResearchMember_24d6ef49-4b84-42fd-bb5b-931d8dfb100e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_5c4a0d64-fd95-46d9-b7fd-74a3869cab98_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_5c4a0d64-fd95-46d9-b7fd-74a3869cab98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_a3e589c2-6bf8-4036-a804-0159aef937cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_a3e589c2-6bf8-4036-a804-0159aef937cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71cecbfb-f1f5-4c8c-9198-09a3f584208c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71cecbfb-f1f5-4c8c-9198-09a3f584208c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended" id="i1625734c5ff940048b91a1cb2124c0e0_IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="extended" id="i5e0efbe1411d4e1c904e567adb28fdf1_IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended" id="iab8f394b57f7409682cbd52959e14043_IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="extended" id="i7ec2a9285f0c40068dfdb14efbe0e224_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="extended" id="i3e609a86b43a43f79c1abe5bc080dc6b_CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2bc7087-1066-449c-9fa9-42773e97cc9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2bc7087-1066-449c-9fa9-42773e97cc9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_5617db84-3617-425c-a138-358d2ea9715e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:to="loc_us-gaap_OtherCommitment_5617db84-3617-425c-a138-358d2ea9715e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:to="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:to="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_46d39ecb-f92b-479a-b058-b09aefe5d8d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_46d39ecb-f92b-479a-b058-b09aefe5d8d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_15223e9a-1f1b-48df-b643-a2cc68696be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:to="loc_us-gaap_LicensingAgreementsMember_15223e9a-1f1b-48df-b643-a2cc68696be3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:to="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a370193f-5879-497c-9c8e-31c8348d07c4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a370193f-5879-497c-9c8e-31c8348d07c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_NorvianoMember_3b4019c4-71bc-4f3f-a3c6-bb7f5a48316e" xlink:href="trov-20201231.xsd#trov_NorvianoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:to="loc_trov_NorvianoMember_3b4019c4-71bc-4f3f-a3c6-bb7f5a48316e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="trov-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="extended" id="i3e8fb50ba6134aa2b3476ccca93ae872_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="extended" id="ia345d411a2fa4e5e931f6c9889526704_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i305c7fe53b1940aab55dd5cbde6976ca_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8b6867e6-3dd6-4b26-9d1b-1650c8ad7f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8b6867e6-3dd6-4b26-9d1b-1650c8ad7f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9d0b082d-c4d1-42d8-b4b8-78e91e251e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9d0b082d-c4d1-42d8-b4b8-78e91e251e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5cc58438-2858-42e9-9ea2-24bb848b70ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5cc58438-2858-42e9-9ea2-24bb848b70ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2c037af5-6648-4b48-a61a-e95772772a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2c037af5-6648-4b48-a61a-e95772772a22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d9917758-64e2-4f14-8284-fa73184d0193_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:to="loc_us-gaap_RelatedPartyDomain_d9917758-64e2-4f14-8284-fa73184d0193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:to="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_f41f6a5f-e0a5-4988-956e-e9d285295e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:to="loc_us-gaap_OtherAffiliatesMember_f41f6a5f-e0a5-4988-956e-e9d285295e96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_973bf695-d210-420d-8321-c0721f614657" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:to="loc_srt_DirectorMember_973bf695-d210-420d-8321-c0721f614657" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/COVID19" xlink:type="extended" id="i58232f2ebe414f2e9cc98f3ea3021207_COVID19"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19Details" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19Details"/>
  <link:definitionLink xlink:role="http://www.trovagene.com/role/COVID19Details" xlink:type="extended" id="icfa110ae9d3b402385aa5fb6cc11cc35_COVID19Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_acacf1fe-1e5f-44ce-8429-cf462857bd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:to="loc_us-gaap_NotesPayable_acacf1fe-1e5f-44ce-8429-cf462857bd19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c5bebc6-a2ac-45d6-9b22-6aabdf87cf00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c5bebc6-a2ac-45d6-9b22-6aabdf87cf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f4fdd47-af88-4eb5-b6b9-f44e224eece2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f4fdd47-af88-4eb5-b6b9-f44e224eece2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PaycheckProtectionProgramCARESActMember_2b6439e5-076b-460c-8cb3-b4e00fed3d37" xlink:href="trov-20201231.xsd#trov_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:to="loc_trov_PaycheckProtectionProgramCARESActMember_2b6439e5-076b-460c-8cb3-b4e00fed3d37" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>trov-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_DocumentType_375c95d2-389b-4d70-bd2a-85e1174b5e52_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e602d934-9161-42f1-8438-ad5f682bfb96_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e041f5c2-e39b-4f8d-827f-9a20e3790a3a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a34b1028-a2b9-4c1f-a864-c716d6e43300_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_33a97af6-1ab3-4b61-b1f9-4a91adc8cb9b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0aa2a61c-3cbc-47c3-938b-a639064f52fd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_57af49f4-c802-49cc-95db-7c62fe291f08_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_6b9994cf-4677-4860-b5ae-38fb55f2b4ff_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_05e91c77-ff0a-439d-b0c0-aedecb19ea61_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_76ada95d-5924-4b86-9f4f-c326355939d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesDConvertiblePreferredStockMember_39a49ddf-deec-4596-a7ed-9496e9a93dd1_terseLabel_en-US" xlink:label="lab_trov_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_trov_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_trov_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_trov_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesDConvertiblePreferredStockMember" xlink:to="lab_trov_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2bdf9f59-3a05-4471-ba24-6a36b5e7abd6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3e1e83c5-9495-4877-aa60-21e37ac31717_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_RegisteredDirectOfferingMember_1566bd24-bae5-4b83-a90d-f9aa4fa62cbb_terseLabel_en-US" xlink:label="lab_trov_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_trov_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_trov_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_trov_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_trov_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to registered direct offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_RegisteredDirectOfferingMember" xlink:href="trov-20201231.xsd#trov_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_RegisteredDirectOfferingMember" xlink:to="lab_trov_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_d0f10c5b-56b1-481d-9807-650f6811e987_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_0559f843-4107-4215-b650-d6ade1ac4f8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_fe552c18-1afb-409d-9da5-002651a25b8a_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_81dd5f5c-6ee0-4d8c-9587-534fcf263c38_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_46775c02-89a4-4496-86d4-cbb6cef0ee0b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ad30ef23-b08f-49e9-a28e-875842bbb12d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_aabb6e8b-3deb-487c-8fcc-ae23d7c68cda_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments - Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_cc505e54-4a9e-451c-bae8-04565cef3695_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f56c8e82-e43c-41b8-8a9a-edb799ec6346_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f6f2a986-f209-4393-9b79-72340012fd52_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b82199ef-9e30-488b-975b-b54dc4013ed3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_ef94c8d9-ae96-4e61-9e15-df0a7eab2a15_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Losses on Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_af96af1f-d797-4fac-a1bc-1c8b7eba0f3a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c1a7234f-0e3a-445c-af53-1b52407fb250_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a9ae81f6-8c55-4f08-b427-214ab647b177_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9b85410f-a49e-4c81-84ee-1d71d0c3a1ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees and outside services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_1c583cde-4abc-45cd-b339-843607c491a5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_74d429fe-39fc-44d8-b285-1352c729955c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c7c350cf-b70d-4678-b4ad-0f114756090c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c9869a34-8258-4a1f-8af7-75e02f022a98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ccd7c37a-77aa-473d-a372-d63368141725_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ServiceReceivableMember_de3f579d-624f-4367-bd0e-23cba9defab8_terseLabel_en-US" xlink:label="lab_trov_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_trov_ServiceReceivableMember_label_en-US" xlink:label="lab_trov_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_trov_ServiceReceivableMember_documentation_en-US" xlink:label="lab_trov_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ServiceReceivableMember" xlink:href="trov-20201231.xsd#trov_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ServiceReceivableMember" xlink:to="lab_trov_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Patentlicenseandotherfeespayable_473814b1-ada9-4e72-9b5e-55d7823abeca_terseLabel_en-US" xlink:label="lab_trov_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees</link:label>
    <link:label id="lab_trov_Patentlicenseandotherfeespayable_label_en-US" xlink:label="lab_trov_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:label id="lab_trov_Patentlicenseandotherfeespayable_documentation_en-US" xlink:label="lab_trov_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Patentlicenseandotherfeespayable" xlink:href="trov-20201231.xsd#trov_Patentlicenseandotherfeespayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Patentlicenseandotherfeespayable" xlink:to="lab_trov_Patentlicenseandotherfeespayable" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross_4b58419b-a8f9-4552-96e1-86298b04a6d2_terseLabel_en-US" xlink:label="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:label id="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="trov-20201231.xsd#trov_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_trov_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LessorNumberOfSubleases_2f9950de-d62a-42c1-9c0d-7abca26b5926_terseLabel_en-US" xlink:label="lab_trov_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subleases</link:label>
    <link:label id="lab_trov_LessorNumberOfSubleases_label_en-US" xlink:label="lab_trov_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:label id="lab_trov_LessorNumberOfSubleases_documentation_en-US" xlink:label="lab_trov_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LessorNumberOfSubleases" xlink:href="trov-20201231.xsd#trov_LessorNumberOfSubleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LessorNumberOfSubleases" xlink:to="lab_trov_LessorNumberOfSubleases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_572c9464-e5ba-4ca0-b813-28a0c4ac3cd1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2b99328f-f96d-4c41-bb12-8ac4567244fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3fe429a6-bf49-4fe0-b722-db702a833a38_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax computed at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_74e56023-8ed0-45b2-ac70-7dffc1f79bf1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b7f0d85c-7263-49f3-a56b-495bcbecd826_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_786a4e20-108b-4426-8b4c-8bec3e53b8e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_51149156-ca72-400d-b867-04cfb53c630e_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemLineItems_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems" xlink:to="lab_us-gaap_UnusualOrInfrequentItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c1b1fde2-ebda-4c86-8ea0-71f6ee890ed2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised_8d7dc147-fa7a-4cd1-bfba-de4c60b8390c_terseLabel_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The equity impact during the period due to the cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_trov_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0e6e8f68-5706-4879-bc9c-9a32c1a5af5b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_f2a421df-b46e-400b-a230-1f2c8c45a2cd_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_81f341ea-e95b-4450-b2d3-a9f9509494a3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_8b8c274d-f631-4c77-8142-197a26fc8a97_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f68ddd40-70a7-44f9-853a-0f47511e9827_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40ba6063-8bef-4250-9d7b-fee862bdd107_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_59d64824-30a1-4969-bd58-937ee6891114_terseLabel_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_eab81b85-4bb7-433c-a8f3-f4382bd06669_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_417432aa-bf36-49d6-8a52-ed326322b10c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_cca1b205-ec51-405b-a3d4-372b832a71ee_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 20,000,000 shares authorized; (Note 5)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_07a6e9f8-0e17-473d-8ce4-6d67545ae76e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_617dd29b-3281-484a-9fc1-42032c705542_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_ca7cb2f6-7bd7-4188-93ce-8776b922fd9c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e3b98cd3-e0f6-424f-ab04-34b68bafb9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9f4bb2e3-101b-4f97-9f43-33442f80b4bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_01d09aa1-e13d-45b0-a8d6-9b16445aab4f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of note payable</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_e1ffe598-5115-41f1-9721-cd622945cf83_negatedTerseLabel_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_99aceead-2162-44f3-9485-c9579cc17df6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_42aa31f1-8648-479e-b7ab-2e42bcce1c65_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ReleaseOfClinicalTrialFundingCommitment_b12321d2-227f-4d8d-9159-179448bd234f_terseLabel_en-US" xlink:label="lab_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_trov_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_trov_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:href="trov-20201231.xsd#trov_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_trov_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_d57afe4c-4ce1-4b06-852a-cec6bdd966d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_38441516-90d9-41f5-993a-b220ce52b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cd1ed1d7-98fb-4aad-acce-212c1199c8bb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_c8f54605-f9cf-4201-9906-7149a81616fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_88385259-6e90-496f-9f65-039e9a480a4d_terseLabel_en-US" xlink:label="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:href="trov-20201231.xsd#trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:to="lab_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_649024f1-8f8d-4b4b-a151-e78cf60e4fe3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f63a4d5f-7c47-41e1-ab33-03bbd9cc2d92_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_80804894-785f-4eff-af1d-ac8330c4af3b_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e9b52a2f-25d9-4fdd-b014-5ce3465d65b5_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_daa5a283-aabc-4c2b-8911-dd41a94c6bc8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_4e7b63e4-e95c-4b2e-bbe7-e126531851f7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8dcb4f47-6e8c-4770-95c3-7feed4f6dd0a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_0d2c45aa-a4ef-4980-9710-ba00b3831723_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_20026cfa-a23e-4ff6-84e1-334851a74a68_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and/or penalties incurred</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_4b1ab33d-7c18-4c2f-ab9d-db5d49279a52_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract_label_en-US" xlink:label="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:to="lab_us-gaap_ExtraordinaryAndUnusualItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_8ae4909d-cce1-488c-8ca6-1d77ebd87d37_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_73bb90cc-618d-497f-affc-ddb31bad2841_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_35a56a33-ac32-4daa-a808-d0a68f781e46_periodStartLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_07524e6c-e943-42a2-a4c4-a6f30416a348_periodEndLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the end of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b2013867-8d69-43c4-80b8-eee697034210_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_0296b206-e0bb-4f1d-b018-07cde3ae8072_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_36346161-80d7-4ed9-ae19-efe125c91962_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b56f07bc-5645-4e2e-a5ca-3a8109b162f6_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_a0c5ee2c-c601-49a0-9bfc-40066020dad6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other gain (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_f54ff750-6758-45b7-82f5-7ca0dc984f69_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_3c26ac96-d866-41d0-9615-6adb72af7998_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_825f6241-a1af-483d-91a4-9c06ff648c1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_f81990b8-2b55-4f45-b4b9-d887f5f405fd_terseLabel_en-US" xlink:label="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_label_en-US" xlink:label="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:label id="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_documentation_en-US" xlink:label="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:href="trov-20201231.xsd#trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:to="lab_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_96debfc2-0083-4fe2-9976-1f6af8f69288_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61d62820-e922-4372-ac91-657203a3e379_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_b2529b05-e26e-4586-9320-871a4c2c0c74_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f05baa65-8e4d-454d-8773-4d6bb5c94146_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $7,507,123 and $158,678 respectively</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_12480028-6979-48a3-a846-db652c422836_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_81d9e765-503d-4fd4-9f4b-7d592a15c375_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options true-up</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2b11ebcb-ad94-4d5c-a885-fd271af1f35f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_aaf45873-c73e-4503-9847-47ca4698e009_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_44156358-5a50-4ccd-a53c-643daac39222_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c58fafc6-39d9-43c7-aae0-341d1fe5f23c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_22a7282b-322a-436d-b918-93e2d3791deb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage_37b73056-022a-4a08-8f99-6490798fdd37_terseLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_2b011ffe-5fa8-4950-9f6f-617d9bb48833_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_cbd7cfed-24e7-4881-a727-38a879be8c9b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued cumulative unpaid preferred stock dividends</link:label>
    <link:label id="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_label_en-US" xlink:label="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Amount of Preferred Dividends in Arrears</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="lab_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_716da7b7-6d2b-4aef-956e-1550f1a9341c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_11a8d215-2ccb-43f8-9efd-ac5aceb478be_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_dffc3731-6b61-4a9b-9b79-b461fd1f8c33_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_065516c7-7058-4703-855d-52f7eacc0994_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_43a28428-14e0-4ff0-98ca-63c642692c8b_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Granted</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:to="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7fb0cd13-37d0-43d5-aefc-8ef9b9ff7598_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_32b4a160-eabd-4bf1-b589-42bde2ed00b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_d25d08eb-b328-496c-a5de-4a551c01810b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4b311576-9a3c-4944-8cd2-dab33a10dc3a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreFundedWarrantsMember_178d7651-b043-496c-8f14-8479bcb0e455_terseLabel_en-US" xlink:label="lab_trov_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_trov_PreFundedWarrantsMember_label_en-US" xlink:label="lab_trov_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_trov_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_trov_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreFundedWarrantsMember" xlink:href="trov-20201231.xsd#trov_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreFundedWarrantsMember" xlink:to="lab_trov_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_1f7a9f12-da02-4502-ba42-a90dd106c01c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments&#8212;Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_21b500b6-586c-4ff6-aef5-ba13aceb5f21_terseLabel_en-US" xlink:label="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_label_en-US" xlink:label="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Specified Volume of Common Stock Traded Per Day during Trading Days</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_documentation_en-US" xlink:label="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:to="lab_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_f55d6400-ca9c-43fd-a638-02f5876fd914_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_4697bdb6-beef-4f5d-a694-a1f59e829d04_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost for non-vested options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_2b83c73b-9111-4352-a830-cf87424d5412_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberExercised_9f1ad447-bc79-42af-92d0-dea7644116f3_negatedTerseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberExercised_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Exercised</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberExercised_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberExercised" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightNumberExercised" xlink:to="lab_trov_ClassOfWarrantOrRightNumberExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_d5978d79-ee41-43af-b658-c24416c8370e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e00acdbd-dc73-4b04-8bfd-2330bcb67215_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c1b3ce7d-063e-4db5-adc5-5bf562e8a5f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_1ab78751-2021-461d-9360-d92bc7cbcbbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_71f7687b-282c-4dd4-bb3c-a16bc122341f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_50fa6f2b-1889-4884-85b7-a8915341ccef_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_acbb8d3b-08b2-4b76-970b-a5c35a45fd41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f539a18a-2660-43c0-891e-0b59fd7afbce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_76594349-4532-443f-97bb-0d7e0d2fda89_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_5ca109a1-5a4a-4d43-a96b-0ad2326644df_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_e25e4c71-5ac8-4b7f-a7c1-9b9cd7c1fb61_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_NorvianoMember_b0d231b3-092a-4946-9fbe-a402205df716_terseLabel_en-US" xlink:label="lab_trov_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norviano</link:label>
    <link:label id="lab_trov_NorvianoMember_label_en-US" xlink:label="lab_trov_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Norviano [Member]</link:label>
    <link:label id="lab_trov_NorvianoMember_documentation_en-US" xlink:label="lab_trov_NorvianoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nerviano [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_NorvianoMember" xlink:href="trov-20201231.xsd#trov_NorvianoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_NorvianoMember" xlink:to="lab_trov_NorvianoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_WarrantsFairValue_10910892-71c7-480c-a957-9566394cbc3d_terseLabel_en-US" xlink:label="lab_trov_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_trov_WarrantsFairValue_bf0915c8-80a5-4c6f-aa81-48ca1eaf3857_verboseLabel_en-US" xlink:label="lab_trov_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:label id="lab_trov_WarrantsFairValue_label_en-US" xlink:label="lab_trov_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:label id="lab_trov_WarrantsFairValue_documentation_en-US" xlink:label="lab_trov_WarrantsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsFairValue" xlink:href="trov-20201231.xsd#trov_WarrantsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_WarrantsFairValue" xlink:to="lab_trov_WarrantsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1d58001b-d6bd-4634-9bf4-e835cfc68503_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_dbcf7f5c-284b-498a-a5d6-c4f52cedf27d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_52d1e9b0-6287-4ccf-b44d-b157f3c9e31c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_1c4c0923-42ba-4cd0-99b5-06611223b07f_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_b2c7fb54-d7c4-4b2d-8fbc-a93e483ddd84_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_32157831-c814-45b5-baa1-62fc2d0e5127_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_2138e571-d268-4c3a-97de-b39709c23433_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_86f94b03-c85d-48ba-a9da-ab2166f32c2f_terseLabel_en-US" xlink:label="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assumptions Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average remaining contractual period for which the instrument, asset or liability is expected to be outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:href="trov-20201231.xsd#trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:to="lab_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_29b7923f-a4f5-4ae0-8d57-79ed81bbbc2a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_f05f6279-ea3e-4779-91cb-d4d92bb6ae25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f50da5c5-9dcb-4c21-882c-ee0d0869848c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_b7e6d0f9-8d4c-40b1-bc6d-a410a5fd3c71_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7f14eba9-dbe8-435b-9c29-f02a2b91a3fd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_80bbd2de-9c92-4db9-92c8-3546b4c9f8b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_d85f8fec-16b6-47e2-9dd6-bdb69842a56c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f7f853c8-e794-4b94-91bb-a0ad097b2ab9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_bf7e0b82-62dc-4b0f-8af4-ac8a45e89348_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_9d65a70d-e15c-4afb-a040-6d9acce28553_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_5d8a2fd2-ae96-4ef8-9425-8f96318935de_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credits</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c907d23d-11ff-4807-8e7b-969eb3b9a262_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_ad932f0d-d34e-45cf-8034-dd22c727cd55_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_79247826-ec7f-419d-bc9d-3622d79a11a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes Based on Losses from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_f79d1c97-013f-4615-a01c-8841932182ed_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7f9d2e44-1cff-43de-80bb-e20cb1780d5e_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a9250047-e627-4594-a462-d9b18936f786_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockDividendAccrued_eafdc150-c42b-422e-8d68-bf2fff64177e_terseLabel_en-US" xlink:label="lab_trov_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_PreferredStockDividendAccrued_label_en-US" xlink:label="lab_trov_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividend Accrued</link:label>
    <link:label id="lab_trov_PreferredStockDividendAccrued_documentation_en-US" xlink:label="lab_trov_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the value of preferred stock dividend accrued during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockDividendAccrued" xlink:href="trov-20201231.xsd#trov_PreferredStockDividendAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockDividendAccrued" xlink:to="lab_trov_PreferredStockDividendAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e6406585-a23b-44c3-9c49-fc08e017fd03_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_618aac60-3192-4204-9c31-d7eddc102744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (range)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_47ccf770-aa63-4d02-950d-5b72a25caf7f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_09744254-1a6d-4b0f-b603-453429cd8eca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bddd87bd-4d63-4af6-9685-bc334e945f38_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_df85c574-8994-4054-b8d5-533e090f89ac_totalLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:to="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_989c7098-f260-4f7d-830e-1e383a9a1c94_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_43dc0217-9e23-4296-8c54-c0788cbb77db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_ad1bdb28-a87d-4753-9f6e-411a1e368f24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_793bbdde-8c24-4a83-a157-d406fbc351c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseMonthlyRentPayment_aa68aa18-d75b-4971-8629-3d22f3321629_terseLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_trov_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2e2f0584-ef6a-4fa8-b69f-f0b44cca666d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable&#160;to&#160;common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_16e355b8-ba41-405f-a3f3-b447acd8d09b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f35f2ac7-cc06-40de-86a3-871edfc83d3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_CommonStockAndWarrantsMember_ffeba421-23ac-436d-bc8d-f9a05061c22e_terseLabel_en-US" xlink:label="lab_trov_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants</link:label>
    <link:label id="lab_trov_CommonStockAndWarrantsMember_label_en-US" xlink:label="lab_trov_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants [Member]</link:label>
    <link:label id="lab_trov_CommonStockAndWarrantsMember_documentation_en-US" xlink:label="lab_trov_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CommonStockAndWarrantsMember" xlink:href="trov-20201231.xsd#trov_CommonStockAndWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_CommonStockAndWarrantsMember" xlink:to="lab_trov_CommonStockAndWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_3d151734-dc3f-4c14-a5dd-2f2a36756dcd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from changes in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_fa30ce0d-c2b5-41cf-bc39-ee6dab35f237_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_215f3ba7-199f-4938-ba23-cb4d7a158d7c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised_b87e1b80-dd7d-48a4-9697-8b0337175283_terseLabel_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period upon cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_trov_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_baecaf62-d238-4153-89e0-367af5ec5f3a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7262ae2c-2a86-495a-9f21-1915f73f9562_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f894c653-b0ca-45b7-a20f-afae37450c48_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_46ac49d1-4278-4d91-8885-5d541faecea9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesNWarrantMember_81c09449-d224-4527-97e2-ce05dd386710_terseLabel_en-US" xlink:label="lab_trov_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:label id="lab_trov_SeriesNWarrantMember_label_en-US" xlink:label="lab_trov_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant [Member]</link:label>
    <link:label id="lab_trov_SeriesNWarrantMember_documentation_en-US" xlink:label="lab_trov_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesNWarrantMember" xlink:href="trov-20201231.xsd#trov_SeriesNWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesNWarrantMember" xlink:to="lab_trov_SeriesNWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SharePriceForAutomaticConversion_6e8e14b1-a913-4184-939d-53ce205a1702_terseLabel_en-US" xlink:label="lab_trov_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price for 20 consecutive trading days for automatic conversion</link:label>
    <link:label id="lab_trov_SharePriceForAutomaticConversion_label_en-US" xlink:label="lab_trov_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price for Automatic Conversion</link:label>
    <link:label id="lab_trov_SharePriceForAutomaticConversion_documentation_en-US" xlink:label="lab_trov_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SharePriceForAutomaticConversion" xlink:href="trov-20201231.xsd#trov_SharePriceForAutomaticConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SharePriceForAutomaticConversion" xlink:to="lab_trov_SharePriceForAutomaticConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e5d09d14-8a0f-4ca5-9009-621a599a79de_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c8f62eac-2e5e-4984-a4ca-1873ba57a58a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_b1832b4f-cde5-4ed3-8829-86cffe45b475_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_63a50afa-b3e5-43bb-bf24-cbb810fa6ff0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_5788217f-69f0-4b2e-a11d-a8651c7c1959_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseLiability_2a682a9e-cd85-4e3d-9a37-d3ac34a7c729_terseLabel_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseLiability_documentation_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_trov_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_bb966ac1-6c9d-4309-8136-e74859212eb0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e221dbd3-92dc-4de7-9ec7-14c18a87dc98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_13e59eb9-6d62-4178-8940-a57d68d2b3a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_23826df1-2e16-4752-a5cc-4f7c6aa4fb96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_7aaa4789-0b7b-4d07-884b-cdfa9717db74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightExpirationTerm_755640e2-c126-44d5-be11-c64f19ff00e6_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightExpirationTerm_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightExpirationTerm_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightExpirationTerm" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightExpirationTerm" xlink:to="lab_trov_ClassOfWarrantOrRightExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ac37c7cd-0488-4c72-a822-b1c36a410727_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1a5cfeb1-7056-4625-8d49-84f79973a121_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_f4028af9-5176-4393-82b6-3cc877443e5d_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f7143d29-2147-41db-ba3c-d651649aad55_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8d70b7ca-3ccc-4e4f-99cb-5e5a8cf4853e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_ddf7f9a6-44d9-41fd-b4c1-d7ec72ffda39_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_d3ea3db9-93a6-4a99-87a4-84d743459566_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_a6e242c2-26f7-4326-8525-19153ccded6a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable_9bba4a16-3f3b-43fb-9d6c-3056e6a98af4_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Months until exercisable</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:to="lab_trov_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4417dbd-77a6-4a9f-91ca-4f1ceced2e10_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bb48004b-7695-416c-a284-17304c5bd848_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_2c7109b7-db5a-430e-89ce-64de53217162_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_befc6535-5a3e-403b-b0e3-c3cbd685d3c4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_db8990fb-435b-483f-ba7c-1b7e2a23e8dd_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DocumentAndEntityInformationAbstract_383a0740-4143-4ff8-9ec3-cd26ec11003e_terseLabel_en-US" xlink:label="lab_trov_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_trov_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_trov_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DocumentAndEntityInformationAbstract" xlink:href="trov-20201231.xsd#trov_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DocumentAndEntityInformationAbstract" xlink:to="lab_trov_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_fe7d47c5-6220-4812-af28-1ea923b15cfd_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesEConvertiblePreferredStockMember_85e54559-cdac-4b59-9971-7da9dbcb608f_terseLabel_en-US" xlink:label="lab_trov_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_trov_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_trov_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_trov_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesEConvertiblePreferredStockMember" xlink:to="lab_trov_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cfdb09ad-18b7-4c58-9541-35e2c7a75be3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d6f5c0cf-5121-470a-98c7-ae1c4d1348c7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_928c7804-fe95-420e-a58b-8a22a6a3c7fb_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_172e5784-04ab-4da1-aee5-fcb973987349_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_aef31b61-c6c0-4b15-ac82-e1f964a3594b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_555b020b-2843-4cb4-8ae4-85f9e22bbaa8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options true-up</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b3be1f3e-ed37-4e17-a1c0-21e90c2f601b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_27d0f6da-cafe-48fa-9b61-7808361d9ead_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_813d2199-07b6-4d87-bd37-e627cc41bbc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Taxes and the Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AccruedClinicalTrialExpenses_75108617-27e3-4636-bd3d-e1359bf33c25_terseLabel_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_trov_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_trov_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrialExpenses" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AccruedClinicalTrialExpenses" xlink:to="lab_trov_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesCConvertiblePreferredStockMember_ed68fd64-5350-4cf1-8222-44f919291e6c_terseLabel_en-US" xlink:label="lab_trov_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_trov_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_trov_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_trov_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesCConvertiblePreferredStockMember" xlink:to="lab_trov_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_IncomeTaxReconciliationPermanentItems_fe3e2ee1-52df-4664-9268-1316962742bb_terseLabel_en-US" xlink:label="lab_trov_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent Items</link:label>
    <link:label id="lab_trov_IncomeTaxReconciliationPermanentItems_label_en-US" xlink:label="lab_trov_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Permanent Items</link:label>
    <link:label id="lab_trov_IncomeTaxReconciliationPermanentItems_documentation_en-US" xlink:label="lab_trov_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncomeTaxReconciliationPermanentItems" xlink:href="trov-20201231.xsd#trov_IncomeTaxReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_IncomeTaxReconciliationPermanentItems" xlink:to="lab_trov_IncomeTaxReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_9db42e3a-636d-42d3-ba1c-1d4c7559b5dc_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_36489f99-ff72-4e1f-b9bd-0cfa1401dad9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1156fe90-b7f2-471b-97e0-a9c23a424548_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3ce2e912-7112-4461-ae5e-e4d5f272c56d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_43432b73-311a-41f0-a625-67e67fac2010_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_45403ec2-e212-48ba-b2be-89ba6ef88b68_terseLabel_en-US" xlink:label="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock par value adjustment</link:label>
    <link:label id="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_label_en-US" xlink:label="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock Par Value Adjustment</link:label>
    <link:label id="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_documentation_en-US" xlink:label="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital, Common Stock Par Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:href="trov-20201231.xsd#trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:to="lab_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SaleOfStockCommonAndWarrantsNetShares_9fb69033-0fd7-4102-a654-e3b1564b5220_negatedTerseLabel_en-US" xlink:label="lab_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants, net of expenses (in shares)</link:label>
    <link:label id="lab_trov_SaleOfStockCommonAndWarrantsNetShares_label_en-US" xlink:label="lab_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:label id="lab_trov_SaleOfStockCommonAndWarrantsNetShares_documentation_en-US" xlink:label="lab_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Common And Warrants, Net, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:href="trov-20201231.xsd#trov_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:to="lab_trov_SaleOfStockCommonAndWarrantsNetShares" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_31b33f36-4e0d-456f-9acd-173e474ca77b_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6d37f4b4-2f99-41d5-b827-64f506287d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_bff523b1-ebb2-4513-b37a-1d3ea04991ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_3db876e8-5a2e-47c2-a738-da54084ab4a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_cc323fbc-5a08-4adf-8b22-442d321524df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AmountFinancedUnderAgreement_887dfa36-5f58-4626-b4db-214dd94d16b3_terseLabel_en-US" xlink:label="lab_trov_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount financed under agreement</link:label>
    <link:label id="lab_trov_AmountFinancedUnderAgreement_label_en-US" xlink:label="lab_trov_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Financed Under Agreement</link:label>
    <link:label id="lab_trov_AmountFinancedUnderAgreement_documentation_en-US" xlink:label="lab_trov_AmountFinancedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Financed Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AmountFinancedUnderAgreement" xlink:href="trov-20201231.xsd#trov_AmountFinancedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AmountFinancedUnderAgreement" xlink:to="lab_trov_AmountFinancedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8cbe2507-d740-4be3-acb2-0ba72837bb06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_3b1e1eaf-5647-4582-bf7a-0a69f4662522_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesBConvertiblePreferredStockMember_2c4c4baa-b082-40c7-979f-58927a779860_terseLabel_en-US" xlink:label="lab_trov_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_trov_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_trov_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_trov_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesBConvertiblePreferredStockMember" xlink:href="trov-20201231.xsd#trov_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesBConvertiblePreferredStockMember" xlink:to="lab_trov_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_7614871f-4294-47e7-a271-6369e695299f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs related to the clinical trial funding commitment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_12310216-1c30-440d-936d-e7010d8698cf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_68405bb4-3afe-4e35-8775-fa1ec955ac7e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_37b30e66-9ee4-4102-862c-21e094bd17ed_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_a35ab9c8-6559-4898-9045-2a421e5cc7ed_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance, Current Classification [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesAConvertiblePreferredStockMember_fe3cc125-b56e-488e-9eb2-05498f0e348a_terseLabel_en-US" xlink:label="lab_trov_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_trov_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_trov_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_trov_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesAConvertiblePreferredStockMember" xlink:href="trov-20201231.xsd#trov_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesAConvertiblePreferredStockMember" xlink:to="lab_trov_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb42e73d-9cc6-4b41-a0a3-2e7a02c19556_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0d26b3cf-2963-456f-ad53-0b1d8559b01d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_77638270-2530-47c0-bbaf-455dd684ca32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a97cf488-79b9-48d9-9718-6bcb4b23daff_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_942a0b45-84cc-48be-98ac-ba3f67b2cc82_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a44faf33-ee4f-4e3e-afbc-ef1251816ef3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_BlackScholesOptionPricingMethodMember_b75b32dc-ff1b-48f9-b2ca-79321eec1d44_terseLabel_en-US" xlink:label="lab_trov_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method</link:label>
    <link:label id="lab_trov_BlackScholesOptionPricingMethodMember_label_en-US" xlink:label="lab_trov_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method [Member]</link:label>
    <link:label id="lab_trov_BlackScholesOptionPricingMethodMember_documentation_en-US" xlink:label="lab_trov_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_BlackScholesOptionPricingMethodMember" xlink:to="lab_trov_BlackScholesOptionPricingMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_fe6452d7-6abb-47e4-bce7-f7c824f0b895_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_63d77ee7-fe73-4005-928f-00ae4cfbd285_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2c59ff97-8630-45db-8094-212ff00a1b2d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_515f735e-3f4e-4283-83dc-7ecb369b0796_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SaleOfStockValueCommonAndWarrantsNet_a7a9defd-df1a-4c6e-bb8f-d41fd31a8b1d_negatedTerseLabel_en-US" xlink:label="lab_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of common stock and warrants, net of expenses</link:label>
    <link:label id="lab_trov_SaleOfStockValueCommonAndWarrantsNet_label_en-US" xlink:label="lab_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:label id="lab_trov_SaleOfStockValueCommonAndWarrantsNet_documentation_en-US" xlink:label="lab_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Value, Common And Warrants, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:href="trov-20201231.xsd#trov_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:to="lab_trov_SaleOfStockValueCommonAndWarrantsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_78396e11-40eb-4f66-9d0c-72cd20003373_terseLabel_en-US" xlink:label="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits and other tax credits</link:label>
    <link:label id="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_label_en-US" xlink:label="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Research and Other</link:label>
    <link:label id="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_documentation_en-US" xlink:label="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:to="lab_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6dedc031-514a-4d26-88fd-fbb47059848f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e97779d5-6f58-4af2-83db-e3caab4352d7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_fd843e9a-a262-498c-8dbb-fad3975d9821_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6a23d3e9-9f19-49c9-a817-015e4045799a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_698777c7-8073-4199-87d7-f50d1c04f41b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c4f2220d-30f3-4d0b-9b90-a42618260ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2ed79eef-95a8-4869-bb7e-1e0a1fd83561_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Stock Options - Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_3db816cc-a35f-4b2c-89da-b05c9db3d65e_terseLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Leases</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:to="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6f63ef48-7806-4633-916b-2ea9e8f57c7c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b408fa77-556a-4de0-9309-f28ea0673e13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d60e484a-3ac6-445e-ae06-1885aec2a9fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance_742ee8b0-471b-41db-a553-651e20be8d2b_totalLabel_en-US" xlink:label="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance_label_en-US" xlink:label="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:label id="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance_documentation_en-US" xlink:label="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="lab_trov_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightIssued_2489a65f-0bea-45f4-a266-cca5d1318a88_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightIssued" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightIssued" xlink:to="lab_trov_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dba1bcf0-525b-429d-b58a-3c4c714b86bc_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_322e709f-828c-49f1-a8d1-04a43c76b8cc_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets and liabilities from federal and state income taxes</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAbstract_194d6eb9-56d2-4326-8f99-4c05fe8890bf_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract" xlink:to="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_bc220c42-db8f-4b2f-8013-17845af70315_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_1d785c8f-f91f-4617-b3f5-0fa0d5e4b915_totalLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:to="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b7f85002-e114-4662-8dae-9c892c4f6575_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_8450bb9e-6219-4918-be9e-1137640d5cd2_totalLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Next Twelve Months</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:to="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_5d340201-2f16-4ae3-becf-4bc99b610a53_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fdc5ad1b-479f-4cdf-8f73-389b1fbfa3d1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_13351450-97ef-4063-8d16-db895e480e9d_terseLabel_en-US" xlink:label="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640</link:label>
    <link:label id="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_label_en-US" xlink:label="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:label id="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_documentation_en-US" xlink:label="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:href="trov-20201231.xsd#trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:to="lab_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_65b04b56-8223-4af3-8ed9-67b6b3a5c2e2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_5f978132-10ef-4036-a10d-a2835d5f29e2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_fe73cdcc-ad44-4cfa-97bc-d0fd28f3b650_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_bebb396a-b572-458c-9936-1393f38f1b61_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1618299b-eadf-4c7f-84d3-b7c04704677b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_08efa9f7-4790-4f6f-8b27-e81f3f6d9941_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_2f034f1f-a2da-40c5-9bb0-e9fe21d4f18c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_35f26de2-226c-48cd-a9c1-d80e64cc003a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e0993a77-0819-40ed-9ff0-0012e9589e19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0f94fa39-4351-48e6-9fe2-8741f3878016_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_187d746a-a60a-453e-a6cb-e64a38b7e1ca_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9ac35344-a56d-4dd1-a1d2-6b8fdf5aed58_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8cc816d1-6d4a-4923-97fc-442dcd30b22c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7fd6aecd-c6a2-4bb1-bf5b-52c401ca5184_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a8bef5b5-a419-4695-8ec3-697e9a4d8148_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5ffe194c-444f-485d-8ce9-90e5ca2e547b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits_7d6bd403-6643-4bda-b2be-271d2c6f8c4f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for share rounding as a result of reverse stock split (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_5e6f9eef-4270-48c1-8cb4-75dcef32c802_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AccruedClinicalTrial_fb916c99-28ff-43cf-87af-197e45492a1d_terseLabel_en-US" xlink:label="lab_trov_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_trov_AccruedClinicalTrial_label_en-US" xlink:label="lab_trov_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:label id="lab_trov_AccruedClinicalTrial_documentation_en-US" xlink:label="lab_trov_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrial" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AccruedClinicalTrial" xlink:to="lab_trov_AccruedClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_8f76ea9a-2441-43cf-9d65-c7a59a3cd437_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards (NOLs)</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_6fa2e425-0f09-4d3e-832a-1f19199b41a0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4615aa00-77ec-432b-b4a4-e31817402cba_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_d7e20c8d-4044-4c8c-972d-5ca6b013ceb8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a6ffe61f-b5b9-4c2b-beb6-c6b816c3f356_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_14f1b0e0-d33c-4bff-9da0-6b0eaa9e460f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_4feaf9b6-c797-46e2-b4c1-6a8d1d9e2012_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine the Fair Value of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c7665e21-ee4c-4dcb-a240-1c0e934b08b1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_df628aa1-75dc-471a-a3ec-d20415665681_terseLabel_en-US" xlink:label="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which the conversion price is subject to adjustment for dilutive issuances</link:label>
    <link:label id="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_label_en-US" xlink:label="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Period of Dilutive Issuance for Conversion Price Adjustments</link:label>
    <link:label id="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_documentation_en-US" xlink:label="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the period during which the conversion price is subject to adjustment for dilutive issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:href="trov-20201231.xsd#trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:to="lab_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_150511f3-7d6e-4c7d-b3ba-1154f7223629_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_2c71464c-f863-4fbe-b8a3-30efb22966bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_ff232843-6081-4549-bbb1-89f70a2e2d31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_54e19389-3346-4cfa-b473-e3062e026cd3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesJWarrantMember_357ede20-b967-4660-86e1-9ec667a9290e_terseLabel_en-US" xlink:label="lab_trov_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant</link:label>
    <link:label id="lab_trov_SeriesJWarrantMember_label_en-US" xlink:label="lab_trov_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant [Member]</link:label>
    <link:label id="lab_trov_SeriesJWarrantMember_documentation_en-US" xlink:label="lab_trov_SeriesJWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series J Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesJWarrantMember" xlink:href="trov-20201231.xsd#trov_SeriesJWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesJWarrantMember" xlink:to="lab_trov_SeriesJWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_064acc65-3fb1-41c7-ada8-5729cd9b6e36_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_e0036897-e52b-408f-9eb8-585eb6eb0e1c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_59b4b87b-ffde-41a2-a92c-c9b33bbac587_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3426f26c-861f-408f-bfb5-d903665ec64a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_42ffb243-1d30-458d-a959-65ffd80929a3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7d401a08-5858-4c4a-8a62-79a48b8f5806_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1aed17ed-ce54-4077-98bd-b110cbbfc575_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_01389445-a046-4596-9056-b7529b1892b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0abd2301-b1c8-4014-b4c7-32594669ec14_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberGranted_ba7b63c5-c150-43e5-9767-db3bb17711ef_verboseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberGranted_3ab879db-5e1a-4d54-94b1-1d6b09bf7217_terseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberGranted_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Granted</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightNumberGranted_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightNumberGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberGranted" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightNumberGranted" xlink:to="lab_trov_ClassOfWarrantOrRightNumberGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_00b81e59-93e3-4da8-a0f4-13b69839b3e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Accrueddirectorfees_d9749bbc-bbe9-4f90-86b9-c894e38baa43_terseLabel_en-US" xlink:label="lab_trov_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director fees</link:label>
    <link:label id="lab_trov_Accrueddirectorfees_label_en-US" xlink:label="lab_trov_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:label id="lab_trov_Accrueddirectorfees_documentation_en-US" xlink:label="lab_trov_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued service fees for nonemployee directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accrueddirectorfees" xlink:href="trov-20201231.xsd#trov_Accrueddirectorfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Accrueddirectorfees" xlink:to="lab_trov_Accrueddirectorfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ca7fb59c-e871-4d4a-8a1e-d5d7159074ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8fa867de-0549-46eb-85ee-1b583a37f02a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_f170ad2a-3f7d-4131-b861-0d347ee76dd1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DerivativeFinancialInstrumentsLiabilityRollForward_588e2b16-7c5f-4426-81a2-f70084dc2ffb_terseLabel_en-US" xlink:label="lab_trov_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Company's derivative financial instruments liability balance</link:label>
    <link:label id="lab_trov_DerivativeFinancialInstrumentsLiabilityRollForward_label_en-US" xlink:label="lab_trov_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:href="trov-20201231.xsd#trov_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:to="lab_trov_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_55e53470-985c-4386-af94-d1f1bac76605_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c95afead-e5c1-4060-9603-786148c770d5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_03f7b29f-5fb6-4268-92e8-3099042cd187_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesLWarrantsMember_9da8b177-5189-4d9f-9b8e-56b159a57d67_terseLabel_en-US" xlink:label="lab_trov_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants</link:label>
    <link:label id="lab_trov_SeriesLWarrantsMember_label_en-US" xlink:label="lab_trov_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants [Member]</link:label>
    <link:label id="lab_trov_SeriesLWarrantsMember_documentation_en-US" xlink:label="lab_trov_SeriesLWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series L Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesLWarrantsMember" xlink:href="trov-20201231.xsd#trov_SeriesLWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesLWarrantsMember" xlink:to="lab_trov_SeriesLWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PaycheckProtectionProgramCARESActMember_1fab63d3-d3e2-4d77-be08-cc1a881cce28_terseLabel_en-US" xlink:label="lab_trov_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_trov_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_trov_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_trov_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_trov_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PaycheckProtectionProgramCARESActMember" xlink:href="trov-20201231.xsd#trov_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PaycheckProtectionProgramCARESActMember" xlink:to="lab_trov_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6409686b-8a6f-4697-b3fd-16195dcc7250_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_9728ef0f-2839-4e02-94c5-c7ea1da64d9a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8c19b9f9-4ed5-4f90-9ba9-2d7342b17445_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6c48e579-5889-4ddb-9f02-c17d362c775c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_d078206f-975d-48a7-a400-5466df236544_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_3f2020a5-8a77-4523-81f6-20b3b19f48c9_periodStartLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_b1f8226e-499f-4781-8ea1-84ba93509a55_periodEndLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e726dc70-9e49-4021-bf0c-e35f2ee65eb1_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_a12c2ea2-b620-43dc-95b4-b76e8613ad95_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000,000 shares authorized; 36,780,805 and 8,593,633 shares issued and outstanding at December 31, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_f2616b3e-7b1a-4e48-858b-80b2720511e1_terseLabel_en-US" xlink:label="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent Items</link:label>
    <link:label id="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_label_en-US" xlink:label="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label id="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_documentation_en-US" xlink:label="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:href="trov-20201231.xsd#trov_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="lab_trov_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2a2121b6-2710-42a6-ac3b-5558554ea2dd_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_911a3fb3-1701-4df5-ab44-790e7936ff41_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AccruedPreferredStockDividend_faed57c6-c3a8-4c9d-a442-b4e58c57f29d_terseLabel_en-US" xlink:label="lab_trov_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend</link:label>
    <link:label id="lab_trov_AccruedPreferredStockDividend_label_en-US" xlink:label="lab_trov_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:label id="lab_trov_AccruedPreferredStockDividend_documentation_en-US" xlink:label="lab_trov_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedPreferredStockDividend" xlink:href="trov-20201231.xsd#trov_AccruedPreferredStockDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AccruedPreferredStockDividend" xlink:to="lab_trov_AccruedPreferredStockDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f07e9af1-d70b-4878-94c9-b65e13129c54_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f2acdd1e-1229-4159-8177-25371ffb8865_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b53aaa64-2f38-489c-be6c-67660dc58bff_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_50e3987e-7201-4559-81a2-6b52811941f4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_d90edfbe-2f46-4ac5-ad59-500ced2ffdb2_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2bda27ee-f967-43fe-98ef-bd76ec0e471e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d7354911-8aad-4f2a-a367-5297ea250808_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Accruedresearchagreements_f7a7dc67-66fd-457c-9ad0-ac3e11ea9152_terseLabel_en-US" xlink:label="lab_trov_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_trov_Accruedresearchagreements_label_en-US" xlink:label="lab_trov_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:label id="lab_trov_Accruedresearchagreements_documentation_en-US" xlink:label="lab_trov_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accruedresearchagreements" xlink:href="trov-20201231.xsd#trov_Accruedresearchagreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Accruedresearchagreements" xlink:to="lab_trov_Accruedresearchagreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3fe39be5-1285-4e3a-ba5b-97b981c07e8e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbb31b66-c26e-48da-8037-e16742c66990_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0f610190-54c5-4969-b3a9-e3df1c82ff6f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_76faa79d-9700-456b-bbc0-6b9bb472c47e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4c20950b-7c10-4aa1-b2e5-4990c4321b70_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_0c2edbce-c530-434c-a211-75aad6893dcd_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_aa556178-b91a-4e42-92b8-f131bd6a73c2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e52d899a-e2da-4c0f-8cab-4be26bf553a9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesMWarrantMember_3da44328-830a-4fab-bde2-ef7f01d2ea5e_terseLabel_en-US" xlink:label="lab_trov_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant</link:label>
    <link:label id="lab_trov_SeriesMWarrantMember_label_en-US" xlink:label="lab_trov_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant [Member]</link:label>
    <link:label id="lab_trov_SeriesMWarrantMember_documentation_en-US" xlink:label="lab_trov_SeriesMWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series M Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesMWarrantMember" xlink:href="trov-20201231.xsd#trov_SeriesMWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesMWarrantMember" xlink:to="lab_trov_SeriesMWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_735820c2-5d78-4f4d-b639-2c0771468276_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6d987236-c9c9-4eb8-8669-5fbad404f3d1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b71ce082-7a83-48a0-9d80-897bb978e92c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8f1ead45-9d7d-48f9-8fb8-2b07173861db_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_868d95b5-72c4-43bf-9abd-78a38552b02e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_b277874e-724b-4600-b68a-3f768f82e2de_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2759af4f-a31a-49e7-9098-977e84a6493a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_97228368-ef50-4d48-b910-e458a381e6a1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_4601f2ff-9ed8-46db-b8b1-896fd8dd5a48_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_7736143d-cc6b-4f1e-b346-0efdb67b524d_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_fbb2428c-340e-4f3e-b3e5-943c2456e069_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fafaf72f-2143-4699-a352-419ecab4e04d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a3aa521b-b8d7-4aa1-b9b3-7235b6bef685_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_bc09b768-ab63-4efa-b740-f940f1f751d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_682e616a-025f-4ec0-89eb-87fd26a3d929_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesIWarrantMember_0ed7227d-ba0c-4cb2-9dd3-62d00b2bf342_terseLabel_en-US" xlink:label="lab_trov_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant</link:label>
    <link:label id="lab_trov_SeriesIWarrantMember_label_en-US" xlink:label="lab_trov_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant [Member]</link:label>
    <link:label id="lab_trov_SeriesIWarrantMember_documentation_en-US" xlink:label="lab_trov_SeriesIWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series I Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesIWarrantMember" xlink:href="trov-20201231.xsd#trov_SeriesIWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesIWarrantMember" xlink:to="lab_trov_SeriesIWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c65e9c39-a3ed-48e9-999c-18c9ec0b865c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_956ff984-f9fa-4175-be83-636319c38976_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c5e37676-55b5-46e6-bbab-d526897646f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_05e07c70-d9ca-410e-ae54-7c5e11af4d00_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_cebf0ed4-9b62-4dc0-9379-2d74aca73d86_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_FurnitureAndOfficeEquipmentMember_1530cbc0-94f8-4ff7-8fd3-2cf084144251_terseLabel_en-US" xlink:label="lab_trov_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_trov_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_trov_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_trov_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_trov_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FurnitureAndOfficeEquipmentMember" xlink:href="trov-20201231.xsd#trov_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_FurnitureAndOfficeEquipmentMember" xlink:to="lab_trov_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c333e194-348d-406c-8738-a121e9677206_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d1b74269-39c3-47f8-b18d-f381ee0bad7b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d2afbfe1-3ad8-4864-a9a0-35b512d83232_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_82e67cb9-c837-42b3-aa60-a90207943862_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_36793c31-c956-4bcf-ac11-ecb67501ea93_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0296d7a7-bd13-4360-a3f3-cfe4d700726d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_e87a99b5-d4b5-4aa4-85b5-c84848ee1605_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11f32ba-1baf-4e29-a43a-fa4b971aabeb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_874f55a4-4dbb-41d0-8272-1d1b402ac87b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4b3b5abd-f7aa-45f5-9274-779c7e515085_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_725bc241-a720-422e-8d22-fe07b5172deb_totalLabel_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_label_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:label id="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_documentation_en-US" xlink:label="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:to="lab_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_890d7ded-d506-49d4-98f4-fe55e9860747_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_2c0d5aab-9c7c-474f-a0a9-65d85f36b5bc_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_04356b5c-9ddb-4ce7-b11b-c9f6af18c218_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_1b79cbab-25bd-401b-a9ff-630659885895_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6bf0f30d-e7b3-4a5c-bc77-d48717af97e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b9d9580e-4ae3-4607-bc01-5c64d4f038a9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration_ee7b708d-d5d1-4539-86f5-1df0ea265020_terseLabel_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs, not subject to expiration</link:label>
    <link:label id="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_trov_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_9c90c759-3dd9-46c4-88ec-6bd16afc94c2_negatedTerseLabel_en-US" xlink:label="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_95b5c8be-e6f1-4dc0-9f4f-85b88a7e0046_verboseLabel_en-US" xlink:label="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</link:label>
    <link:label id="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_label_en-US" xlink:label="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock</link:label>
    <link:label id="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_documentation_en-US" xlink:label="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:to="lab_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_adfe08e1-1b81-4ddb-8fc5-e5e5b9ae2f5f_verboseLabel_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_label_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised</link:label>
    <link:label id="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2e24062f-cc08-4818-951a-e5571b99deb3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_16528743-54e4-4b0c-8cb9-a36924702c53_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c1538079-b312-4bd3-9ae0-a401948af645_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f99f55dd-b7f8-4b59-9e81-2863c83eb7ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c006a730-9d59-4ea9-be56-fdcecd49e1cc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c47e3f98-8bf7-4ef4-bc74-37862194e4c2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockConvertibleConversionPrice_9f1d53ea-1eee-411a-932d-618f49978831_terseLabel_en-US" xlink:label="lab_trov_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_trov_PreferredStockConvertibleConversionPrice_label_en-US" xlink:label="lab_trov_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:label id="lab_trov_PreferredStockConvertibleConversionPrice_documentation_en-US" xlink:label="lab_trov_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConvertibleConversionPrice" xlink:href="trov-20201231.xsd#trov_PreferredStockConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockConvertibleConversionPrice" xlink:to="lab_trov_PreferredStockConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ValuationAllowance_973753ee-5574-4f96-bf06-58cd734492d0_terseLabel_en-US" xlink:label="lab_trov_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_trov_ValuationAllowance_label_en-US" xlink:label="lab_trov_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_trov_ValuationAllowance_documentation_en-US" xlink:label="lab_trov_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ValuationAllowance" xlink:href="trov-20201231.xsd#trov_ValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ValuationAllowance" xlink:to="lab_trov_ValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3a557457-6a77-4f4e-b1c9-814dc028a76f_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_fa3069a5-e0d3-4769-a03b-9b6774f10739_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_cd5c6e1f-482c-490b-aab6-dd88761ed477_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2a9fb5d0-08f4-4cba-900c-b22ea45edf18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_cf3cedcb-50e1-4768-9b59-fbfec9b03d96_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7d5e9eaf-ffef-44f4-b07d-7379c9be04ee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_903f7d18-aa10-4c77-9de7-a44f962c59e4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_c0608b2a-1881-4082-8daf-eb4e22783b9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_2ec0f307-3241-4ce9-95c3-47f3bd1b9fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (weighted-average)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_953bcafb-3db7-4a21-bed6-ed96cff76ce0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_511366a8-d8c9-4104-9a14-29441e5f3c73_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative dividend rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_24c4d031-5c92-4acc-8158-717c945ff14c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7f0b9fbe-b74a-44e2-947e-6acd4f6b4e21_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockConversionPricePerShare_44d0ca7c-7f3c-4e32-8958-1b1bd45c05d5_terseLabel_en-US" xlink:label="lab_trov_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_trov_PreferredStockConversionPricePerShare_label_en-US" xlink:label="lab_trov_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Price Per Share</link:label>
    <link:label id="lab_trov_PreferredStockConversionPricePerShare_documentation_en-US" xlink:label="lab_trov_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The price per share of the conversion feature embedded in the convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionPricePerShare" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockConversionPricePerShare" xlink:to="lab_trov_PreferredStockConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_2d068ace-7e70-4149-b730-bf1828c15e3b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_26e92299-68b9-4ab9-9897-c9cb9bbb4db5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c61fc80b-592e-4daa-a858-86f6ed1309d9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_9292a31d-32e8-43bc-80a0-f311ce65b0e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_072d6d6c-a901-4d1e-a9b8-415e05d999d0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e6bc63a6-18aa-43da-9bfe-b22d84502969_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_EquityIncentivePlan2014Member_536a592f-6ef3-40db-be8d-51e762c83b29_terseLabel_en-US" xlink:label="lab_trov_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014</link:label>
    <link:label id="lab_trov_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_trov_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_trov_EquityIncentivePlan2014Member_documentation_en-US" xlink:label="lab_trov_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EquityIncentivePlan2014Member" xlink:href="trov-20201231.xsd#trov_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_EquityIncentivePlan2014Member" xlink:to="lab_trov_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_791da7a2-41f6-43f3-8e75-8d08853b1d4c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_759c2ea2-93f7-4ab1-be00-bbfa5a99713f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c8fde26c-5870-4441-8ca4-701cdacd087b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_ac7392a2-6bbc-42da-bd1e-b1eb6d26bc71_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_582c4e3d-38aa-467e-a018-a43b3c3ea470_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_WarrantsWeightedAverageContractualTerm_36151392-b3ad-41e7-8b36-212026a57e31_terseLabel_en-US" xlink:label="lab_trov_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_trov_WarrantsWeightedAverageContractualTerm_label_en-US" xlink:label="lab_trov_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term</link:label>
    <link:label id="lab_trov_WarrantsWeightedAverageContractualTerm_documentation_en-US" xlink:label="lab_trov_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsWeightedAverageContractualTerm" xlink:href="trov-20201231.xsd#trov_WarrantsWeightedAverageContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_WarrantsWeightedAverageContractualTerm" xlink:to="lab_trov_WarrantsWeightedAverageContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_WarrantsAndRightsRollForward_ddb32bea-d88a-4ecf-b28f-86ee6fceddf4_terseLabel_en-US" xlink:label="lab_trov_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_trov_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_trov_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsAndRightsRollForward" xlink:href="trov-20201231.xsd#trov_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_WarrantsAndRightsRollForward" xlink:to="lab_trov_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5386950a-d0c6-4e20-9c2c-fc7d5c495a90_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_0e089704-0cfb-4e85-b800-d5a1b1c4310b_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_1abcf777-bbd3-4d5e-a797-9bc7dce64468_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued dividend during the period</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_fc9e8d3a-7a50-4d57-9de0-fe41eaae20e0_terseLabel_en-US" xlink:label="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</link:label>
    <link:label id="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_label_en-US" xlink:label="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]</link:label>
    <link:label id="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:href="trov-20201231.xsd#trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:to="lab_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_08bc0b59-17c7-4c75-8014-67f94776f3eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_399ace26-c2fa-4514-9b1c-f1a5f112671f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of assumptions used to determine the fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b57bf2e8-5163-40d3-af5c-c61f565c4bee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f62b8f8f-4ed4-41f8-9d24-268d17fbb783_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3833a9f8-055c-4f99-9dc4-e1255b94948b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ab9a9d09-5140-4f2f-b574-5bb30c10a4e7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b3b09370-0ccc-483d-acb1-6605900b43c8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_51efff34-75d5-4204-a0cf-62b24abb8c86_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_14a3abaa-7289-4df2-9abd-fb13a684b499_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_f7138e85-7380-4df7-9ff9-9873b3ec0548_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities called by each warrant (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_579bda14-93f4-403a-9d72-a829d8564384_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_41a89652-3d39-4735-ab37-7067af37546e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_ecc9cc63-c849-4cc6-82f4-95ec448ec8c3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview and Liquidity</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_af61232f-65b1-4dfd-a135-1c45fecb8cab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Affiliates</link:label>
    <link:label id="lab_us-gaap_OtherAffiliatesMember_label_en-US" xlink:label="lab_us-gaap_OtherAffiliatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Affiliates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAffiliatesMember" xlink:to="lab_us-gaap_OtherAffiliatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d52b38f8-1eca-4ee3-a157-751dd7a6c13e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_0c1d3c18-4e2b-4348-a9ba-019c49b70197_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_8cf05e4e-d4eb-4c55-93aa-236ee90d80fa_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_7e8b6dbc-4927-4284-803b-456f9c272d91_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_8ae95204-ccd7-403c-a19d-9458999e97bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_cb437fa4-693b-46a6-b701-eafa83607cf8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ab4f25f0-be72-47f8-bba2-e269a8186e98_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5eb89da-1e9d-4f7d-b569-af27ba621e66_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a58bffb4-c0b8-4257-96b5-0639d9bb2205_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a1906ff1-cde8-4f23-9eea-308b104fd290_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_34614df1-ca38-4213-9e85-a913f4635895_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2d5c2875-2f3b-4aca-9f32-6a5835d12817_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a342a617-4b5e-4dd2-babf-2f231b7a7c58_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c0b90b55-bfad-4fa8-b944-ba6ca0a3a6cd_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d5945a55-6529-41b8-98ef-d6ef464b979c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockConversionObligationNumberOfTradingDays_7c77535c-c54b-46f3-8b76-b2bd3d2b98cd_terseLabel_en-US" xlink:label="lab_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationNumberOfTradingDays_label_en-US" xlink:label="lab_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Number of Trading Days</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationNumberOfTradingDays_documentation_en-US" xlink:label="lab_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:to="lab_trov_PreferredStockConversionObligationNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_EstimatedFairValueOfWarrant_eeb538fa-74f9-4d14-8f6b-7cff069de3d4_terseLabel_en-US" xlink:label="lab_trov_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of Trovagene common stock (in dollars per share)</link:label>
    <link:label id="lab_trov_EstimatedFairValueOfWarrant_label_en-US" xlink:label="lab_trov_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Warrant</link:label>
    <link:label id="lab_trov_EstimatedFairValueOfWarrant_documentation_en-US" xlink:label="lab_trov_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated fair value of warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EstimatedFairValueOfWarrant" xlink:href="trov-20201231.xsd#trov_EstimatedFairValueOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_EstimatedFairValueOfWarrant" xlink:to="lab_trov_EstimatedFairValueOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock_73ae572c-fe6a-4c08-8cc8-d0a042ff6fbc_terseLabel_en-US" xlink:label="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="trov-20201231.xsd#trov_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_trov_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8b1caa33-96ce-4e63-8673-0a0ba71b9b6d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0d2aa135-889f-49fe-a89b-a08c5eac06f4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7f693a43-85f8-4922-babf-b79ac89ed199_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_36d1385d-b57a-4a3d-b395-5f37255c13ae_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_5e2d3035-a21c-4cf5-b3e2-3e2d1b275033_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_59bbdb44-8b74-4df3-869b-cd39d9dd256c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8649d9de-7295-4f9a-a615-e55560470e6d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_9b20f59d-3890-4cfb-b809-fdc98f0829a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_Servicereceivable_5a6a43fd-9455-4302-ac69-cf05571d6293_negatedTerseLabel_en-US" xlink:label="lab_trov_Servicereceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivables</link:label>
    <link:label id="lab_trov_Servicereceivable_903ca292-b4e2-4eb4-8fae-0f71e223d7e5_terseLabel_en-US" xlink:label="lab_trov_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_trov_Servicereceivable_label_en-US" xlink:label="lab_trov_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_trov_Servicereceivable_documentation_en-US" xlink:label="lab_trov_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_Servicereceivable" xlink:to="lab_trov_Servicereceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4c9d71f7-b5f5-4a32-93e9-6bc7378caf9f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2c3f9f26-e670-4d80-ba9d-b3d1dc922392_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_509a71f4-e962-4842-aacc-1db141f4b7e5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_2e6eba13-fdf3-4011-93f8-c78acd49ffbf_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_b700a326-9f4f-42b1-aeaf-4fd7de957282_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemTable_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable" xlink:to="lab_us-gaap_UnusualOrInfrequentItemTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_eae2733d-fa9b-4430-af37-23d2df191b17_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_df98f5b5-4ead-4f7c-891f-fc339aaab303_terseLabel_en-US" xlink:label="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</link:label>
    <link:label id="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:label id="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:href="trov-20201231.xsd#trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:to="lab_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_7ca6dffc-9270-4b32-97ae-4e119d202683_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1a15dfce-06e5-465f-bd88-06bda1e77bf6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_de706c18-a8b2-46b1-872b-82d77fb4dff8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted&#160;Average Grant Date Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d296b080-cbb8-4913-94c9-6f39f05d52ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2d571ade-78d5-4da3-a0f5-11ca3b317dbb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1df3c1fe-5aa8-4c5b-99df-d0dae9a968a1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_2f29c628-1e2d-4b5d-b984-24cb51b81c32_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_da579292-4722-499d-9007-8251057d2668_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_2e537e11-b28f-4141-a4ee-2cf834da22b4_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Items, or Both, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:to="lab_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4036b089-fb6f-4d32-8a3a-39eebc9a536b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e8b97500-8c69-4248-9a17-2521570f65e4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_8c8c456d-964a-415a-b0d6-f25576e95441_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6e83465f-352c-4a3e-8177-ebd8085df5e1_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dba1c6cf-22d4-4233-9833-100587af106c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_66d1e5b2-a0fa-45c8-b60d-2279a22f445f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_f384f3bc-9b1e-47ec-8a48-026a1c6c2853_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contract term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_93d48e21-c82f-40b4-b646-90d1b498cb32_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_1a34897f-982b-426f-97a8-25ef83c10ce9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_59354621-f398-4b56-b72d-4368cd891b4a_terseLabel_en-US" xlink:label="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</link:label>
    <link:label id="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:href="trov-20201231.xsd#trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:to="lab_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52c1de81-399d-49ab-9abc-9f7797d670d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_ConvertiblePreferredStockStatedValuePerShare_11743e09-6c8e-4d82-8a18-f4eef3b29daf_terseLabel_en-US" xlink:label="lab_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated value (in dollars per share)</link:label>
    <link:label id="lab_trov_ConvertiblePreferredStockStatedValuePerShare_label_en-US" xlink:label="lab_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Stated Value Per Share</link:label>
    <link:label id="lab_trov_ConvertiblePreferredStockStatedValuePerShare_documentation_en-US" xlink:label="lab_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:href="trov-20201231.xsd#trov_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:to="lab_trov_ConvertiblePreferredStockStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_a4e4d414-dccb-4156-b20b-39adf04cd08f_terseLabel_en-US" xlink:label="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_label_en-US" xlink:label="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading Days</link:label>
    <link:label id="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_documentation_en-US" xlink:label="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="lab_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b6a6dcbc-a425-4eb9-9a50-d95b415c4911_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_cec08e54-6d1c-46ec-b502-b9d4e4b720a0_negatedTerseLabel_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_a18c6644-cec8-4234-99eb-2f9c8ecfa52b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing and distribution rights commitment</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_OperatingLossCarryforwardsSubjectToExpiration_738032ef-fa01-4d80-a6db-de62fa9940c5_terseLabel_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs, subject to expiration</link:label>
    <link:label id="lab_trov_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_trov_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_trov_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_65371e12-6721-4aba-a355-d62ebe5701ee_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c437d7a6-9eda-4c71-88fb-d34015f2b5e1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_4a61bc7d-a095-43be-af49-90b3997326a6_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4c1d6d5b-265b-4435-8463-8a27f2fefb63_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1c9fe0d9-4a94-406d-bcca-2e6e3d133c8a_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax computed at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cfa87f4f-16a1-4443-8c37-8c347bc61873_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6de9803d-e48e-4d4e-8c6c-3f4454403a34_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_38cab241-51ec-44c9-91cb-3b019f06c8f0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_e7e4befc-7d54-4d95-9365-5b9e7e56d70d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_43818bc4-0ee4-4472-8248-3556e9723f3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4720a8a9-72da-4fd7-a104-4dfe9b1456d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6d57a88a-b4c2-4e06-bffb-ee0cc70e5d3c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_SeriesKWarrantMember_cdc6873e-87b1-47fb-a89b-29cb8db5138a_terseLabel_en-US" xlink:label="lab_trov_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant</link:label>
    <link:label id="lab_trov_SeriesKWarrantMember_label_en-US" xlink:label="lab_trov_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant [Member]</link:label>
    <link:label id="lab_trov_SeriesKWarrantMember_documentation_en-US" xlink:label="lab_trov_SeriesKWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series K Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesKWarrantMember" xlink:href="trov-20201231.xsd#trov_SeriesKWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_SeriesKWarrantMember" xlink:to="lab_trov_SeriesKWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock_96c2dc24-dec8-4bd2-9c01-fce9774ca2cb_terseLabel_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock_label_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses [Policy Text Block]</link:label>
    <link:label id="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrialExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:to="lab_trov_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_29ce856e-6b16-45a1-b4cf-4d910e90a331_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7ee8ef79-74d0-4e0b-90a3-cfd47bb5dd12_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncement</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a74b31fe-95a9-47e5-9567-d37fedc0c302_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_2c426b15-2bba-4825-9c54-d282081ed640_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>trov-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a6a444f1-29b1-4d58-869f-3096224ae106,g:6e4cdfc6-26ef-4f08-ba3d-0ca15594d6db-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:href="trov-20201231.xsd#trov_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9597129f-5fa8-45b7-899e-ba50f8e9b84f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentType_9597129f-5fa8-45b7-899e-ba50f8e9b84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_dfa8f12d-4a51-450a-9774-823c993930c3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentAnnualReport_dfa8f12d-4a51-450a-9774-823c993930c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0a7d0337-6c76-4d02-998d-fe6ace5a35d2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentPeriodEndDate_0a7d0337-6c76-4d02-998d-fe6ace5a35d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_64d2aa24-676d-4823-9fa3-7dd1dc072bab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_CurrentFiscalYearEndDate_64d2aa24-676d-4823-9fa3-7dd1dc072bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_037a056d-951b-43a8-b16f-fa8f9fa5393a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentTransitionReport_037a056d-951b-43a8-b16f-fa8f9fa5393a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d7491ab6-dd58-4159-ae7b-907f6c3ce71d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityFileNumber_d7491ab6-dd58-4159-ae7b-907f6c3ce71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_8f639beb-ebbf-465d-b3a1-934c08ebf143" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityRegistrantName_8f639beb-ebbf-465d-b3a1-934c08ebf143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_09e81f71-0b2c-4adb-a2e6-faa0b7a3d716" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityIncorporationStateCountryCode_09e81f71-0b2c-4adb-a2e6-faa0b7a3d716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4c4070a9-02b0-4b89-b12c-7719b0caf1c8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityTaxIdentificationNumber_4c4070a9-02b0-4b89-b12c-7719b0caf1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_df4fa64c-3a37-4572-b439-04f4a2af675b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityAddressStateOrProvince_df4fa64c-3a37-4572-b439-04f4a2af675b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1aeaf54c-a9f2-4df6-ad97-388a8aa2c174" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityAddressCityOrTown_1aeaf54c-a9f2-4df6-ad97-388a8aa2c174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d6c9faae-8ec2-423a-b5a3-ee0981d11353" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityAddressAddressLine1_d6c9faae-8ec2-423a-b5a3-ee0981d11353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_37898afb-74ab-4337-9f29-a1c9940ce665" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityAddressPostalZipCode_37898afb-74ab-4337-9f29-a1c9940ce665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f35c1563-0592-4793-9ee2-db96ac2e1893" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_CityAreaCode_f35c1563-0592-4793-9ee2-db96ac2e1893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8497449e-e6dd-45ea-a3eb-3650e4d673bb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_LocalPhoneNumber_8497449e-e6dd-45ea-a3eb-3650e4d673bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7b95168f-24af-41c7-b806-47678838cd41" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_Security12bTitle_7b95168f-24af-41c7-b806-47678838cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_3603a847-1f96-4a18-9daa-9c44eda4edad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_3603a847-1f96-4a18-9daa-9c44eda4edad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_94336daa-360b-4bd6-94cd-708feb544d6a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityVoluntaryFilers_94336daa-360b-4bd6-94cd-708feb544d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2115d7db-ed4e-4184-aad9-25eaa82c5810" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityCurrentReportingStatus_2115d7db-ed4e-4184-aad9-25eaa82c5810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_36e5321b-3d67-4a34-a60b-0ad22bd849dd" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityInteractiveDataCurrent_36e5321b-3d67-4a34-a60b-0ad22bd849dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_99281889-0868-42eb-9f69-c75f2af1b1c0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityFilerCategory_99281889-0868-42eb-9f69-c75f2af1b1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c42f9e3f-740d-4a3e-b175-3e52ff6314f1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityEmergingGrowthCompany_c42f9e3f-740d-4a3e-b175-3e52ff6314f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_043187d5-9077-49bb-b4b1-e94ef12c6aff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntitySmallBusiness_043187d5-9077-49bb-b4b1-e94ef12c6aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d4a330ca-8d36-4ca0-89c2-8ca6a079ebc8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d4a330ca-8d36-4ca0-89c2-8ca6a079ebc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bc9893b2-de04-460e-bbd4-a05297cbfd02" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityShellCompany_bc9893b2-de04-460e-bbd4-a05297cbfd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_69e3f3e9-f60b-406f-a46c-e877fe0c127e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityPublicFloat_69e3f3e9-f60b-406f-a46c-e877fe0c127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_2198ef1d-21f7-46fc-8342-457410893311" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_2198ef1d-21f7-46fc-8342-457410893311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a07992f8-4e7d-4ff5-8c66-ffa30089d018" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_EntityCentralIndexKey_a07992f8-4e7d-4ff5-8c66-ffa30089d018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2d00d0c7-1252-436b-b31c-856aaa490ae6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentFiscalYearFocus_2d00d0c7-1252-436b-b31c-856aaa490ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8c3377b9-5eba-4476-bb66-524d81eb7bc8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8c3377b9-5eba-4476-bb66-524d81eb7bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e7e44d02-7e61-4d7a-8d43-99cd2727689e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DocumentAndEntityInformationAbstract_22d4f6cf-6852-4a29-a41b-91bed629e499" xlink:to="loc_dei_AmendmentFlag_e7e44d02-7e61-4d7a-8d43-99cd2727689e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheets" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_68eb5849-ffda-410e-9e31-c9ff69d210e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68eb5849-ffda-410e-9e31-c9ff69d210e3" xlink:to="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:to="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38e87d0-682a-40bf-a025-986e173423d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f38e87d0-682a-40bf-a025-986e173423d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d1ef0be5-8e0f-44ac-bf5f-a16d57accca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d1ef0be5-8e0f-44ac-bf5f-a16d57accca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e9736bb-ca4b-4a9a-8f95-57130d9f27de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1e9736bb-ca4b-4a9a-8f95-57130d9f27de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b58d58f3-4942-41ab-b525-a76ac574da7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_11cc88f2-575a-42d7-b5d9-126efcf768b5" xlink:to="loc_us-gaap_AssetsCurrent_b58d58f3-4942-41ab-b525-a76ac574da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10d2e20e-88ec-49c5-8694-0091be4029da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10d2e20e-88ec-49c5-8694-0091be4029da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_393a1a3a-b69b-4e4d-888f-cce436ae46ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_393a1a3a-b69b-4e4d-888f-cce436ae46ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_317152c9-6e2c-47ef-8603-75d434e001ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_317152c9-6e2c-47ef-8603-75d434e001ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b4f9c23-cdcd-479e-9228-dc1734dfa5e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5d070f7e-bb68-4342-9e6c-c597bc354307" xlink:to="loc_us-gaap_Assets_6b4f9c23-cdcd-479e-9228-dc1734dfa5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_68eb5849-ffda-410e-9e31-c9ff69d210e3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_59dd8313-0f61-4f22-a459-1d11ec071319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:to="loc_us-gaap_AccountsPayableCurrent_59dd8313-0f61-4f22-a459-1d11ec071319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_086a5ab9-b2d0-4680-8691-821f6c4a0d10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_086a5ab9-b2d0-4680-8691-821f6c4a0d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_74a43930-e1f0-427d-a72d-c1dd5719d984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_74a43930-e1f0-427d-a72d-c1dd5719d984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1dccbdab-3ad7-45dc-a42f-4e5139e57155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1dccbdab-3ad7-45dc-a42f-4e5139e57155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_341fbe64-2caf-4404-98c5-8130c1380290" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c7f6de84-30f7-418d-a312-6713df03fbad" xlink:to="loc_us-gaap_LiabilitiesCurrent_341fbe64-2caf-4404-98c5-8130c1380290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7b2d4035-407d-410e-8c21-9e55b8782aa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7b2d4035-407d-410e-8c21-9e55b8782aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a713c90d-6ff6-4a78-9ad5-fb802444309c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a713c90d-6ff6-4a78-9ad5-fb802444309c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_80658bf6-78b8-488a-9454-a5d538192b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_80658bf6-78b8-488a-9454-a5d538192b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5b82335c-ed3b-4999-b855-593074ef775c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_Liabilities_5b82335c-ed3b-4999-b855-593074ef775c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d09fe448-3a6b-4592-be5b-a1c4f9221901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d09fe448-3a6b-4592-be5b-a1c4f9221901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9a45d638-bbd4-4f73-bc00-9428d2f897a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_us-gaap_PreferredStockValue_9a45d638-bbd4-4f73-bc00-9428d2f897a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c40dea83-1c28-49b1-9128-756268c0a802" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_us-gaap_CommonStockValue_c40dea83-1c28-49b1-9128-756268c0a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a014ba2b-9e4a-489f-8fce-7f62e653a10f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a014ba2b-9e4a-489f-8fce-7f62e653a10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_5d137dad-17f7-4caf-b66b-743501d57cd0" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_trov_Servicereceivable_5d137dad-17f7-4caf-b66b-743501d57cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2725e713-2db1-4b35-a723-acc50ad02a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2725e713-2db1-4b35-a723-acc50ad02a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a65dcb6c-3fd6-4a54-870a-76c95c0794db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0ec83524-684a-4371-8bcf-e36544c31047" xlink:to="loc_us-gaap_StockholdersEquity_a65dcb6c-3fd6-4a54-870a-76c95c0794db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5024e8db-e99d-435b-9aec-c62e51fa988b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8eb48458-df7e-423c-98b0-9e75e2ee1374" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5024e8db-e99d-435b-9aec-c62e51fa988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e2d2f60a-4e48-44ca-934b-6f177e5ce0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e2d2f60a-4e48-44ca-934b-6f177e5ce0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_39994045-9c47-4b02-a5de-bf21b5fe8688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_39994045-9c47-4b02-a5de-bf21b5fe8688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7aeeec01-c648-4957-b746-9ee7ad9478a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7aeeec01-c648-4957-b746-9ee7ad9478a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0e9c144e-4ace-49e9-81bb-d62c7dde95c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0e9c144e-4ace-49e9-81bb-d62c7dde95c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_9e1227a3-e837-4a17-baee-6789db9be954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_CommonStockSharesIssued_9e1227a3-e837-4a17-baee-6789db9be954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_69ebbc2c-3571-46af-804d-d8b2e0efe94f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2b6dd30d-f9f1-4d5d-9bc3-7e7b0b735361" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_69ebbc2c-3571-46af-804d-d8b2e0efe94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofOperations" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_527775e7-c1c6-4b1c-a091-706d4cf221d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_527775e7-c1c6-4b1c-a091-706d4cf221d3" xlink:to="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11771056-87d1-4fe7-acf5-89cf45514c4b" xlink:to="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_53254115-99d1-4a80-bb38-f2a480462eb5" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_53254115-99d1-4a80-bb38-f2a480462eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_6d9adb5a-d410-4636-8c33-9670933ed0aa" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_6d9adb5a-d410-4636-8c33-9670933ed0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_ed5de3ef-6149-4348-9689-b28fe9e12a09" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e7fef4b1-de97-43b5-84a0-1395f7b13270" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_ed5de3ef-6149-4348-9689-b28fe9e12a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:to="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0c333ca6-6184-42f2-9086-e8750a98e396" xlink:to="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_0f53804f-2bba-4534-ab87-56d0152fccb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:to="loc_us-gaap_RoyaltyMember_0f53804f-2bba-4534-ab87-56d0152fccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_53eb73e2-3848-4231-b312-83729997d056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_63bb1a44-95fc-4188-a69d-f375e6995e58" xlink:to="loc_us-gaap_ServiceMember_53eb73e2-3848-4231-b312-83729997d056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3be584ac-7d62-4e51-9c28-877d4003aa7f" xlink:to="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b590cdd6-017f-4fd1-8035-ac34d59729b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b590cdd6-017f-4fd1-8035-ac34d59729b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_4da85fc7-63f8-477f-84ed-c2f8b9681c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_4da85fc7-63f8-477f-84ed-c2f8b9681c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1820ce0c-0370-4771-960f-b202887237a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_Revenues_1820ce0c-0370-4771-960f-b202887237a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_06bcceae-7b00-4ff1-9970-8d2b647047d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_06bcceae-7b00-4ff1-9970-8d2b647047d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6eac2193-41f7-43eb-9056-7351d5c2ef7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6eac2193-41f7-43eb-9056-7351d5c2ef7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_51df5c25-5c5d-4a66-967a-050c8a90d092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_539f97cf-97ab-417a-a3db-451ab76d02df" xlink:to="loc_us-gaap_OperatingExpenses_51df5c25-5c5d-4a66-967a-050c8a90d092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1542083b-a77c-48cc-a50a-3561bb2daa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OperatingIncomeLoss_1542083b-a77c-48cc-a50a-3561bb2daa25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9e9a492b-9847-4f59-8b39-d426210a4917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9e9a492b-9847-4f59-8b39-d426210a4917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_cb7bd9c7-3cc9-4fd8-b82b-8a3cd43f1ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_InterestExpense_cb7bd9c7-3cc9-4fd8-b82b-8a3cd43f1ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_037c2ff4-ad5d-416c-a368-f10ac7e50673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_037c2ff4-ad5d-416c-a368-f10ac7e50673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ceacc0b5-9fac-4ff3-b09c-872ef8e9733b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ceacc0b5-9fac-4ff3-b09c-872ef8e9733b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b3bcd15a-ad50-418c-bf86-b111dfa33a78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_NetIncomeLoss_b3bcd15a-ad50-418c-bf86-b111dfa33a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_c27b5464-b052-47e6-a0b1-071037cb3568" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_c27b5464-b052-47e6-a0b1-071037cb3568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_7b6fd7b6-7056-40bb-92a5-28fadce6b78b" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_7b6fd7b6-7056-40bb-92a5-28fadce6b78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4c4b792-3f2c-4ead-8829-c76a15ba0309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4c4b792-3f2c-4ead-8829-c76a15ba0309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_0ec27523-d725-4ba9-9bdc-1e8a1112f1ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_0ec27523-d725-4ba9-9bdc-1e8a1112f1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_187a5c24-77f5-4742-ac8a-2327b91da67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_848c3e7f-8968-4bf8-ab93-7103f3a8157c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_187a5c24-77f5-4742-ac8a-2327b91da67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8b9301a1-19a9-4013-adbf-e150746d210c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8b9301a1-19a9-4013-adbf-e150746d210c" xlink:to="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4a2d28a7-f8ed-4cc3-85dc-569aa7cf32d5" xlink:to="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ae011492-caad-4307-bd7e-4fff2ee9bfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_PreferredStockMember_ae011492-caad-4307-bd7e-4fff2ee9bfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9923a0be-d60c-409a-8c5f-49ac978fc1df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_CommonStockMember_9923a0be-d60c-409a-8c5f-49ac978fc1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1671d486-670c-463b-aeea-1c61cc983da3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1671d486-670c-463b-aeea-1c61cc983da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ServiceReceivableMember_18a1f4f5-d7db-4bca-afa2-07901fa538b8" xlink:href="trov-20201231.xsd#trov_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_trov_ServiceReceivableMember_18a1f4f5-d7db-4bca-afa2-07901fa538b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b735daac-14e4-45ec-a5ec-5807448e7002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_968ada33-5755-4354-8a2d-76e9d77d8585" xlink:to="loc_us-gaap_RetainedEarningsMember_b735daac-14e4-45ec-a5ec-5807448e7002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_be939d0a-fe11-4d7e-9576-84039c3e1151" xlink:to="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_cb903c03-1db3-42c3-afe0-e15295b64136" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_cb903c03-1db3-42c3-afe0-e15295b64136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_19f90738-fa9b-458a-8c9d-1c6d7423625c" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5bc971d9-a07f-443b-9087-df37e21acd62" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_19f90738-fa9b-458a-8c9d-1c6d7423625c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_25f07406-3ee0-408d-8eed-0ff41792479c" xlink:to="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9ccc9bdf-3ca8-4d7e-8d85-01ce267f524b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e8d3e8d7-a9d5-43b1-bbf9-1abf889ea80f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SharesIssued_e8d3e8d7-a9d5-43b1-bbf9-1abf889ea80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a79974e-b926-4924-9d46-93bdf7050539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockholdersEquity_3a79974e-b926-4924-9d46-93bdf7050539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockCommonAndWarrantsNetShares_aa025bb8-1df2-469a-b45e-ef0986b4b8f6" xlink:href="trov-20201231.xsd#trov_SaleOfStockCommonAndWarrantsNetShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_SaleOfStockCommonAndWarrantsNetShares_aa025bb8-1df2-469a-b45e-ef0986b4b8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockValueCommonAndWarrantsNet_ba8c0d5c-ac87-4a75-94ed-800a02c30d6b" xlink:href="trov-20201231.xsd#trov_SaleOfStockValueCommonAndWarrantsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_SaleOfStockValueCommonAndWarrantsNet_ba8c0d5c-ac87-4a75-94ed-800a02c30d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_30ca52b3-42d2-402b-8669-ab988e2430a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_30ca52b3-42d2-402b-8669-ab988e2430a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_08aa82e0-6760-44a1-8993-b98b826943b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_08aa82e0-6760-44a1-8993-b98b826943b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92f82532-59b8-482a-be32-510e02a1dff9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92f82532-59b8-482a-be32-510e02a1dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised_918aa113-20fd-488d-af6a-d15e921441d4" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_StockIssuedDuringPeriodSharesWarrantsExercised_918aa113-20fd-488d-af6a-d15e921441d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised_0e6e621c-8694-4f2a-be0f-5604020fb595" xlink:href="trov-20201231.xsd#trov_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_StockIssuedDuringPeriodValueWarrantsExercised_0e6e621c-8694-4f2a-be0f-5604020fb595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_eeac2576-094e-4d1e-9e46-6063792f99fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_eeac2576-094e-4d1e-9e46-6063792f99fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4079ee7e-547f-401d-9a32-fc56b0d02f35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_4079ee7e-547f-401d-9a32-fc56b0d02f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_a6bcecd4-1308-448e-acb0-d624a12ae8e8" xlink:href="trov-20201231.xsd#trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock_a6bcecd4-1308-448e-acb0-d624a12ae8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31f8e561-a636-48ff-9d1b-30f530180f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_31f8e561-a636-48ff-9d1b-30f530180f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_312ad5f3-aa45-4fea-ae51-bb08f3d9a410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_312ad5f3-aa45-4fea-ae51-bb08f3d9a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_cbfcdf3e-d7ab-4dc2-9dfa-fe3116e0f86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_DividendsPreferredStock_cbfcdf3e-d7ab-4dc2-9dfa-fe3116e0f86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_83a8a95c-9817-4dca-bb03-f914d39c3602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockSplits_83a8a95c-9817-4dca-bb03-f914d39c3602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ReleaseOfClinicalTrialFundingCommitment_18353064-6a0e-458a-96d8-5d5b38c48f5e" xlink:href="trov-20201231.xsd#trov_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_ReleaseOfClinicalTrialFundingCommitment_18353064-6a0e-458a-96d8-5d5b38c48f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0d87a912-b8ef-4ca2-b9c5-d37022ca403a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_NetIncomeLoss_0d87a912-b8ef-4ca2-b9c5-d37022ca403a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a7d9a2a-f557-4c71-8396-482b5186ad90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a7d9a2a-f557-4c71-8396-482b5186ad90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac1cc251-10b5-47a2-8238-7f07fbe104f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ac1cc251-10b5-47a2-8238-7f07fbe104f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_4584b288-09ea-461f-bd58-a42e21372641" xlink:href="trov-20201231.xsd#trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment_4584b288-09ea-461f-bd58-a42e21372641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e80a20e-32dd-4cba-8b4a-5a01e5589a23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e80a20e-32dd-4cba-8b4a-5a01e5589a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87f4ce8a-5970-4282-86e6-6915b453a3ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87f4ce8a-5970-4282-86e6-6915b453a3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6b2691ff-e03b-4b4a-a23e-2aebc40f9468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_SharesIssued_6b2691ff-e03b-4b4a-a23e-2aebc40f9468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_34891307-e015-49d5-a3be-dde12026cac0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3fc397fe-799c-48b4-b017-cb1fd079c4dd" xlink:to="loc_us-gaap_StockholdersEquity_34891307-e015-49d5-a3be-dde12026cac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a4ef203b-9935-4a2b-9a50-831cf6f3aa83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_ac6a93cb-91e3-42d6-885c-112441c443fa" xlink:href="trov-20201231.xsd#trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a4ef203b-9935-4a2b-9a50-831cf6f3aa83" xlink:to="loc_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_ac6a93cb-91e3-42d6-885c-112441c443fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsFairValue_5f30ce6f-a771-4726-8270-8efd8ebd71a3" xlink:href="trov-20201231.xsd#trov_WarrantsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a4ef203b-9935-4a2b-9a50-831cf6f3aa83" xlink:to="loc_trov_WarrantsFairValue_5f30ce6f-a771-4726-8270-8efd8ebd71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e02fed74-04ef-470b-96b2-e636396d2d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e02fed74-04ef-470b-96b2-e636396d2d9c" xlink:to="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6041e890-68f8-4185-90aa-9c995c15a53c" xlink:to="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CommonStockAndWarrantsMember_e1ce06f6-d3f5-4f04-9b80-7a83b09e1717" xlink:href="trov-20201231.xsd#trov_CommonStockAndWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_CommonStockAndWarrantsMember_e1ce06f6-d3f5-4f04-9b80-7a83b09e1717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_405e0d17-d3da-485e-8415-f0ab484cb2ee" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_405e0d17-d3da-485e-8415-f0ab484cb2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_4be1ad97-2387-49fa-bed7-c17139dea01e" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_4be1ad97-2387-49fa-bed7-c17139dea01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_fc3f82e0-2527-4c10-b684-ec25211e39cb" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8a62045d-6501-4cbe-b732-0dc1743e55c4" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_fc3f82e0-2527-4c10-b684-ec25211e39cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f8964430-2d52-4709-9ce6-3a2700526544" xlink:to="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a5c8f17-22ae-4267-ae4f-23e2f009e783" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_NetIncomeLoss_8a5c8f17-22ae-4267-ae4f-23e2f009e783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_cd937201-5034-4fee-b62f-4c4ceb85d7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_cd937201-5034-4fee-b62f-4c4ceb85d7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_062aa050-8c6d-4fbc-9a45-da71fafc893d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_062aa050-8c6d-4fbc-9a45-da71fafc893d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c59bad9a-9699-4ca5-ad85-c841a6e994da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_ShareBasedCompensation_c59bad9a-9699-4ca5-ad85-c841a6e994da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_ffdde75d-86ce-42c0-b4c2-fa3682248e32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_ffdde75d-86ce-42c0-b4c2-fa3682248e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_10e0f20d-8ed1-48c3-bdc0-f8ba269dbb30" xlink:href="trov-20201231.xsd#trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived_10e0f20d-8ed1-48c3-bdc0-f8ba269dbb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bb3f5a49-7045-4e03-816f-c14659f0f431" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_969fc2c8-3e14-49ef-bc23-101d91366d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_969fc2c8-3e14-49ef-bc23-101d91366d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9cac653-2531-4336-b947-c4c19b5e3928" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c9cac653-2531-4336-b947-c4c19b5e3928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5f987f54-0fa2-4749-97ff-dbe187981052" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5f987f54-0fa2-4749-97ff-dbe187981052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_940c3c5e-6778-4bbd-a490-58ee81b095ec" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_940c3c5e-6778-4bbd-a490-58ee81b095ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d88694e-3c62-4e3f-bdd2-f7d5dbfce250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d88694e-3c62-4e3f-bdd2-f7d5dbfce250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_84a4cf24-b64b-4a4e-b359-4408b739d3f9" xlink:href="trov-20201231.xsd#trov_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_trov_IncreaseDecreaseInOperatingLeaseLiability_84a4cf24-b64b-4a4e-b359-4408b739d3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2de632e3-3c7b-4789-8b18-842359c80146" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_53e78044-6610-43e7-b1d3-985d4a43d303" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2de632e3-3c7b-4789-8b18-842359c80146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59b27d42-3662-4ae6-bc94-9917ff73728a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ad3ec9a6-0cd6-42ad-841a-44cccced2260" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_59b27d42-3662-4ae6-bc94-9917ff73728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc68d03e-2350-40a0-857e-82d0d232d01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bc68d03e-2350-40a0-857e-82d0d232d01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0703661-a40f-4cfe-bb70-ff4e9a009a2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_d2cb2824-d41f-4f2d-803d-391b79b56772" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d0703661-a40f-4cfe-bb70-ff4e9a009a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d73c04e-6540-436a-ba1b-159476b33636" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7d73c04e-6540-436a-ba1b-159476b33636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5b5697b7-a56d-458a-b15c-eb927b89aaab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5b5697b7-a56d-458a-b15c-eb927b89aaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29b723d3-df73-45d3-9191-cd774cefc6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29b723d3-df73-45d3-9191-cd774cefc6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_38a0e8c0-14a7-4e49-8ce5-662711846d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_38a0e8c0-14a7-4e49-8ce5-662711846d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1eccf688-b716-4289-a9c7-55b182904c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1eccf688-b716-4289-a9c7-55b182904c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6073893b-48e4-4744-a530-d4dacda511e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_6073893b-48e4-4744-a530-d4dacda511e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84e58fef-7645-441e-869c-2710936f66a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_20ebc6d6-e7fb-46fe-95ba-3de75b47d4dd" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84e58fef-7645-441e-869c-2710936f66a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b382ad44-7ec8-4366-b749-c66d424eaf4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b382ad44-7ec8-4366-b749-c66d424eaf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dd5a923-43c5-4314-ad84-e257756fc741" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4dd5a923-43c5-4314-ad84-e257756fc741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b01e0af2-79a5-4846-a544-b586c4ea37ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b01e0af2-79a5-4846-a544-b586c4ea37ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e16a53e9-d8fc-4b0b-96ff-6c3e62ad2284" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0635ac9c-252e-450c-8062-c70cf90b4358" xlink:to="loc_us-gaap_IncomeTaxesPaid_e16a53e9-d8fc-4b0b-96ff-6c3e62ad2284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11d31243-b65e-4b74-8a37-12885fb1861f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockDividendAccrued_450f5da7-f854-4be3-8a18-18dbc1ea9121" xlink:href="trov-20201231.xsd#trov_PreferredStockDividendAccrued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_PreferredStockDividendAccrued_450f5da7-f854-4be3-8a18-18dbc1ea9121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a307ef61-f5bb-46fb-b3ad-f565420a1150" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_a307ef61-f5bb-46fb-b3ad-f565420a1150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_14478a26-acca-4204-940a-a28847d36d69" xlink:href="trov-20201231.xsd#trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment_14478a26-acca-4204-940a-a28847d36d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_0bae15e3-3681-44fd-9758-9666ad57606e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_b910d552-8d9b-4fe8-bbb9-42e8de6e3573" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_0bae15e3-3681-44fd-9758-9666ad57606e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="trov-20201231.xsd#StatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_7822e2fb-b261-400e-b11f-2c0268ad7048" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_7822e2fb-b261-400e-b11f-2c0268ad7048" xlink:to="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4563707e-4d9e-4acc-9fe7-d136efdcb417" xlink:to="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_CommonStockAndWarrantsMember_b65dc4f6-aea7-4032-b863-9eb1d00e1272" xlink:href="trov-20201231.xsd#trov_CommonStockAndWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_CommonStockAndWarrantsMember_b65dc4f6-aea7-4032-b863-9eb1d00e1272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_42f0f311-6ac5-475f-b6b0-1fcb0b9d228f" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_42f0f311-6ac5-475f-b6b0-1fcb0b9d228f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_d3dbbdc8-0cbd-42b3-b399-ed5251f8cb2a" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1ac42a33-3b01-47f9-882c-1df096c10ee7" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_d3dbbdc8-0cbd-42b3-b399-ed5251f8cb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_82c562c7-7f2e-4b85-ba7b-d77a60f998a4" xlink:to="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_12f37002-b886-4238-9d97-947dddc4aabe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_12f37002-b886-4238-9d97-947dddc4aabe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_35f8a55e-7840-4d54-b524-65f683f3dfe7" xlink:href="trov-20201231.xsd#trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_99b8de20-1ac6-465b-b287-f28fc9931994" xlink:to="loc_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment_35f8a55e-7840-4d54-b524-65f683f3dfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidity"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a8d9432-7fda-4f18-8434-abd25578af9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62545da5-54d2-4966-8881-faed5309d2d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9a8d9432-7fda-4f18-8434-abd25578af9d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_62545da5-54d2-4966-8881-faed5309d2d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BusinessOverviewandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ea9746dd-9bda-44c3-bacb-b83023306f6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a76beef-b852-49a0-96fc-365c37743168" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ea9746dd-9bda-44c3-bacb-b83023306f6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a76beef-b852-49a0-96fc-365c37743168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2627628c-81ae-44c1-8034-68676dce47ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8dc03bed-13d6-4d9a-be40-85843af9cba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2627628c-81ae-44c1-8034-68676dce47ee" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_8dc03bed-13d6-4d9a-be40-85843af9cba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cad868ca-4f7d-4349-af47-4db350d3ed95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_cad868ca-4f7d-4349-af47-4db350d3ed95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5176803a-7d09-4d24-ad36-5d967fb673ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_UseOfEstimates_5176803a-7d09-4d24-ad36-5d967fb673ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrialExpensesPolicyTextBlock_7fb602dc-0d49-4557-941b-4a52241a3d2a" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrialExpensesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_trov_AccruedClinicalTrialExpensesPolicyTextBlock_7fb602dc-0d49-4557-941b-4a52241a3d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a9957e3e-0e78-473a-a4a5-b630d929f9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a9957e3e-0e78-473a-a4a5-b630d929f9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b6deaaba-84d8-463a-aa6b-f8760ed0b3ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b6deaaba-84d8-463a-aa6b-f8760ed0b3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_46ca6264-c588-4d29-8738-1ca0d998972d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_46ca6264-c588-4d29-8738-1ca0d998972d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_469edc65-3079-4572-aee5-ab4055028e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_469edc65-3079-4572-aee5-ab4055028e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ec1febc-96e8-49be-88ba-428e6563108d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6ec1febc-96e8-49be-88ba-428e6563108d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3a7fd147-3a2b-440d-bcd6-63945fa83600" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_3a7fd147-3a2b-440d-bcd6-63945fa83600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b2c7aa8-1199-4899-be57-eea80cd2006b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6b2c7aa8-1199-4899-be57-eea80cd2006b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_cbe33e82-7304-4b48-962e-e9e886126449" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_cbe33e82-7304-4b48-962e-e9e886126449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_50f4d8bf-8a80-439e-a789-11e7d36f0761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_50f4d8bf-8a80-439e-a789-11e7d36f0761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_b22f203a-5fb4-46c2-841a-a77fc232d2f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_b22f203a-5fb4-46c2-841a-a77fc232d2f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_ce787c4f-6f4d-46fe-8f75-4efb49429daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_ce787c4f-6f4d-46fe-8f75-4efb49429daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e6fdaf8b-5e1c-4af1-bdab-20f55a595642" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e6fdaf8b-5e1c-4af1-bdab-20f55a595642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f3f3799-b4cd-4600-9850-3e2d3455aa45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9f3f3799-b4cd-4600-9850-3e2d3455aa45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c536bbfc-1d31-4ca3-b5e9-db2472071b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e8e3615-a402-428a-9edd-448d8991f10a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c536bbfc-1d31-4ca3-b5e9-db2472071b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b20778a3-d694-488d-9f13-1d05333065d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_89ac70a1-ee0c-4a38-abb8-ea31d225946b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b20778a3-d694-488d-9f13-1d05333065d5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_89ac70a1-ee0c-4a38-abb8-ea31d225946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_575f93ee-0bd3-4c28-978b-9ba8275eccec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_259582ec-c17c-48f8-b3d1-cdb5988a134d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575f93ee-0bd3-4c28-978b-9ba8275eccec" xlink:to="loc_us-gaap_NumberOfOperatingSegments_259582ec-c17c-48f8-b3d1-cdb5988a134d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrialExpenses_f7e1390b-402f-4c04-8e39-a4575d80f3b7" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575f93ee-0bd3-4c28-978b-9ba8275eccec" xlink:to="loc_trov_AccruedClinicalTrialExpenses_f7e1390b-402f-4c04-8e39-a4575d80f3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6f6fe984-57e9-4e04-9a94-9a2295f61edc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575f93ee-0bd3-4c28-978b-9ba8275eccec" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6f6fe984-57e9-4e04-9a94-9a2295f61edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_610c480b-8410-400d-b92d-f79bfd2eec1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_575f93ee-0bd3-4c28-978b-9ba8275eccec" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_610c480b-8410-400d-b92d-f79bfd2eec1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4b237aa3-2708-4845-b978-a9c7da95ce57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4b237aa3-2708-4845-b978-a9c7da95ce57" xlink:to="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_146ed21a-f062-4118-b77e-e478c17c6915" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_728cd0d6-03e5-4e78-b771-e86567eeda26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_21e3caeb-d568-41f8-8d02-5af86c2f4477" xlink:to="loc_us-gaap_WarrantMember_728cd0d6-03e5-4e78-b771-e86567eeda26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:to="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_ec543c39-0278-4b19-ba0a-f9485c1696fd" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_7068056c-0d1a-474b-be5d-a439cac58422" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_a5109753-128c-4a01-a389-09ddc3e3e5e1" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_7068056c-0d1a-474b-be5d-a439cac58422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_4619ac0c-7e66-4822-9660-e82c9df77ad1" xlink:to="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0e94e23d-9a51-4fac-8ade-06a09ef4f9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_fe83446e-1659-4f0b-a23f-6a8529bbab07" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0e94e23d-9a51-4fac-8ade-06a09ef4f9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a3999ec0-2395-4f81-a3d8-b2620634818b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a3999ec0-2395-4f81-a3d8-b2620634818b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e8f9051e-746a-4570-82a1-ea3943686ca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_71b12bc4-2d23-4c8d-8129-a45c1bd47e95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:to="loc_us-gaap_EquipmentMember_71b12bc4-2d23-4c8d-8129-a45c1bd47e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FurnitureAndOfficeEquipmentMember_8080fc5f-1359-4f13-ad25-36f6a59e496b" xlink:href="trov-20201231.xsd#trov_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22ad4f4c-1a1e-43ce-8281-037bf423dd11" xlink:to="loc_trov_FurnitureAndOfficeEquipmentMember_8080fc5f-1359-4f13-ad25-36f6a59e496b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:to="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38b94ea4-a4dd-4842-8e84-4c6bc39c80ec" xlink:to="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ea508a4d-44ab-48f3-9f67-8cc9a06e81cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:to="loc_srt_MinimumMember_ea508a4d-44ab-48f3-9f67-8cc9a06e81cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e47d454-8b0a-400c-b1b5-3c4a99b3b553" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_586447a5-4bf6-4353-be65-c63385690efb" xlink:to="loc_srt_MaximumMember_5e47d454-8b0a-400c-b1b5-3c4a99b3b553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4f8f4f1a-4784-426d-bcbd-a053a0340e3e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d8bbad3-604c-4e28-9658-14709cbaa394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_08db014c-d767-4005-8b10-f9e3bf37e5bd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9d8bbad3-604c-4e28-9658-14709cbaa394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e8d987cc-d016-46e4-9182-37d631eea776" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8d987cc-d016-46e4-9182-37d631eea776" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c7e54fd0-6fb7-426b-81c6-80674d4d7236" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40aec47b-d814-455f-bf77-53356f8f5072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40aec47b-d814-455f-bf77-53356f8f5072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_322e6d27-b9cf-43f4-a420-33e7646063f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_WarrantMember_322e6d27-b9cf-43f4-a420-33e7646063f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_eb25da96-c6a0-4dd9-8818-f3554260cbac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_eb25da96-c6a0-4dd9-8818-f3554260cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_88d2fba3-6f80-4eb0-963e-9d2dc4b95bb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_88d2fba3-6f80-4eb0-963e-9d2dc4b95bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_bf973dd3-08b6-45f0-acaf-273774c46423" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8da3306d-a287-4a70-b038-285796834730" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_bf973dd3-08b6-45f0-acaf-273774c46423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_329ea2ea-4a74-4719-a0d9-781f4492d87a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5638c4f-cc29-44f5-a76f-2d5c715a3c38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fd93ded-92f0-430e-8520-dd52f62ed300" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d5638c4f-cc29-44f5-a76f-2d5c715a3c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8054f6cb-4511-4099-a552-0b999b43b1bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_01076090-d042-42d1-8ba6-ecb75d4e3890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8054f6cb-4511-4099-a552-0b999b43b1bc" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_01076090-d042-42d1-8ba6-ecb75d4e3890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_148cb2df-88b7-4a0f-93b1-cc4c73511bf4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a73f7b31-8101-40c8-9c2d-38fb504aa4e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_148cb2df-88b7-4a0f-93b1-cc4c73511bf4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a73f7b31-8101-40c8-9c2d-38fb504aa4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a10c689e-1f9f-4743-ac05-201cb4353a91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_148cb2df-88b7-4a0f-93b1-cc4c73511bf4" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a10c689e-1f9f-4743-ac05-201cb4353a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99a2315b-f18a-4e37-aabc-5470a775504f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_99a2315b-f18a-4e37-aabc-5470a775504f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_016fb8d4-c4d8-4965-96fb-24302d24f0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FurnitureAndOfficeEquipmentMember_d87a8e3d-533b-406f-ad23-51f66a254e57" xlink:href="trov-20201231.xsd#trov_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_trov_FurnitureAndOfficeEquipmentMember_d87a8e3d-533b-406f-ad23-51f66a254e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_69586d4d-5715-4f1f-bc5b-902c0956aeb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_69586d4d-5715-4f1f-bc5b-902c0956aeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_ab062f97-7e16-42b1-9e5d-4b3afdebf033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bfc46122-7ef5-4a6b-96f9-d530512c7b7c" xlink:to="loc_us-gaap_EquipmentMember_ab062f97-7e16-42b1-9e5d-4b3afdebf033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6a991806-ee1d-4829-a056-4df4fb235ee0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_ce060c2c-2a4b-4734-9142-da8c8d221381" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_Depreciation_ce060c2c-2a4b-4734-9142-da8c8d221381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d0c4b6e8-a83e-4ffa-a185-fbb710b68007" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d0c4b6e8-a83e-4ffa-a185-fbb710b68007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a87d419-37f8-449d-b252-f54b86b3fea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7a87d419-37f8-449d-b252-f54b86b3fea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e38be577-c489-4155-a284-2ce869f05445" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cc9f5f55-a4c9-41f0-a802-7a1f076461d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e38be577-c489-4155-a284-2ce869f05445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6f1c48a6-9c41-463d-aec3-d81920c514c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_6f1c48a6-9c41-463d-aec3-d81920c514c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedPreferredStockDividend_f23044b0-03f9-4587-8788-a3653fd96ab5" xlink:href="trov-20201231.xsd#trov_AccruedPreferredStockDividend"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_trov_AccruedPreferredStockDividend_f23044b0-03f9-4587-8788-a3653fd96ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AccruedClinicalTrial_0df7b7c0-2343-4c3b-a1ad-5bef34a15509" xlink:href="trov-20201231.xsd#trov_AccruedClinicalTrial"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_trov_AccruedClinicalTrial_0df7b7c0-2343-4c3b-a1ad-5bef34a15509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accruedresearchagreements_dcfe73a9-f3b9-4923-9e7b-09d827a92e28" xlink:href="trov-20201231.xsd#trov_Accruedresearchagreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_trov_Accruedresearchagreements_dcfe73a9-f3b9-4923-9e7b-09d827a92e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Accrueddirectorfees_05bde03d-49bf-4252-beba-32197a5efc04" xlink:href="trov-20201231.xsd#trov_Accrueddirectorfees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_trov_Accrueddirectorfees_05bde03d-49bf-4252-beba-32197a5efc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a16b2a37-d842-4ee7-817c-18fb308da2e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a16b2a37-d842-4ee7-817c-18fb308da2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Patentlicenseandotherfeespayable_b2e196c8-cbef-4016-8c0f-69ec7b38df8c" xlink:href="trov-20201231.xsd#trov_Patentlicenseandotherfeespayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_trov_Patentlicenseandotherfeespayable_b2e196c8-cbef-4016-8c0f-69ec7b38df8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63f31756-a014-46b3-815c-401c4ddd811e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_63f31756-a014-46b3-815c-401c4ddd811e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3461c001-f40f-4a16-98b0-70b5866d5778" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_67ebbb8b-6521-4711-af71-5b9462a277c7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3461c001-f40f-4a16-98b0-70b5866d5778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/Leases" xlink:type="simple" xlink:href="trov-20201231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5067f771-bc31-45bc-b15d-f6abf8e8fd41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_dcd1012c-e14a-44a3-9e7d-587888964b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5067f771-bc31-45bc-b15d-f6abf8e8fd41" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_dcd1012c-e14a-44a3-9e7d-587888964b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_ebaab297-3151-43f4-becd-8b86e041c693" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5067f771-bc31-45bc-b15d-f6abf8e8fd41" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_ebaab297-3151-43f4-becd-8b86e041c693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f8baec80-b9b6-4dff-9cbd-c28fc3e60518" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_b42b6142-57d5-4caf-90de-059cb68e6a9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8baec80-b9b6-4dff-9cbd-c28fc3e60518" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_b42b6142-57d5-4caf-90de-059cb68e6a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AssetsAndLiabilitiesLesseeTableTextBlock_a5b2bdef-bd94-44fc-8063-e3b93f096ab1" xlink:href="trov-20201231.xsd#trov_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8baec80-b9b6-4dff-9cbd-c28fc3e60518" xlink:to="loc_trov_AssetsAndLiabilitiesLesseeTableTextBlock_a5b2bdef-bd94-44fc-8063-e3b93f096ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d9693209-86f3-4e71-9120-479ae66a2ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8baec80-b9b6-4dff-9cbd-c28fc3e60518" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d9693209-86f3-4e71-9120-479ae66a2ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6c471593-0457-4207-aab0-4eb0a9ae0934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseMonthlyRentPayment_50084516-308a-4b53-8888-88f8093fe7cb" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c471593-0457-4207-aab0-4eb0a9ae0934" xlink:to="loc_trov_LesseeOperatingLeaseMonthlyRentPayment_50084516-308a-4b53-8888-88f8093fe7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage_70e7bc58-7d3f-4f1e-bdf3-48f1b07faf16" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c471593-0457-4207-aab0-4eb0a9ae0934" xlink:to="loc_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage_70e7bc58-7d3f-4f1e-bdf3-48f1b07faf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LessorNumberOfSubleases_52c9954e-cbff-4ed9-9c2f-0b2bfdca5a89" xlink:href="trov-20201231.xsd#trov_LessorNumberOfSubleases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c471593-0457-4207-aab0-4eb0a9ae0934" xlink:to="loc_trov_LessorNumberOfSubleases_52c9954e-cbff-4ed9-9c2f-0b2bfdca5a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_ea8fdab5-2b6b-497b-90e1-49f1fdcdd287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c471593-0457-4207-aab0-4eb0a9ae0934" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_ea8fdab5-2b6b-497b-90e1-49f1fdcdd287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d28b069d-2f2e-4140-adc4-b5be4c49d5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_33b637e3-4f1a-4aa2-b85a-e6f1c05f353e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d28b069d-2f2e-4140-adc4-b5be4c49d5b2" xlink:to="loc_us-gaap_OperatingLeaseCost_33b637e3-4f1a-4aa2-b85a-e6f1c05f353e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_eefb55e6-0628-4002-b52f-e30312effd27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d28b069d-2f2e-4140-adc4-b5be4c49d5b2" xlink:to="loc_us-gaap_SubleaseIncome_eefb55e6-0628-4002-b52f-e30312effd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_b2f5ad5c-8f5f-4ac3-bbb1-33d1573972d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d28b069d-2f2e-4140-adc4-b5be4c49d5b2" xlink:to="loc_us-gaap_LeaseCost_b2f5ad5c-8f5f-4ac3-bbb1-33d1573972d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1bbb3f0d-b5c2-4ed9-81f4-5a15c01cb1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1bbb3f0d-b5c2-4ed9-81f4-5a15c01cb1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_998719b2-b36b-4e53-ae92-e8d78fa9e8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_998719b2-b36b-4e53-ae92-e8d78fa9e8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c90bc15d-6fda-4fb2-af22-7fdee5a65462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c90bc15d-6fda-4fb2-af22-7fdee5a65462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_1f74ca02-fb76-4851-8bd9-2838dc794993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseLiability_1f74ca02-fb76-4851-8bd9-2838dc794993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_daeb61c3-db5f-4861-a328-a84edf2d9cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_daeb61c3-db5f-4861-a328-a84edf2d9cfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d5f2014-0257-4397-ae83-1e2e07e3a765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0d90f6da-f6a1-4f28-8351-90fbe95d31ea" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5d5f2014-0257-4397-ae83-1e2e07e3a765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_66739e12-c882-4c6b-8115-da8065182979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5fa70465-8a5f-408c-b16f-1757d27310b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_66739e12-c882-4c6b-8115-da8065182979" xlink:to="loc_us-gaap_OperatingLeasePayments_5fa70465-8a5f-408c-b16f-1757d27310b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cf906aff-24bc-48aa-9e11-c6379e4ca4ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf906aff-24bc-48aa-9e11-c6379e4ca4ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b1a07d09-265c-4980-b7bb-868d896e7cf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b1a07d09-265c-4980-b7bb-868d896e7cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_929e13f9-f18f-4c96-aac8-cdd2ef426b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_929e13f9-f18f-4c96-aac8-cdd2ef426b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d2315a72-a2b6-428c-a799-e0241b2206b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d2315a72-a2b6-428c-a799-e0241b2206b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_95c183cd-c42e-4ad9-8010-bbbf1e17d039" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_95c183cd-c42e-4ad9-8010-bbbf1e17d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef005d2f-c63d-486a-8081-b5eaa5042cc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef005d2f-c63d-486a-8081-b5eaa5042cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fc2e1ce6-272c-41b4-8cf4-3118e800544a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bdd66aef-e2c6-408d-86c6-65d1f87354cb" xlink:to="loc_us-gaap_OperatingLeaseLiability_fc2e1ce6-272c-41b4-8cf4-3118e800544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf906aff-24bc-48aa-9e11-c6379e4ca4ab" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_df12a39f-00cd-4891-a4e1-956773818158" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_df12a39f-00cd-4891-a4e1-956773818158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_1ca72abb-f652-4d59-a909-005978f78278" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_1ca72abb-f652-4d59-a909-005978f78278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_17118010-f177-41d9-952e-a171fcb816de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_17118010-f177-41d9-952e-a171fcb816de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1db3b80f-9304-40ae-ada5-8dd29c3b9130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_93988210-e3e9-4f2a-b98e-412149195849" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_1db3b80f-9304-40ae-ada5-8dd29c3b9130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cf906aff-24bc-48aa-9e11-c6379e4ca4ab" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_c4ae5f90-0443-4ab8-954f-51e54c971085" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths_c4ae5f90-0443-4ab8-954f-51e54c971085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_a2980376-90fc-484b-bc47-8290081981c3" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo_a2980376-90fc-484b-bc47-8290081981c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_4f3ccf90-0db5-49de-8a09-ee4faabfe866" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree_4f3ccf90-0db5-49de-8a09-ee4faabfe866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_a20d8225-0ec5-47cb-89dc-800508a795cb" xlink:href="trov-20201231.xsd#trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract_c3843bff-70e5-40d2-999b-3b27a2569b9b" xlink:to="loc_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue_a20d8225-0ec5-47cb-89dc-800508a795cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="trov-20201231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquity" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_8af8d3dd-21ba-4af4-8fb6-2e6dc545a657" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ff50eb12-e85c-4c0a-bf2f-640f9fab12b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_8af8d3dd-21ba-4af4-8fb6-2e6dc545a657" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ff50eb12-e85c-4c0a-bf2f-640f9fab12b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0edfd2f0-bd8f-4cca-8cb9-23063964fdcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_5b29f9bd-7acc-4a0b-b31e-3f800beb6448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0edfd2f0-bd8f-4cca-8cb9-23063964fdcf" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_5b29f9bd-7acc-4a0b-b31e-3f800beb6448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_4dc454f9-2e3a-4e36-9abc-65d72c56b3c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0edfd2f0-bd8f-4cca-8cb9-23063964fdcf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_4dc454f9-2e3a-4e36-9abc-65d72c56b3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquityScheduleofWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6341e0c1-fbb5-4d0b-9ba5-fa22d57916bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6341e0c1-fbb5-4d0b-9ba5-fa22d57916bf" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f41746b5-d71c-4872-8214-9359db536bad" xlink:to="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreFundedWarrantsMember_cb8a838b-1c0c-4aa2-a777-4eb3339fbce9" xlink:href="trov-20201231.xsd#trov_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f7ceb1c7-4ece-4a37-8f13-90e13ba98bdb" xlink:to="loc_trov_PreFundedWarrantsMember_cb8a838b-1c0c-4aa2-a777-4eb3339fbce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1cd70d26-e499-4d93-9ea7-fdb313435a1c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:href="trov-20201231.xsd#trov_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5283bc3b-e014-4bde-81a3-635ec114f340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5283bc3b-e014-4bde-81a3-635ec114f340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberGranted_21723ab4-3e8e-41dc-a11f-215ba38fe1fb" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_trov_ClassOfWarrantOrRightNumberGranted_21723ab4-3e8e-41dc-a11f-215ba38fe1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberExercised_e585c916-4a04-4d43-8e2c-f1265eadf05f" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_trov_ClassOfWarrantOrRightNumberExercised_e585c916-4a04-4d43-8e2c-f1265eadf05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5b03f32a-2c15-4306-92b8-e5a5950ded3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_WarrantsAndRightsRollForward_c3ae9d1a-b8b8-454e-b71f-35431e2e01f2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5b03f32a-2c15-4306-92b8-e5a5950ded3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c0ad2943-c4b0-458f-8df6-79124fbbf1f2" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c0ad2943-c4b0-458f-8df6-79124fbbf1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_665e6df4-8145-4a15-84b3-4c67097d4a0e" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted_665e6df4-8145-4a15-84b3-4c67097d4a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_c09d628f-0165-4da0-b9d5-eb68e4d2e088" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_c09d628f-0165-4da0-b9d5-eb68e4d2e088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e518ea97-3bae-43bf-9866-59c065904e23" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_a6f066c9-b9cb-4159-9f03-d9a7aa1458b0" xlink:to="loc_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_e518ea97-3bae-43bf-9866-59c065904e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsWeightedAverageContractualTerm_7430712c-b57f-4246-9798-586a9cbc5c8a" xlink:href="trov-20201231.xsd#trov_WarrantsWeightedAverageContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_6234a403-384e-4802-a40b-00a355efbe3a" xlink:to="loc_trov_WarrantsWeightedAverageContractualTerm_7430712c-b57f-4246-9798-586a9cbc5c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e58ea7a3-6904-41fc-b435-5cf43357c36c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_556f16d3-c81f-45fa-bf94-7a14fc41b029" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e58ea7a3-6904-41fc-b435-5cf43357c36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e97af09a-c3d0-472f-acc3-49cc9aa8e88f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e97af09a-c3d0-472f-acc3-49cc9aa8e88f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6c213278-4058-4710-9a10-57ff77e62024" xlink:to="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesAConvertiblePreferredStockMember_53e6c107-f75d-4434-b739-4ec4f41aab6b" xlink:href="trov-20201231.xsd#trov_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesAConvertiblePreferredStockMember_53e6c107-f75d-4434-b739-4ec4f41aab6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesBConvertiblePreferredStockMember_e069845f-f7a0-4077-a114-142c1ba2d1a3" xlink:href="trov-20201231.xsd#trov_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesBConvertiblePreferredStockMember_e069845f-f7a0-4077-a114-142c1ba2d1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_27b249a4-52c2-42a1-ac14-744b166acf15" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_27b249a4-52c2-42a1-ac14-744b166acf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_cb1a2210-b720-4994-997a-393bb27ba764" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_cb1a2210-b720-4994-997a-393bb27ba764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_893043af-a194-4968-a068-a31e4e3e8197" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_01812617-1f5c-4a47-ba5c-af725cffe879" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_893043af-a194-4968-a068-a31e4e3e8197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5cfd13f3-9b2a-4eeb-833c-1d44ee16cafe" xlink:to="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bd68724-8e1f-47b4-ab49-dd5e975decf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2bd68724-8e1f-47b4-ab49-dd5e975decf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_af4bc6d0-93f1-4e06-ba21-53ca33e6a0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_af4bc6d0-93f1-4e06-ba21-53ca33e6a0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_bacceab5-3629-40f3-a986-43ae1b7ba7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_bacceab5-3629-40f3-a986-43ae1b7ba7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_78a6cce6-b7e3-483c-89e2-86cc29e7df8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8246914a-a2f5-404c-95a6-523a278195e7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_78a6cce6-b7e3-483c-89e2-86cc29e7df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesAConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_544a2930-2bd1-4929-b12a-15579a0694bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_544a2930-2bd1-4929-b12a-15579a0694bf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d742a147-e2c4-4d7e-a096-6fa3950359c1" xlink:to="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesAConvertiblePreferredStockMember_94bebfbc-12e8-4c1a-a891-4b9b3b081dbe" xlink:href="trov-20201231.xsd#trov_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0e906919-a347-4b12-b7e7-5abcfc6ba925" xlink:to="loc_trov_SeriesAConvertiblePreferredStockMember_94bebfbc-12e8-4c1a-a891-4b9b3b081dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0e78f353-6c95-4f42-baff-a2a43e1cc2b6" xlink:to="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b96703b6-3269-4232-afed-1ba5f6f5460f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d37ed69a-6a81-469e-b68f-b8d8440fd984" xlink:to="loc_us-gaap_RetainedEarningsMember_b96703b6-3269-4232-afed-1ba5f6f5460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_193f28a5-8db8-4791-ba07-f1e2d2fa582f" xlink:to="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_13bf0ae7-244f-4c51-b401-b7229ec91f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_13bf0ae7-244f-4c51-b401-b7229ec91f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_681ce971-061b-435a-b9f3-48c254ed0d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_681ce971-061b-435a-b9f3-48c254ed0d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_79f61bc2-d3cd-4f61-ac55-4c79cfd9b0f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_us-gaap_DividendsPreferredStock_79f61bc2-d3cd-4f61-ac55-4c79cfd9b0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ConvertiblePreferredStockStatedValuePerShare_255adddf-4a45-4e26-938d-f8971119aac2" xlink:href="trov-20201231.xsd#trov_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_ConvertiblePreferredStockStatedValuePerShare_255adddf-4a45-4e26-938d-f8971119aac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionPricePerShare_74e536b0-082f-4a14-8f00-0ce50035258b" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionPricePerShare_74e536b0-082f-4a14-8f00-0ce50035258b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_35d86698-c9cc-429f-b926-ec5d33c091fd" xlink:href="trov-20201231.xsd#trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_35d86698-c9cc-429f-b926-ec5d33c091fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SharePriceForAutomaticConversion_7712db3f-4af8-4483-b4a0-bc0c4783cb8f" xlink:href="trov-20201231.xsd#trov_SharePriceForAutomaticConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_SharePriceForAutomaticConversion_7712db3f-4af8-4483-b4a0-bc0c4783cb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_5c33e407-1ce0-41ab-b809-7db17bca5381" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_5c33e407-1ce0-41ab-b809-7db17bca5381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_306fd519-22e5-44ec-a1f8-d09a743e7070" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_306fd519-22e5-44ec-a1f8-d09a743e7070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConversionObligationNumberOfTradingDays_03d7dda7-6c3b-4956-8c83-fbee4f784ce5" xlink:href="trov-20201231.xsd#trov_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_58c32168-577c-4e47-a1d8-078b416bb83e" xlink:to="loc_trov_PreferredStockConversionObligationNumberOfTradingDays_03d7dda7-6c3b-4956-8c83-fbee4f784ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesCConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b7f9e76d-afd8-4a95-b6df-8ab0b8334133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b7f9e76d-afd8-4a95-b6df-8ab0b8334133" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d8ee1c18-f69e-41d8-9fa0-64f04e9dea35" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_16a729f3-04ee-4bf0-b48c-0c8cdcaecf45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_23a10347-8813-4fb1-95f6-04e809306b68" xlink:to="loc_us-gaap_PrivatePlacementMember_16a729f3-04ee-4bf0-b48c-0c8cdcaecf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_937caeda-bf18-4a4c-bb7d-10a0c7f3e07b" xlink:to="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_877223e1-eac6-4ba8-820f-ce49257c67c4" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_41f98cfd-70c4-4443-829d-b0d458e48225" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_877223e1-eac6-4ba8-820f-ce49257c67c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6f48bf94-8361-45da-a117-2dd7eb1920ac" xlink:to="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_29da9105-349b-4213-a32e-872e12abde23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:to="loc_us-gaap_CommonStockMember_29da9105-349b-4213-a32e-872e12abde23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesCConvertiblePreferredStockMember_30c138b8-fb28-4794-a3ae-1a9e411270ca" xlink:href="trov-20201231.xsd#trov_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_95683e46-1ad0-47a4-a7fa-192055ae770c" xlink:to="loc_trov_SeriesCConvertiblePreferredStockMember_30c138b8-fb28-4794-a3ae-1a9e411270ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_60588fa8-8ccf-496d-879e-68c30deb0612" xlink:to="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AmountFinancedUnderAgreement_1588ac65-5ca9-4a17-94cc-ea24a3069f20" xlink:href="trov-20201231.xsd#trov_AmountFinancedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_AmountFinancedUnderAgreement_1588ac65-5ca9-4a17-94cc-ea24a3069f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d7a745fe-fa58-49dd-aa7e-c9d4160e842e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d7a745fe-fa58-49dd-aa7e-c9d4160e842e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightNumberGranted_c6a52bb1-3439-47fc-a57e-48ac664a4847" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightNumberGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_ClassOfWarrantOrRightNumberGranted_c6a52bb1-3439-47fc-a57e-48ac664a4847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b032a22-4a95-4ae4-b344-81ef247560b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2b032a22-4a95-4ae4-b344-81ef247560b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5b8d1a35-c588-4eeb-9794-4d256918342f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_5b8d1a35-c588-4eeb-9794-4d256918342f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_abb8b5c1-1490-454a-bfa9-21f0af44f047" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_abb8b5c1-1490-454a-bfa9-21f0af44f047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_af378ffd-9018-4f46-9df7-5142efa0d3bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_af378ffd-9018-4f46-9df7-5142efa0d3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_fa1b88c3-de9e-463d-a01c-f84ce8cb1517" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_Servicereceivable_fa1b88c3-de9e-463d-a01c-f84ce8cb1517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_efa83635-f865-491a-a676-b2a31dcb21ed" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0cbad37c-45b7-449c-b0cb-c9da41d550a9" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_efa83635-f865-491a-a676-b2a31dcb21ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesDConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_110da669-8b2c-4077-bef8-a50c383652af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_110da669-8b2c-4077-bef8-a50c383652af" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a1d664a1-9235-4ee6-a2c3-744228762880" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4fa659e3-dd7e-49a3-922c-77e93d64df74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f6223f2a-3bba-4dc8-9953-6d4f7b12702a" xlink:to="loc_us-gaap_PrivatePlacementMember_4fa659e3-dd7e-49a3-922c-77e93d64df74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6a161cf4-dc68-43c8-b1fa-eb813f8fc0c1" xlink:to="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4db4853a-25f9-4f3a-babf-960933371d2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:to="loc_us-gaap_CommonStockMember_4db4853a-25f9-4f3a-babf-960933371d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesDConvertiblePreferredStockMember_10f0f1b0-359c-4bbb-b592-a553581adaa7" xlink:href="trov-20201231.xsd#trov_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4099d3eb-2e24-4beb-9fc5-6771ca0fff2e" xlink:to="loc_trov_SeriesDConvertiblePreferredStockMember_10f0f1b0-359c-4bbb-b592-a553581adaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_a29854f3-22e2-4d48-966b-b78b6b172e81" xlink:to="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_AmountFinancedUnderAgreement_a8bc57af-3690-4518-842f-773916867c6d" xlink:href="trov-20201231.xsd#trov_AmountFinancedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_AmountFinancedUnderAgreement_a8bc57af-3690-4518-842f-773916867c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25bafb38-fd90-417a-984d-2ad46bd839d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_25bafb38-fd90-417a-984d-2ad46bd839d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6ea63cc9-2ffb-4ceb-bc4e-a01fc3b0c9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6ea63cc9-2ffb-4ceb-bc4e-a01fc3b0c9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e77eab5c-3614-455b-906e-f9b1ced4d1f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e77eab5c-3614-455b-906e-f9b1ced4d1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_cbcabbad-8c30-483e-a058-039f5a319417" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_cbcabbad-8c30-483e-a058-039f5a319417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_5375f946-a593-4d98-a7f6-e5cc5a9135dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_5375f946-a593-4d98-a7f6-e5cc5a9135dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_Servicereceivable_fb5e3c54-0158-4b77-b499-fb4f7917f2ca" xlink:href="trov-20201231.xsd#trov_Servicereceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_Servicereceivable_fb5e3c54-0158-4b77-b499-fb4f7917f2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_d9710a26-0dab-401f-9a7d-440de5d47dc5" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_d9710a26-0dab-401f-9a7d-440de5d47dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_17f4ed01-34dc-46e5-9870-51d59426f3ce" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_4cb06fb1-2897-4520-b818-33f9594e7c6c" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_17f4ed01-34dc-46e5-9870-51d59426f3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_37938cf0-206b-4407-8a99-478f727530c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_37938cf0-206b-4407-8a99-478f727530c9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c426d810-9364-4ba1-a737-83221c638a84" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_RegisteredDirectOfferingMember_bfa65e3d-82d9-4fa4-b824-c4a22eecbcb1" xlink:href="trov-20201231.xsd#trov_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:to="loc_trov_RegisteredDirectOfferingMember_bfa65e3d-82d9-4fa4-b824-c4a22eecbcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_42db420b-4b87-44a2-b947-7453f97866b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a1ad9437-dca3-4a77-bc7f-b0c6fdf2027f" xlink:to="loc_us-gaap_PrivatePlacementMember_42db420b-4b87-44a2-b947-7453f97866b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ffd9382d-bfee-49c8-b3f3-aeb8359e55f4" xlink:to="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesEConvertiblePreferredStockMember_dc5bb2ce-d043-4b89-9d9d-63d2cdf82304" xlink:href="trov-20201231.xsd#trov_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e7cb174a-2162-4f89-a649-b397b50466d3" xlink:to="loc_trov_SeriesEConvertiblePreferredStockMember_dc5bb2ce-d043-4b89-9d9d-63d2cdf82304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_da276d53-1bbe-4da3-a497-34e8c4a22fc4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesNWarrantMember_67a77470-e05a-47e2-ae17-5b7b52cc9e76" xlink:href="trov-20201231.xsd#trov_SeriesNWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_033a3e0f-057d-4166-8b2e-73e3a73657b1" xlink:to="loc_trov_SeriesNWarrantMember_67a77470-e05a-47e2-ae17-5b7b52cc9e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5bf2a77a-992d-48ea-99ff-0b673a1bc506" xlink:to="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_809a9e6a-2d1d-43b2-87c7-9044b8b69961" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_809a9e6a-2d1d-43b2-87c7-9044b8b69961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2311223c-db6b-4701-98f0-740278302673" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2311223c-db6b-4701-98f0-740278302673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PreferredStockConvertibleConversionPrice_e97c6363-1a96-4b16-ae5f-6bc6420d1536" xlink:href="trov-20201231.xsd#trov_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_PreferredStockConvertibleConversionPrice_e97c6363-1a96-4b16-ae5f-6bc6420d1536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_6f8d56b7-60b7-4ee3-9dbc-cf4cf4276c77" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_6f8d56b7-60b7-4ee3-9dbc-cf4cf4276c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1df154cf-a923-44b0-ab8a-6621d3c32476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1df154cf-a923-44b0-ab8a-6621d3c32476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_a5ee5d76-4881-4f7a-9e31-c48d91b68360" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_a5ee5d76-4881-4f7a-9e31-c48d91b68360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d64c813e-0afd-4cc6-862e-0bda458f405c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_d64c813e-0afd-4cc6-862e-0bda458f405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightIssued_952ba52b-2a9a-4491-b94f-e3a3fe87e16e" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightIssued_952ba52b-2a9a-4491-b94f-e3a3fe87e16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_881bfdc9-b29d-437c-9717-ab303d0d191e" xlink:href="trov-20201231.xsd#trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock_881bfdc9-b29d-437c-9717-ab303d0d191e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightExpirationTerm_557f0451-9010-4bc5-9542-2d6eb24860e2" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightExpirationTerm"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_ClassOfWarrantOrRightExpirationTerm_557f0451-9010-4bc5-9542-2d6eb24860e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_WarrantsFairValue_3e3a785a-f748-4c98-a064-85c16fa32e37" xlink:href="trov-20201231.xsd#trov_WarrantsFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_2482cf55-5757-454d-a2bd-2aa501d8a813" xlink:to="loc_trov_WarrantsFairValue_3e3a785a-f748-4c98-a064-85c16fa32e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockholdersEquitySecuritiesPurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e9bda451-443d-4901-b46d-5d7b491e1c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9bda451-443d-4901-b46d-5d7b491e1c61" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1f933687-ee2a-4a9a-b9c3-626dec63d835" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesIWarrantMember_fc83943f-914b-4d53-960f-911135941a5f" xlink:href="trov-20201231.xsd#trov_SeriesIWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesIWarrantMember_fc83943f-914b-4d53-960f-911135941a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesJWarrantMember_f50068d6-f6a5-4a42-8567-f2857f9bafb6" xlink:href="trov-20201231.xsd#trov_SeriesJWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesJWarrantMember_f50068d6-f6a5-4a42-8567-f2857f9bafb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesKWarrantMember_83455aed-1332-4cd9-a0a5-d7a4980e58f5" xlink:href="trov-20201231.xsd#trov_SeriesKWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesKWarrantMember_83455aed-1332-4cd9-a0a5-d7a4980e58f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesLWarrantsMember_eb0c5fa7-f378-41e9-87bd-433943fc7c83" xlink:href="trov-20201231.xsd#trov_SeriesLWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesLWarrantsMember_eb0c5fa7-f378-41e9-87bd-433943fc7c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SeriesMWarrantMember_335992fa-c8c1-476d-b99d-e4c6e59dff61" xlink:href="trov-20201231.xsd#trov_SeriesMWarrantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8d5daaf5-46a2-4e4a-9490-82d8fc9cecfa" xlink:to="loc_trov_SeriesMWarrantMember_335992fa-c8c1-476d-b99d-e4c6e59dff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4c72e91d-dc4b-4786-a734-43cb94144b27" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_9c942b85-b8b9-410e-a5e7-6f5434d051fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20f65db2-6edd-4d89-b1c2-8c2fbab993ba" xlink:to="loc_us-gaap_OverAllotmentOptionMember_9c942b85-b8b9-410e-a5e7-6f5434d051fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_8753568e-33d7-4f0d-bdfc-5b901dcfb575" xlink:to="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cb95d240-aade-4a16-9632-9cbaa097d256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_cb95d240-aade-4a16-9632-9cbaa097d256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0bc36609-1cd6-42ea-bb73-da329fd2f2f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0bc36609-1cd6-42ea-bb73-da329fd2f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ec1cd43a-14a9-4748-a4a2-fa73b2fd1573" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_ec1cd43a-14a9-4748-a4a2-fa73b2fd1573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_ff5b95f9-0110-462f-b329-014cf193eea8" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_ClassOfWarrantOrRightMonthsUntilExercisable_ff5b95f9-0110-462f-b329-014cf193eea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14824c7c-d9e7-4787-acf8-ce8ff6e2258e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14824c7c-d9e7-4787-acf8-ce8ff6e2258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ClassOfWarrantOrRightExpirationTerm_50bcbf9b-913d-4afd-ba39-842dc87decec" xlink:href="trov-20201231.xsd#trov_ClassOfWarrantOrRightExpirationTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_ClassOfWarrantOrRightExpirationTerm_50bcbf9b-913d-4afd-ba39-842dc87decec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross_506ca675-5323-4913-a29a-c2c095b01e5e" xlink:href="trov-20201231.xsd#trov_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_trov_SaleOfStockConsiderationReceivedOnTransactionGross_506ca675-5323-4913-a29a-c2c095b01e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_74db3cf3-fa59-4811-b3f9-3bf22d182091" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_74db3cf3-fa59-4811-b3f9-3bf22d182091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c78be281-49da-4a9e-adce-cd8078f99ed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_ee298f3d-5c38-4a33-8640-2609a0c6f3cd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c78be281-49da-4a9e-adce-cd8078f99ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16bb6796-408b-4de9-afe1-46a7d5a79f1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0b7c353c-ab20-43e5-a9a4-cff2f52b7fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16bb6796-408b-4de9-afe1-46a7d5a79f1b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0b7c353c-ab20-43e5-a9a4-cff2f52b7fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d663aca1-90e0-40d6-b8ab-ee2b44c7d752" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dc40aa6f-4790-42fc-a2d6-48bbefbf253e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d663aca1-90e0-40d6-b8ab-ee2b44c7d752" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_dc40aa6f-4790-42fc-a2d6-48bbefbf253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_caef15cb-3843-42f6-90f8-4b1a6c4cb5fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d663aca1-90e0-40d6-b8ab-ee2b44c7d752" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_caef15cb-3843-42f6-90f8-4b1a6c4cb5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_36404284-290c-4332-bea3-d8af898472ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d663aca1-90e0-40d6-b8ab-ee2b44c7d752" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_36404284-290c-4332-bea3-d8af898472ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_34233317-7475-4df9-afd1-33d6b280c4de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d663aca1-90e0-40d6-b8ab-ee2b44c7d752" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_34233317-7475-4df9-afd1-33d6b280c4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8287e987-ce22-47c3-95df-20c72de4ae6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8287e987-ce22-47c3-95df-20c72de4ae6e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:to="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c19effd8-c484-460a-83d3-50971008c042" xlink:to="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EquityIncentivePlan2014Member_96bf9a9a-d2e4-48ab-81c4-c311b351af2d" xlink:href="trov-20201231.xsd#trov_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1288184-2734-48e9-92a2-181c8723d656" xlink:to="loc_trov_EquityIncentivePlan2014Member_96bf9a9a-d2e4-48ab-81c4-c311b351af2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:to="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3a901c88-5ccc-4c0f-bafa-553b0a2f38a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b6a6a887-52c7-4f94-857d-8f9767ff4e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b6a6a887-52c7-4f94-857d-8f9767ff4e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2864967e-ab81-4346-9a9a-01e1e65043af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_60c16318-2939-4056-9fad-966b661d3e25" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2864967e-ab81-4346-9a9a-01e1e65043af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deee9caa-afe3-486d-b10c-bba11e4f17bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e6d387b-18ff-4d75-bd97-405020bd9222" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e6d387b-18ff-4d75-bd97-405020bd9222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c688bad5-987b-4607-99ae-b9a15a02a297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c688bad5-987b-4607-99ae-b9a15a02a297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc9df738-206e-4744-ac3a-22d2dcd7770d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dc9df738-206e-4744-ac3a-22d2dcd7770d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f60676ca-ca3f-4675-a8c6-21b44536dde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f60676ca-ca3f-4675-a8c6-21b44536dde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39fe492f-8c0b-43b4-8138-220c2d27ffd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_39fe492f-8c0b-43b4-8138-220c2d27ffd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_83cf8106-cd2d-4060-99fb-93fd6e68923f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_83cf8106-cd2d-4060-99fb-93fd6e68923f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3acfd42d-d194-4add-b8d1-05e0cd680c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3acfd42d-d194-4add-b8d1-05e0cd680c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_37e25110-5afd-4995-9406-90c47045ee75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_62ea45ac-fced-4901-bf9f-4aebc6938898" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_37e25110-5afd-4995-9406-90c47045ee75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93fb4764-91ae-480c-a6d5-8e0e6596916c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93fb4764-91ae-480c-a6d5-8e0e6596916c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc5178f9-6b5f-4f96-83a8-e74ef76edcb6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e33bda24-344b-41e4-9b51-6a4c2e976eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_e33bda24-344b-41e4-9b51-6a4c2e976eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_479a26b5-1844-4d57-84e5-bdddc77d5103" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_324c8b18-f72c-4448-9fb3-964c49d0e5f9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_479a26b5-1844-4d57-84e5-bdddc77d5103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_8be93538-97a9-4829-9dce-3f8501c495df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b183622-6a35-4761-a75b-6e26f417f34a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a0f28eab-8e40-42fa-802d-d4036e038d31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0b183622-6a35-4761-a75b-6e26f417f34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea46d533-d92e-4b07-a7b4-218d0fd11927" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ea46d533-d92e-4b07-a7b4-218d0fd11927" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:to="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9d00e4a5-3cd1-4544-b2cf-dac0a99aeb8a" xlink:to="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e7243134-3438-4b91-99d8-d1362c730bec" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:to="loc_srt_MinimumMember_e7243134-3438-4b91-99d8-d1362c730bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_17d34363-4177-44a7-b1fe-9ffa0a922222" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_204c6712-9a3d-4711-a6bb-6e7eb9409f71" xlink:to="loc_srt_MaximumMember_17d34363-4177-44a7-b1fe-9ffa0a922222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:to="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b4bb0f69-2391-4cf0-92a8-cfa0285ab16f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_9560c0c0-9cad-43f5-ae9e-afcb7a3d9eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10f5b1b5-9f4e-4280-9f60-35e84134e77e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_9560c0c0-9cad-43f5-ae9e-afcb7a3d9eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_a939ed3a-adb9-4fa2-ba05-6ff9e736007e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_015c0973-7c50-4bbd-bf7b-c2b683937a32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_015c0973-7c50-4bbd-bf7b-c2b683937a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b52727d4-bdd3-40b3-94b2-1f64701b893f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b52727d4-bdd3-40b3-94b2-1f64701b893f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d90d912-0e29-432d-a6c1-e50e2f616cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d90d912-0e29-432d-a6c1-e50e2f616cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dbb0bc13-d599-4520-9bf7-db3efbb848a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_dbb0bc13-d599-4520-9bf7-db3efbb848a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47df3cc4-7785-4a1b-aba0-5077448c8b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c7ad5671-b1f8-4073-8dd9-7936a1b0c00d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_47df3cc4-7785-4a1b-aba0-5077448c8b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationSummaryofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4b0383f-28be-47c4-ba72-72e373c630d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e4b0383f-28be-47c4-ba72-72e373c630d0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:to="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_09f567bd-f5fd-40f6-a213-5c7f0ea64f5e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28a4675f-d9e2-4520-8c36-f1e5ac8368a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_968b7e0f-2f76-45cb-98d2-2d798a8aef52" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28a4675f-d9e2-4520-8c36-f1e5ac8368a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7579457-efd3-4bdc-8541-47ea03353872" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ccec90e-b7ac-4143-ba2a-3fb407ae8b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ccec90e-b7ac-4143-ba2a-3fb407ae8b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b302e4c3-bf7d-4829-81eb-8250d054bc6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b302e4c3-bf7d-4829-81eb-8250d054bc6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f44052f-7fa4-4087-9612-5eee64a90990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7f44052f-7fa4-4087-9612-5eee64a90990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d46d5234-323a-4633-b11f-bb2555fd6b91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d46d5234-323a-4633-b11f-bb2555fd6b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_24df315a-da71-40d3-9400-c79256157c48" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_24df315a-da71-40d3-9400-c79256157c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1715cd6-1acc-4b5b-9ecd-f079bd902f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1f54db-0c08-4ee1-bb53-92c7a29ebdd6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f1715cd6-1acc-4b5b-9ecd-f079bd902f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7877b46d-5e27-4d23-a2e7-6ed57cd77c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7877b46d-5e27-4d23-a2e7-6ed57cd77c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a9df1243-efd5-4590-aa8a-0cbf4e802ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a9df1243-efd5-4590-aa8a-0cbf4e802ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37f31017-4de3-4fff-9eec-3e9a70b9c6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37f31017-4de3-4fff-9eec-3e9a70b9c6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8f11e4a6-61e7-4822-9087-9b99daa55ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8f11e4a6-61e7-4822-9087-9b99daa55ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_454bf878-ce53-448d-89fc-82013a5716ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_454bf878-ce53-448d-89fc-82013a5716ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ffe91d7-c9ba-497b-b741-c3ca31be408e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0ffe91d7-c9ba-497b-b741-c3ca31be408e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_4d18f725-1128-447f-9c85-dfa69ebfec5d" xlink:href="trov-20201231.xsd#trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_4d18f725-1128-447f-9c85-dfa69ebfec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_61209c04-a516-412e-87ad-2670b1998be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_b4ce71ee-15b7-4681-982e-cbbc372558eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_61209c04-a516-412e-87ad-2670b1998be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a05e1a7f-c654-4370-b35a-2e7f64b0ef08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a05e1a7f-c654-4370-b35a-2e7f64b0ef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_25623b32-b018-4220-a563-71cf69627c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_25623b32-b018-4220-a563-71cf69627c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26470187-1be6-4199-b8d7-4b8f67dfb9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26470187-1be6-4199-b8d7-4b8f67dfb9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4bccb71a-b369-42be-8d65-82ff3b4178ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4bccb71a-b369-42be-8d65-82ff3b4178ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6d3588b3-31f6-4dbc-83ca-02ca3acc3d49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6d3588b3-31f6-4dbc-83ca-02ca3acc3d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8cc847d3-91b9-4957-b351-d392856d85f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8cc847d3-91b9-4957-b351-d392856d85f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e380261a-ccfe-4843-bd8c-ec5a0d2ea226" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e380261a-ccfe-4843-bd8c-ec5a0d2ea226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a316dcbf-4438-4427-bd12-76c5c5f351fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a316dcbf-4438-4427-bd12-76c5c5f351fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6569be86-cbf8-4019-88c7-f7f10c042940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6ad6586-a888-4260-945d-4f9d1f76543b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6569be86-cbf8-4019-88c7-f7f10c042940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#StockBasedCompensationRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b103232-871a-4ebc-9070-a2aa8a307629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9b103232-871a-4ebc-9070-a2aa8a307629" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:to="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7cd357b0-0cda-4a77-a66c-62bbef0a6560" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4e3ada5b-04b9-4da2-aff8-d4d49f47c18e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6995c4a7-18d3-41f0-bbc6-17bcae303fb6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4e3ada5b-04b9-4da2-aff8-d4d49f47c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_20c43622-6ba3-4556-870a-038197639c52" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e5eb6744-bfe5-4921-819d-9e72d44dd1b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e5eb6744-bfe5-4921-819d-9e72d44dd1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_847e744a-5887-4dbe-9b2c-a22744e6de40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_847e744a-5887-4dbe-9b2c-a22744e6de40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a80f156e-db34-4827-af65-5351f6aad814" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a80f156e-db34-4827-af65-5351f6aad814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c5aa9193-573e-4d47-99d0-b94cb158f698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c5aa9193-573e-4d47-99d0-b94cb158f698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3eff8982-c75b-4b9b-b8d3-c219b599cf50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_ec65f171-5f89-49ba-9bfa-5fe56841a132" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3eff8982-c75b-4b9b-b8d3-c219b599cf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f7308f5-6ace-4d68-8c4e-aeae34009c83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0f7308f5-6ace-4d68-8c4e-aeae34009c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8301a065-7309-49b9-92e4-4de3d7968b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8301a065-7309-49b9-92e4-4de3d7968b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_46ce0ab5-64cd-4b39-9813-ce6130729544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_46ce0ab5-64cd-4b39-9813-ce6130729544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dfba400d-fd62-4eb7-b059-acbaf6793d9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_dfba400d-fd62-4eb7-b059-acbaf6793d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7eef2c1-6ae8-4f76-9844-6a4c6fc50413" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_891328e3-2063-4ca8-8c17-6967f87bfb2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7eef2c1-6ae8-4f76-9844-6a4c6fc50413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_3f566762-49ae-49ed-9a49-2194cebc540d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6187be46-bef3-42ce-b02e-961cf9105aa2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_3f566762-49ae-49ed-9a49-2194cebc540d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_73ef62f4-1719-4778-9829-4f7520fb25ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_fdbe4753-a97e-4068-8e69-ffdb3a5339e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_73ef62f4-1719-4778-9829-4f7520fb25ac" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_fdbe4753-a97e-4068-8e69-ffdb3a5339e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_01c0e284-0b08-4eca-ae18-c8755e686ce1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_01c0e284-0b08-4eca-ae18-c8755e686ce1" xlink:to="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_7dc73ea5-a26a-4a66-9ac1-225c826a14a5" xlink:to="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_eaa80835-0b53-4fef-9f62-502acc8fe4ed" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_49f34992-0342-4483-9f5d-c18380ea3ee9" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_eaa80835-0b53-4fef-9f62-502acc8fe4ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_cb4a97b6-8ca8-4ce1-930a-a781abcae75c" xlink:to="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a9ca3683-cd89-4635-8b35-9b298ffa0569" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a9ca3683-cd89-4635-8b35-9b298ffa0569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_72200cbb-5494-4172-9e99-8f0cf646b991" xlink:href="trov-20201231.xsd#trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ef8338bd-d99b-47a4-a6c7-6d6d29247486" xlink:to="loc_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_72200cbb-5494-4172-9e99-8f0cf646b991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e0835ac7-3bae-4db7-8fd2-e82593b6e88a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e0835ac7-3bae-4db7-8fd2-e82593b6e88a" xlink:to="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6b9dfc19-45ee-4637-aabf-40f7fc93d376" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1543d0b1-f129-431f-85c8-ba882a5cac43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1543d0b1-f129-431f-85c8-ba882a5cac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_28f09244-b65c-430d-ac4d-5a9df0a726ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_28f09244-b65c-430d-ac4d-5a9df0a726ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_6922ef60-23c3-400b-b7aa-7fb5dfaa1496" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_6922ef60-23c3-400b-b7aa-7fb5dfaa1496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9fbec5f-6030-4be6-9e9f-b5e09b49a5dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_26076d73-f046-4aee-8df5-f0d58ecfeebc" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_b9fbec5f-6030-4be6-9e9f-b5e09b49a5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cfe790a6-12e0-4dcd-9119-b3d7918ed96e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_04c343f1-4b7e-4922-b00b-e94f2a32c584" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_eb0e7740-ad33-4c27-8388-7df6972390cd" xlink:to="loc_us-gaap_WarrantMember_04c343f1-4b7e-4922-b00b-e94f2a32c584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_bbf260c7-1c12-4393-ab92-bbbb2dfb7cb7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_BlackScholesOptionPricingMethodMember_f36f99a3-9178-481e-9391-03c864551789" xlink:href="trov-20201231.xsd#trov_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_51776870-8f2a-4747-877f-67ef7c37b077" xlink:to="loc_trov_BlackScholesOptionPricingMethodMember_f36f99a3-9178-481e-9391-03c864551789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_52ee06fb-2c8a-43ff-a02a-a8f96cadbdd1" xlink:to="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2741ce83-a08d-43d7-9c28-3aa8884b1154" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_MinimumMember_2741ce83-a08d-43d7-9c28-3aa8884b1154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3b3c1c99-c51b-4dc5-a598-39df4e4916d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_MaximumMember_3b3c1c99-c51b-4dc5-a598-39df4e4916d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2b394764-381c-4ade-809f-0787f030e8fe" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_9f8b00f6-3776-4da4-b40e-b47f1f3404c0" xlink:to="loc_srt_WeightedAverageMember_2b394764-381c-4ade-809f-0787f030e8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_fd7bcd14-d581-41be-9019-b60f6a561d65" xlink:to="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EstimatedFairValueOfWarrant_c99c7215-aaf7-4685-96eb-0204791a99e4" xlink:href="trov-20201231.xsd#trov_EstimatedFairValueOfWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_trov_EstimatedFairValueOfWarrant_c99c7215-aaf7-4685-96eb-0204791a99e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_33a8737f-f964-4446-bdde-be13852ef321" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_33a8737f-f964-4446-bdde-be13852ef321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18791ebd-b904-4698-9e50-3fa1a926412c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_cc770b8a-aad1-4266-8237-42441fde16e5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18791ebd-b904-4698-9e50-3fa1a926412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:href="trov-20201231.xsd#trov_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3d9815e1-4620-4312-9f41-750a098c224c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3d9815e1-4620-4312-9f41-750a098c224c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71801ba6-1c3d-4967-b504-6c0287b488c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_71801ba6-1c3d-4967-b504-6c0287b488c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_efdd9159-7437-4d76-afbd-7bf23e5e24ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_efdd9159-7437-4d76-afbd-7bf23e5e24ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_d03cec9d-ec11-4948-8a5e-0f61522fdc67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_d03cec9d-ec11-4948-8a5e-0f61522fdc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e4731ca5-7080-44e1-b55b-df96bb3d2817" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_trov_DerivativeFinancialInstrumentsLiabilityRollForward_171cc7d0-ffc9-41ae-8609-b11a4d64602f" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_e4731ca5-7080-44e1-b55b-df96bb3d2817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_a6ab4d53-d0df-4b71-b38b-70a5a9b47df6" xlink:href="trov-20201231.xsd#trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_a114659e-0d05-4232-b786-59d2f6bfc3ac" xlink:to="loc_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm_a6ab4d53-d0df-4b71-b38b-70a5a9b47df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d6cb16ce-6958-4662-808a-b0794ea14552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_54f41135-d020-4551-b874-a3cb0aa8a968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d6cb16ce-6958-4662-808a-b0794ea14552" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_54f41135-d020-4551-b874-a3cb0aa8a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0bd52f95-afee-4d4c-8077-f7e31463e355" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f8e3b66f-741d-4abf-9f32-91051060a6d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0bd52f95-afee-4d4c-8077-f7e31463e355" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_f8e3b66f-741d-4abf-9f32-91051060a6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_33fd333b-581b-4556-ba7b-e1e7e0ebc5c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_33fd333b-581b-4556-ba7b-e1e7e0ebc5c1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_294f992f-7cc0-48ae-bdfe-f3df5516d246" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f188cfa3-1fd4-4607-81e8-97a4d9b65a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b2533a6d-724d-4e95-a262-aeb77e33108f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f188cfa3-1fd4-4607-81e8-97a4d9b65a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_eaaac25e-af04-41f9-bbe6-1b2b805820d5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_28078708-d63b-4feb-9878-2bb60b033306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_28078708-d63b-4feb-9878-2bb60b033306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_124e23f0-7c3e-4b0f-96ea-86b8fc94ba01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_124e23f0-7c3e-4b0f-96ea-86b8fc94ba01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5fdd52b3-1b5d-4071-b2da-4efe51409553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c46864d3-462c-486d-9e6a-8f4bb5d6f58f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5fdd52b3-1b5d-4071-b2da-4efe51409553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_6a519621-a957-4d86-a2ab-a5fe27fd3d60" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_842d35a4-c590-45ad-8434-6d8beae0a106" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d325820f-8aa0-4d91-bfb9-516b37ac9fdf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_2005d0b0-c9e7-429f-b463-fefabd6ddcd8" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d325820f-8aa0-4d91-bfb9-516b37ac9fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7686bb41-a8ce-4ce1-b776-91d9e67d6c8b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_003d80ba-28a0-4c61-bf55-0700779fd017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_003d80ba-28a0-4c61-bf55-0700779fd017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c3aa762f-02c0-4711-aa7c-7ce4e0f30276" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cb0b3bfe-139f-4b7a-b2cf-99eab7d977e6" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c3aa762f-02c0-4711-aa7c-7ce4e0f30276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_03220e85-4a29-4189-872f-959b84c810f5" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_195aded2-ee05-494c-af2d-caf4cda19ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_195aded2-ee05-494c-af2d-caf4cda19ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_b147c0aa-bacf-48cc-8667-b4da3f7d485c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5a1f76e9-d12f-4679-8bcf-c4427a05f354" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_b147c0aa-bacf-48cc-8667-b4da3f7d485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_916b32c2-0eb0-4fa5-8938-a9f227a2c268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_808bd815-4356-41b9-aab5-d780e187dcfa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_916b32c2-0eb0-4fa5-8938-a9f227a2c268" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_808bd815-4356-41b9-aab5-d780e187dcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd426a3-11d7-46f6-bad9-17d30edf7a7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_12842956-1598-4480-b2f0-9446d1fc8876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd426a3-11d7-46f6-bad9-17d30edf7a7f" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_12842956-1598-4480-b2f0-9446d1fc8876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_88c269f8-7c59-47fd-a7d7-eeb653539b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd426a3-11d7-46f6-bad9-17d30edf7a7f" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_88c269f8-7c59-47fd-a7d7-eeb653539b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7e7d203a-cbd1-4867-9919-1fbdffdb6451" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1dd426a3-11d7-46f6-bad9-17d30edf7a7f" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_7e7d203a-cbd1-4867-9919-1fbdffdb6451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e23c6af7-648b-48d9-9525-58fee205d970" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e23c6af7-648b-48d9-9525-58fee205d970" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_57d1ca07-8c00-4cbf-9529-f736184291f4" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_be84f7c7-26c3-4dde-ad82-93fa7be68e31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_be84f7c7-26c3-4dde-ad82-93fa7be68e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_24d6ef49-4b84-42fd-bb5b-931d8dfb100e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_709b65b1-4006-4940-9f2e-a3e776835c1a" xlink:to="loc_us-gaap_ResearchMember_24d6ef49-4b84-42fd-bb5b-931d8dfb100e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5c4a0d64-fd95-46d9-b7fd-74a3869cab98" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_a3e589c2-6bf8-4036-a804-0159aef937cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_a3e589c2-6bf8-4036-a804-0159aef937cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71cecbfb-f1f5-4c8c-9198-09a3f584208c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f762a586-f9e4-4966-a95f-684bcd0cba85" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_71cecbfb-f1f5-4c8c-9198-09a3f584208c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_6493afdf-4f60-4c85-a75e-ac6cb8c6d30a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsSubjectToExpiration_84f514c7-c1a5-41fd-943f-2387bd1ece18" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_trov_OperatingLossCarryforwardsSubjectToExpiration_84f514c7-c1a5-41fd-943f-2387bd1ece18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration_1d704349-55ab-42eb-85c9-7340f7213960" xlink:href="trov-20201231.xsd#trov_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_trov_OperatingLossCarryforwardsNotSubjectToExpiration_1d704349-55ab-42eb-85c9-7340f7213960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_89494938-5d3b-4f20-a416-89bd72bb49e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_89494938-5d3b-4f20-a416-89bd72bb49e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_c03cff9e-6600-4429-993e-69ecc7b11ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_c03cff9e-6600-4429-993e-69ecc7b11ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_d9213963-88e9-4524-b879-a476da3f5f30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_611752ba-e303-4eac-8eab-3526917d4c8b" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_d9213963-88e9-4524-b879-a476da3f5f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_88d4f7a4-c84c-4d0c-91f3-8e49ee6b784b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAbstract_aa8b6c84-c56d-4b04-a71c-9f7154f98643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d4f7a4-c84c-4d0c-91f3-8e49ee6b784b" xlink:to="loc_us-gaap_TaxesPayableCurrentAbstract_aa8b6c84-c56d-4b04-a71c-9f7154f98643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b92bd0c9-3b33-4111-b982-d81641a11c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract_aa8b6c84-c56d-4b04-a71c-9f7154f98643" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b92bd0c9-3b33-4111-b982-d81641a11c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_838cfaaa-d995-4a9a-ac3b-e3f67b2b237a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract_aa8b6c84-c56d-4b04-a71c-9f7154f98643" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_838cfaaa-d995-4a9a-ac3b-e3f67b2b237a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_cd1e0e6d-20d1-4430-b77b-98f7c5233fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d4f7a4-c84c-4d0c-91f3-8e49ee6b784b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_cd1e0e6d-20d1-4430-b77b-98f7c5233fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_065f0fc5-d492-4bf4-8742-db13f0c682ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_cd1e0e6d-20d1-4430-b77b-98f7c5233fa9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_065f0fc5-d492-4bf4-8742-db13f0c682ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1b69c14c-adac-44cb-ab4f-a89ffe5cb2cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_cd1e0e6d-20d1-4430-b77b-98f7c5233fa9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1b69c14c-adac-44cb-ab4f-a89ffe5cb2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_582c8f24-bb8d-469e-b058-cffbcea68115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_cd1e0e6d-20d1-4430-b77b-98f7c5233fa9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_582c8f24-bb8d-469e-b058-cffbcea68115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_ValuationAllowance_0724437a-7046-409a-8237-4ee9d30f29a8" xlink:href="trov-20201231.xsd#trov_ValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d4f7a4-c84c-4d0c-91f3-8e49ee6b784b" xlink:to="loc_trov_ValuationAllowance_0724437a-7046-409a-8237-4ee9d30f29a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b9bf8652-8a49-4371-8c50-13eabaa1dded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_88d4f7a4-c84c-4d0c-91f3-8e49ee6b784b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b9bf8652-8a49-4371-8c50-13eabaa1dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_401f217e-8954-4dcb-981a-b9348018c338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_401f217e-8954-4dcb-981a-b9348018c338" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fa2cf6bc-6c8e-45d0-ba96-ca7a0e21d9de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_fa2cf6bc-6c8e-45d0-ba96-ca7a0e21d9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_52be91af-77c7-45d5-ac9a-dcb58d946d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_52be91af-77c7-45d5-ac9a-dcb58d946d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_IncomeTaxReconciliationPermanentItems_e4a6efbd-b6f0-4efb-a1d6-3abf3385653d" xlink:href="trov-20201231.xsd#trov_IncomeTaxReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_trov_IncomeTaxReconciliationPermanentItems_e4a6efbd-b6f0-4efb-a1d6-3abf3385653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea7be128-b743-4ec9-97dd-65eb3c3cedef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_ea7be128-b743-4ec9-97dd-65eb3c3cedef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_3907f279-ef8e-42d1-8bea-1ca72d8c3602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_3907f279-ef8e-42d1-8bea-1ca72d8c3602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_052075ec-1879-48a7-bb8f-980eeb12ad1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_052075ec-1879-48a7-bb8f-980eeb12ad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a16e0f58-164d-4565-813f-0ecbc257ba90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_a393a1fa-30c4-4bdc-9fa8-da083ffa3ebf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a16e0f58-164d-4565-813f-0ecbc257ba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_401f217e-8954-4dcb-981a-b9348018c338" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ad5b2f60-44c5-492f-8501-1d6a183352e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ad5b2f60-44c5-492f-8501-1d6a183352e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5ad44bf0-f094-439a-b98c-745a489e32ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5ad44bf0-f094-439a-b98c-745a489e32ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_d5c943d9-ab90-4b8f-a10d-155fe7608d3d" xlink:href="trov-20201231.xsd#trov_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_trov_EffectiveIncomeTaxRateReconciliationPermanentItems_d5c943d9-ab90-4b8f-a10d-155fe7608d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_af7f013a-a207-4816-b7c2-6194a58ce47a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_af7f013a-a207-4816-b7c2-6194a58ce47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_144b0e2b-d605-4260-b04b-ca53ef022d52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_144b0e2b-d605-4260-b04b-ca53ef022d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_539613f9-e574-4a45-82a3-81d4963cec94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_539613f9-e574-4a45-82a3-81d4963cec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1c10409-216b-43e6-b3d6-315221ff539e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_166a7760-05b6-463a-a413-3a5e1d77266b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1c10409-216b-43e6-b3d6-315221ff539e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ace9d8f5-a9fc-42f2-985a-2154b5ee3979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ace9d8f5-a9fc-42f2-985a-2154b5ee3979" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:to="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ae3ccbfb-b09c-4645-9f49-d9d6c89da3f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ae3ccbfb-b09c-4645-9f49-d9d6c89da3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_05e7e461-e09a-4ec2-8cb6-fd5318b5e518" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:to="loc_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_05e7e461-e09a-4ec2-8cb6-fd5318b5e518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ce70db-9585-424b-bd9a-5837e2034543" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ce70db-9585-424b-bd9a-5837e2034543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_db039592-42a5-4820-8bc7-8a916120e6e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_db039592-42a5-4820-8bc7-8a916120e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2457c043-818f-4900-96bb-0756c3d7991d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract_26432c2a-f130-49a9-864d-d95c590a6cc2" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2457c043-818f-4900-96bb-0756c3d7991d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b3fd8736-d385-4f16-ab1e-3b494641cbee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b3fd8736-d385-4f16-ab1e-3b494641cbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_688fb528-5a92-40fb-966f-48499bd0a253" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b3fd8736-d385-4f16-ab1e-3b494641cbee" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_688fb528-5a92-40fb-966f-48499bd0a253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_56d3c633-4977-43b8-b51e-2d2a6655ae3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b3fd8736-d385-4f16-ab1e-3b494641cbee" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_56d3c633-4977-43b8-b51e-2d2a6655ae3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_65bf353a-56f8-442e-84f7-18058dee8de5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b3fd8736-d385-4f16-ab1e-3b494641cbee" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_65bf353a-56f8-442e-84f7-18058dee8de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_377fe1a8-e8f7-4b26-bc27-347fa5f7a599" xlink:href="trov-20201231.xsd#trov_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:to="loc_trov_DeferredTaxAssetsNetBeforeValuationAllowance_377fe1a8-e8f7-4b26-bc27-347fa5f7a599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_73313568-896b-49e4-af8d-b3a7e9901a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_73313568-896b-49e4-af8d-b3a7e9901a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_51556026-69c6-460b-b324-1df6ef1a0a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_4d64ec12-f6a9-4cf8-98d2-c53b2e7fda9c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_51556026-69c6-460b-b324-1df6ef1a0a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d931dad-7f26-4b4a-861c-0aae85e8801d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_86a4ebdc-f09e-4829-9fc7-7e834cfc0ade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7d931dad-7f26-4b4a-861c-0aae85e8801d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_86a4ebdc-f09e-4829-9fc7-7e834cfc0ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87a89216-203b-4e75-ada1-2db6358cd575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_87a89216-203b-4e75-ada1-2db6358cd575" xlink:to="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:to="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_46d39ecb-f92b-479a-b058-b09aefe5d8d6" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_15223e9a-1f1b-48df-b643-a2cc68696be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9d96199f-7f79-40ff-b22b-8333aa08f1b8" xlink:to="loc_us-gaap_LicensingAgreementsMember_15223e9a-1f1b-48df-b643-a2cc68696be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:to="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a370193f-5879-497c-9c8e-31c8348d07c4" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_NorvianoMember_3b4019c4-71bc-4f3f-a3c6-bb7f5a48316e" xlink:href="trov-20201231.xsd#trov_NorvianoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_feeb5138-abc9-4504-928c-ff68936659c4" xlink:to="loc_trov_NorvianoMember_3b4019c4-71bc-4f3f-a3c6-bb7f5a48316e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a550f665-0ef7-4bb0-8123-44505f81a129" xlink:to="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2bc7087-1066-449c-9fa9-42773e97cc9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2bc7087-1066-449c-9fa9-42773e97cc9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_5617db84-3617-425c-a138-358d2ea9715e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_141c8edc-21e7-4825-8fe3-da9b9e69a15a" xlink:to="loc_us-gaap_OtherCommitment_5617db84-3617-425c-a138-358d2ea9715e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="trov-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_86041c8a-0953-4dc0-bc99-fd7d8352d826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7ab23a28-17a0-4817-a655-b42f14457879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_86041c8a-0953-4dc0-bc99-fd7d8352d826" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_7ab23a28-17a0-4817-a655-b42f14457879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_62a8a163-aa9f-47e3-b0a7-87df8e7e9c4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_809296e0-578f-45ff-b18d-9082ddb40dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_62a8a163-aa9f-47e3-b0a7-87df8e7e9c4b" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_809296e0-578f-45ff-b18d-9082ddb40dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="trov-20201231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e4093b5d-e4e6-4fd8-8716-ee68e4034860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e4093b5d-e4e6-4fd8-8716-ee68e4034860" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9917758-64e2-4f14-8284-fa73184d0193" xlink:to="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAffiliatesMember_f41f6a5f-e0a5-4988-956e-e9d285295e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAffiliatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:to="loc_us-gaap_OtherAffiliatesMember_f41f6a5f-e0a5-4988-956e-e9d285295e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_973bf695-d210-420d-8321-c0721f614657" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7aebc677-b536-4d5e-a3c8-ab22a116f86f" xlink:to="loc_srt_DirectorMember_973bf695-d210-420d-8321-c0721f614657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f4f23668-5a26-476d-9f6d-956584cbb3e0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8b6867e6-3dd6-4b26-9d1b-1650c8ad7f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8b6867e6-3dd6-4b26-9d1b-1650c8ad7f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9d0b082d-c4d1-42d8-b4b8-78e91e251e44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9d0b082d-c4d1-42d8-b4b8-78e91e251e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_5cc58438-2858-42e9-9ea2-24bb848b70ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_5cc58438-2858-42e9-9ea2-24bb848b70ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2c037af5-6648-4b48-a61a-e95772772a22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_07a29bd4-24b0-4bb5-a3ab-4c34720c9a5e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2c037af5-6648-4b48-a61a-e95772772a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/COVID19" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_b758b0ef-566e-4d85-979c-d00f40bd2066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_cfcd2fe1-196b-493e-bd0f-1433cb1b854f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_b758b0ef-566e-4d85-979c-d00f40bd2066" xlink:to="loc_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock_cfcd2fe1-196b-493e-bd0f-1433cb1b854f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.trovagene.com/role/COVID19Details" xlink:type="simple" xlink:href="trov-20201231.xsd#COVID19Details"/>
  <link:presentationLink xlink:role="http://www.trovagene.com/role/COVID19Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_cd203daa-6e74-4d24-a8de-92c63a2e8ff4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtraordinaryAndUnusualItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtraordinaryAndUnusualItemsAbstract_cd203daa-6e74-4d24-a8de-92c63a2e8ff4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f4fdd47-af88-4eb5-b6b9-f44e224eece2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_trov_PaycheckProtectionProgramCARESActMember_2b6439e5-076b-460c-8cb3-b4e00fed3d37" xlink:href="trov-20201231.xsd#trov_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e1fa6d27-d4a8-4ad6-bdfd-426dc7e3487f" xlink:to="loc_trov_PaycheckProtectionProgramCARESActMember_2b6439e5-076b-460c-8cb3-b4e00fed3d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemTable_d5e9884e-cb6c-4f7f-9182-7171408ba20e" xlink:to="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_acacf1fe-1e5f-44ce-8429-cf462857bd19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:to="loc_us-gaap_NotesPayable_acacf1fe-1e5f-44ce-8429-cf462857bd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c5bebc6-a2ac-45d6-9b22-6aabdf87cf00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemLineItems_599ff8b4-a48e-49f1-b2a9-9e798f7e0c3c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8c5bebc6-a2ac-45d6-9b22-6aabdf87cf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>trov-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:trov="http://www.trovagene.com/20201231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="trov-20201231.xsd" xlink:type="simple"/>
    <context id="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1213689b20964f7fbaa4756853223720_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8031ad7778c04e03886ac0ae3c6c9cbf_I20210218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="i076def4a10c84321bb8feceb11551055_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1033093be1a94f1586671f93e4cc0292_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i974c8d2976844fc9bd37ad841b476746_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9f64d58d38fe4c52a90346b804d8222a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8dfeebbffde848a39dd21015892f17ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if31167c9f6df4b2e98fed3a3ab5827c9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i90cbda9b433948c4bfec12adb85eece5_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i283c7589044745a697aba89af3b8c955_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id1fd37d65d4a45768c5f933a4c55cf0f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i03f11be824704ccaaa3be62c269b68d3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i489cb20610fb450193a4a09194d885a8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6e8da706562440a48c86522c944d0df6_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie1533dc281f3416c87c9cc063e238300_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e843a6b44054990807074b9f697e695_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45d5e02556184c789e5d3265173db41e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifb0dc0c25b98439290e7f74e7dbe5c33_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i45ab9019c9754577b27a546943f63815_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c0726d301e947e5a55d7dfb699e13f1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id024008e76784d04a81dc04cad256492_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b60188329974ccba428036634f386c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i775f6829cd0442b4abd291c9e9c043f2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7848a306518c4d3c8d2ceace32f45c19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iede24d64c8eb47a38bf93edc43a4580d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01b536880233430693517dce3f18592b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08acffb99e614dc58b610354b475758f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0556eb8a6c2a44c2be25fabc0712fbd4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0656cf347232476bae791a60c6bd570f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1105733d073744cd9a3e52b232486c1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1514b777a3114342923aade0d19fa7c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64c8a7607231401e81a5f9c31f0790fd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic8aaa0c125e84dba929af4a1e45d11b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4f241b55b904f8e929edc9f63cfb4ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb66c3828dd94b5e81231528bde5fed7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia954f550392d4591a6b546fb05b6c57d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba7031dc6fd14ef19e26c971fe76416a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if7aa2f04b48e40b6bb9e10276579135f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04cf8ba00be248f88818392f53a19b98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id9ad1a7639b14aabab7b8f0710ecdb7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4c13518b4c74daca4beaea86298f527_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6436bbbd26f24becadccf4b1d782084d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i975673dd341547dabdaf95c95b6524fb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib040744e101141f9aea1e9d4756978f4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic35f2ef7d35840b9bfab3082034c4696_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">trov:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iddb22003c74244c696720a265e0f7c37_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if08e7553905d4d068f485877b9048505_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2b16d8ca860f495a9615c84058672eac_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i73a4197db9564a4db2a4ad3445548a58_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92fe3d8ede834ee9b4dfe1e82c7e0271_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id7f65a990a66462c9a37eb46069c65f5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i421f1d41857b4805963135b3663ab8d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icd98c4fc531042d897b1d757e7b223e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6f48dc38e8b943eb97849002ada03817_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3451a9182b0d4178a8fc3c09f942e860_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11d1170ef6f54edc88cd4268fb361f16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i256c4368010c4206a56da927baa4bb4e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i776cee27efa541a2acc891f09e09f352_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id456584ebb174aeabb2b1a0753b4e83e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i471d5f109548413d9e884f49a86cd7e3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0d0b2dbac0ba4dff9255fe336b8f7f15_D20050701-20050930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-07-01</startDate>
            <endDate>2005-09-30</endDate>
        </period>
    </context>
    <context id="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-03-17</startDate>
            <endDate>2006-03-17</endDate>
        </period>
    </context>
    <context id="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="ie42a61e34be3441d8bb072f33438bcea_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="if8a1c4888a02426788234b406ae96f2e_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="iaee37ec60282489987c4762ccebbab95_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="i2f5153c4279f4ab9989ac4ac9a3a516d_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="ia02b699fc73a48aa943cf6fb99f91912_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i231a9537948e4825940975cf85f361b7_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="id008b8758bbe4bd891a3f82bf9a4b6a6_I20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2019-01-25</instant>
        </period>
    </context>
    <context id="iba125ce9af574f5f8548ad377e3f93e9_D20190125-20190125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-25</startDate>
            <endDate>2019-01-25</endDate>
        </period>
    </context>
    <context id="iccf104fb4e174434837dcfd628d05782_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i076c4c3a873c4a759be050208a345aa5_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i2d3f12d14ad342198f5284373cca8a23_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="i1ce3c54cec224ad18a266a3636ffa8b2_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="icdfaba1492ec4f509a70416341174b1f_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5a917753e1624c298122e4b830a4e135_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i18b02bac98214f3d9f8953ec814372be_I20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-08</instant>
        </period>
    </context>
    <context id="i52c1c34006664ee7ac7c7c4e9e79e509_D20200508-20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">trov:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="i0668fc29bb0148d58510684753bd2cfc_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">trov:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i9b284544740a435bad1c3cec495cbf9f_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i27074d7d656d4fbf85a8b9980795b54a_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="ifdfc040695af4d6a9817380661ebcf2e_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="ib6b57d40d4354884b0510a8fef627c3d_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i95bc585cf217481b97c06b8337a64fe3_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">trov:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="ibfb24decc5bd454e83658b10c3fc8307_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesIWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="i896119a0fd374e00971913227a456947_I20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesJWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-30</instant>
        </period>
    </context>
    <context id="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesJWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="i8be9212423e34a67a70f23c6f9b5ddf4_I20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesKWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="i81d26bfbbbd5422086f3c9920448c373_I20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesLWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesLWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-09</startDate>
            <endDate>2020-04-09</endDate>
        </period>
    </context>
    <context id="i3b38eb10663b489e9809321fc0276e7c_D20200511-20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-11</endDate>
        </period>
    </context>
    <context id="i0f6a9b93851e4335a8b8cb89237848bc_I20200511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-05-11</instant>
        </period>
    </context>
    <context id="i56c03a47441c4536b67faa8e4cf731b7_D20200514-20200514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-14</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="ibf127176380c423fa60e0abdd61fd762_I20200514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-05-14</instant>
        </period>
    </context>
    <context id="i2e071b9425b74972bb38758dd9e5d35d_D20200511-20200514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-11</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesMWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">trov:SeriesMWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-10-02</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i544a15f619624305a7fd2f23ac7f07e8_I20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-10-02</instant>
        </period>
    </context>
    <context id="i201a9eb09e9e4e4d976772527902f4c8_D20201002-20201002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-02</startDate>
            <endDate>2020-10-02</endDate>
        </period>
    </context>
    <context id="i26ddee99771547b8a737dfc7a950fa46_I20140917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-09-17</instant>
        </period>
    </context>
    <context id="i091e321edee343b38a892516ab3dfeee_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i86676dbd4e74419a825725ca27223263_I20190606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-06</instant>
        </period>
    </context>
    <context id="ideda534790df48cc8af65a740c9c751e_I20200406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-06</instant>
        </period>
    </context>
    <context id="ieac8de1ad73340dabca4d672d5539b0c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">trov:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5389a4fe9a914abba2617db418a0173f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bd6a7a4e022447ca67831dd187fe59e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9460ddaf54074df7bfec5889e2b4845d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia4aec0ea85e845048d3ce2ddb7213732_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i282b0d837b364a6894a32526001160d0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if99ea3b979294094999f121f98b5bde6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibeeb551ace7d42168313ad655821639d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4fd318c67b6c46e1981c21a7ac58d178_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d3e6472816445c1a3ca937b4efafb70_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie72aca79d4804a8284025a9bab28eb5e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i978ad2c8eb824931bb5e88b64023d145_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ica41068d79e14cf38ab901aaf00addb4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i229ba083ae0546d499ab31088af51e73_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i32ab39cf4fc841beb603ef348cdce603_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4d8190644bee425ea8f517bd7095ed17_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1742e003e63146e896137b7e99fc50bf_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i018bdbce7fca40e082dacb672d84b913_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i44266fc1522f4f4eb8386f8c708948d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id3fca2ac35d14a2384fef909655332d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic0b1c58ab8b54dfc863c667221a34301_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie85416ca7f414db49fe52bc843a8e2d4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3794493459f24ebfbe863d8937e8cad5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fb8cbc4edb14870b358d288e5800248_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d3620e40923403582678ccccc8f11fa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib4f8972453604ec193d1df9f7e4ddac0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2cc7198d6c034a22b424dd61cae5fd7c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1106ab4e606c4769a8f986403de38037_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id76a88eeb56a477fa5ae7aa8b08acf1d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd3060e53a504b04a348d4ba80c3b484_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfe962c2ee074fbe9e3a0a8ee9b2fc05_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i090a771b6a4c49029aca107400020091_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73ffea244a27445a8d5f0970bdc9898e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i031d703e2ea24364b5f7af43c8fb47c0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5ac205ca24f94fe293ef86874c82e1e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ice81c716c97c41b5bc001dfa532b8fdb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3345cb0517cc4b0284c813555e82d7d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b746e4199184cacad6f602a3b40b8e9_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i747d6a62e34a472c83d5644420b34a22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i984ff34a2fe742088f9f828b91b563ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">trov:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iffe390a53d1244859cc856f61f4542ae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ice44ef262276432684d43f12b496e84d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9cdcc0804110481f8528b0ba7253bd83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5e1bf59004804ff0a735f759a0b05ec6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if6111128fd05424493681c4a0b3eb66d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57e9a24fb323452cbc514841b9fbe098_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if2cad480a48a41da8b00597bbd01b912_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idbc8e0a3804c47c4ae77c14738fc2399_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iedf02bb4675b4a2d940c16f6f69cb7c4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9b865da6863477b8c4c5144516016d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id661a46404df44e0b0e9dbdd6e3e8364_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29a27f9e1adc4f6dacd046a2f6a03585_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac1d9ffb9c364277ad0f0ae113dd82f7_D20170301-20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">trov:NorvianoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="i9f2ba9a7769e4c3981f5515bac81bee0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">trov:NorvianoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i014c4430e11a4a7ba478369860aa6b07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94d1eafc280542e8a75a72c3e54779ac_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OtherAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="id9ba25d98442435ab13367e9dd32ebd2_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i7103d5be24a4480abffa7afe4b21824f_I20200415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">trov:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-15</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>trov:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl80LTEtMS0xLTA_0176921b-48b7-40c0-97cc-bce08ba7c664">0001213037</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl85LTEtMS0xLTA_515f2481-56a9-4715-95ad-736999a11eb1">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl8xMC0xLTEtMS0w_5e719e23-56b9-47ca-9e41-dd465d0ac350">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF80L2ZyYWc6NGJiZjk2MzZhOTllNDAwYTg1NzRiZDY3YmI1OWU1OTgvdGFibGU6OGJmYmZmM2Q5ZWFmNDc1YTg3NzdmYzYwODRmMjRkZTIvdGFibGVyYW5nZTo4YmZiZmYzZDllYWY0NzVhODc3N2ZjNjA4NGYyNGRlMl8xMS0xLTEtMS0w_ab5cfa64-b54c-4d91-9013-fe8efc7b70ab">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i64c8a7607231401e81a5f9c31f0790fd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentType
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjA3_dc307505-b7ab-4a32-8866-0a55015628cc">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NTYyZGYyNDI2NjNhNGNiNTk5MTZkMzdiNDAwZDkxYjIvdGFibGVyYW5nZTo1NjJkZjI0MjY2M2E0Y2I1OTkxNmQzN2I0MDBkOTFiMl8wLTAtMS0xLTQwMzM_ed5ecc43-7b22-4707-a9df-1a0acddb3853">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjY0_73869461-e93d-4085-b9c6-b34fc24b2fa6">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjY0_764fa1f3-3e13-4764-a342-459e218908a0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6OWIyZmEzOGFiZjBmNDQyMmI3OTNhNDZlMzliNzMyZWQvdGFibGVyYW5nZTo5YjJmYTM4YWJmMGY0NDIyYjc5M2E0NmUzOWI3MzJlZF8wLTAtMS0xLTQwMzY_c2d0b682-e073-4456-81a5-a9c73e041d6f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjA4_a5d76c63-9488-4f73-ad8c-5c2616230377">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjEx_2687050c-f0ed-4c2f-a94b-476822e30790">CARDIFF ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8wLTAtMS0xLTQwNTQ_47fb88ca-9efe-4c31-82f7-d46070902012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8wLTItMS0xLTQwNTY_550e6344-e4f6-40fb-a516-848ea8a7c635">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODQ3_cc0f8ca1-ff2c-4c59-b559-7d04a05dd678">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODU5_e14e1d25-b902-4e5d-a318-a618c18c9254">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTAtMS0xLTQxMDkvdGV4dHJlZ2lvbjo5NWE2ODhlYTlhM2U0MDdlYmIxNTE3YWFmYzZkOWY0Zl8xMDk5NTExNjI3ODcy_b5b9fee8-549c-4243-abaa-9abb1f0acc12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF8yLTItMS0xLTQwNTg_8a617306-1100-4f37-a9f0-5ca24da51f4b">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF80LTAtMS0xLTQxMTIvdGV4dHJlZ2lvbjoyN2U0YzlkYzYzNjM0NTczOWUwODk5NTVhNjMzMGZlYV8xMDk5NTExNjI3Nzk3_2a49c72d-034f-4df9-a047-5d393f34ece8">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF80LTAtMS0xLTQxMTIvdGV4dHJlZ2lvbjoyN2U0YzlkYzYzNjM0NTczOWUwODk5NTVhNjMzMGZlYV8xMDk5NTExNjI3ODA4_611ab1bb-0160-4cd7-9f03-ecac822baaf2">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6ZjU5NjQwMzZhNGZjNDJjMWFjNGJmYmY2Nzc0MzZlNzgvdGFibGVyYW5nZTpmNTk2NDAzNmE0ZmM0MmMxYWM0YmZiZjY3NzQzNmU3OF84LTAtMS0xLTQwNjA_60262024-f7a6-4aac-9bf7-408b79f4be7f">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM2_f9e1e491-bee5-469f-a6ef-4905c1224aab">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM3_4048ed76-f1e9-4b69-86c5-c6a357670d8e">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM4_9606915d-9d1f-4708-9142-196438c26abc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjM5_059efa0a-87c2-43b0-b0fe-a0cbb06b7695">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTQtMS0xLTQxMTUvdGV4dHJlZ2lvbjplYjgwNDM1NTdlMmE0MzY1OGVmYTY3ZDcwNjQ3OWU3Yl8xMDk5NTExNjI3ODI5_daf54356-3e0a-4181-8df6-af8bbc0f4119">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTYtMS0xLTQxMTgvdGV4dHJlZ2lvbjphMGNiYWMwYjM5ODc0ZDZiYThkYTQwNzFiZjg2MTkzZl8xMDk5NTExNjI3ODEy_d050b77a-05e0-48ba-b1f0-b196827d8b04">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGFibGU6NGU0ZTU4NGUxMGU2NDQ2Yjg0YjA3MmM0NmI5OGEzMDEvdGFibGVyYW5nZTo0ZTRlNTg0ZTEwZTY0NDZiODRiMDcyYzQ2Yjk4YTMwMV8wLTgtMS0xLTQxMjEvdGV4dHJlZ2lvbjo3NTk4MjRkZWU0Yjc0ZGViYmExYzI4ODJhMTQ4MzQ0ZV8xMDk5NTExNjI3ODE0_18866fef-64a4-4e93-8a95-f7e83e02bdc5">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMzNzg0_dfa8146c-7461-41ff-9449-7d1a5d5e7060">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8xMDk5NTExNjMwNjQw_7215f9cb-b8b0-4088-b768-d77ff1b3b1dc">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i1213689b20964f7fbaa4756853223720_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8yNjc4_df3a1079-6680-41fd-8174-3f993b1bb7bb"
      unitRef="usd">103720151</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8031ad7778c04e03886ac0ae3c6c9cbf_I20210218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8xL2ZyYWc6YTU0ZGU1MDRiYzliNGVlNzhjNjIxMDc3YjAxMGZlMjYvdGV4dHJlZ2lvbjphNTRkZTUwNGJjOWI0ZWU3OGM2MjEwNzdiMDEwZmUyNl8yNjkz_caac5338-b565-4298-824b-7eccd74a8552"
      unitRef="shares">37052129</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMtMS0xLTEtMA_993af1d2-36d8-4a14-a7c5-befb2a256e42"
      unitRef="usd">130980681</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMtMy0xLTEtMA_afdf2418-4564-4771-9e78-bcf24a921bcc"
      unitRef="usd">10195292</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzUtMS0xLTEtMA_d641c79e-93ab-4933-989c-ed612166bdbe"
      unitRef="usd">320458</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzUtMy0xLTEtMA_a4eca15e-8b75-489d-a062-d88473eee436"
      unitRef="usd">203480</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzYtMS0xLTEtMA_2cb9d23d-bb41-445a-90bb-3cae2685826a"
      unitRef="usd">2055321</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzYtMy0xLTEtMA_19b50b4f-920b-478b-9478-36e46ceab5ad"
      unitRef="usd">954957</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzctMS0xLTEtMA_c25d577b-7d6b-4981-9b10-27330a404968"
      unitRef="usd">133356460</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzctMy0xLTEtMA_b414242b-19dc-4ede-ab7d-7ffb85417ee4"
      unitRef="usd">11353729</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzgtMS0xLTEtMA_de31ac7c-68d8-4f05-9508-a62d77b95992"
      unitRef="usd">623694</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzgtMy0xLTEtMA_f5093453-f387-4b9c-9ab0-68848a42f143"
      unitRef="usd">877823</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzktMS0xLTEtMA_ad367ff0-8407-498f-b7e3-e1e2ca7a745c"
      unitRef="usd">343001</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzktMy0xLTEtMA_4fb49bc8-81ea-4432-880b-be9956483b0b"
      unitRef="usd">697418</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzEwLTEtMS0xLTA_42c697c6-09de-4723-a778-48d76ce182ca"
      unitRef="usd">404232</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzEwLTMtMS0xLTA_4605fc76-852e-4965-ae46-1f811acd6805"
      unitRef="usd">157576</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzExLTEtMS0xLTA_c0375079-0d29-432d-bdaa-b813bb6af7a3"
      unitRef="usd">134727387</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzExLTMtMS0xLTA_f143ad67-bb58-45b0-b732-06f04d0579ad"
      unitRef="usd">13086546</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE1LTEtMS0xLTA_c4fc6541-54cc-4efc-9f52-a43eb44f11c3"
      unitRef="usd">1366008</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE1LTMtMS0xLTA_ce9c5fa6-e0a5-4d1c-8d61-4a83a52965d8"
      unitRef="usd">656304</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE2LTEtMS0xLTA_a1024d19-4f33-4b1b-9dbc-c51a330d7510"
      unitRef="usd">3850763</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE2LTMtMS0xLTA_d5b6d4d9-d01a-4573-9fa7-7735e7459e80"
      unitRef="usd">3260061</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE4LTEtMS0xLTA_eb816f5d-6b26-4ce7-b62f-7b4d3d0db90f"
      unitRef="usd">860206</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE4LTMtMS0xLTA_d24a3b36-c37e-40b3-876b-2662820021c9"
      unitRef="usd">865379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE5LTEtMS0xLTE2NzY_2db1855e-288e-45f6-8405-cf47fe9ceef5"
      unitRef="usd">42000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzE5LTMtMS0xLTE2NzY_63a75994-8bd8-4dfa-8122-a794930c9f67"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIwLTEtMS0xLTA_90001259-8e3b-48a7-a631-c9ad345f29ac"
      unitRef="usd">6118977</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIwLTMtMS0xLTA_7d355ada-226d-45ad-b039-8d6b8c0493a9"
      unitRef="usd">4781744</us-gaap:LiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIyLTEtMS0xLTA_f79239b6-a31d-4222-b6f8-84ad2c20f868"
      unitRef="usd">284971</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIyLTMtMS0xLTA_e707702f-0947-4fc2-aae4-53288382a076"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIzLTEtMS0xLTA_8cc7bb16-8f81-4044-aad8-055e79c73be8"
      unitRef="usd">9291</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzIzLTMtMS0xLTA_d834c593-7f30-4b8c-b3b9-f915211a0adb"
      unitRef="usd">860963</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI1LTEtMS0xLTA_2072b3ab-1ca8-4e7a-bb13-fa7de599d14c"
      unitRef="usd">156266</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI1LTMtMS0xLTA_4afb79dd-7652-4381-88cd-0585ded99578"
      unitRef="usd">128368</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI2LTEtMS0xLTA_bca39d76-6554-4a76-acd9-52742f662c31"
      unitRef="usd">6569505</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI2LTMtMS0xLTA_238373db-d00a-4653-99e2-ce48d302b45c"
      unitRef="usd">5775202</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI4LTEtMS0xLTA_cfcfc7ba-38b2-45ad-b9d7-bdfa90e7c2b8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzI4LTMtMS0xLTA_103b53c3-823d-4beb-8fae-cb0767fea3c3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzEy_492c4252-1163-4a83-80c6-c0ca068d9b2b"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzEy_88311fd3-8d89-4ae1-ab59-4030ab1c4f89"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzI1_cc541971-ae3a-4a8f-915f-9f390d3bceb5"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTAtMS0xLTAvdGV4dHJlZ2lvbjowNTM3N2Q5OTBmZTc0NzIwOGEyYmFmMzBhNzAyNjkzN18xMDk5NTExNjI4MzI1_dd7aea53-0562-4f08-b7d4-a2da6efeecb1"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTEtMS0xLTA_cfd28210-bbcb-42f2-b5ab-2579d0df9910"
      unitRef="usd">716</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMxLTMtMS0xLTA_daacb5e8-8a60-4c5a-abba-42f8d67cb444"
      unitRef="usd">60</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTYy_cb934514-e0f7-414f-9900-c25ff6d02a35"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTYy_d5b5c191-721e-4d7b-b53a-0aa0b8bceb4c"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTc2_2708dc86-cef9-4cdb-9f90-519b6ddd93eb"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTc2_ece2dc6d-7445-406f-9198-79a69d149e14"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTg4_3517a79b-7db2-42ae-8ea8-d9ccf49afb66"
      unitRef="shares">36780805</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI3OTg4_f845276c-a825-44ac-b8c2-5de9dc44c0af"
      unitRef="shares">36780805</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI4MDAw_8c07a703-db6f-49fc-aff2-117e07dd07e1"
      unitRef="shares">8593633</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTAtMS0xLTAvdGV4dHJlZ2lvbjozNTE0OWM0ZGQ5N2Q0NWFlOWM3ZWU0NDA5NDNmNzM0Zl8xMDk5NTExNjI4MDAw_aa6df686-861d-4a34-aadb-1f642cc04425"
      unitRef="shares">8593633</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTEtMS0xLTA_ea0c358e-7826-4c4f-af03-e27744437f72"
      unitRef="usd">3678</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMyLTMtMS0xLTA_e24fcb8a-1a2f-478f-a4b0-b500e4822de9"
      unitRef="usd">8312</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMzLTEtMS0xLTA_518f5ef9-5a18-490f-a421-0ad2a0ae1567"
      unitRef="usd">361820025</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzMzLTMtMS0xLTA_642aef90-0acb-4230-8ba6-a83f8221e608"
      unitRef="usd">217172528</us-gaap:AdditionalPaidInCapital>
    <trov:Servicereceivable
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM1LTEtMS0xLTA_24c0ab15-87f8-41b6-aa28-5cff1d8b62a9"
      unitRef="usd">2171258</trov:Servicereceivable>
    <trov:Servicereceivable
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM1LTMtMS0xLTA_db5bb344-c415-41e0-bf4b-bf37bb59efb4"
      unitRef="usd">971673</trov:Servicereceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM2LTEtMS0xLTA_f40549c0-625d-401a-b0a1-663e8432125c"
      unitRef="usd">-231495279</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM2LTMtMS0xLTA_afcac260-fc35-435d-a8ea-06ffa543596a"
      unitRef="usd">-208897883</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM3LTEtMS0xLTA_164af2a0-7a5e-4016-9572-8fb7b9cd6cf9"
      unitRef="usd">128157882</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM3LTMtMS0xLTA_87026a3d-87b7-42e2-9eb8-1984cb044c13"
      unitRef="usd">7311344</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM4LTEtMS0xLTA_fcb7a433-c0af-4bcf-87d5-051cb7f2d1fb"
      unitRef="usd">134727387</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzIvZnJhZzo4N2EwZTdkNDYzMzM0NDU0YjkyNGU5ZDBkZGI3YTgxNC90YWJsZTplZGI0N2NlZjAwOGM0NGQ4YjVmMTIzY2U2YmNiODUxMC90YWJsZXJhbmdlOmVkYjQ3Y2VmMDA4YzQ0ZDhiNWYxMjNjZTZiY2I4NTEwXzM4LTMtMS0xLTA_83411724-4756-4b66-aa27-3cb4c1f2dca7"
      unitRef="usd">13086546</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i974c8d2976844fc9bd37ad841b476746_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMtMS0xLTEtMA_fc06cb78-1902-4eee-9d7a-2341071bf4be"
      unitRef="usd">365993</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f64d58d38fe4c52a90346b804d8222a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMtMy0xLTEtMA_0b8d5857-09a9-4d62-aa2f-14829f08e2c6"
      unitRef="usd">243137</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i8dfeebbffde848a39dd21015892f17ee_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzYtMS0xLTEtMA_374404a4-a7a1-467f-bbc4-a1e43944691e"
      unitRef="usd">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="if31167c9f6df4b2e98fed3a3ab5827c9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzYtMy0xLTEtMA_e8636e4a-9a1b-4249-baa6-eee19747fc69"
      unitRef="usd">1495</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzgtMS0xLTEtMA_a272aeb4-8e7a-4253-beea-39fcf0928763"
      unitRef="usd">365993</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzgtMy0xLTEtMA_ac29ceaa-b9fa-47a5-ad6c-20be38ee62e9"
      unitRef="usd">244632</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzExLTEtMS0xLTA_54cdcd1f-68b5-4ac5-9a00-7a3b816ffddd"
      unitRef="usd">11235396</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzExLTMtMS0xLTA_a7bdc178-b7d2-4ac1-814b-791d22a33b2a"
      unitRef="usd">11162236</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzEyLTEtMS0xLTA_cdb0f64d-8e3d-4838-9f36-f7df6d58d976"
      unitRef="usd">8216471</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzEyLTMtMS0xLTA_7ef23814-f6ad-439c-aa50-f0b3787eba38"
      unitRef="usd">5760890</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE1LTEtMS0xLTA_028c8bb8-7351-402b-aa7a-2b5e758fd6ab"
      unitRef="usd">19451867</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE1LTMtMS0xLTA_5461ebd6-01e5-4d65-92b0-a0ef50ef5c6a"
      unitRef="usd">16923126</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE3LTEtMS0xLTA_f31427f9-ce76-48ce-8c93-b33f01bd7058"
      unitRef="usd">-19085874</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE3LTMtMS0xLTA_0a877e31-2abb-47f5-adfe-825dc7e55355"
      unitRef="usd">-16678494</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE5LTEtMS0xLTA_f30b2603-377a-43ed-8ab3-9469abe7c0f0"
      unitRef="usd">89809</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzE5LTMtMS0xLTA_8251b1c9-484e-4b7e-b861-b17436b2d13d"
      unitRef="usd">234169</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIwLTEtMS0xLTA_a1f7cf68-14b0-4e6b-8bdc-18ad3a561fcb"
      unitRef="usd">1519</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIwLTMtMS0xLTA_b19fa447-87e7-4f6c-bea4-7e233fb9f794"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIxLTEtMS0xLTA_920d23b6-6d6d-4ec1-8eb2-ea4ad0785e07"
      unitRef="usd">-28244</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIxLTMtMS0xLTA_d0c516d4-33e4-4282-a6a5-5f891ba6a542"
      unitRef="usd">1978</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIzLTEtMS0xLTA_f6fa637e-9b7a-4814-9cc1-9780237879fd"
      unitRef="usd">-280844</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzIzLTMtMS0xLTA_bbc5bb68-f65a-4b52-b871-0355bb745deb"
      unitRef="usd">28188</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:NetIncomeLoss
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI0LTEtMS0xLTA_e383d515-bbbd-4398-93ef-c0d65852bbb0"
      unitRef="usd">-19306672</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI0LTMtMS0xLTA_0e1722d7-f670-46c4-a4e9-8ae204ff897a"
      unitRef="usd">-16414159</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI2LTEtMS0xLTA_f2c0a508-967d-4d35-87fb-cd849696ab6d"
      unitRef="usd">24240</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI2LTMtMS0xLTA_3ef5ad5d-d90e-4798-b13e-818eb4729dfb"
      unitRef="usd">24240</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI4LTEtMS0xLTA_97438e71-13ed-4fe8-a7d8-d84ff8e3a500"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI4LTMtMS0xLTA_3f6be8f8-cc2d-4e6d-aa89-c9b5d8ec45e2"
      unitRef="usd">268269</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTEtMS0xLTE2OTU_9a5ea0db-4e8e-4e47-b1de-44e407bfaee3"
      unitRef="usd">601767</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTMtMS0xLTE2OTU_0c8fa2ee-d671-4ed6-90bd-909d73192ad7"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMwLTEtMS0xLTE2OTU_948f1572-ca6f-4601-bc0e-a7cf05991b90"
      unitRef="usd">2664717</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMwLTMtMS0xLTE2OTU_0835d810-a17b-42f7-b576-80e6d1244868"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTEtMS0xLTA_c70e33eb-15f7-4e72-8862-8bbae94939c6"
      unitRef="usd">-22597396</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzI5LTMtMS0xLTA_cef0e47a-ba7f-41e1-aaba-589f6d07e006"
      unitRef="usd">-16706668</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMxLTEtMS0xLTA_30ad0949-39ba-444a-8301-1cec5cdaf32a"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzMxLTMtMS0xLTA_1135f1ca-76e2-49ac-9e26-f8fa656464dc"
      unitRef="usdPerShare">-2.80</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzM0LTEtMS0xLTA_897f2333-55c0-4049-a253-e9bd43cf58fa"
      unitRef="shares">20874665</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yMzgvZnJhZzozNzhkN2IzNGVmNDA0NDc0YmNmZjcyNzRlYTY3MDQ4MS90YWJsZTo3Y2FhMTA5OWZiOTA0MzAyYjI1MzhlNTU0Y2M4OTQ1ZC90YWJsZXJhbmdlOjdjYWExMDk5ZmI5MDQzMDJiMjUzOGU1NTRjYzg5NDVkXzM0LTMtMS0xLTA_d2bbb105-6abe-47f7-b818-6f39820c0ce4"
      unitRef="shares">5973906</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i90cbda9b433948c4bfec12adb85eece5_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTEtMS0xLTA_a0ddcea3-6e26-4b52-ab0c-7832661c63a5"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i90cbda9b433948c4bfec12adb85eece5_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTMtMS0xLTA_02a17061-9ef4-4e95-8f37-aa9320f33005"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i283c7589044745a697aba89af3b8c955_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTUtMS0xLTA_84ddd1fd-fc49-46b5-97e0-28cd038b8826"
      unitRef="shares">3831879</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i283c7589044745a697aba89af3b8c955_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTctMS0xLTA_e42c6fe2-2058-4dd1-8843-57796ca13490"
      unitRef="usd">7742</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1fd37d65d4a45768c5f933a4c55cf0f_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTktMS0xLTA_848e4c7c-1194-4c48-a9cd-d8d91e744324"
      unitRef="usd">202267605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i03f11be824704ccaaa3be62c269b68d3_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTExLTEtMS0w_115ed770-49e6-4859-bd3e-e1d32881ff7f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i489cb20610fb450193a4a09194d885a8_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTE1LTEtMS0w_c5131479-d901-4d8f-a00a-f85009b07deb"
      unitRef="usd">-192191215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e8da706562440a48c86522c944d0df6_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ3LTE3LTEtMS0w_9fa91d78-5e4e-4afa-8790-f6437706c29d"
      unitRef="usd">10084192</us-gaap:StockholdersEquity>
    <trov:SaleOfStockCommonAndWarrantsNetShares
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTUtMS0xLTA_9c3e43cc-b5c6-44f3-980a-309224262f9f"
      unitRef="shares">-1994929</trov:SaleOfStockCommonAndWarrantsNetShares>
    <trov:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTctMS0xLTA_d704820b-23d9-419d-aab0-38a90e7d77bc"
      unitRef="usd">-199</trov:SaleOfStockValueCommonAndWarrantsNet>
    <trov:SaleOfStockValueCommonAndWarrantsNet
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTktMS0xLTA_9c7cc98c-ad21-44c0-94a1-bec8c1beefb5"
      unitRef="usd">-8817573</trov:SaleOfStockValueCommonAndWarrantsNet>
    <trov:SaleOfStockValueCommonAndWarrantsNet
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ4LTE3LTEtMS0w_0e75b024-005b-4e21-a756-3b8228f6ad3c"
      unitRef="usd">-8817772</trov:SaleOfStockValueCommonAndWarrantsNet>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTEtMS0xLTA_e088d52e-dab6-4a64-9b8f-f3e8b0e8eab3"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTMtMS0xLTA_c1e16236-347d-42a6-87aa-a904e6b30960"
      unitRef="usd">200</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTUtMS0xLTA_2ee5a22c-7376-47eb-97f9-837257186e6f"
      unitRef="shares">183334</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTctMS0xLTA_3f8bf0dc-a1c2-478b-b2e9-56364a2737f9"
      unitRef="usd">110</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTktMS0xLTA_70310fb5-acb8-4a73-b8a0-1d86517086a8"
      unitRef="usd">1634690</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTExLTEtMS0w_beaf641f-ee16-4027-adfc-29819ea4cf03"
      unitRef="usd">-1675000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzQ5LTE3LTEtMS0w_eae4410e-c1f0-4bdd-b65f-bae7e000115d"
      unitRef="usd">-40000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUwLTktMS0xLTA_f295da2e-19e2-4d50-b885-60ba7aefa0d7"
      unitRef="usd">884942</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUwLTE3LTEtMS0w_2e83bab0-ac26-418b-83b9-3658852a9085"
      unitRef="usd">884942</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <trov:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTUtMS0xLTA_00fefd3f-697a-4c6c-b916-563821c66603"
      unitRef="shares">2221635</trov:StockIssuedDuringPeriodSharesWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTctMS0xLTA_c5fa4b57-fd09-49fa-9b00-537ed9a0387a"
      unitRef="usd">223</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTktMS0xLTA_6283418b-0f70-4167-863c-8fddf31a2fe8"
      unitRef="usd">3299287</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUxLTE3LTEtMS0w_d28f8faf-fa1e-4fd0-aa20-12fd1d6b6b70"
      unitRef="usd">3299510</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTUtMS0xLTA_6463489d-dce4-4b2e-a701-787ceb92a0d6"
      unitRef="shares">22057</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTctMS0xLTA_b29aec29-e453-435e-8671-a6c30c7df653"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTktMS0xLTA_6bfbda19-c099-4b9e-97a4-2f0e6c44d56d"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUyLTE3LTEtMS0w_798a8254-545c-435a-b0da-3fa08cbc4e33"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTktMS0xLTA_f95d42c0-5e9d-4ded-b74f-8fb002a6a8e7"
      unitRef="usd">268269</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTE1LTEtMS0w_7b6eacf2-2cea-4182-94d4-d2d4eb722172"
      unitRef="usd">-268269</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzUzLTE3LTEtMS0w_79608760-16d9-4597-9a8f-24929c13309c"
      unitRef="usd">0</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTEtMS0xLTA_23b7f6be-43d1-468f-9544-f8dbbf1fb92f"
      unitRef="shares">-200000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i156cfc282c334c98a614b483ef5fec17_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTMtMS0xLTA_89a7dfb0-1456-4e66-963f-f0e69ded8eb9"
      unitRef="usd">-200</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTUtMS0xLTA_096b87c5-5adc-4180-8f95-67862acf9548"
      unitRef="shares">333333</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTctMS0xLTA_f21ae747-ec46-49f7-9e5e-7848b0397a9f"
      unitRef="usd">33</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7be77a1e8c314cb79ff9d3fc0d2eca0e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTktMS0xLTA_328cff8b-a25e-425b-ab2a-c33c51c4dba6"
      unitRef="usd">167</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU0LTE3LTEtMS0w_21c3efb9-ecd5-4a2d-bafc-c95d5d91bee9"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU1LTE1LTEtMS0w_bbd71bfd-28c1-4f83-be7e-5d3221e4f9ff"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU1LTE3LTEtMS0w_9e3c83e0-2c06-4b47-b982-c15ed974bccd"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits
      contextRef="i33236cbd1fe14e47b06630a517781be3_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU2LTUtMS0xLTA_803603ba-127a-467c-8882-f44db317bdde"
      unitRef="shares">6466</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <trov:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i903ce2b271c243e0a46e2db72452b60e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU3LTExLTEtMS0w_348cb94e-3331-4876-bcba-9c5042222239"
      unitRef="usd">703327</trov:ReleaseOfClinicalTrialFundingCommitment>
    <trov:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU3LTE3LTEtMS0w_213fe0f1-87e9-4b03-b384-085b66f6eaef"
      unitRef="usd">703327</trov:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU4LTE1LTEtMS0w_96f72273-5383-4444-a04f-4a011836b2a5"
      unitRef="usd">-16414159</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU4LTE3LTEtMS0w_1f31d147-f891-4bea-b658-b1b505bc03ae"
      unitRef="usd">-16414159</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTEtMS0xLTA_70b87fff-fe30-400b-886b-8b02eb9ecd31"
      unitRef="shares">60600</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i7df6d21ab6a1412eb4819a8b7904b4c5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTMtMS0xLTA_9062d36f-9240-47a7-b187-3ef0eed621b3"
      unitRef="usd">60</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ie1533dc281f3416c87c9cc063e238300_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTUtMS0xLTA_76a06980-1a82-461a-aeaf-064c45266634"
      unitRef="shares">8593633</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ie1533dc281f3416c87c9cc063e238300_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTctMS0xLTA_639fde36-7a08-4c0c-b65f-f2bad89b8f8e"
      unitRef="usd">8312</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e843a6b44054990807074b9f697e695_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTktMS0xLTA_a0cf97de-3ffd-4689-a3e8-491c17f8fdc0"
      unitRef="usd">217172528</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i45d5e02556184c789e5d3265173db41e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTExLTEtMS0w_0bc207eb-6dc6-48c3-b1fc-a23636a602db"
      unitRef="usd">-971673</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifb0dc0c25b98439290e7f74e7dbe5c33_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTE1LTEtMS0w_f636befa-e4db-452c-b711-b381b40c136b"
      unitRef="usd">-208897883</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzU5LTE3LTEtMS0w_0a750663-3dbb-4ba4-bc1e-44ed5d544b63"
      unitRef="usd">7311344</us-gaap:StockholdersEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f"
      unitRef="shares">865824</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee"
      unitRef="usd">866</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2"
      unitRef="shares">12964313</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f"
      unitRef="usd">1297</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373"
      unitRef="usd">112297786</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b"
      unitRef="usd">112299949</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTEtMS0xLTE3NzQ_c87a733e-28bf-463d-8d83-914c3687f2d8"
      unitRef="shares">154670</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ie98ec0841c544b57a06ef05b7c7a42c8_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTMtMS0xLTE3NzQ_ecc7e417-a59a-4380-a832-95bfa6184ff5"
      unitRef="usd">15</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTUtMS0xLTE3NzQ_ec864365-514f-4140-bf96-f2c75263ea4a"
      unitRef="shares">602833</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTctMS0xLTE3NzQ_a38600e4-f22d-4193-bb36-eb0c03942a86"
      unitRef="usd">60</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTktMS0xLTE3NzQ_a3182bd8-3ebe-4cd5-9af1-8671e4fce0a1"
      unitRef="usd">2292425</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTExLTEtMS0xNzc0_2f02bc56-504c-4627-86c9-806944ff7483"
      unitRef="usd">-2300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYxLTE3LTEtMS0xNzc0_c96e4303-587f-4197-be78-e33f468b93e5"
      unitRef="usd">-7500</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYyLTktMS0xLTE3NzQ_ab0e7e74-4c68-4e59-ab69-9ff55daabd5e"
      unitRef="usd">1764804</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYyLTE3LTEtMS0xNzc0_852af7d0-b8e1-45a8-be16-f88412e2a09a"
      unitRef="usd">1764804</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <trov:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTUtMS0xLTE3NzQ_e1c0e253-240c-44f4-a73c-29fd473d9181"
      unitRef="shares">12138469</trov:StockIssuedDuringPeriodSharesWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTctMS0xLTE3NzQ_3b6650da-94bc-49a0-9989-c049e497bedb"
      unitRef="usd">1214</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTktMS0xLTE3NzQ_ad0c37b8-82f0-423a-b842-0b50de06bfdc"
      unitRef="usd">24870372</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <trov:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYzLTE3LTEtMS0xNzc0_edb70611-8257-4bd4-9ee9-074536a01ebb"
      unitRef="usd">24871586</trov:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTUtMS0xLTE3NzQ_1d84826e-4bb0-423d-8de0-9555263e66dd"
      unitRef="shares">10810</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTctMS0xLTE3NzQ_9bddcb5a-35c9-487c-8477-b37ca0ae7a93"
      unitRef="usd">1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTktMS0xLTE3NzQ_5a61dc17-99d4-4c5c-960e-d0e8a7ba99fa"
      unitRef="usd">-1</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY0LTE3LTEtMS0xNzc0_89524660-a5b4-43df-8d2c-92533f1142bb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTktMS0xLTE3NzQ_ce7fb358-d39b-468d-8c49-312066e0e528"
      unitRef="usd">601767</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i45ab9019c9754577b27a546943f63815_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTE1LTEtMS0xNzc0_c2b277a4-410e-4361-b4ad-553ff685ced2"
      unitRef="usd">-601767</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY1LTE3LTEtMS0xNzc0_bd27533d-9e45-496a-bd8e-dd4492aef676"
      unitRef="usd">0</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTktMS0xLTE3NzQ_96357246-8dfa-4a2e-ba9c-42507c4d069f"
      unitRef="usd">2664717</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="i9c0726d301e947e5a55d7dfb699e13f1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTE1LTEtMS0xNzc0_bb6ffdc6-8888-40ef-9866-4eeea226bc91"
      unitRef="usd">-2664717</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock
      contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY2LTE3LTEtMS0xNzc0_7ae6c232-c506-48af-b49a-15c82758c128"
      unitRef="usd">0</trov:BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTEtMS0xLTE3NzQ_bce34515-f2e2-4b8a-8942-1541c8a75d87"
      unitRef="shares">-154670</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7465c8fd09274943a0d81c01e439b98d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTMtMS0xLTE3NzQ_6edd9365-d826-430b-b2d7-bf3b2f357100"
      unitRef="usd">-15</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTUtMS0xLTE3NzQ_42a187b0-a58f-4424-b404-759b4f1baa13"
      unitRef="shares">1546700</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i09e311374e614fd5bd1465edd7a8ebd2_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTctMS0xLTE3NzQ_6530e7eb-f060-44d2-b340-9bd9ba36951f"
      unitRef="usd">155</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib00cd8cd58c64e479fb9daed91f14dff_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTktMS0xLTE3NzQ_7ccbab59-c652-40ea-b339-620f3f65da32"
      unitRef="usd">-140</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY3LTE3LTEtMS0xNzc0_c04d397d-c874-4edb-b4c5-6131949ef215"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTEtMS0xLTE3NzQ_f7ade7fc-726b-4ea7-9152-98c5acc3c783"
      unitRef="shares">-210780</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="id4510c0d43444d239f62625ce81acdd6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTMtMS0xLTE3NzQ_89eeb495-75d9-4df7-b911-ec2448d53036"
      unitRef="usd">-210</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTUtMS0xLTE3NzQ_c58c11ac-3716-43ca-84c6-1f26d6bf314e"
      unitRef="shares">863852</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib2e991fd4e1d45928a0cef776dfcb49e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTctMS0xLTE3NzQ_4e20047d-88dc-4c35-a8bb-bd93125135b6"
      unitRef="usd">86</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i4693b0605b384552bda0e63b5b001aab_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTktMS0xLTE3NzQ_827ba553-81ea-49ae-85fe-6a10ce09fb88"
      unitRef="usd">124</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY4LTE3LTEtMS0xNzc0_58a8c42e-60b8-4170-b83a-b93bd1a12edc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:DividendsPreferredStock
      contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY5LTE1LTEtMS0xNzc0_5bd4db76-8eed-4590-8428-5185b05221c4"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzY5LTE3LTEtMS0xNzc0_9fc8e9e7-422c-4082-9d29-4a02a2d98cb8"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <trov:ReleaseOfClinicalTrialFundingCommitment
      contextRef="icc2bb9b1afbe45eb83ee6736a9fb7775_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcwLTExLTEtMS0xNzc0_728cbfbc-501b-4a7f-832e-0598bde26377"
      unitRef="usd">1100415</trov:ReleaseOfClinicalTrialFundingCommitment>
    <trov:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcwLTE3LTEtMS0xNzc0_acea5c7e-57d2-441c-a15d-cc9446868a71"
      unitRef="usd">1100415</trov:ReleaseOfClinicalTrialFundingCommitment>
    <trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTctMS0xLTE3NzQ_2cb42d9e-7af5-4a51-bedd-416ce6ac5044"
      unitRef="usd">-7453</trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment>
    <trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTktMS0xLTE3NzQ_a84fa506-e7dd-4543-a187-9acd6a5a44b9"
      unitRef="usd">7453</trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment>
    <trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcxLTE3LTEtMS0xNzc0_fbd6f170-413b-444d-b32d-0060aece64cd"
      unitRef="usd">0</trov:AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTUtMS0xLTE3NzQ_56f145fd-e6fe-4c5b-9a93-cc181bc29436"
      unitRef="shares">60195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i269bcd78d6334b7cb6f3e63d685aa292_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTctMS0xLTE3NzQ_7878798d-5c3e-4ea5-a72e-a9ef7d1c3fe9"
      unitRef="usd">6</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8dbc2f0313db438a83e34517868fd998_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTktMS0xLTE3NzQ_f57fd520-711c-44b8-9e7b-ee7ee2160ef9"
      unitRef="usd">148190</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzcyLTE3LTEtMS0xNzc0_f7a8652e-a34a-4e08-b22a-765faede1aec"
      unitRef="usd">148196</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzczLTE1LTEtMS0xNzc0_160c09b9-bae6-4a38-b681-79218438b3d2"
      unitRef="usd">-19306672</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzczLTE3LTEtMS0xNzc0_33041b25-2966-46ac-8d8d-823e654fbcd3"
      unitRef="usd">-19306672</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i2b60188329974ccba428036634f386c6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTEtMS0xLTE3NzA_886d0aac-7b90-4ba3-9d56-8d2ba6cc05d1"
      unitRef="shares">715644</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i2b60188329974ccba428036634f386c6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTMtMS0xLTE3NzA_1c4622ba-0a79-49bb-b874-df3fb84e1042"
      unitRef="usd">716</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i775f6829cd0442b4abd291c9e9c043f2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTUtMS0xLTE3NzA_84fd19f7-3dfb-4e40-80a2-a5a40345de2b"
      unitRef="shares">36780805</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i775f6829cd0442b4abd291c9e9c043f2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTctMS0xLTE3NzA_c9ddeb28-15a6-4155-9443-2f2e0d915e60"
      unitRef="usd">3678</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7848a306518c4d3c8d2ceace32f45c19_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTktMS0xLTE3NzA_2307eab7-131a-4f05-969e-673dced04f6e"
      unitRef="usd">361820025</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iede24d64c8eb47a38bf93edc43a4580d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTExLTEtMS0xNzcw_40f56741-6972-4abf-84fd-63a0ebe0a65a"
      unitRef="usd">-2171258</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01b536880233430693517dce3f18592b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTE1LTEtMS0xNzcw_b555b698-59a2-4085-bf06-8b8710b51ffe"
      unitRef="usd">-231495279</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzc0LTE3LTEtMS0xNzcw_d703defe-75d0-4ac7-bcd4-0f5854885569"
      unitRef="usd">128157882</us-gaap:StockholdersEquity>
    <trov:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzE2NDkyNjc0NDE5MDE_129aec48-0ea3-4144-a109-09aa5f91649c"
      unitRef="usd">7507123</trov:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <trov:WarrantsFairValue
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMjc_319d52f4-e735-4cab-bcdf-216a19dee449"
      unitRef="usd">370666</trov:WarrantsFairValue>
    <us-gaap:NetIncomeLoss
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMtMS0xLTEtMA_64a81a31-f0ce-4f2e-9956-012562b1d7cc"
      unitRef="usd">-19306672</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMtMy0xLTEtMA_350c6f95-5009-40d3-91ae-6c0a3a962a5e"
      unitRef="usd">-16414159</us-gaap:NetIncomeLoss>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYtMS0xLTEtMA_2db562ba-241c-4e4a-bc54-fd7d7e2884cf"
      unitRef="usd">34169</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYtMy0xLTEtMA_6654a324-0030-4902-981c-b8831a165627"
      unitRef="usd">0</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzctMS0xLTEtMA_c3d31295-11c8-40e8-a662-93dae2a070c3"
      unitRef="usd">466009</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzctMy0xLTEtMA_1f00696f-06d2-41e3-bd2f-999bce07492f"
      unitRef="usd">494232</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzgtMS0xLTEtMA_ed3dd197-b182-4ac0-acf2-994c0a295a68"
      unitRef="usd">1764804</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzgtMy0xLTEtMA_54ff9451-b779-4d0d-a728-fcca8260384a"
      unitRef="usd">884943</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE2LTEtMS0xLTA_4252fb99-1807-4f85-ace9-b4709120058e"
      unitRef="usd">-280844</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE2LTMtMS0xLTA_c2f706c8-5745-439b-ad15-5abb125ff9d6"
      unitRef="usd">28188</us-gaap:UnrealizedGainLossOnDerivatives>
    <trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE3LTEtMS0xLTA_66183beb-80bf-4b2d-8123-8a44ab36d504"
      unitRef="usd">1100415</trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzE3LTMtMS0xLTA_11690ec9-aeaf-43ab-867c-adf97d46f898"
      unitRef="usd">703327</trov:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIwLTEtMS0xLTA_3c62cbbd-1c00-481c-86a3-74a1641838f3"
      unitRef="usd">246656</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIwLTMtMS0xLTA_1a7a752b-7746-4787-8ac6-139040fba720"
      unitRef="usd">54778</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIxLTEtMS0xLTA_89d91b25-3ee1-4384-9a05-36076e5d8c7e"
      unitRef="usd">116978</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIxLTMtMS0xLTA_65b535e3-f143-4cfe-b277-03423962bb68"
      unitRef="usd">35725</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIyLTEtMS0xLTA_d7649d16-9d1a-4d56-83ae-77f999a9f93c"
      unitRef="usd">1100364</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIyLTMtMS0xLTA_64083b92-132e-476c-8e11-c49d607b0099"
      unitRef="usd">-115459</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIzLTEtMS0xLTA_dc523360-0568-4b1c-a1de-025966f2a211"
      unitRef="usd">-320248</trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzIzLTMtMS0xLTA_669729fb-8ace-41de-991f-700a79719cb4"
      unitRef="usd">-302491</trov:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI0LTEtMS0xLTA_2c27aab3-3890-408c-be80-e0c190d91dd9"
      unitRef="usd">1276166</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI0LTMtMS0xLTA_107a8127-1016-453b-ad4d-af608de515e7"
      unitRef="usd">1455336</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <trov:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI1LTEtMS0xLTA_94e62423-f071-4bd1-807c-b1afccfc1819"
      unitRef="usd">-856845</trov:IncreaseDecreaseInOperatingLeaseLiability>
    <trov:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI1LTMtMS0xLTA_3ee3c13c-6159-44a9-9d6c-e9f4b1387151"
      unitRef="usd">-776806</trov:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI2LTEtMS0xLTA_4b9e6a78-e423-4507-8468-f617b017a9ba"
      unitRef="usd">69898</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI2LTMtMS0xLTA_63b50482-bc80-4fce-beba-ddc35a70968a"
      unitRef="usd">86368</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI3LTEtMS0xLTA_b0d276c7-7764-4aed-9816-2c4899584c94"
      unitRef="usd">-16314962</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzI3LTMtMS0xLTA_880b682a-ded2-4bce-8307-c89a4ea874c5"
      unitRef="usd">-13267500</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMwLTEtMS0xLTA_6a4d3b81-860e-47a4-820e-ac7006ed33c9"
      unitRef="usd">211880</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzMwLTMtMS0xLTA_db431591-4971-4df2-943e-a499ad20cb55"
      unitRef="usd">67622</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM1LTEtMS0xLTA_606ca0bb-f00f-45f4-a9b6-98148a4f8387"
      unitRef="usd">-211880</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM1LTMtMS0xLTA_71d57646-43c9-4436-8c0f-71c3eeffb7cd"
      unitRef="usd">-67622</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i08acffb99e614dc58b610354b475758f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNjU3MzAwYzQ5Njc0MTNkYjZkYWMwNjlhMzYyMzlmOV8xMDk5NTExNjI3ODkx_8a124ec8-0a27-407d-b209-e23bb9b96db6"
      unitRef="usd">7507123</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0556eb8a6c2a44c2be25fabc0712fbd4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjpkNjU3MzAwYzQ5Njc0MTNkYjZkYWMwNjlhMzYyMzlmOV8xMDk5NTExNjI3OTAz_a89ebba6-4f0e-4bd6-9944-0e4155b34938"
      unitRef="usd">158678</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTEtMS0xLTA_4f87d1e1-5d1f-4064-9391-25fc038da000"
      unitRef="usd">112299949</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzM4LTMtMS0xLTA_e12dc9e7-725d-422a-84f1-71cdc380cc1e"
      unitRef="usd">8817772</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQxLTEtMS0xLTA_7de85364-ca4d-494f-b0b9-1efb5d81d89d"
      unitRef="usd">-7500</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQxLTMtMS0xLTA_25dcec08-ff7c-43f1-9762-e2c6236c6591"
      unitRef="usd">-40000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQyLTEtMS0xLTA_9be89f58-205c-4814-9e49-215acf398f3c"
      unitRef="usd">24871586</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQyLTMtMS0xLTA_361e94f9-99e9-4b59-8fa9-50d3e89a5123"
      unitRef="usd">3299509</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQzLTEtMS0xLTA_20209d97-47da-46fe-8c47-653cd213264a"
      unitRef="usd">148196</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQzLTMtMS0xLTA_445a2fc6-5b1a-40d8-a44f-90f16c335faf"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ2LTEtMS0xLTA_3113b23e-cad7-4b33-8eed-035ab7a83b44"
      unitRef="usd">305000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ2LTMtMS0xLTA_50b81851-78c0-4b59-82b0-d1ca1f7ba892"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ3LTEtMS0xLTA_6e37e804-74f3-4f95-91a6-d35c0b35dab7"
      unitRef="usd">305000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ3LTMtMS0xLTA_558fc841-576f-42a3-970c-cde503c89394"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ5LTEtMS0xLTA_81cdda9e-881b-4e00-8c4f-e080a804c543"
      unitRef="usd">137312231</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzQ5LTMtMS0xLTA_df2a467b-2712-4476-9d29-5806d838bc7f"
      unitRef="usd">12077281</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUxLTEtMS0xLTA_08dbdddd-a3be-4a85-8906-39da5f8343d9"
      unitRef="usd">120785389</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUxLTMtMS0xLTA_4ae755f0-38e5-475e-ba51-5e6c7d994c05"
      unitRef="usd">-1257841</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUyLTEtMS0xLTA_5a5c1989-2f31-4cb5-9146-2f5310f46d80"
      unitRef="usd">10195292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e8da706562440a48c86522c944d0df6_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUyLTMtMS0xLTA_2da04ffe-426d-46b0-84ca-d9aaac8953c1"
      unitRef="usd">11453133</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUzLTEtMS0xLTA_30ce9ab5-51d2-45d6-82d2-c452f92ee7c2"
      unitRef="usd">130980681</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzUzLTMtMS0xLTA_ebb4a4c9-0904-4da7-bd4c-52e61727e9e8"
      unitRef="usd">10195292</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzU1LTEtMS0xLTA_843893a1-fa63-418b-9dc3-13e487e6e171"
      unitRef="usd">800</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzU1LTMtMS0xLTA_1eee3f23-c825-40b0-b281-8ba78c2189b9"
      unitRef="usd">800</us-gaap:IncomeTaxesPaid>
    <trov:PreferredStockDividendAccrued
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYxLTEtMS0xLTA_3ea90098-6510-4d93-bac0-fd069755ef61"
      unitRef="usd">24240</trov:PreferredStockDividendAccrued>
    <trov:PreferredStockDividendAccrued
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYxLTMtMS0xLTA_ff319cba-5456-42e5-b9cb-5d55db2be776"
      unitRef="usd">24240</trov:PreferredStockDividendAccrued>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYzLTEtMS0xLTA_314eb440-b308-449c-9e1f-4565b850cba9"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzYzLTMtMS0xLTA_18df931c-ddcb-4ffd-90d7-42716302c691"
      unitRef="usd">268269</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTEtMS0xLTE3MzM_f2ac619b-1f70-46dd-9a49-630a374051b4"
      unitRef="usd">601767</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTMtMS0xLTE3MzM_ea383009-317b-42cf-8249-497e7d7e2072"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTEtMS0xLTE3MzM_b0655bbc-fbf0-4af4-be50-ea60128d1ef1"
      unitRef="usd">2664717</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTMtMS0xLTE3MzM_ad1a88f4-65d2-4361-a34b-a0cbdab19807"
      unitRef="usd">0</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTAtMS0xLTAvdGV4dHJlZ2lvbjpkZGM3ZjViNWMwYmQ0OGZjYjhhOWM2M2ZiMGZlNDU5Zl8xMDk5NTExNjI3OTQw_9f788b15-4b52-49e8-8030-90447f267e52"
      unitRef="usd">235640</trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTEtMS0xLTA_a6c4ee79-97b0-4d88-8c2d-e7fbb8bfaf8f"
      unitRef="usd">0</trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY0LTMtMS0xLTA_9edb1c78-eff1-4896-b128-7d6190dee5a3"
      unitRef="usd">1675000</trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY1LTAtMS0xLTgzNy90ZXh0cmVnaW9uOmVjNGUxYTIyYWFjZjRlZDk5MWQ2Zjg4MzVmMmJkMThiXzIxOTkwMjMyNTU3MDE_e46ac66e-26c8-4f59-9924-fcd7fdd1f83e"
      unitRef="usd">488270</trov:DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment>
    <trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY3LTEtMS0xLTE3MjE_eaae4dbe-6e16-4994-9aac-d1bd214a9032"
      unitRef="usd">2300000</trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment
      contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY3LTMtMS0xLTE3MjE_a8ebe505-5925-40b4-bbbd-ef0ff0f7918b"
      unitRef="usd">0</trov:Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ic42a8d0b5a7244a8b54bacf1a4ab377e_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY2LTEtMS0xLTA_c164d374-e6a3-4860-9444-ce9777ebf49c"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i04e90fda9f854b7e998aa04ae54ea76a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzY2LTMtMS0xLTA_c52b2ca6-1003-483a-91fb-e796dcef335f"
      unitRef="usd">33</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i0c5e5d31b1884d3c9d8862df9eaefa58_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcwLTEtMS0xLTE3Mzc_23502484-e842-4524-b1d8-9c4ac6ba861a"
      unitRef="usd">155</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ie45fe55abbd04689abd81216dd5700e9_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcwLTMtMS0xLTE3Mzc_4f654c0a-d816-4d61-b2bb-bcc03ccbce41"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ibe669f95e16a45a1b3859d04f9042960_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcxLTEtMS0xLTE3Mzc_0018e49d-2180-4adb-bc57-cf0236bcd72b"
      unitRef="usd">86</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i7b61ec8e1ae749c796a8b3025ca00e93_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDcvZnJhZzpjMGM5ZjkwZDk2YjU0OTgwYmIzMTg1NWM1NWIxZDM5My90YWJsZToxMzhmMjU1MDUyMTk0NGZmOTJlMTFjOGZjZWQ5M2U5NS90YWJsZXJhbmdlOjEzOGYyNTUwNTIxOTQ0ZmY5MmUxMWM4ZmNlZDkzZTk1XzcxLTMtMS0xLTE3Mzc_9feb71a1-d419-428a-adc4-86e8acf5df14"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTYvZnJhZzo4YmUwOTg0YzgwYzQ0ODYwODg3YTg5YzNiOTVlYmIzNS90ZXh0cmVnaW9uOjhiZTA5ODRjODBjNDQ4NjA4ODdhODljM2I5NWViYjM1XzQxMTk_dc9a1d4c-8b5a-48d8-af59-a0b72110e863">Business Overview and Liquidity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology,&#160;Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, Zytiga&#xae;-resistant metastatic castration-resistant prostate cancer and leukemias. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2020, the Company had $131.0 million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 13 to the financial statements for further information.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTYvZnJhZzo4YmUwOTg0YzgwYzQ0ODYwODg3YTg5YzNiOTVlYmIzNS90ZXh0cmVnaW9uOjhiZTA5ODRjODBjNDQ4NjA4ODdhODljM2I5NWViYjM1XzE2NDkyNjc0NTE2MTY_3d7d9c66-7dbf-4d6f-ad9f-5336a5130745"
      unitRef="usd">131000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjE5_6e4ebf1f-92f3-4374-a486-69d36371f4f5">Basis of Presentation and Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6, effective February&#160;19, 2019. All share and per share information in the financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Trial Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#x201c;service providers&#x201d;). As of December 31, 2020 the Company&#x2019;s Clinical trial accrual balance of $1,683,195 is included in accrued liabilities and other liabilities. The Company&#x2019;s related 2020 clinical trial expenses are included in research and development expense of $11,235,396. Certain accrued clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of operating and money market accounts as of December&#160;31, 2020 and 2019 on deposit. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.&#160;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#x2019;s use. The Company estimates and records licensee&#x2019;s sales based on historical usage rate and collectability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Minimum royalties are generally due quarterly or annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Financial Instruments&#x2014;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued common stock warrants in connection with the execution of certain equity financings.&#160;Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#x2019; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of the Company&#x2019;s Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#x201c;Change in fair value of derivative instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#x2019;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below).&#160;At December&#160;31, 2020 and 2019, the fair value of these warrants was $284,971 and $4,127, respectively, and was recorded as a liability under the caption &#x201c;derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants&#x201d; on the balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Instruments where significant value drivers are unobservable to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property and equipment. The Company records property and equipment at cost, and records other intangible assets based on their fair values at the date of acquisition. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of five years for laboratory equipment and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb"&gt;three&lt;/span&gt; to five years for furniture and office equipment. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company&#x2019;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,807,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,617,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements. &lt;/span&gt;&lt;/div&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;)&lt;/span&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjM3_69c0c8c6-5224-4c55-b842-8670a4508f16">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzEwMzY_d26fd6a4-bd5e-4dd6-90ad-1c70e6cf0c19"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTU4_d4cc92ca-381d-4ca3-b74c-459b161ecb5f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <trov:AccruedClinicalTrialExpensesPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzEwOTk1MTE2Njg4NTY_9614dc84-cd49-4051-bd34-1fc8eef76ef6">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Trial Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#x201c;service providers&#x201d;). As of December 31, 2020 the Company&#x2019;s Clinical trial accrual balance of $1,683,195 is included in accrued liabilities and other liabilities. The Company&#x2019;s related 2020 clinical trial expenses are included in research and development expense of $11,235,396. Certain accrued clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.&lt;/span&gt;&lt;/div&gt;</trov:AccruedClinicalTrialExpensesPolicyTextBlock>
    <trov:AccruedClinicalTrialExpenses
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE2NDkyNjc0ODE2NTI_3a7f6617-8cd7-425c-905e-20ae1efb9c80"
      unitRef="usd">1683195</trov:AccruedClinicalTrialExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE2NDkyNjc0ODAwMDM_d6534c58-57f5-4d5d-a779-58ab35fee04c"
      unitRef="usd">11235396</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc1_7e59d529-7a23-49f1-944f-97dd6e099ea7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;Cash and cash equivalents consist of operating and money market accounts as of December&#160;31, 2020 and 2019 on deposit. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTkw_9ae847d4-aaf4-42cd-854f-a2d6fbbf58ab">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTYy_110e5211-6edd-4659-90e6-44eacda22c6e">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.&#160;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#x2019;s use. The Company estimates and records licensee&#x2019;s sales based on historical usage rate and collectability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Minimum royalties are generally due quarterly or annually.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjIw_1cb969f9-5762-41df-b4d4-493ea1150a5d">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjMx_53ef1846-be6d-4f05-9d41-aa0c5e90bf06">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Financial Instruments&#x2014;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued common stock warrants in connection with the execution of certain equity financings.&#160;Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#x2019; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of the Company&#x2019;s Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#x201c;Change in fair value of derivative instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#x2019;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments" &lt;/span&gt;below).</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0656cf347232476bae791a60c6bd570f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzY4MzA_939986b1-1dc3-46bb-a96e-9b1cf1e58106"
      unitRef="usd">284971</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzY4Mzc_b3c518a0-6f1b-4f00-917b-605da47aeb61"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc2_b71ec729-6cde-4933-9201-835d6369ec1f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTUz_1187aff3-4038-4df9-9dda-c1f388247dba">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Instruments where significant value drivers are unobservable to third parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTU0_848f875a-5959-4853-9fbd-83ab9ce70544">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;Long-lived assets consist of property and equipment. The Company records property and equipment at cost, and records other intangible assets based on their fair values at the date of acquisition. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of five years for laboratory equipment and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb"&gt;three&lt;/span&gt; to five years for furniture and office equipment. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1514b777a3114342923aade0d19fa7c0_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzM4NDgyOTA3MTY4NzA_4a34ba36-0776-404d-9363-0dc11054e7d9">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic8aaa0c125e84dba929af4a1e45d11b7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzM4NDgyOTA3MTY4OTA_bc8483ba-9d9e-4656-8f30-5500200aad79">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTYz_16ac1fff-ee04-44e5-807c-4559ae576b08">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjQw_59db30d1-75a3-4138-997d-675f9208a158">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company&#x2019;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. &lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NjA0_28bd6cc7-e80e-44bf-9578-e4dccfb0c5b5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTg3_176f35a2-1d8c-4839-9372-23851fdfa26a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTcy_51c15b1e-1928-48a7-b88d-bd1e1f4ef214">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.&lt;/span&gt;&lt;/div&gt;Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTc4_432be31d-86a6-43aa-a718-e4355f0804d8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTcz_947c8099-dbc6-4445-a816-528398cecf95">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,807,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,617,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id4f241b55b904f8e929edc9f63cfb4ce_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzItMS0xLTEtMA_a07fa594-d031-42cb-be9d-0050d72e6eeb"
      unitRef="shares">1860507</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icb66c3828dd94b5e81231528bde5fed7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzItMy0xLTEtMA_f3d2bc02-ffe9-4da3-a338-94e9fc9883c3"
      unitRef="shares">1015418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia954f550392d4591a6b546fb05b6c57d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzMtMS0xLTEtMA_8bcce4c9-6bd0-4db2-b455-123c92a144c0"
      unitRef="shares">5260992</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iba7031dc6fd14ef19e26c971fe76416a_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzMtMy0xLTEtMA_7fcdb4c2-d122-447d-92dc-7641454d927b"
      unitRef="shares">10589482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if7aa2f04b48e40b6bb9e10276579135f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzUtMS0xLTEtMA_2039def7-049c-4371-b1c6-d0c0127282f8"
      unitRef="shares">491</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i04cf8ba00be248f88818392f53a19b98_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzUtMy0xLTEtMA_516af3b1-cf87-48c3-8bd0-5f10aa9691d3"
      unitRef="shares">11301</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id9ad1a7639b14aabab7b8f0710ecdb7d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzYtMS0xLTEtMA_f4470135-d4aa-462d-aa6a-da6f32ac502c"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib4c13518b4c74daca4beaea86298f527_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzYtMy0xLTEtMA_48bf7cae-e1dd-4c54-910d-db24aad5b766"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6436bbbd26f24becadccf4b1d782084d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMS0xLTEtOTIx_4d738b2e-344f-4998-87b8-7c322d91dd22"
      unitRef="shares">2684607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i975673dd341547dabdaf95c95b6524fb_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMy0xLTEtOTIx_98c69827-56bd-4645-94cb-ab8a87f9e586"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMS0xLTEtMA_dc85dbe9-1aad-4600-84a2-a5a83e04c945"
      unitRef="shares">9807474</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90YWJsZTplOTJmOTllMDVmM2I0N2Y1ODIxN2Y5NmU0Y2IxNmJjMy90YWJsZXJhbmdlOmU5MmY5OWUwNWYzYjQ3ZjU4MjE3Zjk2ZTRjYjE2YmMzXzctMy0xLTEtMA_d88886d6-a00c-461e-83de-aeb5c14230b7"
      unitRef="shares">11617078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2XzE5NTQ4_e282f0d5-4957-46df-a68d-5564d6ce4533">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes to the Disclosure Requirements for Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements. &lt;/span&gt;&lt;/div&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;)&lt;/span&gt;. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzMw_44eeb07f-149f-4b46-8f15-24f1c6b97dc9">Supplementary Balance Sheet Information&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2020 and 2019 was $466,009 and $494,232, respectively. Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,627,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,004,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,260,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:Depreciation
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzI3OQ_de896e7e-3d0f-40d3-9d59-15bc08f1bd59"
      unitRef="usd">466009</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzI4Ng_84ec72d0-fcd5-44ff-aa5a-fa729fbecaad"
      unitRef="usd">494232</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzMQ_7feb45e9-3492-498d-9f2c-ac5da2679d51">Property and equipment consisted of the following:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;797,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;867,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,627,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,004,025)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,604,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib040744e101141f9aea1e9d4756978f4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzItMS0xLTEtMA_901ced57-9a64-47e9-a4a1-1e6dd5411ae4"
      unitRef="usd">797739</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic35f2ef7d35840b9bfab3082034c4696_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzItMy0xLTEtMA_fb1a62f3-4968-406c-a8ab-50ca50ec4052"
      unitRef="usd">775030</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iddb22003c74244c696720a265e0f7c37_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzMtMS0xLTEtMA_1a78be38-8e5c-4c53-8976-585f3c4a2dd1"
      unitRef="usd">1962230</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if08e7553905d4d068f485877b9048505_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzMtMy0xLTEtMA_0f12491f-4139-480c-bab9-4cbc3d8c158f"
      unitRef="usd">1962230</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b16d8ca860f495a9615c84058672eac_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzQtMS0xLTEtMA_d0f7755e-bc7c-447d-9789-16cf0a936b34"
      unitRef="usd">867750</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i73a4197db9564a4db2a4ad3445548a58_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzQtMy0xLTEtMA_043b0758-539c-4ce6-be73-5f6ff64bf470"
      unitRef="usd">744856</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzUtMS0xLTEtMA_252570a6-5251-4630-9f14-be757493d365"
      unitRef="usd">3627719</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzUtMy0xLTEtMA_31d8822e-bb82-4adf-84b3-39f93d4fae47"
      unitRef="usd">3482116</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzYtMS0xLTEtMA_5fee9e37-1bbb-4d02-96a0-60f2d3fdf813"
      unitRef="usd">3004025</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzYtMy0xLTEtMA_409c9556-ae8b-462c-aaeb-36500fc0d9d4"
      unitRef="usd">2604293</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzctMS0xLTEtMA_ac11df92-6bff-4c88-af15-8edaa2159ad0"
      unitRef="usd">623694</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZTowMDMyYjdmZDRlMjg0NmU2Yjk2MzhhMjA5YTZhMjg3Mi90YWJsZXJhbmdlOjAwMzJiN2ZkNGUyODQ2ZTZiOTYzOGEyMDlhNmEyODcyXzctMy0xLTEtMA_85c520bc-2c91-4fe5-9e7d-be8531d298d6"
      unitRef="usd">877823</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90ZXh0cmVnaW9uOjU1NjRkZTgxMGM3ODQ2YzI5ZWZlOTkwM2ZlYmRmMWQ4XzQzOA_369cd43a-9205-4bcd-b00e-c6143acbeddd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,504,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees and outside services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,850,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,260,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzItMS0xLTEtMA_144067ab-9b42-4aaf-9bfc-1764a40812c2"
      unitRef="usd">1523321</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzItMy0xLTEtMA_b0f81062-1501-4b38-bfce-30486fc4b250"
      unitRef="usd">1003383</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <trov:AccruedPreferredStockDividend
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzMtMS0xLTEtMA_2943c652-6b5e-4720-8b6b-260f15e57252"
      unitRef="usd">389495</trov:AccruedPreferredStockDividend>
    <trov:AccruedPreferredStockDividend
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzMtMy0xLTEtMA_5fa61370-2bac-48aa-b5b9-84698ac573b6"
      unitRef="usd">365255</trov:AccruedPreferredStockDividend>
    <trov:AccruedClinicalTrial
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzQtMS0xLTEtMA_d07e1a91-b945-4170-9c85-c9a217500a5f"
      unitRef="usd">1557134</trov:AccruedClinicalTrial>
    <trov:AccruedClinicalTrial
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzQtMy0xLTEtMA_1d264428-236c-4c8f-b73a-fd1e66b4b0b7"
      unitRef="usd">1504660</trov:AccruedClinicalTrial>
    <trov:Accruedresearchagreements
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMS0xLTEtMjc4OA_debfc8a9-3afd-4aab-8d50-5e123800d69e"
      unitRef="usd">66593</trov:Accruedresearchagreements>
    <trov:Accruedresearchagreements
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMy0xLTEtMjc4OA_04e8397b-7cd1-4ef9-ab0d-683e1fadf8e9"
      unitRef="usd">181408</trov:Accruedresearchagreements>
    <trov:Accrueddirectorfees
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMS0xLTEtMA_eb54c793-eb77-4651-b888-f6e420aa71d2"
      unitRef="usd">92500</trov:Accrueddirectorfees>
    <trov:Accrueddirectorfees
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzUtMy0xLTEtMA_44177389-c056-48e7-a231-92070c6212d2"
      unitRef="usd">67500</trov:Accrueddirectorfees>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzYtMS0xLTEtMA_18eddb06-57de-4396-8c60-3280ec08d6cb"
      unitRef="usd">38180</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzYtMy0xLTEtMA_fa04d20b-79eb-4931-8294-7cc381c334be"
      unitRef="usd">21000</us-gaap:AccruedProfessionalFeesCurrent>
    <trov:Patentlicenseandotherfeespayable
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzctMS0xLTEtMA_80f3dbac-12b2-475b-9694-9460f3b7fbe0"
      unitRef="usd">117440</trov:Patentlicenseandotherfeespayable>
    <trov:Patentlicenseandotherfeespayable
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzctMy0xLTEtMA_a4ecfa2a-afea-4256-9ba1-7ec8737acbdb"
      unitRef="usd">69950</trov:Patentlicenseandotherfeespayable>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzktMS0xLTEtMA_f12bf1f8-a366-4280-a6c0-234dfa333d47"
      unitRef="usd">66100</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzktMy0xLTEtMA_d8e31c29-6c2f-4145-9274-d4cbe2c9748f"
      unitRef="usd">46905</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzEwLTEtMS0xLTA_61e06510-154a-4ca7-83ec-7511a8faae3c"
      unitRef="usd">3850763</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjUvZnJhZzo1NTY0ZGU4MTBjNzg0NmMyOWVmZTk5MDNmZWJkZjFkOC90YWJsZToyMDQwYzJhOWI0N2I0NWRjODMwZGIzMTVlMDQ2MGEwYi90YWJsZXJhbmdlOjIwNDBjMmE5YjQ3YjQ1ZGM4MzBkYjMxNWUwNDYwYTBiXzEwLTMtMS0xLTA_1fdee98c-8abe-4e59-8b47-ebca4cec08c4"
      unitRef="usd">3260061</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODA_f197b77a-6251-4589-a9dc-8062f9fc3d1d">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased space to third parties under three separate sublease agreements, which all expire December 31, 2021. Income is recognized on a straight-line basis over the term of the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded an impairment loss of $34,169 and $0 for the twelve months ending December 31, 2020 and 2019, respectively. The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss. The loss was recorded within operating expenses in the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODE_05019a2f-96f2-4023-95d7-537f0ba4ab6e">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased space to third parties under three separate sublease agreements, which all expire December 31, 2021. Income is recognized on a straight-line basis over the term of the sublease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impairment of Right-of-Use Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded an impairment loss of $34,169 and $0 for the twelve months ending December 31, 2020 and 2019, respectively. The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss. The loss was recorded within operating expenses in the statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <trov:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzYxNA_94a92ef9-bce5-4af8-8199-7b42b4c02448"
      unitRef="usd">78000</trov:LesseeOperatingLeaseMonthlyRentPayment>
    <trov:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzYyMw_be07949b-3d10-4398-8460-c7071fff7a74"
      unitRef="number">0.03</trov:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <trov:LessorNumberOfSubleases
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzExNTA_ff54c55b-80db-4dc1-b119-67e0f8484168"
      unitRef="number">3</trov:LessorNumberOfSubleases>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzIxOTkwMjMyNTg2OTU_5b1142ae-c519-4d8e-8430-f7afc7295299"
      unitRef="usd">34169</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzIxOTkwMjMyNTg2OTE_990d2268-5212-43ea-a2ba-12b46bf93fa1"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODI_327e5437-0e3d-48cc-a96d-f390876dcf78">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.108%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,173)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381,653)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzEtNC0xLTEtOTM4_e40e1ada-09c4-4c48-a856-e4c20d1702f2"
      unitRef="usd">441529</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzEtNC0xLTEtMA_b67d6e3f-d04d-4af2-a8f3-933993cd3cb0"
      unitRef="usd">444878</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzItNC0xLTEtOTM4_2338f900-1d37-46d0-84f2-188f719ff5a4"
      unitRef="usd">291173</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzItNC0xLTEtMA_a662104b-4e3a-4a10-8f3f-38444ef2085b"
      unitRef="usd">381653</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzMtNC0xLTEtOTM4_a73afbfd-d603-4721-9132-932ba153c805"
      unitRef="usd">150356</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTphNWYxNzE1ZDI0YWQ0ZWU2YTAwMTg1ZTU3OGIwYzc1Yi90YWJsZXJhbmdlOmE1ZjE3MTVkMjRhZDRlZTZhMDAxODVlNTc4YjBjNzViXzMtNC0xLTEtMA_aca7c3b7-6d74-4298-b766-2a9281c77b60"
      unitRef="usd">63225</us-gaap:LeaseCost>
    <trov:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzI0ODM_9b0d1232-ead9-407c-b9a0-8c7b4af204f8">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;860,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</trov:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzEtMS0xLTEtOTc4_6ce0e4ec-cf39-465d-aaf2-7c06c83fa2ad"
      unitRef="usd">343001</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzEtMi0xLTEtMA_06b0c827-64a5-4fab-a468-30c1979d97d2"
      unitRef="usd">697418</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzMtMS0xLTEtOTc4_8af6fbc5-bd8e-4c1d-b84b-15c6b64009bc"
      unitRef="usd">860206</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzMtMi0xLTEtMA_83f84350-2d0f-44c3-b269-6100f1ebde8c"
      unitRef="usd">865379</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzQtMS0xLTEtOTc4_c4d32b43-ec9b-4904-acf7-045d68e1703b"
      unitRef="usd">9291</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzQtMi0xLTEtMA_855c543d-5d85-4646-a841-8c86e684894f"
      unitRef="usd">860963</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzUtMS0xLTEtOTc4_a505d09f-5fb1-4507-a5b0-4588d22c7e09"
      unitRef="usd">869497</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzUtMi0xLTEtMA_e5854e73-6426-482d-b0e6-16e459c1424f"
      unitRef="usd">1726342</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzctMS0xLTEtOTc4_0484822e-75df-4f28-b86f-95eb2a2e628b">P1Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzctMi0xLTEtMA_36e853e0-fca6-4ee1-a983-f72c88fefbbd">P2Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzgtMS0xLTEtOTc4_fb9c6066-70c5-4377-813e-9cebcea1b2ba"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo2ZDdhNDVhMTA0ZWI0OTBkOGE1NTEyOGViNTQ4NzgzZC90YWJsZXJhbmdlOjZkN2E0NWExMDRlYjQ5MGQ4YTU1MTI4ZWI1NDg3ODNkXzgtMi0xLTEtMA_6440830e-7833-4866-a7eb-9968f17d17bb"
      unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo1N2QwODRkYmNjOGU0MWY2OTI3MmZiYjRkZjdkMzlmYi90YWJsZXJhbmdlOjU3ZDA4NGRiY2M4ZTQxZjY5MjcyZmJiNGRmN2QzOWZiXzItMS0xLTEtMTU1Mw_36b92760-0b29-43ed-ba24-0ae55071d68a"
      unitRef="usd">943959</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo1N2QwODRkYmNjOGU0MWY2OTI3MmZiYjRkZjdkMzlmYi90YWJsZXJhbmdlOjU3ZDA4NGRiY2M4ZTQxZjY5MjcyZmJiNGRmN2QzOWZiXzItNC0xLTEtMA_2e4bdb29-694b-447d-b433-dd73978a5e67"
      unitRef="usd">916762</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90ZXh0cmVnaW9uOmMwZjNhY2RiMDllMTRlYzZiOWQyZjY5MjViZjAzYzgyXzEwOTk1MTE2MzI1NjM_b27dc2a2-a575-4614-a40a-30d464f9e0e8">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Sublease Income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Net Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;898,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;869,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItMi0xLTEtMA_2e23c29b-5230-4484-a739-c44f8d72d3d3"
      unitRef="usd">889586</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItNC0xLTEtMA_0cd85bb3-c76d-4976-8e22-8fefc2207821"
      unitRef="usd">403345</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzItNi0xLTEtMA_c631b938-ef3c-41a0-95f1-7843ca3000d1"
      unitRef="usd">486241</trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtMi0xLTEtMA_4433777e-a99a-454f-a07f-bddcac674c89"
      unitRef="usd">5868</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtNC0xLTEtMA_d66f9fd8-e973-4525-a071-ca54b8f64301"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzMtNi0xLTEtMA_a8bc62c0-b548-4b6c-a51c-3840317f8800"
      unitRef="usd">5868</trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtMi0xLTEtMA_232adb3c-f61c-443c-a510-aaaceeabfe33"
      unitRef="usd">3423</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtNC0xLTEtMA_de3f9c15-342b-472b-a65f-9fa9864ef896"
      unitRef="usd">0</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzQtNi0xLTEtMA_44135859-d38d-42fc-8674-5181ed4f272f"
      unitRef="usd">3423</trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtMi0xLTEtMA_9475242e-fa4a-49d4-86f4-26f0b4f72998"
      unitRef="usd">898877</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtNC0xLTEtMA_495eb47b-f8de-486b-bbe7-67e6eace3224"
      unitRef="usd">403345</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzYtNi0xLTEtMA_a2ccc514-2a03-4d35-8ba1-b82e766cbf73"
      unitRef="usd">495532</trov:LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzctMi0xLTEtMA_b2469b30-2920-4cd7-9ce4-bd106edea22e"
      unitRef="usd">29380</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNjgvZnJhZzpjMGYzYWNkYjA5ZTE0ZWM2YjlkMmY2OTI1YmYwM2M4Mi90YWJsZTo3MWE0MDZjYmI4Njc0NTQzOWQ2MDY4MGRjMjIxM2M4Ni90YWJsZXJhbmdlOjcxYTQwNmNiYjg2NzQ1NDM5ZDYwNjgwZGMyMjEzYzg2XzgtMi0xLTEtMA_207bb247-203f-44cb-837a-585cc0253c9e"
      unitRef="usd">869497</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzExNTEw_5991b7f2-c7e6-4982-9bf5-d502cf761a13">Stockholders&#x2019; Equity&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.150%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,437,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,159,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The above table excludes pre-funded warrants with a nominal exercise price of $.01 per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;605,072 pre-funded warrants outstanding as of December 31, 2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;386,967 pre-funded warrants which were issued during the twelve months ending December 31, 2020;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;All 992,039 pre-funded warrants were exercised in full during the twelve months ending December 31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The material terms of the Series A Convertible Preferred Stock consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Dividends. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Company&#x2019;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#x2019;s sole election, in cash or shares of common stock. As of December&#160;31, 2020 and 2019, the Company had $389,495 and $365,255, respectively in accrued cumulative unpaid preferred stock dividends, included in accrued liabilities in the Company&#x2019;s balance sheets, and $24,240 and $24,240 of accrued dividends were recorded during the years ended December&#160;31, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Voting Rights. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Liquidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $10 per share plus any accrued and unpaid dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Conversion Rights. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, which at the time of issuance was $928.80 per share, and subsequently adjusted to $691.20 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Subsequent Equity Sales. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock. The relevant registration statement became effective on March 17, 2006 and the conversion price was adjusted to $691.20 per share.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt; Automatic Conversion. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the price of the Company&#x2019;s common stock equals $1,857.60 per share for 20 consecutive trading days, and an average of 116 shares of common stock per day are traded during the 20 trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series C Convertible Preferred Stock and Service Receivable&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#x201c;PoC&#x201d;), whereby PoC agreed to finance $1.675&#160;million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in patients with metastatic Colorectal Cancer (&#x201c;mCRC&#x201d;) harboring KRAS mutation in exchange for (i)183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which was convertible into 1.67 shares of common stock. In April of 2019, all 200,000 shares of Series C Convertible Preferred Stock were converted into 333,333 shares of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $1.675&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3&#160;million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series D Convertible Preferred Stock and Service Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $2.3&#160;million for a clinical trial in exchange for (i) 602,833 shares of its common stock (the &#x201c;Common Stock&#x201d;), (ii) 154,670 shares of its Series D Preferred Stock and (iii) a warrant exercisable for 859,813 shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019, as amended. The warrant will be exercisable six months following the date of issuance at an exercise price of $1.50 per share and will expire on November 7, 2025. In June of 2020, all 154,670 Series D Preferred Stock were converted to 1,546,700 shares of Common Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $2.3&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.6&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#x201c;CDK&#x201d;) and Third Street Holdings LLC (&#x201c;Third Street&#x201d;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#x201c;Series E Preferred Stock&#x201d;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. Certain investors converted 210,780 shares of Series E Convertible Preferred stock to 863,852 shares of Common Stock during December 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $2.7&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#x2019;s net loss attributable to common stockholders and net loss per share.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants are classified as equity and its estimated fair value of $370,666 was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Purchase Agreements with Lincoln Park Capital Fund, LLC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#x201c;LPC&#x201d;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 800,000 shares of common stock and (b) Series I warrants to purchase up to 131,967 shares (the &#x201c;Series I Warrant Shares&#x201d;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#x201c;Series J Warrants&#x201d;) to purchase one share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable six months following the date of issuance at an exercise price of $0.948 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.0&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 904,970 shares of common stock and (b) Series K warrants to purchase up to 255,000 shares (the &#x201c;Series K Warrant Shares&#x201d;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#x201c;Series L Warrants&#x201d;) to purchase one share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable six months following the date of issuance at an exercise price of $0.81 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Purchase Agreement with Certain Directors and Executives&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold 447,761 shares of common stock at a purchase price of $1.34 per share and 146,854 shares of common stock at a purchase price of $1.43 per share. The gross proceeds from these purchases were $810,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Securities Purchase Agreement with Acorn Bioventures LP&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of 1,205,400 shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to 482,160 shares of common stock. The Series M Warrants are exercisable six months following the date of issuance at an exercise price of $2.024 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $2.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Underwritten Public Offering&lt;/span&gt;&lt;/div&gt;On October 2, 2020 the Company completed an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $13.50 per share. In addition, the underwriters exercised in full an option to purchase an additional 975,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $100.9&#160;million, and net proceeds of approximately $94.0&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzExNTE0_18b84b16-5519-48ab-b98c-c5fffcf44ce7">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.150%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.753%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,649,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,437,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(497,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,589,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,831,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,159,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The above table excludes pre-funded warrants with a nominal exercise price of $.01 per share: &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;605,072 pre-funded warrants outstanding as of December 31, 2019; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;386,967 pre-funded warrants which were issued during the twelve months ending December 31, 2020;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;All 992,039 pre-funded warrants were exercised in full during the twelve months ending December 31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6e8da706562440a48c86522c944d0df6_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtMS0xLTEtMA_391f3204-6450-42b0-b7d4-938a2c2ae003"
      unitRef="shares">3649341</us-gaap:ClassOfWarrantOrRightOutstanding>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i6e8da706562440a48c86522c944d0df6_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtMy0xLTEtMA_824f8e23-ae57-49b4-bbf0-fd118eab3fc7"
      unitRef="usdPerShare">8.91</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <trov:WarrantsWeightedAverageContractualTerm
      contextRef="i92fe3d8ede834ee9b4dfe1e82c7e0271_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzUtNS0xLTEtMA_599ff1d0-077d-4551-8228-c681abba8a79">P4Y4M24D</trov:WarrantsWeightedAverageContractualTerm>
    <trov:ClassOfWarrantOrRightNumberGranted
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzYtMS0xLTEtMA_77e4ef71-3f18-493b-bd4b-b4ab1f92eac2"
      unitRef="shares">7437454</trov:ClassOfWarrantOrRightNumberGranted>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzYtMy0xLTEtMA_4d687274-d556-45a0-9c59-5eeb0a836e1d"
      unitRef="usdPerShare">1.87</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <trov:ClassOfWarrantOrRightNumberExercised
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzctMS0xLTEtMA_92d08811-3ae0-4c1d-8ff9-d9a97adbba7c"
      unitRef="shares">497313</trov:ClassOfWarrantOrRightNumberExercised>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzctMy0xLTEtMA_68993ddb-95df-4bb7-9c92-cbcf79ea9535"
      unitRef="usdPerShare">6.60</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktMS0xLTEtMA_d2259b0e-0669-4099-b940-741c69c4304d"
      unitRef="shares">10589482</us-gaap:ClassOfWarrantOrRightOutstanding>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktMy0xLTEtMA_9419cc86-eaa4-4e67-bff0-858f39853f58"
      unitRef="usdPerShare">4.08</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <trov:WarrantsWeightedAverageContractualTerm
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzktNS0xLTEtMA_86184924-462e-4aa7-921a-2e6d1bf5b9ca">P3Y8M12D</trov:WarrantsWeightedAverageContractualTerm>
    <trov:ClassOfWarrantOrRightNumberGranted
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEwLTEtMS0xLTA_39b4c491-1d45-43af-b9b5-3fdd13c3b906"
      unitRef="shares">5831451</trov:ClassOfWarrantOrRightNumberGranted>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEwLTMtMS0xLTA_e75e07fa-5dd8-4021-a242-6835509d352a"
      unitRef="usdPerShare">1.70</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted>
    <trov:ClassOfWarrantOrRightNumberExercised
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzExLTEtMS0xLTA_4823cda8-aa40-43a4-b9d8-a47eb8f51b7c"
      unitRef="shares">11159941</trov:ClassOfWarrantOrRightNumberExercised>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzExLTMtMS0xLTA_5c87120d-486a-4c97-842a-af8d005c5ea4"
      unitRef="usdPerShare">2.31</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTEtMS0xLTA_2dad6cf8-bb06-4c97-9a28-8c67b434190a"
      unitRef="shares">5260992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTMtMS0xLTA_01f64952-164b-49e3-aebf-0bd5032d2280"
      unitRef="usdPerShare">5.19</trov:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <trov:WarrantsWeightedAverageContractualTerm
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo5MDhmNTVkMzBmNDQ0Mjc0OTZmMzA1NDdiYjE2ZmNjYi90YWJsZXJhbmdlOjkwOGY1NWQzMGY0NDQyNzQ5NmYzMDU0N2JiMTZmY2NiXzEzLTUtMS0xLTA_cb78bd34-e80a-443e-bc1a-b96d85e32592">P4Y1M6D</trov:WarrantsWeightedAverageContractualTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxODQ_53e70483-907e-41e9-87e4-7ee0ab0798e0"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id7f65a990a66462c9a37eb46069c65f5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzM0NDI_e90bb5a8-1b28-4e17-b8af-76e0462b4009"
      unitRef="shares">605072</us-gaap:ClassOfWarrantOrRightOutstanding>
    <trov:ClassOfWarrantOrRightNumberGranted
      contextRef="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzQyNTY_96d728d4-a71c-40d0-bf9f-a61e07c305c4"
      unitRef="shares">386967</trov:ClassOfWarrantOrRightNumberGranted>
    <trov:ClassOfWarrantOrRightNumberExercised
      contextRef="i533aaa5a0d8a4924be7b20d2522706a9_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzQyNjU_2000fba6-b9e9-4149-ad72-bc2900673b81"
      unitRef="shares">992039</trov:ClassOfWarrantOrRightNumberExercised>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxODI_3b88dc1f-368d-4b28-aa68-d16dbf1529ba">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation preference&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItMi0xLTEtMzcyNQ_f4098c72-e12c-43fb-aa71-9d86abe8558e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItNC0xLTEtMzcyNQ_e45df128-d76a-4920-90ed-7b0caa74f8a9"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItNi0xLTEtMzcyNQ_83f145d5-de6f-4b47-9dc1-97b8ad6ce1e1"
      unitRef="usd">606000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItOC0xLTEtMzcyNQ_f8d4ac35-e378-4d85-98c2-b71307caa9ec"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i421f1d41857b4805963135b3663ab8d6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzItMTAtMS0xLTM3MjU_80259cc8-7f8d-4619-ab50-e154ba0b76c9"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtMi0xLTEtMzcyNQ_e3866d23-1c22-4fe2-8bf1-7c6f6ed24372"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtNC0xLTEtMzcyNQ_3cbc5b2e-8770-4c72-80f0-32bb9661a08b"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icd98c4fc531042d897b1d757e7b223e7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtOC0xLTEtMzcyNQ_7cd661d5-0172-4131-872c-77e8f2e20231"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6f48dc38e8b943eb97849002ada03817_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzMtMTAtMS0xLTM3MjU_9a7c3220-1c2b-4a48-bbf9-2cdd3702f709"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtMi0xLTEtMzcyNQ_4bf72005-cd8f-4c2a-be93-f97931d38984"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtNC0xLTEtMzcyNQ_ca3ba3a0-275e-4963-be19-998b7e2e69eb"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i92ab0aa2f5c04e72b192c009f77a8cdb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtOC0xLTEtMzcyNQ_6cec43a8-a4c9-4df9-af4f-f91b1c5b62bb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3451a9182b0d4178a8fc3c09f942e860_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzQtMTAtMS0xLTM3MjU_d4f44a7a-8bee-4679-bf45-eef9c3efe760"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtMi0xLTEtMzcyNQ_6bb1c0e0-c9c7-483e-b5ee-48c9187ca089"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtNC0xLTEtMzcyNQ_5a521562-026f-4841-9a62-d161bf130312"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i11d1170ef6f54edc88cd4268fb361f16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtOC0xLTEtMzcyNQ_d5e8dd8e-d0e8-4272-992d-1b9f7ac5ed26"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i256c4368010c4206a56da927baa4bb4e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzUtMTAtMS0xLTM3MjU_b92fc469-8256-43db-a9da-cf1a258e96fc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i776cee27efa541a2acc891f09e09f352_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtMi0xLTEtMzcyNQ_bfd8e4d6-0bea-4f19-b0dd-6bd332641dad"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i776cee27efa541a2acc891f09e09f352_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtNC0xLTEtMzcyNQ_0dca01eb-80a1-41be-8934-527be419fdc1"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i776cee27efa541a2acc891f09e09f352_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtOC0xLTEtMzcyNQ_4bcb85cb-40ec-40ac-8b10-dec6cdebb4da"
      unitRef="shares">655044</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id456584ebb174aeabb2b1a0753b4e83e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90YWJsZTo0YjgyZTM0ZjBhZTY0ZDY5YjllNGRkMWZlNTFmZGVhZS90YWJsZXJhbmdlOjRiODJlMzRmMGFlNjRkNjliOWU0ZGQxZmU1MWZkZWFlXzYtMTAtMS0xLTM3MjU_b72bc285-8cef-4c4e-a3f8-92f1915a3891"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM2Mzk_3d598e13-4b51-489f-a706-66251f2e0bcb"
      unitRef="number">0.04</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM4ODE_40b2e87c-8eed-45b5-9b03-bd040172cd95"
      unitRef="usd">389495</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
    <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears
      contextRef="i471d5f109548413d9e884f49a86cd7e3_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzM4ODg_520595c6-34b1-4413-9838-cadac6904b97"
      unitRef="usd">365255</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
    <us-gaap:DividendsPreferredStock
      contextRef="id024008e76784d04a81dc04cad256492_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzQwMzA_73147fb2-82d4-46d6-b871-35612bfa4770"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="ib35649721b904fb6bfd39add17891e5e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzQwMzc_160964eb-481b-4c05-83de-c705460357e3"
      unitRef="usd">24240</us-gaap:DividendsPreferredStock>
    <trov:ConvertiblePreferredStockStatedValuePerShare
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzUxMjk_2a146e7e-4e32-4e49-a3b9-38d5a447e314"
      unitRef="usdPerShare">10</trov:ConvertiblePreferredStockStatedValuePerShare>
    <trov:ConvertiblePreferredStockStatedValuePerShare
      contextRef="i6cf54a66629e481797b44e8a6b0fa9b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzUzOTI_d8dda24b-7654-425f-8e22-97abd3748fb0"
      unitRef="usdPerShare">10</trov:ConvertiblePreferredStockStatedValuePerShare>
    <trov:PreferredStockConversionPricePerShare
      contextRef="i0d0b2dbac0ba4dff9255fe336b8f7f15_D20050701-20050930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU0NjU_05efd61c-8f36-4af4-b98e-1387eed22c09"
      unitRef="usdPerShare">928.80</trov:PreferredStockConversionPricePerShare>
    <trov:PreferredStockConversionPricePerShare
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU1MDg_10a273a5-2819-43f1-9661-0b171a2e91ea"
      unitRef="usdPerShare">691.20</trov:PreferredStockConversionPricePerShare>
    <trov:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments
      contextRef="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU2MzY_19a818ec-630c-4828-8360-7824503d04e0">P12M</trov:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments>
    <trov:PreferredStockConversionPricePerShare
      contextRef="id0d3d24dcbb946a88c46b91f1a8fcf8e_D20060317-20060317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU4NTI_2dce21e6-86ec-4a11-8551-5e234030165d"
      unitRef="usdPerShare">691.20</trov:PreferredStockConversionPricePerShare>
    <trov:SharePriceForAutomaticConversion
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU5NDM_755ac59e-8d80-4590-9680-3981c82bf093"
      unitRef="usdPerShare">1857.60</trov:SharePriceForAutomaticConversion>
    <trov:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzU5NjA_e9f14d7a-a0c9-4d55-b88c-8eea4e9980b9">P20D</trov:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
    <trov:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzYwMDc_a30ac0d2-2288-419c-9b15-403b8040283a"
      unitRef="shares">116</trov:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays>
    <trov:PreferredStockConversionObligationNumberOfTradingDays
      contextRef="ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzYwNjM_2b503b76-8cee-4bb5-acef-969ad8bd842d">P20D</trov:PreferredStockConversionObligationNumberOfTradingDays>
    <trov:AmountFinancedUnderAgreement
      contextRef="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MDQ_fa25543f-28da-4b4c-9623-921b50999da7"
      unitRef="usd">1675000</trov:AmountFinancedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie42a61e34be3441d8bb072f33438bcea_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU1OTU_9ce0eeb7-73db-423f-a855-6dfaef4b90c1"
      unitRef="shares">183334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <trov:ClassOfWarrantOrRightNumberGranted
      contextRef="i7f62975a62984e5fbc9741c397cf0608_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxOTA_79d91950-8468-4281-8599-26a9cafd4227"
      unitRef="shares">150000</trov:ClassOfWarrantOrRightNumberGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if8a1c4888a02426788234b406ae96f2e_I20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIxOTk_9f695c5a-cbb2-4f35-9faf-25c9e2529de9"
      unitRef="usdPerShare">3.762</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iaee37ec60282489987c4762ccebbab95_D20190125-20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MjA_23aadb88-d620-43c0-adcb-6c59aba5c132"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i2f5153c4279f4ab9989ac4ac9a3a516d_I20190125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2Mjk_fda5bfd1-ded4-426d-a4c7-8c48c7dbd17e"
      unitRef="shares">1.67</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="ia02b699fc73a48aa943cf6fb99f91912_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2MzU_496216b4-2ebd-4da7-a83f-bd8dfc9b5acb"
      unitRef="shares">200000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i231a9537948e4825940975cf85f361b7_D20190401-20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2NDQ_54c8613f-0b3f-48f3-99a0-1660d20b80bc"
      unitRef="shares">333333</us-gaap:ConversionOfStockSharesIssued1>
    <trov:Servicereceivable
      contextRef="id008b8758bbe4bd891a3f82bf9a4b6a6_I20190125"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2NTM_521119dc-8479-4037-b224-bcb86e483008"
      unitRef="usd">1675000</trov:Servicereceivable>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="iba125ce9af574f5f8548ad377e3f93e9_D20190125-20190125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMDc_3bd393e5-9f50-476b-9d67-14adfe54a424"
      unitRef="usd">300000</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:AmountFinancedUnderAgreement
      contextRef="iccf104fb4e174434837dcfd628d05782_D20200508-20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2Njk_eee47db7-c940-41ca-9471-0220e99718be"
      unitRef="usd">2300000</trov:AmountFinancedUnderAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i076c4c3a873c4a759be050208a345aa5_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2ODM_699510a2-369b-4efc-a4a4-3c9157a32d0d"
      unitRef="shares">602833</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2d3f12d14ad342198f5284373cca8a23_D20200508-20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MDE_f2a0c6bf-b83c-4da9-adc9-70aeba1f2aac"
      unitRef="shares">154670</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU2OTI_48697acd-c079-4dc1-a954-76ac1f6ffdf5"
      unitRef="shares">859813</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i1ce3c54cec224ad18a266a3636ffa8b2_D20200508-20200508"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMzU_ea9b8962-e5d8-41f9-a9e1-03b8564e9775">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2eb2d561492b4b5ca602b2abbb0c7c4f_I20200508"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MTk_be9cb2a5-9225-4409-9a6a-28842491083f"
      unitRef="usdPerShare">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="icdfaba1492ec4f509a70416341174b1f_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MTA_8a48f608-8e8c-4eef-ade7-47648c40e44c"
      unitRef="shares">154670</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i5a917753e1624c298122e4b830a4e135_D20200601-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3MjY_cefe434b-172b-4618-9697-36ca690cb7ed"
      unitRef="shares">1546700</us-gaap:ConversionOfStockSharesIssued1>
    <trov:Servicereceivable
      contextRef="i18b02bac98214f3d9f8953ec814372be_I20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3Mzc_e374c1cf-1a9a-413a-97c4-704b568a84b5"
      unitRef="usd">2300000</trov:Servicereceivable>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="i52c1c34006664ee7ac7c7c4e9e79e509_D20200508-20200508"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NTE_6ef2cce2-7967-4535-915a-5c2ec8a09249"
      unitRef="usd">600000</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0668fc29bb0148d58510684753bd2cfc_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NjU_0f8e5462-07a4-4a88-8194-6e549002877c"
      unitRef="shares">1984328</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i9b284544740a435bad1c3cec495cbf9f_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3NzY_f4506df8-1568-4742-8928-0c16718c8bb6"
      unitRef="shares">865824</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3ODU_2004b6bb-b558-43d4-a216-8df2e7ebb4be"
      unitRef="shares">2213115</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU3OTY_06603e16-b5dc-40ea-b9f4-1cb89c346f4e"
      unitRef="usdPerShare">10</us-gaap:PreferredStockParOrStatedValuePerShare>
    <trov:PreferredStockConvertibleConversionPrice
      contextRef="i0f2bdf19a41047c79ea9eb1f372b5f61_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MDE_6ad2db62-9dfc-4b75-a00e-14e15c3c3313"
      unitRef="usdPerShare">2.44</trov:PreferredStockConvertibleConversionPrice>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="ifdfc040695af4d6a9817380661ebcf2e_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyMjA_d2e07fbc-6161-41c3-a4d2-c2cd9fa9e843">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib6b57d40d4354884b0510a8fef627c3d_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MDg_0095fcf1-9780-4f3d-bfae-35ff4d80fdd3"
      unitRef="usdPerShare">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i95bc585cf217481b97c06b8337a64fe3_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MTU_7c16423b-5a51-448d-acbe-6ac5548257ce"
      unitRef="shares">210780</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MjQ_4e32c971-0576-40cb-aa43-9da5966d0808"
      unitRef="shares">863852</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
      contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4MzM_c97440b3-c51a-4df6-8666-a180ca4e18c0"
      unitRef="usd">2700000</trov:DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock>
    <trov:ClassOfWarrantOrRightIssued
      contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NDc_3491bdf0-9b90-468b-9e08-9912a6d574f6"
      unitRef="shares">184426</trov:ClassOfWarrantOrRightIssued>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNTA_a9436aeb-18f4-49fc-bb0c-37191c86cca4">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i27074d7d656d4fbf85a8b9980795b54a_I20200615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NTY_08d4b1a5-a507-43da-b66c-693b22096ee9"
      unitRef="usdPerShare">3.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <trov:ClassOfWarrantOrRightExpirationTerm
      contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NjU_04eaacc5-7111-48e5-86c1-5f9045f1fc57">P5Y6M</trov:ClassOfWarrantOrRightExpirationTerm>
    <trov:WarrantsFairValue
      contextRef="id4b7d82335f5445e8b4a0bc42f2de4f6_D20200615-20200615"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4NzA_cf843f65-2305-49d8-a1e7-3d39aa0893bc"
      unitRef="usd">370666</trov:WarrantsFairValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4ODA_2f9acb81-fcde-4896-9e71-1bb3c5dc1e54"
      unitRef="shares">800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ibfb24decc5bd454e83658b10c3fc8307_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4ODk_c793b0c3-c15c-4e27-ba8d-2354de053baf"
      unitRef="shares">131967</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i896119a0fd374e00971913227a456947_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNjU_cbd955c6-8879-4c50-8ca7-a3f894b15e0e"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIyNzM_fc9cbf53-0fb4-4a46-8997-126cab90c054">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i896119a0fd374e00971913227a456947_I20200330"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU4OTg_8b82bf82-f1b1-4917-9aac-2d152602ccbd"
      unitRef="usdPerShare">0.948</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <trov:ClassOfWarrantOrRightExpirationTerm
      contextRef="iae90e0c705744d039d42b6bc7f79119f_D20200330-20200330"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MjA_d178e9ee-a061-4552-82ff-a86de77e5679">P5Y6M</trov:ClassOfWarrantOrRightExpirationTerm>
    <trov:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="ib78e87b174ed4b218ac8e7f8c50979db_D20200330-20200330"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MDY_4bb488d1-6be2-47b4-a58e-4fdc2d509ef5"
      unitRef="usd">1000000.0</trov:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMDA_5ef63716-c5f7-4cc9-a575-ea1f55942f33"
      unitRef="shares">904970</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i8be9212423e34a67a70f23c6f9b5ddf4_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMDk_51b90ce4-6896-4cf8-9c25-b5f92d6ffe84"
      unitRef="shares">255000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i81d26bfbbbd5422086f3c9920448c373_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMjQ_23e1e28d-a004-43f5-8540-144122e68f3e"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMzI_77d4af00-b671-4eba-8b04-466f8181f24e">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i81d26bfbbbd5422086f3c9920448c373_I20200409"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzMTg_5e6fe183-a2dd-43c1-bb66-537c615845c0"
      unitRef="usdPerShare">0.81</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <trov:ClassOfWarrantOrRightExpirationTerm
      contextRef="i711c1244823f4bc0a65a32b8ec2ebf12_D20200409-20200409"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNDg_b865dd06-ab40-4006-8078-072c2b8229f6">P5Y6M</trov:ClassOfWarrantOrRightExpirationTerm>
    <trov:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i60fcc2b4743f4bae97a414aae731a011_D20200409-20200409"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNjM_298dac78-1087-4777-b05a-76d8f3911198"
      unitRef="usd">1100000</trov:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3b38eb10663b489e9809321fc0276e7c_D20200511-20200511"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MjU_f3493afd-6f01-40b3-83c2-d6c4023853f0"
      unitRef="shares">447761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i0f6a9b93851e4335a8b8cb89237848bc_I20200511"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5MzQ_5bdef5e5-579e-4512-bdae-e995b08d9fe1"
      unitRef="usdPerShare">1.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i56c03a47441c4536b67faa8e4cf731b7_D20200514-20200514"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NDE_1d04a21e-600a-4453-a265-923483d8aa63"
      unitRef="shares">146854</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ibf127176380c423fa60e0abdd61fd762_I20200514"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NTA_5d33d750-0a30-46c2-b61b-c93a83e364ba"
      unitRef="usdPerShare">1.43</us-gaap:SaleOfStockPricePerShare>
    <trov:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i2e071b9425b74972bb38758dd9e5d35d_D20200511-20200514"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5NTc_efce3244-ebee-423a-a727-92335166b67b"
      unitRef="usd">810000</trov:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5Njc_4e2deab4-6197-4f03-ad6c-1c0f5682ba29"
      unitRef="shares">1205400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5Nzg_69146c08-af2a-4f33-96a3-c85c9f40630d"
      unitRef="shares">482160</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <trov:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzNzY_4494370d-925d-4c9b-babb-f2fa2f91da4a">P6M</trov:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7d54dfdae9b6415f90c911ad769c6a6b_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5ODc_9b4579df-aa80-4203-a8b5-6a0657189e43"
      unitRef="usdPerShare">2.024</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <trov:ClassOfWarrantOrRightExpirationTerm
      contextRef="i05c841806cf3415c8b7866697a1f3fd8_D20200526-20200526"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzEwOTk1MTE2NjIzOTI_9fe0e3d0-92d7-43bd-8093-3c27d5c4d809">P5Y6M</trov:ClassOfWarrantOrRightExpirationTerm>
    <trov:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i399406de7f73421bb69d298b3d13ae36_D20200526-20200526"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzU5OTU_865a4002-01a9-4f94-9e39-4e572bddd294"
      unitRef="usd">2500000</trov:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMDk_fbae78ad-84f1-4d01-92b6-36e77fd201e9"
      unitRef="shares">6500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i544a15f619624305a7fd2f23ac7f07e8_I20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMjA_644faef8-f31d-4f58-a912-9664f2547c5a"
      unitRef="usdPerShare">13.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i201a9eb09e9e4e4d976772527902f4c8_D20201002-20201002"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMjg_f9df3a39-c8e9-4063-b6eb-43dd9e932429"
      unitRef="shares">975000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <trov:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwMzc_8b645bde-6a22-4113-969e-43587b3636ca"
      unitRef="usd">100900000</trov:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzEvZnJhZzo0MjQ4NzUyNzVkOWQ0YjQyYmYxNzhjZTBmOTdiYzQwYS90ZXh0cmVnaW9uOjQyNDg3NTI3NWQ5ZDRiNDJiZjE3OGNlMGY5N2JjNDBhXzE2NDkyNjc0NzYwNTM_6bd12a6f-bdb5-4c0d-aa20-2c289d3a879c"
      unitRef="usd">94000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTI_0999bd45-c49b-4719-a249-ab940a3fb8ca">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:38.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Cardiff Oncology, Inc. 2014 Equity Incentive Plan (the &#x201c;2014 EIP&#x201d;), authorizing up to 34,722 shares of common stock for issuance under the 2014 EIP, was approved by the Board in June 2014 and approved by the stockholders of the Company at the September 17, 2014 Annual Meeting of Stockholders. The total number of authorized shares was increased to 243,056 between the inception of the 2014 EIP through December 31, 2018. At the June 6, 2019 Annual Meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to 1,243,056. At the April 6, 2020 Annual meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to 2,243,056 &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:38.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there were 260,446 shares available for issuance under the 2014 EIP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:38.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation has been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39% - 0.93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66% - 2.33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (range)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102% - 106%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95% - 99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (weighted-average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Based on the historical volatility of Cardiff Oncology&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which averages an award&#x2019;s weighted-average vesting period and expected term for &#x201c;plain vanilla&#x201d; share options. Options are considered to be &#x201c;plain vanilla&#x201d; if they have the following basic characteristics: (1) are granted &#x201c;at-the-money&#x201d;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forfeitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates forfeitures based on its historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2020 and 2019, estimated as of the grant date using the Black-Scholes option valuation model, was $2.09 and $1.91 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2020 was $1,519,004. The weighted-average remaining amortization period at December&#160;31, 2020 for non-vested stock options was 1.9 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of shares vested during the years ended December&#160;31, 2020 and 2019 was $1,522,984 and $386,654, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of stock options exercised during the year ended December 31, 2019 was $0. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and of changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,963,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,682,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU's are measured at the grant date based on the closing market price of the Company&#x2019;s common stock at the grant date and recognized ratably over the service period through the vesting date. All RSU's were granted with no purchase price. Vesting of the RSU's is generally subject to service conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU's activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The total fair values of RSU's vested during the year ended December&#160;31, 2020 and 2019 were $101,290 and $191,436, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i26ddee99771547b8a737dfc7a950fa46_I20140917"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzExOA_0b37b288-2686-454e-8190-3e8279e327aa"
      unitRef="shares">34722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i091e321edee343b38a892516ab3dfeee_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM3Nw_e53cee46-1a32-466a-b4ef-02a965ef32fb"
      unitRef="shares">243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i86676dbd4e74419a825725ca27223263_I20190606"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzczMQ_9a62972d-72b3-4d11-af93-6116c2aa482b"
      unitRef="shares">1243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ideda534790df48cc8af65a740c9c751e_I20200406"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzIxOTkwMjMyNTkyNTU_c898b1d2-f9a1-492e-950b-21ffa4d0e034"
      unitRef="shares">2243056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ieac8de1ad73340dabca4d672d5539b0c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzc1OQ_4d826219-c8bc-47c0-b928-1ea07bf259dc"
      unitRef="shares">260446</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NjI_b5583301-1f10-495b-afe4-b46df0654b10">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation has been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;354,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,410,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,764,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5389a4fe9a914abba2617db418a0173f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzMtMS0xLTEtMA_95be235d-e021-42b4-9d47-1b5d3ab91dd9"
      unitRef="usd">354692</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1bd6a7a4e022447ca67831dd187fe59e_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzMtMy0xLTEtMA_384b4b0c-b2c7-44bc-85d5-3b33bc19f587"
      unitRef="usd">399687</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9460ddaf54074df7bfec5889e2b4845d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzUtMS0xLTEtMA_bd9b7515-926e-4eb8-8b39-42a1ce571046"
      unitRef="usd">1410112</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia4aec0ea85e845048d3ce2ddb7213732_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzUtMy0xLTEtMA_e425cc60-bf1c-457b-bfbf-71e0e1fe6224"
      unitRef="usd">485256</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzctMS0xLTEtMA_74a61bf0-c031-4bba-87e6-fbc891795e9a"
      unitRef="usd">1764804</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTplN2E0Njk1MTZmMDQ0OWM0OTE2MTFmNmU5Y2IwNmIwMi90YWJsZXJhbmdlOmU3YTQ2OTUxNmYwNDQ5YzQ5MTYxMWY2ZTljYjA2YjAyXzctMy0xLTEtMA_9a07e692-3ab0-4fec-8565-5059e92f46f4"
      unitRef="usd">884943</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NDk_9b0e8c5c-7f5b-4952-ada6-2db125e6b9c8">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39% - 0.93%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.66% - 2.33%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (range)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102% - 106%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95% - 99%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (weighted-average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY3YzRkODNiNjIzYTQ4NGFhMmU0ZDE1YWZhMmI3NTliXzM4NDgyOTA2OTcyMzg_58c9a51a-d7ed-412f-832b-d66c34d323da"
      unitRef="number">0.0039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i282b0d837b364a6894a32526001160d0_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY3YzRkODNiNjIzYTQ4NGFhMmU0ZDE1YWZhMmI3NTliXzM4NDgyOTA2OTcyNDY_2e6e97c3-ddd4-4d52-a254-4e51b29f4efd"
      unitRef="number">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if99ea3b979294094999f121f98b5bde6_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMy0xLTEtMC90ZXh0cmVnaW9uOjYyZDFiMDZmNTYyZDQzMTFhOGI1ZmIxYTNlYTAxMjczXzM4NDgyOTA2OTcyMzg_903abedb-ede9-448d-8faf-d0535a751dd6"
      unitRef="number">0.0166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzItMy0xLTEtMC90ZXh0cmVnaW9uOjYyZDFiMDZmNTYyZDQzMTFhOGI1ZmIxYTNlYTAxMjczXzM4NDgyOTA2OTcyNDY_903d3cba-03e7-448b-8208-ce07044f281a"
      unitRef="number">0.0233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzMtMS0xLTEtMA_f121a7be-ea1e-459e-b1d1-fcb649845dea"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzMtMy0xLTEtMA_d41897b9-d4f8-4cc3-a52c-4e08f29123d2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i4607b3d0e6ea4494a30c6685fd0d2fda_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOmI1Y2I2MGFhYWQ3MjQ5YzNiZjNhMmM4ZDQxYjczODNmXzM4NDgyOTA2OTcyMzI_3070397e-5b0a-419e-9f5c-c9d6484a2e9f"
      unitRef="number">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i282b0d837b364a6894a32526001160d0_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMS0xLTEtMC90ZXh0cmVnaW9uOmI1Y2I2MGFhYWQ3MjQ5YzNiZjNhMmM4ZDQxYjczODNmXzM4NDgyOTA2OTcyMzg_714a245e-a02d-49f5-b88d-03ca39fecd47"
      unitRef="number">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if99ea3b979294094999f121f98b5bde6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjVkMDQzMGI2ZDQzMjQ2NGE4NDNiNjg0YjJmNzg2NTQzXzM4NDgyOTA2OTcyMzI_33d649ca-ede3-4931-b613-1786c78f041f"
      unitRef="number">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idbf207a4c4e74ead8078b8987ad1beb0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzQtMy0xLTEtMC90ZXh0cmVnaW9uOjVkMDQzMGI2ZDQzMjQ2NGE4NDNiNjg0YjJmNzg2NTQzXzM4NDgyOTA2OTcyMzg_603b3dd1-399c-4047-a639-5a93b3b3a05a"
      unitRef="number">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzUtMS0xLTEtMA_dd5bceb5-f639-4709-b3c0-45392c273ebd"
      unitRef="number">1.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzUtMy0xLTEtMA_55187f9e-330e-4c3e-9bce-51b1014f13ce"
      unitRef="number">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzYtMS0xLTEtMA_e7130680-198d-4bea-8ed4-ec843073e209">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1MWEzNWI4NzMwOTY0ZjEwYWRmZmJlZTUzNzM0Y2ZiNi90YWJsZXJhbmdlOjUxYTM1Yjg3MzA5NjRmMTBhZGZmYmVlNTM3MzRjZmI2XzYtMy0xLTEtMA_15f5f3a2-9d5f-4517-af3b-86e1c3ff7282">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI0NzE_05eb6c5c-8df6-4782-a001-a8ab8fc2f991"
      unitRef="usdPerShare">2.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI0Nzg_d1ecc55d-30a6-454b-8d04-663518fd264e"
      unitRef="usdPerShare">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI2MDg_81facc58-a7ac-44d0-8cd3-c5b17ff18bca"
      unitRef="usd">1519004</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI3MzA_76c2f2e5-cbc8-47ab-aada-17b35b4d49f2">P1Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI4MzI_b2d64e57-caad-4cab-b91f-4d561262894f"
      unitRef="usd">1522984</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzI4Mzk_70af91f1-85dd-4521-a5ce-300a2e7aeea7"
      unitRef="usd">386654</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzE2NDkyNjc0NDU3ODU_a9cdc733-57ac-47db-8ee0-688a0a445c2f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTA_d871dde1-ac94-4934-b0bb-8538ea3f845d">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and of changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,860,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,963,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,837,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,777,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,682,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTEtMS0xLTA_3f0106e8-17d8-4e90-9323-cacabc8fcc98"
      unitRef="shares">1015418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTMtMS0xLTA_c5cdcd3b-3c45-416d-a4b5-2bb08e0da363"
      unitRef="usdPerShare">12.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i8d3e6472816445c1a3ca937b4efafb70_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTUtMS0xLTA_e66f4959-f56d-444c-a898-df39ccd6a2f1"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="if8badc7c075d44a19f1ceef574efbeb0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEwLTctMS0xLTA_0a4aeb2d-8994-4bf1-a31e-e4d035d92808">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzExLTEtMS0xLTA_aab7c560-6dd2-49fe-becc-b8ecf444de87"
      unitRef="shares">969965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzExLTMtMS0xLTA_e0e755dc-3a09-43a4-acc4-f9f71d6fee44"
      unitRef="usdPerShare">2.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTEtMS0xLTA_a32ca087-14a3-46c8-9ea9-bd5eab5b5847"
      unitRef="shares">60195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTMtMS0xLTA_db95b6ac-771d-4571-9617-8feacf081f41"
      unitRef="usdPerShare">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEyLTUtMS0xLTI2ODk_b530837d-26d2-4906-b917-90906f079a44"
      unitRef="usd">970145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEzLTEtMS0xLTA_7c551138-c53d-4b8e-b76e-b3355c380655"
      unitRef="shares">48537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzEzLTMtMS0xLTA_5299020d-a8c6-49eb-ae3e-cf7008111289"
      unitRef="usdPerShare">22.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <trov:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE0LTEtMS0xLTA_bd162d96-a484-482c-b170-43d319865875"
      unitRef="shares">16144</trov:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <trov:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE0LTMtMS0xLTA_43e4c181-3215-429c-b2f0-95e87690f582"
      unitRef="usdPerShare">21.29</trov:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTEtMS0xLTA_a394f890-76a4-4daf-9478-e44bb81cd520"
      unitRef="shares">1860507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTMtMS0xLTA_26a8ece8-24ec-4a8f-8329-6afce6e00358"
      unitRef="usdPerShare">7.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTUtMS0xLTA_5e19d661-60db-48c2-9a89-36e10d6a830e"
      unitRef="usd">27963363</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE1LTctMS0xLTA_32acacaf-f466-4d9d-bedd-caf788b93071">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTEtMS0xLTA_0781810d-e13f-46e0-86b3-bb24d003d754"
      unitRef="shares">753206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTMtMS0xLTA_b428f586-3fcb-470f-8834-8de153caf290"
      unitRef="usdPerShare">14.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTUtMS0xLTA_1b0ecda2-f0e4-4b42-9c79-77a04af5dbd8"
      unitRef="usd">10837211</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE2LTctMS0xLTA_ed651b38-ab13-47f6-b6b1-06b51420aae6">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTEtMS0xLTI2OTY_8bd9b39a-6923-4d30-9578-ced4b80af53c"
      unitRef="shares">1777407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTMtMS0xLTI2OTY_8bee0d24-d298-4e1b-9f8c-696973320142"
      unitRef="usdPerShare">7.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i4fd318c67b6c46e1981c21a7ac58d178_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTUtMS0xLTI2OTY_2df6003d-be3d-4e26-9f13-549d46ac0599"
      unitRef="usd">26682849</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ibeeb551ace7d42168313ad655821639d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTo1ZDVlMGVhZjFlNDE0NzIzOWNlNGU2MmI2OTlhMjU4Zi90YWJsZXJhbmdlOjVkNWUwZWFmMWU0MTQ3MjM5Y2U0ZTYyYjY5OWEyNThmXzE3LTctMS0xLTI2OTY_471589eb-212b-471e-9807-3760cf308bde">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0NTg_6640951c-5fa6-4e1a-a4d0-c3debb351687">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the RSU's activity is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.832%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.175%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&#160;Average&lt;br/&gt;Grant Date Fair Value&lt;br/&gt;Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,057)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,810)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested RSU's outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtMS0xLTEtMA_be82b37a-070f-432e-835e-17a205fc636c"
      unitRef="shares">30132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtMy0xLTEtMA_93988c3c-f1bc-40c9-9dd9-7e6fb5d5cfb3"
      unitRef="usdPerShare">14.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ie72aca79d4804a8284025a9bab28eb5e_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzEtNS0xLTEtMA_f655c52b-08ad-4c87-ad18-237ea9dbea64"
      unitRef="usd">95005</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzItMS0xLTEtMA_30dcd7d5-497c-410b-b7c5-95aa47a80e78"
      unitRef="shares">9167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzItMy0xLTEtMA_2b4355b2-0a1d-44c1-a836-f165660ce3a1"
      unitRef="usdPerShare">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzMtMS0xLTEtMA_d5700651-5581-424b-9924-fa91153c1d66"
      unitRef="shares">22057</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzMtMy0xLTEtMA_a81f3d10-3034-4ace-86e2-703f44bbebad"
      unitRef="usdPerShare">8.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzQtMS0xLTEtMA_65c0c331-744b-4a82-bc61-d611eee27312"
      unitRef="shares">5941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzQtMy0xLTEtMA_8881af51-0c67-4883-a516-4a5b2f6ca608"
      unitRef="usdPerShare">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtMS0xLTEtMA_55b91b37-7761-4202-a4c1-583fc2c45bea"
      unitRef="shares">11301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtMy0xLTEtMA_c8edd50e-3d76-4bff-a817-e11841f97579"
      unitRef="usdPerShare">15.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i978ad2c8eb824931bb5e88b64023d145_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzUtNS0xLTEtMA_a0a6ee34-a54a-49a6-825e-f8276f342ee3"
      unitRef="usd">14013</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzctMS0xLTEtMA_f7a1c158-fd3e-424a-9f64-68ef1ac24f0e"
      unitRef="shares">10810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzctMy0xLTEtMA_c7f1261e-9d0c-4706-95b9-dea82e8e6de4"
      unitRef="usdPerShare">9.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktMS0xLTEtMA_364a6844-b28a-48e8-ad55-b178464144ed"
      unitRef="shares">491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktMy0xLTEtMA_5d9ac826-5070-424e-ac84-5a3e5d69d2eb"
      unitRef="usdPerShare">147.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ica41068d79e14cf38ab901aaf00addb4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90YWJsZTpiNmYyMmY4YTcxNDE0ODI2OWU5NTAyZmNjOWEzYjQwYi90YWJsZXJhbmdlOmI2ZjIyZjhhNzE0MTQ4MjY5ZTk1MDJmY2M5YTNiNDBiXzktNS0xLTEtMA_5393dc5e-91bb-49e2-9f17-63313bba4a83"
      unitRef="usd">7641</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i37ef470613374ffcbf406ef536404dcb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0MjM_27a4b70b-543b-4854-b5c8-033ed3e32ab7"
      unitRef="usd">101290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7b2085d1a59c4b089cf2cda730295b37_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNzcvZnJhZzo0ZjEzYzViZGIwNDI0MWI0YjVkZGFjMzhlNjVjZmU5Zi90ZXh0cmVnaW9uOjRmMTNjNWJkYjA0MjQxYjRiNWRkYWMzOGU2NWNmZTlmXzM0MzA_390088c4-97d9-4f6b-ae00-21562a9138a8"
      unitRef="usd">191436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2Njg_9f743abf-d7d5-442b-bd23-42dee29769b8">Derivative Financial Instruments &#x2014; Warrants&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#x2019;s equity financings are accounted for as derivative liabilities.  Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model.  Changes in fair value are recorded within Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.01 - $17.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 - 3.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1 - 4.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13% - 1.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56% - 2.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110% - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102% - 111%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2) The weighted average was calculated using the relative fair value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility is based on the historical volatility of Cardiff Oncology&#x2019;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the year recognized as a gain in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants  during the year recognized as a loss in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The remaining contractual term of the warrants outstanding at December&#160;31, 2020 and 2019 was approximately 2.1 and 3.1 years, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i229ba083ae0546d499ab31088af51e73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2NzE_aadea163-ca9e-45a0-ba6d-3271df0cbcb2">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.01 - $17.99&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24 - $3.75&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 - 3.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1 - 4.1 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13% - 1.62%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.56% - 2.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110% - 118%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102% - 111%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. &lt;/span&gt;&lt;/div&gt;(2) The weighted average was calculated using the relative fair value method.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <trov:EstimatedFairValueOfWarrant
      contextRef="i32ab39cf4fc841beb603ef348cdce603_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMS0xLTEtMC90ZXh0cmVnaW9uOjhhNjVhNTcwYTc5NzQzMGY4ZmQyY2IyODNiZDQ0OGYwXzM4NDgyOTA2OTcyMzg_47456436-b589-4fa3-b13d-a9874da77790"
      unitRef="usdPerShare">1.01</trov:EstimatedFairValueOfWarrant>
    <trov:EstimatedFairValueOfWarrant
      contextRef="i4d8190644bee425ea8f517bd7095ed17_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMS0xLTEtMC90ZXh0cmVnaW9uOjhhNjVhNTcwYTc5NzQzMGY4ZmQyY2IyODNiZDQ0OGYwXzM4NDgyOTA2OTcyNDY_bc57f9f7-6b20-488a-9ece-fd12aadb2421"
      unitRef="usdPerShare">17.99</trov:EstimatedFairValueOfWarrant>
    <trov:EstimatedFairValueOfWarrant
      contextRef="i1742e003e63146e896137b7e99fc50bf_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMy0xLTEtMC90ZXh0cmVnaW9uOmU3MDYxYzM4ZjJlZDRlOGNiNjJjZTBjMjJjYTdkZWVhXzM4NDgyOTA2OTcyMzg_5549b2b0-9695-4dde-b937-7abdcedcfb1a"
      unitRef="usdPerShare">1.24</trov:EstimatedFairValueOfWarrant>
    <trov:EstimatedFairValueOfWarrant
      contextRef="i018bdbce7fca40e082dacb672d84b913_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzItMy0xLTEtMC90ZXh0cmVnaW9uOmU3MDYxYzM4ZjJlZDRlOGNiNjJjZTBjMjJjYTdkZWVhXzM4NDgyOTA2OTcyNDY_3d1de484-bf62-4f06-b0c9-437145aa44ae"
      unitRef="usdPerShare">3.75</trov:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i44266fc1522f4f4eb8386f8c708948d6_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFmZGY1YzcwOThjYTRmNGJiZDE0NDRiNjA4Zjc2ZWRlXzM4NDgyOTA2OTcyMzg_5160814e-b5b9-4695-810d-aa4674dec368">P2Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="id3fca2ac35d14a2384fef909655332d4_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjFmZGY1YzcwOThjYTRmNGJiZDE0NDRiNjA4Zjc2ZWRlXzM4NDgyOTA2OTcyNDQ_ff374c02-e68c-47cf-8802-0613d1865bb8">P3Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ic0b1c58ab8b54dfc863c667221a34301_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjA2MTA1ZjZmOGE0MzQ0MmZhNzhjZTY2NzJiOWFlYzcwXzM4NDgyOTA2OTcyMzg_9be260b4-0ae0-4acc-bf69-21f475b69ca8">P3Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ie85416ca7f414db49fe52bc843a8e2d4_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjA2MTA1ZjZmOGE0MzQ0MmZhNzhjZTY2NzJiOWFlYzcwXzM4NDgyOTA2OTcyNDQ_bd7ba974-9910-4959-b9e0-eaa552b20032">P4Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3794493459f24ebfbe863d8937e8cad5_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc2NDUyMDZiN2ZjNjQ5MzRiMzI2ZjhjNmJmNjIxZDZlXzM4NDgyOTA2OTcyMzg_45c3885c-e5cb-4b30-baa3-b7de33cbf52f"
      unitRef="number">0.0013</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0fb8cbc4edb14870b358d288e5800248_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMS0xLTEtMC90ZXh0cmVnaW9uOjc2NDUyMDZiN2ZjNjQ5MzRiMzI2ZjhjNmJmNjIxZDZlXzM4NDgyOTA2OTcyNDY_4ed10f9a-2c7a-4aa4-bb00-e92a86d77042"
      unitRef="number">0.0162</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i7d3620e40923403582678ccccc8f11fa_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY5NzE5YzQ5N2Y5NjRjMGE5MTYzM2VmOGJlNmUwZmQwXzM4NDgyOTA2OTcyMzg_656151a0-9e10-4de3-93df-7163b2c208fd"
      unitRef="number">0.0156</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib4f8972453604ec193d1df9f7e4ddac0_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzQtMy0xLTEtMC90ZXh0cmVnaW9uOmY5NzE5YzQ5N2Y5NjRjMGE5MTYzM2VmOGJlNmUwZmQwXzM4NDgyOTA2OTcyNDY_30a19f20-7cb3-4adc-890c-94b727eb3d76"
      unitRef="number">0.0249</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2cc7198d6c034a22b424dd61cae5fd7c_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjA4MWNmMGQ0MjRlYjQ5MmRhZDhlMTRiODA1NWQxNWM1XzM4NDgyOTA2OTcyMzU_f437c671-6372-48a7-802b-3dfa63ad8ae2"
      unitRef="number">1.10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1106ab4e606c4769a8f986403de38037_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjA4MWNmMGQ0MjRlYjQ5MmRhZDhlMTRiODA1NWQxNWM1XzM4NDgyOTA2OTcyNDI_5ea0a4c4-0077-4762-a8c0-822963bae974"
      unitRef="number">1.18</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id76a88eeb56a477fa5ae7aa8b08acf1d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMy0xLTEtMC90ZXh0cmVnaW9uOmU4YWVmZTgxYmYyYTRiMzZhMGM2MWZkMTQ0OTg0MjI4XzM4NDgyOTA2OTcyMzU_e667386a-5ad8-4903-9bb5-ce3ab7679584"
      unitRef="number">1.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ifd3060e53a504b04a348d4ba80c3b484_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzUtMy0xLTEtMC90ZXh0cmVnaW9uOmU4YWVmZTgxYmYyYTRiMzZhMGM2MWZkMTQ0OTg0MjI4XzM4NDgyOTA2OTcyNDI_6b5e82dd-e06d-413e-8f97-25fd2bc7791a"
      unitRef="number">1.11</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ibfe962c2ee074fbe9e3a0a8ee9b2fc05_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzYtMS0xLTEtMA_7a5c3d25-07bd-4488-b8b8-b64cc1a55037"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i090a771b6a4c49029aca107400020091_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzYtMy0xLTEtMA_ee8bd7de-ecb1-4987-987b-502e9145406d"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <trov:EstimatedFairValueOfWarrant
      contextRef="i73ffea244a27445a8d5f0970bdc9898e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEwLTEtMS0xLTEyMDE_79fc9bee-846a-4ee7-891f-c27e35a9404c"
      unitRef="usdPerShare">17.99</trov:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i031d703e2ea24364b5f7af43c8fb47c0_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzExLTEtMS0xLTEyMDE_fbb5df18-1088-4fbe-938b-5d404c6ca687">P2Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i5ac205ca24f94fe293ef86874c82e1e2_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEyLTEtMS0xLTEyMDE_9fd31fef-4cbb-4eba-93d5-c6694a79391c"
      unitRef="number">0.0013</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ice81c716c97c41b5bc001dfa532b8fdb_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzEzLTEtMS0xLTEyMDE_b938d224-7efa-46fd-abc7-826778a9be82"
      unitRef="number">1.16</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i3345cb0517cc4b0284c813555e82d7d2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTozNDNmYTMxNDkwZGI0NDYzYjkzMTQzMGViMWQ2MTFmYi90YWJsZXJhbmdlOjM0M2ZhMzE0OTBkYjQ0NjNiOTMxNDMwZWIxZDYxMWZiXzE0LTEtMS0xLTEyMDE_da327878-3278-4d4a-a214-9f3dc3a090e2"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <trov:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock
      contextRef="i229ba083ae0546d499ab31088af51e73_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzE2NzQ_3887e0fe-e489-4e8c-9578-675e66b35ebd">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.468%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.618%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the year recognized as a gain in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants  during the year recognized as a loss in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</trov:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2b746e4199184cacad6f602a3b40b8e9_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzEtNC0xLTEtMA_27a13b76-c8f1-4143-8ead-714577912d92"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i2b746e4199184cacad6f602a3b40b8e9_I20181231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzEtNi0xLTEtMA_b2d08098-faab-480e-b8ee-6ccd0391492e"
      unitRef="usd">32315</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i747d6a62e34a472c83d5644420b34a22_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzMtNi0xLTEtMA_ba99f6f1-4413-4baf-9e22-024a32331609"
      unitRef="usd">28188</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzQtNC0xLTEtMA_bf25e59e-06ce-46b6-b3ae-d281b36b7ebc"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i1105733d073744cd9a3e52b232486c1e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzQtNi0xLTEtMA_baed9f8a-b5ef-494b-a072-5a74c7fbfa3e"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i984ff34a2fe742088f9f828b91b563ea_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzYtNi0xLTEtMA_b4a29f4f-dac8-4794-a151-89b8c68f096f"
      unitRef="usd">-280844</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0656cf347232476bae791a60c6bd570f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzctNC0xLTEtMA_1dc30525-60ff-4c44-92bd-332ff4ede9cd"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i0656cf347232476bae791a60c6bd570f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90YWJsZTpkOWRmMmJmZWE4MGU0ZDY5OWNjN2I1N2NkZGU0MWNhNi90YWJsZXJhbmdlOmQ5ZGYyYmZlYTgwZTRkNjk5Y2M3YjU3Y2RkZTQxY2E2XzctNi0xLTEtMA_4ab8abe7-b013-4bb4-abf3-b5863d0daa5e"
      unitRef="usd">284971</us-gaap:DerivativeLiabilitiesNoncurrent>
    <trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm
      contextRef="iffe390a53d1244859cc856f61f4542ae_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzEzMzQ_71b4edf5-c69f-4700-91b9-822b561d81d3">P2Y1M6D</trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm>
    <trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm
      contextRef="ice44ef262276432684d43f12b496e84d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODMvZnJhZzo4NmI0MjQ3ODI3NjM0YWE0YWU1YjdlMTU5YmI5ZWMwZi90ZXh0cmVnaW9uOjg2YjQyNDc4Mjc2MzRhYTRhZTViN2UxNTliYjllYzBmXzEzNDE_4be6dc8c-d7f6-41f6-a730-b566b2eb864d">P3Y1M6D</trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90ZXh0cmVnaW9uOmMyYTA2NDY0NTEyMDRlYzA5NjE3MTM4M2JmMWFlNTJhXzEwNTM_4136c392-97ca-47dd-ad8c-735595e0c469">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets and Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets and Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included as a component of cash and cash equivalents on the accompanying balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the fair value of the &#x201c;derivative financial instruments&#x2014;warrants&#x201d; is recorded as a gain or loss in the Company&#x2019;s statement of operations. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90ZXh0cmVnaW9uOmMyYTA2NDY0NTEyMDRlYzA5NjE3MTM4M2JmMWFlNTJhXzEwNTE_7df802bc-598b-4bdc-a67c-b24ebbcc2890">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets and Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,987,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets and Liabilities&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Money market fund (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,131,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Included as a component of cash and cash equivalents on the accompanying balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtMS0xLTEtMA_b7c134da-9f12-42e8-a13f-b8c289cea0de"
      unitRef="usd">129987804</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtMy0xLTEtMA_a0a08325-994d-4ddd-940f-7f010093b7d9"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtNS0xLTEtMA_a3a12bb1-949a-40ad-ba5d-c32338a4f15e"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzMtNy0xLTEtMA_6a3bd062-5da4-4166-84d9-bc84ac743191"
      unitRef="usd">129987804</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctMS0xLTEtMA_f37e7cf8-f8e3-4da1-a4e9-3a97a1a8d913"
      unitRef="usd">129987804</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctMy0xLTEtMA_24b75b71-3d09-4047-8d92-8ec562d96f3f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctNS0xLTEtMA_ecd7b9a3-30df-4959-b80c-0635f9739875"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzctNy0xLTEtMA_83f5f9f0-594f-4a8c-a9b9-adb488ed57bd"
      unitRef="usd">129987804</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktMS0xLTEtMA_aee71586-8bf2-4abf-9f1e-2dbb9bd4d2fb"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktMy0xLTEtMA_6bfbbdf5-b4ef-472b-a6d4-d9e49b21fb70"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktNS0xLTEtMA_fb6aae4f-92eb-4e47-8d7f-17697133feef"
      unitRef="usd">284971</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzktNy0xLTEtMA_b6eb2ff6-41b4-4b22-9a9c-e4ab0345c576"
      unitRef="usd">284971</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9cdcc0804110481f8528b0ba7253bd83_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTEtMS0xLTA_d3b8f9be-3c1c-4404-bf61-1c21718533d0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5e1bf59004804ff0a735f759a0b05ec6_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTMtMS0xLTA_eab22ce5-4eaa-45ff-8958-15c7f2b109aa"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if6111128fd05424493681c4a0b3eb66d_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTUtMS0xLTA_bd1a6ece-fa32-4a78-98d1-b54c5670a343"
      unitRef="usd">284971</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i57e9a24fb323452cbc514841b9fbe098_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZTowM2NkZmJmYjQ1MTg0MDk3YWU1MGU4M2NjMGQ0ODkyNy90YWJsZXJhbmdlOjAzY2RmYmZiNDUxODQwOTdhZTUwZTgzY2MwZDQ4OTI3XzEwLTctMS0xLTA_e35eb192-8b16-4108-b179-7145f70dc72b"
      unitRef="usd">284971</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtMS0xLTEtMA_8a93a0f7-0220-4e96-af00-0eb289771a22"
      unitRef="usd">10131240</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtMy0xLTEtMA_adda4828-8817-49e2-bf0c-05731b1fdae5"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtNS0xLTEtMA_5870210c-94a5-4bc4-b072-e3cb3eff28e9"
      unitRef="usd">0</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzMtNy0xLTEtMA_cd26097d-e153-46ca-bc9b-4494df9bcc0d"
      unitRef="usd">10131240</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctMS0xLTEtMA_6d18f45e-c787-49a7-a9d5-7d4bdb66b651"
      unitRef="usd">10131240</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctMy0xLTEtMA_bed769fe-9c9c-4fd6-ab41-3a0a09bd4875"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctNS0xLTEtMA_1b60cef3-4afb-40c5-83c0-2c6d9e612736"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzctNy0xLTEtMA_b2dab4ea-ee78-49d2-b178-3b67530b28d6"
      unitRef="usd">10131240</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktMS0xLTEtMA_6bc1c56c-898b-4a18-aa1a-e88e6a1fb73e"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktMy0xLTEtMA_ad792ead-ab79-46f4-b754-3a732f6acd0a"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktNS0xLTEtMA_aa1f4cbc-2621-4964-80ad-52c6c56744c4"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzktNy0xLTEtMA_0db936ea-5fc1-4e1c-b046-d0aeb9ef3039"
      unitRef="usd">4127</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iefd5b9d46a2c41119b2db92f9d2479e9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTEtMS0xLTA_4773bc95-2ed5-4fd0-a3b2-5123bfed7f4b"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8a39b3fd068e454697f74ce2c0d30cbc_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTMtMS0xLTA_5247d8f2-0381-41c7-9f8b-c9fa87313343"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if2cad480a48a41da8b00597bbd01b912_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTUtMS0xLTA_76f34688-ed20-4679-b4b1-c922711f917a"
      unitRef="usd">4127</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id28dc18f34d940bb9fcc4de9a9f313f9_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yODkvZnJhZzpjMmEwNjQ2NDUxMjA0ZWMwOTYxNzEzODNiZjFhZTUyYS90YWJsZToxNjgwNmNhMzYxMjA0OGFhOTU2NGQzZjQwM2M4NGE5ZS90YWJsZXJhbmdlOjE2ODA2Y2EzNjEyMDQ4YWE5NTY0ZDNmNDAzYzg0YTllXzEwLTctMS0xLTA_83077580-9aff-414e-a7c5-9dcb033806f4"
      unitRef="usd">4127</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIwOTY_e630ad9f-8caa-480f-878b-cd79d8bde55f">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, Cardiff Oncology had federal net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $128.9 million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $48.4 million, which do not expire. Cardiff Oncology also has California NOLs of approximately $70.7 million which, if not used, will begin to expire in 2029. Cardiff Oncology has Federal and California capital loss carryforwards of $0.7 million which, if not used, will begin to expire in 2022. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $2.5 million and $1.8 million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) Sections 382 and 383, annual use of a company&#x2019;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has not completed such an analysis pursuant to Sections 382 and 383 and therefore has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#x2019;s unrecognized tax benefits will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s taxes and the rates as of December 31 are shown below (in thousands, except percentages): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax computed at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and none have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <trov:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="idbc8e0a3804c47c4ae77c14738fc2399_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzExMg_0c0e4080-0f7e-42be-92cb-588435273e82"
      unitRef="usd">128900000</trov:OperatingLossCarryforwardsSubjectToExpiration>
    <trov:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="idbc8e0a3804c47c4ae77c14738fc2399_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIyMQ_9e854e6f-adab-43d0-8fb1-f5f4aa698061"
      unitRef="usd">48400000</trov:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iedf02bb4675b4a2d940c16f6f69cb7c4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzI5OA_4197710b-ea4e-4049-94f9-2937b1bbd715"
      unitRef="usd">70700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic9b865da6863477b8c4c5144516016d8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzE2NDkyNjc0NDYwOTg_6bf58e50-e330-4932-8c04-836da6cafc12"
      unitRef="usd">700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="id661a46404df44e0b0e9dbdd6e3e8364_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzQ2NA_1cef7df4-e325-442b-a326-1ae82d8e25c2"
      unitRef="usd">2500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i29a27f9e1adc4f6dacd046a2f6a03585_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzQ3MQ_29958a80-9433-4d3f-8d98-2758cb69933e"
      unitRef="usd">1800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTM_1b25e5f1-cdb7-4084-aba1-c40a1d8e623e">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzQtMS0xLTEtMA_3e69dfd6-f4a3-4cde-ab96-c719d29fac7f"
      unitRef="usd">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzQtMy0xLTEtMA_f6baae06-b414-4b9e-bf38-9f97e722fd81"
      unitRef="usd">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzUtMS0xLTEtMA_b2ea64c0-cdaa-4283-a756-30c66f5760df"
      unitRef="usd">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzUtMy0xLTEtMA_ed28a624-f258-4e5a-9ec3-a98a4aeee5b4"
      unitRef="usd">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzctMS0xLTEtMA_19b99ed7-6aaa-478d-9397-08f48a2be917"
      unitRef="usd">-4043000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzctMy0xLTEtMA_220ba88d-95eb-4c2e-b682-8d11bcadd5dc"
      unitRef="usd">-2634000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzgtMS0xLTEtMA_3163e6a9-7561-46ed-b586-3dda2c8f28d2"
      unitRef="usd">-92000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzgtMy0xLTEtMA_07221610-621c-4990-9c14-9b3909c5b625"
      unitRef="usd">-148000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEwLTEtMS0xLTA_daf0a7f3-e180-4973-b499-6612fd8b0344"
      unitRef="usd">-4135000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEwLTMtMS0xLTA_af20fcb0-539b-4804-bcba-31c947b3dfd7"
      unitRef="usd">-2782000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <trov:ValuationAllowance
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzExLTEtMS0xLTA_409981d7-4ab4-4453-8ec8-6b7c12c01fbd"
      unitRef="usd">4134000</trov:ValuationAllowance>
    <trov:ValuationAllowance
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzExLTMtMS0xLTA_94eb7d6a-a303-473f-8eb7-d663805b6832"
      unitRef="usd">2781000</trov:ValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEyLTEtMS0xLTA_8f5dd19f-08fc-4a2d-ac6c-df6d28166965"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpjZDAyMTM4ZmE5MmQ0ZjIyOTA1ZDk1YzU0ZWZjNjljNC90YWJsZXJhbmdlOmNkMDIxMzhmYTkyZDRmMjI5MDVkOTVjNTRlZmM2OWM0XzEyLTMtMS0xLTA_79558e95-f9e5-4fc8-bf9e-ff46cb249371"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTA_49b90d96-bb22-4156-bf8a-9db62658f698">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s taxes and the rates as of December 31 are shown below (in thousands, except percentages): &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax computed at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(122)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent Items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options true-up&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItMS0xLTEtMA_f37b12b9-ad95-4f87-a0c2-106c3ced9d58"
      unitRef="usd">-4054000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItMy0xLTEtMA_c45e6581-9e1b-4d67-87fa-09e1a952d934"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItNS0xLTEtMA_57e6b8bb-6f12-4edd-a637-8728f2e4fb38"
      unitRef="usd">-3447000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzItNy0xLTEtMA_5c78c745-2409-42c7-a476-d8ef5a9ca742"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtMS0xLTEtMA_79930f4a-69cc-40c1-ac3c-db05264936d4"
      unitRef="usd">-122000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtMy0xLTEtMA_949b0c91-9537-4b88-9207-c2dee37c11f5"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtNS0xLTEtMA_31b9f2ba-d6ca-4201-bac9-b27de9d12051"
      unitRef="usd">-177000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzMtNy0xLTEtMA_89c7d362-fbab-453d-882e-ac1b9a98699f"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <trov:IncomeTaxReconciliationPermanentItems
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtMS0xLTEtMA_6c724d0f-cb13-45cf-9084-bbeee0dcac22"
      unitRef="usd">261000</trov:IncomeTaxReconciliationPermanentItems>
    <trov:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtMy0xLTEtMA_a765eab2-8265-47ed-88af-b1825d4b2255"
      unitRef="number">-0.01</trov:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <trov:IncomeTaxReconciliationPermanentItems
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtNS0xLTEtMA_7ac1dade-0179-4829-b39f-15055370d65f"
      unitRef="usd">353000</trov:IncomeTaxReconciliationPermanentItems>
    <trov:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzUtNy0xLTEtMA_73b00ca7-5822-4d75-9b06-ce9133c250bd"
      unitRef="number">-0.02</trov:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtMS0xLTEtMA_d21f580f-c829-4207-940a-e2ddc6ae5da8"
      unitRef="usd">81000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtMy0xLTEtMA_5eefcb14-e85c-49b4-9a33-e184e4a84941"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtNS0xLTEtMA_f846f424-3836-4557-8ea9-3e986fb1b2cd"
      unitRef="usd">875000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzYtNy0xLTEtMA_71c159a2-6be4-46e6-b68f-ddd08a1d6e89"
      unitRef="number">-0.05</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctMS0xLTEtMA_040f0d0f-8677-4d0a-b602-ddf6ad72fbdf"
      unitRef="usd">300000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctMy0xLTEtMA_2cce8c57-cc53-49b6-a8ce-d97295136447"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctNS0xLTEtMA_97b80712-c15d-4f54-9240-fea71614a700"
      unitRef="usd">384000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzctNy0xLTEtMA_493df92b-f95e-4e31-946f-74cb7be7eef6"
      unitRef="number">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtMS0xLTEtMA_db3b9938-909d-4d58-aad8-753a1049e6b6"
      unitRef="usd">4134000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtMy0xLTEtMA_24e0f5e2-e71e-4388-bc16-d9276f792570"
      unitRef="number">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtNS0xLTEtMA_8dd2771a-76bc-4f5d-8111-d15c6820f74a"
      unitRef="usd">2780000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzgtNy0xLTEtMA_3f4bb7cd-5cf2-4d28-8ae7-af6058b5dda5"
      unitRef="number">-0.17</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTEtMS0xLTA_e5a4f95f-03a0-4742-8967-8f8552483dfb"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTMtMS0xLTA_cb5fc666-1227-4d02-891d-ea45bb80d955"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTUtMS0xLTA_cb831085-3f92-4c43-b2e3-af2756009f63"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTpkYjg4ODI0Y2Y0ZGY0ZWY0YWYyY2QyZTNlMGIxYmI2My90YWJsZXJhbmdlOmRiODg4MjRjZjRkZjRlZjRhZjJjZDJlM2UwYjFiYjYzXzEwLTctMS0xLTA_41f3135a-1c79-4773-9b8b-bf8a4cceb468"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIxMTE_9e2da743-88fd-46ff-834a-8ada8324828a">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,821)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzMtMS0xLTEtMA_c7b8858c-736e-4a00-85a2-7f997f7502ae"
      unitRef="usd">42331000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzMtMy0xLTEtMA_7fee9673-caa2-4eff-a267-4a540da68600"
      unitRef="usd">38494000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzQtMS0xLTEtMA_6a21da92-360d-46d1-a232-df3100986706"
      unitRef="usd">3904000</trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzQtMy0xLTEtMA_349feeb5-e49e-4639-9e1b-998cbc4739e1"
      unitRef="usd">3710000</trov:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzUtMS0xLTEtMA_220dda54-80a8-4671-a587-534851017a1d"
      unitRef="usd">684000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzUtMy0xLTEtMA_77b3b726-674d-4645-a1e1-2117c4c66ca5"
      unitRef="usd">531000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzYtMS0xLTEtMA_c6b3c32d-fdbb-4531-867f-dfda840b3382"
      unitRef="usd">1116000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzYtMy0xLTEtMA_ef1bdb08-3fec-4076-8c53-303979c68d53"
      unitRef="usd">1252000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzctMS0xLTEtMA_e1a68c55-2777-474e-92de-c757c4c00b32"
      unitRef="usd">48035000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzctMy0xLTEtMA_9b3ccdcb-cb06-466a-8777-94bca6994b38"
      unitRef="usd">43987000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzktMS0xLTEtMA_42f599ea-3a5b-4994-90ae-195da5c2fa83"
      unitRef="usd">74000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzktMy0xLTEtMA_2899547a-de39-4af9-a889-ca3ad62309d9"
      unitRef="usd">154000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEwLTEtMS0xLTA_dbe0a937-3554-421c-b9bd-3b87452b5c5f"
      unitRef="usd">6000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEwLTMtMS0xLTA_88d500fb-b637-457d-bd4a-dbb5780974f2"
      unitRef="usd">12000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzExLTEtMS0xLTA_3827565d-0098-4212-9adc-ba2ee148594b"
      unitRef="usd">80000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzExLTMtMS0xLTA_8b88dfc8-b4ee-4196-ad82-dfaabadbed78"
      unitRef="usd">166000</us-gaap:DeferredIncomeTaxLiabilities>
    <trov:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEyLTEtMS0xLTA_44ae6d31-d89f-4d1c-8d38-ee336f822b18"
      unitRef="usd">47955000</trov:DeferredTaxAssetsNetBeforeValuationAllowance>
    <trov:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEyLTMtMS0xLTA_3c11d468-b761-44a2-be7d-d3806df32a4f"
      unitRef="usd">43821000</trov:DeferredTaxAssetsNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEzLTEtMS0xLTA_da24c8e1-8af1-4705-bce6-7f3fa835d7dd"
      unitRef="usd">47955000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzEzLTMtMS0xLTA_cfd69c28-34e5-4af3-b908-1dfc4eea9ae3"
      unitRef="usd">43821000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i076def4a10c84321bb8feceb11551055_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzE0LTEtMS0xLTA_3f6176d5-f9d2-4b61-956d-85ea1360272c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i1033093be1a94f1586671f93e4cc0292_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90YWJsZTo4ZWYwYjVjMmI0NDM0NmExOTIyMmQ2YTQyMDAxMWNhNi90YWJsZXJhbmdlOjhlZjBiNWMyYjQ0MzQ2YTE5MjIyZDZhNDIwMDExY2E2XzE0LTMtMS0xLTA_ee353d91-2703-4cdf-8e56-3f5e1610a821"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTUvZnJhZzoxZGM5OTgxMjk3YmU0MDFkYWNkMjE2Y2I0NzBiODYzMi90ZXh0cmVnaW9uOjFkYzk5ODEyOTdiZTQwMWRhY2QyMTZjYjQ3MGI4NjMyXzIwNjU_2094d459-c350-42d0-bc19-cb2ec450f485"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3XzIxMTg_ada04545-6419-4d7d-b8d1-a141e37179bc">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development and Clinical Trial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise &lt;/span&gt;&lt;/div&gt;from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iac1d9ffb9c364277ad0f0ae113dd82f7_D20170301-20170331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3Xzc1NA_cb23b467-1be5-4367-9cc7-ef822b09cf76"
      unitRef="usd">2000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment
      contextRef="i9f2ba9a7769e4c3981f5515bac81bee0_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yOTgvZnJhZzplMGUxZDQ2ZTUxMGU0OGRiOWQ0YjdkMDhkMTVlMGNjNy90ZXh0cmVnaW9uOmUwZTFkNDZlNTEwZTQ4ZGI5ZDRiN2QwOGQxNWUwY2M3Xzg2MQ_04311c01-95e3-49d9-b451-d6b7b070d714"
      unitRef="usd">1000000.0</us-gaap:OtherCommitment>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDEvZnJhZzo2NTc4YmEwNDA5ZTg0MTk5ODE0YTNkN2IzZDYyZTY2Ny90ZXh0cmVnaW9uOjY1NzhiYTA0MDllODQxOTk4MTRhM2Q3YjNkNjJlNjY3XzM4Nw_df31955c-17c5-46d6-9e66-60cf1350b043">Employee Benefit Plan&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzgzMg_81da19df-1a97-405a-83e1-22e0e48fca57">Related Party Transactions&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leucadia Life Sciences&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the Company entered into a Material Transfer Agreement (&#x201c;MTA&#x201d;) with Leucadia Life Sciences (&#x201c;Leucadia&#x201d;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#x201c;AML&#x201d;).  One of the Company&#x2019;s Directors, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp;amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the years ended December&#160;31, 2020 and 2019, the Company incurred and recorded approximately $1,083,000 and $1,005,000, respectively, of research and development expenses for services performed by Leucadia and Tommy Adams. The assay was completed in December 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gary Pace Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased 447,761 shares of the Company's common stock at $1.34 per share for an aggregate purchase price of $600,000 (see Note 5).</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i014c4430e11a4a7ba478369860aa6b07_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzcxNw_66bcf723-b591-49c6-83c0-981d15a11ef5"
      unitRef="usd">1083000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i94d1eafc280542e8a75a72c3e54779ac_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzcyNA_2b58abe3-f35e-4242-9a58-80ab99bd24d1"
      unitRef="usd">1005000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNDQ_004f791d-3582-4c0a-ad80-685ecc8e48b9"
      unitRef="shares">447761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="id9ba25d98442435ab13367e9dd32ebd2_I20200531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNTM_898889ee-cd19-43e5-bc16-79b3264d22af"
      unitRef="usdPerShare">1.34</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5c4f8028837f47fe87c5be5591b4e556_D20200501-20200531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8zMDcvZnJhZzozNjcyOTllYjFkODA0YTRlOThiYTQ0Y2ZiMzc3ODBlNC90ZXh0cmVnaW9uOjM2NzI5OWViMWQ4MDRhNGU5OGJhNDRjZmIzNzc4MGU0XzEwOTk1MTE2MzEzNjA_ab5665b8-1d84-483b-9e73-dd8bf1397ab6"
      unitRef="usd">600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock
      contextRef="i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xMDk5NTExNjMwMTUx_05edb536-3064-4c32-83c2-21baf1594b61">COVID-19&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's financial statements for the twelve months ended December&#160;31, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the twelve months ended December&#160;31, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Repayment of Small Business Administration Payroll Protection Program Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;On April 15, 2020, the Company was granted a loan (the &#x201c;Loan&#x201d;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $305,000, pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) under Division A, Title I of the CARES Act with an interest rate of 0.98% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.&lt;/span&gt;&lt;/div&gt;</us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock>
    <us-gaap:NotesPayable
      contextRef="i7103d5be24a4480abffa7afe4b21824f_I20200415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xNjQ5MjY3NDQzNjIz_eb5012e2-46b5-4338-8171-a1986a146984"
      unitRef="usd">305000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7103d5be24a4480abffa7afe4b21824f_I20200415"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTY2L2ZyYWc6N2Q5ZGQ3ZTlmZDZiNGY3YTlhYzhhYWZiOGI5YzEwYzQvdGV4dHJlZ2lvbjo3ZDlkZDdlOWZkNmI0ZjdhOWFjOGFhZmI4YjljMTBjNF8xNjQ5MjY3NDQzNzUy_fe18ac3c-e7ae-411f-ae7c-5b9862c9244d"
      unitRef="number">0.0098</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of expenses of $7,507,123, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTktMS0xLTE3NzQ_25b675d9-4e34-4e09-badf-b7e3d54e3373"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTEtMS0xLTE3NzQ_f7fe538f-3b64-40f7-9333-1b3f6784f39f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTE3LTEtMS0xNzc0_9a97aa50-af34-4b59-a254-0b3649ca2c2b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTctMS0xLTE3NzQ_cb487de0-d58d-4af2-ad61-2d195fec309f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTMtMS0xLTE3NzQ_d7227025-592e-4344-9d24-2891f81d8dee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90YWJsZTo3N2I3ZGQxMzNiZTg0MDRhOTFjNmI1NWQ0ZmIzMTBkMC90YWJsZXJhbmdlOjc3YjdkZDEzM2JlODQwNGE5MWM2YjU1ZDRmYjMxMGQwXzYwLTUtMS0xLTE3NzQ_88b2fc78-516b-4aa3-b98a-7e6ced04b7e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNDQvZnJhZzpkNjAyNTBhNTk4ODQ0MWIxOGY4NzA3ZTJhODQzZTIzNS90ZXh0cmVnaW9uOmQ2MDI1MGE1OTg4NDQxYjE4Zjg3MDdlMmE4NDNlMjM1XzEwOTk1MTE2MjgwMzY_b78317e3-5de7-4a14-84ad-d8d44bb700ac"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099857665304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,720,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,052,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099849447000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130,980,681<span></span>
</td>
<td class="nump">$ 10,195,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">320,458<span></span>
</td>
<td class="nump">203,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,055,321<span></span>
</td>
<td class="nump">954,957<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">133,356,460<span></span>
</td>
<td class="nump">11,353,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">623,694<span></span>
</td>
<td class="nump">877,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">343,001<span></span>
</td>
<td class="nump">697,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">404,232<span></span>
</td>
<td class="nump">157,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">134,727,387<span></span>
</td>
<td class="nump">13,086,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,366,008<span></span>
</td>
<td class="nump">656,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,850,763<span></span>
</td>
<td class="nump">3,260,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">860,206<span></span>
</td>
<td class="nump">865,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">42,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,118,977<span></span>
</td>
<td class="nump">4,781,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">284,971<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">9,291<span></span>
</td>
<td class="nump">860,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">156,266<span></span>
</td>
<td class="nump">128,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,569,505<span></span>
</td>
<td class="nump">5,775,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 20,000,000 shares authorized; (Note 5)</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000,000 shares authorized; 36,780,805 and 8,593,633 shares issued and outstanding at December 31, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">3,678<span></span>
</td>
<td class="nump">8,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">361,820,025<span></span>
</td>
<td class="nump">217,172,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Servicereceivable', window );">Service receivables</a></td>
<td class="num">(2,171,258)<span></span>
</td>
<td class="num">(971,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(231,495,279)<span></span>
</td>
<td class="num">(208,897,883)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">128,157,882<span></span>
</td>
<td class="nump">7,311,344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 134,727,387<span></span>
</td>
<td class="nump">$ 13,086,546<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099867686920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">36,780,805<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,780,805<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845902488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 365,993<span></span>
</td>
<td class="nump">$ 244,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">11,235,396<span></span>
</td>
<td class="nump">11,162,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">8,216,471<span></span>
</td>
<td class="nump">5,760,890<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,451,867<span></span>
</td>
<td class="nump">16,923,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,085,874)<span></span>
</td>
<td class="num">(16,678,494)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">89,809<span></span>
</td>
<td class="nump">234,169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,519)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other gain (loss), net</a></td>
<td class="num">(28,244)<span></span>
</td>
<td class="nump">1,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) from changes in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="num">(280,844)<span></span>
</td>
<td class="nump">28,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,306,672)<span></span>
</td>
<td class="num">(16,414,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(24,240)<span></span>
</td>
<td class="num">(24,240)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable&#160;to&#160;common stockholders</a></td>
<td class="num">$ (22,597,396)<span></span>
</td>
<td class="num">$ (16,706,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (2.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">20,874,665<span></span>
</td>
<td class="nump">5,973,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalties</a></td>
<td class="nump">$ 365,993<span></span>
</td>
<td class="nump">$ 243,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Services</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(268,269)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="num">(601,767)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Convertible Preferred Stock issuance</a></td>
<td class="num">$ (2,664,717)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099764756776">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series D Convertible Preferred Stock</div></th>
<th class="th"><div>Series E Convertible Preferred Stock</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Series E Convertible Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series E Convertible Preferred Stock</div>
</th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Series E Convertible Preferred Stock</div>
</th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series D Convertible Preferred Stock</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series E Convertible Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,084,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 202,267,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (192,191,215)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_SaleOfStockCommonAndWarrantsNetShares', window );">Sale of common stock and warrants, net of expenses (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_SaleOfStockValueCommonAndWarrantsNet', window );">Sale of common stock and warrants, net of expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,817,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,817,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(40,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,634,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,675,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">884,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">884,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,221,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,299,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,299,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268,269)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Issuance of common stock for share rounding as a result of reverse stock split (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">703,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,414,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,414,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,593,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,311,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,172,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(971,673)<span></span>
</td>
<td class="num">(208,897,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,292,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,764,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,764,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,138,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,871,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,870,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Issuance of common stock upon vesting of restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock', window );">Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 601,767<span></span>
</td>
<td class="nump">$ 2,664,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (601,767)<span></span>
</td>
<td class="num">$ (2,664,717)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154,670)<span></span>
</td>
<td class="num">(210,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="nump">863,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (210)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (140)<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,100,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(19,306,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,306,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,964,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">112,299,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,297,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment', window );">Common Stock par value adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">715,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,780,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 128,157,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361,820,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,171,258)<span></span>
</td>
<td class="num">$ (231,495,279)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $7,507,123, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Common Stock Par Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_SaleOfStockCommonAndWarrantsNetShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Common And Warrants, Net, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_SaleOfStockCommonAndWarrantsNetShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_SaleOfStockValueCommonAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Value, Common And Warrants, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_SaleOfStockValueCommonAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period upon cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity impact during the period due to the cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099849637848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Shareholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</a></td>
<td class="nump">$ 7,507,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_WarrantsFairValue', window );">Fair value</a></td>
<td class="nump">$ 370,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_WarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_WarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845983864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,306,672)<span></span>
</td>
<td class="num">$ (16,414,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Impairment loss</a></td>
<td class="nump">34,169<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">466,009<span></span>
</td>
<td class="nump">494,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,764,804<span></span>
</td>
<td class="nump">884,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">280,844<span></span>
</td>
<td class="num">(28,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived', window );">Release of clinical trial funding commitment</a></td>
<td class="nump">1,100,415<span></span>
</td>
<td class="nump">703,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(246,656)<span></span>
</td>
<td class="num">(54,778)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="num">(116,978)<span></span>
</td>
<td class="num">(35,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,100,364)<span></span>
</td>
<td class="nump">115,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">320,248<span></span>
</td>
<td class="nump">302,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">1,276,166<span></span>
</td>
<td class="nump">1,455,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(856,845)<span></span>
</td>
<td class="num">(776,806)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">69,898<span></span>
</td>
<td class="nump">86,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,314,962)<span></span>
</td>
<td class="num">(13,267,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(211,880)<span></span>
</td>
<td class="num">(67,622)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(211,880)<span></span>
</td>
<td class="num">(67,622)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $7,507,123 and $158,678 respectively</a></td>
<td class="nump">112,299,949<span></span>
</td>
<td class="nump">8,817,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Costs related to the clinical trial funding commitment</a></td>
<td class="num">(7,500)<span></span>
</td>
<td class="num">(40,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">24,871,586<span></span>
</td>
<td class="nump">3,299,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">148,196<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Borrowings under note payable</a></td>
<td class="nump">305,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayments of note payable</a></td>
<td class="num">(305,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">137,312,231<span></span>
</td>
<td class="nump">12,077,281<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">120,785,389<span></span>
</td>
<td class="num">(1,257,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="nump">10,195,292<span></span>
</td>
<td class="nump">11,453,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="nump">130,980,681<span></span>
</td>
<td class="nump">10,195,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockDividendAccrued', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="nump">24,240<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">268,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment', window );">Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,675,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued upon conversion of Convertible Preferred Stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="nump">601,767<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment', window );">Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued upon conversion of Convertible Preferred Stock</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="nump">2,664,717<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Common stock issued upon conversion of Convertible Preferred Stock</a></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockDividendAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of preferred stock dividend accrued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockDividendAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Release of clinical trial funding commitment for services received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845848808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_CommonStockAndWarrantsMember', window );">Common Stock And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 7,507,123<span></span>
</td>
<td class="nump">$ 158,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment', window );">Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment</a></td>
<td class="nump">$ 488,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842119400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Overview and Liquidity</a></td>
<td class="text">Business Overview and Liquidity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology,&#160;Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, Zytiga&#174;-resistant metastatic castration-resistant prostate cancer and leukemias. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Through the integration of tumor genomics and biomarker technology, we are able to assess patient response to treatment.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2020, the Company had $131.0 million in cash and cash equivalents and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution. The economic effects of COVID-19 could also have an adverse effect on the Company's ability to raise additional capital. See Note 13 to the financial statements for further information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843527640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6, effective February&#160;19, 2019. All share and per share information in the financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December 31, 2020 the Company&#8217;s Clinical trial accrual balance of $1,683,195 is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $11,235,396. Certain accrued clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of operating and money market accounts as of December&#160;31, 2020 and 2019 on deposit. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.&#160;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Minimum royalties are generally due quarterly or annually. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings.&#160;Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#8217; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of the Company&#8217;s Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below).&#160;At December&#160;31, 2020 and 2019, the fair value of these warrants was $284,971 and $4,127, respectively, and was recorded as a liability under the caption &#8220;derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants&#8221; on the balance sheets.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment. The Company records property and equipment at cost, and records other intangible assets based on their fair values at the date of acquisition. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of five years for laboratory equipment and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb">three</span> to five years for furniture and office equipment. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company&#8217;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,807,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,617,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements. </span></div>Recent Accounting Pronouncement Not Yet Adopted<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;)</span>. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842196744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplementary Balance Sheet Information</a></td>
<td class="text">Supplementary Balance Sheet Information<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2020 and 2019 was $466,009 and $494,232, respectively. Property and equipment consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,116&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,694&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,823&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842024008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased space to third parties under three separate sublease agreements, which all expire December 31, 2021. Income is recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $34,169 and $0 for the twelve months ending December 31, 2020 and 2019, respectively. The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss. The loss was recorded within operating expenses in the statement of operations. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,653)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases a building in San Diego under an operating lease that expires on December&#160;31, 2021. The lease currently requires fixed monthly rent payments of approximately $78,000, with 3% annual escalation. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased space to third parties under three separate sublease agreements, which all expire December 31, 2021. Income is recognized on a straight-line basis over the term of the sublease.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairment of Right-of-Use Assets</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded an impairment loss of $34,169 and $0 for the twelve months ending December 31, 2020 and 2019, respectively. The loss related to a vacated portion of the facility that was no longer being subleased. The Company determined that the prolonged loss of sublease income and an adverse commercial real estate market caused by COVID-19 were indicators of impairment. A fair value approach using quoted prices for similar assets was used to determine the impairment loss. The loss was recorded within operating expenses in the statement of operations. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,653)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph Note 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842061960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.150%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,437,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,159,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above table excludes pre-funded warrants with a nominal exercise price of $.01 per share: </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">605,072 pre-funded warrants outstanding as of December 31, 2019; </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">386,967 pre-funded warrants which were issued during the twelve months ending December 31, 2020;</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">All 992,039 pre-funded warrants were exercised in full during the twelve months ending December 31, 2020.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material terms of the Series A Convertible Preferred Stock consist of:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Dividends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Company&#8217;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#8217;s sole election, in cash or shares of common stock. As of December&#160;31, 2020 and 2019, the Company had $389,495 and $365,255, respectively in accrued cumulative unpaid preferred stock dividends, included in accrued liabilities in the Company&#8217;s balance sheets, and $24,240 and $24,240 of accrued dividends were recorded during the years ended December&#160;31, 2020 and 2019, respectively.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Voting Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Liquidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $10 per share plus any accrued and unpaid dividends.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Conversion Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, which at the time of issuance was $928.80 per share, and subsequently adjusted to $691.20 per share.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Subsequent Equity Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning upon registration of the common stock underlying the Series A Convertible Preferred Stock. The relevant registration statement became effective on March 17, 2006 and the conversion price was adjusted to $691.20 per share.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"> Automatic Conversion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the price of the Company&#8217;s common stock equals $1,857.60 per share for 20 consecutive trading days, and an average of 116 shares of common stock per day are traded during the 20 trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series C Convertible Preferred Stock and Service Receivable</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC Capital, LLC (&#8220;PoC&#8221;), whereby PoC agreed to finance $1.675&#160;million for the development costs associated with Phase 1b/2 study of onvansertib in combination with FOLFIRI and Avastin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in patients with metastatic Colorectal Cancer (&#8220;mCRC&#8221;) harboring KRAS mutation in exchange for (i)183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which was convertible into 1.67 shares of common stock. In April of 2019, all 200,000 shares of Series C Convertible Preferred Stock were converted into 333,333 shares of the Company's common stock.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $1.675&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series C Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3&#160;million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series D Convertible Preferred Stock and Service Receivable</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2020, the Company entered into a Stock and Warrant Subscription Agreement with PoC, whereby PoC agreed to finance an additional $2.3&#160;million for a clinical trial in exchange for (i) 602,833 shares of its common stock (the &#8220;Common Stock&#8221;), (ii) 154,670 shares of its Series D Preferred Stock and (iii) a warrant exercisable for 859,813 shares of its Common Stock. In exchange, PoC is funding our clinical development of onvansertib in metastatic colorectal cancer pursuant to a Master Services Agreement dated as of January 25, 2019, as amended. The warrant will be exercisable six months following the date of issuance at an exercise price of $1.50 per share and will expire on November 7, 2025. In June of 2020, all 154,670 Series D Preferred Stock were converted to 1,546,700 shares of Common Stock. </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and non-forfeitable. Since the equity awards were for clinical trial services yet to be provided, the Company recognized $2.3&#160;million service receivables as contra equity. The Company releases the service receivables as clinical trial services are performed. The conversion feature of the Series D Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series D Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.6&#160;million related to the beneficial conversion feature arising from the issuance of Series D Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with Acorn Bioventures LP ("Acorn"), CDK Associates, L.L.C. (&#8220;CDK&#8221;) and Third Street Holdings LLC (&#8220;Third Street&#8221;), pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. Certain investors converted 210,780 shares of Series E Convertible Preferred stock to 863,852 shares of Common Stock during December 2020.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion feature of the Series E Convertible Preferred Stock at the time of issuance was determined to be beneficial on the commitment date. Because the Series E Convertible Preferred Stock was perpetual with no stated maturity date, and the conversions could occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $2.7&#160;million related to the beneficial conversion feature arising from the issuance of Series E Convertible Preferred Stock. This non-cash deemed dividend increased the Company&#8217;s net loss attributable to common stockholders and net loss per share.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants are classified as equity and its estimated fair value of $370,666 was recognized as additional paid in capital on the issuance date. The estimated fair value is determined using the Black-Scholes Option Pricing Model which is based on the value of the underlying common stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreements with Lincoln Park Capital Fund, LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On March 30, 2020, the Company entered into a Securities Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;LPC&#8221;), pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 800,000 shares of common stock and (b) Series I warrants to purchase up to 131,967 shares (the &#8220;Series I Warrant Shares&#8221;) of  common stock. In a concurrent private placement, the Company also sold to LPC Series J warrants (the &#8220;Series J Warrants&#8221;) to purchase one share of common stock for each Share and for each Series I Warrant purchased for cash in the registered direct offering. The Series J Warrants are exercisable six months following the date of issuance at an exercise price of $0.948 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.0&#160;million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 9, 2020, the Company entered into a Securities Purchase Agreement with LPC, pursuant to which the Company agreed to offer, issue and sell to LPC, (i) in a registered direct offering, an aggregate of (a) 904,970 shares of common stock and (b) Series K warrants to purchase up to 255,000 shares (the &#8220;Series K Warrant Shares&#8221;) of common stock. In a concurrent private placement, the Company also sold to LPC Series L warrants (the &#8220;Series L Warrants&#8221;) to purchase one share of Common Stock for each Share and for each Series K Warrant purchased for cash in the registered direct offering. The Series L Warrants are exercisable six months following the date of issuance at an exercise price of $0.81 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $1.1&#160;million.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Purchase Agreement with Certain Directors and Executives</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 11, 2020 and May 14, 2020, the Company entered into Securities Purchase Agreements with certain directors and executives of the Company pursuant to which the Company sold 447,761 shares of common stock at a purchase price of $1.34 per share and 146,854 shares of common stock at a purchase price of $1.43 per share. The gross proceeds from these purchases were $810,000. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Securities Purchase Agreement with Acorn Bioventures LP</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 26, 2020, the Company entered into a Securities Purchase Agreement with Acorn, pursuant to which the Company agreed to offer, issue and sell to Acorn, (i) in a registered direct offering, an aggregate of 1,205,400 shares of common stock and (ii) in a concurrent private placement, Series M warrants to purchase up to 482,160 shares of common stock. The Series M Warrants are exercisable six months following the date of issuance at an exercise price of $2.024 per share and will expire 5.5 years following the date of issuance. The gross proceeds from this purchase were $2.5&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Underwritten Public Offering</span></div>On October 2, 2020 the Company completed an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $13.50 per share. In addition, the underwriters exercised in full an option to purchase an additional 975,000 shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering were sold by the Company, with gross proceeds of approximately $100.9&#160;million, and net proceeds of approximately $94.0&#160;million, after deducting underwriting discounts, commissions and estimated offering expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843235800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cardiff Oncology, Inc. 2014 Equity Incentive Plan (the &#8220;2014 EIP&#8221;), authorizing up to 34,722 shares of common stock for issuance under the 2014 EIP, was approved by the Board in June 2014 and approved by the stockholders of the Company at the September 17, 2014 Annual Meeting of Stockholders. The total number of authorized shares was increased to 243,056 between the inception of the 2014 EIP through December 31, 2018. At the June 6, 2019 Annual Meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to 1,243,056. At the April 6, 2020 Annual meeting of Stockholders, the stockholders approved the increase of number of authorized shares in the 2014 EIP to 2,243,056 </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were 260,446 shares available for issuance under the 2014 EIP.</span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39% - 0.93%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66% - 2.33%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102% - 106%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95% - 99%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#8217;s stock options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the historical volatility of Cardiff Oncology&#8217;s common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain vanilla&#8221; share options. Options are considered to be &#8220;plain vanilla&#8221; if they have the following basic characteristics: (1) are granted &#8220;at-the-money&#8221;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates forfeitures based on its historical experience.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2020 and 2019, estimated as of the grant date using the Black-Scholes option valuation model, was $2.09 and $1.91 per share, respectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2020 was $1,519,004. The weighted-average remaining amortization period at December&#160;31, 2020 for non-vested stock options was 1.9 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested during the years ended December&#160;31, 2020 and 2019 was $1,522,984 and $386,654, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of stock options exercised during the year ended December 31, 2019 was $0. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,963,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,206&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,682,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU's are measured at the grant date based on the closing market price of the Company&#8217;s common stock at the grant date and recognized ratably over the service period through the vesting date. All RSU's were granted with no purchase price. Vesting of the RSU's is generally subject to service conditions. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU's activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The total fair values of RSU's vested during the year ended December&#160;31, 2020 and 2019 were $101,290 and $191,436, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843499528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments - Warrants</a></td>
<td class="text">Derivative Financial Instruments &#8212; Warrants<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#8217;s equity financings are accounted for as derivative liabilities.  Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model.  Changes in fair value are recorded within Company&#8217;s statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.01 - $17.99</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24 - $3.75</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 - 3.1 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 4.1 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13% - 1.62%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56% - 2.49%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110% - 118%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102% - 111%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The weighted average was calculated using the relative fair value method. </span></div><div style="padding-left:36pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of Cardiff Oncology&#8217;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining contractual term of the warrants outstanding at December&#160;31, 2020 and 2019 was approximately 2.1 and 3.1 years, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844069784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2020 and 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included as a component of cash and cash equivalents on the accompanying balance sheet.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the &#8220;derivative financial instruments&#8212;warrants&#8221; is recorded as a gain or loss in the Company&#8217;s statement of operations. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843581368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, Cardiff Oncology had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $128.9 million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $48.4 million, which do not expire. Cardiff Oncology also has California NOLs of approximately $70.7 million which, if not used, will begin to expire in 2029. Cardiff Oncology has Federal and California capital loss carryforwards of $0.7 million which, if not used, will begin to expire in 2022. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $2.5 million and $1.8 million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of a company&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has not completed such an analysis pursuant to Sections 382 and 383 and therefore has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,135)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,782)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below (in thousands, except percentages): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent Items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and none have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842182584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib.  Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. The Company was committed to order $1.0 million of future services provided by Nerviano, such as the cost to manufacture drug product, no later than June 30, 2019, and these services have been purchased. Terms of the agreement also provide for the Company to pay development milestones and royalties based on sales volume.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise </span></div>from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842054696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099857748136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leucadia Life Sciences</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company entered into a Material Transfer Agreement (&#8220;MTA&#8221;) with Leucadia Life Sciences (&#8220;Leucadia&#8221;) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for Acute Myeloid Leukemia (&#8220;AML&#8221;).  One of the Company&#8217;s Directors, Dr. Thomas Adams, is a principal stockholder of Leucadia.&#160;In connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, Co-Founder &amp; Chief Operating Officer of Leucadia, who is the son of Dr. Adams. During the years ended December&#160;31, 2020 and 2019, the Company incurred and recorded approximately $1,083,000 and $1,005,000, respectively, of research and development expenses for services performed by Leucadia and Tommy Adams. The assay was completed in December 2020. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gary Pace Securities Purchase Agreement</span></div>In May 2020, the Company entered into a Securities Purchase Agreement with Gary W. Pace, one of the Company's directors. Dr. Pace purchased 447,761 shares of the Company's common stock at $1.34 per share for an aggregate purchase price of $600,000 (see Note 5).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842114968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract', window );"><strong>Unusual or Infrequent Items, or Both [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock', window );">COVID-19</a></td>
<td class="text">COVID-19<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak in the United States has caused significant business disruption. The extent of the impact of COVID-19 on the Company's future operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, and impact on the Company's clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company's future financial condition or results of operations is uncertain. While there has not been a material impact on the Company's financial statements for the twelve months ended December&#160;31, 2020, a prolonged outbreak could have a material adverse impact on financial results and business operations of the Company, including the timing and ability of the Company to complete certain clinical trials and other efforts required to advance the development of its drugs and raise additional capital.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law on March 27, 2020.  The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company is utilizing the deferment of employer social security payments. The CARES Act did not have a material impact on our income tax provision for the twelve months ended December&#160;31, 2020. We continue to monitor changes and revisions of the CARES Act and its impact on our financial position, results of operations and cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Repayment of Small Business Administration Payroll Protection Program Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On April 15, 2020, the Company was granted a loan (the &#8220;Loan&#8221;) from JPMorgan Chase Bank, N.A. in the aggregate amount of $305,000, pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act with an interest rate of 0.98% per annum. On October 19, 2020 the Company repaid in full the outstanding principal and interest of the PPP Loan.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtraordinaryAndUnusualItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtraordinaryAndUnusualItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=114868817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845633288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates involve accrued clinical trial expenses and determining the assumptions made for stock-based compensation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AccruedClinicalTrialExpensesPolicyTextBlock', window );">Accrued Clinical Trial Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the clinical research organizations (CROs), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December 31, 2020 the Company&#8217;s Clinical trial accrual balance of $1,683,195 is included in accrued liabilities and other liabilities. The Company&#8217;s related 2020 clinical trial expenses are included in research and development expense of $11,235,396. Certain accrued clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Cash and cash equivalents consist of operating and money market accounts as of December&#160;31, 2020 and 2019 on deposit. Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners.&#160;These agreements may involve multiple elements such as license fees, royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Minimum royalties are generally due quarterly or annually.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments&#8212;Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings.&#160;Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period. Such warrants do not meet the exemption that a contract should not be considered a derivative instrument if it is (1) indexed to its own stock and (2) classified in stockholders&#8217; equity. The warrants contain a feature that could require the transfer of cash in the event a change of control occurs without an authorization of the Company&#8217;s Board of Directors, and therefore classified as a liability. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span>below).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Long-lived assets consist of property and equipment. The Company records property and equipment at cost, and records other intangible assets based on their fair values at the date of acquisition. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of five years for laboratory equipment and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMxOGZiYWQ5MTk1YjQwZDVhOThjN2Y0NjZlOGE2MTE4L3NlYzpjMThmYmFkOTE5NWI0MGQ1YTk4YzdmNDY2ZThhNjExOF8yNTkvZnJhZzoyZTE5ODE1ZGYxNDQ0ZGI0ODg2MDU5OWZlYjc5NmNmNi90ZXh0cmVnaW9uOjJlMTk4MTVkZjE0NDRkYjQ4ODYwNTk5ZmViNzk2Y2Y2Xzk1MDE_a6d05cae-91b4-4830-8dfb-bf4911b283eb">three</span> to five years for furniture and office equipment. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment Losses on Long-Lived Assets</a></td>
<td class="text">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the Company&#8217;s operating leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div>Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div>Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncement</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU&#160;No. 2018-13 ("ASU 2018-13"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes to the Disclosure Requirements for Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company has prospectively adopted ASU 2018-13 as of January 1, 2020 for periods presented after adoption. The adoption of ASU 2018-13 did not have a material impact on the Company's financial statements. </span></div>Recent Accounting Pronouncement Not Yet Adopted<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;)</span>. ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for public business entities for fiscal years beginning after December 15, 2021 (or December 15, 2023 for companies who meet the SEC definition of Smaller Reporting Companies), and interim periods within those fiscal years. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AccruedClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AccruedClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099846213784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share</a></td>
<td class="text">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,807,474&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,617,078&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099841980952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of Property and Equipment</a></td>
<td class="text">Property and equipment consisted of the following:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">867,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,627,719&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482,116&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,004,025)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,604,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623,694&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,823&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,504,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees and outside services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,850,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,260,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845436552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.174%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.108%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,173)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381,653)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,356&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,225&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943,959&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0 year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.996%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Sublease Income </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Net Operating Leases </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,241&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403,345)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,532&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">869,497&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843452408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.150%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,649,341&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,437,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(497,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,589,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,831,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,159,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above table excludes pre-funded warrants with a nominal exercise price of $.01 per share: </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">605,072 pre-funded warrants outstanding as of December 31, 2019; </span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">386,967 pre-funded warrants which were issued during the twelve months ending December 31, 2020;</span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">All 992,039 pre-funded warrants were exercised in full during the twelve months ending December 31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.435%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.549%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation preference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843442424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation recognized</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399,687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,410,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,764,804&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Estimated Fair Value of Stock Options - Assumptions</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39% - 0.93%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.66% - 2.33%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102% - 106%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95% - 99%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,144)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,860,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,963,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753,206&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,837,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,777,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,682,849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU's activity is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:51.832%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.175%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted&#160;Average<br/>Grant Date Fair Value<br/>Per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,057)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,810)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested RSU's outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842004568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used to Determine the Fair Value of Warrants</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.01 - $17.99</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24 - $3.75</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 - 3.1 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 - 4.1 years</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13% - 1.62%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.56% - 2.49%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110% - 118%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102% - 111%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average is only disclosed for periods after January 1, 2020 under the adoption of ASU 2018-13. </span></div>(2) The weighted average was calculated using the relative fair value method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock', window );">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:15.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.618%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843269464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2020 and 2019:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,987,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,971&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:41.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets and Liabilities<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Money market fund (1)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,131,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Included as a component of cash and cash equivalents on the accompanying balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842078152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes Based on Losses from Continuing Operations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31 (in thousands):</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,634)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,135)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,782)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Significant Components of the Company&#8217;s Taxes and the Rates</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below (in thousands, except percentages): </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,054)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent Items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options true-up</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,821)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843377880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Overview and Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130,980,681<span></span>
</td>
<td class="nump">$ 10,195,292<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099866682776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AccruedClinicalTrialExpenses', window );">Accrued Clinical Trial Expenses</a></td>
<td class="nump">$ 1,683,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 11,235,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Payment terms</a></td>
<td class="text">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099853989352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="nump">$ 32,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099858996264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845943848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,807,474<span></span>
</td>
<td class="nump">11,617,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">1,860,507<span></span>
</td>
<td class="nump">1,015,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,260,992<span></span>
</td>
<td class="nump">10,589,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trov_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,684,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trov_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=trov_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099937063928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 466,009<span></span>
</td>
<td class="nump">$ 494,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,627,719<span></span>
</td>
<td class="nump">3,482,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation</a></td>
<td class="num">(3,004,025)<span></span>
</td>
<td class="num">(2,604,293)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">623,694<span></span>
</td>
<td class="nump">877,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">797,739<span></span>
</td>
<td class="nump">775,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,962,230<span></span>
</td>
<td class="nump">1,962,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 867,750<span></span>
</td>
<td class="nump">$ 744,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=trov_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099846477256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,523,321<span></span>
</td>
<td class="nump">$ 1,003,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AccruedPreferredStockDividend', window );">Preferred stock dividend</a></td>
<td class="nump">389,495<span></span>
</td>
<td class="nump">365,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AccruedClinicalTrial', window );">Clinical trials</a></td>
<td class="nump">1,557,134<span></span>
</td>
<td class="nump">1,504,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Accruedresearchagreements', window );">Clinical trials</a></td>
<td class="nump">66,593<span></span>
</td>
<td class="nump">181,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Accrueddirectorfees', window );">Director fees</a></td>
<td class="nump">92,500<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees and outside services</a></td>
<td class="nump">38,180<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Patentlicenseandotherfeespayable', window );">Patent, license and other fees</a></td>
<td class="nump">117,440<span></span>
</td>
<td class="nump">69,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">66,100<span></span>
</td>
<td class="nump">46,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 3,850,763<span></span>
</td>
<td class="nump">$ 3,260,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AccruedClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AccruedClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AccruedPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Preferred Stock Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AccruedPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Accrueddirectorfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued service fees for nonemployee directors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Accrueddirectorfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Accruedresearchagreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Accruedresearchagreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Patentlicenseandotherfeespayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent, license and other fees payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Patentlicenseandotherfeespayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099849885800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments</a></td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LessorNumberOfSubleases', window );">Number of subleases</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 34,169<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LessorNumberOfSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Number Of Subleases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LessorNumberOfSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121593497&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099858988584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 441,529<span></span>
</td>
<td class="nump">$ 444,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="num">(291,173)<span></span>
</td>
<td class="num">(381,653)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 150,356<span></span>
</td>
<td class="nump">$ 63,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099857462904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 343,001<span></span>
</td>
<td class="nump">$ 697,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">860,206<span></span>
</td>
<td class="nump">865,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">9,291<span></span>
</td>
<td class="nump">860,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 869,497<span></span>
</td>
<td class="nump">$ 1,726,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099842113288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 943,959<span></span>
</td>
<td class="nump">$ 916,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099853799064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 889,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">898,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(29,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">869,497<span></span>
</td>
<td class="nump">$ 1,726,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2021</a></td>
<td class="num">(403,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total future minimum lease payments</a></td>
<td class="num">(403,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract', window );"><strong>Net Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths', window );">2021</a></td>
<td class="nump">486,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo', window );">2022</a></td>
<td class="nump">5,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree', window );">2023</a></td>
<td class="nump">3,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue', window );">Total future minimum lease payments</a></td>
<td class="nump">$ 495,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121576215&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844892472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">10,589,482<span></span>
</td>
<td class="nump">3,649,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberGranted', window );">Granted (in shares)</a></td>
<td class="nump">5,831,451<span></span>
</td>
<td class="nump">7,437,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberExercised', window );">Exercised (in shares)</a></td>
<td class="num">(11,159,941)<span></span>
</td>
<td class="num">(497,313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="nump">5,260,992<span></span>
</td>
<td class="nump">10,589,482<span></span>
</td>
<td class="nump">3,649,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 8.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.70<span></span>
</td>
<td class="nump">1.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.31<span></span>
</td>
<td class="nump">6.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="nump">$ 8.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_WarrantsWeightedAverageContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=trov_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">605,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberGranted', window );">Granted (in shares)</a></td>
<td class="nump">386,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberExercised', window );">Exercised (in shares)</a></td>
<td class="num">(992,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightNumberExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightNumberExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_WarrantsWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_WarrantsWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=trov_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=trov_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844868072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Series A Convertible Preferred Stock, liquidation preference</a></td>
<td class="nump">$ 606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">655,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845552200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series A Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2006</div></th>
<th class="th"><div>Sep. 30, 2005</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Accrued dividend during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Accrued dividend during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,240<span></span>
</td>
<td class="nump">24,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cumulative dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Accrued cumulative unpaid preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 389,495<span></span>
</td>
<td class="nump">$ 365,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ConvertiblePreferredStockStatedValuePerShare', window );">Stated value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockConversionPricePerShare', window );">Conversion price per share (in dollars per share)</a></td>
<td class="nump">$ 691.20<span></span>
</td>
<td class="nump">$ 928.80<span></span>
</td>
<td class="nump">691.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments', window );">Period during which the conversion price is subject to adjustment for dilutive issuances</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_SharePriceForAutomaticConversion', window );">Share price for 20 consecutive trading days for automatic conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,857.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays', window );">Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays', window );">Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockConversionObligationNumberOfTradingDays', window );">Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ConvertiblePreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ConvertiblePreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockConversionObligationNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockConversionObligationNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period during which the conversion price is subject to adjustment for dilutive issuances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_SharePriceForAutomaticConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_SharePriceForAutomaticConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099843678152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series C Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,831,451<span></span>
</td>
<td class="nump">7,437,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,171,258<span></span>
</td>
<td class="nump">$ 971,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 268,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AmountFinancedUnderAgreement', window );">Amount financed under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightNumberGranted', window );">Warrants granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AmountFinancedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Financed Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AmountFinancedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099850027000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series D Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546,700<span></span>
</td>
<td class="nump">333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,171,258<span></span>
</td>
<td class="nump">$ 971,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=trov_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_Servicereceivable', window );">Service receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_AmountFinancedUnderAgreement', window );">Amount financed under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 1,675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,833<span></span>
</td>
<td class="nump">183,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_AmountFinancedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount Financed Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_AmountFinancedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=trov_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=trov_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844388232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series E Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,852<span></span>
</td>
<td class="nump">863,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_WarrantsFairValue', window );">Warrants, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesNWarrantMember', window );">Series N Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_PreferredStockConvertibleConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock', window );">Deemed dividend recognized on beneficial conversion features of convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,664,717<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=trov_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">859,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_WarrantsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_WarrantsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesNWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesNWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=trov_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=trov_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=trov_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099767909288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Securities Purchase Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross proceeds</a></td>
<td class="nump">$ 100,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,299,949<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesIWarrantMember', window );">Series I Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesJWarrantMember', window );">Series J Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesKWarrantMember', window );">Series K Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesLWarrantsMember', window );">Series L Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesMWarrantMember', window );">Series M Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">482,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $7,507,123, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesIWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesIWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesJWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesJWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesKWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesKWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesLWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesLWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesMWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=trov_SeriesMWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845201992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 06, 2020</div></th>
<th class="th"><div>Jun. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 17, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 1,522,984<span></span>
</td>
<td class="nump">$ 386,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost for non-vested options</a></td>
<td class="nump">$ 1,519,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">1 year 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">$ 970,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of vested awards</a></td>
<td class="nump">$ 101,290<span></span>
</td>
<td class="nump">$ 191,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=trov_EquityIncentivePlan2014Member', window );">Equity Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,243,056<span></span>
</td>
<td class="nump">1,243,056<span></span>
</td>
<td class="nump">243,056<span></span>
</td>
<td class="nump">34,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">260,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=trov_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=trov_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099855894328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,764,804<span></span>
</td>
<td class="nump">$ 884,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">354,692<span></span>
</td>
<td class="nump">399,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 1,410,112<span></span>
</td>
<td class="nump">$ 485,256<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099846449688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details) - Options to purchase Common Stock<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility (weighted-average)</a></td>
<td class="nump">105.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.39%<span></span>
</td>
<td class="nump">1.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (range)</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.93%<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (range)</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844811784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">1,015,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">969,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(60,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="num">(48,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(16,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,860,507<span></span>
</td>
<td class="nump">1,015,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">753,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">1,777,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 12.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">22.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">21.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">7.43<span></span>
</td>
<td class="nump">$ 12.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">14.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 7.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding</a></td>
<td class="nump">$ 27,963,363<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">970,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, vested and exercisable</a></td>
<td class="nump">10,837,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 26,682,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contract term, outstanding</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099845146600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">11,301<span></span>
</td>
<td class="nump">30,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(10,810)<span></span>
</td>
<td class="num">(22,057)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">11,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted&#160;Average Grant Date Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 147.60<span></span>
</td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="nump">9.37<span></span>
</td>
<td class="nump">8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeitures (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 15.38<span></span>
</td>
<td class="nump">$ 14.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Intrinsic value, outstanding</a></td>
<td class="nump">$ 7,641<span></span>
</td>
<td class="nump">$ 14,013<span></span>
</td>
<td class="nump">$ 95,005<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099767945624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="nump">10,589,482<span></span>
</td>
<td class="nump">3,649,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">5,260,992<span></span>
</td>
<td class="nump">10,589,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations</a></td>
<td class="nump">280,844<span></span>
</td>
<td class="num">$ (28,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm', window );">Weighted average remaining contractual life</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period</a></td>
<td class="nump">$ 4,127<span></span>
</td>
<td class="nump">$ 32,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations</a></td>
<td class="nump">280,844<span></span>
</td>
<td class="num">(28,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.99<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0013<span></span>
</td>
<td class="nump">0.0156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0162<span></span>
</td>
<td class="nump">0.0249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.10<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Warrants to purchase Common Stock | Black Scholes Option Pricing Method | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">1.18<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DerivativeFinancialInstrumentsLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DerivativeFinancialInstrumentsLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_EstimatedFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_EstimatedFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average remaining contractual period for which the instrument, asset or liability is expected to be outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=trov_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844171544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">129,987,804<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">129,987,804<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">284,971<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">284,971<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">129,987,804<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">129,987,804<span></span>
</td>
<td class="nump">10,131,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level 2) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level 3) | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">284,971<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 284,971<span></span>
</td>
<td class="nump">$ 4,127<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099867960888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and/or penalties incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_OperatingLossCarryforwardsSubjectToExpiration', window );">NOLs, subject to expiration</a></td>
<td class="nump">128,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_OperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs, not subject to expiration</a></td>
<td class="nump">48,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOLs</a></td>
<td class="nump">70,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember', window );">Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credits | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credits | California Franchise Tax Board</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099867981784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,043)<span></span>
</td>
<td class="num">(2,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(148)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred (benefit) expense</a></td>
<td class="num">(4,135)<span></span>
</td>
<td class="num">(2,782)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_ValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_ValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_ValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099857667960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Company's Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the federal statutory rate</a></td>
<td class="num">$ (4,054)<span></span>
</td>
<td class="num">$ (3,447)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="num">(122)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_IncomeTaxReconciliationPermanentItems', window );">Permanent Items</a></td>
<td class="nump">261<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock options true-up</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(300)<span></span>
</td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">2,780<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent Items</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock options true-up</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844800456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 42,331<span></span>
</td>
<td class="nump">$ 38,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther', window );">Research and development credits and other tax credits</a></td>
<td class="nump">3,904<span></span>
</td>
<td class="nump">3,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">48,035<span></span>
</td>
<td class="nump">43,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_trov_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">47,955<span></span>
</td>
<td class="nump">43,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(47,955)<span></span>
</td>
<td class="num">(43,821)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>trov_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099868249448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,235,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=trov_NorvianoMember', window );">Norviano</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Licensing and distribution rights commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements | Norviano</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=trov_NorvianoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=trov_NorvianoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099844704408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 02, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>May 11, 2020</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,235,396<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="nump">1,205,400<span></span>
</td>
<td class="nump">146,854<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="nump">904,970<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="nump">$ 13.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 94,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,299,949<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember', window );">Other Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,083,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,005,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">447,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="11"></td></tr>
<tr><td colspan="11"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $7,507,123, and fair value of warrants issued as a transaction advisory fee as of the date of issuance of $370,666</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OtherAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140099841944488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COVID-19 (Details) - Paycheck Protection Program, CARES Act<br></strong></div></th>
<th class="th">
<div>Apr. 15, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemLineItems', window );"><strong>Unusual or Infrequent Item, or Both [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable</a></td>
<td class="nump">$ 305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">0.98%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=trov_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=trov_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "2 65('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  D@%E2C5CS5^X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>R'9I#R;-I6.G#08K;.QF;+4UB_]@:R1]^R59FS*V!]C1TL^?
M/H$:DY2)&9]S3)C)8;D;?!>*,FG+3D1) 11S0J]+/2;"V#S$[#6-SWR$I,V'
M/B)(SC?@D;35I&$"5FDALK:Q1IF,FF*^X*U9\.DS=S/,&L ./08J(&H!K)TF
MIO/0-7 #3##"[,MW >U"G*M_8N<.L$MR*&Y)]7U?]ZLY-^X@X.WI\65>MW*A
MD X&QU_%*3HGW++KY-?5[G[_P%K)I:BXK.1Z+S:*<[46[Y/K#[^;L(_6'=P_
M-KX*M@W\NHOV"U!+ P04    "  D@%E2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M "2 65*W[*\:B04  "47   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5C1<MHX%'WN?H6&Z4,[$X(E0T@Z26:(*5VV:<*$M)WLF[ %>&)+K"2'Y._W
MRC@VR9AKS^X+V++OT?&5=(YTS[=*/YJU$)8\IXDT%YVUM9LOO9X)UR+EYEAM
MA(0G2Z53;N%6KWIFHP6/\J TZ3'/.^FE/):=R_.\;:8OSU5FDUB*F28F2U.N
M7ZY$HK87'=IY;;B+5VOK&GJ7YQN^$G-A?VYF&NYZ)4H4IT*:6$FBQ?*B,Z)?
MQG[?!>1O_(K%UNQ=$_<I"Z4>W<TTNNAXCI%(1&@=!(>_)Q&()'%(P..? K13
M]ND"]Z]?T2?YQ\/'++@1@4I^QY%=7W1..R022YXE]DYM_Q3%!PT<7J@2D_^2
M[>[=_EF'A)FQ*BV"@4$:R]T_?RX2L1?@LP,!K A@[P)H_T" 7P3X;0/Z14">
MZM[N4_(\C+GEE^=:;8EV;P.:N\B3F4?#Y\?2C?O<:G@:0YR]'*LP@V&TA,N(
M?)4VMB]D*G?SR8U+E_R<C\FGCY_/>Q:Z<T&]L("^VD&S ]"4D1]*VK4!W$A$
M;P%ZP+,DRU[)7C$4<2S"8^+3(\(\YM40"O#PB5@<$WJ:A].:\#$>_E<FH7>O
MKO<W7^.7J?=S//^_I1[IH5_VT,][Z#?U</^R$74#B(=3K_L=83$H60S:L1A)
MF?&$W(F-TK:.#HYC=280.B<EG9-V=&9"Q\IE/B*P=&KSTX!43,<_/GQHF!+#
MDML010PRK1VU26Q"R-2#X!KEAZ-UNY1U?8KP.BUYG;:<2)J#Y.?*<'@8<:PE
M3PPVCF<EIS,4IU@QDS@1Y"9+%T+7<<$Q/(]V_<%@<(KPH5XEI5X;1G=B%1L+
MB;+DAJ>UX]8 %(SNQM/)A-S>!+?7M]\>CLCT)CC&..[)/6W#<2I#I6'\<J4Y
M(G,+$XPH30*52:M?X#^J)XZCC[]B)%E%DK4A><^?R32":1<OXW!G1X<'N@&2
M#;NP%>K[IPQC6$DW]=LP'$61%L;L)7"FU5,LP_KDX9C!"*-6:3[%5?L]M<#=
M ;-[M96UK'"X.9=D'(N5PLA55D!Q#7]/KK@@U_ >N97U:<,A*?4& S*!9ONH
M8!!&3T*B1D$KIZ"XP+]G.U/&@BS_'6\.+Q <\8S1]UN/M]PJIZ -5I$S@ZW^
M82HXP"FN>I4U4%S/KY6SJME:24R'&T#.!JP[' PQ#Z65,5!<U>]C"YZ@EH2R
M3XO/9"["3$.V:FGA2(%*4U"=N57AXQ'YZ!U[X!AD Z[\Q!-TDK'*-5@KU_@-
M1Y_NHX1%"H2Y@6Q&9&I,5I_.!LP;;+6RRBQ8*[/XI1)P!3@5YF:K32TA' DG
M5!D#:V4,K]NDW18DEJM<?[-Z8CCB@S 8L\H06"M#F$HK].XLZS9M_)5J+3,<
ML8%9Y0>LE1_D0T<"L*F5TK5KH0'G1LDN#T,XL<.N 29G#H@QK$R!M3*%KZG0
M*S>8WP#!KD'7T@V7]51QP*8M)JL<@+5R@'G*DX1<908>F_IIAN,TG%U8)?L,
M5^UI,+DCHRR*+5CZR%H!CI3OC"8)7]42P_$:4U7Y ,,E_#55:Q R=.S^W_&
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M%@  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*U8VV[C-A#]%<)=++:
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M1AR16>Y_C[6Q?@H)1M%7E92FO1CZ*-@'*1_02]**#SE%?=[*EY"X<,I[NS"
MHX+Q 86DK0C14T3H#9:T+R]07=,8QQV: 6"<)#$,(@,\6QFB9+SG-T6A79/
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M5,V=U4R,K-QK?R$-7B)N6. U#\H&X/Y22O,ZL3=)]\=A\@]02P,$%     @
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M%KFYW3 *K5II /^OA-#'A_(%S1'K_#]02P,$%     @ )(!94HW)-'RE"0
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M23;&75NF6OY$]WDK"C1W0B%"P)'G<ZZ_%P5 ?62DS 0IM_2L02C$L>L:+1,
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MTR09Q8H+'>59\,UMGID:I= PM\S52G'[.@5I=I.H'^T=]V)=H7?$>;;A:U@
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M:_A2EC^+HEU?S9)94/!5MBO;+_+Y.]XK%*KY<EDV^F_PW,NB69#OFE9N^L&
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M=3>MW.HS-P^R;>5&7ZYY5O!:"<#O*RG;_8UZP7!LZ_HW4$L#!!0    ( "2
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M..(W.N)M."(7V7@NZKEN00\9 # <;DO206]4MNM1:C0B4O8M6.]"]!:^USW
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M$2=32(F7;)NI8'#I2.'*(&.9Q4%*0TJ&[H$BVJ] ]+^,Z#M0:P+)@81:.6_
M;CH0DK\(1GH.!QD*4R%/J0-XX,"JOA38!G825*_Q$'JU# _QC.HC@"7YGT;"
M/=8-27(\^W"Q69(]L.C30Q="!38Q![N";JTU!*<4E+ 0'@41!=$2^"7']!3I
M^9 '[4,81^A"-".9;CRL. CXL@Q#.>#T2BR/)(9AH\.%\0C@5(D9JN0P1Q\'
MS820'-[ 7[_W6(ZLF*F<,V5<?0R!E*)BL.K1?8*PGW@=C4WF<2*8Q"T.+490
MZHS&"(KM0E0$'(-S&[.T74 [D%\9RWNQW7*[!EU/YU:&?F9_11]#:IB98"R&
MHLE/*>EX=[(4/J:W:)]3?CRB[-"D!=P1]A,4BE14Z*(07[0/N;ID.K9RF-%C
MZB#QS C40FV,3J(4$* =,0NA((Z<8^^Y?.$69!;P:2#ND7,FWS(&E,Y$3$[)
MCFN =H&M0?")%P:K*?!? Y#!*@KS**1(%A$L+>>ZL(I@"S0*62C0:*+>$2 0
M=4A>U;J]KMDR=H^C(&DJQK&TY;E]DK0AQ+>TM7(E9" %PG!N\[=.L!C(+042
MX(:2\HQX3H:/G0)IE>@[G!5_2H0]A\4@A"'N";]#GO!)]D&>_@(<P_#YJ"6O
M^:'8OWX1OY/]UAA501"P6K-Y71O8=5URY(@;$"4AW*5X&-3%M9@QA6QA82$L
M*]<-UPL14G#6'+^@O*T@-F3?M='[F$]O(#_'(J&"B)V?<@#C ZP0&.&ID97L
MNBQPHL/*BPB&CZX+E34RN$KL*<%'0LBDT3/"YP6Z\(4#"))-VV"T[=7. (=$
M:9;@T=T.)/!'3M>>OU2?MQ=@P8!0$#& IX+ @.Q&#BZ&N+[77)O)$(=WT2))
M5#2.ZJ2:TH]J5 ,E8IL5L=,^%4<<XYFJEWG-)0)!Y!/O78?^"GN_!>(QB7C^
M"FYITV]RRA\<#AE<@Z4$<BB#]_B)9/P"FI#(Q,2Q]R/C,BQ;X5EMY0_7L2+&
MO<%[HQBB4/9>@\.G.B1%[XRCF+Z$VR.&8I?A^/_$/'P<&$^F2\,!JE</6-]>
M[*,/P_H&:+WK(9;F!2GH#K4B'>J0M"VF='*"I-*74\3KZAF(X!X.7'94M:7:
MS.2$7*5#,.> Z+V%19B+H0=N>GPR@=RWA3R,2_,QKG^?LD,2D/G+/W0+WJ'S
M!YF3];[G<EML#*A=>)GKKHVH!(4-I$]?3=F'*%R<4Z@52'+1K,#\W*/9BIN1
MS4PE!HVY0X1]7&8)>M5B:81%#>+ZI:;@GM(/:EA( <!H..BPXCD\OW*4YVVP
M-RQ8< 520I\4:/DUU4;Q[<6@0J!SD%,*KNQ2$LGSV1/XO8*M8U2/P1>3%?$Z
MGS_)B6#EV=K5H<P%VBRT9#L0X4?PJ-@#]A3S&\-P<QU7A(\0&\0!D@<2P@]D
M[)2D "E*8 7UQ&#L7F#NT</'5JJ"0?G&1:[7#D(1*L# T247"B4) R_@#OBM
M(YL!MSN"@F2,V,K\A,U.244N$8)1+)9G]2)48'8JY.(TLU@*BWSHHV?FE151
MGLB#B=0AB3'#'9+.^!3)5:KW(?A\#=GYEXO[$EB-)I' NL"D!5_8.,AXY>6\
M-)ZB/=PB,^H0*0"X%+P>Z4Q&#@W46A(HML^8 ..^M5U&CQAPB%RDZ@>X=H-D
M 9S %Y$CH5(.*1VKFC+-J';1K7OR99Y1NR " SUB8\NC&Z""S[87X^ 6&%V'
MZ@'W^D3;*?:*9.4P))*?3^Y]Q&-(:J9ME$2)II)9\NH7++6J2W5^#XB>J7>X
M\^^!L4>MZAE6D-P.Z]'=(^7'8@2I .@SK=[!^3_,;ZZ*%]<S6O?#53&;7Q>8
MF6U3<9Q"%.TSFSA0I],2GTGV\FCU<"SC0<0E0 G%<IK)0)M./9K7%"+<93T:
M>7#8O(G%:U ,2,:XD"3!PPI/Y*!L$!6%F*<ZI)W2.S0ZDH)FH1?.,F"8?H&5
M(P51;"N2#H;10YR;NA8LLK(=6&L+V33V!58B_!*,[K>H:>!O#1;../:EGDCF
M8;Y#5$X4;;-"][B>6J1:92K/9S^&$AMW"8X9RU$[:KNM4>YO[^_4#4@GYJ9)
M%DXT*;-R 'F62NKA.0LSYN!R"/XOOG]?]*[?MS=VJY$2?4O=S04.?804ZKA,
MX_[D&[+8(>E3;D<ADVNIFB6]U5@OW$+T_Y6$, <E%7\M3CE O'&!-DDU[) Y
M0]K'D03JRX&$2\@RM*',)'&T'?,02Y^D;JD>BGJ>0;"VX.7:<KUG2EH_TIRO
M7<AH:K)J(%__Z"L><^BEOAW4ZXAU.LZU"0AT"$?9IIT ._;B>\]55BFG=LE
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M7T#SC=9N/_ )#M]#BW\ 4$L#!!0    ( "2 65+FF0T;V08  "@<   9
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MG=.5?^3)51HFP/N5QJG6+5A!_W'P\M]02P,$%     @ )(!94G"A_\@7$
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M88-"*]*E(4%> ><%:+9-'@JM6@N&+8"N'%W[4 $#IAE@JH##(OF/0% 1-(O
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M:AO]4)_T3+^1&Z)'_,E^-74":SH^U*_>[6U(\(YJZZ(#AOSNC_:KR[U^=?D
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M#5N43)1<6:$5&9Z?]^;QZ<78RP>!CX*O;6=-WI.%UG=^<Y6=]R)/B$N>.H_
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M6E6XR[7@*/6T .\SI6Q[0QMT7TNO_@M02P,$%     @ )(!94FVWAA-D!0
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M.=^">1CM^;MFW&%<7F-"E8]8:D?!;@%7E5Y*5=D'34$\6(S< N8J)QX3W'P
M,+2+%LUNJ*H3+#MV&DL4[(OM==+E%08+JQ<RH:JS0JRH0PN^ L1!_H\99)S.
M>?0MGIT4Z# 31SY;"4(;(C"0$1W:42,6=&/\)I%"VNB/>GJ<6*!"8Q]E!J&B
MZ+RC2E[P.VD33Q)>@AH5(**$A-AXFSLZ3B$7+PR&5"QON,=S',^6[#BEE2R3
M#A0B3:1:5]N$5S97AK(Y<MW"K2E3AW&O#%G-,;89V13:R#7J/AE5P?I#KT$V
MR)XRGTS%ZW&E2&0?PQ'GUNY0CU9ESKUFM@ >'0ZDL@ZL/4$HHPVY3/&D%GJ
M/%,K$\>X8^:'&)$0M L$3KZ.S$*7\ZE2UC'3F"*,JS8W0OYF6F@/%U7'&KBO
M[I SL(U.6V,>6B,;8TTAIYQR:(#<R,:6"8S;6O0.;^@@'Z/AST4PT.=LN%4,
M)PI7)!4R#$)%#XMP*EX&WXF$JQB3R?_'3=FA<!I"Q_!L035LRM =6+=R&[/9
M[Z0*&-@4D<9R&@";2 =NT6Y8)DBG\CG4!=-DGFDQ'J4*U1!S\P<F'^/"6$/3
MHVZSVR\<SD?M&E2(U%A@,(9!@/L:NT+Z$\]AAE_]_].>GXVN5ICZZW*!Y/F0
M7:JWK.'K<$>]JE>SK^+U@HM%M3:.25M!=3Y]\FA2-\?A)?F^7-0:GW#M*X\M
M[MD46 #G*^_3X84=##?WR[\ 4$L#!!0    ( "2 65)USGQ DP(  ,(%   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;*542V_:0!#^*R.?$BG"QI V
MB@ I)*F:0Z0(^CA4/2SV@%?LP]T=0_CWG5T;%Z0FA_:"=W;G>\RR,Y.]=5M?
M(1*\:F7\-*F(ZMLT]46%6OB!K='PR=HZ+8A#MTE][5"4$:15FF?9AU0+:9+9
M).Z]N-G$-J2DP1<'OM%:N,,<E=U/DV%RW%C(345A(YU-:K'!)=+7^L5QE/8L
MI=1HO+0&'*ZGR=WP=CX.^3'AF\2]/UE#J&1E[38$3^4TR8(A5%A08!#\V>$]
M*A6(V,:OCC/I)0/P='UD_Q1KYUI6PN.]5=]E2=4TN4F@Q+5H%"WL_C-V]5P'
MOL(J'W]AW^:.6+%H/%G=@3G6TK1?\=K=PPG@)GL#D'> //INA:++!T%B-G%V
M#RYD,UM8Q%(CFLU)$_Z4)3D^E8RCV:.NE3T@PAP-KB7!BQ)FDA)3AX2TZ&CF
M+4W^!LTPAV=KJ/+P:$HLSPE2]M0;RX_&YOF[C ]8#& TO((\R[-W^$9]H:/(
M-WJ#;X$D'?)SHF.I'G[<K3PY?A@_WQ$8]P+C*##^WYO\!QKX4B'<6UT+<X!*
M>!#AY3&RA(*OW<E50VV7]$76 =;PG^%@V77 .!M>;"_!KH&8[LD0.B,4+'"'
MID%.<SM9(%PD3XME<LEZ)3+]#ITT&PCWA9TW/XB&HH10W-<G1T V>$-W!4T=
M@J#%#U;J1K?)6%ZQ_QI=P3ZY\3M#TH$TA=7(@;/-ICHKS1^I6E%_I(+5 =AN
M-#LXNZ;2LAECB;O(.592![:Q#5ZHJ$)%9_2#O[V ]*2O-+I-G!Z>@8VAML7Z
MW7Y W;5]^2>]G6[/PFTD5Z%PS=!L\/$Z ==.C#8@6\<N75GBGH_+BH<LNI#
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M-"OQ97(W$?]Y??T9*/QGJX',GB0D5(U!GBCA,C.@XK:>_NUZPS1M5K(1<K$
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M"HM!"$,@%GZ'A.;6PT&>?@2.89Q_T))7_-#;OW8>OY/]EACF052R7+%Y72F
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MBXS!AA?"8-4HN0Z!:8^A5(0,ZT!2< JE$*J^U];4-)U-)^YK7)0Y 6F["9;
M\<!0=P>:H"4?P \T34SI^VQ.\_!,8!*QT$;C,5,3)J,-)SPE]4B)BR&MX:6A
M 4M%#.E,#9*PBU'Q/D=TA3. RA8XKT^/C3=_9$?S*DNF5,2J;F4D8TI?5SZU
M&$ 704&]K8T=*U\8C@^\X>-OZ7K!*'8.?540%%WR,(ZJ>5C_=]_MHPL[[$%]
M#2%8+*>^LPLK-/J$U%%S)"[UL@J+X^O#O9<T"CT='EW^4!?8'?I-?COB!A^^
M7/@O#7WAT:4#U5POQYGIW'$% (NBF!6G"RL4WF= )^*++T\CE?P:''4) T"T
M<]?!+%HN^,MO%." <J)1<MX4,*>HB)]WW1X^\^\M_CV%3=0FTZ!?;_L8X9P]
M>Q:>LF<<YJK9*K_I@;%_#@P!\3G9\:%J]<"5!,I=RS]:1]$43GNG]@$"M[$I
MBM\JN?6)?WB-6JZU1%I-J/SF;3VFPK(N5"_LI=FILBU4ART!P<Q&K+'+4>FO
M./="X2HZ*=]/HD/[L1&R$[ZA!&I'QMF7<^C>3,CY 30/ZUC.[E(6EW!E6^+K
M8&8!VINJ*'G"%:HX@T%F&A.>?F=..%P#P<M7!Y7L!]9C=0CEI4:O6V$/RW(%
M)]S\&>U)"=5,PG"MX1',(H>9[%NEEC@7BO-J"ILG+!A%)?4Z14C8Z/)%EK2I
M[ZBQ9]QBH&%#KPRB@X;&\-FE (@1JA9"0H[!@R6NJ_T 9YCL1Z\SRIM\))RM
M;GC@'Z?M^,I+\IXX.Q*,RBC*M-^?"FMH72P7=:@I^_[Z[@T5:W\S&_#$CZXN
M@'X=>A^@9Y@>(*KMDS.7\C#\$"0[V;S89X\7)$(>F+(CA@VZP;(??&K,CB9[
MN(W\[8#.(<E>AF(6V$NCG"\)AVF$I>2&=78(M,%5TK@A34@SY]/A,?';_ K!
MVW2%X*!2_!PH<?N=:PJQX-6]:'.@88^1<CU>&4Q%CEY^B+-*0'H'64^<60(S
MOECP)9M1[TX""G +P"27$,9A/O3H)CRRLFPKVHC! Y-H5K @OX:S3N@Q::(I
MFS2*G?D.;)J,YL#E&@+*41C06H!H8J9%,\4QNNG>U,C*!&PM<.3:E^0'.MB^
MHLTNJ<04P-$<_WT$/^(,>7!V>9J&EZ?#T\N_*JX+B<]@..Y6@/E!(?N)0>9]
MR$.AV"R-P<R&QV!N%4;JH-[7)03"6,'*KNZ"@3.MSZ8.'>3_"C;:R.MV"=&"
MF%U,GW)R2$;2C[M<WWT1OYH)/1U/+\7I"?[BOYV<C>)T@D^ WJ8;D;?L:CE/
MP4@DZ^C]DA7P_=0TPE5XFP#S#)3JLG2A6,OMZ)!;9+<N;7^/K'Z4-0FH>8WE
MTN#(,A +*]<*;^.C\4:GR=$&Z'-=8J,64$N3< L_5X6Z2"%7M^&77UQE^O%S
MA[9@!PJ)/F"I:TJ(Y0)GP.+EL>D57AZ;/AMYE<49P[7OT[K45#'4F4L ]Z^9
MP#%".PZSV2 !B6U^%NB_9-WBG?EP:0U1#=OYD!IUF; D*)2L423FOR&4'&ZI
M>1:(4B/,F&A.LJ):(M@DTRD>_8<[2+A)1R1G%T,B.;L87SR.(DG?4"3?JGDC
MQOP?67;P\'0OPU_ _D2!XR>?Z)[>M?.&HX$G%^/9Q9EW,:'YRT+X=U4ND6EC
M"A?0Q)(/>8=RD.+R3]N:+F[A-;4(]NGT:OP(P(8Z789MJ-<=,BCGV=])6"N[
MI+\&09=WZX;_9$+\-?[%B6O^.POI=?YS%;](N^2T=P%++R9/KDZX\A:^ *+T
M5Q?FIFG,FCZNE 2KCR_ \X4Q3?B"&\2_P_'ZGU!+ P04    "  D@%E2.O=]
M(!L#  !\!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R-5=MNXS80
M_96!"A0MH$:7R+:<V@;L)$4+=%$C[G8?BC[0U,@B0I%:DHK3O^^0DM442(P^
M2.)ESCES(4>KLS;/MD%T\-I*9==1XUQWER26-]@R>Z,[5+13:],R1U-S2FQG
MD%4!U,HD3]-YTC*AHLTJK.W-9J5[)X7"O0';MRTS?^]0ZO,ZRJ++PI,X-<XO
M))M5QTYX0/>YVQN:)1-+)5I45F@%!NMUM,WN=H6W#P9_"#S;-V/PD1RU?O:3
M7ZIUE'J'4")WGH'1YP7O44I/1&Y\'3FC2=(#WXXO[#^%V"F6([-XK^474;EF
M'9415%BS7KHG??X9QWAFGH]K:<,;SJ-M&@'OK=/M""8/6J&&+WL=\_!_ /D(
MR(/?@U#P\H$YMED9?0;CK8G-#T*H 4W.">6+<G"&=@7AW&;'K+"@:]@;M*@<
M&W*E*C@,9?)[!W%2HA:<*0=;SG6OG% GV&LIN$ +W_W.CA+M]ZO$D4N>..&C
M_&Z0SS^0SW+XI)5K+#RJ"JO_$B04RQ10?@EHEU]E?$!^ [=9#'F:IU?X;J<$
MW0:^VP_XWHOWS^W1.D,'ZJ\K L4D4 2!X@.! ]VSJI?H$[TEH4K(WI]4."#O
MC7!>\/&5RY[R [71+;@&X9Y)WLNA6@3T9>2A; \>3I:_:FMACP8.#3/X7F6N
MNN6;P9WM&,=UU/FC85XPV@0N"[TE :& 7YR@Y%2CKJ)&(KUV1]I<MRTY:#T,
M< @"F"5'G?AA"M3'4VM)_<$3C<9?>_'"))U(>P=44VR/Q'>I*[VR)?S6^? M
M. U=;WA#EQ/N!\6#T_P9LKB<I_$L7= HS69QD97PA1E#\E=0LS@GU'*90T;@
M<AD790Y/2!47W$<X6'U6@DB*9099%M^F&97+^%)MB4R]H'&"KH2_534:,Z'*
MQ2(\H_'C5>,\GI=%/"?WO_VFS+/\1UC&9;J(BT7A1>?9(DX7);QW!I,W':%%
M<PI]ST(XRD-SF%:GUKH=.LJ_YD-?_L3,25"6)=8$36\6LPC,T.N&B=-=Z"]'
M[:A;A6%#OP<TWH#V:ZW=9>(%IA_.YA]02P,$%     @ )(!94JNVNNSI P
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M6EDM13/FS52#'@RWOD!A0K?H3BBHDF 2/<%D*)Y%?UVMK#,@LK]/,$KWC-+
M*'V#T8WN>JT"+L1[,' &C?L>R+S_.HC>ASS6B9.H_GQ?VI[5?!'U/B7SPJ/E
M#^!\!XYJJ(*PCC>>@-MPU&H)!UBH]26Z"JR@"[Q;<;/O!#SB"MT-1@DW&!X
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MW<;L<$777Y3&@/XOA-";B5F@OU!/_@-02P,$%     @ )(!94H>XP4]A!
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M67SS=L,:/W6$)@'<GRME]Q,RT'\\W?P/4$L#!!0    ( "2 65+*F<LB@P0
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MH/\%J.P!VD^D--7$&JC_:8S_!5!+ P04    "  D@%E2HHWSEJ #  #H"0
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M&V[H)P-J%J#]E5*VF["!W8^0Q7]02P,$%     @ )(!94J'?:E@L @  H00
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M9?OJ%ZYTEVZ'N7Y(@3 &>G_#N3I,S '=TVSZ'U!+ P04    "  D@%E2B+H
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MM ;F_5H(O5_8 ,V8/O\!4$L#!!0    ( "2 65*YBCST60,  /H)   9
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;*66WX_;*!#'_Q5DW4,K[:W!OV)7
M2:3=I-7UH>JJN?8>3GT@-D[08L@!2?;NK[\!>]UL[*0K]24Q,#-\^#(P3(]*
M/YHM8Q8]-4*:6;"U=O<N#$VY90TUMVK')(S42C?40E-O0K/3C%;>J1%AA'$6
M-I3+8#[U?0]Z/E5[*[AD#QJ9?=-0_>\]$^HX"TCPW/&%;[;6=83SZ8YNV(K9
MK[L'#:VPCU+QADG#E42:U;/@CKQ;$._@+;YQ=C0GW\@M9:W4HVM\K&8!=D1,
ML-*Z$!3^#FS!A'"1@..?+FC0S^D<3[^?HW_PBX?%K*EA"R7^XI7=SH(\0!6K
MZ5[8+^KX!^L6E+IXI1+&_Z)C9XL#5.Z-54WG# 0-E^T_?>J$.'$@R06'J'.(
M7NL0=PZQ7VA+YI>UI);.IUH=D7;6$,U]>&V\-ZR&2[>-*ZMAE(.?G:_VNYU@
ML"\6-A'=4T%ER=#*9]!'V::)D_MW=%>6>L\J]/X)4L@P@]XLF:5<F+<P^'6U
M1&]^>SL-+3"YR&'9S7_?SA]=F'_)REL4DQL4X0B/N"]>[4Z*E^XA*-'+$?5R
M1#Y>?"'>9[VADO_GUWR#%DH:)7C52D!EA1XT,TXKWZ%J](%+$(Q3@5;0Z74T
MZ.^[M;$:$O3[%:*X)XH]47*!Z%GV4C5.=S_SF,QME-1'<6?W,"=I%,<1F8:'
M4SU'[#".XSSN[5Y@)CUF<A43A*F9U@ **5L^HHH?>,5D-8;:1LI.$.*\2(KT
MC'3$+$NC-!T'37O0]"KH CIX"1MF-6R;&>-+!Q.3-)V0.#D#'+/#29;A<<*L
M)\Q^E3 ;S)QE:1&?\0VM2$X2G(_C37J\R56\)==P!2N-:L9&X2:#:8LHQ?@,
M;FB534ZM7K#E/5O^DRQ4-3.NQ(!\CL\?6JA>!I(1&:8/O!R'SD=RDN3GT$.K
M"$[/!>BBARZN0\/%(>T-$L &%VN+;+?LLL+%<&/))$G.:8=F65&D%V@)_E$Q
M\%7>SYZ-=O>2X'3-!;=\'+6+]3)5R2 ;1LR2K, 7SCHYJ6[D*NN?RD(FO):5
M#.[&.$_Q)#L_6&.&408/)W+&&YX49O<J^D3UADN#!*O!$]].((1N'QIMPZJ=
MK]5K9:'R^\\M/,Z8=@8P7BMEGQNN_/?/O?G_4$L#!!0    ( "2 65(&FZQ0
M@0(  '8&   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(U5V6[;,!#\
M%4)H@01(K<M'$M@"?+1H@"8($J1]*/I 2VN+"$6J)&4G?]\E):MN(@M]D<@E
M9W9V**ZF>ZF>=0Y@R$O!A9YYN3'EM>_K-(>"ZH$L0>#*1JJ"&IRJK:]+!31S
MH(+[41",_8(RX253%[M7R516AC,!]XKHJBBH>ET E_N9%WJ'P /;YL8&_&1:
MTBT\@GDJ[Q7._)8E8P4(S:0@"C8S;QY>+R=VO]OPG<%>'XV)K60MY;.=W&0S
M+[""@$-J+ /%UPZ6P+DE0AF_&TZO36F!Q^,#^Q=7.]:RIAJ6DO]@F<EGWJ5'
M,MC0BIL'N?\*33TCRY=*KMV3[.N]\95'TDH;631@5% P4;_I2^/#$2 <GP!$
M#2!Z"QB> ,0-(':%ULI<62MJ:#)5<D^4W8UL=N"\<6BLA@E[BH]&X2I#G$F^
M 7J@R2=R1Y6BUE)RM@)#&=?G&'UZ7)&S#^=3WV NB_#3AG=1\T8G>,.(W$IA
M<DT^BPRR?PE\%-DJC0Y*%U$OXPK2 8G#"Q(%4= A:/G?\/"J1T[<&A<[OKC?
MN)_SM38*/\9?/9S#EG/H.(<G.)UC_!5OAS"DI*]X6XSN\KZF&3D:>T]WR>0R
M"-"574?V49M]U)M]+D1%>9V<B539 B]("2K%"-[H+B']C/$@"#[V^#)NE8U[
M>>ZJ8@V*R TVFS5WQG>)J4G&1Z[$W8Y,VKR3WKPW14F9LJ= N-2=.2?O3B(>
MAN.K-F_]:;[?]?:L_*,K7(#:NLZF22HK8>H[TD;;YCEW/>--?(%-M>Z!?VGJ
MCGQ+U98)33ALD#(83%"/JKM</3&R=(UB+0VV'3?,\<< RF[ ]8V4YC"Q"=I?
M3?('4$L#!!0    ( "2 65)A?IL';P(  $D&   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;(V576_:,!2&_XH5[:*5UB9Q/DHKB%2@TR:M&VK5[6+:
MA4D.Q&IB9[8IW;_?L1,R2@%Q0_QQWL?O.8D/P[54S[H$,.2UKH0>>:4QS8WO
MZ[R$FNE+V8# G854-3,X54M?-PI8X41UY=,@2/V:<>%E0[<V4]E0KDS%!<P4
MT:NZ9NKO&"JY'GFAMUEXX,O2V 4_&S9L"8]@GIJ9PIG?4PI>@]!<"J)@,?)N
MPYM):N-=P \.:[TU)C:3N93/=O*E&'F!-005Y,82&#Y>8 )594%HXT_']/HC
MK7![O*%_<KEC+G.F82*KG[PPY<@;>*2 !5M5YD&N/T.73V)YN:RT^R7K-C:.
M/)*OM)%U)T8'-1?MD[UV==@2A.D! >T$=%<0'Q!$G2!RB;;.7%I39E@V5')-
ME(U&FAVXVC@U9L.%?8N/1N$N1YW)O@+60),+X@;D[A4_#WR>3<$P7NESW'EZ
MG)*S#^=#W^!Y5N7G'7O<LND!=DC)O12FU.1.%%"\!?AHM'=+-V[']"AQ"ODE
MB<*/A 8TV&-H<K(\O#YB)^J+%SE>=+QXOV[GVBC\('\?8<8],W;,^ #S>P.*
M&2Z6I')O))?:["M]2TD<Q5[5ERR.PX1B6B_;!=D7%@^N!GW8&Y-);S(YT:1>
MS5N?7.2RAGU.6U2Z9>&"7H?A5;1C=4]<- C3)-KO->V]ID>]?L-6*$\L:OJN
M6F$21$FZX_1]6!I1FNSX]+=N90UJZ9J5QK-7PK2??+_:]\-;UP9VUL?8)]NV
M]A_3-ME[II9<:,QJ@<C@\@H]J;9QM1,C&W?WY])@)W'#$GL]*!N ^PLIS69B
M#^C_/;)_4$L#!!0    ( "2 65+1 $O%T (  &L(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#0P+GAM;)U6:V_:,!3]*U;V4"L-\B2$#I!:JFF5]JC*NGZ8
M]L&$"UAUXLQVH/WWNW9H1B&-RKXD=G+/\3G7U[D9;H2\5RL 31XRGJN1L]*Z
M.'-=E:X@HZHK"LCQS4+(C&J<RJ6K"@ET;D$9=P//B]V,LMP9#^VS:SD>BE)S
MEL.U)*K,,BH?+X"+S<CQG:<'-VRYTN:!.QX6= E3T+?%M<296[/,60:Y8B(G
M$A8CY]P_FR0FW@;\9+!1.V-BG,R$N#>3J_G(\8P@X)!JPT#QMH8)<&Z(4,:?
M+:=3+VF N^,G]D_6.WJ94043P>_87*]&3N*0.2QHR?6-V'R&K9^>X4L%5_9*
M-E5LC,%IJ;3(MF!4D+&\NM.';1YV '[T B#8 H+7 L(M(+1&*V76UB75=#R4
M8D.DB48V,["YL6ATPW*SBU,M\2U#G!Y_ <R!(ATR+8N" ^Z/IIQ<4$[S%,C4
M%M)57E6+2?O))6C*N#I%R.WTDIR\/1VZ&H48.C?=+GI1+1J\L.@EI%T2^A](
MX 5> WSR:K@_> YWT7Z=@Z#.06#YPO8<_#J?*2VQKGZW<(8U9V@YHQ<XOQ<@
M,6/YDG##3J0IIXY8=$J<4*5 JZ:\5:0]2VH.X'H<1J'G^4-WO9N?P[!XT(_\
MI Y[ICFJ-4>MFB>EE+C_1.QIYXS.&&>:0:/FBC3>$9/$N*_QGN:FL%[8'S1K
M[M6:>ZV:OXF\D_Z?[MZ!H$$PV,_T81":&\1AL^JX5AVWJOXAS"D[4F]\L.E)
M/(@&_3W%AV%^/XC#*&B6W*\E]ULEW]D/(LP[=(VJEUC18)K$/_4:9/;^31+X
M_L<]8XUNVE?SR2-0V?1I:,<%%J=:#G!2^TV.\SMG*A4EEAE:@R.,MB\3=WO>
MNR:?1\,JE^Y.*S!M^"N52Y8KU+= (J_;Q\*056NK)EH4MCO,A,9>8X<K_!L
M:0+P_4((_30Q#:?^OQC_!5!+ P04    "  D@%E2;*WLIT "   @!0  &0
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M^(2!- YXG@NA#X8),#Z*R1]02P,$%     @ )(!94H7TPFH, P  "0L  !D
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MMMU=5;^ZB*@N(C+Q_)9XHPP+H6M55NB_CVH<O)<D%_\?B>[7T7T3/6B);A=
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M3Z5(0.D/Y.:AY.:)_$;6H#AH<D66,M^!,GPC@-QB#D$I2(A#D8L5&,:%_HB
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M/YQ@(:G#Z>QP8V3ACA\;:5">NTSQ1 O*#L#W6RG-\<:>:.HS\N)_4$L#!!0
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MWBB^S#\R/'&E>)I?+H!JM34&^OV,<[6[,=\MBH]SPW\!4$L#!!0    ( "2
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M%AU1?"<I3A3?Y&_=<Z[T.WQ^N :JM<XLT/>7G*OG$_,B7WVMFOP-4$L#!!0
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MQBB5"2@X^#BD@D0Q_R1-?SP,P<</G_H](9N3.^V%JNJ+LFI44_6W4'2!A4X
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M2XK'.243RG(#^7V:96+]DE>PN5P=_ =02P,$%     @ )(!94N(;Z1E*!
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M,:C0!O!^P[EZ'^@ S9^6^7]02P,$%     @ )(!94OI]G(35!@  42H  !D
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MG2\.[Y$..XIO\U<Q2ZX4C_/-#= 01!:@SZ^X7L47.]G;G?)MWN)_4$L#!!0
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MT4G;9)=%AU9,M,A=5S01VO18;IB:KI9(N\&\GPJAUQ.;H.R3!W\!4$L#!!0
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MPACH]PGG:C<P#NK&>_X/4$L#!!0    ( "2 65)%9PWB>P,  )$+   9
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M- +X/15"OTQ,5]9UX>O_ %!+ P04    "  D@%E2%.;WQ+$"  #I!P  &0
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M\"B )9356[+J:%&43X!'H>%)4387\/YFT@C ]T0(_=HQ!IH7_?1?4$L#!!0
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M-VNPOYO'"Q9=P>&_1?(74$L#!!0    ( "2 65*7BKL<P    !,"   +
M7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_
MK]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?2
M0$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-
MTG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z
M6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ )(!94D.H4T #!0
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MR*I19"U09"U09"U09"W^4]9G:Y=_'#\\\];4W2&?#?]VFKT!4$L! A0#%
M  @ )(!94@=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  D@%E2C5CS5^X    K @  $0
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M=#(N>&UL4$L! A0#%     @ )(!94LTESVJH @  1 @  !@
M ("!\A,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "2
M65(A?]@PBP4  &X5   8              " @= 6  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  D@%E2C<DT?*4)  #B,P  &
M        @(&1'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ )(!94JN]_PM? @  - 4  !@              ("!;"8  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "2 65+!<AX\3P@  ,(E   8
M              " @0$I  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  D@%E2>OSEI+L"  "$!P  &               @(&&,0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ )(!94O@E+2<J!0
M2@L  !@              ("!=S0  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( "2 65(*'HK:4Q@  /1&   9              " @=<Y
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ )(!94N2:
MI^<@!   &PD  !D              ("!85(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  D@%E2YID-&]D&   H'   &0
M    @(&X5@  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M "2 65)PH?_(%Q   &([   9              " @<A=  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ )(!94OP/3R<P"0  JA<  !D
M             ("!%FX  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  D@%E2-"?/Z*@%  "+#P  &0              @(%]=P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "2 65++O\" ;00
M "8,   9              " @5Q]  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ )(!94K=Q+1<W"   .14  !D              ("!
M ((  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  D@%E2
M;;>&$V0%  #%"P  &0              @(%NB@  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( "2 65)USGQ DP(  ,(%   9
M      " @0F0  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ )(!94JNAX'F= P  X <  !D              ("!TY(  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  D@%E2$4*LI]8%   N#0
M&0              @(&GE@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( "2 65*V2;/FG!4  )-#   9              " @;2<  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ )(!94CKW?2 ;
M P  ? 8  !D              ("!A[(  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  D@%E2J[:Z[.D#  "("   &0
M@('9M0  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "2
M65(TNC_!<P0  %P+   9              " @?FY  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ )(!94H>XP4]A!   V H  !D
M         ("!H[X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    "  D@%E2+-;T&&0%  !(#0  &0              @($[PP  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "2 65+*F<LB@P0  '4,
M   9              " @=;(  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ )(!94J*-\Y:@ P  Z D  !D              ("!D,T
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  D@%E2/Z>V
M[NH$  "0#   &0              @(%GT0  >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( "2 65*AWVI8+ (  *$$   9
M  " @8C6  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M)(!94O?;21W@ @  PP8  !D              ("!Z]@  'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  D@%E2IVYY:X8"  #R!@  &0
M            @($"W   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( "2 65)H$R+5G (  -P'   9              " @;_>  !X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ )(!94@+LVI^+ P
MI@T  !D              ("!DN$  'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  D@%E2B+H 7VT#  "R"P  &0              @(%4
MY0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "2 65*Y
MBCST60,  /H)   9              " @?CH  !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ )(!94@:;K%"! @  =@8  !D
M     ("!B.P  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "2 65*GB[K)8P0  .$1   9              "
M@:?Z  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ )(!9
M4N9[=-#4 P  -Q0  !D              ("!0?\  'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  D@%E2<':(ZE $   O#P  &0
M        @(%, P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( "2 65+OE_'GKP0  *@3   9              " @=,' 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ )(!94HCVM,F.!   N1(
M !D              ("!N0P! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  D@%E2\(@TRG %  #!&   &0              @(%^$0$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "2 65+C8*%!
M!@8  &@=   9              " @247 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ )(!94N(;Z1E*!   1@\  !D
M ("!8AT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  D
M@%E2\3\G$N("  "S"   &0              @('C(0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "2 65)=63J-:@,  %(,   9
M          " @?PD 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#
M%     @ )(!94@;,B^C2!   1A0  !D              ("!G2@! 'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  D@%E2';@52+8#  #
M#   &0              @(&F+0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM
M;%!+ 0(4 Q0    ( "2 65+Z?9R$U08  %$J   9              " @9,Q
M 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ )(!94O%B
M]HL3!   V1,  !D              ("!GS@! 'AL+W=O<FMS:&5E=',O<VAE
M970U-BYX;6Q02P$"% ,4    "  D@%E2)/W.3" #   S"P  &0
M    @('I/ $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M "2 65((L:=$Z (  /\(   9              " @4!  0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ )(!94CN]^"GT P  A \  !D
M             ("!7T,! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    "  D@%E216<-XGL#  "1"P  &0              @(&*1P$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "2 65(4YO?$L0(
M .D'   9              " @3Q+ 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ )(!94KN,3H@M!   W0\  !D              ("!
M)$X! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  D@%E2
M6"[$91\"  !P!   &0              @(&(4@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( "2 65(T)@3G4P(  &@,   -
M      "  =Y4 0!X;"]S='EL97,N>&UL4$L! A0#%     @ )(!94I>*NQS
M    $P(   L              ( !7%<! %]R96QS+RYR96QS4$L! A0#%
M  @ )(!94D.H4T #!0  Y"D   \              ( !15@! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( "2 65(G9=6E# (  (0E   :
M  "  75= 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M "2 65+NU>T8Y@$  /4D   3              "  ;E? 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !' $< :!,  -!A 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>406</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StatementsofStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Statement of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical</Role>
      <ShortName>Statement of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StatementsofCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business Overview and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BusinessOverviewandLiquidity</Role>
      <ShortName>Business Overview and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Supplementary Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/SupplementaryBalanceSheetInformation</Role>
      <ShortName>Supplementary Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130106 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2137107 - Disclosure - Derivative Financial Instruments - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants</Role>
      <ShortName>Derivative Financial Instruments - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2151111 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2152112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2154113 - Disclosure - COVID-19</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/COVID19</Role>
      <ShortName>COVID-19</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Supplementary Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables</Role>
      <ShortName>Supplementary Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/SupplementaryBalanceSheetInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2331305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2338306 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2341307 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business Overview and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails</Role>
      <ShortName>Business Overview and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/BusinessOverviewandLiquidity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Leases - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesLeaseExpenseDetails</Role>
      <ShortName>Leases - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series A Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series C Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2427417 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series D Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2428418 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series E Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429419 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails</Role>
      <ShortName>Stockholders' Equity - Securities Purchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2432420 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2433421 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2435423 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436424 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Derivative Financial Instruments - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2442426 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2446428 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2447429 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Company's Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2448430 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2450431 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/RelatedPartyTransactions</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="trov-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - COVID-19 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.trovagene.com/role/COVID19Details</Role>
      <ShortName>COVID-19 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.trovagene.com/role/COVID19</ParentRole>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="trov-20201231.htm">trov-20201231.htm</File>
    <File>a1016ex022521.htm</File>
    <File>a1017ex022321.htm</File>
    <File>a109ex022521.htm</File>
    <File>a231exq42020.htm</File>
    <File>a311exq42020.htm</File>
    <File>a312exq42020.htm</File>
    <File>a321exq42020.htm</File>
    <File>a322exq42020.htm</File>
    <File>trov-20201231.xsd</File>
    <File>trov-20201231_cal.xml</File>
    <File>trov-20201231_def.xml</File>
    <File>trov-20201231_lab.xml</File>
    <File>trov-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "trov-20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 206,
   "dts": {
    "calculationLink": {
     "local": [
      "trov-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "trov-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "trov-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "trov-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "trov-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "trov-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 524,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 5
   },
   "keyCustom": 63,
   "keyStandard": 343,
   "memberCustom": 20,
   "memberStandard": 35,
   "nsprefix": "trov",
   "nsuri": "http://www.trovagene.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.trovagene.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Supplementary Balance Sheet Information",
     "role": "http://www.trovagene.com/role/SupplementaryBalanceSheetInformation",
     "shortName": "Supplementary Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Leases",
     "role": "http://www.trovagene.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Stockholders' Equity",
     "role": "http://www.trovagene.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130106 - Disclosure - Stock-Based Compensation",
     "role": "http://www.trovagene.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137107 - Disclosure - Derivative Financial Instruments - Warrants",
     "role": "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants",
     "shortName": "Derivative Financial Instruments - Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140108 - Disclosure - Fair Value Measurements",
     "role": "http://www.trovagene.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Income Taxes",
     "role": "http://www.trovagene.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.trovagene.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2151111 - Disclosure - Employee Benefit Plan",
     "role": "http://www.trovagene.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Balance Sheets",
     "role": "http://www.trovagene.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152112 - Disclosure - Related Party Transactions",
     "role": "http://www.trovagene.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2154113 - Disclosure - COVID-19",
     "role": "http://www.trovagene.com/role/COVID19",
     "shortName": "COVID-19",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnusualOrInfrequentItemsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Supplementary Balance Sheet Information (Tables)",
     "role": "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables",
     "shortName": "Supplementary Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Leases (Tables)",
     "role": "http://www.trovagene.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.trovagene.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i229ba083ae0546d499ab31088af51e73_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338306 - Disclosure - Derivative Financial Instruments - Warrants (Tables)",
     "role": "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables",
     "shortName": "Derivative Financial Instruments - Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i229ba083ae0546d499ab31088af51e73_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341307 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.trovagene.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://www.trovagene.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.trovagene.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business Overview and Liquidity (Details)",
     "role": "http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails",
     "shortName": "Business Overview and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i1514b777a3114342923aade0d19fa7c0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i1514b777a3114342923aade0d19fa7c0_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)",
     "role": "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "role": "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails",
     "shortName": "Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)",
     "role": "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails",
     "shortName": "Supplementary Balance Sheet Information - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "trov:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.trovagene.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "trov:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Leases - Lease Expense (Details)",
     "role": "http://www.trovagene.com/role/LeasesLeaseExpenseDetails",
     "shortName": "Leases - Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Statements of Operations",
     "role": "http://www.trovagene.com/role/StatementsofOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "trov:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "role": "http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "role": "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i1033093be1a94f1586671f93e4cc0292_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "trov:ClassOfWarrantOrRightNumberExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i6cf54a66629e481797b44e8a6b0fa9b1_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPreferredStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series A Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ia1936ada99b844a98161cd8a59a0cc9c_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "trov:ClassOfWarrantOrRightNumberGranted",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Stockholders' Equity - Series C Convertible Preferred Stock (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series C Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ia02b699fc73a48aa943cf6fb99f91912_D20190401-20190430",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i27074d7d656d4fbf85a8b9980795b54a_I20200615",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427417 - Disclosure - Stockholders' Equity - Series D Convertible Preferred Stock (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series D Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "icdfaba1492ec4f509a70416341174b1f_D20200601-20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428418 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i27074d7d656d4fbf85a8b9980795b54a_I20200615",
      "decimals": "INF",
      "lang": "en-US",
      "name": "trov:ClassOfWarrantOrRightIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429419 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)",
     "role": "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
     "shortName": "Stockholders' Equity - Securities Purchase Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i49a86e4aa51c46c7900b7f688f0239ce_D20201002-20201002",
      "decimals": "-5",
      "lang": "en-US",
      "name": "trov:SaleOfStockConsiderationReceivedOnTransactionGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i90cbda9b433948c4bfec12adb85eece5_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Statements of Stockholders' Equity",
     "role": "http://www.trovagene.com/role/StatementsofStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i90cbda9b433948c4bfec12adb85eece5_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432420 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433421 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ibeeb551ace7d42168313ad655821639d_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ibeeb551ace7d42168313ad655821639d_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ie7f45e2fb41d4a1e93becedfc38abed4_D20190101-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435423 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ibeeb551ace7d42168313ad655821639d_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i978ad2c8eb824931bb5e88b64023d145_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436424 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)",
     "role": "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "ie72aca79d4804a8284025a9bab28eb5e_I20181231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i1033093be1a94f1586671f93e4cc0292_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Derivative Financial Instruments - Warrants (Details)",
     "role": "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
     "shortName": "Derivative Financial Instruments - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "iffe390a53d1244859cc856f61f4542ae_D20200101-20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "trov:FairValueAssumptionsWeightedAverageRemainingContractualTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442426 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.trovagene.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i57e9a24fb323452cbc514841b9fbe098_I20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446428 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447429 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)",
     "role": "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails",
     "shortName": "Income Taxes - Significant Components of Company's Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "trov:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Statement of Shareholders' Equity (Parenthetical)",
     "role": "http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical",
     "shortName": "Statement of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "trov:CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448430 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i076def4a10c84321bb8feceb11551055_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "trov:AccruedClinicalTrialExpensesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450431 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)",
     "role": "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails",
     "shortName": "Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i9f2ba9a7769e4c3981f5515bac81bee0_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherCommitment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "trov:AccruedClinicalTrialExpensesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.trovagene.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i014c4430e11a4a7ba478369860aa6b07_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i7103d5be24a4480abffa7afe4b21824f_I20200415",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - COVID-19 (Details)",
     "role": "http://www.trovagene.com/role/COVID19Details",
     "shortName": "COVID-19 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i7103d5be24a4480abffa7afe4b21824f_I20200415",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Statements of Cash Flows",
     "role": "http://www.trovagene.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i08acffb99e614dc58b610354b475758f_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Statements of Cash Flows (Parenthetical)",
     "role": "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i08acffb99e614dc58b610354b475758f_D20200101-20201231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business Overview and Liquidity",
     "role": "http://www.trovagene.com/role/BusinessOverviewandLiquidity",
     "shortName": "Business Overview and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "trov-20201231.htm",
      "contextRef": "i15d5004991164f9287579e8f3ffb7e54_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r436",
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r47",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r219",
      "r220",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r197",
      "r198",
      "r385",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r197",
      "r198",
      "r385",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r199",
      "r219",
      "r220",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r199",
      "r219",
      "r220",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r378",
      "r380",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_AccruedClinicalTrial": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial",
        "label": "Accrued Clinical Trial",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrial",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expenses",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued Clinical Trial Expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_AccruedClinicalTrialExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expenses",
        "label": "Accrued Clinical Trial Expenses [Policy Text Block]",
        "terseLabel": "Accrued Clinical Trial Expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesPolicyTextBlock",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trov_AccruedPreferredStockDividend": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Preferred Stock Dividend",
        "label": "Accrued Preferred Stock Dividend",
        "terseLabel": "Preferred stock dividend"
       }
      }
     },
     "localname": "AccruedPreferredStockDividend",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_Accrueddirectorfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued service fees for nonemployee directors",
        "label": "Accrued director fees",
        "terseLabel": "Director fees"
       }
      }
     },
     "localname": "Accrueddirectorfees",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_Accruedresearchagreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research agreements",
        "label": "Accrued research agreements",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "Accruedresearchagreements",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments To Additional Paid In Capital, Common Stock Par Value Adjustment",
        "label": "Adjustments To Additional Paid In Capital, Common Stock Par Value Adjustment",
        "terseLabel": "Common Stock par value adjustment"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalCommonStockParValueAdjustment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_AmountFinancedUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount Financed Under Agreement",
        "label": "Amount Financed Under Agreement",
        "terseLabel": "Amount financed under agreement"
       }
      }
     },
     "localname": "AmountFinancedUnderAgreement",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trov_BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "label": "Beneficial Conversion Feature For Issuance Of Convertible Preferred Stock",
        "terseLabel": "Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance"
       }
      }
     },
     "localname": "BeneficialConversionFeatureForIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_BlackScholesOptionPricingMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.",
        "label": "Black Scholes Option Pricing Method [Member]",
        "terseLabel": "Black Scholes Option Pricing Method"
       }
      }
     },
     "localname": "BlackScholesOptionPricingMethodMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_ClassOfWarrantOrRightExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Term",
        "label": "Class Of Warrant Or Right, Expiration Term",
        "terseLabel": "Expiration term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationTerm",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued",
        "label": "Class Of Warrant Or Right, Issued",
        "terseLabel": "Class Of Warrant Or Right, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_ClassOfWarrantOrRightMonthsUntilExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Months Until Exercisable",
        "label": "Class Of Warrant Or Right, Months Until Exercisable",
        "terseLabel": "Months until exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMonthsUntilExercisable",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_ClassOfWarrantOrRightNumberExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Number Exercised",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberExercised",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_ClassOfWarrantOrRightNumberGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right Number Granted",
        "terseLabel": "Warrants granted (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberGranted",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights granted during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Granted",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_CommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock And Warrants [Member]",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common Stock And Warrants"
       }
      }
     },
     "localname": "CommonStockAndWarrantsMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "label": "Common stock, preferred stock and warrants issued in connection with clinical trial funding commitment",
        "terseLabel": "Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640"
       }
      }
     },
     "localname": "Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_ConvertiblePreferredStockStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Stated Value Per Share",
        "label": "Convertible Preferred Stock, Stated Value Per Share",
        "terseLabel": "Stated value (in dollars per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockStatedValuePerShare",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "label": "Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "terseLabel": "Cost of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment"
       }
      }
     },
     "localname": "CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend recognized on beneficial conversion features of Series B Convertible Preferred Stock issuance",
        "label": "Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock",
        "negatedTerseLabel": "Deemed dividend recognized on beneficial conversion features of Convertible Preferred Stock issuance",
        "verboseLabel": "Deemed dividend recognized on beneficial conversion features of convertible preferred stock"
       }
      }
     },
     "localname": "DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "totalLabel": "Net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Other",
        "terseLabel": "Research and development credits and other tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_DerivativeFinancialInstrumentsLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments Liability [Roll Forward]",
        "terseLabel": "Changes in the Company's derivative financial instruments liability balance"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilityRollForward",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trov_DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "label": "Discount of Issuance of Common Stock, Preferred Stock and Warrants for Clinical Trial Funding Commitment",
        "terseLabel": "Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment"
       }
      }
     },
     "localname": "DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.trovagene.com/20201231",
     "xbrltype": "stringItemType"
    },
    "trov_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent Items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "trov_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "Equity Incentive Plan 2014"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_EstimatedFairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated fair value of warrant.",
        "label": "Estimated Fair Value of Warrant",
        "terseLabel": "Estimated fair value of Trovagene common stock (in dollars per share)"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrant",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_FairValueAssumptionsWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average remaining contractual period for which the instrument, asset or liability is expected to be outstanding.",
        "label": "Fair Value Assumptions Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "FairValueAssumptionsWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent Items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Liability",
        "label": "Increase (Decrease) In Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Three",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Due Year Two",
        "totalLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Next Twelve Months",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Of Sublease Income, Next Twelve Months",
        "totalLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Payments, Net Sublease Income, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Net Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsNetSubleaseIncomeFiscalYearMaturityAbstract",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trov_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_LessorNumberOfSubleases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Number Of Subleases",
        "label": "Lessor, Number Of Subleases",
        "terseLabel": "Number of subleases"
       }
      }
     },
     "localname": "LessorNumberOfSubleases",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "trov_NorvianoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nerviano [Member]",
        "label": "Norviano [Member]",
        "terseLabel": "Norviano"
       }
      }
     },
     "localname": "NorvianoMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "terseLabel": "NOLs, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Subject To Expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "terseLabel": "NOLs, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_Patentlicenseandotherfeespayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent, license and other fees payable",
        "label": "Patent, license and other fees payable",
        "terseLabel": "Patent, license and other fees"
       }
      }
     },
     "localname": "Patentlicenseandotherfeespayable",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants [Member]",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading Days",
        "terseLabel": "Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_PreferredStockConversionObligationNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Number of Trading Days",
        "terseLabel": "Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationNumberOfTradingDays",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Specified Volume of Common Stock Traded Per Day during Trading Days",
        "terseLabel": "Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the convertible preferred stock.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Convertible, Conversion Price",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_PreferredStockDividendAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of preferred stock dividend accrued during the reporting period.",
        "label": "Preferred Stock Dividend Accrued",
        "terseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendAccrued",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period during which the conversion price is subject to adjustment for dilutive issuances.",
        "label": "Preferred Stock Period of Dilutive Issuance for Conversion Price Adjustments",
        "terseLabel": "Period during which the conversion price is subject to adjustment for dilutive issuances"
       }
      }
     },
     "localname": "PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "trov_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to registered direct offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_Releaseofclinicaltrialfundingcommitmentforservicesreceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of clinical trial funding commitment for services received",
        "label": "Release of clinical trial funding commitment for services received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "Releaseofclinicaltrialfundingcommitmentforservicesreceived",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_SaleOfStockCommonAndWarrantsNetShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Common And Warrants, Net, Shares",
        "label": "Sale Of Stock, Common And Warrants, Net, Shares",
        "negatedTerseLabel": "Sale of common stock and warrants, net of expenses (in shares)"
       }
      }
     },
     "localname": "SaleOfStockCommonAndWarrantsNetShares",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "label": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_SaleOfStockValueCommonAndWarrantsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Value, Common And Warrants, Net",
        "label": "Sale Of Stock, Value, Common And Warrants, Net",
        "negatedTerseLabel": "Sale of common stock and warrants, net of expenses"
       }
      }
     },
     "localname": "SaleOfStockValueCommonAndWarrantsNet",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.",
        "label": "Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]",
        "terseLabel": "Schedule of Components of Changes in the Company\u2019s Derivative Financial Instruments Liability Balance"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "trov_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesIWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series I Warrant",
        "label": "Series I Warrant [Member]",
        "terseLabel": "Series I Warrant"
       }
      }
     },
     "localname": "SeriesIWarrantMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesJWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series J Warrant",
        "label": "Series J Warrant [Member]",
        "terseLabel": "Series J Warrant"
       }
      }
     },
     "localname": "SeriesJWarrantMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesKWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series K Warrant",
        "label": "Series K Warrant [Member]",
        "terseLabel": "Series K Warrant"
       }
      }
     },
     "localname": "SeriesKWarrantMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesLWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series L Warrants [Member]",
        "label": "Series L Warrants [Member]",
        "terseLabel": "Series L Warrants"
       }
      }
     },
     "localname": "SeriesLWarrantsMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesMWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series M Warrant",
        "label": "Series M Warrant [Member]",
        "terseLabel": "Series M Warrant"
       }
      }
     },
     "localname": "SeriesMWarrantMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_SeriesNWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series N Warrant",
        "label": "Series N Warrant [Member]",
        "terseLabel": "Series N Warrant"
       }
      }
     },
     "localname": "SeriesNWarrantMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "trov_Servicereceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants",
        "label": "Service receivable",
        "negatedTerseLabel": "Service receivables",
        "terseLabel": "Service receivable"
       }
      }
     },
     "localname": "Servicereceivable",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_SharePriceForAutomaticConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.",
        "label": "Share Price for Automatic Conversion",
        "terseLabel": "Share price for 20 consecutive trading days for automatic conversion"
       }
      }
     },
     "localname": "SharePriceForAutomaticConversion",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "trov_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued during the period upon cash exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "trov_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity impact during the period due to the cash exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_ValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance",
        "label": "Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowance",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "trov_WarrantsFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Fair Value",
        "label": "Warrants, Fair Value",
        "terseLabel": "Fair value",
        "verboseLabel": "Warrants, Fair Value"
       }
      }
     },
     "localname": "WarrantsFairValue",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StatementofShareholdersEquityParenthetical",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "trov_WarrantsWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Weighted Average Contractual Term",
        "label": "Warrants, Weighted Average Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WarrantsWeightedAverageContractualTerm",
     "nsuri": "http://www.trovagene.com/20201231",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r21",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r36"
     ],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees and outside services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r162"
     ],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less\u2014accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r261"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r258",
      "r259",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r222",
      "r224",
      "r264",
      "r265"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r224",
      "r254",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r134",
      "r143",
      "r149",
      "r158",
      "r305",
      "r307",
      "r339",
      "r398",
      "r411"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r45",
      "r83",
      "r158",
      "r305",
      "r307",
      "r339"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.trovagene.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r225",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California Franchise Tax Board"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year.",
        "label": "Capital Loss Carryforward [Member]",
        "terseLabel": "Capital Loss Carryforward"
       }
      }
     },
     "localname": "CapitalLossCarryforwardMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r29",
      "r71"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/BusinessOverviewandLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r72",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r65",
      "r71",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r340"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r81",
      "r83",
      "r104",
      "r105",
      "r106",
      "r109",
      "r111",
      "r116",
      "r117",
      "r118",
      "r158",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r193",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Number of securities called by each warrant (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r193",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r168",
      "r403",
      "r416"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r178",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000,000 shares authorized; 36,780,805 and 8,593,633 shares issued and outstanding at December 31, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and liabilities from federal and state income taxes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r121",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Common stock issued upon conversion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r18",
      "r19",
      "r184",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r288",
      "r295",
      "r297"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r288",
      "r295"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r399",
      "r401",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r289",
      "r295"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r84",
      "r289",
      "r295",
      "r296",
      "r297"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r278",
      "r400",
      "r409"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "trov_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r289",
      "r295"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r279"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "trov_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetCurrentClassificationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance, Current Classification [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetCurrentClassificationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r280"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r286",
      "r287"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r132"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r315",
      "r316",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments - Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Balance of derivative financial instruments liability at the end of the period",
        "periodStartLabel": "Balance of derivative financial instruments liability at the beginning of the period",
        "terseLabel": "Derivative financial instruments\u2014warrants",
        "verboseLabel": "Derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r317",
      "r318",
      "r320",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r87",
      "r310",
      "r311",
      "r313",
      "r314",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments\u2014Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r192",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "terseLabel": "Accrued dividend during the period"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Tax computed at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r266",
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock options true-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r266",
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock options true-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost for non-vested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r115",
      "r159",
      "r183",
      "r192",
      "r258",
      "r259",
      "r260",
      "r291",
      "r292",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimate of Fair Value Measurement"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtraordinaryAndUnusualItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unusual or Infrequent Items, or Both [Abstract]"
       }
      }
     },
     "localname": "ExtraordinaryAndUnusualItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Fair Value of Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r215",
      "r326",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r325",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r329",
      "r330",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r200",
      "r202",
      "r207",
      "r215",
      "r326",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r200",
      "r202",
      "r207",
      "r215",
      "r326",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r215",
      "r326",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Range of assumptions used to determine the fair value of warrants"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r215",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r331",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r78",
      "r335",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment Losses on Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r273",
      "r276",
      "r283",
      "r293",
      "r299",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest and/or penalties incurred"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r84",
      "r100",
      "r101",
      "r133",
      "r271",
      "r294",
      "r300",
      "r418"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Total income tax provision",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r78",
      "r269",
      "r270",
      "r276",
      "r277",
      "r282",
      "r290",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax computed at the federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax, net of federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r66",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r52",
      "r131",
      "r347",
      "r348",
      "r405"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r56",
      "r130"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r361",
      "r363"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Income"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "negatedTotalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "trov_LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeNextTwelveMonths",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "negatedTerseLabel": "2021"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "negatedTerseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "negatedTerseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r83",
      "r144",
      "r158",
      "r306",
      "r307",
      "r308",
      "r339"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r83",
      "r158",
      "r339",
      "r402",
      "r414"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r83",
      "r158",
      "r306",
      "r307",
      "r308",
      "r339"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.trovagene.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]",
        "terseLabel": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r49",
      "r50",
      "r54",
      "r70",
      "r83",
      "r93",
      "r95",
      "r96",
      "r97",
      "r98",
      "r100",
      "r101",
      "r107",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r158",
      "r339",
      "r404",
      "r417"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r102",
      "r103",
      "r108",
      "r111",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable\u00a0to\u00a0common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncement"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r15",
      "r401",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r356",
      "r363"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r353"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r354",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r352"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r360",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r359",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r349",
      "r350",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOLs"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carryforwards (NOLs)"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business Overview and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BusinessOverviewandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAffiliatesMember": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A category that identifies other affiliates.",
        "label": "Other Affiliates [Member]",
        "terseLabel": "Other Affiliates"
       }
      }
     },
     "localname": "OtherAffiliatesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "terseLabel": "Licensing and distribution rights commitment"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r36"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other gain (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayments of note payable"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r199",
      "r201",
      "r207",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r225",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of cumulative preferred dividends in arrears.",
        "label": "Preferred Stock, Amount of Preferred Dividends in Arrears",
        "terseLabel": "Accrued cumulative unpaid preferred stock dividends"
       }
      }
     },
     "localname": "PreferredStockAmountOfPreferredDividendsInArrears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Cumulative dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Series A Convertible Preferred Stock, liquidation preference"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheetsParenthetical",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value, 20,000,000 shares authorized; (Note 5)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r27",
      "r28"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $7,507,123 and $158,678 respectively"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Borrowings under note payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r62",
      "r64",
      "r88"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Costs related to the clinical trial funding commitment"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r60",
      "r257"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r32",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r31",
      "r161"
     ],
     "calculation": {
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r163",
      "r415"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r78",
      "r163",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r209",
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r209",
      "r369",
      "r372",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r367",
      "r368",
      "r370",
      "r373",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r268",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.trovagene.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails",
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r268"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r78",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r192",
      "r261",
      "r413",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r159",
      "r258",
      "r259",
      "r260",
      "r291",
      "r292",
      "r423",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r196",
      "r197",
      "r385"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r53",
      "r83",
      "r128",
      "r129",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r158",
      "r339",
      "r406"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes Based on Losses from Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Company\u2019s Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Company\u2019s Taxes and the Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r224",
      "r253",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r224",
      "r253",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r32",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r85",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r225",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r230",
      "r242",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Stock Options - Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r81",
      "r116",
      "r117",
      "r179",
      "r181",
      "r182",
      "r184",
      "r185",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r180",
      "r181",
      "r182",
      "r184",
      "r185",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r193",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeitures (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Beginning weighted average grant date fair value (in dollars per share)",
        "periodStartLabel": "Ending weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted\u00a0Average Grant Date Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of vested awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (range)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility (weighted-average)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r231",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r232",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding (in dollars per share)",
        "periodStartLabel": "Outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r223",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r78",
      "r225",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Intrinsic value, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r248",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contract term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r81",
      "r83",
      "r104",
      "r105",
      "r106",
      "r109",
      "r111",
      "r116",
      "r117",
      "r118",
      "r158",
      "r183",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r90",
      "r91",
      "r92",
      "r94",
      "r99",
      "r101",
      "r115",
      "r159",
      "r183",
      "r192",
      "r258",
      "r259",
      "r260",
      "r291",
      "r292",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockholdersEquityScheduleofWarrantsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r92",
      "r115",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofCashFlowsParenthetical",
      "http://www.trovagene.com/role/StatementsofOperations",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r183",
      "r184",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r183",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r183",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r183",
      "r192",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity",
      "http://www.trovagene.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "auth_ref": [
      "r19",
      "r20",
      "r183",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of a stock split.",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "terseLabel": "Issuance of common stock for share rounding as a result of reverse stock split (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r183",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r19",
      "r20",
      "r183",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r183",
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r83",
      "r157",
      "r158",
      "r339"
     ],
     "calculation": {
      "http://www.trovagene.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets",
      "http://www.trovagene.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r192",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r357",
      "r363"
     ],
     "calculation": {
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesCConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesDConvertiblePreferredStockDetails",
      "http://www.trovagene.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplementary Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/SupplementaryBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "TaxesPayableCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.trovagene.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.trovagene.com/role/StatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative financial instruments\u2014warrants",
        "negatedTerseLabel": "Change in fair value of derivative financial instruments\u2014warrants during the year recognized as a loss in the statement of operations",
        "terseLabel": "Gain (loss) from changes in fair value of derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/StatementsofCashFlows",
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Unusual or Infrequent Item, or Both [Line Items]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Line Items]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemTable": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the nature and financial statement effect of an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Table]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Table]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Items, or Both, Disclosure [Text Block]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/COVID19"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.trovagene.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.trovagene.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 1",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "Note 3",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121593497&loc=SL77918431-209957"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919396-209981"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888252"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(1)(a)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r435": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r436": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r437": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r438": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r439": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r441": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/subtopic&trid=114868817"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001628280-21-003277-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-003277-xbrl.zip
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M\3<3*N'M^?7PTR$_ "Q:1"[@"L)S(TS%(=4.K\4@:%GE*9L*\Y(8-*< X;2
MK99B@FX(B2ZX7>$/)UO#'RX=C&7P-J5^<'A-;RJ. ]UDDQ3NUMPC0EH&$IP8
MY,FH+AI^>Y$6SJ2Q!\2'OZ"#(JS=;W%(^5I.-:\:(]_LJTM@&F([@D0[85?@
M( @6N_42$]%3KWCF(:I><B\5KXNQF"-JA#1B;K1:$<*7=#ZIC0#Z<XAAA8B6
MC"D1"XYA87[5>@JN)#"BA0U9P\#B"M3D&.SS))LSU%9&TU3AF>6Q8]M;PD/,
M*F MH"K#T0-5 6$)QJUK6"9>!_8AYX/I5<?/*H9DZMZ_^(R,4_^0=48,T[2K
M DJYR+_(FMV+1!:/$:E>1*3.'R-2]UNP^C!A^BYZR29+PQ+L69C-*V0SYB.F
M^FQ<+M!Q2YU9^%")Q.,>/HPS-U 7;O>*H1DPF7H-PNBC**H!&6Z!@)8,8GMX
MQ?@YF?=&)!4YKW$'*R("-NRZ4A/J=Z'G/Z5\9\YYT*(&V'QHD'"U(>_D/3A*
M<K,V64<E&J["0@VJ;Q.B5.TE7:Z>;4:M-:MD(OG'(DJRV^XQT43285%JY(2A
M "J9:T(QT< 5Q2_<5K;=2"1NB\!A/,)4C"08#N.NU;\-EMM2^$&7CQ3%<3"T
M@PNZ:J8^'2%<L;'!7A<FJVXT8($<S[%[$FI75[)TG5V8P^V0RZ8V+O0 F\H_
M%MH1PUDE09PA^L3FDZ19,!;-,NHZ*(ND0':<Z^^),^"3G :$Q%QJ#T3(BA_8
M@1A%2W'%4!&;@"5$>4=<>V*.^DF1Y?8485G[&[W^JVJK<#XG0Z5A@Q3Q=#W*
M!*TBUCN"418O/?^-TSBVY#34@?;)S+5?YS<XF46L;)X+I[HZ=14RLUMAO5>8
M ".^&"64"R(TEAW=IT 1)BUIY<[6HPUM$BLIEGI7=;S8BBM;6D*B$,HSL.L#
M?MI JZOL4:+<KO;Y!,6KT.E1]^=)[ )@\))!B,)^ELMFR" (?OTVGMG,O\4#
M!>_+=%CMUM6TR,NVLT#.%*G*.\/@&+K8Z"*R9OO8@>JP173YD 7EE@?1;H2&
MT2;^:%)6Z5KBQ=-5<.IBK.XR^7:]/+U!-K4=:+DT:(_FQMB$#)5:.'J7:=E5
M]TASSJ[1\2>V&%LC#=,/)KQ-,;&$''@M/_X65[9]O=DH+1.!$:-Z\51JW:(V
M^+TK'K/3K?&8O<O2 ZKJ5:HZ:Q8__$1<LMRXS;(K512VJ5=2312;;GAT[<E2
M9!L4GC-&AHW_:GNC6;[$=GYUJCYAJ:$.--95C3=_0]UE?#%>VZE&YK)FYC9_
M1.5#HT(]=6N5/:,[[6$PPV@WMK^1<>NB]':5'Q+E12L>.B8SI4X# @4LG6 H
M0FL#=2 672JF21.[> E(54O>I@44>H8KV@C6<5OGRB->0(%RD],DM=)/M4R7
MC@+"OUM( Z&OJ/C:-$MB1"J@&0-+_%L& PI0$E<Y?FPJ;P7FNC*'TRUADS!?
M.<5/G/A1! :4*LEF8=<L?\#Y]*E<U@F"' @GH&M1"K#:BJFN3J#COCHX3<I(
M/6W]T@9X@@V>E+O0L(?WM5EU6W:9(W.O<BET0+XQCHYB6Z<8ZV-4<,\=7LUI
M]\#51;E[#*X@*&5:KK1^;1)8SU>Y)J'^K"]U@9;HX9U/L9$HHG+K>J"_IA3
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M/(.WJ7S'.-R.J?IO<I#=.3(N([T-:<SKJH;CFA17$HXN["QO)EZ,! %J+%(
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M?AB(X*U,Q4(4,H")S/5<'L 27^2SN<B60UC@_6^4(;^3@+SKRGX,+H.+X%T
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M6N7LC6^9-@YNU7)-9E-D?2,X:\(4'.7<$A/('\NN%NB1^8@>G5KZYV%T<(*
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M@I'N;W+@F@.1<D'0Q:EL9B27_W=Y\<O5N_^]'*;$]2SVT;,#H\EN5&V]@T1
M'A!<%F AQAO#9CD28;U8&.IB/WGM+6-P7__<%_7VG>;-J/A=P^\;;CO8O_6-
MW]T_<8/-.V@[^W=R7YW=L4B$5[+N_$XTL7)V=R>O@2S4D]=_PWJ#H")\E-0:
MJ>OCO6G7#Q[/RA_CK+SYPY^5=E7/5;4\!WX&GF)I9?C?M)JEK_\?4$L#!!0
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M/@7/;T&??,Q9S)#0P/;N(CZ,-4%RJ30>S/.'63V&&$GC.LFI?BPEX0%*YAV
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MY.V]GEQ^^LO2[MKVQ?\ 4$L#!!0    ( "2 65(=PJ923 @  !TN   0
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MO1-Q3]??)L)6!#[YRH/$.A *U+6)NLZT=&"XY3T3W"/C*$<OWKS;>73:UG@
M[CX=O+;]?B>87C2=9*@NJ+X,)/<5V3MF;T'I[U-Z:X+2QG(7C6 MRYD#?*QQ
M2P/<:\6@0G322F0L4'KYP];J?8@MF%-&"B2!B@SAH+#A43N*(Y(:1?\-06Y
MS.N/1?\H%(.SCP!'!LL]OPJXXRB1^7,9XK#S(8]ANL0^:V\?'N_V_MK?/>^?
M[4+[C955O/M^Y[2]\@GMOE]#&RM[9'WE,]_XLMO9.7"\W85_<XUV_[V/7/?O
MGOFBAQL'?W5@;&Q]^^_#W8-5U%[9/(1QLHV5G1/HG^]V_\[;YX=D!_[]]_DA
M7E]9_6J$1]R9T-+8,K"P%+64C[9E(P/ALD31 #3[2*^+YZO+ *H(,10!,&MY
M ^Y+F/!U6;DH0-.LPO.O!X#V_OFBS+M'G006J]_VBT3R2Q!OZ;3TT,6KRWW4
MS[]X:#.&LC\LJF\5PG[=\%%-VA]1&J..0H7C1M]RG[['/!19-:!PH[OT=NU?
MEV')U9O?C'ZZW/M196M&W\ 1* 8KX+R^&2%QA$?W75P;#]-?-,6D1?'%(^HK
MH^^CA[RZ-%&C?H:]O)ZT837W]8_=8,IA$=XT'N/KSULKH]M'ET;?T_TWTP#F
M0BAM";C,+$IP@ V37"A.":&2H*]K%0T$13,P];47-F@F7H"?/^ZHN7+/V2SW
M#;#HM0EMB%E=O/>,*D2Q\5)*Y1 +B"HEC$,F4"><=C96,XKA/S5;,XJ30X[5
MC\WHI1E 4O@0F<'(*4;!4; J!@>8$7..$><U3\V(.%_BJ4L2^A,S@!&E2%,;
ML-$L8JZ$D#AJ&IASB&B29@#KF9L!K']F!B9U%,#SK20^X]?S^3$,:[)I9;?,
MH%_\H#J[=G_Z<27T^MV\=U.W=Q7J2UV\NCSZ[\F^E@"-/-%2*,:BT]93:;QB
M8,JED$Q,P:(UKQWV$KJJOWIXV.E1)W?Y8#UT+3S"YW"UCMB6Q2"A,S]T@XUB
M*Q3'N0O+ISDHR1%VV^R?F<[@K+[UCU<W]CB>JO&#9]6R7J9?%"F*["DH+.8X
M,1I1)JQ"S"M"B$GTP[JAW],(\)S2#U3)7>EW5>O\!/T *8=@;8P^**8,U=Z#
MJ07]JTG$,H1G(7_-C\]1_B(%5T Z$$,?F25!@QQZ:B@XLHK [\]"_IZ$?M.1
MOR CXX%$R[ '_!<2!'+!1T>5L<&S*=!O+N;-,6*41Y8;21@SRG)FC8O8,&.I
ME/.@M\;</8 Y2/>\[9BRW(A;@[X[K 4@11$2]^>A?/NVWSL.Q2"WG?"Q"AH4
MP5=-GZ-: S\PQ<6,C@H(*X/6RAC$3. L&"GF 5;,!WFG([W(\< ]Q18KQ3QU
MVH//3WS4P81HN'IVTKOR2TEO8#P&SHVU'C&AM+%>P=0+[[E$*,P#*)D/\DY'
M>FT00D?- Q:&<8,M55P#I:-&C&B!GIWTKOY2TBNMP,&I@$V03#NI!< KB@AW
M)@DO?7;2.RWR3D=Z-7(6@)5EE&JF'+,Q.$R,MXH'<#VJ6#-6<T'5M 8Z.'O;
M[Q[U>_"UO.PU/C8I)Z+ ZL'BX$11)[D"3<HDZ%:AI;$&+&BD5CG-GP]UX/=N
MOS=/I/$X>BJ]X."H,RZ%<CQJ2@USG+N(XK,AS;+W>4HZ-9V/)O=KO;?F*!^8
MSIR0"=&(L0V*,(F8<\88"H"%."*T%<K3N2?3R'*ED-@F:.S\V(#AFA/J,*6=
M)4A@%"WC8-= ?@S26#-P ;E1<T^=\9I!&)B\%_RJ*7IY;Z^<$_J(H+R12'!!
M&$,& ((2G!"G&?/(1_%T])G6#%!*J "(A&/ +#!ID1 4&8ZE5*!7YA+^3M$4
M3Q_P2AND-#@H1S%S5NH8M:?1(4\"N#3A^1'TR0SX](F+N7#1$44<I<SIM.^(
M6:9HB#SY-?+Y$?=7\%"I"\02B1UA-( 5$H%X*PGCQ(KG)+!/!>6F3U-+N6!:
M$FS!M8U66/"EM/$>2Z5QX,^(ID\' *=/50F(T!-LK#"881) \V)M%-A8!%K8
M\:?+VIMSI?M0&867EV$PI]2#<<21,BR<DDX[AP0-A"J*T+.ASE/%DAZ.-"PH
M1HVPX&-QIC522"+)K(Y"RR#T\Q&<:<22'I!,W/. ".<"*^; 5*55:R+ %Z3>
M,ASFGDQ3B"4]''6B1=XA1[C5($V::!1DE"Q(;P,'?V#NJ3.56-(#VA^M@D.*
M8<<9LUP:)$)$W$HG#2-N+K,\9L<WF\[B<(JB.R^5%^!O R6MB#0(ZH7BQJ1]
M&L^.ID\6'9L.096WCD1$<;)H5!E% V5@X)10T6O]#(5T*M&QZ1#7.6*MMMA$
M&Q@/%H@;A*3"Z&BEE/SY$'<:D93IT-0BY+QRGBLGTOH$D%)[$[S&$3,?XSS2
M]'&2ZQ:*XX>9C'%C-6!!IR5G7$I+I.%,:$:CH K/I>*8#R9[VK#AE+A+:&J1
M %> *L8YL=X@ )&6@V[#QMAYY*['4!T/S.._5AJK=D@2X2G"03,9N.'<2Q^M
MT#I@&O'S8[)[JHX%=_W,R@<3W(&'A#21#,RB05YA![S&J+9:W5C19]:Y:SX,
MY//G+:0#Q9A*%@1FT7/K,7!;\%X:%:R?RQC+?/#6,X_U>,8Q<L@SRACSA.HH
MB"#<I7IDSOMY*+;QF,IB81!_)BQ!@M8X>A8PL)DFRB 7HI3"1V>9GLL-V0^E
M+!:,]3-*"Q&&D I22,4\8D9A[Q!SQI.44C27UG 1 DB)?%@I2G2J .6L840A
M*@1ED2KAQ--5/)LE"_13*[</6(U-2AZ%(MJ!O#%BF0'4J;'3 9QJ1B-Y-M1Y
MHLRAAR1-5:8)"8Z52Z43E"<N&!<HB8P[K)\-:::0.?2 9 H^$.93W=]@F314
MV53,T#M&#>,*^;DGT]-G#CT@=1"VG JE$*&4@3!IRK'T($01*\"N=NZI,XW,
MH8>DCS(N1JMUBH!XQY45&%'.0)2XY.HYK7%.6*#EGO]BB@+F[%E"/L2Y"%89
MX8AAS!$;"(_&.B0QB78JI<Z>$U&?; ? 12WH>J37BD%74]!<'/5QYV+0:>NI
MBY1)0@F3PIH@-38".6%3]: X^ZKY;],95H<V;0>WW\O_=Q@F..//CG&'6VZ_
MWPGEQE%J];& [GI[ZV&PW_</%4A8 0H>PR".PQIHX:(Z!F0S+P\O6X>&,>?$
M*&",N*34(TDEZ ^O#0V<V,0GX#'.0S+V@C,>)]$8<\Q2/INA&#/*B";4&!^0
MQSH:Z>:I(-6MQWS\>9:.%KM,I?'%YP@7?N3,E!DC:JILNVEZ>PW9TM?UO)=W
MA]V'DN8[L4NE7MX-P0,8@ F&5ALQ@M?VK+D'>,<8Y##A03%OC2;:I ,6 N,>
M8ROGE'O,Z8)[GF2A-!*&+>?5;F45@'N"3T6VJ8N6N7E:S%J&'GS>&2:+OQ7<
ML,@':0GIU'6&/OAW1;^;8@?#085+-N(H4# ZCN+/LYL[N&*(ND>=_ED(E<=3
M@Y?GR!;."N&H(LI[S2QHED1X3I3U@<?@YZG8Q/-DB^GL@C>:L\@YHIJDI6_P
M5BUG(EK$K7!<S@-2>5*V>#3G8OH:PAJ)*/9.1(]9B.G42.&TQ#%(P?!<U2U_
M/JPP':T0I3$DICH8*C!DA;4Z8$2DX%)CRN<IAOTDK+ 9RD&1NT&S4OX9\&:Y
MN?7Y.6H)Q%Q4UB!D V$J*J6P N,1.34X90\OM,0,L,9TM(;7QF,C!=46,V.L
ML=*JB"1&P7F[P!)76>.72H4#UQ,L!U;PMV3>.,-L,,$H0;2*G"S\C]E@CNEH
M#L$H8 SKB8@$^,(9[UQD%GNI"%)LH3G*7SR15DLN)/6>,LR9],9Z$S5W&KQ4
M3EBT"^TQ,PPRI1J-B"')&'@I&#,<-9@6'+1/IUMKJ2*;_:7W&0UH/\IRN ,?
MDH0H/>4*_$MMH[$4@:ZGS#&AQ>POA\\\M1YPB=I[2\#Z4@!NA#$'])$$&2)X
M0%$Z*I^);(T:?PBF#/O]CE_K'@$!JURI>4D^C&FS">=4(^Z91P(TG^)*RK06
MI#B:@]J,LTVJ!Y0J8K'PRH$'A"+3W&B!N0-MR!6(5S#NF4G5O)DH20W#6GJK
MN6"&@0HTS #^9)PSE8YY?%Z2- <V:9R[V1NFL5Q+W6SZ@(^C#NZ<N*E)#-2K
MX(.B+ 1MF8\!!T6<#(C(JMX&5B/W8E:.$+F$NM7=4;=ZN(B?C (TET9&"":(
MTX;*8)E 0CO!XQR8F[OL% 'OZ=VP!\[9XR5#/XJ%X90:8W@J[V&83H$5:0GR
MA!,BD3!ZCJ(J,T*FZ0="A(N<@;0)H@-36&IIP>M51E@4C;9X]E'#W?:)+S]A
M].)1\ ,C.&+/L.) (86X%A13;M,V86.5GP,7=Y8)]8!:TGFM'(N.4XP8\0HD
M"GO)95*6A(8Y\&[O1J@_YUVB!/BRWE$5E-6,!JNE8AHA8KQ!%%3A<Y&HZ1#J
M 25*$V-12B#A#K$@P='5Q"&DHY1&.3]/.U2_2:BW\RY1J5BVT5@1B\!22654
M=-0!H30C08EY.F1E!@GUD)N$L,=8HA %H+_@G0(Q8D2H"'@"8,8\51QYG&)J
MLR)1A O'J$BA L<(.%E<>*.)M,8P:]D<[/.;94(]H$1)*5P(1(9H.,.&&.>4
MQA'I .J/\GFJ$C,S];8>1:(\XX(K%JS%DIE@K 4\89#D%,1)T6<C4=,AU -*
ME,&:"L#B6EO%F-$*"^R\,EP;Y)QV\QAMFAG/=_J!)R:QYQ$CS9EBF'H=E&*1
M::.$\W(^CY:>2?).)W\&>62)M\8A:]))')IP'@.EPJHH8WUH N)(5N2%#YJB
M!7E_A+R(MY"\&WE34]VBZ"$6:I"GGC#OK-5,&/ ?F+#IU)7D\D55;0I% E$L
M6Z,/"_+^$'E%"]$6EG<A[Y6F/U/1/0JB)3<IF9H%'JW3DF%'M701J#G>E$%X
M:_1A9LD[M&7N<U.<;9E.N$3>BX7M5 4D?.P8%QY_%W>MCPF_FSZ^U/0G*!H8
M,0('RBS\S[!7UB))8BKYIJP+9IXH.KV2Q M>JI+"E,&.*:4,(HP(J10!OF)(
MF*!%)(T+-=,L- N$O.0U7:+-SWA-(5 9G$!$$::T5M(Q*8ASX/ :J_GSD?.'
MB,?.%\-,7_))Y)A3QXC4D0$[::6-8R;EZ1B.A9\#R?^UC<?CZ!Q$TDE2T:4<
M1V6,9M1%D4J61IT\]T;GL,:51VP.?+W'TSD/(/CLSNX\-'T0?X]0;#2G4J<-
M_(IPS1#X!^#I\4A%4T+JB4D\%_/F$5)620YP.S#KE<:&1D5LU(998<33*<QI
M*0=K<#I51YO()8L<. 94A*=2!IJJ@.MY!"0SLS@\?43@7,2(1<L"EHQ1IJCT
M+GI!E$=<JM&))!RIUNC#S))W%@STU< \;R%UM\#\I:8_$[F5PC%'C9( ](SD
MV@:@&D'*4,:-X?-$T5\;[$V?EXBG$1./JYTN!%>5&12CP%G.*$/H\^&EISW!
M;\%=%7<%2SP7F&EBF>7."'!$B+'6(B<=:\JCSS13S0(A+Z597*+-SV28N4 =
M9RXX0D#Z,4B[$(8**F(TRDX#%\P%3SL?#4!F8.D ',R1-A(Q+"C#@*\L'E5*
M$TW6 Q+/P9=^RNROJR06=\Y\@*8/XA-RH[&4G 8L"'-$*TP(.(>*(@,HFO(I
MD'@NY@TK"_K=.*T(9I%Z'96&670* Z(@-LR!NI])B7@4_<^)PXXRX%XA6 C2
M@$4&FQQTD#J 6EL@O[F'7T!:%4%_ =S"3'FN.$9"L91)Z8F+HP0]@7EK]&%F
M27P[#JO(NQGV\G(0@)HK>1'<8",";:OC2![?/.&[1'2N-OV9TE@67#3.F&1@
MCRBW -X<!1S'-'<VZO@\R/J#\/K^2F-FDG2GSUE$(LF\]((+SZ*-BH,GH+5"
M4G/+F6D,^!,PU+VMXN0,_,Q9?I%8'[$V#",&!E$'HP.@^H1?>!3XZ6;@IXWA
MS/#UHQ J^N@00T)S$YD7*?M<4@46#P?K4HK+_"C!AE!-$8.-8C/?VQ]<HUC[
MR0K1/[W>L<)RZ1GR8,Z84LPB0"I&Q1 %D8[ZV9>Z:=/P460,E+X#T CBA"53
MV&KID  WF$HC6 Q-<!B39[/!8XK6'I,IG!MDI5>$4AX!3?*@+#/(.D8B\8%%
M,045.A_:2JJ@9-J=%F *"5;&J2"C<N U2^UM,V^4HM;HPPS.&YV(^7QGWNC#
MA(=LM(3YX!RW'OR7H*C@RF+D:'2*HJ;NQE-,U^-J^;4GTO*39/D)+:^TP !X
M4?04.!H!#V.-*2'2,"XT>S9D^6N^R&*"1@$YB;ADS".J/2. DYR,4@.]XA2T
MS+S29_JJ3Z#H'+%,,AJ9!=*"<&%F3) 4&X1Q0TR&=&OT809-!FLA?<=YFVSZ
M$_.F;- $$T9HH,P(:20XZ-2)J"WW?E3D^RFFZW%Y_U]/I)LFR?(S)@-[(L"<
M6^LY(P0I$:G3FB#&E*.2/A>R?'B*^H\/2!>)L0-I80#J0<TX9 0WE%@5' DV
M8C(%-3.W!)J^\J.6J@#X6 AJF=)!*Z0IP=&E<]F"'"W?<-PL0\.'&30:O(7O
MN@P]V?1GEKVB,-IJJC@.#+Q;HZQR5FE"I6+*NM$R]$Q,U]6U7?P@=6"%0]0
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MC/UM.L-J_64[N/U>_K_#R02'/SO&'6ZY_7XGE#7^^PA$JZKE#?;[_CE*'"5
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M7Y#S'W(]5W&&A3,R,LR\93H&3JQ3C!H5&IT_/YR_T/D+SK_[<IYF3%/&=22
M\J,-H/6]TE0&Y8SG\X5V%CI_2IR?AO2N"##(=/91.=@$MW-.4 ^*J2J?8\%;
MS)1$EG+EB5*!*X0(F^&,MX7N7TC @Z1->2H("@QI0AD"]B="*I?^41'C:.8+
M_2QLP"\B 0^(@BR+2DN22I0B%AS6U&,?=92!>6_<#*?8+FS 0@(>).7(.8FU
M\JE@+S.$6$98*C?K3.#1RSDHH')_<B56#7_W.\!8'7B3G^6;A3%Z@I6Q1P%
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MM@@^'[PU17$&U$B'N5PETU$^,)T/_;*<;#0G)/)"8,.JDY$B8P%9%+2WWHM
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MDXW*WO\-[[I^GL:^\_=E#- ^/Z1?B0';+XEO(<IBB_FH6P8QV>*>:AHI"RZ
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MS<(/G='WB16-;-GVAX.LB6>D?/&%ZGT^7,#10O?.)_%&J/BV3/\%W6:6;A=
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M%>&H#ZIZG)=1:>N7J=-]<QRR'CQV6!2A:E&MM,,;PJO[?M5;/PNG"3N/PGC
M":EI$Z>M@OCFZ*B3NPH"=,S)9"Y*%= K @P1'ICBQ<"_9W?)0TE$&=.JHL45
M<J4%H6H2)F:[&>&(BM^CW0,O#2^2(^\LQ_3VY,A%GN,BS_&I\QPGTL8NMO7<
MR T_9R:M<8=[11_FL=6\6JS^^?TI$V_&F3;YI;R:$L0BCZ#%DVZ_)<>FLFY=
M<YA,7LI(#.6@6YN-; B='04W[%R<'9QZ.5O*_@2K=Y*,35G-;'(<3U(_\$N3
MME9E^B3%?30N/Y+NS6*=R <C'C3VHAE8$2I;DF[I]RI[4B<2P VASB XN\B&
M=- \#E.Z8A&2 6G6E7IEGO(*:H,(QMA?Y ,V7NNE,32VL\GR [=UT G^IK3#
M)FT,#%]_+U2+5F.OJ5[#RB_.X;@#8%G*UFI;UR"4",B]?Y(,8C,75>0DS8$#
M(UYFOP$+YQ-WI%2R3EXF#!DZ93A)UO@N.*GJ[A\OJXD8<<S+9)&']=KMRPEO
MSXVR)%]>K/;&B=6$]#/@H&%#F\9;O$CTJM-+TTHR<'5_6,+;[)NB&_Q2MNSK
MGAN6N)4I3VHF&O;,2?J['U_6>7OUI0;>=,XN<5QBH5$RZ\L*7YD.H!T+"@\@
M4]Y-DY*D8<0"56_& RPK$X@Q,2;1F9R@ZXCBQPS,(RJ[;QF8S6J&-R]BITE=
MC%)M?TPA7G(WDD;\&<]O.5'JMI<G<^GOT:5J!K[4'&DF$RT _:3DAJ,J\ZE*
MQ#K+>LDI2*D5/6@+ A3SP>.\RG@VJQY?YP. 3>X.EO2>$K!@D_NR29UX$VKY
M+$Q>U@Y04E1)%9L+?>G,42);:M>XGHWE&^7+5"'<WC&,,6W4L]75I,VBR3M)
M05_D 8X6\\%Z]*J'AYH=P9"E309E_8R..4N:W@]3= *XM)-"NY4K=A$"GO2"
MTV][A:ESJ"\B4LDNA@A=#^ZK3Q?<="]NVAC>D)#Y<I(E7B:,V""?E,]U5JNE
MRYD[DQ1-+)17%GV<E'6<C^*/1>A66UTF0.<H[G )%H2KV68OKZ<)W9",6HY3
M1VNDL!=Z $ 2-,I["?5<!$ F1YPB"=E1@AN '8?5?M7KDU*!L N(D=R9A)C'
M>6\)#?CC.BQ7C*6M?\O\3F+P2IQMF-Q4TT"?!>L_(NNOQ6:;T1BMWL!VV0W)
MK"GC\!:Z3NY@JK:'5'"Q")/\/DZ4AFX:?@>[FE+:KNO BR.I7S:,%\TQ7*R<
MZ6*43UN%\<8 >B+)MGJA8=+430I6\G.*R@.YQ/_%)8M@!A,.T TO>;*?N_WF
M>5=X]F>0\()][\^^%[%_\*U\<E"&1T"[DWV@]DFH0[DU2AB%7/N5IS9LG)8[
M<KSOU_L)ZPS<BG$!']2==8^@Y\J]+:&U&^?QUDY?[;)/=-WT>!MW7<D4?UEM
ML*H0A'\Y>F[U8<SQ('+#XE+D8@+_C')%[\ZT"RC]ZXC0ER88D>A_:37T9=8=
MEH-+S%VM>)0IK+57G7S6K=<_QJQ>;4XMJFA2_P((W,CB@_VBV@YX%88<I>.N
MRR:\T:EW7';.;MR'4R=95 G2H_TP5ZS2&+-]7MI:JG?@V*)O%ICBL9VS:CDM
MN3U5N WT3Y&GTO2WX,YDB\U1!3IOVAC5H-EZ\:Q>_NM5-9F3!<_3T7R)44(Y
MZG:T2':=Z>K-UF9OU&(BS_?2DN""/QZ3/]Y>,:RC'?TFZX3>WF#_K$FZ/FIT
MS4@E5"H(7F$<]00:#E*(LE9@$QAVM.5F9'(K#KK8A-5LUVDV33=;F1L46C4;
M];7@@\?D@Y4$;RK)NX!:H?8*:HA24R$U 'R3*B&$T3Z8M/(_2B;HI V0E[-[
M:H]W$$;A]@4='Y..VY4#>7U/;".W89Q4\FYE>11Y [Q>^6])I0-JS<P0?,4B
MK]1X\O$:35"E189JD6HXW@HUBF( +!CV&B%.G=5J(+\(4%S AXM810,D;AKO
M-US:&T,5$^'&1;3BJ=R]FPU[7DZ0N-Z&$%+L-%3J?01?:\ (2L07PSU0(J;8
MJ_'CJ&(%S#>HH6;C3_DM9IB(Z_6/TOK8L)=TSX@UZN"OOQ3]O8$W%@DS]UZX
M9XN$F47"S.T),PL]^X!18>A[F-;\ 1=?#:I5H;11_*O6D;=X^B]'KA6 _&%W
M(DVAR9M, 3E3F?F4E6#*O'SYK=A:;^]JS&$BYS*-Y?(*1M+TE]_CY2B'-.7(
MU/"QO,DOO;I$^.V \,+N3V&!+J7W5. MQ?:!9TJ30.#(P]NK D87N]WJ8DA'
M^V=E.NDTQ66/@*;CK.2*X1.6K/)XNMW*H#=9N_:L#F:,(PNC.EPW.1L+K_&Q
M==/)I67"9.?=?KT2%$UR&.M".8F@[710E^GUL^71&M++B]\JL%9%JNJU4GAN
ME3@]"K;7>[I&-U9,,@ZX=]+"EDL.2^*7T=)5U<<XSGZR6!R:NE_:'PXJ'#AR
M07N@+))\%_V>.<Z+89G2'5-DX67V=N/OM946UB^O+Y!<Y+KEX+E>R76[)=>O
M7LJ_*37P8GVT\B0N1\-^D"6>?%O*[?G#UQ+GUB9WMGYL=K8N./_1=>3E) VP
MDX-1FN;->XTG_.4Q2+*7NZAV\5RN8E*OJB=9J/D9'K+?@W??R\,539AD)R]&
M[G-=*2"%?=,Z4<JF>6ZL/WG2>I*#MX J $)6YZ<OV/^1X:*K)[M,DUUMLA[S
M,_@AH*$[H4'XB3-C9YAD89"R"GVEYGOU/9>7S"_BT9.9AJD82:@38NJ= /UB
M8=@??>&@RFZ'OR;6KHNC?H7#'>"L054I,>W)@S87%643R5H#<QC2\G72?,=Y
M57>S=DJ;ZL[UBD)1;82 GE/Z\?@6,QB$[M&H%G7%7:D"6_*/$WN-=U.,,Y06
M0;\'"/KQVX-^_NY'"-#%$0*+2.%4N?MFY) .=_WO_\0"_;XV\Y)8C_/Z,.\H
M@N+%77C_46=[;7MU/<-+6?;GYZVU]NK6UIV )9%3V^H_\T<[9(^##^X&41[I
MX7=[\VN[E5K5MH"7F<W[8S_H;+1YZ>5D@E(/1C  NU/O&^TWM86J.JXI6EE<
M!">K](>+=<GQ)LJ]=#? S7'4,NU'F8PN_&MS>:O53=L4TRZ5,#"IJ$#NLFIV
M4NG9SNA9OXU.)WB[^;;9MOF/%!ZMLBZJ6ZIV+R_U A\2W&H!*LXK,%QM9!Q4
M".Q:MQ_'_5:PK!.&AZ&;FW(I^_.L<D?WBKI$*LQ<M4Q;[31-Z_63(9*;]LQ4
MKNIHW77DJ8Z/F!C/XLE^OZ)5%X:8=?+#A/*KE.#RZ/]G[UV[VS:R;=&_@M%G
M[WWM<2"U)3^2=,8Y8RARG+@[CGUM]^Y[SC>0+))H@P ; "4SO_ZNN1[U $%9
M2IQ(5G.//=*61 (%5-6J]9AKSD;0P6$VBFD+@L$BJS>K"3T'FCSDB?KM6N%$
M$25)-#M7\(U\\3H%7$JYHCVFR.9EVV&T1].JZ!CW7+:S(\V/<^J+3GGA45[2
MQ=%%PT0>R *\H2<YPKQD?ROKHG/9B5\^;W[ZVTE8/?0J&B3>D"];+YMNO<2*
ML\^>O7_C/QHG&<J:=7^;]CC#Y3!>0%,D@IMKET#)*3ZK+2G!U]1Q3[0$"@D
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MQ"]^Y65AE)'R?/*.EH(9A?LY\^5+@UZ"7LL]F7[$\+=J9O"$F=VY+9 GV(#
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MS>X?MAJ]QWO- $X.:X[Z7$WQ5Y5MUEB)3YZ$F @R;6 O%.\PNA1%&:);$4>
MUAJ]BUD=@8]\2<[2>_-]3R9T7"V"+AF2^VG<X6&Q:=QQR6V[<*BY<U?ABI(N
MH=#C[^_.LY^;EL))L(#2)Y>J;:6N9N3 8RROBFV3"50Z.VO+7YJZD/#A1UH
MOQS]M>G<//O)U;_DV9GQ>V3/2[BOZLU[C:VW,8O#>7/TDU UZ%3^@-PF@GKN
MCO6N;Q>''MS$=*WQYS<*,]BHL \@@4;V/HI ;!;&P[SK#J<?O,L'^C+S[%59
M4P35]%+P>4'+K)P5%&W_C581S?#?ZY)+*;0;1F*L\[.W[U_:O>P%'X@>/\-&
M_.H )3U 27\%E/2+2CJ<,5C_E8+U?U*P_OU,Y;T$+I "OVO7E,92$H,LQ$W*
M33O>:-2/LJ?SXNS53U&!Y#C+7B;8QAM$H8-Q?[+++P5B8AS6CAB"-0V8.$1^
M3<<]\CO?[*G9Z>&-\=!A7N/P?-VNE[0*N WYN4,*7%/0:3E^WXOA=FGM]'([
M$\-OCI^-'N;GYL)GG[X2]Y2]4/V:@%GTB?'Y%V[22ICUZ.1K?KRSS0("Q!IV
M?;WO\;[? *M!#\4G-7LQ9PM7D[_ZF1[:X*S^1N0=1&W;W__=-XK>SSW\/G79
M=A/Q-*2HF5560(P'&L06C/'1'J5IQ)CR6W?SV XZ]B,7BD(N.+H [[QJL+D"
MIP1UE,MWN0U+D"B[9&V>#VCF1$5&2(%81HI14I$)L#7&5QTFX%$R*^M--,;C
M['O>/K8N[9,[:.[31Z>/[BN1VIL41-:- :G(*S''.N[<L%7&?1 <P$G@JQBP
MB!+,+QA<;1"/>(3E2,BR.V=9DDPQE%W"_:"7B]?(>$N) O=NN"4X\=3BI[#
MXYTHL7_(&]P))M\O,H7PL@ZYP; ?D_4TS"S(&@DGHY$K[MW:=M[S%O_#G=U]
M/2=]TXLWP[^68BL7VC5D%RQ; ,QZV*0$]I74^G_TN$8Z\M&:D/U?1R%Y3:'Z
M=]^]H__^^(Z3'0%_-:>E*ZT&>O [I ;^3T$QA18]HS_EX09;$:3O_:>3I,'U
MSO"[10=^3?+U;VZ??/WUNB]7 F]4;RSDP*5A);+>WWGK?49.W1;LL"(S=%ZV
M4Z/HY4X)<.A^@?-VMRR8$2'!/^:H1J"A=#''\HFP4[QQ2NO<B+BZV>\)C.>E
M;\M&]"2-D@,6(Q\HI#3EPJ$A6-A_;9C+U"@5Y;3BBY [OW!>MC,I'J)A<]/.
M/(\"Q)W1<#ZIP,&$1.<Q*N,L)]_9_?G;:.^@^(1"3XKEW+\V'$,\>'7VXJ%"
MEP*IA8#P8<@#:7CKC,0O:B(%R&DSZ?AJ?=86LQ)YU3690$_V[-'4C#7GY=PM
MV[+^\ 5)8NT)'+P4V)191+B_8&6D]@(*K]R4D?L1D6S@5M5D-"]+Z90-M,3X
M0\ST7@#MQ=/*7!B>N?V#VT:WF;6<V(THW2.XF&'L6?CG @M?[UU)@P-C()F\
M@%4$L3B-%SYFFV OU#</N]K-2Q&-8G)1\&AHU!NU\Q[3V;:C(S N(_"'J CP
MEN7N$*8?YE?=B/$>876>;",!N.!T^V;K 0K=VJB_[-6-=G)R[)$$!1$9.HR1
M9"C=HLG)IZA*FH:Z+')=N9TV>>]_BT)J(DL#KKR";_>4C/5=7LG*OR<6XM-4
MG31QPIB2!#RVKEK3DX!&F=G8.B.UXV8$B2!T<W('DK=AG*;#D]$HC<=FSI1N
M70D0JK7_2..*<,-++,W1R/&M!AZW6G4_FXDNJ(!TF< Y.E?!I#]1RACT7-%I
MTI+!0ASG\;AXS[Y&2^_TST@F2&O0EB&U8.KF/:CG$F20U2YH?U8XC":^/6K+
M)RVMI"(D5F*3)1DXH1T(#9 #30WM@32(ZRW/\V=+BUS/XSX]O0L>M_%SO]/P
M$[ON!^?=D)>\VWE*OVAS3.ZKB.\Z$2AP7J#7 N_<#BFTJ E%L"=#0S=B'_<7
M<@MR*M:,W/>L86WQ"#2AK/,L,4Y76KC(P5L(4T=MMV._0V7"@1J?)L5K<E^P
M^[&;R<]F&9"7:-4TW6 @^[W^O!78@^!PSJ-2-7,SWD>K@M4[ @&^D').5;DF
M4)1&3R=2Z\A* >#/_D0N3=+"J[S[V/F>YX:[PJ,Z I2&.25:<I'8T6H=7< E
MWRS#6H3/(6-QD&E1L(M)K&,T50-=R%(<9SSXKW0G#N7Y:^^QKS^'#N/ITX,.
MXZ&F?VL'HN"KR+OJ;V8N_GB^DD^B"[[T\WI,.V]/S.M;DJTM35J2I7GJQG'1
M'JFR[)I29:R/XA5Y3#IN+TM2W+*_8I-$?RPCROO;#7KN5XF0'8NHRN<929/U
MH#$MPSMI_CF39\RA7MLJ2>J@1,P P#2!V7V;+9M+W"./J=WVR3SQHO*CV*.[
M)!<V'1U/I2J0"T:9<'UOOTB4/EW1_^4SS_%GU2?__'T$=TBI_ G@Y'_ZWR5G
MWH+(S-R+*XE5.0I6Q92:F"^9F5LX/:Y3NAV(F3PX")+<=(D\-$6G4ZGL__2W
MQZ93E3W-Z=Y'\Z::276VZ+W\TXC8\=AN>/;XL(E^MTW$J/L1>:UK*&M=<_J>
M/KEB'@X3^MDG%& LSYS'_/5R-BY<-2W6V'PKS3-><P(/A]CO.5U%53674EB:
M5^XC**:,EBD%Q!UFZP[,UI)I-%9-+06XV2B><6^;U[?XRV$:;W\:0;RYI8 4
MD"A.CHYH@VQ6KN6&LT1F09S),2D$@U\)]_22T[=Q[2B;;0(RT<M1W]M0,=O4
MQ73JUKT*QTO13"H"I3B B;R#"4E<-)"+"/K,WS4.D(T%DX70&4;W6>7\DB=D
M*#=,=P<5AN#N[T0%D5<JHLHKW M);KIH<'0>I&[.R>.GXN<\%*]5&#V%3)#%
M,A'VTB-N[#BU!0 H@UX#PXQA#INZHX]V<U78\G%I*-="P@^UBGM,\>D[#D*W
MP^^HDC;$L:/K(&[2'4&G_WD 3O>(<\;5C#-_6LO"J_?/4Z4YK6>-'0=W)$MU
M.P;"<Q\S(5'&C*6TRT94C#R@9EQD[]_X+2+1*U2QPXUTU2[::>803J(_6&SO
MJ^.O?P.GP)/CT[O-*2 -#/)F4UVR7[_>14J12]< Q/\J$VI,H[OB!"G6\TII
MO-^;;^*>KPT#!XS3]X#2C/R=X^RSV$@12/PWMI%G7(*("+M.'V'C[ K3#FF
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M1CMU+B)F6QX!.3-E#4R22D2*Y=*(,=3V\#(DAI77]MDWV $2<7U(Q,D!$G&
M1'P!D(BS[/&CHQD9E,NB%(P978=,=S KD?-%3\@.BUH:[R8(^;9::?.I/*!Y
M:-O)163:+3H*7LZ]84=63*J__PP0/+5J,.XF *7#E6'F:;;96V*QT.J+X@I2
M,UN48Q[XO? ZS@?NJ3K:XMI%\9S,H@$I.B!9M0-2='^A*8T4X!:<Z:BRL_IZ
MQ%046C"[S1II0EL914;.<R7 _W!M /R&8U,_W;P0F2GV-4HFN+_2WV#'PL^X
M=RM"<O\\)/<CSTJ&[0FX@)$L!-7#8E\FG>Z]=1YJKOB ME@!4MEI"^]&%U<4
MUT?.OZ+NHP  #;\TJX5^W<C!Z8#^'KO)!J5SQF/2K=+4'G14^O;<0/@6ODH#
MK&<:X^O;_93[I%OCOFZ(]_K$7-5N;<T"!D+&'E4OP(,@B(OWR+5L=JC\%BF&
M9@5@%21+2M'\+9F-0EU.GQ8!JJ7LC4.G"PB2(6-RI\ 9J<Q%^Z"8(@L5]H&D
M5R(?N_'5!2R'5!&!8H,/W@X/K*(N(0T QIU7K<3!4>86P[J3F#YXSO,F92T;
MAL6\^KC>/ER"!2C.:%GW&S4XP/W37$^:HIWY[?OR[7=^^S)J0>-9P(0S^F.H
MYQM$:>19]9V3KVF,?TNR:8!*N%+2A;H,RBI=". E8M&<\=P:;QD9(.A%DGD1
MQ64:7+(P,+7E9R80NEO[;&C<43K;K#E[B>0>W@K2=9:C*=I!3D_Z50V-%I4Z
M6A>E+9(M(NVS:@,QWTQ2W@GY*A>SA.B3M_X%.73%FOG-E<L\U^.OU-ZR/BD!
M[ST:@PPD8WSLF!0&44VJ)D=EOO]:("2EW^K&D!@?'2"3IBJ[E4_!-Q]*)@4-
M27E)'6&)^S0L.I7EO-EE12VY*XO+11"4X/.#D7<! .N*MD(Z G@E:(/7Z>%U
M[(GF-]TF3>%Y3X-1@D)UN]N6GJ?]Z[NGXU7OG"V )&FG=+TV3I4U\4] _#0=
M]&A%0@./PM4%M,MO5OK'/&Y0E.P?D@$HJG712PRZ*;"G':\=P:%U,=(OEB?%
M0%FZE,\&*+\<894"^Y:T4EOTOZ[=!NY#D2Y&64S>4>X42YNL?F]]R9V3T@=;
MUA&_[;Z:G)=S.4Q&%DPDH]5%BWH^6'.29HY!J3KA-+4,_2UKO^Y#IHX6F?SR
M\:[X:^O$Q41^E;/4BF*-*$9V$U#^*HFDDPY%]A7H[%KH1DV$H28R+MXXTG&W
M<&#P6R_U-T"_84WO9*EP) H5#<Z\LO>.X5"TIF$97K#_U6Y>]D?L64BBAU[$
MLEQ?N6^53QBV'.;))]:'G@3T5JVX=E]7ZQE'TI(=CP\9'ST/ V18*9R=&4B<
MR]3T%+Y\ !08':PY-P*WCFRD<O^,^?W':3E!1Y <NQ[T'P?V6CM)T.)Q-M^'
MU:-U'Y4K&;T+^XF6%^_3C##6750?RE,XF19\+5',25F\W;(*30M%;^JC]<)>
M@X[9.V]QQCP?SP&[/$D!W]<5:J$24C#/'M';VW8BDU8RFGWJRK4EW&598N&E
MQ_KETNEAE+AW@4&4+:V;B7<M@;?O/Y3>?;+46S\Y.#R[)?1][1[6:0B@EF*U
M8#1+ 2/K]G*19?,E*\8B(-0X!AV &R:U(&VZ.[K<6T9>WYV<.$<S^MS27RY^
M<8R#%*(';6:A<;"UPST7C;I*LM0Y\&%6EY&]0>OL%>A4Q5<8^LIH%E8*QVT"
MSY1#2*ZM_A_NY[N K/#"]U8DCV')&;4QL^X3>2CI7(:G'9UAVE D&'>A<T.!
M/[;KP?[,-JTE6.R104!+89=G1&_= DP-P_*,"C/H^>$S>6'6PKN/XL&Y:\?>
MUX6K!B^J:0>_X&5EF+W0*T !1N?Y7$Q*KPVGM42UY#^6G4A^K_C)77(X@QN!
M1A"S1G1JT<I"DUIBTY2&4D)0>6-Y4BAD6P>8"C*L,U\]I&'LVW^TA]#-,G%>
MY"*\.<M!<".,3OS@XK+IQQX0H5;9*QLOGG/>B.8LK]KT,MS@Q@>)#$+:@T?7
M?MAV;#EBX(!0:,5\/4&VH>R=E4N9NG^02_SA_,U]M=UG?F\B=Y&\/'MEW-A6
M3(4H4>D(]&?N9>DU-/<@!=],U<5G8;1R^/)8.P;VP5>OX;'@]S@Z-G7EA)LA
MF:;S3=MB UX%X?[3^0^OWG1_>L@G0!')7EKJ==S=P!%>P(RS:Z#;79S3F&W7
M1PP^;Q>]"QB %-YASQI%I:(@0N\JC)\SZ/. F5,*N6&!G5ZL/_YT6_GO1& ;
MTZ*\M][(F:\\8:E94-)%:XS74)CO>)V$=9V+F]!M..L1?%^!B3%-3_ :3!9(
M_WJ<G>W]&[1469U$&P/%!YG&_;'!MQ"0X-;G*N.U%IVJ/MV?@!=P/<E<&XF(
M!FJPKA&7:K3.N:+&Z*4EHE!F($N&R)TF )_C]BVPO))T9O<[KO/MW4H#(P,Y
M&I,5DS8L<XZBVI[?JZ5+FBJO'E@>.89JT3"=([.9>F)V2LWD76$TOADS?DR9
ML,N&FSC+C^;;2(^;5E\,WB3-O_'4"!4)/69O!^FFYA39<+9TT/L7U %O\1GP
M%J<'O,4!;S&&M[@EZ0TE=!BM!0Z=+!@/=BY<#9"GAACJ8H3?1=><-<X*B*DZ
MEO@W(023D)"<+'YA7(]22KE[ZS[LGO7%ADY"D)=V<2_B3E(KF1;1_39Q-H2&
MT[:<# -53OO;AQ*U$&Z_\=4_=H2ODWT+I^L^MR%M+8C38!3Z7#@Z)MFA1A^G
MP!-VGLU[F2,1K3DL>XJ8,9[2\K8XS_JVM'I4:+L'VW^K[ ^\G,?3<![":@AF
MZ3R:E[V2NVO:ALEZX14,VY)\%@-S-FN+RQH5KF%PH3@2A K>A;;-%U&J".4'
M[9:5Y%,B-DN)<&4)E'VRA.Y;I]-KGO>WX96]C1$(]]-P\"(KXA #F4'-FN2"
M_%73(#G-J.O)I_R2S1G# XZS%^S=8^VAW\"V^;2B?18UI:I29=H_%"S%L.>O
MC]1GQQJUPE(?=BS.&8D/NKNCOM&>/=C*T&&8TPWF*OCM;YK[IMDC]F(;E DB
M1B".CVD85@Y2.NB(-$.ND_XI0CXM30T ,I/W<Z5]YS,!:KB\YFQ35UL?/WA9
MVIC^5@ Z.R@AM:R"QO,U=7^%4&,[7X+96F :RG32:T. 4E?[KA8-#>MPF>2@
M"HMLJM=,10SCMCG&>,1Q>N@D9;1-"-JC(R\.HH?E*]%WQ2;5O<K, DK^JU4K
M;9H D;>RP'AZ?P1N9X/O*=A TMD^GQ,RD#JR+E)+8E^KI!52*/JU\ U0Y&\L
MN/LK>6>6M,#C;#K=[%VQ<O)"9NA.DS2OP<GJ*()-Q\NT8^8+#C\G6@5["+9L
M!$H*8Q(FWMC'(3>?NN'5SY6Y90<"X2EFK <C+-GD#_N_&$,[D)%@&=BMR'8D
M;%'WTRB<&0H%3#.A1S24='UJ1J#/+&:]9E6ON&(;G)3=+4/K(F1*O(Z%[3@^
M<\)1XXO1P@!$:TVP#T_"7Q@3,*A/4-RA6 "CI/8-D5?YIX:]T8*#&9RH:VQ=
M%=/$3C5UD@E2C1\A+Q.'5#S?J'LS"P(9D2O*^![+QN6"8NZW5O6-0<2A[)UT
M$*^+Z8=BX=MXO6,<[6G-]@:6!U!$41B!?W)&6P'W >Z8YH^Y#*U[6$9?ME@6
M,662Q'I!N)IV-#V[) GIT]ZN1T14'A8<75[:K]D&^*D;-'G[%;BI86$V-*$S
M*S>4RIEHE]8B8"@QJ'71CW=[$[@1-&ZG4( W1A:<#T'Z5I56[=N1]\T\!4)0
MD&/E.=^I":2B&FW6XA@T .-3PR41JTWM&5OD.VOXR<^$#6=ARD@@TXA.. 1_
M!UW,; !]QS;PJ=T0G3H6X>0*2/:<>5T(;ZZ(9_C$+N<Q-_>F1MIY4;,&2!(B
M)0+D@17LLQGJNQ(4,1+_A1*^G#=MNUGWV1O?@ !"@_MY-.'(^/3#YU*'9JIZ
M%UL,CMB9[1D[6737(U^6GK><;;#Z&7/BZ@7;4@:7JTF*(H6 K..]PO_RS#K2
MA%36\VKC))H#"@XPE*;]H-<L8$#GPF8P+<AT<X9!LOAT.+F%T!BLBRW'/Z[5
MG]B-L422]H5LK<>)]B0S4.#?. ^=0 .VGA]H$<B5[.YY_$O:L'/PP@/F!_J(
M2B7BA 24B4/M5S$.F4_ P&WYJ3<3V/U^S3NZ9]OY140YPGBU[$5;; 1#=S:!
MF_!3<>GY7;X(ZKHOPYP(Q]14M&BY!L^L'<MM%R%B4@[<+?P;\@ 93M.6*S3P
MT$'L"_!#3 QG&CAEN_:80,.E>OZ%$1BWF"_=1KM="8FGB TES3DA_0FG-,DK
M[^72V4O5Y]23 P,,%T$E20,71Q'O]F._;+DT,"5?AT+Y5B4F(:N!E&O@@9G[
M=5WPN@Z(HV68BC%JJ,QKT44)W-BFS"G$K=E,%"U+9JU\EUJ,%>[\6+4)Y*K'
MU]PQ7F(N,CRLL6!NO-L_DYXL-:))4ZB2<>]:GT+?_.6>[BX<UM8[>09UD[^5
MTP\3BE#8R.']R1SX,SGG@TH/ =0"Z$NTZ7 8CW,L(2!DI]OSU\TW%;,ZSIT%
M1%NA-Z)#:UIZAY*AI(+^JA%WKC8FY1Y6^7"1XXC47T_UWPPQFA;=4CY[1*?6
M+)>#GU:!DSM=HJG,NKW80M#@C#JXJ"._ V=T;KBH]::=+@O)?E9._\$@#'L(
M6>@<JJ3?<?(-QY\2W(9X!O$NH\6W8KR!$NR1=[":;-I.Q"*9O;N12AUW>K2T
M!:1S]164M H@DN5?Y2Q/$RLZY\@?\J:D1;Y,#.VB+582_C,WA?;;Q;.@C7>>
MH-#;$D[(DD%53$70OAIX/;@\L!ZZT/QU!M\OF 04_XB-AJEZ7&D9.3F$*XM2
MSP$[\3FP$X\/V(D#=N+N8">LV"YNH1I7TR9"T@R=@%L8!EJ28A,XXRX>#7WH
M.#LCN\?^!GXGP6@1-5&)@6(:IH^(G2(RHY!" 2"#3-&DD9P)L]>CV*$QJ34/
MAM"4P]>([$V*?(,[))<MF&$9!>N:3&%SB;--?%>+J[6D(%P.L:UFF\J0_7#P
M12B%\.(Z.WIC0+85GF*^VVE+HT8>GM.+6U-C$%('%1BIP^.(](%_F/N:EH_=
MJ7E1052C*LJ59F29]P_91)8($ + +;N?<7V,4Z'&TLO7.)=K<-9$W#$!7'0)
M[; G%%0:**YA.>2-I]*J0:'0!<N!T0+\Q=7!S9:!_<ZQZ]YX>_Q-_FM39GVQ
MNM6 VG=-AXS4KW9^M5W$_$)@L[3;;.+LCP(<X'4#LDBZ>X]T*H=.",HV%1.G
M8S4HLX*DE+1ES19>2!3QK<(81.@Y-]&XX2A6!>(?'8 D]B4%U1K9J6%TA -4
M/C<V./SYHH'3.7/<4N[19(Y3*!0S5U;WT7R9)-GW/LF@ZE+HC2*^MAX)YN K
M=Y$X YO:(KN@ ##AM+DZ\ '(@?DGL*.N>%B>B4TK&U*O/-RW.P3+!3WP+#0V
MX=7[,@C'W]_+QO7LRF\=!S1;3AS3!4X?/?IF^![H_NJG2\0DI0$@-QQMAIDY
M[,RAP*];X$LBE.'7H$T"YW#WSD#J:*NU6;H*>C_L,P3FG^'+X**E8<[#T2$P
M1#.8/L*CT4293TWNV*G#1R($!7C4^O",>[2''4#LZ<WMG<GN.#L?86%E8 _*
MG\:"$(NF!WH5:5.ZWN:]8IF_<]Q*/8QK1I,P4M])\? V<#!NV@Q8CH,/922M
MW:RR=CG9'RZTKJ!,9"FB4/9#06S:1UV5#)<(GY.^,4  [*$TANQ"X&OUT]<*
M$[QR\//(/"4G:3_@BC&<JX>F<,W+ P;W-B.S]$L=(;8XC;CIN&4R#;2!O?AW
M\%B4SO]EW6V$$^--TQJL4A+=4ZX+VJ_4%)U\\\TSS\CSX\LW9V>!;1G>ROC1
M:"Z,)SZ&W9#K,M7M1]Y^LL6T:*%'E?R))5#0A^VDM]C2EDD"1?D(;#'&;I9Y
M0[NIX_TY*Q1<?OFETE%U/=TH.E^NNF^4]YIT?;N9JKWP3Y\0(\@)$5T/R;+:
MQ,99.AL1A$Y;>(/8Y-:MQ@[+WB?!EB(_G=T!/9?-)V#-/?KW9LUMEWKBP]9G
MP>[A/4>(W4^9/>],:-%:;68DKA?LJ>I*UWK5[+(M;1W,FNF&CP%]K "($HR$
ME/]^Y=#4H6-],%RL5B$_;P-GKBKY"&[F>1:Y7YP1U!GG1K*!)W)/53!XI^=,
M3KM*VL&]&0G(]_<FAR;KT+- Z4<CGR8R).^_/_\Q$>N! ^Y!>8(ECXC^X\C(
MQ]T)%]HNQP.9@.D6=8/IIF6RW)X,7Q=#"54#+2"LN+7+LL'(=BKDFYT>V;()
MZ)]YKSE0*%TB&8,1T(X-'+_Z9>@_TN/$YWSE"FS)9;-15J9!LE:J8H87Y*XZ
M0==<1 48S_9D-D((!X+#K ?U*DTCW.1ACS.9-?&7Q$[-&"-)#R]]K:-!L""'
M=!7QNO(BGO+YE"'?![K>28S*5_ /=A]9+.<"GH8BEOJ^:<D'#MVS&*:!;[9>
MU5/O/XU@T,6J6 @4-6+WA]%@C]E;Y68#M!W+R[,KG[A\\I"^BL:R@GY(ZKS0
MARV8;[H1NBX*.KH-GS]VRWBL]]3JQ/Z*+P*'2!C;%^0VP(RE?'O +_<\$BGN
M&)L:3XO:G#?^@F_D@EWV;H.:9"WB1A947-<8&5C2K-%JV.6-XB1+L/,.S..N
M;Z CN7:C.F@FS*CU.'U@Q"9>2W5?[<?*5>?+LIK1N_'.\:[#)_Y*]H 7F W;
M?03A"1[LH2 %57BD%J-@\6(BXO <'$.](5[T1GBH'YFT[)T9'6_N?WSG;7UL
M/DUM4=($WH507Q+3/==W*4@:CJ3QX0 0>(#6X3HM1I$GT;.KQP:-J=:;-8*9
MOI6?UA2>%_*#;$%R$YNU@B?E..IQ,F#FETVW1F*KRV/X)Y0G6^:^*FKCN%71
M"W).F,B=XV5DYH9H!MCP<H7Y9\PS;R3%^]S7C2V@FB)222/KF&$#T<3*M,^]
M<#/#+R?@DC!;(%G40)??ET<?+*/#%XUC2/FPARNHSV#8?",,,2=:*('BKC7K
M>_.ER;'LDT20XA8AI@Q1/N./=Z..W=BDQ,;\-YMR]4X\SCS-@X2L =ZZF=\8
M5FMYAWR'BW5P*>M,\M90J!"+=AM?;K$IX??7+FB?D$ER%T5Z5WS,;K_:5 NV
M6>H/[\G+PFRVMCS5IB[*>:\CIW@OP).LZ2*JZ'BVH]38C2:*(N#4CHA6;@[1
MZ#1$2G7J+:N_(@XS]N*(SRLDN9WPS*1.XX"QPM?'RI9".VEW&[:D]:-^=3P<
M;JU13[UN^I!7Y0>1$S-ZDFG#.L&<Q]P@. 0,N6HZ3^&V3F3<Y>9'=A*%-VC/
MF"4:(JR6XQ6E00^%E\U@5;9>VO&2U&Y0&Y<+,X.GU_YNW1$2'[*6-.#B)%50
M#8^(0:+U*$CU^VHXODMS?ICY66\'0RQ<B+]*L30FCXVKJDK\$I*[O.RYV2V$
M$:%JJXGNN)ESB90JVL;$_8HIIU \9E%W&H^ :;IILU9:H"C!GYYL'I(&'GH/
M:I;&'KMK6ZS+F?6K&8>2$B*Y^H)\%8,/QW:@1:O;*L\X.BR5*2NK\&;MW52P
M2-)_;A$5R!4=IOR G_D<^)DG!_S, 3]S=_ S Q#O<9:]V%'7C&W5A (C*]K
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M48:[\K4D9<))U[8Q[@]Z,&Y@%&D%>5B?DH\&CA?D!Q^09,?96;V-V^;8=RC
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M\W#VB=\-9ISLFJ=/OJB2?(@":>G-X&XE 2# %;6PM#E6=_B5FUOQ?,K;9:7
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M_O !!CR\)JL@?!*^#6>W;0, T-J-]*2V7J'I>IS[G_M<.P .KP\X/#T #@^
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M\/80O-L#P>O5MC852503B0^IZQJ<%--F.R #MWVF<>2$\_14<_5V$ =7W?I
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MD'&-U_$7#=F"018+!M(W1:BL5]@PN$DC<GO"W=,]I\/D8@R]%PA*!\+$@&\
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M7P=(0,1\4I.67V#J%A$:(81"F1'085>1W%[3\D$FG \13?9L&&/)R6P:9(Y
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M&M-OR()&G0*IG8+!.7K@#L\/L_@@)7<R<2V4'XOV2/=U31L=B_KY(<SXZ<L
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M[2?K]DU6I[D,EO*<".XLAM/V. ZFI/8S>^MGUGT&);%+]>26\WSOL-S&N0N
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MZ/CMB]'IV=FO_E?O?_UP\LOQV<NST;M7\EW49'[]<'J+@LT_D$MGZTQ(Y='
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M/_U+$]?D>J6(2)%F^#=G5%">(HOG';:C)Y14^T'H7=WGR=P'2I<HO5?U?'H
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M1</Z07Z9_RTO0;@S.GJJ7#M,CSHZ7CB0H)2CLVJBI;10GGI73K@_\6>4ABL
MD.%/([?!U39OGZB+S7L["EXY/CMY=_#SJ0)8LG21=/R.#;Z&MS1L>XX>Q^7
MGMA83EK]9N97S!X6^Q5@L4_VL-@]+'8(%OMMUN.#[Q__R0<PDPN@(*8$2:U7
MA3V%'KS_\/#YZ/MH(/A@(!E(R$2.WG]X[HV_ME!?44JB)->L%=!KT];GKEXG
M'Z-<.X%I[)7DZ[.9!(<B+$<NEHHFL:RE=^P1"!#+45&/CI[Y]W2?]+&89K_Q
M!O?P=SKE=_0QOJ6+\>/HP;,?_.PF)SU-,G@$L#('^]VQ7M&']PPJ6:L+[0GS
M(5AY+HSBSPZ/\)4C?_K*AWR0(2SCO)8(284)K5FLCKY&-(KALC;QB@43^NU'
M1X\(__FXN^;(&6%X$I0T5^Q/^YAC.GU_\@%'K:9V1@^ =!IP89*OO?WY[.%A
M/(9U-(#6,;TVFLV-8#S['$VW'_2)?S^ KYA?R[^DCW X! O\#]HJ1&,0'J\D
MJ6\');)931*D_L!^\.;XE=^?. 3\[N'6(00,8;+21[5CVIF(!YB)T(ET\,./
M?\)L'."LH*;B8L[)%S/J5Q=5:,>"QZ_+A\(PX$2;5:JG3N_BGWCTX.#ITS^1
MZW'P^-F?_""_3S*4_G$(@Y=ZG _.7CP<K3A=H\V=:(2J"?T4WCC<A&**-/7I
M\GJ^CBUDE^;B[U\\O#ZRDK#I+S;)@DQ5+OBN3O=F;-K\Z4_4*#HW!/:7]%@/
MCE\V#Z5<< [.4?C?-9C;?Z:?ON]^@28T7WDG?MR*&#.FA8*\L?>-.+M/D9Z&
MCO8U:G?N-V)I)6TEYR3!0Q2XY>74I.MI*0#H:B(*S(54SKB%,DK3\9JFE__Y
MR5]^_G[D7S1VI_H;>=?TQT=/G]OUY$@WN?4^[M)!R.1!^5\_/@R/BK\RJ(TW
M-3)U_F:Y=SXEH)Q1+69D^$/^XG\DA5Q*O>6VL!)'[#F:Y,U3R!'#<9(<,>:Q
M#D=O@:[[!_H2:QO;FTSDP"Q9Q_H.U"=N6H)Q:UR\&7UP+.+R>^KB?6/T]D 8
M=X7]7U8MM44CE0&4:%TAA>1C%^X:H#@P+,'(7H,H444:#69>SHMN:G$@'VP*
M.E3]DGU9D*,V*TJ6'2&[#DCJ2_!0PH@>4[MW0#\^>'G\GDH]N,:]#LS]%)ZY
MY8K5C8Y^4!KHWV\2.=;.8J"="UN3=(E8OJ:M\\OE37.(<_K@90O;E*8/%/\0
ML@</OGMY]N;==P]'_UW4*_ L^JB#SL$O*?W>RDG]FS?&HY\&IQ.CQ%LBL/9L
MVPK?^;W@1ZK#'+0CB=6&<DQ&E_NB(JWXB*@&RQLMDDYPO-VK%\?P(%B$^Q4
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M>8[*G*B84.=M,00SSQ@G8P<9//^[!BCY!PYWENFWW3JY[S@.0'3W)%U?F [
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M 6.AAJ+SO&CM'HNAL/0,6(JHLC+C@"V$V8(+GN%O0>6^,!#F;E3AYI\WG4)
MUAO?\^^Q383=2,,.,!0K 5'4J>4=1GD^1G$?B?5URIUAT4=5-SPQT2I& %<Z
MX@$/\#+.U=R36]Z:SX&V10%%S\[/"PSRIK OP%\V@F,NX^*OF-5U+([Z*1T)
MFQ.'7VE!RXM]*NP+8"J.D+-)SOTT&0W+5AS,*BZ\!C6#?LI^K?EFD- )VV_Q
M%/J\%WY=Y"&/!D#X,[X*O!J) ^9)"&C,(H2X.X\7*BP8M9@TYROFF!I3ADX^
M9=Z .*BN3.IU@/F>3&JV^X<7Y_DK] ?<X'RN">^6BJE4O)0X(@F?%VO]&(>T
MZ*;*(H*E&]A0='GR#R=;0/*N6\6J]H$2>D7D#K?/18S S O*? SI@.U.>;]5
M>NP85$SO,IP"5CXBO<(Q\9LFVZXA@RZ,#A5QNKSHL6"1:0CFBZK]M2.AGE4<
M GOWU'O+@^&NJNH=]QDE?(::K!N6;'AV1SKD;IUR<G>]*.-1,\*O7^P@IQPT
MU["B/8@-T(A$ZAG650>9AF$@,]7NRS/"D85SAX;;U]Z%1VW"0#<\#+=2=+%C
M4S:J:[I?28:!L:VYL3R^,JR)0=^AX63LPZW82Z&2)>*FI.SM3?EUDO M"BH7
MU"@TE@1+U5^.6&2#&(RE'E1$S'(4RZ.=9ES.$T&:A;Q_$G<81YA9R7V>O$,\
MNS &K0>O4F;5G,GWAZG$',N4#HM5] =%_?DAKUH[Q"@IS+M%A0B_[;.<7>R;
MF_'BJ-64XY(&I3B2XB%BTK[VBMTA_>1R!BL<X%6\""F!=>WKK^J;$(O/NFFO
M $J\>.5[R<,_ROGC]!B<2!'ECE V;ZZ\"0571'@#740\62(@>;=L*,%JXQ)Q
MIUSHI%C^I.AL(()4,29@!#]F15$3X?>>O0"3"V4TXVFVD^=+RF.%M1QV>;%7
MC&W!8^3GQWI?S*>".@6(%91*,)O1H,PZYOYI)B )/U(ABJYQP_;QNN851]9@
MB5E42G=UQ$]M<*X(B@+T-FG6%739$=*]Z8#7>$1&9I^DR0J'<U::&"QCO/H?
MY85E][Y'@A_*90#P@7HG(WVE"(;#&KP]\>6Z59O1:XS/$$-T8P"@C"D/-RE>
MC!2AU--!'F5T](2H8!%RLC S,28<QV4=SX467*Q!KLS6./^A1'CCCM% K&Y(
MQLWO(0=R#M]8JZ##7#]LLH6..;E#]3>PRB,BGYY?^%6\SL._*WN66WP'PT4W
MR#Q(7?/FO3.?D"H8V?2;[IJRYVCLL=],6=.=R<!V<;E)\II,FX#'Q0C6XM(#
M<4G 4E$DJC C\B[(_RU5A2^1Y11N<V*T(Q [$X"MSKO<!.O[%]3VK[3@ $'Z
M8(:-LE+IY.EVW"<W472LP))P#B*16]231#$DY/AKL-"Q# =H9C@=7O\3LWX$
M<(+NQN+G2LN9(Z 8#I-6P)!&8_A:8"GW;PS' P3NWA@51M+C&9DW_(J_5(*_
M5G.=7E!MYD),3$D4)D) CUZT;W7]#!7$1?I9O6(;VYQ<JM7-ED8]/C]8R$U1
M1JKL;\1JR.,V8\.9:M/3+*+<\\.66.XRWX.9TV!=!,C4"?C\(J(X!_[%0@=?
M="JBMOG"0XOK#NHR3(6]A)\:WZAJ1\7\<.6=";8NR1*7?G'YY?_F]Q H]R^5
MY :[3WQL_U8L<)(T[E&J^3(GB;N<1$T;F> *]'<SW8/;:&7\_$QXO?A^-?F5
M[UN?'=WFP-NR5[3&YJ]HSZ-(>2]DX"7*0.D@8^TW)K2(#4N0AT7&/?<L)YV8
MDYHCBRX,8^X\8 X6#/%*8?,G%!")U#:?NT**&UY_S"]V#=78)Z_V35;#\H)'
M4R$H7"K_7EMLPK+T:V^>?B\HA@A-7 5G:54-NZ7@E10A,+[:Z('&1@\P@4_J
MMZHL,#7@<<2U*_$Z RP&A380<OE 2+L-A&P#(><%0LZ-XS.72:E85LAZ31"R
M/" $MN2\- 163*A<<KF:OOGE?F,%AH]9O/KLG73A YS5^YOB7GE^D;R(;'C.
M1&,WJF'J%X8@#--A/>&(YV@;MB5[GL']R+IIRK:AEUF78T:M=():%[JMI\NJ
M3+R,W6CF+(D\FHSD>M/X(P0-[QH$*U9$XM#+VP26&DL&DD#!T!2L??&F^.$M
MZ%*#'AF_B1/V,O;06S&64'/FU&!G],(_%K+;\SJ6K:'X'F;P_V'Q8B'9.TRR
MOQZ&LY^93L>VM(4?JYW%G]TUK&9U3,]XT+!W?V899CM9SUIJV->,&#A!8!X4
MD.X_]XR]2E\,\0KKC3[X*6E 935UKT>CV9I>C.#6CDWW%D*98[^*A9=KTJQE
M%L5UV.=9UG1%M?G+^G 'AJ+$GUCPBSG-:DT"-Q%5860)C+PXE(KI;=5)HQQ<
MUX)57.[>B]DXS6LW[@$;=R*J^;_>/Q*MFU^M B<^"7Y<9RF8L(J8<!!0"M9S
M,W#F_AI-S )(QZ0W9)UATCZ=)J/[5KHT+:C2-FS&;T^W_OJZ,WQEHQ8NS)?Y
M4F=MFX"?KK@9=^'0?>PWC64M,;\,8M9-0]8,IR7FEIBWGY@U79==RVXH,=^C
M(16^FR1EEPUWT/\V?W-E-3%B_[-5:N)EF=?$/)$+S0U]M67/!9_F,:&X55^1
M"><?\Y,*C:E7+K3F=O.86-VP]I":?4C[[)1>;>* UF3/LW<[/"Z@R9@]>7?T
M0-U!7+$8L.PP'>&%33'Q5L-<VP8UFV/7X1Q8PRYMA\'5\LN+YQ=Q_=_R2\LO
M+;\LY>+09,/6MI5?F%;YFL6E-#@^MO&A55<L7XY?P_&B+2+FJ1Y%=4\0%>^R
M0;*J^.\@B^'Q*L&+MU.'V?.B E%OA 6U>*Z;R';">L&YR/""9T<YBQEFOV;L
ML@QK'&!D-ZM0@YG0K)K.B)?3A5<-QU(O#D2URU%2JUY4Z_/3D43L79'W594T
MI^(]8XF7-,^+G*M:V6/,#,-NX&RR];I&8@0Q <RQ:_K!-SDZLE8WZ*A6-VAA
M :_F)+@UZXPO[BL+VT8VMI&-;61C&]G81C:VD8T[%V?61C:VD8TO,K(1=G)3
M]]6D!V:>*$F8#TD4\:JP;8#C"PVCD1W=D&WU<5ZF77&ZMN2\]>1LN99LN"TY
MM^2\"^1LN+*NJPTEYO7:7AO4B184@ULBF&\+XXP,RY1M[^Y;V*>#NA6"N[9Q
M;SU/MMV[(^S;O7U@?)QIRM[B +D&Q<$U%^G*?BNLJP)K5CG$2O!E?P5>UK='
M?"D?#0:]>#8\;JDHS#G[LB54YH+RZ,JF^\ HE0;IB#M_4+JERH;VP/"[]J">
M4X?5;&]SQ[0K:NH'$M3[B9QCF,5NJJB.[<JV?K<-WZI1#]M;3[=EU[H[&Z3=
MVX>F<%@@E@QS@SIJ\[( -Y!9V+P)-R*]\M%9.YN3?47*SCW14L\7)/N"O*B/
MWIUF@W;5W_"Y ZV;9(2TG-)RRA*<HMDZ<$O+*2VGM)QREP%K *<\[MIN4UPR
M/VMGF_ILWQ]37Z33L-8DO_'#PC246J_C%;)K6,+,;Q4X+ONHYO&&1/7DGGQ!
M>-9DBDXX8MT !_#BE*7HR%(?]FI8#L6?KY;9I21D319FW\B')WF>!C%+QV$]
M<<OVR_".ZXST1>_IR=N">5.K)?7 F&0\<0"BFU,VBEFWAXBEX4RYM7CV4$B+
MJ<^LNOIHF!$8FST5I$E$,XK=:,I39CO$&FI@.R92GQJF,X79Z%H*X.$8FS7)
MDSE(1_Q=A^=_GAPIFE<,5/:.90-B0R_6F9;E*/&1;^*,93Q5$VHSC1Z1:71)
M>_#':UGZR!N0L<,^"/M G=CXC#61;)..5IQAN:G7M4TEDYO:YA^U^4<-2.G9
MJLFV^4=M_M'.GN8N9H.T^4=M_M'S;EQ#\H\V6S*S34%J@]SK8"*;ABK;3INS
MT9+S#I"S)GN6)1OJJ@576W)NR;F!Y&PZ0,QV6V>]P=]\ICKK6YF@M4L5HC79
MU%19TU;-36A+>3\W9KJ6K*_<FZ(]IF</A38?T$*D>777FPO<YU/I9<SD'V1I
M1/,<\)OTV!WP"TLQTV7;\&13;3.7&GY08,FYMJP:&\Q=:@]JF8.R+0-L%+.Q
M*6;-,QE:,^3Q"7CID@EXNZ0R:;)CV++NMMV$&G]0AF'*NK=J$&I[4,]M*ZH:
MEK5HK!'2/#G3)A0V18#O0ANP_/Y@R+5&\+?I'X_>FF8#NBOKFBV;C[S.?M0.
M;<?58,L?+Y(_+-FQ5=E=63-M^:/ECY? '[IL6I9L/;*$[4;X8XF.7[/9+]N1
M5"BME#0SF6!8GBC+,2SU@^53#&618UA"YX-3#-,(-F[^97HQ>QZ6N50>8BVC
M#B=S20<DXV,=7&>4LIP_EDYXU843R*6#$#,);[MQT,4I]48AZ]$5T![L* YT
M0W.6&0C37$@0XEA,G5L8@Y2GW[UADX%3$,DWG)GJ#PJ64*M'B \,,!HN?F11
MD[IE:';.8\]-M*8S.<7Z?[M9E:. ?=R /GXH)(+)OB&]6S+.]UY/YE+%B3*U
M]6O:M85[$T5/MC<<V$(:I)Q@WP"0T@R_!7,EC9F+U,UH],^]?\2!YD8^"3W-
MLWQ3#2WBN8$3F;9-76)KFONW _8L2VX#UCF$%\*^Y__SFKR;1P ;R]1CT".E
M@[*M(!D,LO0GP,F0 IS\9KF&##/@T"JEF'L'KP<3'9OZ86[O@(P9J,"COQFJ
MBE^>S6B>KFDZ_])Y(9+UZ+5 ]P'!;>3?QGQF>'3\B[+D80:<PYBA?@^^FP=D
MP)$3YXK@EQ2/,^E K\>S$XWF93XCS$JW )8BW9F4"<\L/QQ%.?\9ID"Q7.O$
MD$>PCEN241 8L&'=&/XZ)#_YADY^,T[R$=]4!NR=507PJLS\S(G#)X@[($VD
M$[91C4]5;8B:4VX;IR]&B+^YGNRJ'B.BWW3#Q&J>$PK(=)+<=/=1> Y5$1GK
M=PTHMN0$;N?L4-(V<'0\]>ZXY($<1$D<@=J9#(%7>^DM\ E!3+BFU5/(9?A$
MA@K$O+:G7!UJ+"4TA7,.NR1A^RI]('$F_4EZ(W8\1_""&Z[G?H@30(X88/(D
M 7@;(2;G__4/5]?TMU])!K R;$PV_G(<YW9T:V-,]Y5*72!G(/A\A 4XQ ZR
M A:C+.@B?^1=(..R%2^0=3]-N"H/;$B&$F(^:-)8XP.&0.Y$$5(=62\FOA V
M'<Z?!SD_U?D&QY Q9_EX5)YX/'/BY7QK[Z@+U)P&P)3LK\4*@6.QCS&2%OO*
M;[IKRIZC,8@8]9@-  1(IL0ED.--08[P")A"ILE-H_G&C^1/E1 9#43'X* D
M<M;9F.TC?"V@1367CFY*L*T+QF6U8IR.YRWZ#FXAXE[U+C0*V:]H9@5L:VC6
MEZ6;%,T6V+4Q+X\2YS^4"/2':6 K '?B\5F=@N\/PC:V3\X0EN'G)$T4[,!,
MV,[VTGR%[M'+EB_9* LU%T[/Z%#Z!!N^77BX.0T$]XL1*-/ 0= SY)-('Z$M
MY]!!<E&%)&]KD+0U2-H:)&T-DK8&R4LXS24J0FQ7.8BF%"#9MEUK1O61[=JU
MMO1(I5RN+8_Y!=VY;_>M^K[FR89JR[:C+^K.\<@-V(Z@DI:$MYB$;=G43%FS
MO):$6Q+>1A+69=?39>NA3?N>(7KI\?EK//R]X>3W.:,1S?!BC/N^P_@F#L',
M?&'I;/NZ*>NFNCR<MNE1[0FU)S3ELV&W@(U-8%LM;:GAN'V$495A"==2FF!K
M@CJ4O[!B&ON&K-N@%[L+FRZV]1DV?TBZ[<(QK6ZVM$?T?)JYYV%D^@.K5C9(
M_VXT?E>WV\-A%OLC?AD\3"<B>KII#\R<Y9V48A]>IGF\VN*;S83[.AC'GH/]
MIU96>)OAX;E'%6Y)>.=)6+-E!_WLMMN2<$O"VTC"%F;8R8[N/LRD?18G93&+
M8N(F#RU;LZJ[Q!BUU4[GFJYC^':*<X=_4:KR@%8![RP65'B<,+H[#GB7SQC3
M.&>\UX_VMC5N4U9&Y"W"W7VMHZZN-&R1:M"26Y/6MJ]WW*V^5VC);:O(3>NL
M$GKT?/<CS:M#]X2U[5J]^45/<>=+%']EO]!0*=*CB[S1T3 ?8J_SY'IY]7F5
MB^N[RPYMXX6(*KN.*=OV TNS+K\A6Q2>L'.G;,F>8\B>^L F(.TA;\,A:R:<
ML"H[UJJ-')[ME%L5;6'UN*;E\S8D37JZJMMOI==:2E:X8UY8!:E>+0B&#R?C
MCO(Y@4>\*$,11B!/%X?S:4*CF)60"-($N %K,?&"#%@5@E4B@A&F!YVN7 1?
M*=?'7R@BBF<+W55L/ZOJ2+=+*$KUC2FJ4K#R$+B>G/1X/8ZI6AP (-==:0#X
M4+XQHP&6K()UP0AY61>BONR)0=BFT)\T"V*^DJ+"!E_C;VA)3E2%FEU>4G>>
M<J\IUH2(^P/"BD?X8SZ%6N6(A63#'B_HI9Q\,N_UQ:Y*BW=U786F'OA4'/YS
M[_YJ:IIF[3TC!LVO'/$I_L\H#HO"((=D@#4GI N:IZ,LH&U!B160\O#\SY,C
M1?.0$%FEPZ(8RY<D1G*]'+(:*UVL&$5&K&[G*(>1@!M 4F4C7K&.LQ^L2I2@
M8WS .(I5W2O?P8O*B'HKK. <'F!50@<^B-*LSWC_-N[U@)<'(I@S "V!P-Q"
M>D-[Z8"5V9%%K4R$'U:69R2*;++:G "8)"QF4RR/%Y\IYL;G$\#6H (B 7>3
M'HQ*^X->.J:B^MP-S"#-X,\$)H28PZIT(G",DF)6^+V )$DZ!#A'J YC1!.Q
M+P#K:1^   QS +Q\>DZ <:,>($,O3WFY(R %$J(@H.*18J:\BM 8L2<C"(&H
M88F=##@;=*2#(8R.TBN-DZ$L2N.PDX''^.3+$^F3<;D9,'XT&HZR>DTCF#E_
M@91F NMYJ:7B")F<+/>!K3>CC%SX7E"L5815##-6(JG<=YS5(98@2\;_-Z^]
M,$=Z8X=;UN$9WM(>; I(@6'W[H)JZT;0MJ#J\@55W;:@:EM0=88 FB?T[B[N
M=HO8%8(B::BRYZJR[6HH$ .2=P7&PP\4M(\;4'*9WHF7\>RO3#ABV;2RFAC!
M@HZ\O-O2-<5X74G-E@U4TFU=GBC4"/.2==N1+76E0M?G .TCKC"SJ>([*A6>
M"& OQ-*$%5$EAZ]2E)N$WT=Y46X/](A^#C(@3B8-J87EMME[9<<V95<UF;E4
M&"Z3DAK$%3='T$:(AV7]6TT&H)!--+68YD]!'H-P*<<&6I95510 Q]5.UKRK
M'6">TR%7 NH5_-@1V98I6X96J/ML&G/( )4C4560B]A@!#8<3)2;;T.P^P9L
M0WJHU]1$JZA&QTB25[;CABH\DO#:G_!F5 GJ%,=F &I%U$MOR_-*@/%$I> >
M+YNSLIQL5><YM=BJXP:;,4Z*"NTUKF>$HFN:[+J\V.MOP+NVKJ^C1NS)O!>*
M&J_+(4TQ,A)5'C-V%0A0UM9D@,&M*P0]IG4O6_6PI9[[J6>0I>@V8A0D=. Y
M%*09#H@#7=8!;E8YX6G9H<NJX\@ZB+3RO5@\=-Y[EW\-RI</CQNB3HN%?*C$
M$TJ*PJ-TR)U!ER@Y9*E*U19_*"KL%G7- TK#G#NFYCN-GL?CTB05IX8G0M>Y
M3;,?7'9P1F<25 <Z :HS74/@EFPYV/39FE>JNN[QFAYMPHLJBE9/>\D6:E?\
MZ%8@T$5VX=3MQE;XA0QF^6R(A,K"RPG35RJW*;P"=)V U_K''P:EPX4]D-!K
M7A=Y2BE!C008;KW:M_"L2C[MQ:#?\.?AWWP4H4,=U2SV"-!<G]+"Q<%UQ@S'
MR6JN!@(+!(H<5CJ3IA=.!UY3M2"XTCT= E0)F9G3N4Z,CO20TUX%9C9*)D4Q
M1M@_V '*K$+N0[I7;Q7$Q"H[\Z.8X\S"KT>CC+5_(.$-*0AOR@X J+_.L($.
M\_N-!H,TXX?-&T?45'$)"+ORTQ7>.UXGO'I[02/,!0G?(S<D[G&3-V%=>0;B
M"H!F?=#0.?&07@_@,)WPM^&XM^R-L_XZ?$G.5$<@)WP;[L)P7"L*+E<EN(M+
M!O37X:YF0-S!Q'#L?@-^7.QR+)U^ZW4W/C%];TZ,HM4\+<XF4*/NH68W4\FH
M3[-TE&/_DF&:Y37WM#\:,H]H+^['M;N_A'!F8;U-V T2?,[;/.$!(%>1+.@*
M.[;T?)<4+R0;D!UBD2 8?@M26OOLC)DGMI+$4]- !0N_/T."8OR-<,V3<$RM
M84:-94XB?"%WZ1>7>XLH7KKMPE8*0@AQ&7.7!^/AJ]GFSS3J"$'+'<M2'N"^
M8W0%#A/&>063K,E ==YP_J]3GNR!>BSIQ;]*?T::4'R\#QB,=!&. A1[<!9(
M$M/7%N6<:E[Y@ODG;T6F4!,?9)#ATVKQL+#]^!6G$<!_O,GHP9&C=Q')'\7J
M[(S8L2<2$#9(;3PMO Z%0T\X7-_BMM\RB/)Q$_(X8_M*^#T0V]ZJLT,/;Z(B
M<I/R+[%A^LC$M<'JM/@6MVH_+B8-YD:<P&+0;9+5'L$HC)1;"RQ(A;6<&-*@
MFP#X7#-*F[.P:KEY2<5\)=7(;)M@,'&ZTM2I,OF6XX4'BR08);6UX<K96>#"
M68\(X:;" Q:MH^X@7+E2NC-X.9"9C/7B;RD\SKHBP,1%SR.9]9A(4!R@*&7.
MNHPFUT,D?22.7GD#6]QPR#4"$QWLA&H@5*<WTK[V2KJ R=4!=4Y8P(#UUJ %
M=Y?A 6^E??V5=)(,V18SE"Q(E#U774S6& ?TA&',-%*V-WXF&F@D("/$+K"U
M 9;"^ 9,D$X.SMR+V-\/<0=%4AR-^1AP'KB[^3BA&9+$6S:+??.5=)Q<DVOQ
M(M'D"M8&EO@0OIIWXX%01#BWP_&-F:L17:X(7RA06)1%C_ 3Y5*965R\DU:A
MWN+O89@53U:GDJ#EN[V=J^8+9+QLR("< 'B..6V<3X2.?.8T5/YQ%S43#<O8
M7U(JG:7 (E8AP.?;'NO;@*:0P!G)0_(?=G/<B]$<6##3QI\CUS 3[ PZY+7K
M+>9-<YCFD(&!#.R.O?YN0;,!M0B5Q[()C]@%_!,'HU%-WN#].VIJ:#B7V\2;
MC8KG/L7<<7PQ JEB69:Z3UXAM$9,%G$-!&\\1,=1?EE?[+S [5.2_:!#)D#P
M4VSVVA_U)3\.1;>@>?V8T+AGBB@8[.DMAFNI:BT."]]OJ,P=#1H=\R)4F$[&
M(LKDC&\$CI6 ,0FB,XR9N"A-%YQ0.?O9:?!;H9G)52M'GLI(2.]<NL2N3KGV
M/.[[:8]E#^B@BU^<_\E^U-ZBEY[UGLK">P[!U=3]X!7(G_V#5Z4?9 038J\#
ML<JIPY69@*?79,[ISC^'FL72AD=L+CS":\,CVO"(+0B/^"HD"-A%US%SYP$H
M,\,\9_8%<_2"Z58J71C]*[K4HH< 0\&8G?:!^MF(9&-)TXO6<"BA9NQSUNB6
MBSK4Q]$.Y7B< [@-"_P6[?$X<%=QR%7OOPDH%Z9B-05/KNX\N)Q@+\SCGVQ]
M:$&OZ^4=":0ZQVRM:(HW*=%[% 1Z5I?D:&YAW..4*$<9P+%>1$BLAO92<9;Y
MR/\N_+"D$#^?24)!MJ1@'L$&U"6-IA;=[;[>,VW<XU,P]W1/W"W-705*]CG2
M"LX=5#[&*',DXAS;92W1R[JV^>CEDZOC4\DYZ$C2'U\.SJY.K@ZN3OX\E@[.
MCO /GXK?CTXN#S^=7WZY.+Z4#MZ??[F23@\N_GU\)5V<7/Z[L5=933$4RG:]
M%Z@;7L3YC\9N6<,D +J]%]^X52YD$362\R08ILEQB0!02,=2GVO)Y2<P+]!N
M6*1#Y>^2?)+\R-&(6'@K6'BX >ZN4](K&[WR@!ON#$^!)L8,: ;H,<]N2M]H
MZ?J*1KTH[O6*&+$I3XD(0T?/#\J+@#L:2@\Z"QDOWY?S@#J^$\RYG.88-8VW
MC'S1V*H4;[ZG^S;G*$79%?:X<)?!MT@AD'!K)CNB7M.$16V5P6&3K4]EYE.*
M@U&/9' B/F4A^E/;(SI#HBNJFV9#!=V($V<D;NW0MSYUJ[YD:%)'.JHN]FLO
M*</QYQU9-HS@V-(R;:8P&G@;:[Z%V)H^[M'9Y]&K#6(M!%ZI!>]-]87EGE<T
MA:<=WI.F(NN>*TZN;**+[RLG*<,HV51L8!D,G]4ON'<SH 04@3 5 ?W\ICV]
M$R3X)7SMIH6=)L.)B&"D*=.H\K=2-[U%M4O<EL#YH5U;?[!H;EKGQ-DH@.'$
M'<AD1^9X.!*>\>+*(,84LH#R ->(ALAA/71:(Q>'_&H,>/PC$*-HB2Q"-D'S
M$Q>B^.#<M\CU<(32)8,78KA[M7LH<?W-21 O' 1.[IK/]@.<")RG=,CV$%"Z
M0:)X0510\Y@O(@&/L<"=#(J=9$P%HK,>O\V,?'$]P;Q828Y!4TC_L(X4=',6
M71>7PV L%8^28%=G7SJ7'>#U7@^CA*7#2AK-O!U8B ,O!UL,<<#+I6$UT?(;
M:,$PH!1$#S,;\1N0, Z%KQ)#0NJ,/_.^Z4$>$$*[R*;8O K8%&X]KJ)%3I*H
MQZ1W8S>M>7PZ)209_L?%/G+9A1PA,JB#V3#&)0F9>0;(!+],WMW/S=1;3K1H
M[KHRA76S(;:V"Z;VAY.S@[/#DX-/TB78U\>GQV=7E\SDOOSR^?,G]OO!Q3?I
MZ.#JH"$$OQW2Z0!4F[HJQ-)W&;F702(LHQ[LG),A[3-[9S@D09>B'S&CZ)/B
M(9<LSS?B7\TH"^'S*?!*(BZAT#DN?5 T;HWE[&F6>!&DV0 =MOQ5+"8<5:RU
MZ>++DKO3$'('>TPZ_/W@[./QI71RQHC\Z.3RX./%L2#[KR=7OTL'AX?G7X#H
M\0_G9\6O)V<?V0,5NU1NJ)8O5DGQ (ODN2G04)M"@>C</#P_N[HX_\11]O/%
M^>'Q$?HR&T)%3=#!YN_@49P'/>Y1$@$O(KH%\UE 7YA3WV*N'-<Z^N8"PQNO
MK3$O9S>F$68&B6"#%,.J,-*<!Z$EF)I9EV[%YR+TCG+'51F<E0B7 BI@876(
M0?T0!^4A+N/T9/$.S)4F8@ON'U86H0<X?$@C=G4$YAN[4^&#:@91-&N?B@A(
M?%RSPOJ?JLB&RS*R5CHNK+D#7M1#\PR3A7^0/M-964 O/E/_HBSU*<:P34R6
MFYNUG8#1"$]52\:5FP8C/Z\3'HY!$^YA%0KUK(XQ9'&I8GNX(E -*9RI7*D0
MCJ 83,RXQV,V\Y&/+I]:1,?$8ID^@C$<N$@V;3! X<=\U$=7^"]Q-<B'QP_P
M?DN\<P@TBQ$N<1KF&-@7@+[.3V1J>W&$\JV8YA;G>.'**E(Z;V$&U0$R7W6:
ME<'?TBESK3._*DX4C()?M/!W)>.%E(+A,["/>*G736]Y'&BYZ>R@F.F *T+K
M7N0,@BK&TKA)GO)0:9+#V135F@CRU(TP:>),2MG-(XN^9%<#U4P3BOLH,M#Q
M+A#]#' (WT?AM8C<K,>X,C]<F@\57BUK*/S%8-9TXP$KCY7"AN%\%BRWV*RC
M^SE3A*_R@TQ'(FB?\"C710\UB5Q)$(SZ(YY(R:Q.H*<1)LS40O[%VTH"JXZF
M7E4GYE<^ @HKJ+P'(G..#'BU#]]"IQ#J^1@(S#@"CKP-*GJ\#+/4-JBH#2J:
M%U2T&7J$-<8\2@BC5K)ZFF58TX@*)'[/*G^D(I&HP'K$V)1?K\Z@SK(*&F T
M0_"PBCE:0B'C<4^%-B?TLPG/1"'*88@;6G=M'"08QB]=<+<%AAX!YDN:JOQ[
M.1M0-S>9Q=E<6ZC2;$HY5>WQ29&!(<PDZ1P.I:A%4)X&$&%K+ZW'7JII;TPG
MS@<8 E(&">+U:"\&?0Q3DIBRQR]TV>\AX #J 67:3!EC@8=6L7!6'!KR7SX*
MNMS^B2>LF0E]!TV;"<LF>E4@S,G2+T.EJ=#M*U6N%N(] LZ_8>C&D\Z+$#P>
M@($U?&J!#O-UJ4>B&@O]+I3PN?IWA;HBH"*>>U]=VV(1>S& /Y$J5F-A-3Z,
M V7[.1AEF![';@:GX]OQ=XPGY)<<N!K46T4D"RK[+%6R,H(F"TW"ZP_Z0*(!
MZ4CH6YZAEWR<8SVI.ZT7N2A>@#[BI*Z_YZ)"(5XORA+E-_R8Z">&A2&0WN*D
M5-(K@;"<$<3V0-3(8.GKLYLYL=_\U&D.?V=_:&LS/6V%MX;Q]"W31S!EE-EJ
M-36HU#[F^9>6AU&_TK(P>XCT*>:T(_,5Y]B,J^=I::[@'Z[YM<Z'<MK[NJH9
MKYYXYG>3OX@&%W6BF:L&4(AIYI<H$%-VHWN>79-$)&F7BN055J0%XZOFX.G4
MU6"40BP/E)/9)-E-:;7RG0Y$>44JP3I3%=+5: :Q,<AB%CBWA=#4%$6V%DFS
M7K5UZV()JP+!+!,0I/AD]<7E:;86.P&Z98:: /-$<TZ8SQ?\-V85XA2*B%!4
M2T04+O-C,_56"'<LEO&#\D)D,]]?D<^>_4;0:,J-X/N.))U?_7Y\(9V<?3B_
M.#VX.CD_:\A=X*[=*)OWY[,O1S^ZY4[DRVS. 3J?M#X?7%SQPSLY.5G97?OH
MO6E*P(=6WA<>G5P<'UZ=7US*TO'_'A]^88E$YQ\^G!P>7_"+^,/SB\_G%P=7
MQ]+'\S^/+S#*8U%@Q];(D[O#CF(1=K0P4*CJ7%(?!Z&<% X'!/DC]#_$3#_Z
MG*4_Q]QB[8NZ^CYE%S0U*^+^RSV>%I<DE$7H5D\*;^(II44*^V4]8Y*_K4M[
M;&H@U31I'Q\3=\3L#U,S%)?"K^KF3Q=T49;%*9X[[HEYH%+).K.D&=Z:L2>?
M5V[IMM:44!9- \%5\=+A^>GGX[/+NZ17RS8EV^"'\\AQE@I+(BPMZ,-:1?"%
M5+@>8E,;T-*&$YL.Q"9= K%=G%Q]D\Z_G@%L_W[R&2!< @2_.C@YD]X?GQT#
MGF-H'O^<P?KIP=G!1Q;>QWZ]./X$$'\D75Z='_[[]_-/1Z!W@<IU!5]OB,[5
M>"]2PQBDA&DA5L;2^:TH)L7N!$5-OO=5+S'^.9,]M0 1_/5"U%BN217X"KI2
M-X;W:F/PWD 6+)B-\1% /3+AY01G75T<@!@X9!_*(L:6ZUY@X!P=@Y X.EZL
M6K7<MB7<5O#512W:*)]@HJM:CM6&N,?R&B/ 3.">SQ<G9X<GGT% U8+*/QP?
MBWR+XXL_P1QIY=!V<D;!&/#%09J#F-'?8(D%EH94O[4X&+#V8T6^/5X?GR2\
M5B[^Z8)>8\<)7(>HVG=071M^B+,^NV_\$&.%5.D;%G@_YD57"K>>)#QZ6E%J
MJPTH6T- F;8XH&P%/-(JIU$;AO:2P] :["_\\VEL2<V<YR^%^08*[$$&>L(;
M'C8^WM 6<#%M%0[#X__]_>3]R16HL',2)*7+P]^/C[Y\:HRPOL=1#]MZ#?@Q
M3 =ON ><ES8IX9SU*F<5J@<Y?5/\\+;HN!TG[(WLH;=B+"$#$(>FVI0SFN8?
M"XCRO(ZC.HA2HE^Y>+$ L X#L*G.ZOPSI^.:YL)/U8[VP,\LPWC0DW?-U?4Z
MNK[<L/?T;I]J#U]O#-^CT>*^\&NE//<^KF%RY_AG-_;C(<.&LQ'J'R41+N[D
M?L?Z. H^SPJUI58XQ5J-7]5RYW9$\R"+66ETOL TXO\6!UI?[SWD*O #T076
M+8$F&(=2L8(5:1D&V=YC?C[F7/.:UGF"Y8(W87"S96/19NW5QJ*XYD^J"F,I
M;<BI=-4GD S/P$TS^L@.<--ZUR2Q?[W-G-:]ZJ-:N%+FQC;/]ZD07CJ5A?<Q
M+PE8;#QN%ROY\;O2F0H5?/NP3$51RV*9W)"2)UXS[;,1)E2K@N^J"NXU#)>6
ME'?^*TFH;?DJ>ELCUKB<NKJ;2OB+6=7N$&)K[S9M52O;NYLU;3?A<%>7=;A/
MN&,I)_6W&Y^@\,)WA\/!F]>O;V]O.S#-SG5Z\_H@"[I80N,U#:])]CHD0_):
MTS5#-9S7,%U-4TW;\N ?V]8<[S71-$5W=<?^6Z,_C5#K=(= CD9'F^.I?UDF
M2]-=.,N9,0>\X(Z(0F!F3,@"@/@E+.75.XO+8'$G>Y6E-P23,&5Q 9($'6E_
M\9WQ,"V4+9% T=&*RB&'4Y5#T)X1";BJHND?12 LO/<LO:GE8.B\AY'V:H[=
MLV9?0 L_SP\_6)C45!%^=,6V;?=O+:219I("?O07#S];@S!38,( IXCD>"[T
M.1BP-I@_I?>+<&<Z5@5>=8EU1;&AFF8>5##$^MH(#&+-;32]Q:"=Q* %*I!>
M8)#18M"V8-#[L?*)W.;KT5WT5G=I<6,N;GB&IEN:B_^KFZ]#RW,-#127GT9I
M-ID/P@P5#WQO-UCQL>I Q;_2\JPKW6-Q2*[R[XI;_S5*0.CS'JDMC^XHCWJJ
M#;(]M.&,76^"1ZV61R=9[HA50BKU[\\EA^6R=(&/\22&3U5A))9FBMV)<M"X
M#].$K0SO[OBS69$OM"+[+F)5O>75'>953]4US01Y:GNZ91H3O&JWO+I&7CV\
MBU<?S:HD8?US==$_M^767>564[4LX%;3,0U]@EN=%\^ME;H+/+)UK&MH+>ON
M-.N:IJ>"4NQH\"=K@G7=%\^Z"PU785<^TI?]9-9LV;A>N*M;[MTQ[K5U5W=5
M'7ZT+1"\0R IU5)M7:WSK]?R[Y;R[RD92S8O./@*RTE(+??N)O<Z-ABYR+-!
M%D:JI1FZ6D;;J"W[KE%9/GI*91GY53,*AFV9M=',FC^86SW+,%\3P:PV?% Q
MZ\-BXUIFG<^LQT]JV3+_L=URZU9PZQKC.,PBE-5L0UFW!U>J" M6,Z3?QS M
MA@,+;XD?%N5AMA&J+:K,1Q75<%W#54VTMPT-%';3P$)8[@_5 1EB=H8_AX@J
M$Q&JF^"5_VXA;1L@#71)4V#8.<NUD3[W8!8K896Q"*L.1UG&*Z35\X7Y8U-Z
M4&\L0(U=SZGFJQ:U=@FUA"YDJJ;GZ ;H0J:BV8;G<5U(+W0A!EHO>Q,>%M:[
M2]8;,Y- B?I*LHQP!^GG$6PMR>FDTK422"T,FYT/4M-V6F\L0O+,5J':4:ZT
M=,?5.%<ZEJE-YOR\&&RZ>Q>V3ZO<)62<ONY!.)*._S/"$NKP!T QUM'C?@6N
M3$@Z6(2*=W0(69B;Q%!2-UJ8W&& L#7#-!Q47FQ%LTS+F/)FO0B4O'L3V@#N
MY36XDV7<Y^9B]SD"#G.?:W8+.#O&:XM2)<R7 C;W;4 ;??Y\0-/F>>PLGU67
MZKJI8P@,6Y&IV?\Q,5ZQ )LV>KQ6D:EHC<%[7R#O_=^\WB5PHB=&EH\$<UZ*
M4I.:7@Q0>Z;L*G@0L'1,P#]S><:U2\[%<I3SXD^=]II]%]FW+-FB>B[S7!37
M[";]J:FAP?E74Q]XT;Y+#'S)VS6P&VJ:]5F8RR>*PO+@.J/<N@\9H_%^[.?!
M,*TNE%UV,^-)/AW>8KOKN9?<&$CS_O1"N4R95S65OM)\*'WZ=+B*MQ8.:^&=
MTO3]]^N#65X7GUMM?907R/!FR?!ME::M0::)R)H/<0:8,1$A?SD$8"%9B(VW
M1J!P8-'K,SH4Z,4QZY(.AO4 &)<'P#P/7IE/BU<+:VEO04>P>1V#9DN/;J@&
MN*4O;A/6G(9?=VWEXHW;>#>P34F>#;<(:PO'3WW6Q,+QK<:W,QJ?56I\;4V\
M[=3X+H%>0!%;6>6;-%"?3=FS6N.TA:H[H<I2-0_^"E!E*9IKFWA!#$AEETCU
ML$I\+5)M&JFNNG'V:*#B%TGZ \!*ECY]7C;-&ZC,7@14BQLY394:+FZ]K!:H
M7A)0.250/2R:I06J30/5AW24#;NK(U71E%Y %6-^8SFD.DP)J%/>:A#EM!#5
M0M1#(,HM(>IA<3 M1&T<HN+H(0AU2@H;RN2AQD^(3FZ+3BTZW8-.EENBDZ[:
MFH GK82G-G#H,O[Y$$;G47<\[<I:E<E7=.DLS+?_8T2R(1#+>&X6*S#\'Q7#
M'XRN82V  BW'[S3'NZ:G6HSC=51.9CC>;=.D-JUD\')Y(>TGO"P'1AU604[
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MS;%=F_$::)&ZKM4YS=JT>^EE7XE?T@')IF_!2Z=T%UZ02P<AZ?,;[@7&Y62
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MU")(YXK'#*S+\!9XS93Q/RWZPS08]2>\ &SP4A0PIP-\.LIAN$JZ" E4/C6
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M9C?:4 .9X%8F[#=WX5@:__FQPK'8_7C^P6>_3\K@Q_;\ [J]B+W18V+']/D
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M>5'*=FE#E[9%O$4E%AL*ZZM::$%,7[\-^BILQ[*GHO;'4'NY*SHP9(J+K&M
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M0L3 39;CP%0P.M@0J!+(LW--:=4G#P[SR\VC6CFJK*&$.<,)*.:(0Y<(51!
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M@\['4KK7<?']Z?#'8S8K&VE>NU1AM5*U4K52M=)2<FM<61^B-E$) 5X'KY)
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M5$)B FBBI B1,\$5N*UM!J9A=F$I4R,U[47T<J7,5QSTHQL>5C#?/9@OI0R
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MP?E4=XWH*&1Y28"K2$!Y2@P$1Z)US@5CI0BL]))L0(J&B:LM@-N&\QKB6D@
M[>2W;I0^=^M_MNZ0XW_<W?VOS=I M8J8LL--@P'!F?<F^ZKH&9.242G+VO"
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M6GB%?ZB8B;>CP6 TK *<>[<+@,!<G7-5% H[G2+WA4^PM\%H.'05ZISGXY/
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MS41&5WX<;M(K/[ONMI1N)G%ZK]M>_QF/'VFP\K:W?6I7WHVU4.325U?PU0I
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MK&%$8 Z3R;C-*'LYARQ=6$$W"8^?[/K"$U#W3UR@C!D-X-D7&/<_'(WA[JJ
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M8R^#Y23#XOJ(<_[[@'$#!^*+$MO4P"CP)D5%\;W&4B#> ,=C+X1#$*N 1L$
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M7]'X[GG:'7@UA9=03R"37DU6T2_QN]/%!/9SY7N@$GT/5&X&6^B!.ZF"(VP
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MEL%/;S_LE3]CH-M7',^Q&H\*,*O.BE'F?*0=*H5J7/C+KSD>Z59F5W64#8K
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M8GX^V*=^0AU]&8<("XP#J[F !^+Y5!.OO[FX,X+5"G/V4#P(KXOM8H  >H!
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M[?JC\Y]7V'<5&]H:WY0DTUL0C%G-^.EJG\-RWRE+.N&)R6*61G'$TD0KETJ
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M)<;X1 UG6[9</!W;#-YG3>VJZ86M%,FZS9T?+A:+\=[FV>"KCUN1:>W M^;
MH"KBJ2]:98P61C$'*Z4OBN]L>7-XG/_Z<C+_0V#-XV[L/V%IG/L3P;++BN>[
M\ Y'7%H= X\G8*3'A-%8$"E32Y*4PQR'0E$NECHGR51F(E.)9BGCPBAF4IE0
MRV,+_TSD6AOH?O%O)ZJQCR2YAV:<N_ Y3\M:I3WSS&<D8WQ^W< Y]UD0.!]H
MC>9#X\XJ^W-OVJ_(?[K<Z6\T_X6J%" 9903/;'^JDR<^['UJ.ES6D-&;'N,O
MWF Q<1T#LV[SW?KP=C&E^E[Y!B]SM6&6&_PN7*/05LV)7Z-9P=DJZ:5_4>>:
M8J^-FE=6L^S9915 L#CIL^?XS/RY<E"^(WAU25-L$:0G][Z):9NHBJTNBEG0
M>I6ET]R%,FICG].*?5B\)"^'=S<CG"JNA3%-W2&SM_5M6'TK[BL2]4>+VZ*N
MA5"71<9)!1T-,)17<2GSA6XG3?E,V$A5/ !V;1T5A2\66=5?FWN%?%B9?SBS
MLY+(*U\]'RZ7O;Y^ BJ?US5#R2L>4-3^J6G C3^ :K_7N:^<4!4"1PF )WA^
MXF]7';QC23DL/@80?5FW< &;%"L]#[#6Q.7L2-XOBYH>@M5"V- 5'R7?!%8L
M+*@OZ=!<!Y*"'6-,X(9?\V(TG'GY%L%D*G.!ZI>C!N3*JKG/_!-\"W5/[JH/
M\B8S9];*>'4SU9F(-=5,JTI*HSJ]&V-Q,&#'>LO.KV(3EE-=VA1J]MD(JAP-
M01(NI@$0RRN2][&+IBM,7M;E+48ULGOMUTZ7:&TJOU3SOL/6HBSNE;T)^C--
MLT%K-3(M7EF7V9A^4&-Z]2^T>T?#*G"X*>!:YZC#1E=5XQR'X6B $I_K>JL.
MX\ J:ES'%3>(5;H;GE)M:%1WL^*:I1>7X7&_N7CZ]<5HLMOZRE^F_KBB\>%-
M#*_F477Y?;2S<JS=-W5*T&BQ2> L4K&VST9SNOO_+&GM.BZQ%1O88B.U"-]1
M:F_?CG -SF>Z*/,'B3*/NBCS+LK\=E'F-T:-+]C!+@RM 3S4.N4LE4R'FKG4
MH:,_5J%QC^^H'(+6<OOJ6^?,V#W="H\BH6UB3$J<"!UA3&=$\E00QZPQ/EE
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MWBH]5\HFQ3"?=MT:94#GJUKY?G9[0=^ITF%3"^17P.U;Q&G6LFQV 3;'/BO
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MK"+B)!JD5>1(Q8BMP\KH",9K$U\/5M7.P/LM7+97-P\<&& ^RCRTD/C7XRI
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ME))PFU3%9 4'/;?>:T,2-A&;Q 2MPD9/"=*'TV$CEX!K\2 1=M$BGHA!#H>
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M^J8**QY4D$(&GES2PNI\PA(K(YS@=N F+R6!567":H1R;_N@ <^".^D<<D*
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MYGZH0JL S$I1)2<4-"@PL0)9@55.5EGDI/1(&N8HQ4;&LGDQGI&GNCD \QB
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M^\>=4*]]/V[FX4YEZ ZN-NAO,Y++Z2Q'[5MND@,7'BPK ^>DE<Z&/W^<XM?
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M"T#/'$I&1,0C(\APF9#BWBD7%0BP+)7]ZTGNF-$B.'<+[$;;BY5?8,\6/]U
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M#,9"=<V;"V8 ,"=0%(/VR"S.\S%44[",-H"9G8LEQMZ@V<^/&L<Q\O"'SW^
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MN!O8[XQ<SD3]^T=V+2/"N>188-[0Q",+VK DG:%8,!$(%C-,J1=!YX?ZF.+
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M%:: -G^F'I".5#&F-)PO^"?ZC2)_>ND!^_NSS>($2%U,;FB YOQFVEN R"_
M"V%T0\NCI*G')&H20FT[EC5,'WG-MYV$3(80RA!2]2.Q#":7L1+,X)(90K35
MC3-&)-W!V-93?_5X0@*]L<V<;X4'_7?H0FTHQ]8PN_B=XV023S=LX![W>C"
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M>:$,H*7<6&7E(3J:_5EGJ[5/A<DNH?0.6$\IRF[)HV[Z:E]'<L591)M"L<:
MK3>5J.(].*%XO4Y.%2U1>MGE^.N#:?@>;B*ZPI6M)]%1D@/45H(+UI*G0J\2
M4\J)+CG%>C=Q(CNR.^K\#K)O)^3V#/Z^'YAR8,@+);%&$8QZKZ7W <$KK5,T
M&6FD1ZA:./)2?FNM[R?WOC5/5XMFUIP<W+/$YZZSB"U+?1Y"W;+^B7K[%*9X
MK;>]"\6V:+VM\+8<3>-"LGH-\ZO1Y.O>=60_&FK.K3LP-JHBJW<+4P?O",.0
M6GO^[==9+<1Y-1R'<5K4YE#:N+P+(:+C9"\4U*"9#(9!",&1^2E2^ZA3"KE+
M&K\YQ 95^PDQSVH@^'HVNZBUC6_+E7VM03'H(K<,#%IRG$Z3S[2:9&"X5IQ)
M;_LD=P\B.Z6(I1.GUM3X-]16RZ,?WV&]"]\6L_C59+I8N%LK@J ]!B7!RY)(
M!'5'!R,EK"9Z1>)1ID_\OB7.4TKZCD"PUIKL0K=_A^DTU/I*G*9AC?&RD3JY
M7,M[:EU[Q S.H0=1+Z]AFC'6YT;1^T"=TBF3(Q!I+QVU8\V*SF_+"XP$IF8&
M%\/9I_K#6GT[&YBB7"Q& \]UG1@3D3FK4,F,D2GI3:=#:@\AVW)?I_M&WT$(
MU%1=76S/PN.^_;PX[W!)[CR0(6ACR1I:;HGA)GOP& .X;)W0(02KNBSD/(CL
MQ#9_#FV%]M=6%Q+]"./>3,8?/^#TO/)]H+F42/\':,DZ*I$C>!82.&FY<5Q:
M';NLC3\,;1,:F3\NC1KHJV75W;KA?U_XNC)\9$)QS1",]Z(^KV3 <:?!QN*Y
MY\('V\6W;0ZQ;0FB4BQYGL@OV$)YD%(&HHD9LO2I7E#G;>B28IQRU7T/KMQ?
M<+^-%AIN1<[FTXLTOYC2L!:A0CTU4P^]UM+LX70107P*TX]U15B4@,X6R+:>
ML\J9071% .9LDBDLL3Z',[; ^ BRT-8DZJ7!AO>^?YYB&BY$1O\>X4(?A/%\
M,IT/_WOQ\P'34O)B.&"][D<I0>07*D/46F,TG ?6)1#<!-PCR$A;DZJYSMJ=
MP*S; <\#C?IL<EZWJI98O'6!*VT@)_JB>"8L64N(R:2L'9/(N]08KH=S8K6%
MAV!, [T<K.#0:E$(%P(BKTLJ0= XO:Q%LI+R&)=B[E)EUK;@\"@K%ZUITU)5
M;4Z&O<=1O0)D4A+]NNXPSJ?#,"H7XUKAD[Y?\5PFT]GRUK/9\MHSRH]1L4@)
MDX;"*6,BUCMPWM8K[&S)J295-R^<O>-$V.X8'D'"V8I"A]16P],1:5H!O\#E
M?TD<URJV5U?94)!6GQ;+D$1-NTTHX)@J$*27Q0BN8^ET:&(3>)N0S/[!#%4'
MQ74DU>U'@@>.XOO 7814ZE''DHGN2)XXR:*9,JEPU^4JL4W ;4(H]X<GU)Y*
MZTBGZX\)#YPV.@N"$4PAR\EX 6_)*:.Q6J98=#!=*CT> K8)C?P?GD9[**M-
M!+7&5-Y[NUIA]31+CJ3V3#:3N0"A/FX?4$5E<LA<N(W"IBT[WFC%D?U!^-)=
M,P?P9JM7G>LZQ*U7?0<V,A_2HD UU7I5GPFFJZ\/&)6X$"*5+HOVN\'=B'M_
ML.7N RCV, ;L^]MG ZZS*I+2!V>UKR77-$%D(0L;=:P9148FFYBN[UUN1)P_
MR!)W1V4<+*&[RF0?D&47,SC!8WT^F/[E<P+G')<$.K/0Y2+7+3!N1*\_V&)W
M+Q6V>]F&A%#_OY:_?PDC7.0(L_ETF.:8ZR^>U>MOKO[@RB??X70XR;?'N#JS
M]O+W]"F,/^+[,,>7I6":#S)#BA)- DM2!84UATV" V*,NO#H7.IR>^%AA]FI
MGF!=.47=6G-9"& EVH7?JB5\"@S/T@<FK;6]]M=WJHP_[N;[";-]S09^#P[T
MKGE97AASPX!&)F2P#*3 5.M^R'D:;X!S[5/D.IK4Y?7MS2&>TM[^X^?HOAPX
M1EV68\[I@A:X%>1\?5$0?$H@E"IUMUFE/HYIU[JLXY8*/'Z.[LN!8]C1BD,K
MY6@.^5H_J<C.,UN &Y2>!<M#[E*(L*L=W?ULP(?)ZF+N.Q]3&20NM>58(#!+
M&5FPH7+"0Y$V8BG!9]=EHWUSB%L&/D=9 MR79G>=%FBLP,,= O]^Y+7=N>:[
M6^UW8+?O.>;G%[/A&&>SMU_JQC=^#>/\9DB*S3N>F;^WO3:OA6R,N+-X7M2'
M"D<['?K>I-GNPEJ+OX7,PFQ(!'XWQ1D1=X&:NOVE6K?IMTGY9?AQ/"Q$9C(B
MRX5=LEGO)J/AXA7X782Y3W^-'K!I->(CB_]8:C@==9RD6C[4;8^#*V75Z]%5
MLF[T1U;(S_7X;2T]W,<'M.S_Z$JZ7R)'5M?JM/3L2-JZV?W1E76O/(ZLJWH$
M\$VMO%R6RAU)97>@.+KF-I'.D17XC+[+P]%%-0:+<O\KZT5'TN8FD(ZNVJWE
MUN(6JXO/)/J:<1*^J\\POAZ7R72Y&K%3PKQ)NVU2YJU'<""Q[1ZS;='ZP438
M*0;;I.O+9:=P9<5I#SNR;Y<'$_G&XVYTA]N]CUT+PQ4ZIB")>FDD9PF<]1:T
MQRQD#$KD+M=K;O[8>,,!_V-:#UH'SI5R]75@Q7.M$S+@!'V+SJ 5/"16>MVH
M=0^L4]J";\:8C=]=WUXSS39WR&%?G%\L'H_:Y-CKW8OEDL>4A?*@@U2@C!<0
M)/> -!AO4A)"EAZ\:C6 D[K@MAL%CZ+NSGLC&SB=56'MY?6^G?WL';T=S,5N
M,MI&WO5VQ?+9Q;1N[ RB9SXH'2&45 \8!@9DVQQDYP4WW*0BNKC6.Q'M:RE?
M$CTFWQ!73^VM&7+04G-M'?!<ZK:DHR$+PR"J8BU*FY/OLOO](+)3\JYM&'/3
MKK553IM"^M5(U[\%.L"8N6;&DS+K:%EF$&(FHZX#=XX)BQN>^[FWFU,J&VNK
M^<8B;JKRZ>IE]_!QBLN-[T$(7OK"8ZV %$2_+*'6E-$71C%>L#JBWD;=M[LX
MI>JK?JK>4[1-U9R'%$#1QPK6TBSD5A63(<?"*2ISG (B^L*4"E9F)\/-QYON
M5_#5QD_I1I5^JMU9G"V3H:4YF12<U9=SP^@5_AB@+2@]H0*6ZLMC-AD(WDMP
MBO(TZTH1L4OJ?#^L4[JLLX]S;ZB6-O/_'<48X_EHF&I\'<9Y4D_,5-I^7A[E
M&Z2"IM2+6PQ+%&Q('0A-RO7"T!A=BCQFL9$Q>*BG4[KQI(-E:"KHMB]^WCU:
MQ2C$S!B LG3"Y(*$$+@ +@2W4AO-^USK>S^L+:\M>41,Z:"6IF'"V6AY.<^'
M>CG/P"J;F:$8A<AJ0 FA(&09"0;FP@WYM^RWB1.NM;[E52*/2,EM!-IW)6IQ
M(G>G5:757S99(5J'HL&>UK+9W;?_KOU]PX%VVL);-MZB(.J.EAJ*H'N1TK*;
MQ=?5HN+>\EC76$.1/(BUT?KGHI]Z[^P@EB!<T4AIIR,S)*4!+S6#$I,PT@J.
MOLL-4]\1-'M\\,>8BA;<R>R!++:I-Z%S<,8C2)ND+BIK([N<8+D-Y916,'?3
M^9UO#NXF[G97RE[$T>ITV^0<!\X'3;XX0RJNOGN9+'G3%,!P95@HC*L^5Q%?
MAW%2FW%M]+V'G \1M5S95QK=L:VTM\W?HH^&KF#7D37R$'?=UR)UI&Q5*1#%
M$@%XB?6!605H@C"NQ)A8E^.\&]VLTVR8WY.O8HR+VD/&F$$%R2GYB@6TBMFF
MA-[)+O=3W0_KE+Q*"Y[<[V/V4DK[-XZO8_IY,DXK6"9CHC0ND=^K#Q,R2>FA
M]/7>M:1#MA@P=*DD>1#9*6VF'9 N.ZKFT%[K\F1I+X]U3_N=O-6F(VJ6X;VZ
MF%],\9_#\?#\XGSQH\O3TGM+\N&F&PIQRW'LZ>D72U-O<#9#O&,&7?;^,\[?
MENN!X(L+'&A3D )("[E^4=HYB"YI,LO><>8SBSH^).5]0>RUT+EKOS^3Y#]\
MQ=$7_.=D//\T&\3H5<HE0_T'!=A<0>"*Q.&+%2%0[!U85TG<1'0*$<)!^75M
MO?4H>FVS]KZ'O/X/ANF'KY.!#4SG(A"L7+S^%B/!3QP\4RDH&3F7N?>T7&$Y
MA<CC\=%P1UV>!@&)43CP7KO@BP2;*&15C%&H%=" 238SY%[0( Y"P8KF% J,
M'B\)M];G:="0YHX4: /EB6"%)M"Z@DZ>9I&P4O@@8[CYV/&![. NR_4;(+@R
M=!.4%PQ9I8<FOV5M?<M" 2O9EH(V.=FEB'E+G'^$*&47MMU,8'NJM]D"2 4Y
MF5X'^>-2JN?X?O5$#P&L.&>#$&WR)0?P5B=05I#)*DJ0*TLRJQB\PBYE9]L"
M/8E%^U.A83<-']<MW(KLA67.()''\%(]6CVT9AF"<%(S52RCP.N(&5L_%W%+
M$BK*[&WT$++SH*)60+Z>XDQR]8FA<A&[+.CO"OC1.XV]N+BKZ]A+[0?W(;?0
MZF)MEHEXA*&*2'B@F)>!9)Y^$:QF?8XH[0KX\?N4YBSMKO?32#P6^9+,7&4L
MA::4R.1[.8/ 3-UY\!&+DH7%<I#4XW;^VSGY6 P_IQB#H_C41N;J>PL&?"H<
MO,XZ&B.4Z%-_LS721^]+=F;=7BG(UDH^?!)2(2Z#5.E-%('0L9(DJ.PE>,XY
M9(7)1!6MT5VV\+>'^OB=1E,Z=M1S4SYN,FT&5K#H;$@07*V1<R:#XY;$$EV]
M$]HDGL0Q3>+1TH^@8I8H-.3$-"@O"I#U2,"U2S[H@N7FN8+_GWYT95^S#&,;
MS1Y\0EZNEQ"6(IVI9R]R!!6"@(",D+H0(RM&:7O4[/>$-M).DG6[Z/$X9%MN
MI*1DA:;\R19.3HI9"5%*!L5([:6WTLHNC_!VB8P/=2K_] BWM2X/'@ /.%+\
M[1C-!2T#24 $"(&B+ZNS"90\.QW2,</>HRTE"6]D4D&#(Y, JB0/3K ,OD2L
MQ>W,F$X'7OHM)1TRX&C.OF:+1=MH]GC;8I85[E+EA\T*E$KDJ;CW(+.4!IW1
M/G3+!#INB_V_P[N=-'G,%9"2M2:D 6(H]8G=HL!KKR#6Y=.4-+FJ+H7I?59
M#AEUG [G=M/F(6K9'RQ:'MPX$-:T_)H:/V0!]LVQ'+L$VU2.R<C!VTQQ+B&!
MF%@ F[)3MB#/J7NMY\'6T*1-/&!,H(.UH P9G:"Y@^(D9F]%L?TBM^W7T![G
M;L)6C-HUA]I*DX=/G0KWRC$>P7I.%E8% 9Y+ R7(G'02OJ [G=3ID>X3[$VT
MYJH\_*8 %@RU6@NDJ/53QD1*6%2$DKUGS))X>+? [.B; K^.\W"V>'6C7OF;
MZ*//SNMW XJ:$T]D#9*-CN(I6\!QDT DHXUC.EH\O)F_"^TIV/RNO-O*QC?1
M:>\CNP.N98S29Y!D<.K&! -?+]YC+A1F@]"YSUT1&QUA/WZBW9U"+?32^]W:
M2?KMTV1$LI_5N^-W>WQU32N-WJ6]'UV+EV!N=;'' SIWM=5)&+T>Q[G5T2_I
M$^:+$4Y*@Q?MMFF^D^ V'$\?65X^RG7C3NRF KV_CUY2W6)D?42+T_J>V=ED
M_ 6G\R%-CIXRWK"S7L+>9:P=I7YV2*D_W%E7J6\YUHY2?W%(J3_<65>I;SG6
MCE)_>4BI/]Q95ZEO.=9.4D\7T\4%M>\NZLL",WSV_7&!QA)_N*-NTMYRC*TD
M_9RZRF>3\WH39]CYW<WU+;63U0,HNPECSV3@KO8Z"J9G4G"KLQ;7[V[8<D>1
M=;^>=WVWZW_:7)+W=]-1K%N,KYN,G\UF%^>?Z[]FO\Z&XX_/1R']1ND?_<6L
M3*8O9_/A>7V/ZE483O\51A>4$BX:>KO\F^;*:(2GH]9Z2*S?%/K^PO45",\2
MS65RJ>UGTB:]]9Q06X^VF^#?XVP^':;Y*A;\=3S</Q3;JI..8MYX; VD^X*"
M["\+W_-J. [C- RCUV/J_F(1^%VN3NTBT@U;;B+'749Q,.'M'L)MU?X!!=DI
MQ-NL\SUF^78='%"@O6;W=Q_Y3PRSB^GJ&< =)+>^H282V@!C+TGL/C/O:ZZ?
M5#K-N[5][3'-[FVOGW2ZOF(\F^%\]KW;%\-9&DUJSP-3F(\\%TC%8CW_(B'4
MY\8<4\B$+XZY/D_^W85HW[W\?T[&^.V?8?H;SE]=C//LV?R,K-0WBL07'0V"
M2B$E[H%G74")Q>/BC-&HHV')>29-EU*:!W"=4GE(&[;<W,QOJ9AV%5@_'N]:
M-UZG@LN<6Q"%U?%Z6<L/"Y3 BBO!Z(*A2X71O;#V'?0/IWZEGRN7H&<A"R:C
M($850#GF(1H;0,=, A')N]3E(H0'<)W2%&G(FYOSI*5V^A:_+$LT/X3?=PM"
MKOYY$[=Z)YX&0<:5MG</NVXWTGK<G4*L*SVT6+*^K[G6$NF^.'VEKW?TVV%]
MO[=,IE=^W$92#S3>6F[;C*51E+IZMN5[;ZOG[9X3Q#*<#T(,,3&=P2B50"4O
M( 2FP6NTW)LLQ<TC+&W<TOVP]G7&J]9_F8<Y/AOG-Y/Z[N>ML?,0)7<H("7O
M006,X'+.8'G!*+3V%"YU'/O]Z$[),3?DT$W'W%Y3S<+8%ZO"@KN&[3#9G#D#
MY&A!61G!.QF@\*22*28FT26.?0!7JV&_0N)879E:/_JD2J#(B$'D%"<I7=_0
M#C3ZP(T.B6=K^I1Q;P;OE&9/2Q[=CFN;*ZOY_+DVM^]"J$4(D25)T;P@A!XS
M..WJ[0&>)^.5='W.Y6\#\I2."AR"5,T5=[#,Z9?AQ_&P#%,8S^LFVF1<UP(G
MI?X[C+_-&@:0V_34.IK<>92-0LN[*%$D#\9I#C'[^EI&3A",<%"*"CE9[7SN
M\OY!)X?XO=GWF";C-!P-%WJ[H[=G\Y4MKK/G@EK^]N/O:3H-I.3<Q+*8D_0%
M35W%L!9R%E*JDGGN<R%FTU&<DGMMP<*;%O!X*F_F?>\8PGJ;CK,!AH+92@<2
MZ_$O610XP4U]UE-($:2Z]8A:5U[>A?.4?/ !F==$;6VNZ+X#X3N<GH?J@5Z3
MS&8#FP,O;/%2M4$BOB5<AJ($9HV4,4=]*SFZXVJ,C;H[I9MK6K*BD\![&QGZ
MP1G%C\/Y;&"D8[HD!.E%O7S8!(I#A:7,(T7/0BZ\J .:E1_(-J&,.M1C\0>T
M)#OJIC=ESCZ%\4=\/;[,/>@#RQW3N@NTU,MH-/E:WV$?4&:##!-E-+;F-I%K
M<)Y;T)X5B=RA\EW6[?:'O@GI]".T4T=2;C-2OBP%:\DJ7@O<;KC@3V&*M^HR
ME_<LT!]<QH++&Q<4X_5FA;HD6F\^\9)!2%& 5!@Q:V]\[O(&0^N!;$)8\X@)
M>U3%=Z;OV60\'XXOAN./JRL?)N/90 9FDS("L,@"JK@()*3ZEITJ&(+G3G7Q
MQYM#/,1<?BAC,T$H&ZT 9E)=U%)8%[4D%*.Y08\\A"XK& VPGU)JWHF7NTSB
MEAH_K-NY*_,SPFHR<!XH_^,4\&>R-%9)X"QQGZS@!?717,PCR-Y/B)Q-=-PF
MN]\$[HW,,[O"A8L,7*ZU4\QYBMAT?7C&5NF0R/QFJ?[V?9]2WM^93X?0SD$-
MVY5$5";-I7,.?*YO%<F4""-JBJ%\4HF9(M31HN6=5PP>,]D.H,>#<FV;!-3%
M&'C@%++'^G!.*8)2464 O>".?J5-/F"$_(=8:C@AMO9BP@DN19 C2+6V64J3
M*$=V()TP%-KJZ@LD0HH4ZBK%:-9V62YK/I)36HPX(4KW8\.QZS5N3=) ,?*/
M^OVN%1P;]GV@FHY=)-&HRN-6U_^83F:S@9-::\\CI*(C5.) M#Q!]LH)&<G=
M]WEE=CV<5K5JWUM]._^$TT'443)=7S,3B@(:BQY\* X$#35Z$;(Q7:O2KL,Y
MI:6=!JRXJ^QL#QTTKUW\CH7^<?FSU?+S56-+N?O*S,[66^.SR6P^8-HY94T&
M+HU>F5Y5Z%NEC??%"0J2#\*F!H,YI96<0W#QT/IOLYJS;AC+9&UQ3+1,IE_#
M-,_>XPRIJT\TC.6<\R@"BU'5%Y54?<\Q4<CBL.ZPZ"A8\2KYAUSL/@!.:5VG
M(;L.II-^=O#'[>$DA&N !\QA#%D;,"A2?5*B'M(@B4A3N.<IE5RZ/-RQ!<93
M6L(YB =MHZU^1VJNQ+"#^BAY<(51GE3?#S720"@*@=F@&)=,*=GEUH3[0#6<
M/U=:K3?ODU*>U8M>/BXOJAA8S@6/ 4$$5]\SK8?TM=-0?)9<1Q39=*F_W!CA
M*4:?>_/HGAG44%\]S/$5>$O_$%+6,F8%"9D%)33%R58@Z$A@DLXU5#X<@39V
MXT<[,-.7,MOKI)_/_AGG@Y)*DDC!)BI)YEY90E+/ZJB$O(9L)HE.UT_<!M,V
MI*4&GR.Y-5RS@HL<D?QI O*I-$EYEK4Z6@*/1001L13A=HMC[^GU% WESERX
M/W1M)?M^W%\#3/A,EKK"D9;2L!@X!*4$V!A2\JBBL[T-Y3Z;-MW?EFO.G5[*
MZ90CWT?JD'PN*5@H,=IZ$#U Y%I#+L89@3*QFWLIS0U*XZC;1F&UD0R,221P
MDQ <=QX,DUJFX(707<J(-H^Z'[2@'9]8[$:.N^;&WCKJ9TJ7^6E!X8W*-"TI
M^JU'R1VXDFFD(I-)*%S%>)@E\37K_L>),(]#E#W4TG=;[VQR?CZ<+Y*D,,[+
M'5'Z1!KN=KW3?<TUV7S;&&^#:XWNZ>MRO8]^_@*_X&CRN7ZL?HHZ&M9;4:;#
M,&KRQD@'%+TUT40Z#13XDN0[^8:79P_>C<).3Y.L:Z:)"!_$UT &[W%4[]I_
M%Z;S;Q^F83P+:5FXOX,@[FRKB30V0]I1)'M,TH>:["J@7M/G[.V_7K_@?B>C
MM?K3-I9F'8YVX]O'-E]OH>5H'U3J*A"H7V*8X=__]#]02P,$%     @ )(!9
M4E9MG@'A;@  [N@$ !4   !T<F]V+3(P,C Q,C,Q7V1E9BYX;6SLO5MW6SF2
M)OH^OR)/]NM!)^Z76ET]RYE.U_*,*^WES*R:\\05  (VIRC235+.=/_Z$Z D
M6Z)$<6]R@Q?9W54NB9+V_A#Q 8@ XO(?__//B\EW'W&^&,^F?_U>_#O__CN<
MIED>3]_]]?O??WO!_/?_\S__Q__XC_^'L?_SX]M7WSV?I<L+G"Z_^VF.L,3\
MW1_CY?OO_IEQ\:_ORGQV\=T_9_-_C3\"8_^Y^J.?9A\^S<?OWB^_DUR*]9_.
M_P(6M-9%,!FB8#H;S[P-A2D>K)0:4'#[_[[[BT6=<DF628N%Z<(]BZ RXPF$
M,4%GF^/JH9/Q]%]_J?]$6.!W-+CI8O7M7[]_OUQ^^,L//_SQQQ___F><3_Y]
M-G_W@^1<_7#SV]]?__J?]W[_#[7Z;1%"^&'UT\^_NA@_](OT6/'#__G[JU_3
M>[P -IXNEC!-7UY K\_+SW]X&XWYX>J']*N+\5\6J[]_-4NP7*EGZQ"^V_@;
M]3MV\VNL?L2$9$K\^Y^+_/U__H_OOKN2',S3?#;!MUB^N_[R][<O[R,=3Y<_
MY/'%#]>_\P-,)H1X]83EIP_XU^\7XXL/$[SY[/T<RT;T-T.NH$R%\V_U:3_L
MC>D] 9FGRXB,/L5I)?B &!]Z^OZ8/S^+92QP.5D.B/C^LP?%.[N \9 "OO?H
M ="N'L0N\"+B?$BH=YY["^<-R'6$]9'+^>PCO,,I_GN:7?RPPG>SML(T_SQ=
MCI>?7D[+;'ZQFOS;X=8'$B;)A;R:UO_VZ/-NP20^C*?C^NDK^O;ZH171<(#Q
MSR5.,^;OOQOGOWX_Q@ 0 E=96JV#]4$G)6S.X'7Q*-VH*_2>$OX1)G4A_O4]
MXG*QBTCO/F (&3X":4UH.4D9M??:)J6M@P!1.9UYPF0DZ#3:"&X?*;V!.>GA
M/2['"3HL\EM$=O=I@\OO$;!KPK369AES<(A9>ZZ]52"S*9X'^J_#43?8/27[
MZY)LILKKQ:R\I@UDQ>>=B+CA24-(M O(-6FZP"U/WN7DK8[>!.DR.A4E?9")
MHZ,-SZQH;_!.9NG.*R;5[)E]7J<G$'&R^G1TN6#O #Y\>2@-$%_2EXN1USXI
M=(5Y6E68CL4SB$$Q)[@J"KPP+CVXRJ]6^ *+N%KFK]_P0Q7Y#SA9+FX^62F!
M<7%M.?W;9BA7JMA]<&_Q(TXO\079U#_-ILLYI.4_R=3^Z7*QG%W@_.<_T^2R
M6NG/%@ND_^3?X,]1-(&GG"T!=-5*SH)YK@P#6C"R"8YL;-EB]#M@O2N>+UQ]
M-K\1U/6NO>.V7GV10=FRG!U6/U<\H3%^_]ULGG'^U^_Y0)3Z9;;<A'JD:0LV
M)3EF%0E#NRH;C9DE67PD(8DD?4,&/0+MJ1!F*.G?YX<8B!^+D?"2K J>&%>.
M5QR"!<L+BZ0][YU4#EJR8/%4=-U/DO<U*O?5Z/56.WWW\Y\?R)O"Q;.X6-%N
M9%0HP:7"@H/(M'# 0&7ZR@B(SF8N<VFAXHV(SE[GP\CZ/@G4_M-Z@?3 ]\^F
M^3GQ<C+[4 =]C?++/I7^ZW(\Q_QR^F8^2[1E_31;+$?<QI00D+G(B;^E$'\#
M,=F3\6RUX]IEW68EV!GSX8DTD.;OK2&'45N#C>17G-"/WOV-W(HY3&@ S_(%
M::$*93G^B-=C&%F$) 5-+RV*8UIA9($;RYPR(ILDL3AH8JQW@O=4>-1 &8?8
MJ4;TVD+O-<PDDYD&:VGKI(%S0YXF!)YY:.+,W$/R5(BPGX@;;$R? ;V<)K)_
M7\T69# 9+;E7D8%SB=%VG!@8#DP9*V*4&4":IEK_@N7I6"0[RO>^RO6^*G\Y
M_8B+91WB%::7TR7.Z9-1P  Z2%ITO*;EIYC ?%2!92VM%)Q^)EP+O6\"=/;*
M'T32]QE@]F? %8Z;?2=%%W,@GU>E%.J9B&?1$SH/*F6MBBBEB86YAN,)Z'MW
MN=Y7L]U[;5^^Q_G: G0-[1<D U6Y) D!@UQW'F%I&5(TYD($3 X-MTXU6>8?
MA77V)!A0ZO<YX?;EQ._3.<)D_-^8_T:RJ=O1Z^ESG(\_K@S1Q8@\EI1X-"P4
M2-5K42SRD)AW9'UZ#$ZIV((46W"=/2N&E/M]6OA]:4',O&6@1!53%@8J1\EU
M%3XQ&JQE40BR5D$I<$W.'N^@.'N5[R[3^PH.^RKX#:D)YW/,ORYGZ5_/QQ_'
M&:=Y<07P\\!?7GRH'DZ2+AIM-5'02*8=6@8\"L;KL%V*9*@VT7\?D&=/CV8:
M>> P:>=KJWHU/7J.!"7?('R+DQIT^-OL1YR2U-,8)C_-IM?ABR\0EI=S?%WN
MCF[DHBV9_F&NGF=H'LGTE6"8] 5R0AN=7]M6[E^W#X3E;(ES#%T\P*6]3R;O
MK(O//L*8?F>"O\U^FEU<S*8KC.]G$WK9XD=8C-,(=-+1!<E4D;0U(F3FO0PL
M.0O"1."*A^:[T7:<9\NK0^CE 1[M?5SY,\RG9&$OWN#\U_<PQQ6J>E(_GES2
MI!AQI%732,6RDX9D 8&%F!,3Z($V75D$-(E#V8+K['DRI-P?X,7>1YK_Q!KK
MCOD9K8/P#G^YK-)Y75987U\N:QQXO;59ARV\ Y.D9LX5@NVT9) \,*EH[PTB
M@VT3MK0;W+-GT0&T] "Y]CX\_2R%W^KB.%(1C=?DL;ELR2Y#(UA(TI/;YK+F
M7 &X)E?X=V$,2(9;603-*;"'+!^Z,/WN*B;\+VDR6V"N%N0E?OEP-EWBG\N?
M)ZL7_O7[!;ZK7PQ&AY\F0"Y]6>V2S_X<+T9".)(!&5C>94$./3HB*E'6AU2T
M,:)NGDV9L8YH0)(\DM;Q"&EVT/(FPNPE[0:7[;?Q/%\MIYT0C=8R3(;DP7U(
M0VX9FW)D'E'_?CJ;-1'X8:A RR,63=YZQE"O]2.!TL"94,$4%P5M7?R<*7 G
M[>B(#.@CYP$UO_++?\7Y&!<_77G?RS&M='>][K^OK*N14=)H(0P+H8X8/&<Q
M*L^*A)H!827&M:OU#><@W=YW>"MQ7[7,VLITP(CN6Q"?;X-H<X <#;"L!6?:
M*J)\4JI&>O"@%&8.T$/MV][W%-0^J$S;S/:?MT'$;#(J+,P*'4@$VK.::,>B
M] 4#"@GK)U>/JGW;^YZ"V@>5Z8 Q<HOY<O1F/LN7:?EZ3E _CA.N]C!.G%,)
M+.'QFFE9) O<6X;>&0[!HPJVP^9.S[^UL=-WZYOZ)@!G;-8/(M,V.EX\F^9K
M1(MK8G<!U<.@[Z/P^V@.:\L/HZC[6A](R@.N[H^#LRI& 5HS6LI2O</U#&S(
MK"AGT(9@: Z<J>HWV/ 'U'P?X;9(O)I]@LGRT_4NPXM19#L6)F,$IHW2#*)W
MS-C,A9$EI74[?:"<B]LH#K>?#ZB9]0R*G<7:(/GR>ER?_0:,3J%DRI,1H<G@
M8E$)R;QR,H3@,GFF;5(?;J%X"CK>7:P;Y_%__+ FCU?T[2 I_[?O,7_^K\OQ
M\M-=,/U3_Q]XXM E +:!7B_M@5R@1[.J2<&+#"8KJXP.X%(Q3H^V/'OPD@ A
MI11B+HRV#.)$=LA\]H8F1T)I73&R\6'XJZ%* KR<ICG" I_CU?^^G-Z7W]O9
M9/)B-O\#YGFD2E*!7"+F0JBQ_K&&\ C'4A0E<Q>2SKE-:'4OG"=QG=B')?=#
MK]OII<5.5*\Y%R\7BTO,(_19T7\=@Y!-=9EIQ8PE, &Q>!\0/&]SB7@+Q.$)
MT%1CZSO4KN)ND9AY;Y0C!30FIY'%("W30=(VG+5E0=%L<-QPHYI$.&W:N9XL
M#?83_8!'#5<G7C#!Z\.SJQ@K,LO^"?,YT+[\"RZO2#L"X-+$Z)G(Y&1I&X!%
M;9!AX<';J*,O=INYTOUU3Y, C<0]8#[F.L)_P.02'X(YBN 3SR;5N!?'-#C#
M0BU0XCDGZ$GQ;+N%TG9YV]=!AV&$W2!5<X7N:MMZ?CD?3]^]P?EXEJ^HNDHT
M&BF>P,BHR-/*Q%=>T\NL#34*QWN46G%HDJ*]'=K3Y$XCU33(\MR <$7V*X#<
M WB)G%EG.=,:!/,A*-H+??32!K*-VMD=CR'[*JFSHV(:)(X^R__W\BIO>?';
M[%G.*]G#Y V,\\OI3_!AO(3)BNBUD'&FA;-F-Z[*";Y%DM1BO,3K,Z&KD;W%
M-'MWI<'5($=!%B^-DLP$VFFUE[3)8OU6<.02:.LM38C7>F!/F[<G18L!<V.O
MS(''UO,;D^#G/W&>QC2X41 T1850Q+22":K/#(H%EH7!((768KTHTR8KK-=[
MGR;!6BM@P(39QZ"N2'P?*4>+5HI4B^IKILN*U;PP8SG9!+Q$$SK&?/5Y[=?'
ME '$WR#Q]E%:O\7%<CY.R^L0EV=5+G^;UW1AK*6@C+.,D[_!=!;( FK+++?*
MT3H90GFX5'I+LWXCW*=)M@.J<,B<W2YFYF;4FH2!Z) 97>OC<I%9 -J#2S(V
M\LQE44UNOG="^U7R;D %#IG>NUJ:'\E#)HG4L=2"[J_+QBB_$=B8,&7-A.)D
M VJ/#%+D+%M);I $].@[[99[0WF:Y#J"FEHD_SZZ)G\9U)TA_(J)?G4YQL5(
MB>+16,&@Q@UK7PH+642F:H0*%Y[^IU'>WCZPGR8CCZ#2%FG'CZW67=!+R*8H
M!J!-384!!C6(-D;NB\H!M&B2([07ZJ^2CPT4VB)1^7-!F;6%.\62<E'(\JIZ
M:4Z2IDD!5E )8<DQ\K9)P=\->)XVA890P@/D:'4U<+74KG[XZX?)>+D8>04>
M@DDL>!HR 85*8,5*$#JKD)3EA[]=N@7P:=.GB9H>X-/.%P8K8_(M3JH@:"&D
M']?F3+_-R;!\<;FJWU!O5<>K,^.1\(HV8JN9!4[^L/' @LV>F6RB\HEV;+,U
M[K+/"Y\F-YJ)_ %>[%UM\FX)/)Z]@R DB[XV$$U 7X5D6%:.2YE <]5DZSER
M6<%#KAB["_P!]>]=5?)6B,6=^B[7D7@OI[_-8;J 5.4_LN#(*I*T"1I#:UAR
M@GD5JB4OHQ&T(>;0Q@+N ?)IDZ>9NA[@UO[GZK>CN:8+,K/FUU>-"<<?,;^^
M@Q:22$F2^2UJC57M:"9XJ3QSA;L247!=6I-K.\JOAET#*^R!N,S]LOJ[7'3?
MJHKW!N8KI_#+GXUHJ]51>L]X(,=/6U%8K'VU04N40CEIM>ADZ^P-Y6F2Z@AJ
M>H!EP\2"/VK@O_ZPZM+YY3I3H><@R9I3,F=:=R,PDA@P UR@,9[6Y"95V_M#
M?9K,.Y#J'F!;JS/SU:1X&+%W12<DK\'4SE5:>EJ%+5IF@S!1&P4*#GD+O1GI
M5\FU@13W -7V/PR_G7!CHZ3WEL*0J\ATI3PQ'9D$C$GS$G2;<N*;\YN&R=K1
M/@C%'0U+D(E2DXE U>(9&04AL@E2NR/[1[)V=AG<G5H>TI"1I;EE"I'(PWUF
M'C$S7HH6+DA-;&V:K7GLHI;[)"+N(<N3*VIYQ:X:R#F;5BMK5?E!@\S2@V/%
M8]W%DF+>Y,2,#5#SBVES:Q0@\@BJ$ZF"TTO;FXBSM]0;)"VN8;HN&M %5,L:
MEP^B.G*9R_VUMUYN>S#1'XP7P7K(H!0SSM0,6Z.9)[S,60S9.5I*?9,EXH!\
MZ%KS\D!TZ"/Q!C1XL%(;D%TD=) L = HJZ44ZU:J2RD2,<32)C/M-$KC#:"G
M1QO&["#D!G4,;AVO7 ,*02K@=?>TG/P<'LC)3::0?0PI.%^2:-/4_!Z2IZ#R
M_<3;8*)O.&6[!B>L$UE[<C-=!6=KBU-$8")901:U5R2'-FE=CZ!Z"CP83NR#
MUS"X2NBZ.L2O-O -)@^BZ&)8=K4U<DSD\]-2Q+@+7!0PRL=N8;P;7G#.6AU,
M< WZ0;_%)0T+\TV3EVM4T2F3 1(3&C73!FO+8OK'>/)WM$?'V\0!/0SGG)4_
MH*";%!S85*L]8E A\QJC)L35F4BHR2U>\QI@1!\:T8(!I][/8A"7?R]I#[BD
M?[8[[M=U[H+HZ^YGT4MGV[L9["+PP_2S,)%,39$# UXSC#39&X%[QW)1#J6
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M:ZQ#S"";5"Z_@^*8YN6^"IH-)=T&5N4_8'*Y<N9^P_1^.OZO2UPQ&Y/1*JG
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MKGBF=<B,G&;)BM'1VZ@*0A,?=*@!/#G>'46S#0X_-@+[!9<C5#ZB<8XE[:N
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M2DP8.ODY&UYP>)MS -G/!A;<QF"9@1.Z[@>AW71ZNUN\=-@(OL??T2B,K\?
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M4\67Q!MW[SB7"->]C)'!5'"P2MU=0'V+<.VKO6X1KCN(_F 1KIJ'D!5&1K-
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MQ@>3X+:_LD4"'*(,OJC,3%*UJ:%2S%O-F;0\0#WR4JE-U=>C)\"E&$R6-%2
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MC" $ZB)<;&-$#36"0R4F'IOG1]'XJ>0\OIG M(:$7#6]$0')9_&UQ;*N9\K
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M,]Z$W*1;UEZ*SG%U,;0 'XPT&8+[ X_)?EW+6O+J+URMO]9LH,T^0&D9][*
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M[_U-R/SOGLK6#][?UMG?TR<*P+^7#[U>/SYGZ=U]X4$?!H=_S?Z5QA0AI (
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M=:(/GMU9$TYOG#!AHH^F^[D2O=XPA"?LBRF]_DG]FE>MR1:^C"56,091XL<
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MG$0)X3Q(A')JK71NH+E=EFSE]&X?'[,UY??E3?A6:N];);=CZX6S.-N=289
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M[S+YCXU<\>?;'VF^\.,H"F*>@,0W?;D2/P0XB@2(H$HDY=PGQ*EJF<68<V.
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MV6L/;GE5 FN7$QBHA!(5&!O+AZ9X*@2,(@@H\84(_%B?W)R*3IT?:FXTV#J
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MG6V:!"J)<<( Q)!K\U0@P+3!"F@0,QY &*+ B4KLAYX;LS02>L^I7%HZ(GH
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MTVYI+S,_1_OB"XG1MU7F2K\YUP-_4JU"L^_S7._HP8(E,A:^(OI CSA /@L
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M"_<R7#L4IF>9>; !>MQZM@Q1_?Z_49.G4.2U@:*4U-8B#  ,*0<HC$T7&2R
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M<$@R#D_V-%E612K2Y<9<G_UBXA3*4(:/^EOT9FV*%"Y03#DB(@ ()OJ (D@
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M%S,!XEA;VP].M^Z2SOZD!6!;2+TIO3"!L-9A8S:)&%=/U?\8 :_#QB-8].M
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MHF"K:1N Z;DHN8BJXV(D!%:Q%R'G8(K@,[^*1=!%QT5AXRXVKME\LLBX>L.
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M?K%8_6[= G=):UAR:%D4EAR,:TB"]%=B5&X<C-$Q+0Y_T. CZ/MKQW9:94)
ME .>%[;C?:G,:M'&I^68ECI5&2Z9YQ'T-9E38[WV5.\^Z!'T5>"=CZ!#PCG.
M$70ODL./H*]"ZGT$'1+:<8^@;X1XR!&T*U@.1]!7'S7V$;2K;6>.H)UO'7P$
M?;Z\_S\KI9\7O\ZUFFG;N8AD$E A"H YAH"E+ /FARQ% M(\]XHQ=I Y-0Y_
M5VWFC_4Q\W.M8[*8?_=N&N( M?/Q<4@ XQ\9[[<$.>P(<I<T.B=6Z:"GQ*X(
M!3X9OBIV[--@5QS.G  [WSK<[:C4X3:^^JI^;'XV)OS7+)6HX)G0 -$B:^IZ
M,9EG(.50EK9C6@J]W8N7Q4V-<1KU_+V'/8"Z>PG#P#2"-U"I$V^@34$WVB:U
MNH$=?M=Q">W8ZY$XN@/ONO7G''4.=PVCCU_8O"D=^W9>B<7*'HQ46[</(456
M(I("E-O0$")2P#G3AD9R*8L2"Y9YI3WT"9L:=5A=VRK*>]JZ^'?\<7;CE%#H
M16:4X<!YLXD+(B&YI%?>J$SB8ODQCSC=,\")5;O%/NJV..G']>?YMX?-ORO[
M7R7OS;:+?5/O?JBUF%=F\S47:GMMU5Z\^Q(8)4+CL@2$<NOMEQ10 DM0<,$Q
M1YEDVBD8+;1B4V.GS@K0FI%T=B2U(38DJ@F'\G#@A!Q'!\?9*XU.9/:KK;*'
M!JVNYC-*:F63SK3DPI#M[JFV-_G/-\%'TL-?]THC.I)3[\,JD4K/EW4I_H1]
M9_.%K0$4R'T7 ;M>'U](>>,Y B.@=. MC/'\@<'<XD')9UL"_-WCTV+UHM07
MM?YN))[/>;8'D\VQU$=MN[1_6\[_1\DF*++.\&B*J%&,6,IQ#LS:7=@F10K0
MD@G 6:8+PI$0I=>"/HJ64YMKK^;^M_FHLG;*M<TYK&%W25LI9%!!O#AO@-M6
MX]7'-?896/0A]8\FCPEYT&#S*(J.&XL>$^N34/6HPH:F"K%-_:9;?_3FQ<I?
M+6W@5QURS3#63&<94 IK&\ZN +.5")6&*(<E+)1V*B7F)&UJ;-_HF.R4'!3.
MW@^P(PF'@BTRF7HC-B#3Q@&)L DU?0)'SIMQL/TT/<;EI@&^GI\73/R7831C
M0/7QR;*470;/E]_^H38/*]G&>'"2\PQ) ;2&W"PS-05F;<D H1F"2@DH,7;V
MXCB)G!J+U$HGK=9)HW;2ZITTBGOLY]U0=_"Y!,<R,K4XP#@D5,D-3P_/1W!<
M1_)I?%9/YG$U9]NT_]H,T,&]:N!^:N%^;.#^_6$N'I)Y96,XI,U8KUNY-L&O
M*YT8'IE_-__ZKI+YTNR$:RNJOP;RDGCAW.O_<'O2>)X-+\L.?!9^=PX-V^>;
M]]OA_&#>J+>K1S9?SK0J<(XD 07CW!;3P( +18 FHD18I[RDN5]T_GE!4^-W
MJV>R4_0NL:HFOS7*>JX5+X+KMDP, 5ED&A^(UH! ^7XHPL;#7Y U<MA[O\6G
MT>U7KA_(#]L3Q8]Z?S/[N2DK4^];Z^UN[7+ILHRV9PQ%)@E1EC84R0!.TQQ0
M5&J0IDQAH;E$I1^+W*3.U+CFBK-J<$C"C8/FR$ZC#<7KN@SC)/X$ 2\HZ]VF
MT;C<& 2]$P8-\]1 Z9--[1<D<JHU): L;)Q6+CDH4XH!@DAK0Z*0(SG;K#9L
MX;H*.R?&BQ>WPN)]D5^M#'LF>YP.>6,VI$\]G=N1BK[T.I/7&+@03C\(49,0
M7Z&03;^U5],);RE$8WO/_F.^G#\^/[8^BASFFF2Y IG&"F!49J#,I !$"9X5
ME*>$.F65G#QY:HN@5CGWILV'./5_S3=9'_D#;O4*W+'YK+6W-FP^?.AH_9K/
MVK+?KOG\!4/2=7<]V>M RG.-V6>,,&HF)0FDA@Q@49A5(S>;&8FAEAED)8>R
MZT?ZU35GUT&PTSM[V)7TZQB[%Z/Z21$]>ZK^>ZOZ7;)LTNR[YJ4^.:<N ^+@
M%P^&[TA[$8OI1]VU6ZY5ODL:I1.C]3:0L"YA$!I/GPS>P+B.E;\;!E_/!%X/
MK/K3=UT>-&+RKH==AZF[/C<.8/.3I9GYRQOS[_GFH-/C9U4I\^ '([@NW#HC
M948+!2' J>( :UN[2Z9FS86$-.BD64;<.ZT-5&)JR[-.OYK9I?JN%JLZS3$1
MM2W[#:GM/JW]J0<S#1TL!_(?80A>8Y-G_]Z8<=1<]F"L:E-&& >/26.$\7B=
MXU76A YR94PP_]H&>MG%S^X0E74UAJKF//7$O9&PS68]Y\\;&PAF*[9+)9]%
M4V1BW8WM[BM+Q,'HVT$W]S3?XMZ=%V]8KC9)I9[8VJP8%R^);/Q?2H8ZT[UQ
MN'NGPJ'/'F]VO-'Z@PGSUF>%Z&+\ZYSQ^<+&'#4UDV:%><=$FD&00VRV0Q(5
MH"S-[DASCDF:TQ*7-_0Q/A8WM7EQEU;=E+-<M/KV5?,?@K*BA! J<U#4W5^9
M1M8/Q('*!&,<9_:,?O9=K?EJ?)SWQ<9#NJO'MAH)<3?_<#@4(R\A3JJ!;G7=
MEKJ+U4[Z$BKQ&DJ?2'S%EM*7K.]O*GWQKI!]4?>.-W]^V5W2GFG59=4_K)9-
MS%$3:+H++:@^/F^J#:O[QGQX;JK8R1)GBC+ 4($ IJ4 I>0<:"8S2G))2P1G
M3TT=]PU;;]QX:@S5?;[38P/B?;(_JV_SY=)^LIPMZEX5PWM.C#'^!4.9-"\
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M&CL9BS'GLU/A_J=7;]MHJJ^&\ZJY%?)9/:W6FYD@19$K!(%2-AE,"@X8PBF
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MYJ#9B(<2QDTF/&O=22[@^:L&A'2?#3)H:F?_W?Y$R1EGA!>9R(& >0IPIG)
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M.F63WQI5/4\G>B%VFQ=" 1>9RP=A-J 2TG4PPI8^ZI$W<JVCZY:?%C=RN&>
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M_PD6Z=^:7T%ZEYAGV532^7>U>/%M;W@TS&[>H%N&+CK7U&/6=BW\MV:<WM=
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M B120B N2D0*'V_BJ8AI.A*K/3W__*<20?*W.FK#MU+!&4@+24N"L@((*BC
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MA6/:<;C3C8>JU5HWSC?,U/QH+)SJP_*)S!93'&>RY D"A"2Q6G.6)<!<E(!
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MRA1A +E, 2:4 TF3C!0(4HB=*EX=-C^V]][40-#B]5SY'(%G]Y[WAR3P^^V
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ML+O>WS,W35-';2:J7<K=O;/I-(-% KGF*))ILS#1'(5R0'"225AD.<*YR[9
M=W=CVQVH-UU:,CNFJ.G&UHZ/_"$6F(7V_O&:?WY9+N1)K<Z9CD-J)2+?Z^$Q
MJXT57EZSVW3W.&R6&ROM3[+=V-W5T^>TKA?>ZN/]9K521#9-><Y25.8@E7HK
MES "L,Q24*C%:);S)$6)DV_9Q9[&9O%L2ZC/^S++94Q)!E-2)"6 -!< <IX"
M2JA4$*=90DM2LMQI']</IH-Q-0F'K!U=>\$K,%-O'[\#6F[$].C0>PT)KRZ]
M%SL;UJGWFLXG;KU7;W!/@&$R&7Y]7"Y$G7%CRF**8YKG@$JB]V@) A1#J(BA
M8"0FF?J'V^:\.&Y\;-1:)^@T C8):NSS6IP U_W*WPI'X+?< 0FG=!675+XA
M0\5)DX,EI;BD3#L/Q<5K^N8RWA:SOE]4ZY6IR5ZI!=[_$?S[;/']3M?6-4RP
MM\!VI2UYCF%.U)M<Y"D&,*$(8"0DX(50JS%(<8F='&)ND&5L+_Y>E:BEBUF+
M--I$>W4.XG9[5I.^91SM;(F!1B<P#X4<F!XYE6^&U&^*Y?[B#)QQ^6;<3A,P
MW]ZD&P.O5\N7Z=?5+O'SDOW7^^7B19&3#KNF\]EW$X"]S5/V;45TTIH/Y+6:
MEJPL\TS7.\VA]CJ2&4"T+ !-*<]X2C&R,Z'ZBS VOMUG_UO70D9<2:E# W]_
MG+%'4_RY>A9L)F=JJ?&RG*L!/DXD%#UMJG5$A6E"7:5]</1]Q^F%UDM]$=FL
ME[K:K4X+^:K:T;"MA>4YZPUCWTW6PXQH\!.$?:I[#?A>@VBO0BOA8Z-%I-4(
MCC]?,D,.YH(W'H<#6<*-QX-XKC-"5.9]6)Q_UWB=Z*E^WTCK;2--':NNMZYY
MY=3[:JBSW[OWY]MGYMO'K9Z0=3MFFDW29I*]H>5!YM;;-=].J1Y:ZC&3?JS6
M,_5,B'VMQEW&SZD0-,^0)*"$4N<V3R! LJ"@9%+&!>8BXU9I-J]U-+99<2=J
M)/4QQXLYYC"$N7Q1;Z1:BA^\B;?4++PZ!A;SEB=D \].>U!;9T?[E,2>X'*8
M9CS!]C:3B;CPB#;Y&WU1N@5&G<3==?]P]&RAQ0$)VUS?@VIKOQA=I6:_4?Q9
MJ"^%J4NQ]W$I,R+R,F5 BH( R&($$&,(\)C$,)6RD'814TZ]CHV$?]T\/\]-
M3 J91^_(W.0P_?51B'5TOU!VSI-YX1QHPQI^"\H- 6KH\R(C<G2W.#HRJL5N
M"M-8^17= *T#/8> >""N]@>U&UN[0M9)W=:-#<?CKOH=D+KSS3WC8-FCX)M=
M)<5WKR:BKBYKA6C"",DR@ LF !1%!E!19D#1.B5E0C$MK/:?+/H:'9LWHN[C
M/.EK5$=^]BH<U@6SW;Z\)_ "L_8-N+E'REY'Q&NL;$=WPT;+7M?[)%[6XI:>
M_'&M9O25DM';@M"[@M'&I>9^L5[-%M6,&6MV&O.4F(R@"&$)()8"$(0I(#%B
MN2 L+J35PGY(H<?&:#OIZL77)!*-$HXQ0X,,N"4ECFP80W.KU@50K4S45CAJ
M::SIMGU=HW5DU)Y$C>*3:*>ZWHO=)NW?/R)&=8],/>! >:7\(>0>=NX8<"1.
M)J$A^^XWFS6[)MKL-A6AJB^;=;4FIH[(SX+HXV MU?WB>;.>EK+ &8'**,XE
MTHF;&J]76F+"$!8\<2NEZ=+YV&:7EGR*492 ;I.*$^YVDT,H- .3_%;L.H[4
M"!ZU))]$;:3O.Y%VIND^D/FD6Z?^!Z7-/L@<TU^O-F[U]OL\6XC[M7BJIEG!
MDPSE.E-"20 DF?J4X1SD,BO3/&=)1IRR;9_I8VRDU'("VX<%S?9^/WU=[_:@
MVE'1C5 %9IP62K]I^2(C8!#WMQ/UP[BU[;MY(W>U$STONZ&=7MHW<Y5ZHV9/
MM6'T?EFMJU^6Z[NY'AVUR&_J5^<BY5FL:\JE"0.0R5QQ@$B!^L,3FI9YG#D5
M4[+I=&RDT,B\6_08L2,E=[03O&>Q<*LAL&,,W\ &IA OF/9(W&0/DM\L3A;]
M#IS2R1Z)T_Q.#O?V-4>>5T)-ON80+<>4<@JA=F6%NMB//E3 %#"N<_YPGN:%
M8S3!OO&Q<4U;-F/0DZ?E:MV48W*U/EH8VIH=_9 );F_LQ?)I9)PJZ]>Z:+4_
ML%EQJMFI/7'FFKY5K.\X5^-=-?]H R69H@+JMU. ,E5K!B@Q :1(<B#R/"]B
M6,;"[BBPLY>QO;ZUH%$CXF3[(3)6\I?%Y0U2!V"[7V5O< 5^IWLCU:-F=0<2
M-]>K/M?VP+6J.]0[K5/==?&-&7 ?A!;9U %3I**^>+\2?+:NIIBFL<PQ!QG"
ML5Y$4$!1C('D#",9HQ23;+H0W[5#VK<>*7$O=6SUN./Z<3_I/MRCK[.3LEK"
MGME;+R)MNU;P =Q /"&E8$U4WBZWZX,:JNA0^(GYH99?L<F3+L\=(./K-<2"
MY'Z]V.G;9(&]AL'%?+!7;^SA<OJKKEG,A+)EQ.S%.,?DI" PDR;]OC(\LC@%
MA!48Z&(]>9GP(L4N;'.^EY%22R-GM!?4)>[I%$L<9XRD. 44BA1 075\!!$@
MEF4BTC3CI<BM_73[@3BD"]<)>C>!UTW&MT,2F'D]H^'@&'L3*@-YP/Z\7(@U
M6;WN Q/D9JW#P9GJ4,>?1>N5/CRH:EVJ)D"MUJD.:%-DN-!SFUKI_SY;/T:S
MJMH8'_"C0+C)2;";WAAHXB \I(?MQKS3A?;TKN%\92]*?. 4>_FJWM;N2I!*
M?!#UO_<+4P#WR[-8J2=N\;UVPIU"AGF9R!+07.;Z["P%.!,8%)2568D8D5AN
M)R%K:]>BXQ[S4F!2K6LSDQX94RVAMK9Y?<$W6"D#(VCTTU;D/VG2J.'<B7TM
M%6T?2]<!)\_FKDW/0]N\#FB<,7Q=[NZ[^_;Q2:QT*HI_7RU_7S]J3RFR>)VF
M+%,<DQ9 %*5:=',4 TJP/L+GB5IW*^,-IV[[;V?[&9L-U^PK;66-:F&C1EK7
M_;?ST-KNP-T,V#![<*Y8]=B!ZT3BYCVX\ZT/O O7J>+I/ESWY7TKU"GC\%Y9
MD8)_,#D7ZB,ZX^9H?CMRB^33/,9$F2D0"%RH]1V":JU,& ,)IPE4WU/+]5UO
M"<9&'_<7;/!H\ZP^;AW@]:_UU\M:']>:=Z[C9&?C!$4_]&K3P%D+']72[YP#
M_E:'']27-#KL_-$O!R/T**37$S^_!?9<A1BX\%Y/C$X+\O5MJ&?]J#H9S$PM
M 0]3D#0E[5-1"$J2#$CM8 #C)%$K-HD *Q%A'&(IJ70JYMW=W]B(3ZV3=5Z[
MNZ@E=W24;\FQ5- 5P.TXS2.,@1FL [CHMUI:GT6[[7#Q6JWG2I?#UN.QT_^D
MXH[E;?TXYJ^+C3(?YE]6]PNY$O_8:.?LM7BJ@W9I&<<D4PLR+*$$,*4)((*H
M3Y*77."\3)'5@LRFL[&Q2R.K C/:2VO<AB?ZNW=+M>SH%27=B;@=P_C",3"]
M^(#0F65LL/%),9W]#<HO-IH?DXO5/7T=(FNNNE3 51"1EEG&@228 @BS&!"9
ME2#->,IE@A.J:U38UU.XTI\3OPQ658%O)]V?:%/S5:W8C-BNGI/=8-OQBD<(
M U/+5M)HF/*YEL#X]<7L[G)@]TPK_4\]-NUNZ^%$43>A@YWV^1@_":+/,S\M
M5]L]D2_RHO4TY1(CF=,<0&%J-Y0,()Q((%F684((S6*K.!$_XHS-_/D@Q)-Z
MO?CL9<;%@NM3X.7WQ>R_U7?+141WZC892^M"W[7"E<F+4B_.WG<MSG;'QPZG
M]+>/>S<5#C^:@9ERKTL[]W"C3?1)VV;;#<0O\O:EM*^7T][U8M#!&LA5(_R@
MN;E:>,.XTS7C]EZ&<^7PALB!ZX>_5F\(L%R0^8-X$8N-:#Q1[A]^;3; 2D8*
M+B4#.-4GM%3[B)1$ITU+$LS5B!;(/;;R<G]CFQ0_"04EF?>(F.S U,XT]XA4
MX EG*VG4B!IMO?)^4M+^*<"^HB4TWJ,C.[H</C#RNOYG8R(M;NM9FU+GM/FF
M[KW[,:NF"4ER+ID <2&4P5WD$E".D/HOY20194EEX52/LMWZV%C""!=IZ:+?
MM'R.^X.'R-FQ0V\\ G.!/13N11#/J>RU\.%!!\,6.SRGVTF!P[,7#9S@4-?.
M7K^VR@P9=[%OCV31G(7^HBV5:BWXWX7.!R/X75U!X]^U)_ 'LA:[=-X/R_E<
M&3FZU2D795RP! &":*KX@B8 E2D%*.5E*2E4-@@:)!=B&/W&QEA;V?_YGY(B
M_DNC0614B+0.[>H 7\6JOLP -E!:Q4"/F1VYCDSJ$=&[AV2--48']>MJ?^&U
M@FF?RG&'U"3:8A5U/Z<A:MR-]$D813;(0"K^,1)'AAU?;SDF XLY-MOC;T:5
M@T2:._FG/,4%C5$,&*4ZL662 0P9!H7,L(QSGJ?$+>_[FZ@Q-DOBTT'AF_I9
MBHA6T]7A]&V>BK>V"'R-]?^8B;\&I)W >3_'_Q$F=IL!_6/,WYV:_ ^9IFU&
M:[C9V$H:MTFW6JVG/Y,?LZ?-T]:)F.=E0G32(\1S #G) (EE#I*$D8QF2<DI
MM9D'3UH>V]34"&<W#9WBU#TSW*1]8+)NY/*X\WY1VPXF4_>T6$S][YC!3AL=
MA%0NZK)]SR]?T,_>/3RP,]10W6W6C\N5]JZ8)EQF+)$"Y(0HNY3E%&#,)> Q
M)P(37""2N-BEW=V-[27='U\W>01,W<Y*5\EM)#:5/>MO+<MY6@)O9_KY@S/P
M6W_D"#"I;;$JV@OKSWRR \6GF7.EQT'-$3OMC\T&R[MN6%/3ZS8)=;9)[KY_
M7YDD#(<E*78;!]-4II@5*0*)2#F 5"=CQPB"%#*:)Q0E+'.*&7@[5<;&C2?%
MC9;[W/H]%M=O\W@X++!'/^C_8Q;9.U".JR.U-MX]+[;?='"]+[C?1IOA%]UO
M.FIG%]YO*]%MD3'?R(\ZGXKZL/VN\9 _T&C!&X?YZOQ>@TYH/N4D+['.>P?+
M5/VEU@P QW$)4)HG<5[RM"B<CLQ#"#FV&=687@USLI:L_6)OO ZGW3SYUH,4
M> ;<1?GH\)Y:P3IIZNZ'1LG)X02ID\UM%9U$%^=1K:W_&*$08Q$BL,BKG&\2
MC10"Z4LA3$'Z\AJR77V856R^U"6V]K7=4Y%GI4@20%,D 4Q@ @@4 J1,H@QR
MDJ;4J:BL0]]C(_OW7_YV_P$DV$NT]EFP[3@[$(2!J?AR+'>U"^:>1'L=HM^T
M%I%1(WQT=Q=X P1[G^U^#+'?7;A8AH)W-M&/P![$FLP6BC_):C%;?*^:$Q88
M9]HC P-)"\55/$L!(AD!&1:",DQR];,+5YWO9FRT=,?8YFDSUVE-M5DS8S/'
MLJ(7T+0CH]LQ"LP[6P&CK80! DBZ0?#)'Q=Z&I0JNK4]9H4K5_L[ FL5"IT*
M1'&9QS% .@L^3"$"F"0E2/,TR<M8%KEPLEJN]#<V2KAT"-;:[_5["M;&OO\Q
M6$]$W^@<[(O%YKF7@[ SL(0^"6MW^>9'86?TMSD+.W=;/[;9^<R\>VV5(%8K
MLUEE0JP00PSF!0>X@$2MD7(":,P+(-,\+PN!<PB=3MRO]#<VMFG7VC9"]HI:
MNP:R':UXA"ZT4XTK:LY<8HF%3RZYUN6@7&*I_S&7V-[6CTMVM9WV%8*4Y?Y^
MN5C/%AM%54VB].6BFA8"92;2-<M3INLI"("2L@2"<A2CG,M<)"[YK>R[=F*8
M 5)=?5TM7V9UAICE*IK5&9O6Y(=MI9\>X-O131A( S./?7FQKT)UZ;.FF#M>
M/MG)H?=!B<H=E6/.ZM'"C:90O9=]M^"?9X2J)V8]$U5#E_S+0CU(FY5.<*PN
M^&6Y6&W_:UCT\[:8^Y13DK""29"F'*IE6I8!C-1?21SGJ"0RB=VJ''N5;FQF
M5BLRYFD_+SDRH-_Q<[3)AAZ5P#RZCR.9-&>+YMRPI5RTU4ZG/-OI9ZYJ:[BU
M_[22]8YX""O0)_I!;$8O KZ-A>D3VXOVJ-=.^M'_+V+]GE2/QA[C@K][_6NE
MXTONC5N+[EM/0D:P:5'P1.0TU<$@:E&<,P1H$7-%]24F:2HAS*6+]6K?]=BL
M5R5YQ)3HT::J ]%F6YDCLA/:C<8=QL&.H\.@&YB -;!:ZF@KMG9F_.FO-<I_
MBG;"1W?787;F57?$?)*F0^^#,J([*L=TUZ.%@5W<&Q^_UO[B4;#[@W@B,WW8
MH0UPG4%B0^;?Q.HIG<H,09E1!C!-!("E8  1B$"<%L823E'NE/[N#708FUF\
MR^9!FFP>JZWD.K.L$3U2<CR]A;?[#4^*'6V/?/P#\[\'__:=!WL+B3,98G9H
M1"TX(HW'"+S:;Q_+4;BSWZ#&'\./_?9Q\N; [D&4GI,N>Q1\,Q=?Y-6H]^I2
MV'M=Z 1G'"*1)H"A5 (84ZC6%[  ..8)A1@QZA@FYDNRL4V06\5,4G4+QJPZ
M*;-?R1I_PVXY+[[%8(:>[88=1_?YRS?F7F<E;\(-.]?XQO1D!O'>0;]YX;.H
MJN6^2O1G73JZZ:/ZMGRGYB-=RU[P;^JA$/\IR$JG!,X@PJ4$&*44P+20.I4X
M FDN),I8$C.!M^7FO]G/ ^Z26''$8?WY;P/POGH3,C>6[C$(=G0<"--A>+<6
M?M*J/V_DG^SX=+V,J#D[-3I,(JU 9%3Q1Z[]$?3)HCVD&)0N^Z-TS(LWM-2C
M%I'VD%]N%NNEW%9H6,KWIA*S\6<[]&Y3]OK?B:;E=267J_>JS1E3QOEJ1N:?
M-L:6U[?.UEK6:8ZS'!;*2I891CJ90@%HJ=,J9 5B'&%E*A/K&D7!Q!R;R;Q5
M5)M:LPO5L2?1\Z&7K3G6^[U1V3BJL$;I:*VUCF2MMFFEUMNA(DZX1Z2;PL<S
M\(%IOCWF[8KHM9Y;W]_C E1ZS/_>'O.MOI%1.&HTCMZ/:\P=JB.-8NP'JIKT
MYL^ 6U&EX$/366PI7._#%6$*CN!!<:;PO05*H'QQZ;<O(;'@7]6K](MZN3XL
M]=;A-$]9P@52-J3.) $QH4#]80#+LL0E+\J8.X7@A!!R;'9'N]I)+:'K/EN(
MD70XBGK#\0EL'K@,C?_LP3=@-VANX#YRCBOS[PU(.^?UO:6O'JO,BS7_?EWK
M/2GC8_95K(Q(TR0I829B# J&!( <Z5CJ! $)A9 933$GTGKAZ-+SV#BY%K%Q
MO-5!DWPYGZOU?O0L5G4 I67\I/L86*S,0B$;F$T["HY.H@;Q7;6@^A C%,@.
M2Z%08 ^TNO$)NMM"I0]PG6L/IP:'6T[TT?-@A="K@1Y3P6'C^U*Q7^A\]KU)
M,[1;E[R?+RNUW/B5S$7U=35CXI>-#N'_(K^MB%Z'?""OU91  3E,(.",41T#
M6P":QE19_X3+&#(>(_OYPKMX8YM4:A'K+<5%)=C&A&.M:X$CKB36?L*_/\[8
M8[1^%!&K=8R>M7[Z-OVE8HS9^O5?JH-MR>AI4ZTC\8\FU8[XP83VC8NJ9\%F
M<J8^UVVHYLW38C8L=&O'NYGUJ0;9K)7=L=9+S_EK4ZJ]*Y?G$(^:Q;3XI@]0
MX+GS>/NI5=][K][!EE74:!@9%2.C8[1_!!LU(ZWGFPZLPU3\I@,\T'S](-0[
M61E/#OV"+JYS!M^8<")_O*$O)\_/<_7^:ZO!!W7\V9--$>P)Z#0\_/<ZG'42
M#+$#$R9<+P-7AVM\)#_^$"LVJ_3S?^0CV?PBC.!36I"",\H @6D.H* 88)+'
M@..<*G.(09PX)0$92.ZQ649-N2Y]IB+V&MRT\![Z2?"T7SK\^(9V8/3HKM_2
M_HR[_A:!VM09096W?F,VBK)NCJ*/:S?7[WAX*]S6L_L>"_W[!5MIWZ4/HO[W
M?G'HT_2@N_TB_UK5T<53)EB,1 Y!P1,&8"$8H'F< HJY6N#3,HU)[.!4V4>&
MD;I3[MW_YEKH:*6E!DL)-NH_Q(1F.RR>7,?%8LT; N9A)H:MY-%/6]EU\.ZI
MPZ71 'R10.E09UP(B+C#8C0@\@,M-0.,@-MJKB>$G6LUUS:'6XGUU/9@G=6W
MC7ZK*%/@I.5 1A+$B@)"H"8,I#/W0("QH""5F"'!),E3IU3+1^V/;57R64W#
MBVJ;NX7/JO5J1C?&>#7S0.7LU'D)6+O%PPUP!>;RNCJ43U>W*SK[-)*/NQC4
MF+V@W['1>>FR'L;AGC"65?6>K%:O<KDRI=9_W=#_)]CZV_+CC^=9G3EL6F8H
MSE(A@20*.<A1#$C!*>"B2"7!&,8LMS[A<>IZ;&SPRY?/:@E:U8+JW4ZQ$]7!
M('%#W\( #(9I:,K86QE*\.A \DG4R!Y]6T8?P\/L8/4%@WL@F\\G[&[&7B_D
M.DT]MQ:',_1Z:7I@YO5KH6]6_=F+6DY_G:L'1C^ 32&((L_*1"0I*,I4$3^A
M!) LSP$O4D%%7L:)$&[)],]U,S:2;Z2,=F*Z9LD_BZ6=>7<[0L'/H(_ "5!4
MHQL$OQGPS_8T<.+[+FU/\]UW7MUSC;?Z3A:S_V[.Z!;5<C[CVYID7^N3://?
M+_+3;$$6;$;FQBW)N++>T<KD"9DRF)6\) 7 @A, 69D A*0R$S,8)[E,J<E:
M[; R]"'5V,BEK90N/=A2RZPPVXKI8_N=:M%>M^BWK7:.00)^QMERH3KTZ(6V
M50<:./?5L4^@O:ZIO0@V[$K<)Y8GZW>OC?<L0O"/S>RY995 4B24E1R0&.<
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M"1:R$#&3TY:'.Z_NIF&W0KQGF^$=0/!= &AC.5^&-7Y>++]/O!>..^>!.>-
M"7+D?3$>DM5%A,(C3\,9GFM+[P:79YO9/5S,7:#DUQ-<?B8S^=?EXH_UEY>+
MDZ]A_GV2E"@>90&K6*U!E0B16PT2M2C%2*[*$/'3 R3LAIIGF]D]7NQ=H.?C
M29C-?CE=3>>X6DV8DMS9K&O9#YE('R-$%3F@5UBX2":4(1X-W+'T;FAYMMG<
MP\4\,DK>I+)\<9JG]!LOUFM<;77R>A8^3S+!6[(4P&5)T5\*#)Q/ EP*)C#K
M,0Y2[' _!;MAYAFF> <2>A\&Y@O.9N?F,2;OO(P",C(%RC RCS&3'\:T\#;%
MDMD0;PINK[P;5)YATO=((7<!D?>G<39-KV>+L)Z8>GI*]% V:0)F"LG!)$!G
M;4&6N+ X&$*N++P;0)YAXO<X$7>!#P+V2:T:7*1_?/Q"XER].UW7=[CU:?-$
M<._HT,P@>*&SU)0$3BI1*W@49[01)!_.T7V(DMT0]&QSP(,IH0](D;"68?9F
MGO'/_X7?)_7H]*)0P(>6_/92-)VHQD I03)B(#,^7.'FC<5W \ZS300?(^I.
M7BY=/K]Z3=]9341F++-D@8LJ$&G(?Y><,*]-"$%Y%G"(JO%[EM\-+\\P_3N$
MN+M"S/:9YY8)EZ2T-GK0& ,H90UY901[+51V'*,=)EJZEX#=GM0^PYSO,"(?
M&3<OB(.\X:(&>6A1;9X!6S2UE8JMX9Z2X'W*P@IKG!_"";ZVZ&[X>(9)WL-%
M.Q@F_OWG6T)]2]\XN*_++V%6N]!0U(?KU75J=VOD<OT#ANG<\@!11[9J.5W!
MYQ"^3C8E^U63[\KKZ9P6F])^7VR?N%[ Q#B,VBF*;DJF3<\I^J5XAT/RI1B?
M!7WCCE+#\ZU3PBINE'FVYG;_X&R].O_.S8VT#W&'6HCS-5ZL5B3;"U9U9I85
M6\/[>E51'6Z/%,@E[<FT2:TDLRU8O4[&.%U?FF'BW'0,(/,1SY3KU)_=@%XP
MP7E*SA4!VFJ2A\@6HLZ>_"N#)14R@O&.VNVA@'.#FG'Q<XQZ[T3*,;+N # O
MP^H+'</U/[_^\W3Z+<R(F=6+]<NP7'ZG4/^_PNRTEAT[=#8S.HL%,<5B@<"$
M!N\,<DM2DW?UACD>0#M1UP.@CD+!HK5*.L#9BY3J ^#5!TQ(+,49_H;K\TJ-
MS+&PB!H<LD*.>T@0BR:&N,G:AI12\$WLTP-$C=.\JAVJ!E- !V!ZO\2O89I_
M_?,KSE=(>^7=^@LNK\ELPM%;:6*$%%2D\,&3XU^\)M%QR;(OPN8[8JKC,;4#
M;>-TNVH'K:'5T0'"KA-/SF36KDA0OB:Y>8@D'+*UP9J0M%4YV#O*) ;VG\9I
M>=70(!TLXL/QL5B'V4 6:/$5E^OO[RD&WJ0QZ*#^6L,2,JH3SK) 04&'<YB(
MH:1K9UP%C-7<A6+"YSNJS(<P/?<3U<-Q-HC7/9CD.[ R[XB34$N>WV)8X8?:
M;/E=^9U,:!77I+;GXJ&^%C:>3":J3&RY BFADB:@,JG)"?8@53V<78/@:#C9
M]P"DRP/WM\4\G1= <\NU2!X,UC8[%@OM!B;!ZDRR0L9X;&*'[J2FA^-K&. <
M+>L. +.E?V*B*CX)"2FG7)\3(W@A'.140\A<@FZ3/-TN/TY#QF:9H+VDV8$/
M\W8:XG0V74]Q1>?HIM+CRV)&0E_5,W7]_4(T#J-R2A,C53Y*R 3>14;RL1H%
M(I=W]9DY'B6[$CBN;],\(]U$3QW8H"M\W8PKDBTFHU,@6:TOXBY#D%R H6@Q
M%R9+O.N-[Z"(ZRIKW08"]^/L&'UT@*SS7-?[\+TFNLYC3.US=I)+8*7>!1<A
M("A-T6KF'!,C7GC3-.-U<KI!U%'*OB?+>(3D^\#/\I16O26C"7,FZ! ]1)$9
M*.-8#3 Y.,&+22JP?-=KX$$@=#=%XYY][5 T@/P[ -+U(/.<G_,7SQ.K@JJ3
M(0!Y(6Z$)1E9D2'QG+7E/GO7Q+%ZF*QQ0_Q&D!I0$SW@JL:@=VP/GE.*.420
M(=>FECF1G14%%&HN/1(GNLE%_SWTC!OSMT+2 ++O $)W<" 5+Q&- I%JBR#%
M%#F/-87*)4M<.B9\D\/M0. TRPPT LZ1$N\@8_ *E]-OH?99N,++E228I5-9
M,:E!L5KJ7Z-<EP2GZ$/KZ*P3H<T]_B-T=>,CM8O=AM3,P4#[ALNX:.LY76$I
MT)9+GF4PI=1F5-:!#UE#B;1ME%*2^?2$SM.><'L*_ZD=W(;53@>GX<U#_0HG
MCAGM(C%A772@G O@E580=-;2<2\B;W,-=R])W;A5#0$VC#XZ0-85)B9D:H64
M.@%F&4%Y3W&LTQHT11Y68;%6-S%95VCHQK-ZDCSF7A+OP,&JCVZGZY--O><\
MOUS,JXW%>:JL9.8+*N4HOC#$2NW_&U''V@M:%2\$]^R.A\\#U.#>3],XT[*>
M%$Q#::0#2_2 A!@F)W6=+NA4 "4M!Q=3 91&*Y4D9ZK)RY(C[_0&?US_I- :
M2!\=(.O]^;H;EK;UZ3XHG8UTVUXDJE@),3&2C!(NB^*\#4W,U1VTC/UB:1@U
MWRZZ/4KF741Y5YI,;#E(BF4,3@)/PM5.612B<OJ3U488EUAP=S4,&N:0NTK(
MV"4%32!SE+2[P,N+G#=U%6'V/DSSF_G+\'5*OM<D,*YB$)'L;I6*\P5<20BV
M&(%&R\!9FP+MN^D9-P/0"#U#R'[$LVKS\/PC+K]-$RXOWL!,=*8C.H<,W-:$
M;DW#1F/JP!6I&<_:IGPCYWW[=?7='SUNE#XP" :0WOZZ]UO=S_%S6&/^-)B[
M\@'783K'_&M8SLF;7[U(Z?3D=%87>85EFJ;KB;!"H^421":CJ**L+Q&$A)"2
M9B$S$>[J,G6\07F<M'$#^$:V96"-=. 2WQ;4)!B=4S0)9,DU):H5.,L"6).\
M3LQZE>^8?],BR!HW;F^$H2,EWD'VY[&H<Z*94.AJ2WSO,XE'TZ$;,$&BDU;S
M$KQS31#T&&'CS#(>*ZEXO&X&PUK31C/O-]+_@NMI(I?V&ND'=)VY_FD-6M \
M0.Y3]J,1T>0L68;B2VTXI#/XF"18M)%%*[4T33R'I^A'<SWG0 )_M]PLFS?A
MY'M<;CI%3E!D40S9686*PDIR"^NX^ BF<&M1)V0W?>H6J9_[R!L[&S0PAA[.
M"PVBHP[<J>M<;1N2OCA=?UDLI_^->2)]'8>I=)U$17%(9*)>!R+$(GC4!9UQ
M=S3;&QIQ-\D:.XGTI$@[2B<=(.Q*<NS>36,#(B:"03)UTWAM(5IEZ@A.&[)7
MUK7):>] V]@II\98&UH[?0'NUMYAZ!-7=>Q52/3%HP?'8X1L1+(Y(T4O30K#
M'Z!I['36TP'L*&WT"*S-],8\\<B%L'7PN)-U'A:G_4%;!HQU/D<?B8^G =66
MGK$364\-J .TT".8KK:!-QYC3"*!U);D8T(!QU2&[*) 1@1[U>3:Y>BV_ US
M6T\-JT/UT6VSVPL1KA;EK,YT,3^HZ^T]GS1,[F$7,@?*.[R9TZIXL>!ERP)A
MK=5H(?%DR,/F"0+S'"PS6:4B!,]-NC?<0\_Q*?.S#_RTN5N2$;6KG>@LG;.;
M5S0420@'SMJL"(VA4=.MZV2,FRT80O.W\^0'B[F#\^B"^I>SL%J]*QM+^.+/
MZ6K"N;6<:4.4Y_K&F*034ATVX5-16G.55*/KE7LHZB31=(":[T/,43+O #Q7
MZ7^U. G3^01MP5)G\9$;3^Z8C$2\"@RX]+K8R*6P37*5MTGI!"['Z?BFMW*<
MP#LH%ZF/]5XNYM]PN9[2/KJ>\_H;GD1<3K046G&NP?LJH> 8Q"@=%!$4^5]&
MX,WVVO?7D.RPWKA .5:EB[;R[0,RKQYCR60?<M0!LN*UCX&D[96D!&\L\U)B
M9B'L 9G'UALW$ST\9 :5;Q^0^?4QEI#B1)18P'#E:X,R1]RXV@G#46"'7) '
MN =D'EMOW(3R\) 95+XC0F:U7-<>J/DTK=\MSRKR-N<T(WS+% S1[Q0H401X
MYDP=\ZA9\ ZEOV-(V2U/AC[_BA=#?[OIP=Q'0">W78>[NX-(M@]D;&I4MARL
MSK:/D3'RH!30;DFU<X&#8'R&(BF0--YK$MC \+A-Q3BNRS"*O8V2(Z7<04#T
M8?$]S-;?SRP@*UJ2/U5 Q#H_34L%(3H+VF3&M2@IM1D3<XV*T2%RK%9OEK8>
M+.(.\'$FAPL_'*.5*$"Z>L%*3D6=RRC 22N\]S93E-@DPW*5BG&.F7;X.%S$
M/>#C_-1].YWC&_KC:D)T)TF^&CA?^^C&0K*(7H+E3!89'->VR1OWVZ1T4A(Q
M8/[M,"EW@),/^ WGI_B:I%2?4-<<]M^GZR\O3U?KQ0DN?_TSS4[K#59MI$S_
MGS^%/R=1>Y9R-J1KXE,5"OU=[6 3DE19>]H/L<E3P -H[21U=R \;KW%:*NK
M?N#XVV)]'Y<3E8,C8V[!R#JZVE99*LR01'&1A%I?3#9$WP.D=1)G#0JVH331
M#[96$^X$2\@2,&E9I9LLOF$%(FG>.2ND#2T1U,OQ-RA.]I-J!T]Z+AIEG0W'
MNC)O0/KB;2K@;8CD,]H 0>;:1H2':"D<$+G)]?:]%'52X#<,7H:1>Q?F9(5$
M0!T(^8KVP&RQF75TQM7E69S^>3HEXM[,*4BAN&3U<K%:3YB)*6% L)'17BF%
M]HJG7>.RB$99ILCU;&.!#J9Y7$]J(-3<LEU/H\(.T/H19_2CSW_%.0ER1@R_
MR"?3^;0*L?:F/.-Y8C DP6DK*UZ?C5/,"[[>,%NI>=9)8+%-!A/M1MZX#E8;
M##903 =PNR6K"9%9B$X-.ND,*AA3K_P",,V2"YYEYIL$C;<H&=?[:@.BX\3=
MDS>VK:M[NUB10ZF58$Y&"-8F()<C0= L@-2&QRAR"*)-R_3;M'12$3^P!W:@
MK#N RYOY-UQM>O]M>7@S)]-%WYEX]$'YVO+&U:=M17MP47K(2AC!&?V,-VF7
M=Q]!G=2\#P.<0:3>P>%T3O?YV9JBC=DG"S(E7W-D#J(C;ER0*2M9>"E-O/$;
M=(S;6'%PK!PNXW[Z$6V:'=^PEV<<U:&V3-HDB' (]:6(XH:LIB11%<)\LJB9
ML4W*_!\F:]R>'T,?5L-IH /+\_M\B6%6GR[^-4SG]>1]-[\<$+":4$"9$HL:
M? FI!I42(O,)G"4'W]5![;))I?PC=.V$*/],$#6D#CJ %.V"*WY<E#%EKD/=
M#ZS>=R<@X1B(G%- $*0,MDEJ^QH5NZ6*V#/!R^$"[L!1OEY/^6KZ;9IQGE<W
M7B^].?FZ&:$C;-3**,*[%G52LH' (@=6Q613I&#@"7IU/$SD;MAZ+C>ZS=1S
MK MU?.WT*R3:\SE+'W#3,O#3XA><;]H&AMFVZG=%FGN-87VZQ'?ENC@F-IJ2
MZ0O8FNE2+%* (8(&X4K("4VT-YNJW5-7?3PMN\&N][O=,133CS-_S9"_^!:F
MLUK_\VEQY>'V6>.X7\)JFB:AOI^R7H L=7 \A@S."0_)FL!U#$S>+.MO<)8^
M3N=NT'PNU\DME=3!>7S>1O6\-<Z&B7K]-)V=KC<-3<C*:R$A6Z%)=,&#CSD!
M1Q?(PQ"%AR8U>H_0M1O&GLL5])!*Z" "^#M./W\ANE^0U0Z?\;?36J_ZKFQ8
MN]*#XB:7W-F@DU!@;2$NK1(0D@L@)/D9GN=@VI2#'D;N;@A\+BGX)U#9L^@B
M<D?#VFOD[]]-Y+X6N(-V%7F,[.&[FC[4.Y= QWC@P#T9*L6XI-@T%D"NF54F
M"\[:EG4_1-W G4>$+L03,R 1*?IFCDY[Q RL%,7)"U"VS63)GCJ/#(^*1_J0
M["/T#H[#"^JW$B''\>MB7O?MYF&9"B(+%RP41RRHE"2X.A!:&Q^"346*W.12
M^4&J.@'4 >J^#SE'R[X#(-W@X>Q%$1WV(0<I05NM:S=Q!8[X FO09VNSTZX)
M@.ZDIA/@'*_MFQ[ZT:+O #]WOF4/R#A7%*^F$&HS>F8AYMKSOI0B$'TLH4D9
M5'_M2@;0\8/9U ,$W@%HKN0YSACP7LC (D(V+)$]]@%<T@64#\E;5Q)O4XY^
MBY)QJR^'A\MQHNX *_?,_3ICAAO+LW(&C*W,F%K<A1B )\-3\DZ2W%K@YD&J
MQBV^'!Y#PZF@@UXW];7SAXL18N<\N,"+*AJRK<6H,04(9#*!6<]X"5JZ>.-2
M\.$Q;#<7&/=QRW"(&$R('1B6FT._SKBH#7!S" FX0@5*8RT2I2_:4<"@'%K6
M9@3HW>2,6Y,[O"D90.@=0.?^;H41O?29!2C(:V]E\L&\M@:<8M(G2=_4;<?O
M'-0%]*G:(@T2=1\E\P[ <T=O,1W)\^+90V#U_;J2]=V+LY"+M"AX2-FT&3O\
M;+J [J7CQ[N [B/P#GR675H.INB93$P"SU&"$DG2Z4N[#+D67D>CN#2[NC!#
MM71\RBZ@>ZGT@):.^\BW#\@\VG*0^^*9K9U,@Z]/L%R-!'VNGGNV2D@C=-H#
M,H.T='S*+J!'0F90^79P,-UQ_>L317 Q%Y IN*W9=>3?T5&24!A;M&C<U/QM
ME]V4!O%C#I-R!SAY,T]+#"M\A=O_OIG?OJ+[L)C-7B^6?X1EGLB2I+<%P7I?
MG]W%6MS)+:3(2Z;@,*F<6X!H3SH[<7T.A,6METGM=-0!!*^--$*7)?W/0O"Y
MQJ.10XS% P^Q..<Q.-9F4L>^TZ1:SNEHI^V;]NM0T1\,FZ]TVB[H8 W+]4#G
MW*WIR3*0)*Q"B%X84&3!P><ZNT_2_K-,,RV;5,$>.,NZF9/TI$ Z3@VCPVGK
M"889GCF5VYN6%_/\][!<AOEZ]1NNMYME$@(3.D9'L4,1H(P/$)5&P,*\,U%%
M5W:,S799;EQ7Z2D@U$CTXU?QWV1L,V'T+NXF,;C$LDZU-K+.\;,:?&U+YQ@C
MCI-DV>SV;&27U<:]OA@#4<,(?GQ 73.VVT/[U>ER.O_\?FL%MS/\ZO/CB60I
M:+');63:*:R^6S?&UWI?YU HR=H4;3Q.VKB7($]^)@ZGIAX\];LYVNRO+4/,
MA> $Q='&&@JF5>#@O)?D [CHA/'D5;;SO1ZB;-RV)AW [D E=8"Z%_G_/=TV
M<5E]6MQ3OK#95)$DF^L%)\Y7&]5^0)+L:KK&LUONK20^8%I\GF\^92.4B1?%
M"2T%:$^^A7*"W JL?^4,F0CD;)0FH&W-V+CM69X2\UU!9/0+@X?.G7/OY]<_
M<9FFJSI$FI,YX%P22DLFUER&4$R S#5ZP97B-SM[WN=\[K7NN#U?GLX-;:>,
M3G&VV3"W.6-HT B>R,'Q"E39["!60!M&?@\K4?L=!QONL^RX?6#&1MD JNC@
M_']P"WW U7HY3>NSR[H758Y_7=:^)UC[C]:R D8A':C,$3PJ X89:<F>>U_P
MR4.@>\D=N0--!P[JD/KL%[6;+7D_DXIDAV@1M*JWV(QG\('\C)*TB2PS462C
MQUX'4#MR9YL.,#N@-L<^S1_HID("K*R'><)WY=XZB4DP,6'*"KADY",KAQ!2
M9)"-H!!3!'2X6]WUT:2,W/OFR8[]I]59OT9U>W1<RN :QQ\QT:^NI[B:2%X<
M:L,AU"&^RI4"/O,(LH[28]S1?]I<+A]%]LCM<CHPLRWTVR^:SZXK'F=6A*R+
MA!"4)B\> X0Z"BY&YHK,/JA+=_&I7(6!L/RL;Y^>7KL=0/FB$>"-\R7%DG*1
M"'DS(B G03NRU,IOR;FAH-.9)M,Y[J%GY)X\3PF_(30R:D_&G<Z$S0\_?IU-
MUZN)D\$%KQ-X1S(BSD+=+1**YRK7AP6FS6.O70G<#7P_\AW4<3H;.T+Z@+,J
M-[+8].-I"K-/2_*\7Y]N&E_5\H+IY@9BPITD;\,H,('AME+<F^Q 9QVE2^26
MZ$<;1.VSX&ZX>M;W/,WDW\'1>;U;,\O.!L\%1(<%5 KT)Y\T9&F9$"DH)IL<
MF >TPW[6ES/'2[\#Z%RI<;K6D.^LHO?-_-,RS%<A5<U-3+#D-@HZZ;4F4YLL
M!R=]#9-$U)Q._>S;Q M[$+D;\)[U?4USW?6%2XIN5N2'+L\NVVN7 <SOKC$7
M$D])4&S#ZPP#96G3.2$=V,)LB<B9*JV!^3B5NY5R_QCW,\VT-[8'MTN9R)4>
M.^_#<A.M7_ZS"7D3*@KG@'F*R)7A!6+6#H(2*+BTPBB^DV]W-"F[ ?)97[Z,
MH+,>C.>CL=.[KU4&5R[T)3H6!#F[4N3:N"X&( $'T(%QU-K1T=&D<=+^I.Z&
MVF=],_-$>NP7J9O]=S>#SA:5D (R70</*^'HL#!HP'BNH](RR/"4-1GW4[H;
M3G_D.Y>!M-@#3*\^<C11$)FE #)9^UK1[J)-A2 "QJ18\:K-Q*"]WY>*'^,2
MY%#9'_DB\-?Y@,GG&^\:E?.\-N5$QLGAK6]E@ZP=&#-R4KY)(;6[=SO@>>D/
M<9MQI!X&15.S\0*+;0;@&IOO-ZKX@NN:\+S.SIZC!A[_](''#NS)SI..( @*
MBZA6R'M)X EU$G#0#)SDJ9@B0W"-/.:&(P@V\=++Q8HD?U[[LRA78Z-K-X'A
M\BED62P?R:F'9(*7B:3$<?-:S8!S.@'G0BF>E)(E/(;$=N1UTNUC,,1="X#'
M5^C8:9MSKEZ'Z3:XG^@B64)3ZO!W#HI">'""?%&')3N,V?*;G8+O@>.MC^ZD
MQ6(;*!TGR&<QG^=E6'UY/5O\L3KJK+SV0<-/X[F'R.%/P(N%+K"#3!3,5@%3
M]8;+,L(.^>6 1AKI31:Y\3R:.X@:>.1.<=Z0_6(@\F;J*//@">,@ R&;:6&T
M4DU9[&ODSG$8>&32SCZR[B$5<&]/4L,41^<9&%=<G9*LP;,0B!OO=>(Z:-EV
M7QS4Z_>I)NSLI>:=>_WN(_,.P'-'TTD7C&!*9S":5*L2A9_12@$L)VZ51*U3
M$U/S?'K][J7CQWO][B/PL=W6*X[ZE;8S9^U$D2=DIAC(L@Y&+$R!CXZ!)=\M
M,H_<7E9L/1)0W;]*=WU]]U+?HH4LQP;%MMOLR\>ZS2JFD65NB:4<0#F-X!37
M4%B(RI'@!.Y60[C;>MUU\ST8* WDVP=D'NUIK2+RD+T%(6LO*U_JJ^YL@03&
MI<]8[Q#W@,P@/<.;79 -#YE!Y=L'9![M:5V2+)M&0$*+6E;&&43C%&"B;W".
MTJ<=^\X-US.\V;77\) 95+X=.+AWM"WF/$LNE"2ZR42J:.MX&&F!"^=TB=P9
MWNC%Y$$]PY]J]LD@\=!A4NX )[_ANB85WM-.F&;,OWS_?54+5M]]W10*SC^_
M2.OIM\TS-MH@](U3^M[9#Q?SRS1$R!*3#P98R@:4"+F>P70:JT3_AUD(T^0B
M=1CR.PFX#@31[2KXI]9H'SB^4OOO@DZND$LH1"#Y"6,AH"ITW*,HC,((V^9*
M\("7%ZU0-08,'GR/L8]..@#4M5K5VD-NGJ8SO,;2I\6.$KZ09HP4U0;EP;+Z
M$AB9!,=-(;]3&>T+*THVF4+6@IEQ#_$.X#TZ0CK8)9M^.:=IO2DVK+?;JQ?S
M_&*U(B&<? W3Y2:/^"4L/^-JDK*7EJ(-T$S65F5('KH1]6F62AB=SC8T>0ZW
M!XWCFNSQ 75K*&0;[78 W%=(*Z?I1K?TYQENE$S<G2PH"/SOS?<GS(@06+V-
M3R833S&!KRT<<K"\A)*<ETT&Y.Q"W+CFMSNH#J[/#C"Z*;G[Y6:7VTG2/H;L
MZTMH[^O#5@VACA]*]>0RZ+W*3>SHW>2,FSOL#H<#Z*P#Y/T^7V*83?\;\U_#
M=%ZE^(YVU7+ZC;CY1L:^E)S1:G*63*J^?&(051)0@C1.".50-FG/\0A=XR8E
MN\/BD%H<M7W,U981BY)FVVK(=:V&+-MJR'11#5D6M DV[;]7R[-'KI/:V+L(
M5H<!9@[*)0DQ$[?%Q2",SR3D&]FIA[MX'$##N*,RNH'F4VJR SMZ^UG%A4#/
MGKM>2%-+M(XI!<9P!HK^!I%G"9Y<9Q64S)(U25GM3N*X8S>Z@7!CW?:)VCIK
MY%*0-0)<3<B5*4DD!Q(Y17P>"\0D)'#&L^?2F"SM$R'V#O)Z&_PX##@>Q^"Q
MFNJB3]QMOEZDM#BEO;]M7+&YN$L^A62T!*$EG052&HA>64@J<1\U2B^://_<
MA;C>ID4^$?J.U%*GV'N_Q*]AFG_]L\9S]9V%=[9H!:R$>F%,QX>WI4".R)WU
MCC/=)/AYC+#>QDL^$>:.T,[X0<T#4GM;__YA^OG+^ETA3V9CRB=>L2231C#6
M.E Q9B#WA8%VB(Y'YC6FG2*9/1?N;=#DH-AJKHE^QDW>;[+?A^_57M>4:4K+
M4R)P&N)TMNU@[+*K\V409#*TJ5#6MCM90+%9YU@2"MVDO.,P<GL;2_G$A^]@
MFAR[\O&Q+7G.U_>)(VFE(A1$HR+07Q"BU!Z48BY:Z;.\.?7O0+-XL61O,RB?
MWB >)OUG$-Y>W2XBHY$")6T72ZQ9Y\%%[L I01PFQ[@R3V/X[J6QM\F0HP2Z
MA^JL SCN7LDRT3X*FY4 "MG)> >D6"IY!=YS<G&MM,*U:BB\(XGCQB =% 4U
MTN;A.%W0%FR)TS?S;[C:0[A9I"@<'199\5('%M8)[3*#]#Q:'S6YTTVBYV'(
M[Z1R_6W+2N&6&NW WI)[?-Z!-/WS=+I$XI^86G]_/POS-7G-M4/'UTUCE9B,
MRZQV-9.:3BP6&#AM$9S(+ M)7]N\F-B=Q"YKC)L":/$DVNPB$[F[>">964;'
M"(>@6*VY*^2"1\N@%(4^$'5!-*E4VYW$+LN%GQ*IC;39KV?P>CH/\[2[< 5#
MVJ+D<:$MY+<;XMKK&$#6(I6HR%7*3XGA/<D?U_-]&L^@I49[\ R6BX285Z])
MO%<';EZT*YC8;&5B"L%H54-8$R &'H%KKZR)4AK9)!WP*&5=^@%-X7+3#QA4
M=YV!\=S)>;U8;M(>=PAVHNGT\39:"+K6-M=)29'K!!B]L-'Y$$)L#<T=Z.S2
M#1@+J$/KM3/8GK5V.6\VOIH('ZV064(N5A(O-?G'/8>4K54)2S*I33SU %%=
M9JS& N11&NL,??>,97"!H4L,N H6%"H/+J$&8X3EW"F36?,3_/ I!<UNV#O#
MX?&ZZPR,ER[)V\7\\R=<GKS"N)YP3*D8YR!:7C/-SD/PR8+6Y)\+SVJ-U-/Y
MDU=)&_<.O3,X#J"]'O!XYFV\*Y7Z7_^L28?3Z>K+YA5G?=PY,<Q*Y^L\!X>J
MUDXI\CHD Y)32#EHSK%);OY1RL:];>\!C8/JKI]ZI-U%.W$*M2M8P)I:JZ\X
M@C,^ =E^YJ4IQH0FY;Z[DSCN37P'*&VDS0Y2G)6M^K]ZF_ MS'!3XTP2FR;:
M#O4'+^;Y^C>N_.9V"-/M$H8T.ZTOGG[],WT)\\_X@;;6KZ5@?9<BG0B9MK#%
MY&JNPM 90^Y.,B8KH3 4U228?UHVQW5Y!TZ9=HR0Y[Y_)F1R=/"" E"9R%A(
MKNKK:04HM+7:E&1O3NKL8#N,ZT'WA.Z]]'?D>"?B>[GN +*1<62A"+ ^$,L4
MG)([1MLU:F<2;4]I8Y-2K?:0;>9F=P79??37RWR[TZ]?9QL!AMGYH(@W\[)8
MGFQ5>.[A,2-U2-77TH*$JED"QXR 9%DJGD4E=9NQB;O1-ZX7/3 (6^BD@U3"
M]LWUI_ GKNKPY@ER0\$F>LBN)!+19@I)*6"21$-^BA"NR>R$&W2,W,>SA:YO
MUT$?+/@.<//;8IY(,I<U+_-\$1QN-MOERWS/6=9:@,L^UG9B#F*,'I1 E]&@
MU+9-!\]=*=P):^Z9F*DV>AG[_=#U/MZOIC4I<?$H:D(;K^@<+!2G%<D+)<F+
M.^ NQ\0Q>"YN!!7WO!EZ<)F1"S/:Z'711,ACP^45TH[*YQQ\P-DFU;GX!>=8
MIFE*1GW3(GY%NGN-87VZQ'?E.O>3()G%8C@4'3?)LPA1ADQ_-5H)%CB_^4[R
M'DP=3\O(A1;M@??$ZCH8G41#7 PW@VA5*;^@8'4V+/2/LRDZT\UT[BEY"?,Y
MIJKM/Z;K+P_W69IPI:P+@B*<E ()OL[<4:P.]'9.V2Q--KN]GFQ%X<@U&NVQ
MW(5J._ /+[?L^=RQD_JD>3MSGD]8#,AU?=EG' >E2@9OM2.7UYB0M37,8 NG
M\&&R1J[<:(K.!HIY7J-GAYO9?O^G-AQ*^Z0SVF]/)[5."!3U6!5TRBK&$"+G
M!41BPKB0+5-M4DU/-Z'6B:2-2!9LJ=%\=!IBL!&RM<&PXKT+__^>4+L/!AZ9
M4+N/K#LXS>Z?I*FTD99\3U#9TQ<ZG,$7M)"Y-%ARBNKFQ,B!0=/UA-J]U+SS
MA-I]9-X!>.X8<<9#4B)(.F5C'7%FBP='L@*>"_,F<8;8!#7/9T+M7CI^?$+M
M/@(?.WOQX%35:'1.JE 8@+5REDD!T1D)'B//9)&YN/GH_D>84+N7^G:>4+N/
M+,<&Q:X35$5A17(.)M3[>:L+1!,9\)(BB[[>(I2=X/%,)]0>#)0&\NT#,H].
M4,TRQYB3 Y9BIA R2HC2>\"LA>;%I2C"'I!Y=A-JCX3,H/+MP%NYXS[*^^@R
MDD-!HC*@C*X1@+-0".S)>\F];QL8O>URW.@@SNUA4NX )Y=U[!NPGS^LV):P
M<U'(>V/U/'7U/85TX.N09J]LSG3F!OJ\ML\/;A/5B:=[H,+O?45PI/3'/J1>
M35>;7I>+<L[#XNI;[^L6-5RZ<&6Q?'F6,/]4$^:OMPGSEY<)<ZF+"UHC6%=?
MB6==2[Z$ J.+<;+(7&[&6/?=X+4BL1-K=APB.])BM_GH7TY7)&-R/+[5*2CX
M!TG@[?2?I]-<VX\>D(E^\/.&R4'O3O) V>=WR\]A?C;>C5RJU6(VS>%L]-O[
M*WR\*V>7(F%VF2>_2%'ZX+)7%,C9D@.HLFD6*16$F(76UH7BFW2>&83Z8X_D
MHXBH6WBV6)TN\1-I])=9O54W0BN=@P:ML@#EC2'7V'$H@9Q7R2C<R4V:10_-
MR+A'_],C^Z:W,"HPGJ55?H7K,)VMAC;.YQ_;WD;?R4!7IAJ#M\KD##[F34=6
MBHM#(H_#22:D9*:8']=4G[U:N/%6X<7Z)3E&W\D#^J\P.\6)"-9$K#-^G*[;
M++!:$YQ &IVDM4IRT^32=2?J?@2CN@\&[WJ5,JP*^[64835=+<I5N9*M^7AZ
M<A*6WQ?EX_3S?%K(B9^OSR87$/OO22.I/J4^Q(0>L]Y MG4PE@<RNK>7N7SH
M;80UPB5P/&!%,:^]+"E&<L::G%!9;))MN9^D8\WC1OKOKDF?MMJ#0K]T3EQ.
M3$;,P&5M^EUG]494M44L.4SD)J48FC0&.H;HD<?5#X.MFQ;RR;3X0QK.L0QH
M1X9T+(/JT:$T7->NO:*V PK@D;P$I5QVWO/"69,GO^T,ZD?\7#V?#_AUL;SX
M_._;KY=[+H7LC*OEQ<42MU)Y"$59VGU1:I8E9J];\+T3==V:R'W0<NL>:'"]
M=' U]/L*WY5?5^OI"3G<JXGFUM"9$<!FYHEF47L&2 ,Z>V-+-%:V<4^NDS%N
MLKT1?(Z0]-@7/V?ORJZE_\\F/ZYNXK_2SD1.P#)!7VE=[[)X'5"EA5 \R+QC
MB<(>BXY;IS P7II*O .+<W<L?I.IX+VV*!$8UD&/EC9*((8@&LFR%[[XT*;J
M<A?JQGU[TL@^#:^7'L"VF"=B8]MN[<-T]8^71,-T7?\TB29C"#& 4YE8,965
M8"(49PW#S*(L3?HB/T#3N-V+6@%K(!UT *</^ WGIQ15I@6%0I6?F_M#F12,
M, J2=JX>ZQZ<E0YX"K0_O/.VS4B81RD;M\M0(V@-JX\. /8*EV1YU]-OMX]Y
M94@LR6B0S-9CW@H(B"2VJ)C63#AT3;H3WD_2N#V#&D%J( UT@*6/7TB.OX05
MN9&+D^HZ;B]9OI[E]MYLK#+Q66=VG?$Z,9AXP9C &Z3MXB."<[&^879HM)&<
MN2;FZP!:QVT%TRK'T%AG'<#R=9@N-_=M5Z[[WLQ)=J<GEP[G1 9;,E<69!"Q
MSC3.$.M<4".]TB4X:5B3<I:=J-L)>OZ906]XO70 MGOG$MZT[2:*9$,@QX![
MLNTD+(A(D31B<"QEHLVT&N2S$X&[9539,\-<$_5T +LW)U]I-VW>9B]?35=?
M%ZLPVXXQ>$O&.[]8K7"]NF@T_(8T.?]<'Z5L?W!/8CFBE.@$6,EJ4R=5&ST(
M!"0%.,/)QU5-IE8TX&4W,#^W^X&QE=X![M\B\8)O:QOM6]ZS9H5B_%C T98%
M)3U"J%/B.<?:$J<P:YJTDWZ IMUP^-PN&H920@=XNFB\>9./*$01]?9$ETC[
MPB2Q'18?K"VI3A46I0F8[B-H-R0]ERN(0<7? 8PNWZBL:H9[,XCC,\XORA:N
M&ERTSB95P-!&V0[B<,5J4$B<>B5\#HV2PKN2N!O4GMWM0QL5=0"^#Z0@(J#>
MK;S";SA;;!S<L\N\LZ@*32&B702-/($*A4/,(1)8BM9!>VU4DQ%0.]"V&]R>
MVYW$T$KI &>_AN6<Q%2GFFRR2#>WC2^R2%L#)Y7JMF$,O-,,)(HL%7$45)."
MH4?HV@U?S^UB8DAE=("MW_"/*X):+N;TQX17\D*W;+26)L92.S-(#BH%"5'7
MANE1*"N8Y?%FF^>AQH;M1^ANZ'MN=QA-U?5#%O!NND0\>?GNV:KC%^_>Q7[[
MTMU(R+*.L):-IRC"N0R^<$D@9%K6%STZ-SF1&I;NIB^83V?XKKR@S\_3V6F]
MK/F(Z72Y&<#WZY\U^X.YCC>M%SRGYP^?;IX75VKK?4B6!0Z(K'HATD&(T0$&
MR;,0VJLVB>GA6>FV*'@?'-ZZL!M7XS^D,?ZM=IRH8CSF9>^0ZX]OH!\627M3
MK:TN7B("BUF2@R <>$NAD8_!":LQ)4S/RU3_=EH[?KTK9\-8YY_/ROM7$]IA
MV@E,D+BE_>>*@R@SAY2C]LX%+E63&HA[*>K6<.Z#BEL^ZB#R[[DR?E(L<NE9
M!/+@"XF'*2"?WI-'3X++CA49=^MJ]- JW;Z5. 0<P\JT@\#YP3S3Q!13T#L%
MVE*PI;#.B0B^?A'"ZV(XYB96]4&JNGU,<8RU&4X/78!J4_5*GN-FS!V%]N_B
M;/IYHZ-7N$K+Z=>MCWG6>>X3+D]6$\-94HYVCE.<U8[P&:(7&8KUL62!F'B3
M0.(@:KM]87$<"%OK[8<,!\X;T(T4#=Q<?OQ@X$&!M(\%5!32!@J7A66N#NG5
M!$A+0:I/-@>O$^HF3[/:Q0*7-=_;;K'*<(K!*?BV: QQ*$2=J<, G4@^%VM#
M;I*]OD%'MW[_/@BXO[Y^?UEW</9>DG]9&UM?,FT&(7!E, L>H-3)LHISBERL
M14!E70UFC.=-$IH/$34NB([2]KW(.5+T7<&HECK43?6)_N59EW/!4:: $;(V
MM+TX!< N,P$Z%&>2*$K9)@;V(:)Z@=&QJK\74T?JH0-,G;D%9ZWLK7 ILVR
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MQ68IAE9M=NZG:N0V.RVA-)PV.H#6R\7\&R[7=5#+^W,2-FR=UQ"X+$H,DAR
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M=X"4>T7SU^5BM9IDEE0TZ$@8$NET+@$"=QI*C):S:!QK,QO@8;(Z]9:&0=.
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M?A1@'Z;A3B/X/<\IU-QA\!9D# CU+0IX9PQHGYC1GBD4N[VI?"J_HTUH]J-
M>2]]=AOIU2%7#PC8"*F"(HE*1U&R<DP _34"8T%JC27BS=3"/IA]>/%QNRL\
M:>0VH!;&=@/.F;BQF5XNYAM>3L.L,CNQ2C++18*H+<E/* />>@?:F4![.>GD
M=@/6;NOU%F<-J?"[;O$&E'ZO]WF/F&=>L[U(QX $XVNVEQ=B5TD-.A4EI;9)
MFJ>KJ'R,VG$[(#4P=D^GN^=4,WYZ<A*6WQ?E_3FAF]\9MG#\X36:58_OP=I
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M$!V@ZOE9C4G:G(Q',.A((8S/$(PK$%QR2K&2O&N2[SR[\::#I+W7>-,AK.\
M/Q]JI#O/Z2=<SF?S3W>S.8,WELE@0 KC00DI $M.P /J8HI6AC6)R9X_3@]E
MV4?)>3$ZTSN SO.I-^VB%-PXT-9&4%G5TJOD@%D7%#<A.-FDJO_PQ^%FJ>]6
M%]CQC.\ /1L)M]G76<KS](&,]>]Y&:N8/A&79"@,R6<42M5%'IJXI$CVP0KA
M<_2\J"8SW_<Y7#_^]H$8>#'O/8) N@/9FR^+Z_G5^X>>KCLB5^](9LN,R]6%
M<3QF;SDPPP/4.<00?*EY_BBTRHDE<0+$[7'2'A^/QX/?V*+J (OW%#RE],+Z
M0N>/ I*,B5Q04PM/-3FCT?I(;D1@1;9 W);S]/A:? RNQF#[U FGK9F09RMW
MM,:44JG5BT1.%@:\= F*(UWAW"/&/0?"#?C6'A^!#T%-6W9/C:.GU-R0N5H7
M3LSB T56Y;K7@VP&^:!U3%==.\KHKS%K.I$6VNW7S[37U_53 CP"<L9G<%^0
M^7T]O^=]^7%V>7TU^YK?K5;7.(_YY\5R@]@WZ?]<KZ[6.Z@OI$[.&.\@^KJ1
M47B*DGU=_1!UDC(R\AK3 8 ZZ#![P<V<)=S:"V=J,*[59TT!T?3F^FKQA207
M'XB[L):+%&15JD)1M7*2PI,ZBRVRJ*R3,6P.3=CVY++CF_:"D3T3&(W*UJDQ
MLLT$OP^7LT]K";U=?/FRF-_\^G*QFLT_?<3+O%HSX&;&^OORQQ)KL=>/^(WX
M&J7,BEF@<(.!XA@@..;!IL!MB*BEXT?=AP<?;2\4NC-!X;2"ZQ^V'__,<59F
MY'\N+J^_Y/?E$3LJU3G1!4!T_WB]) 8\YH-DIB3-/0B1R455N:Z7($5.S*-5
M,EMF]QMDWO"0>T'9OQHHGT:8_8/Z.;5E,MF4T(*I:W24UP9<I"NGA)Q5L4Z1
MFSP27 ^UJ9R]&B0>*X&S*W'>W@G>H,1Y]Y>U+7$>2&R;46;!%I^M28"%,*O0
M:P@F%7 8&"%7*BZ;9#A/-\K,,.U<04=J$DMMZTW@K,]@2&]9RH$9WJ0%J-L2
MYB,0,*1D>0C?.W@"^'@=5K,TP^6WZK@^J:9T.?/('91:2*"J;?>%(BRC"E/9
MIXRR2;WIUA/U6[(\2.:;6!I% #T@Z>'XOV'U'^GZGJ](U4A MP4J0B)GM?+2
M.2Y!E<#!ZV* R*$@B-S(8%P32.T\VL38&@<#F\@:5R =0(S"ZJ_U\?\2X[I^
M[K9(B1NTHCZSTK&)2:$P",I%8-'%%#''HII8JN>/,S&41A;Z=T_B1TN@ QQM
M;R'PTM)Q4QV_S*M7H"*$8!-PABS:(C.SH8F%.JI/9Y)ZYZ,NO5$$T &2GNDQ
M4+QX%TL"RVH7BJH[,(5/$%A2VF7EQ%^]3V>0C'?WZ0QA^-3IISTGOSEKA9"9
M0\9HR)Y6+1.L0,S*"VVCL7'(F+11)NN=LD]GD$@/F*PWA+\=6)F7&P9,46Z]
M+<!)PT%I4BSDW()(R>; O6#89 W#\7TZDY0YCW)O'2V(#E#U?!.!U\;)K QP
M7(]X1P5H"T(]OM:8+:EDN\S8&?7I#)+V7GTZ0UC? 7X>O0_=#2SU"3UG&J3R
M 92@\ *ER*1?(G.!(7VW@&TDUV?S)#UD&H^2[J;7<Q2KS\3ID2QR61>&ER#6
M_2?$((F9^.6SXEP0?_;;6#6BT],LLAH/(ZU8W(.%>?;ED<6 2=9'1QTL.8>>
MP@?Z&412"<63U@R;+TCX95 [5[,JXU9^SO&,G]KFW'1K_#R;UW+#]/<YR>'-
MIV5>7^<7G#A#CG_==H6^5KM:\"I&B@:$0LF,+V*_ZI.7OJ6?H.I "2Y:L+,#
MJ[+F2:U$S>FFEN6F2O5FK-IO^;_7OZK31- J73+4SD?2GY0 T>;**\4-RTZ)
M-KN@]CI>C[U6AZ"KH5"F-D'/+N:[J6VY6S\>#6H1 F% U>TAMD1 ;>M"2M(G
MHU YM=]L\]W?U6,3U<'F:&36=F"4#MOB* *3 H6XJ5]0F!4$J>HV^UR$LMJP
MT.1!]7PW<(YHLMJ+K =<;FT\6UOF&XO]]S]K)?1];;X.KFZST1#),;B9,N]K
MJ*&2T,9S)U6;Z8D'G+7'5J^C,-E87-T@<ETQ6AZ1=DMY3OP"0W!!1PY<>8JB
MM:HO3>29"EX8%E5+)]HL@]AULAX[O8Y'VUBBZ!=;-VI#U!1I72D)/*L/EZ5N
M]4[%@N;D=A9D288V"Z]?/%:/C5\-4'6($*8. 3[FY5?R Y8YYMG7=5:F( _.
M10DIUX(N(RF 83Q"J17L+@:N^=[;C)Y^=(^=5P<[^,<Q;FJQ_U@3(_?S03[D
MR]JC_\?BASS/919G>/D \9\S7ETO\_N-K=X7A&0G#5W*Q1ER$WV=)&FL@2!0
M\A2#X'F_!N7CS])C']3!P#JQ: Y&(ITA+"9I1MF^8ZY!,\KN+VO;C#*0V#;-
M*)RSA,9X<$'$F]6@(1<'J%F4!#4ML$F\=+IF%!3>:55D[1"DR#<I!]Z8 ,&Z
M8 *W(F_V*_^UFE&&(&!(,\H0OG?@?F^O@T>>:M*.@Q>RCK3)!E"0,V"5$L)9
M(YQC30!T?LTH@V2^=S/*$ 'T@*3=9?#%""&+0) A(/$I$I]\';N;5+&AOH6+
M)KN+SK<991 &AC>C#!%(!Q#;T@JA"AKM,\4I=?^ \BB)7634K<U>)J,H5&VT
MU^\LFU$&"7V_9I0A$N@ 1SNJ#)$;'HN"%(T#)8D_@1>$'!R7Q97(&B^..:\A
M_$==?J,)H@-4/5]?IICW2>8 Q!T%=5D%^!(U&&MY1%9*:5/3<'[%O4.DO5=Q
M[Q#6=X"?[RM.50K*:8D@=/% .H80,!32+^:EE):G5J]Z9U#<.TBZ.XM[A[!Z
MZESGKCS*78<H*ZSPP*!N82(&!;+)V@N*<+74CF-"W#OOO<?W]5C<>PA&6K&X
M!POS;&)7Q<!,;4D6SEM0FDP"F5P'4A:OO<HVFC9/;.>UJ^$8/^=XQD]M<UZL
M1D47HK980)KUDS/1X)0HY/Y+SXTS1,A^+R?G5MP[2()[%_<.86<'5F7/.E*A
M Y8@'914J>(6P3N50&!2)B0G?6HSB>1LBWL/05=#H70 M1>*4(E[.1*E5[4I
M!R\O<_KAVV8IX(7):&2,'D0I 50D?R!$57=6\A)E8-'G)OOUCCQWCX7$QX#S
ME&+L%;4[JU:SM1F#CG0+</)=M2;?E9D,Q0=.=X9*O#1)0[V:0N/1$3JJR'K
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M9,I[#9ZL#W@6E65*Y]QH[>DDY$X[S.E<M>YT"#NSKI[G?SIZB\_+7].RWV<
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M#F!Z/_^0X_5R61W$>:W<7][]]0=<S5;?J^5-%/00TJ*/* UI94RUP\"0*KE
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M@N43/V0;;3P8'WF=TI*0%%[% !A4 72^E*QC'8[5$IS['+(3<SDI1$<79D=
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M># R,C,R,2YH=&U02P$"% ,4    "  D@%E2KDUT4"<L  "N* $ $
M        @ %<6   83$P.65X,#(R-3(Q+FAT;5!+ 0(4 Q0    ( "2 65)^
MDD?4. ,  .P+   0              "  ;&$  !A,C,Q97AQ-#(P,C N:'1M
M4$L! A0#%     @ )(!94@.E/U1("   $2X  !               ( !%X@
M &$S,3%E>'$T,C R,"YH=&U02P$"% ,4    "  D@%E2'<*F4DP(   =+@
M$               @ &-D   83,Q,F5X<30R,#(P+FAT;5!+ 0(4 Q0    (
M "2 65)V</U."04  *(7   0              "  0>9  !A,S(Q97AQ-#(P
M,C N:'1M4$L! A0#%     @ )(!94J+0':X0!0  P1<  !
M ( !/IX  &$S,C)E>'$T,C R,"YH=&U02P$"% ,4    "  D@%E2*5B8Y;?K
M @ ?=1P $0              @ %\HP  =')O=BTR,#(P,3(S,2YH=&U02P$"
M% ,4    "  D@%E2,ZE: X 2   TU0  $0              @ %BCP, =')O
M=BTR,#(P,3(S,2YX<V102P$"% ,4    "  D@%E2\(-^M@(E  #OAP$ %0
M            @ $1H@, =')O=BTR,#(P,3(S,5]C86PN>&UL4$L! A0#%
M  @ )(!94E9MG@'A;@  [N@$ !4              ( !1L<# '1R;W8M,C R
M,#$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "2 65("9Q_1,/H  +A_"@ 5
M          "  5HV! !T<F]V+3(P,C Q,C,Q7VQA8BYX;6Q02P$"% ,4
M"  D@%E2Y75T@OJ8  #N,P< %0              @ &], 4 =')O=BTR,#(P
B,3(S,5]P<F4N>&UL4$L%!@     .  X ? ,  .K)!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
